PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mathews, F; Yudkin, P; Neil, A				Mathews, F; Yudkin, P; Neil, A			Influence of maternal nutrition on outcome of pregnancy: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; DIET; WOMEN	Objective To investigate the relations of maternal diet and smoking during pregnancy to placental and birth weights at term. Design Prospective cohort study. Setting District general hospital in the south of England. Participants 693 pregnant nulliparous white women with singleton pregnancies who were selected from antenatal booking clinics with stratified random sampling. Main outcome measures Birth and placental weights at term. Results Placental and birth weights were unrelated to the intake of any macronutrient Early in pregnancy, vitamin C was the only micronutrient independently associated with birth weight after adjustment for maternal height and smoking. Each In mg increase in vitamin C was associated with a 50.8 g (95% confidence interval 4.6 g to 97.0 g) increase in birth weight Vitamin C, vitamin E, and folate were each associated with placental weight after adjustment for maternal characteristics. In simultaneous regression, however, vitamin C was the only nutrient predictive of placental weight: each In mg increase in vitamin C was associated with a 3.2% (0.4 to 6.1) rise in placental weight No nutrient late in pregnancy was associated with either placental or birth weight. Conclusions Concern over the impact of maternal nutrition on the health of the infant has been premature, Maternal nutrition, at least in industrialised populations, seems to have only a small effect on placental and birth weights. Other possible determinants of fetal and placental growth should be investigated.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Mathews, F (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		li, tao/B-2402-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; Bingham SA, 1997, EUR J CANCER PREV, V6, P118; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BINGHAM SA, 1991, DESIGN CONCEPTS NUTR, P151; BOLLING K, 1997, SMOKING PREGNANCY SU; BOTTING B, 1993, POPULATION TRENDS, V74, P27; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; Foster K, 1997, INFANT FEEDING 1995; Fraser R, 1997, BRIT J OBSTET GYNAEC, V104, P645, DOI 10.1111/j.1471-0528.1997.tb11972.x; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; Gregory J., 1990, DIETARY NUTR SURVEY; HASTE FM, 1991, BRIT J NUTR, V65, P347, DOI 10.1079/BJN19910095; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; KRAMER MS, 1994, COCHRANE LIB; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V43, P461; MAHOMED K, 1993, COCHRANE LIB; Mathews F, 1996, NUTR RES REV, V9, P175, DOI 10.1079/NRR19960011; Mathews F, 1998, J HUM NUTR DIET, V11, P151, DOI 10.1046/j.1365-277X.1998.00085.x; MATHEWS F, IN PRESS ANN CLIN BI; Office of Population Censuses and Surveys, 1980, CLASS OCC; Robinson S, 1996, EUR J CLIN NUTR, V50, P302; RUSH D, 1989, EFFECTIVE CARE PREGN, P255; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Willett W, 1990, NUTR EPIDEMIOLOGY, P92	27	233	237	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					339	343		10.1136/bmj.319.7206.339	http://dx.doi.org/10.1136/bmj.319.7206.339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435950	Green Published, Bronze			2022-12-28	WOS:000082001700014
J	Mofenson, LM; Lambert, JS; Stiehm, ER; Bethel, J; Meyer, WA; Whitehouse, J; Moye, J; Reichelderfer, P; Harris, DR; Fowler, MG; Mathieson, BJ; Nemo, GJ				Mofenson, LM; Lambert, JS; Stiehm, ER; Bethel, J; Meyer, WA; Whitehouse, J; Moye, J; Reichelderfer, P; Harris, DR; Fowler, MG; Mathieson, BJ; Nemo, GJ		Pediat AIDS Clin Trials Grp Study 185 Team	Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	12th World AIDS Conference	JUN 28-JUL 03, 1998	GENEVA, SWITZERLAND				MOTHER-TO-CHILD; CLINICAL-TRIALS GROUP; MATERNAL VIRAL LOAD; VERTICAL TRANSMISSION; HIV-1 TRANSMISSION; INFECTION; INFANT; PREGNANCY; AIDS; PREDICTORS	Background Maternal, obstetrical, and infant-related factors associated with the risk of perinatal transmission of human immunodeficiency virus type 1 (HIV-1) were identified before the widespread use of zidovudine therapy in pregnant women. The risk factors for transmission when women and infants receive zidovudine are not well characterized. Methods We examined the effects of maternal, obstetrical, and infant-related characteristics and maternal virologic and immunologic variables on the risk of perinatal transmission of HIV-1 among 480 women and their infants, all of whom received zidovudine. The women and infants were participating in a phase 3 trial of passive immunoprophylaxis for the prevention of perinatal transmission. Results In univariate analyses, the risk of perinatal transmission was associated with each of the following: decreased maternal CD4+ lymphocyte counts at base line; decreased maternal HIV-1 p24 antibody levels at base line and delivery; increased maternal HIV-1 titer at base line and delivery; increased maternal HIV-1 RNA levels at base line and delivery; and the presence of chorioamnionitis at delivery. In multivariate analyses, the only independent risk factor was the maternal HIV-1 RNA level at base line (odds ratio for transmission, 2.4 per log increase in the number of copies; 95 percent confidence interval, 1.2 to 4.7; P = 0.02) and at delivery (odds ratio, 3.4; 95 percent confidence interval, 1.7 to 6.8; P = 0.001). There was no perinatal transmission of HIV-1 among the 84 women who had HIV-1 levels below the limit of detection (500 copies per milliliter) at base line or the 107 women who had undetectable levels at delivery. Conclusions Among pregnant women and their infants, all treated with zidovudine, the maternal plasma HIV-1 RNA level was the best predictor of the risk of perinatal transmission of HIV-1. Antiretroviral therapy that reduces the HIV-1 RNA level to below 500 copies per milliliter appears to minimize the risk of perinatal transmission as well as improve the health of the women. (N Engl J Med 1999;341:385-93.) (C) 1999, Massachusetts Medical Society.	NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Contracept & Reprod Hlth Branch, NIH, Bethesda, MD 20892 USA; NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA; NHLBI, Div Blood Dis & Resources, NIH, Bethesda, MD 20892 USA; Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; WESTAT Corp, Rockville, MD 20850 USA; Quest Diagnost, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Maryland; University of Maryland Baltimore; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Westat	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, NIH, 6100 Execut Blvd,Rm 4B11, Rockville, MD 20852 USA.	lm65d@nih.gov	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808; lambert, john/0000-0001-5404-2415; moye, john/0000-0001-9976-8586				ABRAMS EJ, 1995, PEDIATRICS, V96, P451; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; Bulterys M, 1997, J ACQ IMMUN DEF SYND, V15, P76, DOI 10.1097/00042560-199705010-00012; Burney TL, 1996, J ENDOUROL, V10, P273, DOI 10.1089/end.1996.10.273; BWAYO J, 1995, AM J OBSTET GYNECOL, V172, P700, DOI 10.1016/0002-9378(95)90597-9; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; Colgrove RC, 1998, AIDS, V12, P2281, DOI 10.1097/00002030-199817000-00009; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Contopoulos-Ioannidis DG, 1998, J ACQ IMMUN DEF SYND, V18, P126, DOI 10.1097/00042560-199806010-00004; CUMMINS LM, 1991, BLOOD, V77, P1111; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOSMER DW, 1989, APPL LOGISTIC REGRES; Ladner J, 1998, J ACQ IMMUN DEF SYND, V18, P293, DOI 10.1097/00042560-199807010-00015; Lambert JS, 1997, J INFECT DIS, V175, P283, DOI 10.1093/infdis/175.2.283; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; MOYE J, 1998, P 5 C RETR OPP INF C, P138; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; Newell ML, 1996, AIDS, V10, P1675; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Pitt J, 1997, J INFECT DIS, V175, P567, DOI 10.1093/infdis/175.3.567; *REC US PUBL HLTH, 1994, MMWR-MORBID MORTAL W, V43, P1; Ryan T., 1997, MODERN REGRESSION ME; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Thea DM, 1997, AIDS, V11, P437, DOI 10.1097/00002030-199704000-00006; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; Turner BJ, 1997, J ACQ IMMUN DEF SYND, V14, P327, DOI 10.1097/00042560-199704010-00004; *US PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Van Dyke RB, 1999, J INFECT DIS, V179, P319, DOI 10.1086/314580; Welles S., 1997, Clinical Infectious Diseases, V25, P358; Welsch R, 1980, REGRESSION DIAGNOSTI; 1998, MMWR MORB MORTAL WKL, V47, P619; 1998, MMWR MORB MORTAL WKL, V47, P43	43	372	385	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					385	393		10.1056/NEJM199908053410601	http://dx.doi.org/10.1056/NEJM199908053410601			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	223UN	10432323	Bronze			2022-12-28	WOS:000081860100001
J	Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ				Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ			The will to live among HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Medical-Decision-Making	OCT 25-29, 1997	HOUSTON, TX	Soc Med Decis Making			QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH STATES; VALUES; OUTCOMES; UTILITIES	Background: Patients infected with HIV value both longevity and health, Objective: To understand how HIV-infected patients value their health. Design: Interview study. Setting: Regional treatment center for HIV. Patients: 51 patients with HIV infection. Measurements: Life-satisfaction, health rating, time-tradeoff, and standard-gamble scores. Results: Of the 51 patients, 49% (95% CI, 35% to 63%) said that their life was better currently than it was before they contracted HIV infection; only 29% said that life was currently worse. The mean (+/- SD) time-tradeoff score was 0.95 +/- 0.10, indicating that, on average, patients would give up no more than 5% of their remaining life expectancy in their current state of health in exchange for a shorter but healthy life. The average health rating score was 71.0 +/- 18.7 on a scale of 0 to 100, and the average standard-gamble score was 0.80 +/- 0.27. Factors contributing to life satisfaction and time-tradeoff scores included spirituality and having children. Conclusion: Many patients with HIV have a strong will to live, and many feel that life with HIV is better than it was before they became infected.	Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Cincinnati, OH 45267 USA; SNS Res, Cincinnati, OH 45241 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, New Brunswick, NJ 08903 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	University System of Ohio; University of Cincinnati; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Massachusetts System; University of Massachusetts Boston	Tsevat, J (corresponding author), Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Box 670535, Cincinnati, OH 45267 USA.	Joel.Tsevat@uc.edu			AHRQ HHS [1 R01 HS 09103-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews F. M., 1976, SOCIAL INDICATORS WE; Carson V B, 1993, J Assoc Nurses AIDS Care, V4, P18; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Klitzman R., 1997, BEING POSITIVE LIVES; LAMPING DL, 1994, PSYCHOL HEALTH, V9, P31, DOI 10.1080/08870449408407458; OLEARY JF, 1995, MED DECIS MAKING, V15, P132, DOI 10.1177/0272989X9501500205; Owens DK, 1997, QUAL LIFE RES, V6, P77, DOI 10.1023/A:1026473613487; PEARSON SD, 1995, J GEN INTERN MED, V10, P557, DOI 10.1007/BF02640365; REVICKI DA, 1995, MED CARE, V33, pAS173; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; Wu AW, 1997, QUAL LIFE RES, V6, P531, DOI 10.1023/A:1018460132567	18	83	83	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					194	198		10.7326/0003-4819-131-3-199908030-00006	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	222ME	10428736				2022-12-28	WOS:000081788700005
J	Singh, A; Crockard, HA				Singh, A; Crockard, HA			Quantitative assessment of cervical spondylotic myelopathy by a simple walking test	LANCET			English	Article							SPINAL-CORD INJURY; RHEUMATOID-ARTHRITIS	Background We developed a 30 m walking test as a quantifiable measure of severity of cervical spondylotic myelopathy (CSM), which will be of use in determining the effects of decompressive surgical treatment. Methods Preoperative measurements were made in 41 patients with CSM of 30 m walking times, number of steps taken over this distance, myelopathy disability index (MDI), and Nurick scores. The walking factors were compared with a similar number of age-matched and sex-matched controls. The individuals in the study were patients with CSM and no other relevant pathology consecutively referred for decompressive surgery to the National Hospital for Neurology and Neurosurgery. Findings Both walking time and the number of steps taken were significantly worse in pre-operative patients than in controls. The walking data were highly reproducible over three trials. Postoperatively, there was a significant improvement in walking time (p=0.0018) and number of steps taken (p=5.87x10(-6)). Only two of 41 patients were worse postoperatively. There was also a significant improvement in MDI (two-tailed Wilcoxon, related samples; p<0.0001) and Nurick scores (two-tailed Wilcoxon p<0.0001) postoperatively. The preoperative and postoperative walking scores were significantly and equally correlated with the MDI and Nurick scores. Interpretation Timed walks are an easily performed, quantitative, and valid means of assessing CSM and the effects of surgery.	UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Crockard, HA (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, Queen Sq, London WC1N 3BG, England.	A.Crockard@ion.uci.ac.uk						ALLEN KL, 1952, J NEUROL NEUROSUR PS, V15, P20, DOI 10.1136/jnnp.15.1.20; BAKAY L, 1970, J NEUROL NEUROSUR PS, V33, P20; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Casey ATH, 1996, ANN RHEUM DIS, V55, P901, DOI 10.1136/ard.55.12.901; CLARKE E, 1956, BRAIN, V79, P483, DOI 10.1093/brain/79.3.483; DITUNNO JF, 1992, PARAPLEGIA, V30, P90, DOI 10.1038/sc.1992.31; DONOVAN WH, 1990, J NEURO REHAB, V4, P39; Dun-Rankin P., 1983, SCALING METHODS; GONZALEZFERIA L, 1975, ACTA NEUROCHIR, V31, P185, DOI 10.1007/BF01406291; HADLEY MN, 1995, PRINCIPLES SPINAL SU, P531; HERMANN J, 1994, ADV NEUROSURG, P266; HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; LINDSAY KW, 1991, NEUROLOGY NEUROSURGE, P373; NURICK S, 1972, BRAIN, V95, P87; RANAWAT CS, 1979, J BONE JOINT SURG AM, V61, P1003, DOI 10.2106/00004623-197961070-00006; ROGERS L, 1961, J NEUROSURG, V18, P490, DOI 10.3171/jns.1961.18.4.0490; ROGERS L, 1961, J BONE JOINT SURG BR, V43, P3, DOI 10.1302/0301-620X.43B1.3; SCOVILLE WB, 1961, J NEUROSURG, V18, P423, DOI 10.3171/jns.1961.18.4.0423; STREINER DI, 1996, MEASURING CHANGE HLT, P163; SYPERT GW, 1992, DISORDERS CERVICAL S, P407; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WATERS RL, 1991, PARAPLEGIA, V29, P573, DOI 10.1038/sc.1991.85	23	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					370	373		10.1016/S0140-6736(98)10199-X	http://dx.doi.org/10.1016/S0140-6736(98)10199-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437865				2022-12-28	WOS:000081764900011
J	Greenough, A				Greenough, A			Chronic lung disease of prematurity - prevention by inhaled corticosteroids?	LANCET			English	Editorial Material							METERED-DOSE INHALER; PRETERM; INFANTS; DEXAMETHASONE; STEROIDS; DELIVERY; AEROSOL		Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Greenough, A (corresponding author), Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, Denmark Hill, London SE5 9RS, England.							Arnon S, 1996, PEDIATR PULM, V21, P231; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; Cole CH, 1999, NEW ENGL J MED, V340, P1005, DOI 10.1056/NEJM199904013401304; Dimitriou G, 1997, EUR J PEDIATR, V156, P51; Fok TF, 1999, ARCH DIS CHILD-FETAL, V80, pF203, DOI 10.1136/fn.80.3.F203; Fok TF, 1997, PEDIATR PULM, V24, P204; Giep T, 1996, AM J PERINAT, V13, P5, DOI 10.1055/s-2007-994193; Greenough A, 1998, LANCET, V352, P835, DOI 10.1016/S0140-6736(05)60002-5; Groneck P, 1999, PEDIATR PULM, V27, P383, DOI 10.1002/(SICI)1099-0496(199906)27:6<383::AID-PPUL4>3.0.CO;2-V; HALLIDAY HL, DELAYED GREATER 3 WE; Kovacs L, 1998, ACTA PAEDIATR, V87, P792, DOI 10.1080/080352598750013905; Ng PC, 1998, J CLIN ENDOCR METAB, V83, P2390, DOI 10.1210/jc.83.7.2390; OCALLAGHAN C, 1992, ARCH DIS CHILD-FETAL, V67, P20, DOI 10.1136/adc.67.1_Spec_No.20	13	5	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					266	267		10.1016/S0140-6736(99)00176-2	http://dx.doi.org/10.1016/S0140-6736(99)00176-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440296				2022-12-28	WOS:000081646000002
J	Roberts, JM				Roberts, JM			Evolving ideas about cyclins	CELL			English	Review							S-PHASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; G(1) CYCLINS; KINASE; ACTIVATION; P34(CDC2); P27(KIP1); MITOSIS; ABSENCE		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Howard Hughes Med Inst, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Roberts, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98104 USA.							Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Levine K, 1996, MOL CELL BIOL, V16, P6794; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Oehlen LJWM, 1998, MOL GEN GENET, V258, P183, DOI 10.1007/s004380050722; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stern B, 1996, TRENDS GENET, V12, P345; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	18	137	140	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					129	132		10.1016/S0092-8674(00)81007-7	http://dx.doi.org/10.1016/S0092-8674(00)81007-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428024	Bronze			2022-12-28	WOS:000081632300002
J	Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R				Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R			Signal-regulated activation of serum response factor is mediated by changes in actin dynamics	CELL			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; FILAMENT TURNOVER; SWINHOLIDE-A; ZINC-FINGER; BINDING; VINCULIN; COFILIN; PROTEIN; KINASE	Serum response factor (SRF) regulates transcription of many serum-inducible and muscle-specific genes. Using a functional screen, we identified LIM kinase-l as a potent activator of SRF. We show that SRF activation by LIM kinase-l is dependent on its ability to regulate actin treadmilling. LIM kinase activity is not essential for SRF activation by serum, but signals depend on alterations in actin dynamics. Studies with actin-binding drugs, the actin-specific C2 toxin, and actin overexpression demonstrate that G-actin level controls SRF. Regulation of actin dynamics is necessary for serum induction of a subset of SRF target genes, including vinculin, cytoskeletal actin, and srf itself, and also suffices for their activation. Actin treadmilling provides a convergence point for both serum- and LIM kinase-1-induced signaling to SRF.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	treisman@icrf.icnet.uk	Sotiropoulos, Athanassia/P-4269-2017	Sotiropoulos, Athanassia/0000-0002-7265-1473; Treisman, Richard/0000-0002-9658-0067				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lyubimova A, 1997, J CELL BIOCHEM, V65, P469, DOI 10.1002/(SICI)1097-4644(19970615)65:4<469::AID-JCB3>3.0.CO;2-M; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; Reuner KH, 1996, BIOCHEM J, V319, P843, DOI 10.1042/bj3190843; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Saito S, 1998, J BIOCHEM-TOKYO, V123, P571; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHEVZOV G, 1995, DNA CELL BIOL, V14, P689, DOI 10.1089/dna.1995.14.689; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	53	558	566	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					159	169		10.1016/S0092-8674(00)81011-9	http://dx.doi.org/10.1016/S0092-8674(00)81011-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428028	Bronze			2022-12-28	WOS:000081632300006
J	Willis, KJ; Kleczkowski, A; Briggs, KM; Gilligan, CA				Willis, KJ; Kleczkowski, A; Briggs, KM; Gilligan, CA			The role of sub-Milankovitch climatic forcing in the initiation of the Northern Hemisphere glaciation	SCIENCE			English	Article							PROGRESSIVE INTENSIFICATION; CYCLES	Mechanisms responsible for the initiation of major glaciation in the Northern Hemisphere at about 2.75 million years ago are poorly understood. A Laminated terrestrial sequence from Pula maar, Hungary, containing about 320,000 years in annual Layers between 3.05 and 2.60 million years ago, provides a detailed record of rates of climatic change across this dramatic transition. An analysis of the record implies that climatic variations at sub-Milankovitch frequencies (less than or equal to 15,000 years) were an important driving force during this transitional interval and that, as the threshold was approached, these increased in frequency and amplitude, possibly providing the final trigger for the amplification of Northern Hemisphere ice sheets.	Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Godwin Inst Quaternary Res, Cambridge CB2 3EJ, England	University of Cambridge; University of Cambridge	Kleczkowski, A (corresponding author), Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England.		Kleczkowski, Adam/B-2016-2009	Kleczkowski, Adam/0000-0003-1384-4352; Willis, Katherine/0000-0002-6763-2489				Berger A, 1997, SCIENCE, V278, P1476, DOI 10.1126/science.278.5342.1476; HAGELBERG TK, 1994, PALEOCEANOGRAPHY, V9, P545, DOI 10.1029/94PA00443; HAJOS M, 1989, ANN REPORT HUNGARIAN, P5; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; KUKLA GJ, 1972, BOREAS, V1, P63; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; Li XS, 1998, GEOPHYS RES LETT, V25, P915, DOI 10.1029/98GL00443; Lourens LJ, 1997, QUATERN INT, V40, P43, DOI 10.1016/S1040-6182(96)00060-2; Maslin MA, 1998, QUATERNARY SCI REV, V17, P411, DOI 10.1016/S0277-3791(97)00047-4; Maslin MA, 1996, GEOL RUNDSCH, V85, P452, DOI 10.1007/BF02369002; PERCIVAL DB, 1993, SPECTRAL ANAL PHYSIC; RAVASZ C, 1974, ANN REP HUNG STATE G, P221; RAYMO ME, 1988, GEOLOGY, V16, P649, DOI 10.1130/0091-7613(1988)016<0649:IOLCMB>2.3.CO;2; RUDDIMAN WF, 1989, J GEOPHYS RES-ATMOS, V94, P18409, DOI 10.1029/JD094iD15p18409; Shackleton N.J., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P337, DOI 10.2973/odp.proc.sr.138.117.1995; Willis KJ, 1999, NATURE, V397, P685, DOI 10.1038/17783	16	32	37	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					568	571		10.1126/science.285.5427.568	http://dx.doi.org/10.1126/science.285.5427.568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417383				2022-12-28	WOS:000081609500033
J	Lucas, GM; Chaisson, RE; Moore, RD				Lucas, GM; Chaisson, RE; Moore, RD			Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions	ANNALS OF INTERNAL MEDICINE			English	Article						anti-HIV agents; protease inhibitors; RNA, viral; CD4 lymphocytecount; urban health services	HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA HIV-1 RNA; PROTEASE INHIBITORS; TYPE-1 RNA; INFECTION; PROGRESSION; DISEASE; PREDICTORS; INDINAVIR; ADHERENCE	Background: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection. The performance of such therapy outside of the clinical trial setting is unclear. Objective: To determine factors associated with failure to suppress HIV-1 RNA levels and adverse drug reactions in a cohort of patients in whom protease inhibitor-containing therapy was begun in a large urban clinic. Design: Retrospective cohort study. Setting: Johns Hopkins HIV Clinic in Baltimore, Maryland. Patients: 273 protease inhibitor-naive patients began taking a protease inhibitor regimen containing at least one other antiretroviral drug to which the patients had not previously been exposed. Measurements: Demographic variables, plasma HIV-1 RNA levels, CD4(+) lymphocyte counts, and adverse drug reactions. Results: Levels of HIV-1 RNA were undetectable in 42% of the cohort at 1 to 90 days, in 44% at 3 to 7 months, and in 37% at 7 to 14 months. Factors associated with failure to suppress viral load at two or more time points included higher rates of missed clinic appointments, nonwhite ethnicity, age 40 years or younger, injection drug use, lower baseline CD4(+) lymphocyte count, and higher baseline viral load. In a multivariate model, only higher rates of missed clinic appointments were independently associated with viral suppression at 1 year. Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or nelfinavir, and women experienced significantly more adverse effects than men. Conclusions: Unselected patients in whom HAART is started in a clinic setting achieve viral suppression substantially less frequently than do patients in controlled clinical trials. Missed clinic visits were the most important risk factor for failure to suppress HIV-l RNA levels. Studies are needed to identify interventions that maximize the performance of HAART in inner-city clinics.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University	Moore, RD (corresponding author), 1830 E Monument St,Room 8059, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA11602] Funding Source: Medline; PHS HHS [R01-H507809] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CLUMECK N, 1998, 5 C RETR OPP INF FEB, P386; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEEKS S, 1998, 5 C RETR OPP INF FEB, P419; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Drusano GL, 1998, J INFECT DIS, V178, P360, DOI 10.1086/515631; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; KAHN J, 1998, 5 C RETR OPP INF CHI, P208; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KISSINGER P, 1995, J NATL MED ASSOC, V87, P19; LEVINE AM, 1987, J CLIN ONCOL, V5, P1469, DOI 10.1200/JCO.1987.5.9.1469; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *ROCH LAB, 1997, INV SAQ MES CAPS PRO; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAG M, 1997, INF DIS SOC AM 35 AN, P112; TURNER J, 1995, CHEST, V108, P394, DOI 10.1378/chest.108.2.394; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; WOOD PR, 1985, ANN ALLERGY, V54, P400	31	689	713	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					81	+		10.7326/0003-4819-131-2-199907200-00002	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419445				2022-12-28	WOS:000081509700001
J	Meyers, EN; Martin, GR				Meyers, EN; Martin, GR			Differences in left-right axis pathways in mouse and chick: Functions of FGF8 and SHH	SCIENCE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; PITX2; EMBRYOGENESIS; EXPRESSION; XENOPUS; EMBRYOS; GENE; MORPHOGENESIS	A molecular pathway leading to left-right asymmetry in the chick embryo has been described, in which FGF8 is a right determinant and Sonic Hedgehog a left determinant. Here evidence is presented that the Fgf8 and Sonic Hedgehog genes are required for left-right axis determination in the mouse embryo, but that they have different functions from those previously reported in the chick. In the mouse FGF8 is a left determinant and Sonic Hedgehog is required to prevent left determinants from being expressed on the right.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.	gmartin@itsa.ucsf.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001216, R01HD034380] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01216, R01 HD34380] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Dufort D, 1998, DEVELOPMENT, V125, P3015; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MEYERS EN, UNPUB; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; STURM K, 1993, METHOD ENZYMOL, V225, P164; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	252	256	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					403	406		10.1126/science.285.5426.403	http://dx.doi.org/10.1126/science.285.5426.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411502				2022-12-28	WOS:000081465900053
J	Platt, ML; Glimcher, PW				Platt, ML; Glimcher, PW			Neural correlates of decision variables in parietal cortex	NATURE			English	Article							REPRESENTATION; INTENTION; SELECTION; MEMORY; MONKEY	Decision theory proposes that humans and animals decide what to do in a given situation by assessing the relative value of each possible response, This assessment can be computed, in part, from the probability that each action will result In a gain and the magnitude of the gain expected, Here we show that the gain (or reward) a monkey can expect to realize from an eye-movement response modulates the activity of neurons in the lateral intraparietal area, an area of primate cortex that is thought to transform visual signals into eye-movement commands, We also show that the activity of these neurons is sensitive to the probability that a particular response will result in a gain, When animals can choose freely between two alternative responses, the choices subjects make and neuronal activation in this area are both correlated with the relative amount of gain that the animal can expect from each response. Our data indicate that a decision-theoretic model may provide a powerful new framework for studying the neural processes that intervene between sensation and action.	NYU, Ctr Neural Sci, New York, NY 10003 USA	New York University	Platt, ML (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	mplatt@cns.nyu.edu						ARNAULD A, 1982, ART THINKING PORT RO; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35, DOI 10.1152/jn.1967.30.1.35; Basso MA, 1997, NATURE, V389, P66, DOI 10.1038/37975; Bechara A, 1998, J NEUROSCI, V18, P428; BERNOULLI D, 1982, WORKS; Bernstein Nikolai, 1984, HUMAN MOTOR ACTIONS, P77, DOI DOI 10.1016/S0166-4115(08)61370-9; Bracewell RM, 1996, J NEUROPHYSIOL, V76, P1457, DOI 10.1152/jn.1996.76.3.1457; CATANIA AC, 1963, J EXP ANAL BEHAV, V6, P299, DOI 10.1901/jeab.1963.6-299; DAVENPORT JW, 1966, PSYCHON SCI, V4, P187; Descartes R., 1972, TREATISE MAN; DEVILLIERS PA, 1976, PSYCHOL BULL, V83, P1131, DOI DOI 10.1037/0033-2909.83.6.1131; Dorris MC, 1998, J NEUROSCI, V18, P7015; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267; HERRNSTEIN RJ, 1980, ALLOCATION INDIVIDUA, P143; Kahneman D., 1982, JUDGEMENT UNCERTAINT; KREBS JR, 1978, NATURE, V275, P27, DOI 10.1038/275027a0; Pavlov I.P., 1927, CONDITIONED REFLEXES; Penfield W., 1975, MYSTERY MIND CRITICA; Platt M. L., 1997, Society for Neuroscience Abstracts, V23, P16; Platt ML, 1997, J NEUROPHYSIOL, V78, P1574, DOI 10.1152/jn.1997.78.3.1574; PLATT ML, 1998, INVEST OPHTH VIS SCI, V39, P326; PYKE GH, 1977, Q REV BIOL, V52, P137, DOI 10.1086/409852; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; Schoener T. W., 1971, A Rev Ecol Syst, V2, P369, DOI 10.1146/annurev.es.02.110171.002101; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Sherrington C, 1906, INTEGRATIVE ACTION N; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STADDON JER, 1978, PSYCHOL REV, V85, P436, DOI 10.1037/0033-295X.85.5.436; Stephens D.W., 1986, pi; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; von Holst E, 1973, BEHAV PHYSL ANIMALS; WEISS PAUL, 1941, COMPAR PSYCHOL MONOGR, V17, P1	37	1139	1151	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					233	238		10.1038/22268	http://dx.doi.org/10.1038/22268			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	217MP	10421364				2022-12-28	WOS:000081503800035
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Prescribing for seniors - Neither too much nor too little	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; REPLACEMENT; WOMEN		Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; University of Toronto	Rochon, PA (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Barakat K, 1999, LANCET, V353, P955, DOI 10.1016/S0140-6736(98)07114-1; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Handa VL, 1996, J AM GERIATR SOC, V44, P1; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MYERS MG, 1995, GUIDELINES TREATMENT; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spurgeon D, 1999, BRIT MED J, V318, P961, DOI 10.1136/bmj.318.7189.961b; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111; TAMBLYN R, 1999, EVALUATION IMPACT RE	24	90	94	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					113	115		10.1001/jama.282.2.113	http://dx.doi.org/10.1001/jama.282.2.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411177				2022-12-28	WOS:000081376800002
J	Cleaver, JC				Cleaver, JC			Biomedicine - Stopping DNA replication in its tracks	SCIENCE			English	Editorial Material							XERODERMA-PIGMENTOSUM; REPAIR; BYPASS; CELLS		Univ Calif San Francisco, Dept Dermatol & Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cleaver, JC (corresponding author), Univ Calif San Francisco, Dept Dermatol & Pharmaceut Chem, Box 0808, San Francisco, CA 94143 USA.							Cleaver JE, 1999, CANCER RES, V59, P1102; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WOOD RD, 1997, J BIOL CHEM, V272, P23456; WOODGATE R, COMMUNICATION	13	21	21	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					212	213		10.1126/science.285.5425.212	http://dx.doi.org/10.1126/science.285.5425.212			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10428720				2022-12-28	WOS:000081346000030
J	Magee, T; Marshall, C				Magee, T; Marshall, C			New insights into the interaction of Ras with the plasma membrane	CELL			English	Review							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; CELL-MEMBRANES; PROTEINS; SIGNAL; RAFTS; CAAX		Natl Inst Med Res, Div Membrane Biol, London NW7 1AA, England; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	MRC National Institute for Medical Research; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Magee, T (corresponding author), Natl Inst Med Res, Div Membrane Biol, Ridgeway,Mill Hill, London NW7 1AA, England.		Magee, Anthony/V-8345-2019					Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bijlmakers MJJE, 1999, J CELL BIOL, V145, P457, DOI 10.1083/jcb.145.3.457; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	20	129	132	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					9	12		10.1016/S0092-8674(00)80601-7	http://dx.doi.org/10.1016/S0092-8674(00)80601-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412976	Bronze			2022-12-28	WOS:000081451000003
J	Larner, AJ; Farmer, SF				Larner, AJ; Farmer, SF			Recent advances - Neurology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PLACEBO-CONTROLLED TRIAL; REMITTING MULTIPLE-SCLEROSIS; ADVANCED PARKINSONS-DISEASE; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; ALZHEIMERS-DISEASE; EPILEPSY; LEVODOPA; EFFICACY; STIMULATION		St Marys Hosp, Dept Neurol, London W2 1NY, England	Imperial College London	Farmer, SF (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	s.farmer@ion.ucl.ac.uk	Farmer, Simon F/D-1969-2012	Farmer, Simon F/0000-0001-5193-8195				Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; Appleton RE, 1998, BRIT MED J, V317, P1322, DOI 10.1136/bmj.317.7168.1322; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Association of British Neurologists, 1997, NEUR UK 2000; Baas H, 1997, J NEUROL NEUROSUR PS, V63, P421, DOI 10.1136/jnnp.63.4.421; Barnes D, 1997, LANCET, V349, P902, DOI 10.1016/S0140-6736(96)06453-7; Benavente O, 1998, BMJ-BRIT MED J, V317, P1477, DOI 10.1136/bmj.317.7171.1477; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Ferrari MD, 1998, LANCET, V351, P1043, DOI 10.1016/S0140-6736(97)11370-8; Fowler CJ, 1996, J NEUROL NEUROSUR PS, V60, P6, DOI 10.1136/jnnp.60.1.6; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hughes RAC, 1997, LANCET, V349, P225; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Larner AJ, 1997, EXPERT OPIN THER PAT, V7, P1115, DOI 10.1517/13543776.7.10.1115; Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; LI LM, 1995, J NEUROL NEUROSUR PS, V59, P384, DOI 10.1136/jnnp.59.4.384; Lieberman A, 1997, NEUROLOGY, V49, P162, DOI 10.1212/WNL.49.1.162; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Marson AG, 1996, BMJ-BRIT MED J, V313, P1169, DOI 10.1136/bmj.313.7066.1169; McLachlan RS, 1997, J CLIN NEUROPHYSIOL, V14, P358, DOI 10.1097/00004691-199709000-00002; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; Nohria V, 1997, EUR J NEUROL, V4, P537, DOI 10.1111/j.1468-1331.1997.tb00403.x; Noseworthy JH, 1997, CURR OPIN NEUROL, V10, P201, DOI 10.1097/00019052-199706000-00006; O'Riordan JI, 1998, BRAIN, V121, P495, DOI 10.1093/brain/121.3.495; Quinn N, 1998, BRIT MED J, V316, P1259, DOI 10.1136/bmj.316.7140.1259; Rinne UK, 1997, NEUROLOGY, V48, P363, DOI 10.1212/WNL.48.2.363; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Sandercock P, 1997, LANCET, V349, P1569; Stocchi F, 1997, CLIN NEUROPHARMACOL, V20, P95, DOI 10.1097/00002826-199704000-00001; *UK TIZ TRIAL GROU, 1994, NEUROLOGY S9, V44, pS70; Wardlaw JM, 1997, LANCET, V350, P607, DOI 10.1016/S0140-6736(97)03022-5; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wills AJ, 1998, EUR NEUROL, V39, P3, DOI 10.1159/000007891	44	16	16	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	1999	319	7206					362	366		10.1136/bmj.319.7206.362	http://dx.doi.org/10.1136/bmj.319.7206.362			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435961	Green Published			2022-12-28	WOS:000082001700022
J	Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL				Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL			Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article							MEASLES; RUBELLA		Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland; Kantonsspital, Dept Med, CH-9007 St Gallen, Switzerland; Kantonsspital, Emergency Dept, CH-9007 St Gallen, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Vernazza, PL (corresponding author), Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland.							ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; D'Argenio P, 1998, VACCINE, V16, P818, DOI 10.1016/S0264-410X(97)00270-3; *EXP PROGR IMM, 1993, WKLY EPIDEMIOL REC, V68, P83; Germann D, 1996, SCAND J INFECT DIS, V28, P235, DOI 10.3109/00365549609027163; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					352	353		10.1136/bmj.319.7206.352	http://dx.doi.org/10.1136/bmj.319.7206.352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435956	Bronze, Green Published			2022-12-28	WOS:000082001700019
J	Aronson, J				Aronson, J			Allergy and immunity	BRITISH MEDICAL JOURNAL			English	Article																		Aronson J, 1998, MED HIST, V42, P404, DOI 10.1017/S0025727300064188; BLACKWELL, 1963, CLINICAL ASPECTS IMM, P317; VON PIRQUET, 1906, MUNCHEN MED WOCHEN, V30, P1457	3	0	0	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					308	308		10.1136/bmj.319.7205.308	http://dx.doi.org/10.1136/bmj.319.7205.308			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426752	Green Published			2022-12-28	WOS:000081909100035
J	Bodke, AS; Olschki, DA; Schmidt, LD; Ranzi, E				Bodke, AS; Olschki, DA; Schmidt, LD; Ranzi, E			High selectivities to ethylene by partial oxidation of ethane	SCIENCE			English	Article							SN/PT(111) SURFACE ALLOYS; CHEMISORPTION	At least 85 percent selectivity to ethylene at greater than 70 percent conversion can be obtained by partial oxidation of ethane by adding Large amounts of H-2 to the reaction mixture and using a platinum-tin catalyst operating at 950 degrees C with a contact time of similar to 10(-3) seconds. This system almost totally shuts off the reactions that form undesired CO and CO2, which fall from 20 percent without H-2 to 5 percent when H-2 is added. Although a 2/1 H-2/O-2 mixture should be explosive at high temperatures, no flames or explosions occur in the presence of ethane. The successive reactions on the catalyst generate more H-2 than used in the feed, so with recycle no additional H-2 would be needed. These results are unexpected because ethylene is a nonequilibrium product and entropy considerations argue that all reaction channels open at high temperatures so the products should approach equilibrium, which predicts only a few percent ethylene. This process is promising for the replacement of steam cracking in the production of ethylene.	Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Politecn Milan, Dipartimento Chim Ind & Ingn Chim, I-20133 Milan, Italy	University of Minnesota System; University of Minnesota Twin Cities; Polytechnic University of Milan	Schmidt, LD (corresponding author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.		Ranzi, Eliseo/L-2366-2013	Ranzi, Eliseo/0000-0002-1395-6074				Astbury J. C., 1995, Patent, Patent No. [US5382741, 5382741]; BIELANSKI A, 1991, OXYGEN CATALYSIS; HUFF M, 1993, J PHYS CHEM-US, V97, P11815, DOI 10.1021/j100147a040; Kirk-Othmer, 1991, ENC CHEM TECHN, V12; KUNG H H., 1989, TRANSITION METAL OXI, P112; PAFFETT MT, 1990, J PHYS CHEM-US, V94, P6831, DOI 10.1021/j100380a053; PAFFETT MT, 1989, SURF SCI, V223, P449, DOI 10.1016/0039-6028(89)90673-0; Ranzi E, 1997, COMBUST FLAME, V108, P24, DOI 10.1016/S0010-2180(95)00274-X; Yokoyama C, 1996, CATAL LETT, V38, P181, DOI 10.1007/BF00806566; 1997, CATAL TODAY, V157	10	204	213	2	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					712	715		10.1126/science.285.5428.712	http://dx.doi.org/10.1126/science.285.5428.712			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426988				2022-12-28	WOS:000081765100047
J	Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O				Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O			Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall	SCIENCE			English	Article							GRAM-POSITIVE BACTERIA; RESISTANCE; EXPRESSION; VANCOMYCIN	Surface proteins of Gram-positive bacteria are linked to the bacterial cell wall by a mechanism that involves cleavage of a conserved Leu-Pro-X-Thr-Gly (LPXTG) motif and that occurs during assembly of the peptidoglycan cell wall. A Staphylococcus aureus mutant defective in the anchoring of surface proteins was isolated and shown to carry a mutation in the srtA gene. Overexpression of srtA increased the rate of surface protein anchoring, and homologs of srtA were found in other pathogenic Gram-positive bacteria. The protein specified by srtA, sortase, may be a useful target for the development of new antimicrobial drugs.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Mazmanian, Sarkis/ABD-7729-2021; Ton-That, Hung/AAB-6155-2020	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 07323, AI33987] Funding Source: Medline; NIGMS NIH HHS [T32GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger-Bachi Brigitte, 1994, Trends in Microbiology, V2, P389, DOI 10.1016/0966-842X(94)90617-3; BOOTHBY D, 1971, ANAL BIOCHEM, V44, P645, DOI 10.1016/0003-2697(71)90255-7; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; STROMING.JL, 1973, JOHNS HOPKINS MED J, V133, P63; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; TONTHAT H, IN PRESS J BIOL CHEM; UHLEN M, 1984, J BACTERIOL, V159, P713; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747	20	746	814	1	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					760	763		10.1126/science.285.5428.760	http://dx.doi.org/10.1126/science.285.5428.760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427003				2022-12-28	WOS:000081765100062
J	Bower, B				Bower, B			David Fillmer Alexander - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					261	261		10.1136/bmj.319.7204.261	http://dx.doi.org/10.1136/bmj.319.7204.261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417111	Green Published			2022-12-28	WOS:000081720300062
J	Young, NS				Young, NS			Acquired aplastic anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; ANTITHYMOCYTE GLOBULIN; MALIGNANT-TUMORS; GRAFT; CYCLOSPORINE; ADULTS; CYCLOPHOSPHAMIDE; SUSCEPTIBILITY; TRANSFUSION		NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Young, NS (corresponding author), NHLBI, Hematol Branch, NIH, Bldg 10,Room 7C103,9000 Rockville Pike, Bethesda, MD 20892 USA.	youngn@gwgate.nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002315, Z01HL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; Bacigalupo A, 1998, BLOOD, V92, p158A; BACIGALUPO A, 1994, EBMT WORKING PARTIES, P49; BACIGALUPO A, 1989, CLIN HAEMATOL, V2, P19; BACIGALUPO A, IN PRESS SEMIN HEMAT; Ball SE, 1998, BLOOD, V91, P3582; Bessho M, 1997, EUR J HAEMATOL, V58, P265; BIELORY L, 1988, MEDICINE, V67, P40, DOI 10.1097/00005792-198801000-00003; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Brown KE, 1997, NEW ENGL J MED, V336, P1059, DOI 10.1056/NEJM199704103361504; CAMITTA BM, 1979, BLOOD, V53, P504; CHAMPLIN RE, 1989, BLOOD, V73, P606; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1998, BLOOD, V91, P3637; DUNN DE, 1998, BLOOD S1, V92, P15; Ehrlich P, 1888, CHARITE ANN, V13, P300; GARDNER FH, 1987, BRIT J HAEMATOL, V65, P295, DOI 10.1111/j.1365-2141.1987.tb06856.x; Genestier L, 1998, BLOOD, V91, P2360, DOI 10.1182/blood.V91.7.2360.2360_2360_2368; GERSON WT, 1983, BLOOD, V61, P889; Gluckman E, 1998, BLOOD, V92, p376A; Hinterberger W, 1997, ANN INTERN MED, V126, P116, DOI 10.7326/0003-4819-126-2-199701150-00004; IMASHUKU S, 1994, BLOOD, V84, P2380; *INT AGR APL AN ST, 1990, DRUG ET AGR APL AN; ISSARAGRISIL S, IN PRESS AM J HEMATO; Kaito K, 1998, BRIT J HAEMATOL, V103, P297, DOI 10.1046/j.1365-2141.1998.01014.x; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Killick SB, 1997, BRIT J HAEMATOL, V97, P677, DOI 10.1046/j.1365-2141.1997.812721.x; KOJIMA S, 1994, BLOOD, V83, P1474; KURZROCK R, 1997, BLOOD S, V90, P173; LEWIS CN, 1952, ANTIBIOT CHEMOTHER, V2, P601; Maciejewski JP, 1996, BLOOD, V88, P1983, DOI 10.1182/blood.V88.6.1983.bloodjournal8861983; Margolis D, 1996, BRIT J HAEMATOL, V94, P65, DOI 10.1046/j.1365-2141.1996.d01-1772.x; MARMONT AM, 1993, LEUKEMIA LYMPHOMA, V11, P221, DOI 10.3109/10428199309047890; MARSH JCW, 1994, LANCET, V344, P172, DOI 10.1016/S0140-6736(94)92763-4; MATHE G, 1970, BMJ-BRIT MED J, V2, P131, DOI 10.1136/bmj.2.5702.131; Merion RM, 1998, TRANSPLANTATION, V65, P1481, DOI 10.1097/00007890-199806150-00013; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; NAJEAN Y, 1990, BLOOD, V76, P2222; NAKAO S, 1994, BLOOD, V84, P4257, DOI 10.1182/blood.V84.12.4257.bloodjournal84124257; NIMER SD, 1994, BLOOD, V84, P923; RAGHAVACHAR A, 1997, BLOOD S1, V90, P439; RINGER R, 1994, NY TIMES        1005, pD4; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SANTESSON CG, 1897, ARCH HYG BERL, V31, P336; SHARPE WD, 1993, B NEW YORK ACAD MED, V69, P47; SLOAND E, 1998, BLOOD S1, V92, P158; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; Tsai TW, 1997, ADV INTERNAL MED, V42, P423; Vaquez MH, 1904, B MEM SOC MED HOP P, V21, P288; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WOLK A, 1998, BLOOD S1, V10, P158; YANG C, 1991, Chinese Medical Sciences Journal, V6, P203; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367	57	56	60	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					271	278		10.1001/jama.282.3.271	http://dx.doi.org/10.1001/jama.282.3.271			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422997				2022-12-28	WOS:000081504400034
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1963: Sir Alan Lloyd Hodgkin (1914-98), Sir Andrew Fielding Huxley (b 1917), and Sir John Carew Eccles (1903-97)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	2	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					263	263		10.1016/S0140-6736(05)66341-6	http://dx.doi.org/10.1016/S0140-6736(05)66341-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421343				2022-12-28	WOS:000081504200069
J	Richardson, MK; Reiss, MJ				Richardson, MK; Reiss, MJ			What does the human embryo look like, and does it matter?	LANCET			English	Editorial Material							GENES		St George Hosp, Sch Med, Dept Anat & Dev Biol, London SW17 0RE, England; Hommerton Coll, Cambridge, England	St Georges University London; University of Cambridge	Richardson, MK (corresponding author), St George Hosp, Sch Med, Dept Anat & Dev Biol, Cranmer Terrace, London SW17 0RE, England.		Richardson, Michael K/E-8269-2011; Reiss, Michael Jonathan/P-8205-2017	Richardson, Michael K/0000-0003-1222-8101; Reiss, Michael Jonathan/0000-0003-1207-4229				BURKE AC, 1995, DEVELOPMENT, V121, P333; CAVALIERI P, 1993, GREAT APE PROJECT EQ; DEVINE PE, 1984, PROBLEM ABORTION, P21; EISENBERG A, 1993, WHAT EXPECT WHEN YOU, P88; Gould S. J., 1977, ONTOGENY PHYLOGENY; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; GRISEZ G, 1992, ABORTION NEW GENERAT, P1; GUTUMACHER AF, 1986, PREGNANCY BIRTH FAMI, P58; KITZINGER S, 1997, NEW PREGNANCY CHILDB, P69; Morowitz H. J., 1992, FACTS LIFE SCI ABORT; O'Rahilly R., 1987, CARNEGIE I PUBLICATI, V637; Oderberg DS, 1997, PHILOS PUBLIC AFF, V26, P259, DOI 10.1111/j.1088-4963.1997.tb00055.x; Reichlin M, 1997, BIOETHICS, V11, P1, DOI 10.1111/1467-8519.00041; Richardson MK, 1999, BIOESSAYS, V21, P604, DOI 10.1002/(SICI)1521-1878(199907)21:7<604::AID-BIES9>3.0.CO;2-U; Sagan C., 1977, DRAGONS EDEN; Sagan Carl, 1998, BILLIONS BILLIONS TH; SCHER J, 1985, PREGNANCY EVERYTHING; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Slack JMW, 1983, EGG EMBRYO DETERMINA; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Strachan T., 1997, MOL GENETICS EARLY H; Tautz D, 1998, PHILOS T ROY SOC B, V353, P231, DOI 10.1098/rstb.1998.0205; VieilleGrosjean I, 1997, DEV BIOL, V183, P49, DOI 10.1006/dbio.1996.8450; Watt H, 1996, J MED ETHICS, V22, P222, DOI 10.1136/jme.22.4.222; WATT H, IN PRESS LIFE DEATH	25	2	2	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					246	248		10.1016/S0140-6736(98)11481-2	http://dx.doi.org/10.1016/S0140-6736(98)11481-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421320				2022-12-28	WOS:000081504200044
J	Aranda-Espinoza, H; Chen, Y; Dan, N; Lubensky, TC; Nelson, P; Ramos, L; Weitz, DA				Aranda-Espinoza, H; Chen, Y; Dan, N; Lubensky, TC; Nelson, P; Ramos, L; Weitz, DA			Electrostatic repulsion of positively charged vesicles and negatively charged objects	SCIENCE			English	Article								A positively charged, mixed bilayer vesicle in the presence of negatively charged surfaces (for example, colloidal particles) can spontaneously partition into an adhesion zone of definite area and another zone that repels additional negative objects, Although the membrane itself has nonnegative charge in the repulsive zone, negative counterions on the interior of the vesicle spontaneously aggregate there and present a net negative charge to the exterior. Beyond the fundamental result that oppositely charged objects can repel, this mechanism helps to explain recent experiments on surfactant vesicles.	Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Univ Delaware, Dept Chem Engn, Newark, DE 19716 USA; Univ Montpellier 2, Dynam Phases Condensees Grp, F-34095 Montpellier 05, France	University of Pennsylvania; University of Delaware; Universite de Montpellier	Nelson, P (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.		Nelson, Philip C/I-6251-2015; ramos, laurence/C-4610-2013	Nelson, Philip C/0000-0002-1782-3076; 				Chen Y, UNPUB; Gelbart WM, 1997, PHYS REV E, V55, P831, DOI 10.1103/PhysRevE.55.831; GENIS RB, 1989, BIOMEMBRANES; GULDBRAND L, 1984, J CHEM PHYS, V80, P2221, DOI 10.1063/1.446912; Nardi J, 1998, PHYS REV E, V58, P6340, DOI 10.1103/PhysRevE.58.6340; NOSSAL RJ, 1991, MOL CELL BIOPHYSICS; PARSEGIAN VA, 1972, BIOPHYS J, V12, P1192, DOI 10.1016/S0006-3495(72)86155-1; RAMOS L, UNPUB; Rouzina I, 1996, J PHYS CHEM-US, V100, P9977, DOI 10.1021/jp960458g; Safran S. A., 1994, STAT THERMODYNAMICS	10	58	59	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					394	397		10.1126/science.285.5426.394	http://dx.doi.org/10.1126/science.285.5426.394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411499	Green Submitted			2022-12-28	WOS:000081465900050
J	Roush, S; Birkhead, G; Koo, D; Cobb, A; Fleming, D				Roush, S; Birkhead, G; Koo, D; Cobb, A; Fleming, D			Mandatory reporting of diseases and conditions by health care professionals and laboratories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVEILLANCE	Context Surveillance is a key component of the core public health function of health assessment. Systematic reporting by health care professionals and laboratories, which may vary by state law, statute, or regulation, continues to provide essential data for assessing public health. Objective To describe the state and territorial reporting requirements for diseases and conditions recommended for national public health surveillance. Design, Setting, and Participants Between May and August 1997, the state and territorial epidemiologists from all 50 states, in addition to New York City, Puerto Rico, and Guam, completed questionnaires indicating which diseases and conditions were reportable by health care professionals and laboratories in their jurisdictions, The surveys were subsequently updated to reflect reporting requirements current as of January 1, 1999. The overall response rate for the survey was 100% for US states and 90% overall, including the territories. Main Outcome Measure State and territorial reporting requirements for diseases and conditions of public health concern. Results Of the 58 diseases and conditions recommended for national reporting, 35 (60%) were reportable in greater than 90% of the states and territories, 15 (26%) were reportable in 75% to 90%, and 8 (14%)were reportable in less than 75%. Nineteen of the infectious diseases were reportable in all of the states and territories that responded. Conclusions Required reporting varies substantially by state or territory. Health care professionals are integral to public health efforts at the local, state, and national levels.	Ctr Dis Control & Prevent, Natl Immunizat Program, Child Vaccine Preventable Dis Branch, Council State & Terr Epidemiologists, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Oregon State Dept Hlth, Portland, OR USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Roush, S (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, Child Vaccine Preventable Dis Branch, Council State & Terr Epidemiologists, MS E-61,1600 Clifton Rd, Atlanta, GA 30333 USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560				[Anonymous], 1990, MMWR Recomm Rep, V39, P1; BIRKHEAD GS, 1996, J PUBLIC HLTH MANAGE, V3, P7; *CDCP, 1997, MMWR CDC SURVEILL SU, V46; *CDCP, 1989, MMWR CDC SURVEILL SU, V38; *CDCP, 1993, MMWR CDC SURVEILL SU, V42; *CDCP, 1988, MMWR CDC SURVEILL SU, V37; *CDCP, 1997, HISSB EL LAB REP M M; *CDCP, 1994, MMWR CDC SURVEILL SU, V43; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, pR2; *CDCP, 1990, MMWR CDC SURVEILL SU, V39; *CDCP, 1988, MMWR-MORBID MORTAL W, V37, P8; *CDCP, 1995, MMWR CDC SURVEILL SU, V44; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHORBA TL, 1989, JAMA-J AM MED ASSOC, V262, P3018, DOI 10.1001/jama.262.21.3018; *COUNC STAT TERR E, 1996, CSTE NAT M JUN 2 POR; *COUNC STAT TERR E, 1994, NAT PUBL HLTH SURV M; *COUNC STAT TERR E, 1909, CSTE NAT M MAY 15 AU; Klevens RM, 1997, J ACQ IMMUN DEF SYND, V14, P56, DOI 10.1097/00042560-199701010-00009; Koo D, 1996, J Public Health Manag Pract, V2, P4; *LEW GROUP, 1997, PUBL HLTH LAB HLTH S; Meriwether R A, 1996, J Public Health Manag Pract, V2, P16; Seta J A, 1985, MMWR CDC Surveill Summ, V34, p15SS; TEUTSCH SM, 1994, PRINCIPLES PRACTICE, P31; THACKER SB, 1988, EPIDEMIOL REV, V10, P164, DOI 10.1093/oxfordjournals.epirev.a036021; THACKER SB, 1994, PRINCIPLES PRACTICE, P3; Vogt R L, 1996, J Public Health Manag Pract, V2, P28	26	96	103	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					164	170		10.1001/jama.282.2.164	http://dx.doi.org/10.1001/jama.282.2.164			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411198	Bronze			2022-12-28	WOS:000081376800034
J	Owen, MJ; Cardno, AG				Owen, MJ; Cardno, AG			Psychiatric genetics: progress, problems, and potential	LANCET			English	Article							T102C POLYMORPHISM; SCHIZOPHRENIA; ASSOCIATION; DISEASE; METAANALYSIS; FAMILIES; GENOME; TRAITS; ONSET; AGE		Univ Wales, Coll Med, Div Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Univ Wales, Coll Med, Div Med Genet, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University	Owen, MJ (corresponding author), Univ Wales, Coll Med, Div Psychol Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.							CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeLisi LE, 1999, CURR OPIN PSYCHIATR, V12, P29, DOI 10.1097/00001504-199901000-00014; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; Flint J, 1997, NAT GENET, V17, P250, DOI 10.1038/ng1197-250; Hardy J, 1999, NATURE, V398, P466, DOI 10.1038/18979; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; HOUWEN RHJ, 1994, NAT GENET, V8, P380, DOI 10.1038/ng1294-380; KENDLER KS, 1987, ARCH GEN PSYCHIAT, V44, P881; Kendler KS, 1997, AM J PSYCHIAT, V154, P191; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P716; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; McGuffin P, 1996, COLD SPRING HARB SYM, V61, P815; MCGUFFIN P, 1994, SEMINARS PSYCHIAT GE; MURPHY KC, IN PRESS ARCH GEN PS; Nuffield Council on Bioethics, 1998, MENT DIS GEN ETH CON; Owen MJ, 1997, MOL PSYCHIATR, V2, P270, DOI 10.1038/sj.mp.4000292; Page GP, 1999, AM J HUM GENET, V64, P1194, DOI 10.1086/302331; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SKOULTCHI AI, 1997, AM J HUM GENET, V61, pA296; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; Waldman ID, 1998, AM J HUM GENET, V63, P1767, DOI 10.1086/302132; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Williams J, 1996, LANCET, V347, P1294, DOI 10.1016/S0140-6736(96)90939-3; Williams J, 1997, LANCET, V349, P1221, DOI 10.1016/S0140-6736(05)62413-0	30	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI11	SI14						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437849				2022-12-28	WOS:000081825900004
J	Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S				Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S			Signaling from rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase	SCIENCE			English	Article							DEPOLYMERIZING FACTOR; MYOSIN PHOSPHATASE; FILAMENT TURNOVER; IN-VIVO; COFILIN; PHOSPHORYLATION; DYNAMICS; IDENTIFICATION; ASSOCIATION; MUSCLE	The actin cytoskeleton undergoes extensive remodeling during cell morphogenesis and motility. The small guanosine triphosphatase Rho regulates such remodeling, but the underlying mechanisms of this regulation remain unclear. Cofilin exhibits actin-depolymerizing activity that is inhibited as a result of its phosphorylation by LIM-kinase. Cofilin was phosphorylated in N1E-115 neuroblastoma cells during lysophosphatidic acid-induced, Rho-mediated neurite retraction. This phosphorylation was sensitive to Y-27632, a specific inhibitor of the Rho-associated kinase ROCK. ROCK, which is a downstream effector of Rho, did not phosphorylate cofilin directly but phosphorylated LIM-kinase, which in turn was activated to phosphorylate cofilin, Overexpression of LIM-kinase in HeLa cells induced the formation of actin stress fibers in a Y-27632-sensitive manner. These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan; Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan	Kyoto University; Kirin Brewery Company Limited; Chiba University; Tohoku University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.		Boku, Shuken/H-2776-2017; Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Maekawa M, UNPUB; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ONO S, 1994, J BIOL CHEM, V269, P15280; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WATANABE N, 1997, EMBO J, V16, P1307; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	25	1239	1273	3	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					895	898		10.1126/science.285.5429.895	http://dx.doi.org/10.1126/science.285.5429.895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436159				2022-12-28	WOS:000081860900051
J	Cohen, SM				Cohen, SM			Caput medusae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Digest Care Associates, Peoria, IL 61603 USA		Cohen, SM (corresponding author), Digest Care Associates, Peoria, IL 61603 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					419	419		10.1056/NEJM199908053410605	http://dx.doi.org/10.1056/NEJM199908053410605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10432326				2022-12-28	WOS:000081860100005
J	Willett, WC; Dietz, WH; Colditz, GA				Willett, WC; Dietz, WH; Colditz, GA			Guidelines for healthy weight	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BODY-MASS-INDEX; CORONARY HEART-DISEASE; FAT DISTRIBUTION; DIABETES-MELLITUS; RISK-FACTORS; FOLLOW-UP; US ADULTS; WOMEN; MEN; MORTALITY		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA	Willett, WC (corresponding author), 655 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291				Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; *DEP AGR DEP HHS, 1995, HOM GARD B DEP AGR, V232; *DEP AGR DEP HHS, 1990, HOM GARD B DEP AGR, V232; *DEP AGR DEP HHS, 1980, HOM GARD B DEP AGR, V232; Felson David T., 1996, American Journal of Clinical Nutrition, V63, p430S, DOI 10.1093/ajcn/63.3.430; FOSTER DW, 1994, HARRISONS PRINCIPLES, V1, P221; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; GARRISON RJ, 1985, ANN INTERN MED, V103, P1006, DOI 10.7326/0003-4819-103-6-1006; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; HAN TS, 1995, BRIT MED J, V311, P1401, DOI 10.1136/bmj.311.7017.1401; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; KULLER LH, 1993, REPORT AM I NUTR AIN; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; MEYER HE, 1995, EPIDEMIOLOGY, V6, P299, DOI 10.1097/00001648-199505000-00019; NHLBI Obesity Education Initiative Expert Panel on the Identification Evaluation and Treatment of Obesity in Adults (US), 1998, CLIN GUID ID EV TREA; QUETELET A, 1869, PHYSIQUE SOCIALE ESS; RICHEDWARDS JW, 1994, AM J OBSTET GYNECOL, V171, P171, DOI 10.1016/0002-9378(94)90465-0; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; SEIDELL JC, 1987, AM J CLIN NUTR, V45, P7, DOI 10.1093/ajcn/45.1.7; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; Troiano RP, 1996, INT J OBESITY, V20, P63; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Walker SP, 1996, AM J EPIDEMIOL, V144, P1143, DOI 10.1093/oxfordjournals.aje.a008892; Willet W., 1998, NUTR EPIDEMIOLOGY, P74, DOI DOI 10.1093/ACPROF:OSO/9780195122978.001.0001; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V142, P369; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; World Health Organization, 1995, WHO TECH REP SER, V854, P1; World Health Organization,, 1998, WHO TECHN REP SER	43	866	902	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					427	434		10.1056/NEJM199908053410607	http://dx.doi.org/10.1056/NEJM199908053410607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10432328				2022-12-28	WOS:000081860100007
J	De Jong, PE; Navis, G; de Zeeuw, D				De Jong, PE; Navis, G; de Zeeuw, D			Renoprotective therapy: titration against urinary protein excretion	LANCET			English	Editorial Material							ACE-INHIBITION; RENAL-DISEASE		Univ Groningen Hosp, Dept Internal Med, Div Nephrol, NL-9713 EZ Groningen, Netherlands	University of Groningen	De Jong, PE (corresponding author), Univ Groningen Hosp, Dept Internal Med, Div Nephrol, Oostersingel 59, NL-9713 EZ Groningen, Netherlands.		de Zeeuw, Dick/E-9080-2014	de Zeeuw, Dick/0000-0003-3434-7777				APPERLOO AJ, 1994, KIDNEY INT, V45, P174; Buter H, 1998, NEPHROL DIAL TRANSPL, V13, P1682, DOI 10.1093/ndt/13.7.1682; ELNAHAS AM, 1984, BRIT MED J, V289, P1337, DOI 10.1136/bmj.289.6455.1337; GANSEVOORT RT, 1995, NEPHROL DIAL TRANSPL, V10, P497, DOI 10.1093/ndt/10.4.497; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; HEEG JE, 1991, CLIN SCI, V81, P367, DOI 10.1042/cs0810367; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; Navis G, 1997, LANCET, V349, P1852, DOI 10.1016/S0140-6736(97)22026-X; PETERSON JC, 1995, ANN INTRN MED, V123, P752; ROSSING P, 1994, DIABETOLOGIA, V37, P511, DOI 10.1007/s001250050140; Ruggenenti P, 1997, LANCET, V349, P1857	11	87	88	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					352	353		10.1016/S0140-6736(99)90122-8	http://dx.doi.org/10.1016/S0140-6736(99)90122-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437857				2022-12-28	WOS:000081764900002
J	Ruggenenti, P; Perna, A; Gherardi, G; Garini, G; Zoccali, C; Salvadori, M; Scolari, F; Schena, FP; Remuzzi, G				Ruggenenti, P; Perna, A; Gherardi, G; Garini, G; Zoccali, C; Salvadori, M; Scolari, F; Schena, FP; Remuzzi, G			Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria	LANCET			English	Article							CONVERTING ENZYME-INHIBITION; PROGRESSIVE NEPHROPATHIES; RENAL-DISEASE	Background Stratum 2 of the Ramipril Efficacy in Nephropathy (REIN) study has already shown that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, angiotensin-converting enzyme (ACE) inhibition reduced the rate of decline in glomerular filtration and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF) found in controls on placebo plus conventional antihypertensives, In REIN stratum 1, reported here, 24 h proteinuria was Ig or more but less than 3 g per 24 h. Methods In stratum 1 of this double-blind trial 186 patients were randomised to a ramipril or a control (placebo plus conventional antihypertensive therapy) group targeted at achieving a diastolic blood pressure of less than 90 mm Hg. The primary endpoints were change in glomerular filtration rate (GFR) and time to ESRF or overt proteinuria (greater than or equal to 3 g/24 h). Median follow-up was 31 months. Findings The decline in GFR per month was not significantly different (ramipril 0.26 [SE 0.05] mL per min per 1.73 m(2), control 0.29 [0.06]). Progression to ESRF was significantly less common in the ramipril group (9/99 vs 18/87) for a relative risk (RR) of 2.72 (95% CI 1.22-6.08); so was progression to overt proteinuria (15/99 vs 27/87, RR 2.40 [1.27-4.52]). Patients with a baseline GFR of 45 mL/min/1.73 m(2) or less and proteinuria of 1.5 g/24 h or more had more rapid progression and gained the most from ramipril treatment. Proteinuria decreased by 13% in the ramipril group and increased by 15% in the controls. Cardiovascular events were similar. As expected, the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been in stratum 2. Interpretation In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria.	Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy; Ist Clin Med & Nefrol, Parma, Italy; CNR, Div Nefrol, Ctr Fisiol Clin, Reggio Calabria, Italy; Osped Reg Careggi Monna Tessa, Unit Operat Nefrol, Florence, Italy; Spedali Civili, Div Nefrol & Dial, I-25125 Brescia, Italy; Policlin Bari, Div Nefrol & Dial, Bari, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consiglio Nazionale delle Ricerche (CNR); Hospital Spedali Civili Brescia; Universita degli Studi di Bari Aldo Moro	Ruggenenti, P (corresponding author), Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis Aldo & Cele Dacco, Villa Camozzi,Via Gavazzeni 11, I-24125 Bergamo, Italy.		scolari, francesco/AAC-5957-2022; Perna, Annalisa/AAC-1323-2020; Zoccali, Carmine/B-9445-2009; Schena, Francesco P/K-6982-2016; Remuzzi, Giuseppe/V-9766-2017	Perna, Annalisa/0000-0002-9257-0283; Schena, Francesco P/0000-0001-7927-5207; Zoccali, Carmine/0000-0002-6616-1996; Manno, Carlo/0000-0002-7840-9426; Scolari, Francesco/0000-0003-0233-9705; Remuzzi, Giuseppe/0000-0002-6194-3446				Abbate M, 1998, J AM SOC NEPHROL, V9, P1213; APPERLOO AJ, 1994, KIDNEY INT, V45, pS174; GASPARI F, 1995, J AM SOC NEPHROL, V6, P1; GREENE T, 1995, CONTROL CLIN TRIALS, V16, P655; *GRUPP IT STUD EP, 1991, J NEPHROL, V3, P193; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 1997, KIDNEY INT, V51, P2, DOI 10.1038/ki.1997.2; RICE EW, 1975, CLIN CHEM, V21, P398; ROSSING P, 1994, KIDNEY INT S45, V45, P145; Ruggenenti P, 1999, J AM SOC NEPHROL, V10, P997; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X	18	672	699	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					359	364		10.1016/S0140-6736(98)10363-X	http://dx.doi.org/10.1016/S0140-6736(98)10363-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437863				2022-12-28	WOS:000081764900009
J	Gottlieb, S				Gottlieb, S			US health maintenance organisations: better care from non-profit plans	BRITISH MEDICAL JOURNAL			English	News Item																		Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159	1	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					211	211		10.1136/bmj.319.7204.211	http://dx.doi.org/10.1136/bmj.319.7204.211			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417071	Green Published			2022-12-28	WOS:000081720300010
J	Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM				Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM			mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop	CELL			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; LIGHT; PROTEIN; MOUSE; EXPRESSION; TRANSCRIPTION; CRYPTOCHROME; TIMELESS	We determined that two mouse cryptochrome genes, mCry1 and mCry2, act in the negative limb of the clock feedback loop. In cell lines, mPER proteins (alone or in combination) have modest effects on their cellular location and ability to inhibit CLOCK:BMAL1-mediated transcription. This suggested cryptochrome involvement in the negative limb of the feedback loop. Indeed, mCry1 and mCry2 RNA levels are reduced in the central and peripheral clocks of Clock/Clock mutant mice. mCRY1 and mCRY2 are nuclear proteins that interact with each of the mPER proteins, translocate each mPER protein from cytoplasm to nucleus, and are rhythmically expressed in the suprachiasmatic circadian clock. Luciferase reporter gene assays show that mCRY1 or mCRY2 alone abrogates CLOCK:BMAL1-E box-mediated transcription. The mPER and mCRY proteins appear to inhibit the transcriptional complex differentially.	Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Cambridge	Kume, K (corresponding author), Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Hastings, Michael Harvey/0000-0001-8576-6651; Weaver, David/0000-0001-7941-6719; Kume, Kazuhiko/0000-0003-4232-1657	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011547, F32MH012067] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NIMH NIH HHS [MH11547, MH12067] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hastings M.H., 1999, J NEUROSCI, V11, P1; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	44	1227	1264	6	110	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					193	205		10.1016/S0092-8674(00)81014-4	http://dx.doi.org/10.1016/S0092-8674(00)81014-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428031	Bronze			2022-12-28	WOS:000081632300009
J	Brown, SH; Miller, RA; Camp, HN; Guise, DA; Walker, HKN				Brown, SH; Miller, RA; Camp, HN; Guise, DA; Walker, HKN			Empirical derivation of an electronic clinically useful problem statement system	ANNALS OF INTERNAL MEDICINE			English	Review							MEDICAL-RECORD; HEALTH-CARE; GENERAL-PRACTITIONERS; COMPUTER REMINDERS; INFORMATION; GUIDELINES; SURVEILLANCE; INITIATIVES; MANAGEMENT; DIAGNOSIS	Problem lists are tools to improve patient management. In the medical record, they connect diagnoses to therapy, prognosis, and psychosocial issues. Computer-based problem lists enhance paper-based approaches by enabling cost-containment and quality assurance applications, but they require clinically expressive controlled vocabularies. Because existing controlled vocabularies do not represent problem statements at a clinically useful level, we derived a new canonical problem statement vocabulary through semi-automated analysis and distillation of provider-entered problem lists collected over 6 years from 74 696 patients. We combined automated and manual methods to condense 891 770 problem statements entered by 1961 care providers at Grady Memorial Hospital in Atlanta, Georgia, to 15 534 Canonical Clinical Problem Statement System (CCPSS) terms. The nature and frequency of problem statements were characterized, interrelations among them were enumerated, and a database capturing the epidemiology of problems was created. The authors identified 23 503 problem relations (co-occurrences, sign-symptom complexes, and differential diagnoses) and 22 690 modifier words that further categorized "canonical" problems, To assess completeness, CCPSS content was compared with that of the 1997 Unified Medical Language System Metathesaurus (containing terms from 44 clinical vocabularies). Unified Medical Language System terms expressed 25% of individual CCPSS terms exactly (71% of problems by frequency), 27% partially, and 48% poorly or not at all. Clinicians judged that CCPSS terms completely captured their clinical intent for 84% of 686 randomly selected free-text problem statements. The CCPSS represents clinical concepts at a level exceeding that of previous approaches. A similar national approach could create a standardized, useful, shared resource for clinical practice.	Med Syst Dev Corp, Marietta, GA 30067 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30303 USA; Vanderbilt Univ, Nashville, TN USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA	Emory University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Brown, SH (corresponding author), Eskind Biomed Lib, Div Biomed Informat, Room 402,2209 Garland Ave, Nashville, TN 37232 USA.	steven.brown@med.va.gov			NATIONAL LIBRARY OF MEDICINE [F38LM000021, G08LM005443, R01LM006226] Funding Source: NIH RePORTER; NLM NIH HHS [LM06226-02, 1 F38 LM00021-01A1, 5 G08 LM05443] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*AM MED ASS HLTH C, 1997, DOC GUID EV MAN SERV, P1; [Anonymous], 1986, WEBSTERS 3 NEW INT D, VII; BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BARROWS RC, 1994, COMPUTER APPL MED CA, P211; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; Brown SH, 1997, J AM MED INFORM ASSN, P151; CAMP HN, 1995, IMPLEMENTING THERESA, P83; CAMPBELL JR, 1994, COMPUTER APPL MED CA, P201; Chute CG, 1997, J AM MED INFORM ASSN, P570; Chute CG, 1996, J AM MED INFORM ASSN, V3, P224, DOI 10.1136/jamia.1996.96310636; Cimino JJ, 1996, METHOD INFORM MED, V35, P273; CIMINO JJ, 1992, COMPUTER APPL MED CA, P81; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cote RA, 1993, SYSTEMATIZED NOMENCL; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; DEISHER JB, 1978, J FAM PRACTICE, V7, P1059; DONNELLY WJ, 1992, ARCH INTERN MED, V152, P480; Eagon J C, 1996, Proc AMIA Annu Fall Symp, P130; Eagon JC, 1997, J AM MED INFORM ASSN, P565; EDDY DM, 1982, NEW ENGL J MED, V306, P1263, DOI 10.1056/NEJM198205273062104; Elstein AS, 1978, MED PROBLEM SOLVING; EVANS DA, 1994, J AM MED INFORM ASSN, V1, P207, DOI 10.1136/jamia.1994.95236153; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1993, COMPUTER APPL MED CA, P161; FEINSTEI.AR, 1973, ANN INTERN MED, V78, P751, DOI 10.7326/0003-4819-78-5-751; FEINSTEIN AR, 1973, YALE J BIOL MED, V46, P264; FEINSTEIN AR, 1973, YALE J BIOL MED, V46, P212; FEINSTEIN AR, 1974, YALE J BIOL MED, V47, P5; FERNOW LC, 1977, MED EDUC, V11, P341, DOI 10.1111/j.1365-2923.1977.tb00625.x; FREIDIN RB, 1980, ANN INTERN MED, V93, P490, DOI 10.7326/0003-4819-93-3-490; Geissbuhler A, 1996, Proc AMIA Annu Fall Symp, P689; Giuse D A, 1996, Proc AMIA Annu Fall Symp, P633; GLEDHILL VX, 1973, ANN INTERN MED, V78, P685, DOI 10.7326/0003-4819-78-5-685; GOLDFINGER SE, 1973, NEW ENGL J MED, V288, P606, DOI 10.1056/NEJM197303222881205; GREENES RA, 1970, NEW ENGL J MED, V282, P307, DOI 10.1056/NEJM197002052820605; GROVER FL, 1995, ANN THORAC SURG, V60, P1514, DOI 10.1016/0003-4975(95)00796-N; HAMMOND WE, 1995, INT J BIOMED COMPUT, V39, P87, DOI 10.1016/0020-7101(94)01084-E; *HLTH CAR FIN ADM, 1999, HOSP AUTP PROSP PAYM; Hohnloser JH, 1996, COMPUT BIOMED RES, V29, P41, DOI 10.1006/cbmr.1996.0004; HURS, 1983, WEBSTERS 9 NEW COLLE; HURST JW, 1971, NEW ENGL J MED, V284, P51, DOI 10.1056/NEJM197101072840114; HURST JW, 1971, ARCH INTERN MED, V128, P456, DOI 10.1001/archinte.128.3.456; Hurst JW, 1972, PROBLEM ORIENTED SYS; Ingber J S, 1975, J Dent Educ, V39, P472; *INT CLASS DIS, 1977, MAN INT STAT CLASS D; KAHN MG, 1994, CRIT CARE CLIN, V10, P37, DOI 10.1016/S0749-0704(18)30143-X; KASSIRER JP, 1988, HOSP PRACT, V23, P37; KASSIRER JP, 1988, HOSP PRACT, V23, P21; KASSIRER JP, 1988, HOSP PRACT, V23, P26; KASSIRER JP, 1988, HOSP PRACT, V23, P46; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; KASSIRER JP, 1988, HOSP PRACT, V23, P51; KASSIRER JP, 1988, HOSP PRACT, V23, P55; LAMBERT RP, 1976, MED J AUSTRALIA, V2, P368, DOI 10.5694/j.1326-5377.1976.tb130257.x; Lincoln MJ., 1997, COMP HLTH C, P349; LINDBERG DAB, 1993, METHOD INFORM MED, V32, P281, DOI 10.1055/s-0038-1634945; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; Lloyd S C, 1984, J Med Syst, V8, P35, DOI 10.1007/BF02221866; LONGABAUGH R, 1983, ARCH GEN PSYCHIAT, V40, P453; McCray A T, 1996, Proc AMIA Annu Fall Symp, P164; MCDONALD CJ, 1988, JAMA-J AM MED ASSOC, V259, P3433, DOI 10.1001/jama.259.23.3433; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1992, M D COMPUT, V9, P206; McDonald CJ, 1998, INT J MED INFORM, V48, P5, DOI 10.1016/S1386-5056(97)00102-0; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MEHIGAN JA, 1975, IRISH MED J, V68, P80; MELLNER C, 1976, METHOD INFORM MED, V15, P11; Mullins H C, 1996, Proc AMIA Annu Fall Symp, P135; Munday A, 1997, BRIT J GEN PRACT, V47, P563; Nightingale F., 1863, NOTES ON HOSP; Payne T H, 1993, Proc Annu Symp Comput Appl Med Care, P705; PAYNE TH, 1992, COMPUTER APPL MED CA, P654; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; PHILLIPSHARRIS C, 1995, CLIN GERIATR MED, V11, P481, DOI 10.1016/S0749-0690(18)30281-7; POWSNER SM, 1989, COMPUT BIOMED RES, V22, P552, DOI 10.1016/0010-4809(89)90075-X; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; REINSTEIN L, 1977, ARCH PHYS MED REHAB, V58, P398; ROSENBERG KM, 1994, COMPUER APPL MED CAR, P193; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; SAFRAN C, 1991, M D COMPUT, V8, P291; SAFRAN C, 1997, TELEMEDICINE TELEHEA, V3, P52; SAFRAN C, 1992, MED CARE, P114; SAFRAN C, 1997, TELEMEDICINE TELEHEA, V3, P22; SCHERPBIER HJ, 1994, COMPUTER APPL MED CA, P206; SCHMIDT EC, 1974, MED CARE, V12, P316, DOI 10.1097/00005650-197404000-00003; Schriger DL, 1997, JAMA-J AM MED ASSOC, V278, P1585, DOI 10.1001/jama.278.19.1585; SCHULTZ JR, 1979, P IEEE, V67, P1237, DOI 10.1109/PROC.1979.11439; Selby JV, 1997, ANN INTERN MED, V127, P719, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00056; SLAMECKA V, 1977, INFORM PROCESS MANAG, V13, P273, DOI 10.1016/0306-4573(77)90016-4; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; Stead W W, 1983, J Med Syst, V7, P103, DOI 10.1007/BF00995117; STITT FW, 1993, COMPUTER APPL MED CA, P88; STRATMANN WC, 1980, MED CARE, V18, P456, DOI 10.1097/00005650-198004000-00009; The Joint Commission on Accreditation of Healthcare Organizations, 1996, COMPR ACCR MAN HOSP; Tierney W M, 1996, Proc AMIA Annu Fall Symp, P459; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; TIERNEY WM, 1990, AM J HYPERTENS, V3, P69, DOI 10.1093/ajh/3.1.69; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TIERNEY WM, 1991, STAT MED, V10, P541, DOI 10.1002/sim.4780100406; Walker H K, 1989, Comput Healthc, V10, P36; WALKER HK, 1989, COMPUT HEALTHC, V10, P40; WALKER HK, 1989, COMPUT HEALTHC, V10, P42; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; WEED LL, 1971, ARCH INTERN MED, V127, P101, DOI 10.1001/archinte.127.1.101; WEED LL, 1972, PROBLEM ORIENTED SYS, P23; WEED LL, 1964, IRISH J MED SCI, V17, P271; WHITINGOKEEFE QE, 1988, M D COMPUT, V5, P8; WILTON R, 1991, COMPUTER APPL MED CA, P823; WINICKOFF RN, 1986, J GEN INTERN MED, V1, P78, DOI 10.1007/BF02599804; YARNALL KSH, 1995, J FAM PRACTICE, V40, P257; ZELINGHER J, 1995, COMPUTER APPL MED CA, P416	118	26	26	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					117	126		10.7326/0003-4819-131-2-199907200-00008	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419428				2022-12-28	WOS:000081509700007
J	Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A				Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A			Incidence of contact-lens-associated microbial keratitis and its related morbidity	LANCET			English	Article							ULCERATIVE KERATITIS; EXTENDED-WEAR; ACANTHAMOEBA-KERATITIS; PSEUDOMONAS-AERUGINOSA; CORNEAL ULCERS; OVERNIGHT WEAR; RISK-FACTORS; USERS; CONTAMINATION; ENGLAND	Background The incidence of contact-lens-associated microbial keratitis is uncertain and its related morbidity in the general population of contact-lens wearers is not known. We examined these issues in a prospective epidemiological study. Methods We surveyed all practising ophthalmologists in the Netherlands to identify all new cases of microbial keratitis reported during a 3-month period in 1996. Follow-up telephone calls were made to examine ocular morbidity. We undertook annual nationwide telephone surveys between 1994 and 1997 to estimate the prevalence of contact-lens wear. Findings Of 440 ophthalmologists contacted, 379 provided information. There were 92 cases of microbial keratitis; 17 used daily-wear rigid gas-permeable lenses, 63 daily-wear soft lenses, and 12 extended-wear soft lenses. The estimated annualised incidence of microbial keratitis was 1.1 per 10 000 (95% CI 0.6-1.7) users of daily-wear rigid gas-permeable lenses, 3.5 per 10 000 (2.7-4.5) users of daily-wear soft lenses, and 20.0 per 10 000 (10.3-35.0) users of extended-wear soft lenses (p<0.00001 for comparison between all groups), Five of the 92 patients achieved a final visual acuity of 20/70 or less. Pseudomonas and Serratia sop were the organisms most commonly isolated, Pseudomonas keratitis accounted for the largest mean diameter of corneal ulcers, the highest mean number of days in hospital, the greatest number of mean outpatients visits, and the poorest visual acuity outcome. Interpretation The incidence of microbial keratitis among users of extended-wear soft contact lenses in the Netherlands is similar to that reported in the USA during 1989. Awareness of risk factors and improvement in contact-lens materials have not led to a decrease in incidence. Overnight wear should be strongly discouraged.	Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, NL-1100 AC Amsterdam, Netherlands; Univ Amsterdam, Dept Ophthalmol, Amsterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Coll Econ, Drenthe, Netherlands; Rotterdam Eye Hosp, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Erasmus University Rotterdam; Rotterdam Eye Hospital	Kijlstra, A (corresponding author), Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, POB 12141, NL-1100 AC Amsterdam, Netherlands.							BATES A K, 1989, Eye (London), V3, P803; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; COSTER DJ, 1987, BRIT J OPHTHALMOL, V71, P96, DOI 10.1136/bjo.71.2.96; DART JKG, 1988, BRIT J OPHTHALMOL, V72, P926, DOI 10.1136/bjo.72.12.926; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; DONZIS PB, 1987, AM J OPHTHALMOL, V104, P325, DOI 10.1016/0002-9394(87)90219-4; ERIE JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1665, DOI 10.1001/archopht.1993.01090120087027; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P104, DOI 10.1001/archopht.1991.01080010106041; IMAYASU M, 1994, OPHTHALMOLOGY, V101, P371; KAMATA R, 1985, OPHTHALMOLOGY, V92, P1452; KOCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1453, DOI 10.1001/archopht.1990.01070120101038; KOIDOUTSILIGIANNI A, 1989, AM J OPHTHALMOL, V108, P64, DOI 10.1016/S0002-9394(14)73262-3; LASS JH, 1981, AM J OPHTHALMOL, V92, P384, DOI 10.1016/0002-9394(81)90529-8; LAZACHEK GW, 1971, ARCH OPHTHALMOL-CHIC, V86, P599, DOI 10.1001/archopht.1971.01000010601020; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; Lim-Bon-Siong R, 1998, AM J OPHTHALMOL, V125, P169, DOI 10.1016/S0002-9394(99)80087-7; Mathers WD, 1996, AM J OPHTHALMOL, V121, P129, DOI 10.1016/S0002-9394(14)70577-X; MAYO MS, 1987, J CLIN MICROBIOL, V25, P1398, DOI 10.1128/JCM.25.8.1398-1400.1987; MUMMERT R, 1994, BAUSCH LOMB ANN REPO, P2; Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225; ORMEROD LD, 1986, ARCH OPHTHALMOL-CHIC, V104, P79; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; RADFORD CF, 1995, BRIT MED J, V310, P1567, DOI 10.1136/bmj.310.6994.1567; Radford CF, 1998, BRIT J OPHTHALMOL, V82, P1387, DOI 10.1136/bjo.82.12.1387; Rapuano CJ, 1999, OPHTHALMOLOGY, V106, P422; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; STEIN RM, 1988, AM J OPHTHALMOL, V105, P632, DOI 10.1016/0002-9394(88)90056-6; Taylor HR, 1996, ARCH OPHTHALMOL-CHIC, V114, P248, DOI 10.1001/archopht.1996.01100130244001; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1988, LANCET, V1, P1437	32	372	384	0	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					181	185		10.1016/S0140-6736(98)09385-4	http://dx.doi.org/10.1016/S0140-6736(98)09385-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421298				2022-12-28	WOS:000081504200008
J	Kwakkel, G; Wagenaar, RC; Twisk, JWR; Lankhorst, GJ; Koetsier, JC				Kwakkel, G; Wagenaar, RC; Twisk, JWR; Lankhorst, GJ; Koetsier, JC			Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial	LANCET			English	Article							FUNCTIONAL STATUS; ACTIVITIES INDEX; NATURAL-HISTORY; REHABILITATION; RECOVERY; CLASSIFICATION; INFARCTION	Background We investigated the effects of different intensities of arm and leg rehabilitation training on the functional recovery of activities of daily living (ADL), walking ability, and dexterity of the paretic arm, in a single-blind randomised controlled trial. Methods Within 14 days after stroke onset, 101 severely disabled patients with a primary middle-cerebral-artery stroke were randomly assigned to: a rehabilitation programme with emphasis on arm training; a rehabilitation programme with emphasis on leg training; or a control programme in which the arm and leg were immobilised with an inflatable pressure splint. Each treatment regimen was applied for 30 min, 5 days a week during the first 20 weeks after stroke. In addition, all patients underwent a basic rehabilitation programme. The main outcome measures were ability in ADL (Barthel index), walking ability (functional ambulation categories), and dexterity of the paretic arm (Action Research arm test) at 6, 12, 20, and 26 weeks. Analyses were by intention to treat. Findings At week 20, the leg-training group (n=31) had higher scores than the control group (n=37) for ADL ability (median 19 [IQR 16-20] vs 16 [10-19], p<0.05), walking ability (4 [3-5] vs 3 [1-4], p<0.05), and dexterity (2 [0-56] vs 0 [0-2], p<0.01). The arm-training group (n=33) differed significantly from the control group only in dexterity (9 [0-39] vs 0 [0-2], p<0.01). There were no significant differences in these endpoints at 20 weeks between the arm-training and leg-training groups. Interpretation Greater intensity of leg rehabilitation improves functional recovery and health-related functional status, whereas greater intensity of arm rehabilitation results in small improvements in dexterity, providing further evidence that exercise therapy primarily induces treatment effects on the abilities at which training is specifically aimed.	Vrije Univ Amsterdam, Univ Hosp, Dept Phys Therapy, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Res Inst Fundamental & Clin Human Movement Sci, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Dept Rehabil Med, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Univ Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Phys Therapy, Boston, MA 02215 USA; Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Boston University; Vrije Universiteit Amsterdam	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Univ Hosp, Dept Phys Therapy, POB 7057, NL-1007 MB Amsterdam, Netherlands.	g.kwakkel@azvu.nl						[Anonymous], 1989, STROKE, V20, P1407; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Collen F M, 1990, Int Disabil Stud, V12, P6; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; DEELMAN BG, 1981, SAN TEST APHASIA TES; ERDMAN RAM, 1993, PSYCHOL REP, V72, P1027, DOI 10.2466/pr0.1993.72.3.1027; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GRESHAM GE, 1986, STROKE, V17, P358, DOI 10.1161/01.STR.17.3.358; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; HUNT SM, 1981, J EPIDEMIOL COMMUN H, V35, P297, DOI 10.1136/jech.35.4.297; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; KALRA L, 1993, J AM GERIATR SOC, V41, P396, DOI 10.1111/j.1532-5415.1993.tb06947.x; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; KWAKKEL G, 1998, DYNAMICS FUNCTIONAL, P69; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; POOLE JL, 1990, OCCUP THER J RES, V10, P360, DOI 10.1177/153944929001000605; Post MWM, 1996, ARCH PHYS MED REHAB, V77, P440, DOI 10.1016/S0003-9993(96)90031-3; ROBICHAUD JA, 1992, PHYS THER, V72, P176, DOI 10.1093/ptj/72.3.176; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; SUNDERLAND A, 1994, J NEUROL NEUROSUR PS, V57, P856, DOI 10.1136/jnnp.57.7.856; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WADE DT, 1989, HDB CLIN NEUROLOGY, V11, P233; WAGENAAR RC, 1990, SCAND J REHABIL MED, V22, P1; WAGENAAR RC, 1991, J REHABILITATION SCI, V4, P61; Wardlaw JM, 1996, J NEUROL, V243, P274, DOI 10.1007/BF00868526; WEILLER C, 1993, ANN NEUROL, V33, P181	35	608	640	2	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					191	196		10.1016/S0140-6736(98)09477-X	http://dx.doi.org/10.1016/S0140-6736(98)09477-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	217MU	10421300				2022-12-28	WOS:000081504200010
J	Herman, J				Herman, J			To whom shall I tell my grief?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		EASTER, 1954, COLLECTED POEMS WB Y, P177; GRIEF, 1932, STORIES A TCHEKOV, P103	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					111	112		10.1001/jama.282.2.111	http://dx.doi.org/10.1001/jama.282.2.111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411176				2022-12-28	WOS:000081376800001
J	James, KC; Foster, SD				James, KC; Foster, SD			Weighing up disability	LANCET			English	Editorial Material							HEALTH		Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA 02118 USA	Boston University	James, KC (corresponding author), Boston Univ, Sch Publ Hlth, Dept Int Hlth, 715 Albany St, Boston, MA 02118 USA.		Foster, Samantha Michelle/GQI-0807-2022	Foster, Susan/0000-0002-2751-7582				Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; EVANS TG, 1987, SOC SCI MED, V25, P241, DOI 10.1016/0277-9536(87)90227-9; FOEGE W, 1994, JAMA-J AM MED ASSOC, V271, P1704, DOI 10.1001/jama.271.21.1704; FoxRushby J, 1995, EUR REV APPL PSYCHOL, V45, P257; HUNT SM, 1986, HEALTH POLICY, V6, P149, DOI 10.1016/0168-8510(86)90004-7; Paalman M, 1998, HEALTH POLICY PLANN, V13, P13, DOI 10.1093/heapol/13.1.13; PROST A, 1984, B WORLD HEALTH ORGAN, V62, P795; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; ROSSER R, 1990, LECT LOND SCH HYG TR; Werner D, 1995, CONTACT, V141, P1; WERNER D, 1977, WHERE THERE IS NO DO; *WORLD BANK, 1993, LANCET, V342, P63; 1993, WORLD DEV REPORT, P3	13	17	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					87	88		10.1016/S0140-6736(99)90060-0	http://dx.doi.org/10.1016/S0140-6736(99)90060-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	215HW	10408477	hybrid			2022-12-28	WOS:000081377100003
J	Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V				Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V			G beta gamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D	CELL			English	Article							HETEROTRIMERIC-G-PROTEINS; CONSTITUTIVE TRANSPORT VESICLES; C-MU; DOMAIN; RECEPTOR; BINDING; EPSILON	We have shown previously that the py subunits of the heterotrimeric G proteins regulate the organization of the pericentriolarly localized Golgi stacks. In this report, evidence is presented that the downstream target of G beta gamma is protein kinase D (PKD), an isoform of protein kinase C. PKD, unlike other members of this class of serine/threonine kinases, contains a pleckstrin homology (PH) domain. Our results demonstrate that G beta gamma directly activates PKD by interacting with its PH domain. Inhibition of PKD activity through the use of pharmacological agents, synthetic peptide substrates, and, more specifically, the PH domain of PKD prevents G beta gamma-mediated Golgi breakdown. Our findings suggest a possible mechanism by which the direct interaction of G beta gamma with PKD regulates the dynamics of Golgi membranes and protein secretion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA; Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; Salk Institute; Universite Catholique Louvain	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Van Lint, Johan/P-9073-2019; Yamanouye, Norma/I-3348-2013; Malhotra, Vivek/O-9811-2014	Yamanouye, Norma/0000-0001-6007-0199; Malhotra, Vivek/0000-0001-6198-7943; Van Lint, Johan/0000-0002-0275-571X				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651	28	233	236	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					59	68		10.1016/S0092-8674(00)80606-6	http://dx.doi.org/10.1016/S0092-8674(00)80606-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412981	Bronze			2022-12-28	WOS:000081451000008
J	Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM				Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM			Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1	CELL			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN HOMOLOG; DIET-INDUCED THERMOGENESIS; ACTIVATED RECEPTOR-GAMMA; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; DNA-BINDING; GENE-EXPRESSION; NUCLEAR; OBESITY	Mitochondrial number and function are altered in response to external stimuli in eukaryotes. While several transcription/replication factors directly regulate mitochondrial genes, the coordination of these factors into a program responsive to the environment is not understood. We show here that PGC-1, a cold-inducible coactivator of nuclear receptors, stimulates mitochondrial biogenesis and respiration in muscle cells through an induction of uncoupling protein 2 (UCP-2) and through regulation of the nuclear respiratory factors (NRFs). PGC-1 stimulates a powerful induction of NRF-1 and NRF-5 gene expression; in addition, PGC-1 binds to and coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial transcription factor A (mtTFA), a direct regulator of mitochondrial DNA replication/transcription. These data elucidate a pathway that directly links external physiological stimuli to the regulation of mitochondrial biogenesis and function.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02115 USA; Univ Ancona, Fac Med & Chirurg, Ist Morfol Umana Normale Anat, I-60020 Ancona, Italy	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Marche Polytechnic University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; CINTI, Saverio/0000-0003-0362-5017; Wu, Zhidan/0000-0001-7289-9420	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054477, R56DK054477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477] Funding Source: Medline; NIGMS NIH HHS [GM32525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BROOKS SL, 1980, NATURE, V286, P274, DOI 10.1038/286274a0; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, LAB MANUAL, Vsecond; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V251, P374, DOI 10.1006/bbrc.1998.9479; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089	44	2997	3126	7	250	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					115	124		10.1016/S0092-8674(00)80611-X	http://dx.doi.org/10.1016/S0092-8674(00)80611-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412986	Bronze			2022-12-28	WOS:000081451000013
J	Djerassi, C				Djerassi, C			Essays on science and society - Sex in an age of mechanical reproduction	SCIENCE			English	Article									Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Djerassi, C (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.								0	6	6	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					53	54		10.1126/science.285.5424.53	http://dx.doi.org/10.1126/science.285.5424.53			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10428703				2022-12-28	WOS:000081199800023
J	Ukoumunne, OC; Gulliford, MC; Chinn, S; Sterne, JAC; Burney, PGJ; Donner, A				Ukoumunne, OC; Gulliford, MC; Chinn, S; Sterne, JAC; Burney, PGJ; Donner, A			Methods in health service research - Evaluation of health interventions at area and organisation level	BRITISH MEDICAL JOURNAL			English	Article							CLUSTER RANDOMIZATION TRIALS; SAMPLE-SIZE REQUIREMENTS; DESIGN; COHORT; CARE		Univ Western Ontario, Dept Epidemiol & Biostat, London, ON N6A 5C1, Canada; Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England	Western University (University of Western Ontario); University of London; King's College London	Gulliford, MC (corresponding author), Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England.		Sterne, Jonathan/Z-3106-2019; Gulliford, Martin C/I-8606-2018	Sterne, Jonathan/0000-0001-8496-6053; Gulliford, Martin C/0000-0003-1898-9075; Burney, Peter/0000-0001-8635-5678				Black N, 1996, BRIT MED J, V312, P1215; COOK TD, 1979, QUASI EXPT DESIGN AN; DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309; Diehr P, 1995, J CLIN EPIDEMIOL, V48, P1461, DOI 10.1016/0895-4356(95)00055-0; DONNER A, 1992, STAT MED, V11, P743, DOI 10.1002/sim.4780110605; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; DONNER A, 1994, J STAT PLAN INFER, V42, P37, DOI 10.1016/0378-3758(94)90188-0; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Duncan C, 1998, SOC SCI MED, V46, P97, DOI 10.1016/S0277-9536(97)00148-2; EDWARDS SJL, 1998, HLTH SERVICES RES ME, P98; FELDMAN HA, 1994, STAT MED, V13, P61, DOI 10.1002/sim.4780130108; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Gulliford MC, 1999, AM J EPIDEMIOL, V149, P876; HANNAN PJ, 1994, EPIDEMIOLOGY, V5, P88, DOI 10.1097/00001648-199401000-00013; HSIEH FY, 1988, STAT MED, V7, P1195, DOI 10.1002/sim.4780071113; Klar N, 1997, STAT MED, V16, P1753, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1753::AID-SIM597>3.0.CO;2-E; MARTIN DC, 1993, STAT MED, V46, P123; McKinlay JB, 1996, EVALUATION REV, V20, P237, DOI 10.1177/0193841X9602000301; Murray DM, 1998, DESIGN ANAL GROUP RA; Rice N, 1996, J Health Serv Res Policy, V1, P154; Thompson SG, 1997, STAT MED, V16, P2063, DOI 10.1002/(SICI)1097-0258(19970930)16:18<2063::AID-SIM642>3.0.CO;2-8; Ukoumunne OC, 1999, HLTH TECHNOL ASSESS, V3; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005	24	100	103	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					376	379		10.1136/bmj.319.7206.376	http://dx.doi.org/10.1136/bmj.319.7206.376			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435968	Green Published			2022-12-28	WOS:000082001700033
J	Turner, JA				Turner, JA			A realizable renewable energy future	SCIENCE			English	Editorial Material								The ability of renewable resources to provide all of society's energy needs is shown by using the United States as an example. Various renewable systems are presented, and the issues of energy payback, carbon dioxide abatement, and energy storage are addressed. Pathways for renewable hydrogen generation are shown, and the implementation of hydrogen technologies into the energy infrastructure is presented. The question is asked, should money and energy be spent on carbon dioxide sequestration, or should renewable resources be implemented instead.	Natl Renewable Energy Lab, Golden, CO 80401 USA	United States Department of Energy (DOE); National Renewable Energy Laboratory - USA	Turner, JA (corresponding author), Natl Renewable Energy Lab, Golden, CO 80401 USA.		Connaghan, Karen M./A-4611-2010					Alsema E., 1998, BNL52557; DONES R, 1977, 97072 UTR U; GIPE P, 1992, WIND ENERGY WKLY; HULSTROM RL, COMMUNICATION; KATO K, 1977, 97072 UTR U; Khaselev O, 1998, SCIENCE, V280, P425, DOI 10.1126/science.280.5362.425; KROHN S, 1997, 16 DAN WIND TURB MAN; OGDEN J, 1993, NRELCP470577; OGDEN J, 1998, 982500 SOC AUT ENG; Palz W., 1991, International Journal of Solar Energy, V10, P211, DOI 10.1080/01425919108941464; THOMAS CE, 1998, NRELCP57025315; *US DEP EN, 1999, DOEEIA038399; *WORLDS COMM ENV D, 1987, OUR COMM FUT BRUNTL	13	1178	1229	29	474	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					687	689		10.1126/science.285.5428.687	http://dx.doi.org/10.1126/science.285.5428.687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426982				2022-12-28	WOS:000081765100041
J	Macdonald, D; Gollish, J				Macdonald, D; Gollish, J			Images in clinical medicine - Synovial hemangioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Orthopaed & Arthrit Hosp, Toronto, ON M4Y 1H1, Canada		Macdonald, D (corresponding author), Orthopaed & Arthrit Hosp, Toronto, ON M4Y 1H1, Canada.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					336	336		10.1056/NEJM199907293410505	http://dx.doi.org/10.1056/NEJM199907293410505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423468				2022-12-28	WOS:000081666900005
J	Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A				Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A			Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; INSULIN RESISTANCE; ARTERY DISEASE; SOUTH ASIANS; PREVALENCE; BRADFORD; GLUCOSE; OBESITY; CHINESE	Objective To compare coronary risk factors and disease prevalence among Indians, Pakistanis, and Bangladeshis, and in all South Asians (these three groups together) with Europeans. Design Cross sectional survey. Setting Newcastle upon Tyne. Participants 259 Indian, 305 Pakistani, 120 Bangladeshi, and 825 European men and women aged 25-74 years. Main outcome measures Social and economic circumstances, lifestyle, self reported symptoms and diseases, blood pressure, electrocardiogram, and anthropometric, haematological, and biochemical measurements. Results There were differences in social and economic circumstances, lifestyles, anthropometric measures and disease both bet tween Indians, Pakistanis, and Bangladeshis and between all South Asians and Europeans. Bangladeshis and Pakistanis were the poorest groups. For most risk factors, the Bangladeshis (particularly men) fared the worst: smoking was most common (57%) in that group, and Bangladeshis had the highest concentrations of triglycerides (2.04 mmol/l) and fasting blood glucose (6.6 mmol/l) and the lowest concentration of high density lipoprotein cholesterol (0.97 mmol/l). Blood pressure, however, was lowest in Bangladeshis. Bangladeshis were the shortest(men 164 cm tall v 170 cm for Indians and 174 cm for Europeans). A higher proportion of Pakistani and Bangladeshi men had diabetes (22.4% and 26.6% respectively) than Indians (15.2%). Comparisons of all South Asians with Europeans hid some important differences, but South Asians were still disadvantaged in a wide range of risk factors. Findings in women were similar. Conclusion Risk of coronary heart disease is not uniform among South Asians, and there are important differences between Indians, Pakistanis, and Bangladeshis for many coronary risk factors. The belief that, except for insulin resistance, South Asians have lo lower levels of coronary risk factors than Europeans is incorrect, and may have arisen fi om combining ethnic subgroups and examining a narrow range of factors.	Univ Newcastle Upon Tyne, Sch Med, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Med, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Epidemiol & Publ Hlth, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Clin Biochem, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Bhopal, R (corresponding author), Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.		White, Martin J. R./G-2410-2010	Patel, Sheila/0000-0002-0626-1899; Unwin, Nigel/0000-0002-1368-1648	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1992, STAT PACK SOC SCI SP; ARMITAGE P, 1994, STAT METHODS MED RES, P436; Balarajan R, 1996, HLTH TRENDS, V28, P45; Barker D. J. P., 1994, MOTHERS BABIES DIS L; *BEDF SCI, 1993, OPER MAN MIN MICR SM; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; Bhopal R, 1996, BRIT MED J, V312, P375; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BURRIN JM, 1985, ANN CLIN BIOCHEM, V22, P327, DOI 10.1177/000456328502200401; Church J., 1996, SOCIAL FOCUS ETHNIC; COLDMAN AJ, 1988, J EPIDEMIOL COMMUN H, V42, P390, DOI 10.1136/jech.42.4.390; Coleman D, 1996, DEMOGRAPHIC CHARACTE; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOWLER PBS, 1985, LANCET, V2, P1363; GUPTA S, 1995, BRIT MED J, V311, P1035, DOI 10.1136/bmj.311.7012.1035; Harland JO, 1997, J EPIDEMIOL COMMUN H, V51, P636, DOI 10.1136/jech.51.6.636; HARRINGTON B, 1993, NEWCASTLE HLTH LIFES; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KARN V, 1996, EMPLOYMENT ED HOUSIN; KNIGHT T, 1993, J EPIDEMIOL COMMUN H, V47, P89, DOI 10.1136/jech.47.2.89; KNIGHT TM, 1992, BRIT HEART J, V67, P343; MARMOT MG, 1984, STUDIES MED POPULATI; MCKEIGUE P, 1994, CORONARY HEART DIS S; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; Mendall MA, 1998, BRIT MED J, V316, P953, DOI 10.1136/bmj.316.7136.953; Modood T., 1997, ETHNIC MINORITIES BR; NATH BS, 1988, LANCET, V2, P39, DOI 10.1016/S0140-6736(88)92962-5; NAZROO JY, 1997, HLTH BRITAINS ETHNIC; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PEACH C, 1996, ETHNIC MINORITY POPU; PETRIE JC, 1990, RECOMMENDATIONS BLOO; Prineas R., 1982, MINNESOTA CODE MANUA; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; RATCLIFE P, 1996, SOCIAL GEOGRAPHY ETH; Rose G, 1982, CARDIOVASCULAR SURVE; Rudat K., 1994, BLACK MINORITY ETHNI; SHAUKAT N, 1994, POSTGRAD MED J, V70, P315, DOI 10.1136/pgmj.70.823.315; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; *WHO MONICA PROJ, 1988, WORLD HLTH STAT Q, V41, P115; WILLIAMS R, 1993, J EPIDEMIOL COMMUN H, V47, P96, DOI 10.1136/jech.47.2.96; WILLIAMS R, 1994, INT J EPIDEMIOL, V23, P28, DOI 10.1093/ije/23.1.28	48	409	409	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					215	+		10.1136/bmj.319.7204.215	http://dx.doi.org/10.1136/bmj.319.7204.215			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417082	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000081720300021
J	Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA				Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA			Oxidative protein folding is driven by the electron transport system	CELL			English	Article							DISULFIDE BOND FORMATION; AEROBIC RESPIRATORY-CHAIN; BD TERMINAL OXIDASE; ESCHERICHIA-COLI; FORMATION INVIVO; IN-VIVO; ENDOPLASMIC-RETICULUM; DSBA; PURIFICATION; PATHWAY	Disulfide bond formation is catalyzed in vivo by DsbA and DsbB. Here we reconstitute this oxidative folding system using purified components. We have found the sources of oxidative power for protein folding and show how disulfide bond formation is linked to cellular metabolism. We find that disulfide bond formation and the electron transport chain are directly coupled. DsbB uses quinones as electron accepters, allowing various choices for electron transport to support disulfide bond formation. Electrons flow via cytochrome bo oxidase to oxygen under aerobic conditions or via cytochrome bd oxidase under partially anaerobic conditions. Under truly anaerobic conditions, menaquinone shuttles electrons to alternate final electron accepters such as fumarate. This flexibility reflects the vital nature of the disulfide catalytic system.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	dballou@umich.edu, David P/A-1298-2007					Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1999, NAT CELL BIOL, V1, pE57, DOI 10.1038/11025; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BELIN P, 1994, MOL GEN GENET, V242, P23, DOI 10.1007/BF00277344; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BULL C, 1981, J BIOL CHEM, V256, P2673; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hennecke J, 1997, J BIOL CHEM, V272, P189; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KITA K, 1984, J BIOL CHEM, V259, P3368; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zeng H, 1998, J BACTERIOL, V180, P3681, DOI 10.1128/JB.180.14.3681-3685.1998	34	308	321	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					217	227		10.1016/S0092-8674(00)81016-8	http://dx.doi.org/10.1016/S0092-8674(00)81016-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428033	Bronze			2022-12-28	WOS:000081632300011
J	Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT				Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT			Role of bacterial intimin in colonic hyperplasia and inflammation	SCIENCE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; CELL-BINDING DOMAIN; EPITHELIAL-CELLS; T-CELLS; MICE; PROTEIN; RESPONSES; SIGNALS; DISEASE; GENE	Enteropathogenic Escherichia coli (EPEC) cells adhere to gut epithelial cells through intimin alpha: the ligand for a bacterially derived epithelial transmembrane protein called the translocated intimin receptor, Citrobacter rodentium colonizes the mouse colon in a similar fashion and uses a different intimin: intimin beta. Intimin alpha was found to costimulate submitogenic signals through the T cell receptor. Dead intimin beta(+) C. rodentium, intimin a-transfected C. rodentium or E. coli strain K12, and EPEC induced mucosal hyperplasia identical to that caused by C. rodentium live infection, as well as a massive T helper cell-type 1 immune response in the colonic mucosa, Mutation of cysteine-937 of intimin to alanine reduced costimulatory activity in vitro and prevented immunopathology in vivo. The mucosal changes elicited by C. rodentium were interferon-gamma-dependent. Immunopathology induced by intimin enables the bacteria to promote conditions that are favorable for increased microbial colonization.	St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Univ Nottingham, Sch Biol Sci, Div Food Sci, Loughborough LE12 5RD, Leics, England	University of London; Queen Mary University London; Imperial College London; University of Nottingham	Higgins, LM (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England.			Connerton, Ian/0000-0001-8652-8938; Higgins, Lisa/0000-0003-2672-1490	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADUROBIE J, 1998, J CLIN MICROBIOL, V36, P662; Bajaj-Elliott M, 1998, J CLIN INVEST, V102, P1473, DOI 10.1172/JCI2792; Brandtzaeg P, 1998, CHEM IMMUNOL, V71, P1; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; Ebert EC, 1996, CELL IMMUNOL, V167, P108, DOI 10.1006/cimm.1996.0013; Eckmann L, 1996, J IMMUNOL, V156, P2894; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; HIGGINS LM, UNPUB; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lai LC, 1997, INFECT IMMUN, V65, P2211, DOI 10.1128/IAI.65.6.2211-2217.1997; Leach MW, 1996, AM J PATHOL, V148, P1503; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SPITZ J, 1995, AM J PHYSIOL-GASTR L, V268, pG374, DOI 10.1152/ajpgi.1995.268.2.G374	24	120	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					588	591		10.1126/science.285.5427.588	http://dx.doi.org/10.1126/science.285.5427.588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417389				2022-12-28	WOS:000081609500039
J	Veverka, J; Thomas, PC; Bell, JF; Bell, M; Carcich, B; Clark, B; Harch, A; Joseph, J; Martin, P; Robinson, M; Murchie, S; Izenberg, N; Hawkins, E; Warren, J; Farquhar, R; Cheng, A; Dunham, D; Chapman, C; Merline, WJ; McFadden, L; Wellnitz, D; Malin, M; Owen, WM; Miller, JK; Williams, BG; Yeomans, DK				Veverka, J; Thomas, PC; Bell, JF; Bell, M; Carcich, B; Clark, B; Harch, A; Joseph, J; Martin, P; Robinson, M; Murchie, S; Izenberg, N; Hawkins, E; Warren, J; Farquhar, R; Cheng, A; Dunham, D; Chapman, C; Merline, WJ; McFadden, L; Wellnitz, D; Malin, M; Owen, WM; Miller, JK; Williams, BG; Yeomans, DK			Imaging of asteroid 433 Eros during NEAR's flyby reconnaissance	SCIENCE			English	Article							INFRARED SPECTROMETER; MULTISPECTRAL IMAGER; PHYSICAL-PROPERTIES; RENDEZVOUS MISSION; 433-EROS; 243-IDA; SHAPE; SATELLITE; DISCOVERY; DACTYL	During the 23 December 1998 flyby of asteroid 433 Eros, the Near-Earth Asteroid Rendezvous (NEAR) spacecraft obtained 222 images of Eros, as well as supporting spectral observations. The images cover slightly more than two-thirds of Eros (best resolution is similar to 400 meters per pixel) and reveal an elongated, cratered body with a linear feature extending for at least 20 kilometers. Our observations show that Eros has dimensions of 33 X 13 X 13 kilometers. The volume, combined with the mass determined by the NEAR radio science experiment, Leads to a density of 2.5 +/- 0.8 grams per cubic centimeter. This relatively high density, and the presence of an extensive Linear feature, suggest that Eros may be a structurally coherent body.	Cornell Univ, Ithaca, NY 14853 USA; Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; SW Res Inst, Boulder, CO 80302 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; Main Space Sci Syst Inc, San Diego, CA USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Cornell University; Northwestern University; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University System of Maryland; University of Maryland College Park; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Veverka, J (corresponding author), Cornell Univ, Space Sci Bldg, Ithaca, NY 14853 USA.		Izenberg, Noam R/F-3952-2015; Murchie, Scott L/E-8030-2015; Wellnitz, Dennis/B-4080-2012; McFadden, Lucy-Ann/I-4902-2013; Dunham, David W/A-5214-2014	Izenberg, Noam R/0000-0003-1629-6478; Murchie, Scott L/0000-0002-1616-8751; McFadden, Lucy-Ann/0000-0002-0537-9975; Dunham, David W/0000-0001-7527-4207				Belton MJS, 1996, ICARUS, V120, P1, DOI 10.1006/icar.1996.0032; BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; BOTTKE WF, IN PRESS ASTRON J; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; Chapman CR, 1996, ICARUS, V120, P231, DOI 10.1006/icar.1996.0048; Chapman CR, 1996, ICARUS, V120, P77, DOI 10.1006/icar.1996.0038; CROFT SK, 1992, ICARUS, V99, P402, DOI 10.1016/0019-1035(92)90156-2; Farquhar RW, 1995, J ASTRONAUT SCI, V43, P353; HAMILTON DP, 1991, ICARUS, V92, P118, DOI 10.1016/0019-1035(91)90039-V; Hawkins SE, 1997, SPACE SCI REV, V82, P31, DOI 10.1023/A:1005099211710; HICKS MD, IN PRESS ICARUS; MERLINE WJ, IN PRESS NATURE; Mitchell DL, 1998, ICARUS, V131, P4, DOI 10.1006/icar.1997.5815; Murchie SL, 1996, J GEOPHYS RES-PLANET, V101, P2201, DOI 10.1029/95JE03438; OSTRO SJ, 1990, ICARUS, V84, P334, DOI 10.1016/0019-1035(90)90042-8; Tholen D.J., 1989, ASTEROIDS, VII, P298; VEVERKA J, 1994, ICARUS, V107, P72, DOI 10.1006/icar.1994.1007; Veverka J, 1997, J GEOPHYS RES-PLANET, V102, P23709, DOI 10.1029/97JE01742; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; Warren JW, 1997, SPACE SCI REV, V82, P101, DOI 10.1023/A:1005015719887; Yeomans DK, 1999, SCIENCE, V285, P560, DOI 10.1126/science.285.5427.560; Yeomans DK, 1995, J ASTRONAUT SCI, V43, P417; ZELLNER B, 1976, ICARUS, V28, P149, DOI 10.1016/0019-1035(76)90097-X	24	54	54	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					562	564		10.1126/science.285.5427.562	http://dx.doi.org/10.1126/science.285.5427.562			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417381				2022-12-28	WOS:000081609500031
J	Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K				Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K			Regulation of cell movement is mediated by stretch-activated calcium channels	NATURE			English	Article							KERATOCYTES; LOCOMOTION; TRANSLOCATION; MICROFILAMENT; MECHANISM; ADHESIONS; MIGRATION; DYNAMICS; TENSION; RELEASE	Intracellular calcium regulates many of the molecular processes that are essential for cell movement(1). It is required for the production of actomyosin-based contractile forces(2-4) the regulation of the structure and dynamics of the actin cytoskeleton(5,6), and the formation and disassembly of cell-substratum adhesions(7,8). Calcium also serves as a second messenger in many biochemical signal-transduction pathways(7). However, despite the pivotal role of calcium in motile processes; it is not clear how calcium regulates overall cell movement. Here we show that transient increases in intracellular calcium, [Ca2+](i), during the locomotion of fish epithelial keratocytes, occur more frequently in cells that become temporarily 'stuck' to the substratum or when subjected to mechanical stretching. We find that calcium transients arise from the activation of stretch-activated calcium channels, which triggers an influx of extracellular calcium. In addition, the subsequent increase in [Ca2+](i) is involved in detachment of the rear cell margin. Thus, we have defined a mechanism by which cells can detect and transduce mechanical forces into biochemical signals that can modulate locomotion.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Mol & Cell Physiol, Chapel Hill, NC 27599 USA; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Connecticut	Lee, J (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA.							Anderson KI, 1996, J CELL BIOL, V134, P1209, DOI 10.1083/jcb.134.5.1209; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; GALBRAITH CG, 1997, MOL BIOL CELL S, V8, P385; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; HARTWIG JH, 1988, CELL MOTIL CYTOSKEL, V10, P117, DOI 10.1002/cm.970100116; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ishihara A, 1997, BIOTECHNIQUES, V23, P268, DOI 10.2144/97232st01; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; Lee J, 1997, J CELL SCI, V110, P2833; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; Palecek SP, 1998, J CELL SCI, V111, P929; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; REES DA, 1989, CELL MOTIL CYTOSKEL, V13, P112, DOI 10.1002/cm.970130206; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1996, MOL BIOL MEMBRANE TR, P201; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STROHMEIER R, 1984, EXP CELL RES, V154, P412, DOI 10.1016/0014-4827(84)90165-4; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0	30	305	318	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					382	386		10.1038/22578	http://dx.doi.org/10.1038/22578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432119				2022-12-28	WOS:000081590000055
J	Mazur, B; Krebbers, E; Tingey, S				Mazur, B; Krebbers, E; Tingey, S			Gene discovery and product development for grain quality traits	SCIENCE			English	Review							DIHYDRODIPICOLINATE SYNTHASE; EXPRESSION; LYSINE; PLANTS; CLONING; CELLS	The composition of oils, proteins, and carbohydrates in seeds of corn, soybean, and other crops has been modified to produce grains with enhanced value. Both plant breeding and molecular technologies have been used to produce plants carrying the desired traits. Genomics-based strategies for gene discovery, coupled with high-throughput transformation processes and miniaturized, automated analytical and functionality assays, have accelerated the identification of product candidates. Molecular marker-based breeding strategies have been used to accelerate the process of moving trait genes into high-yielding germplasm for commercialization. These products are being tested for applications in food, feed, and industrial markets.	Dupont Co, Agr Prod Expt Stn, Wilmington, DE 19880 USA	DuPont	Mazur, B (corresponding author), Dupont Co, Agr Prod Expt Stn, POB 80402, Wilmington, DE 19880 USA.							ALEXANDER DE, 1988, P CORN SORGH IND RES, V43, P97; BERGQUIST RR, 1998, Patent No. 5704160; BERGQUIST RR, 1998, Patent No. 5706603; Brenner S., 1997, U.S. Patent, Patent No. [5 695 934, 5695934]; Brenner S., 1996, U.S. Patent, Patent No. [5 552 278, 5552278]; Caimi PG, 1996, PLANT PHYSIOL, V110, P355, DOI 10.1104/pp.110.2.355; CHUI CF, 1992, Patent No. 14822; DEBLAERE R, 1987, METHOD ENZYMOL, V153, P277; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; FADER G, 1997, Patent No. 47731; FADER G, UNPUB; FALCO SC, 1995, BIO-TECHNOL, V13, P577, DOI 10.1038/nbt0695-577; FALCO SC, COMMUNICATION; GALILI G, 1995, PLANT CELL, V7, P899, DOI 10.2307/3870045; GLANCEY JL, 1998, 981999 SAE; GLASSMAN K, 1989, Patent No. 11789; HERSHEY H, 1997, Patent No. 5608143; HITZ WD, 1994, PLANT PHYSIOL, V105, P635, DOI 10.1104/pp.105.2.635; HITZ WD, UNPUB; HITZ WD, 1998, Patent No. 45448; Hitz WD, 1998, U.S. Patent, Patent No. [5,846,784, 5846784]; HITZ WD, 1996, Patent No. 06936; HUBBARD NL, 1997, Patent No. 22703; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; Kinney A.J., 1998, GENETIC MODIFICATION, P193, DOI DOI 10.1007/978-1-4615-5815-6_10; Kinney AJ, 1996, J FOOD LIPIDS, V3, P273, DOI 10.1111/j.1745-4522.1996.tb00074.x; KLEIN TM, 1987, NATURE, V327, P70, DOI 10.1038/327070a0; KNOWLTON S, 1997, Patent No. 40698; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; Mazur Barbara J., 1995, Current Opinion in Biotechnology, V6, P175, DOI 10.1016/0958-1669(95)80028-X; MAZUR BJ, 1995, TRENDS BIOTECHNOL, V13, P319, DOI 10.1016/S0167-7799(00)88975-1; ODELL JT, 1994, PLANT PHYSIOL, V106, P447, DOI 10.1104/pp.106.2.447; ODELL JT, 1998, Patent No. 16650; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; SHAUL O, 1992, PLANT J, V2, P203, DOI 10.1111/j.1365-313X.1992.00203.x; Shaver JM, 1996, P NATL ACAD SCI USA, V93, P1962, DOI 10.1073/pnas.93.5.1962; Spiker S, 1996, PLANT PHYSIOL, V110, P15, DOI 10.1104/pp.110.1.15; Taylor CB, 1997, PLANT CELL, V9, P1245; TINGEY SV, UNPUB; WALDEN R, 1994, PLANT MOL BIOL, V26, P1521, DOI 10.1007/BF00016488; Yates JR, 1998, ELECTROPHORESIS, V19, P893, DOI 10.1002/elps.1150190604; [No title captured], Patent No. 5604097; 1999, NATURE GENET, V21, P61	44	158	186	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					372	375		10.1126/science.285.5426.372	http://dx.doi.org/10.1126/science.285.5426.372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411493				2022-12-28	WOS:000081465900044
J	Despotis, GJ; Levine, V; Saleem, R; Spitznagel, E; Joist, JH				Despotis, GJ; Levine, V; Saleem, R; Spitznagel, E; Joist, JH			Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial	LANCET			English	Article							ARTERY BYPASS-SURGERY; REDUCE BLOOD-LOSS; CARDIOPULMONARY BYPASS; VONWILLEBRAND-FACTOR; PLATELET-AGGREGATION; DOUBLE-BLIND; ACETATE; METAANALYSIS; VASOPRESSIN; HEMOSTASIS	Background Platelet dysfunction is a major cause of excessive microvascular bleeding after cardiac surgery. A new point-of-care test (hemoSTATUS) can identify patients at risk of excessive bleeding. We aimed to find out whether patients who can benefit from desmopressin during cardiac surgery can be identified by this test. Methods We enrolled 203 patients scheduled for elective cardiac surgery in a prospective, double-blind, placebo-controlled trial. Patients with abnormal hemoSTATUS clot-ratio results (<60% of maximum in channel 5) after discontinuation of cardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51). Patients with normal clot ratios were included in an untreated control group (n=72). Findings Intraoperative platelet counts and clot ratios were significantly higher in the untreated control group than in the study-drug groups. In intensive care, clot ratios in patients who received desmopressin were similar to those in the untreated control group, despite significantly lower platelet counts, but were lower in the placebo group than in the other two groups (p=00001). Compared with the placebo group, patients who received desmopressin had less blood loss in 24 h (mean 624 [SD 209] vs 1028 mt [682] p=0.0004) and required less transfusion of red blood cells (1.1[022] vs 2.2 U [0.32] p=0.009), platelets (0.1 [0.04] vs 1.9 U [4.5] p=0.0001), and fresh-frozen plasma (0.1[0.07] vs 0.75 U [0.21] p=0.0008), and had less total blood-donor exposures (1.56 [0.31] vs 5.2 [0.8] p=0.0001). Placebo patients also had substantially higher blood loss and transfusion requirements than untreated control patients. Interpretation Patients identified with hemoSTATUS as being at increased risk of excessive bleeding after cardiac surgery can benefit from administration of desmopressin. Further studies are, however, needed to confirm these findings as well as to identify the mechanism of action and safety of desmopressin in the clinical setting.	Washington Univ, Sch Med, Dept Anesthesiol & Pathol, Div Biostat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Despotis, GJ (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.							ANDERSSON TLG, 1990, CIRCULATION, V81, P872, DOI 10.1161/01.CIR.81.3.872; CATTANEO M, 1995, THROMB HAEMOSTASIS, V74, P1064; CATTANEO M, 1993, ARTERIOSCLER THROMB, V13, P393, DOI 10.1161/01.ATV.13.3.393; CZER LSC, 1987, J AM COLL CARDIOL, V9, P1139, DOI 10.1016/S0735-1097(87)80319-4; Despotis GJ, 1996, ANESTHESIOLOGY, V85, P1311, DOI 10.1097/00000542-199612000-00012; DESPOTIS GJ, 1994, J THORAC CARDIOV SUR, V107, P271; DESPOTIS GJ, 1995, J THORAC CARDIOV SUR, V110, P46, DOI 10.1016/S0022-5223(05)80008-X; FREMES SE, 1994, ANN THORAC SURG, V58, P1580, DOI 10.1016/0003-4975(94)91636-5; GILL JC, 1986, BLOOD, V67, P758; HACKMANN T, 1989, NEW ENGL J MED, V321, P1437, DOI 10.1056/NEJM198911233212104; HARKER LA, 1986, NEW ENGL J MED, V314, P1446, DOI 10.1056/NEJM198605293142209; HORSTMAN LL, 1995, THROMB RES, V79, P163, DOI 10.1016/0049-3848(95)00102-W; HUMPHRIES JE, 1993, AM J HEMATOL, V44, P12, DOI 10.1002/ajh.2830440104; JOHNS RA, 1990, ANESTHESIOLOGY, V72, P858, DOI 10.1097/00000542-199005000-00016; KHURI SF, 1992, J THORAC CARDIOV SUR, V104, P94; Laupacis A, 1997, ANESTH ANALG, V85, P1258, DOI 10.1097/00000539-199712000-00014; LAZENBY WD, 1990, CIRCULATION, V82, P413; LETHAGEN S, 1992, EUR J HAEMATOL, V49, P7; MANNUCCI PM, 1994, THROMB HAEMOSTASIS, V71, P154; MONGAN PD, 1992, ANESTHESIOLOGY, V77, P38, DOI 10.1097/00000542-199207000-00007; OBRIEN JR, 1989, LANCET, V1, P664, DOI 10.1016/S0140-6736(89)92161-2; PERRIN EJ, 1995, BLOOD COAGUL FIBRIN, V6, P650, DOI 10.1097/00001721-199510000-00005; POCOCK SJ, 1982, BIOMETRICS, V38, P153, DOI 10.2307/2530298; RINDER CS, 1991, ANESTHESIOLOGY, V75, P563, DOI 10.1097/00000542-199110000-00004; SAKARIASSEN KS, 1984, BLOOD, V64, P229; SALZMAN EW, 1986, NEW ENGL J MED, V314, P1402, DOI 10.1056/NEJM198605293142202; SLOAND EM, 1994, AM J HEMATOL, V46, P199, DOI 10.1002/ajh.2830460308; Wahba A, 1997, J CARDIOTHOR VASC AN, V11, P824, DOI 10.1016/S1053-0770(97)90113-0; WOODMAN RC, 1990, BLOOD, V76, P1680	29	76	76	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					106	110		10.1016/S0140-6736(98)12494-7	http://dx.doi.org/10.1016/S0140-6736(98)12494-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408485				2022-12-28	WOS:000081377100012
J	Lidegaard, O				Lidegaard, O			Commentary: Oral contraceptives and myocardial infarction: reassuring new findings	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Lidegaard, O (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1583	1584						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428552				2022-12-28	WOS:000080913100020
J	Altkorn, D; Roach, K; Stern, S; Levinson, W				Altkorn, D; Roach, K; Stern, S; Levinson, W			Update in General Internal Medicine	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; TROGLITAZONE; TRIAL; WOMEN; TAMOXIFEN		Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; Univ Chicago, Med Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago Medical Center	Levinson, W (corresponding author), Univ Chicago, Pritzker Sch Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA.							Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#; Buse JB, 1998, DIABETES CARE, V21, P1455, DOI 10.2337/diacare.21.9.1455; Gitlin N, 1998, ANN INTERN MED, V129, P36, DOI 10.7326/0003-4819-129-1-199807010-00008; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Horton ES, 1998, DIABETES CARE, V21, P1462, DOI 10.2337/diacare.21.9.1462; Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140-6736(97)09528-7; Miettinen TA, 1997, CIRCULATION, V96, P4211; Neuschwander-Tetri BA, 1998, ANN INTERN MED, V129, P38, DOI 10.7326/0003-4819-129-1-199807010-00009; Powles T, 1998, LANCET, V352, P98; Rao PM, 1998, NEW ENGL J MED, V338, P141, DOI 10.1056/NEJM199801153380301; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Veronesi U, 1998, LANCET, V352, P93	15	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					199	206		10.7326/0003-4819-131-3-199908030-00007	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428737				2022-12-28	WOS:000081788700006
J	Bassuk, SS; Glass, TA; Berkman, LF				Bassuk, SS; Glass, TA; Berkman, LF			Social disengagement and incident cognitive decline in community-dwelling elderly persons	ANNALS OF INTERNAL MEDICINE			English	Article						community health services; cognition disorders; aged; social support; social isolation	ALZHEIMERS-DISEASE; MENTAL STATUS; DEMENTIA; EDUCATION; RISK; EPIDEMIOLOGY; METHODOLOGY; INFARCTION; POPULATION; IMPAIRMENT	Background: Social engagement, which is defined as the maintenance of many social connections and a high level of participation in social activities, has been thought to prevent cognitive decline in elderly persons. However, few longitudinal studies of this relation have been done. Objective: To determine the relation between social disengagement and incident cognitive decline in community-dwelling elderly persons. Design: Cohort study. Setting: New Haven, Connecticut. Participants: 2812 noninstitutionalized elderly persons (65 years of age or older) who were interviewed in their homes in 1982, 1985, 1988, and 1994. Measurements: A global social disengagement scale was constructed from the following indicators: presence of a spouse, monthly visual contact with three or more relatives or friends, yearly nonvisual contact with 10 or more relatives or friends, attendance at religious services, group membership, and regular social activities. Cognitive function was assessed with the Short Portable Mental Status Questionnaire. Response to the questionnaire was scored as high, medium, or low. Cognitive decline was defined as a transition to a lower category. Results: Compared with persons who had five or six social ties, those who had no social ties were at increased risk for incident cognitive decline after adjustment for age, initial cognitive performance, sex, ethnicity, education, income, housing type, physical disability, cardiovascular profile, sensory impairment, symptoms of depression, smoking, alcohol use, and level of physical activity. The 3-year odds ratio was 2.24 (95% CI, 1.40 to 3.58; P < 0.001), the 6-year odds ratio was 1.91 (CI, 1.14 to 3.18; P = 0.01), and the 12-year odds ratio was 2.37 (CI, 1.07 to 4.88; P = 0.03). Conclusion: Social disengagement is a risk factor for cognitive impairment among elderly persons.	Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02120 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Bassuk, SS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, 1637 Tremont St, Boston, MA 02120 USA.	sbassuk@hsph.harvard.edu		Glass, Thomas/0000-0003-4399-612X	NIA NIH HHS [N01-AG12102, R01-AG11042, N01-AG02105] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG012102, R01AG011042, N01AG002105] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arbuckle TY, 1986, PSYCHOL AGING, V1, P55, DOI 10.1037/0882-7974.1.1.55; ARBUCKLE TY, 1992, PSYCHOL AGING, V7, P25, DOI 10.1037/0882-7974.7.1.25; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; Bassuk SS, 1998, ARCH GEN PSYCHIAT, V55, P1073, DOI 10.1001/archpsyc.55.12.1073; BEARD CM, 1992, NEUROLOGY, V42, P2063, DOI 10.1212/WNL.42.11.2063; BICKEL H, 1994, PSYCHOL MED, V24, P179, DOI 10.1017/S0033291700026945; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Butler RN, 1997, JAMA-J AM MED ASSOC, V278, P1372, DOI 10.1001/jama.278.16.1372; Christensen H, 1996, AGE AGEING, V25, P72, DOI 10.1093/ageing/25.1.72; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; EISDORFER C, 1992, AM J PSYCHIAT, V149, P190; FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; Ferrucci L, 1996, J AM GERIATR SOC, V44, P237; FIELD TS, 1993, THESIS BOSTON U SCH; GRIBBIN K, 1980, J SOC ISSUES, V36, P47, DOI 10.1111/j.1540-4560.1980.tb02021.x; HEBERT R, 1995, NEUROEPIDEMIOLOGY, V14, P240, DOI 10.1159/000109800; HULTSCH DF, 1993, J GERONTOL, V48, pP1, DOI 10.1093/geronj/48.1.P1; Hurst DF, 1997, ARCH FAM MED, V6, P67, DOI 10.1001/archfami.6.1.67; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KOH K, 1994, AGE AGEING, V23, P195, DOI 10.1093/ageing/23.3.195; LANGER EJ, 1979, J PERS SOC PSYCHOL, V37, P2003, DOI 10.1037/0022-3514.37.11.2003; LARSON EB, 1992, ANNU REV PUBL HEALTH, V13, P431, DOI 10.1146/annurev.pu.13.050192.002243; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; ORRELL M, 1995, BMJ-BRIT MED J, V310, P951, DOI 10.1136/bmj.310.6985.951; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RILEY MW, 1994, AM J PUBLIC HEALTH, V84, P1214, DOI 10.2105/AJPH.84.8.1214; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; Sapolsky RM, 1992, STRESS AGING BRAIN M; Schaie, 1987, COGNITIVE FUNCTIONIN, P24; Seeman TE, 1997, J CLIN ENDOCR METAB, V82, P2458, DOI 10.1210/jc.82.8.2458; Shah BV, 1996, SUDAAN USERS MANUAL; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Sturmer T, 1996, AM J EPIDEMIOL, V143, P683; Tate RB., 1991, J AGING HEALTH, V3, P28, DOI [10.1177/089826439100300102, DOI 10.1177/089826439100300102]; Taylor SE, 1995, HLTH PSYCHOL; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	40	641	651	5	139	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					165	+		10.7326/0003-4819-131-3-199908030-00002	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222ME	10428732				2022-12-28	WOS:000081788700001
J	Moffett, JK; Torgerson, D; Bell-Syer, S; Jackson, D; Llewlyn-Phillips, H; Farrin, A; Barber, J				Moffett, JK; Torgerson, D; Bell-Syer, S; Jackson, D; Llewlyn-Phillips, H; Farrin, A; Barber, J			Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences	BRITISH MEDICAL JOURNAL			English	Article							COPING STRATEGIES; FITNESS PROGRAM; FOLLOW-UP; DISABILITY; THERAPY; BELIEFS	Objective To evaluate effectiveness of an exercise programme in a community setting for patients with low back pain to encourage a return to normal activities. Design Randomised controlled trial of progressive exercise programme compared with usual primary care management Patients' preferences for type of management were elicited independently of randomisation. Participants 187 patients aged 18-60 years with mechanical low back pain of 4 weeks to 6 months' duration. Interventions Exercise classes led by a physiotherapist that included strengthening exercises for all main muscle groups, stretching exercises, relaxation session, and brief education on back care. A cognitive-behavioural approach was used. Main outcome measures Assessments of debilitating effects of back pain before and after intervention and at 6 months and 1 year later. Measures included Poland disability questionnaire, Aberdeen back pain scale, pain diaries, and use of healthcare services. Results At 6 weeks after randomisation, the intervention group improved marginally more than the control group on the disability questionnaire and reported less distressing pain. At 6 months and 1 year, the intervention group showed significantly greater improvement in the disability questionnaire score (mean difference in changes 1.35, 95% confidence interval 0.13 to 2.57). At 1 year, the intervention group also showed significantly greater improvement in the Aberdeen back pain scale (4.44, 1.01 to 7.87) and reported only 378 days off work compared with 607 in the control group. The intervention group used fewer healthcare resources. Outcome was not influenced by patients' preferences. Conclusions The exercise class was more clinically effective than traditional general practitioner management, regardless of patient preference, and was cost effective.	Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ York, Dept Hlth Sci & Clin Evaluat, York YO1 5DD, N Yorkshire, England; Univ London, Imperial Coll, Sch Med, Dept Med Stat & Evaluat, London WC1E 7HU, England	University of York - UK; University of York - UK; Imperial College London; University of London	Moffett, JK (corresponding author), Univ Hull, Inst Rehabil, Hull HU3 2PG, N Humberside, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Farrin, Amanda/0000-0002-2876-0584; Barber, Julie/0000-0001-5762-762X				Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Clement S, 1998, BRIT MED J, V317, P78; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; CROFT PR, 1997, LOW BACK PAIN; Efron B., 1994, MONOGRAPHS STAT APPL; ESTLANDER A, 1989, SCAND J BEHAV THER, V18, P56; FAAS A, 1993, SPINE, V18, P1388; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; HOLMES JA, 1990, HEALTH PSYCHOL, V9, P577, DOI 10.1037/0278-6133.9.5.577; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; McPherson K, 1997, J ROY SOC MED, V90, P652, DOI 10.1177/014107689709001205; MEADE TW, 1995, BRIT MED J, V311, P349, DOI 10.1136/bmj.311.7001.349; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; RUTA DA, 1994, SPINE, V19, P1887, DOI 10.1097/00007632-199409000-00004; SLADE PD, 1983, BEHAV RES THER, V21, P409, DOI 10.1016/0005-7967(83)90010-4; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WADDELL G, 1996, LOW BACK PAIN EVIDEN; WILLIAMS DA, 1991, PAIN, V46, P185, DOI 10.1016/0304-3959(91)90074-8; [No title captured]	24	211	215	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					279	283		10.1136/bmj.319.7205.279	http://dx.doi.org/10.1136/bmj.319.7205.279			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426734	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000081909100018
J	de Villiers, S; Nelson, BK				de Villiers, S; Nelson, BK			Detection of low-temperature hydrothermal fluxes by seawater Mg and Ca anomalies	SCIENCE			English	Article							EAST PACIFIC RISE; CHEMISTRY; RIDGE; DIFFUSE; HEAT; CIRCULATION; DISCRETE; HELIUM; FIELD; OCEAN	Geochemical fluxes into and out of the ocean control its chemical composition. Measurements of the magnesium (Mg) content of seawater, an assumed "conservative" element in the ocean, reveal mid-depth Mg depletions in the vicinity of the East Pacific Rise. The magnitude of the anomalies suggests that fluxes associated with the low-temperature circulation of seawater through axial mid-ocean ridge systems are much larger than the high-temperature axial component. A higher total axial hydrothermal flux provides a mechanism that simultaneously satisfies the mass balance requirement of several major seawater constituents.	Univ Cape Town, Dept Geol Sci, ZA-7701 Rondebosch, South Africa	University of Cape Town	de Villiers, S (corresponding author), Univ Cape Town, Dept Geol Sci, Box 35-1310, ZA-7701 Rondebosch, South Africa.		de Villiers, Stephanie/A-6079-2008	de Villiers, Stephanie/0000-0002-7500-6293				BAKER ET, 1993, EARTH PLANET SC LETT, V118, P235, DOI 10.1016/0012-821X(93)90170-E; Berner EK, 1987, GLOBAL WATER CYCLE G; Charlou JL, 1996, GEOPHYS RES LETT, V23, P3491, DOI 10.1029/96GL02141; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; de Villiers S, 1998, EARTH PLANET SC LETT, V164, P627, DOI 10.1016/S0012-821X(98)00232-5; DEWIT MJ, 1993, LITHOS, V30, P309, DOI 10.1016/0024-4937(93)90043-C; DREVER JI, 1977, CYCLES MAJOR ELEMENT; Edmonds HN, 1996, GEOPHYS RES LETT, V23, P3487, DOI 10.1029/96GL01597; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Hardie LA, 1996, GEOLOGY, V24, P279, DOI 10.1130/0091-7613(1996)024<0279:SVISCA>2.3.CO;2; Holland HD., 1984, CHEM EVOLUTION ATMOS; ISHIBASHI JI, 1994, EARTH PLANET SC LETT, V128, P183, DOI 10.1016/0012-821X(94)90144-9; KADKO D, 1995, SEAFLOOR HYDROTHERMA, P446; LUPTON JE, 1981, SCIENCE, V214, P13, DOI 10.1126/science.214.4516.13; MCDUFF RE, 1980, ENVIRON SCI TECHNOL, V14, P1182, DOI 10.1021/es60170a007; MERLIVAT L, 1987, EARTH PLANET SC LETT, V84, P100, DOI 10.1016/0012-821X(87)90180-4; MILLIMAN JD, 1993, GLOBAL BIOGEOCHEM CY, V7, P927, DOI 10.1029/93GB02524; MOTTL MJ, 1994, GEOCHIM COSMOCHIM AC, V58, P2225, DOI 10.1016/0016-7037(94)90007-8; Ostlund H.G., 1987, GEOSECS ATLANTIC PAC; Pilson M. E. Q., 1998, INTRO CHEM SEA; RONA PA, 1992, EARTH PLANET SC LETT, V109, P57, DOI 10.1016/0012-821X(92)90074-6; Schultz A, 1997, PHILOS T R SOC A, V355, P387, DOI 10.1098/rsta.1997.0014; SCHULTZ A, 1992, J GEOPHYS RES-SOL EA, V97, P12299, DOI 10.1029/92JB00889; VONDAMM KL, 1985, GEOCHIM COSMOCHIM AC, V49, P2197, DOI 10.1016/0016-7037(85)90222-4; WHEAT CG, 1994, J GEOPHYS RES-SOL EA, V99, P3067, DOI 10.1029/93JB01612; Wolery T. J., 1988, CHEM CYCLES EVOLUTIO, P77	26	46	47	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					721	723		10.1126/science.285.5428.721	http://dx.doi.org/10.1126/science.285.5428.721			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426991				2022-12-28	WOS:000081765100050
J	DiSalvo, FJ				DiSalvo, FJ			Thermoelectric cooling and power generation	SCIENCE			English	Review							MERIT; FIGURE	In a typical thermoelectric device, a junction is formed from two different conducting materials, one containing positive charge carriers (holes) and the other negative charge carriers (electrons). When an electric current is passed in the appropriate direction through the junction, both types of charge carriers move away from the junction and convey heat away, thus cooling the junction. Similarly, a heat source at the junction causes carriers to flow away from the junction, making an electrical generator. Such devices have the advantage of containing no moving parts, but low efficiencies have limited their use to specialty applications, such as cooling laser diodes. The principles of thermoelectric devices are reviewed and strategies for increasing the efficiency of novel materials are explored. Improved materials would not only help to cool advanced electronics but could also provide energy benefits in refrigeration and when using waste heat to generate electrical power.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	DiSalvo, FJ (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	fjd3@cornell.edu						Balandin A, 1998, J APPL PHYS, V84, P6149, DOI 10.1063/1.368928; Chasmar RP., 1959, J ELECT CONTR, V7, P52, DOI [10.1080/00207215908937186, DOI 10.1080/00207215908937186]; Chen G, 1998, PHYS REV B, V57, P14958, DOI 10.1103/PhysRevB.57.14958; Dreizler R.M., 1990, DENSITY FUNCTIONAL T; Dresselhaus MS, 1997, MATER RES SOC SYMP P, V478, P55, DOI 10.1557/PROC-478-55; GSCHNEIDER KA, 1985, HDB PHYS CHEM RARE E, V2, P797; GSCHNEIDER KA, 1993, HDB PHYS CHEM RARE E, V16, P105; GSCHNEIDER KA, 1994, HDB PHYS CHEM RARE E, V19, P177; Hicks LD, 1996, PHYS REV B, V53, P10493, DOI 10.1103/PhysRevB.53.R10493; Jones CDW, 1998, PHYS REV B, V58, P16057, DOI 10.1103/PhysRevB.58.16057; Mahan G, 1997, PHYS TODAY, V50, P42, DOI 10.1063/1.881752; Mahan GD, 1998, SOLID STATE PHYS, V51, P81; MENG JQ, UNPUB, P76401; RODGERS JP, 1993, MATER RES SOC B, V18; Sales BC, 1998, MRS BULL, V23, P15, DOI 10.1557/S0883769400031419; *SEM, 1994, NAT SEM ROADM; Slack G.A., 1995, CRC HDB THERMOELECTR, P407; Tritt TM, 1999, SCIENCE, V283, P804, DOI 10.1126/science.283.5403.804; VENKATASUBRAMAN.R, COMMUNICATION	19	2458	2600	59	1383	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					703	706		10.1126/science.285.5428.703	http://dx.doi.org/10.1126/science.285.5428.703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426986				2022-12-28	WOS:000081765100045
J	Wu, J; Song, YL; Bakker, ABH; Bauer, S; Spies, T; Lanier, LL; Phillips, JH				Wu, J; Song, YL; Bakker, ABH; Bauer, S; Spies, T; Lanier, LL; Phillips, JH			An activating immunoreceptor complex formed by NKG2D and DAP10	SCIENCE			English	Article							NATURAL-KILLER-CELLS; TYROSINE-PHOSPHATASE 1C; INHIBITORY RECEPTOR; ASSOCIATION; MOTIF; CD28	Many immune receptors are composed of separate Ligand-binding and signal-transducing subunits. In natural killer (NK) and T cells, DAP10 was identified as a cell surface adaptor protein in an activating receptor complex with NKG2D, a receptor for the stress-inducible and tumor-associated major histocompatibility complex molecule MICA. Within the DAP10 cytoplasmic domain, an Src homology 2 (SH2) domain-binding site was capable of recruiting the p85 subunit of the phosphatidylinositol 3-kinase (PI 3-kinase), providing for NKG2D-dependent signal transduction. Thus, NKG2D-DAP10 receptor complexes may activate NK and T cell responses against MICA-bearing tumors.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Fred Hutchinson Cancer Center	Lanier, LL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	lanier@dnax.org	Lanier, Lewis L/E-2139-2014; Bakker, Arnold B./F-8494-2010	Lanier, Lewis L/0000-0003-1308-3952; Bakker, Arnold B./0000-0003-1489-1847; Bauer, Stefan/0000-0002-8462-1845	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030581, R37AI030581] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30581] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZUMA M, 1992, J IMMUNOL, V149, P1115; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; GROH V, 1988, P NATL ACAD SCI USA, V279, P1737; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LANIER LL, 1995, J IMMUNOL, V154, P97; Mason LH, 1996, J EXP MED, V184, P2119, DOI 10.1084/jem.184.6.2119; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; SONGYANG Z, 1996, CELL, V72, P767; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; Wu J.-Y., UNPUB	17	826	891	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					730	732		10.1126/science.285.5428.730	http://dx.doi.org/10.1126/science.285.5428.730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426994				2022-12-28	WOS:000081765100053
J	Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR				Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR			13S condensin actively reconfigures DNA by introducing global positive writhe: Implications for chromosome condensation	CELL			English	Article							TOPOISOMERASE-II; SUPERCOILED DNA; PROTEIN FAMILY; IN-VITRO; SMC; SEGREGATION; MECHANISM; BINDING; RECOMBINATION; REPLICATION	Xenopus 13S condensin converts interphase chromatin into mitotic-like chromosomes, and, in the presence of ATP and a type I topoisomerase, introduces (+) supercoils into DNA. The specific production of (+) trefoil knots in the presence of condensin and a type II topoisomerase shows that condensin reconfigures DNA by introducing an ordered, global, (+) writhe. Knotting required ATP hydrolysis and cell cycle-specific phosphorylation of condensin. Condensin bound preferentially to (+) supercoiled DNA in the presence of ATP but not in its absence. Our results suggest a mechanism for the compaction of chromatin by condensin during mitosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California Berkeley; Cold Spring Harbor Laboratory	Kimura, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NIGMS NIH HHS [GM 31655, GM 53926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926, R01GM031655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DARCY LD, 1997, KNOTS 96, P267; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	37	264	275	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					239	248		10.1016/S0092-8674(00)81018-1	http://dx.doi.org/10.1016/S0092-8674(00)81018-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428035	Bronze			2022-12-28	WOS:000081632300013
J	Dieckmann, U; Doebeli, M				Dieckmann, U; Doebeli, M			On the origin of species by sympatric speciation	NATURE			English	Article							ADAPTIVE RADIATION; NATURAL-SELECTION; SEXUAL SELECTION; MODEL; DYNAMICS; ANIMALS	Understanding speciation is a fundamental biological problem. It is believed that many species originated through allopatric divergence, where new species arise from geographically isolated populations of the same ancestral species(1-3). In contrast, the possibility of sympatric speciation (in which new species arise without geographical isolation) has often been dismissed, partly because of theoretical difficulties(2,3). Most previous models analysing sympatric speciation concentrated on particular aspects of the problem while neglecting others(4-10). Here we present a model that integrates a novel combination of different features and show that sympatric speciation is a likely outcome of competition for resources. We use multilocus genetics to describe sexual reproduction in an individual-based model, and we consider the evolution of assortative mating (where individuals mate preferentially with like individuals) depending either on an ecological character affecting resource use or on a selectively neutral marker trait. In both cases, evolution of assortative mating often leads to reproductive isolation between ecologically diverging subpopulations. When assortative mating depends on a marker trait, and is therefore not directly linked to resource competition, speciation occurs when genetic drift breaks the linkage equilibrium between the marker and the ecological trait. Our theory conforms well with mounting empirical evidence for the-sympatric origin of many species(10-18).	Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria; Univ Basel, Inst Zool, CH-4051 Basel, Switzerland	International Institute for Applied Systems Analysis (IIASA); University of Basel	Dieckmann, U (corresponding author), Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria.		Doebeli, Michael/D-5391-2012; Gilbert, Marcus TP/A-8936-2013; Dieckmann, Ulf/E-1424-2011	Gilbert, Marcus TP/0000-0002-5805-7195; Dieckmann, Ulf/0000-0001-7089-0393				BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Dieckmann U, 1997, TRENDS ECOL EVOL, V12, P128, DOI 10.1016/S0169-5347(97)01004-5; Doebeli M, 1997, EVOLUTION, V51, P1730, DOI 10.1111/j.1558-5646.1997.tb05097.x; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Geritz SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681; Johannesson K, 1995, EVOLUTION, V49, P1180, DOI 10.1111/j.1558-5646.1995.tb04445.x; Johnson PA, 1996, EVOL ECOL, V10, P187, DOI 10.1007/BF01241784; KNOX EB, 1995, P NATL ACAD SCI USA, V92, P10349, DOI 10.1073/pnas.92.22.10349; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mayr E., 1963, ANIMAL SPECIES EVOLU; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MEZ JAJ, 1996, STOCHASTIC SPATIAL S, P183; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; ROSENZWEIG ML, 1978, BIOL J LINN SOC, V10, P275, DOI 10.1111/j.1095-8312.1978.tb00016.x; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; SCHLUTER D, 1993, TRENDS ECOL EVOL, V8, P197, DOI 10.1016/0169-5347(93)90098-A; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; SEGER J, 1985, EVOLUTOIN ESSAYS HON; Taylor EB, 1999, BIOL J LINN SOC, V66, P271, DOI 10.1111/j.1095-8312.1999.tb01891.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093	30	1199	1234	8	631	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					354	357		10.1038/22521	http://dx.doi.org/10.1038/22521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432112	Green Submitted			2022-12-28	WOS:000081590000047
J	Selam, JL				Selam, JL			Implantable insulin pumps	LANCET			English	Editorial Material							INTRAPERITONEAL; MULTICENTER; INFUSION; GLUCOSE		Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Selam, JL (corresponding author), Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France.							ABRAIRA C, 1995, DIABETES CARE, V18, P1112; ALBISSER AM, 1974, DIABETES, V23, P397, DOI 10.2337/diab.23.5.397; BLACKSHEAR P J, 1970, Surgical Forum (Chicago), V21, P136; BLACKSHEAR PJ, 1979, DIABETES, V28, P634, DOI 10.2337/diabetes.28.7.634; BROUSSOLLE C, 1994, LANCET, V343, P514, DOI 10.1016/S0140-6736(94)91462-1; Duckworth WC, 1998, DIABETES CARE, V21, P1596, DOI 10.2337/diacare.21.10.1596; DUCKWORTH WC, 1992, DIABETES, V41, P657, DOI 10.2337/diabetes.41.6.657; HAARDT MJ, 1994, DIABETES CARE, V17, P847, DOI 10.2337/diacare.17.8.847; HANAIREBROUTIN H, 1995, DIABETES CARE, V18, P388, DOI 10.2337/diacare.18.3.388; LassmannVague V, 1997, DIABETES METAB, V23, P234; Laube BL, 1998, CHEST, V114, P1734, DOI 10.1378/chest.114.6.1734; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; Selam JL, 1995, DIABETIC MED, V12, P1102, DOI 10.1111/j.1464-5491.1995.tb00428.x	13	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					178	179		10.1016/S0140-6736(99)90034-X	http://dx.doi.org/10.1016/S0140-6736(99)90034-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421296				2022-12-28	WOS:000081504200006
J	Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG				Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG			Prevention of graft versus host disease by inactivation of host antigen-presenting cells	SCIENCE			English	Article							BONE-MARROW TRANSPLANTATION; CD8+ T-CELLS; HISTOCOMPATIBILITY ANTIGEN; DENDRITIC CELLS; LYMPHOCYTES; DEFICIENT; TOLERANCE; PROTEINS; MICE	Craft versus host disease, an alloimmune attack on host tissues mounted by donor T cells, is the most important toxicity of allogeneic bone marrow transplantation. The mechanism by which allogeneic T cells are initially stimulated is unknown. In a murine allogeneic bone marrow transplantation model it was found that, despite the presence of numerous donor antigen-presenting cells, only host-derived antigen-presenting cells initiated graft versus host disease. Thus, strategies for preventing graft versus host disease could be developed that are based on inactivating host antigen-presenting cells. Such strategies could expand the safety and application of allogeneic bone marrow transplantation in treatment of common genetic and neoplastic diseases.	Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	University of Pennsylvania; University of Pennsylvania; Yale University; Yale University; Yale University; Yale University	Emerson, SG (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959	NHLBI NIH HHS [P50HL-54516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BEVAN MJ, 1995, J EXP MED, V182, P639, DOI 10.1084/jem.182.3.639; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CHAO NJ, 1996, GRAFT VS HOST DIS, P639; DEEG HJ, 1996, GRAFT VS HOST DIS, P311; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; FERRARA JLM, 1994, BONE MARROW TRANSPL, V14, P183; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HOROWITZ MM, 1990, BLOOD, V75, P555; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORNGOLD R, 1982, J EXP MED, V155, P872, DOI 10.1084/jem.155.3.872; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; MAIER T, 1996, GRAFT VS HOST DIS, P75; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; STREILEIN JW, 1970, J EXP MED, V132, P163, DOI 10.1084/jem.132.1.163; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TRUITT RL, 1991, BLOOD, V77, P2515; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; WEIDEN PL, 1976, J IMMUNOL, V116, P1212	23	957	988	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					412	415		10.1126/science.285.5426.412	http://dx.doi.org/10.1126/science.285.5426.412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411505				2022-12-28	WOS:000081465900056
J	Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J				Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J			Vesicular tubular clusters between the ER and Golgi mediate concentration of soluble secretory proteins by exclusion front COPI-coated vesicles	CELL			English	Article							PANCREATIC ACINAR CELL; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; INTERMEDIATE COMPARTMENT; SELECTIVE TRANSPORT; EXOCRINE PANCREAS; THIN-SECTIONS; LIVING CELLS; BULK FLOW; CARGO	We have determined the concentrations of the secretory proteins amylase and chymotrypsinogen and the membrane proteins KDELr and rBet1 in COPII- and COPI-coated pre-Golgi compartments of pancreatic cells by quantitative immunoelectron microscopy. COPII was confined to ER membrane buds and adjacent vesicles. COPI occurred on vesicular tubular clusters (VTCs), Golgi cisternae, the trans-Golgi network, and immature secretory granules. Both secretory proteins exhibited a first, significant concentration step in noncoated segments of VTC tubules and were excluded from COPI-coated tips. By contrast, KDELr and rBet1 showed a first, significant concentration in COPII-coated ER buds and vesicles and were prominently present in COPI-coated tips of VTC tubules. These data suggest an important role of VTCs in soluble cargo concentration by exclusion from COPI-coated domains.	Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Klumperman, J (corresponding author), Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.							Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1998, HISTOCHEM CELL BIOL, V109, P463, DOI 10.1007/s004180050248; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENDAYAN M, 1984, HISTOCHEM J, V16, P85, DOI 10.1007/BF01003438; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DIJKHOF J, 1978, BIOCHIM BIOPHYS ACTA, V543, P167, DOI 10.1016/0304-4165(78)90062-4; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GEUZE HJ, 1980, EUR J CELL BIOL, V21, P93; GEUZE JJ, 1979, J CELL BIOL, V82, P697, DOI 10.1083/jcb.82.3.697; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MartinezMenarguez JA, 1996, EUR J CELL BIOL, V71, P137; Nickel W, 1998, J CELL SCI, V111, P3081; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; POSTHUMA G, 1987, J HISTOCHEM CYTOCHEM, V35, P405, DOI 10.1177/35.4.2434559; POSTHUMA G, 1984, J HISTOCHEM CYTOCHEM, V32, P1028, DOI 10.1177/32.10.6207220; POSTHUMA G, 1988, EUR J CELL BIOL, V46, P327; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEELE G, 1985, J BIOL CHEM, V260, P926; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SESSO A, 1994, J CELL SCI, V107, P517; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	55	247	251	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					81	90		10.1016/S0092-8674(00)80608-X	http://dx.doi.org/10.1016/S0092-8674(00)80608-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412983	Bronze			2022-12-28	WOS:000081451000010
J	Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER				Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER			Analysis of questions asked by family doctors regarding patient care	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; INFORMATION NEEDS; CLINICAL QUESTIONS; PHYSICIANS	Objectives To characterise the information needs of: family doctors by collecting the questions they asked about patient care during consultations and to classify these in ways that would be useful to developers of knowledge bases. Design Observational study in which investigators visited doctors for two half days and collected their questions. Taxonomies were developed to characterise the clinical topic and generic type of information sought for each question. Setting Eastern Iowa. Participants Random sample of 103 family doctors. Main outcome measures Number of questions posed, pursued, and answered; topic and generic type of information sought for each question; time spent pursuing answers; information resources used. Results Participants asked a total of 1101 questions. Questions about drug prescribing obstetrics and gynaecology, and adult infectious disease were most common and comprised 36% of all questions. The taxonomy of generic questions included 69 categories; the three most common types, comprising 24% of all questions, were "What is the cause of symptom X?" "What is the dose of drug X?" and "How should I manage disease or finding X?" Answers to most questions (702, 64%) were not immediately pursued, but, of those pursued, most (318, 80%) were answered. Doctors spent an average of less than 2 minutes pursuing an answer, and they used readily available print and human resources. Only two questions led to a formal literature search. Conclusions Family doctors in this study did not pursue answers to most of their questions. Questions about patient care can be organised into a limited number of generic types, which could help guide the efforts of knowledge base developers.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Amer Coll Phys, Amer Soc Internal Med, Philadelphia, PA USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC USA; Univ Iowa, Student Hlth Serv, Iowa City, IA USA	University of Iowa; American College of Physicians; Michigan State University; Moses Cone Memorial Hospital; University of Iowa	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, 200 Hawkins Dr,01291-D PFP, Iowa City, IA 52242 USA.		Bergus, George/AAS-9522-2021	Levy, Barcey/0000-0002-3315-4116				Chambliss ML, 1996, J FAM PRACTICE, V43, P140; CIMINO JJ, 1993, B MED LIBR ASSOC, V81, P195; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; EBELL MH, 1998, MD COMPUTING, V15, P189; ELY JW, 1992, J FAM PRACTICE, V35, P265; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Haug JD, 1997, B MED LIBR ASSOC, V85, P223; HUTH EJ, 1994, ANN INTERN MED, V120, P889, DOI 10.7326/0003-4819-120-10-199405150-00012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; REYNOLDS RD, 1995, J FAM PRACTICE, V41, P583; Sackett D. L., 1997, EVIDENCE BASED MED P; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Shaughnessy AF, 1998, J FAM PRACTICE, V47, P425; Smith R, 1996, BRIT MED J, V313, P1062; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; VERHOEVEN AAH, 1995, B MED LIBR ASSOC, V83, P85; WILSON SR, 1989, USE CRITICAL INCIDEN; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	23	338	343	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					358	361		10.1136/bmj.319.7206.358	http://dx.doi.org/10.1136/bmj.319.7206.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435959	Bronze, Green Published			2022-12-28	WOS:000082001700021
J	Fleming, R				Fleming, R			Horace Townshend Fleming - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					388	388		10.1136/bmj.319.7206.388	http://dx.doi.org/10.1136/bmj.319.7206.388			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435983	Green Published			2022-12-28	WOS:000082001700064
J	Haggerty, SE				Haggerty, SE			Earth and planetary sciences - A diamond trilogy: Superplumes, supercontinents, and supernovae	SCIENCE			English	Review							CARBON ISOTOPIC COMPOSITION; INTERSTELLAR DIAMONDS; CONTINENTAL-CRUST; METAMORPHIC ROCKS; UPPER-MANTLE; METASTABLE CONDITIONS; PRIMITIVE METEORITES; GRAPHITIZED DIAMONDS; NITROGEN AGGREGATION; PERIDOTITE MASSIF	Diamond is a remarkable mineral and has been long recognized for its unusual physical and chemical properties: robust and widespread in industry, yet regally adorned. This diversity is even greater than formally appreciated because diamond is recognized as an extraordinary recorder of astrophysical and geodynamic events that extend from the far reaches of space to Earth's deep interior. Many diamonds are natural antiques that formed in presolar supernovae by carbon vapor deposition, in asteroidal impacts and meteorite craters by shock metamorphism, and in Earth's mantle 1 to 2 billion years after planetary accretion from fluids and melts. The carbon in diamond is primordial, but there are unexplained isotopic fractionations and uncertainties in heterogeneity.	Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Haggerty, SE (corresponding author), Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA.							AGEE CB, 1993, ANNU REV EARTH PL SC, V21, P19, DOI 10.1146/annurev.earth.21.1.19; Alexander CMO, 1998, METEORIT PLANET SCI, V33, P603, DOI 10.1111/j.1945-5100.1998.tb01667.x; ALLAMANDOLA LJ, 1993, SCIENCE, V260, P64, DOI 10.1126/science.11538059; ALT JC, 1993, EARTH PLANET SC LETT, V119, P477, DOI 10.1016/0012-821X(93)90057-G; ANDERS E, 1994, ICARUS, V112, P303, DOI 10.1006/icar.1994.1185; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; ANDERSON DL, 1994, GEOLOGY, V22, P39, DOI 10.1130/0091-7613(1994)022<0039:SOS>2.3.CO;2; ANDERSON DL, 1984, SCIENCE, V223, P347, DOI 10.1126/science.223.4634.347; ARIMA M, 1993, GEOLOGY, V21, P968, DOI 10.1130/0091-7613(1993)021<0968:CODFAS>2.3.CO;2; ARNETT WD, 1985, NUCLEOSYNTHESIS CHAL; BAI WJ, 1993, CAN J EARTH SCI, V30, P1650, DOI 10.1139/e93-143; BERKLEY JL, 1980, GEOCHIM COSMOCHIM AC, V44, P1579, DOI 10.1016/0016-7037(80)90119-2; BERKLEY JL, 1983, GEOCHIM COSMOCHIM AC, V47, P979, DOI 10.1016/0016-7037(83)90166-7; BERNATOWICZ T, 1987, NATURE, V330, P728, DOI 10.1038/330728a0; BERNATOWICZ T, 1997, PHYSICS TODAY    DEC, P26; BERNATOWICZ TJ, 1990, ASTROPHYS J, V359, P246, DOI 10.1086/169056; BICKFORD ME, 1988, GEOL SOC AM BULL, V100, P1375, DOI 10.1130/0016-7606(1988)100<1375:TFOCCP>2.3.CO;2; BLACK DC, 1969, EARTH PLANET SC LETT, V6, P395, DOI 10.1016/0012-821X(69)90190-3; BOYD FR, 1985, NATURE, V315, P387, DOI 10.1038/315387a0; BOYD FR, 1986, SCIENCE, V232, P472, DOI 10.1126/science.232.4749.472; BOYD SR, 1994, CHEM GEOL, V116, P43, DOI 10.1016/0009-2541(94)90157-0; BOYD SR, 1992, EARTH PLANET SC LETT, V109, P633, DOI 10.1016/0012-821X(92)90121-B; Bruton E, 1978, DIAMONDS; BULANOVA GP, 1995, J GEOCHEM EXPLOR, V53, P1, DOI 10.1016/0375-6742(94)00016-5; BURKE DF, 1988, NATURE, V332, P611; BURKE K, 1986, TECTONICS, V5, P439, DOI 10.1029/TC005i003p00439; CARLISLE DB, 1991, NATURE, V352, P708, DOI 10.1038/352708a0; Cartigny P, 1998, SCIENCE, V280, P1421, DOI 10.1126/science.280.5368.1421; CHASSIDON M, 1987, NATURE, V330, P242; CLARKE RS, 1981, NATURE, V291, P396, DOI 10.1038/291396a0; CLAYTON DD, 1995, ASTROPHYS J, V447, P894, DOI 10.1086/175927; Clayton DD, 1999, SCIENCE, V283, P1290, DOI 10.1126/science.283.5406.1290; CLAYTON DD, 1989, ASTROPHYS J, V340, P613, DOI 10.1086/167422; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P1313, DOI 10.1016/0016-7037(88)90286-4; COFFIN MF, 1994, REV GEOPHYS, V32, P1, DOI 10.1029/93RG02508; COLEMAN RG, 1995, ULTRAHIGH PRESSURE M; CONDIE KC, 1986, PRECAMBRIAN RES, V32, P261, DOI 10.1016/0301-9268(86)90032-X; CROUGH ST, 1980, EARTH PLANET SC LETT, V50, P260, DOI 10.1016/0012-821X(80)90137-5; DALTON TL, 1996, GEOCHIM COSMOCHIM AC, V60, P4853; DAVIES GF, 1979, EARTH PLANET SC LETT, V44, P231, DOI 10.1016/0012-821X(79)90171-7; DAVIES GR, 1993, GEOLOGY, V21, P471, DOI 10.1130/0091-7613(1993)021<0471:TIOGDF>2.3.CO;2; Dawson J.B., 1980, KIMBERLITES THEIR XE; DAWSON JB, 1987, ALKALINE IGNEOUS ROC, P95; DAWSON JB, 1986, NATURE LOWER CONTINE; De Corte K, 1998, GEOCHIM COSMOCHIM AC, V62, P3765, DOI 10.1016/S0016-7037(98)00266-X; De S, 1998, EARTH PLANET SC LETT, V164, P421, DOI 10.1016/S0012-821X(98)00229-5; DECARLI PS, 1961, SCIENCE, V133, P1821, DOI 10.1126/science.133.3467.1821; DEINES P, 1991, GEOCHIM COSMOCHIM AC, V55, P2615, DOI 10.1016/0016-7037(91)90377-H; DEINES P, 1989, GEOCHIM COSMOCHIM AC, V53, P1367, DOI 10.1016/0016-7037(89)90069-0; DEINES P, 1980, GEOCHIM COSMOCHIM AC, V44, P943, DOI 10.1016/0016-7037(80)90284-7; DEINES P, 1995, GEOCHIM COSMOCHIM AC, V59, P3173, DOI 10.1016/0016-7037(95)00205-E; DEINES P, 1992, EARLY ORGANIC EVOLUT, P133; DEINES P, 1989, CARBONATITES GENESIS, P301; DEVRIES RC, 1987, ANNU REV MATER SCI, V17, P161; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; DEWIT MJ, 1993, LITHOS, V30, P309, DOI 10.1016/0024-4937(93)90043-C; DOBRZHINETSKAYA LF, 1995, GEOLOGY, V23, P597, DOI 10.1130/0091-7613(1995)023<0597:MIHGMR>2.3.CO;2; DURRHEIM RJ, 1991, GEOLOGY, V19, P606, DOI 10.1130/0091-7613(1991)019<0606:AAPCEE>2.3.CO;2; EGGLER DH, 1987, MANTLE METASOMATISM, P21; Eide EA, 1996, EARTH PLANET SC LETT, V144, P389, DOI 10.1016/S0012-821X(96)00176-8; ELDRIDGE CS, 1991, NATURE, V353, P649, DOI 10.1038/353649a0; ERNST WG, 1996, GEOPHYS MONOGR SER, V96, P171; EVANS T, 1982, PROC R SOC LON SER-A, V381, P159, DOI 10.1098/rspa.1982.0063; Field E.J., 1992, PROPERTIES NATURAL S; Field J. E., 1979, PROPERTIES DIAMOND; FINGER LW, 1991, ACTA CRYSTALLOGR B, V47, P561, DOI 10.1107/S0108768191004214; FINNIE KS, 1994, GEOCHIM COSMOCHIM AC, V58, P5173, DOI 10.1016/0016-7037(94)90302-6; FOLEY SF, 1990, P INDIAN AS-EARTH, V99, P57; FOUNTAIN DM, 1992, CONTINENTAL LOWER CR, V23; GALIMOV EM, 1991, GEOCHIM COSMOCHIM AC, V55, P1697, DOI 10.1016/0016-7037(91)90140-Z; GOODRICH CA, 1987, GEOCHIM COSMOCHIM AC, V51, P2255, DOI 10.1016/0016-7037(87)90279-1; GOODRICH CA, 1986, GEOCHIM COSMOCHIM AC, V50, P681, DOI 10.1016/0016-7037(86)90345-5; GREINER NR, 1988, NATURE, V333, P440, DOI 10.1038/333440a0; GRIFFITHS RW, 1990, EARTH PLANET SC LETT, V99, P66, DOI 10.1016/0012-821X(90)90071-5; GURNEY JJ, 1989, GEOL SOC AUSTR SPEC, V14, P935; Haggerty S.E., 1998, P 5 NIRIM INT S ADV, P39; HAGGERTY SE, 1995, J GEODYN, V20, P331, DOI 10.1016/0264-3707(95)00016-3; HAGGERTY SE, 1990, SCIENCE, V248, P993, DOI 10.1126/science.248.4958.993; HAGGERTY SE, 1994, EARTH PLANET SC LETT, V122, P57, DOI 10.1016/0012-821X(94)90051-5; HAGGERTY SE, 1986, NATURE, V320, P34, DOI 10.1038/320034a0; Haggerty SE., 1989, CARBONATITES GENESIS, P546; Haggerty SE, 1990, CONTINENTAL MANTLE, P87; HALL HT, 1970, SCIENCE, V169, P868, DOI 10.1126/science.169.3948.868; Hamilton WB, 1998, PRECAMBRIAN RES, V91, P143, DOI 10.1016/S0301-9268(98)00042-4; HARLOW GE, 1998, NATURE DIAMONDS; Harris J, 1997, NATURE, V387, P486, DOI 10.1038/387486a0; Harris J.W., 1992, PROPERTIES NATURAL S, P345; Harte B., 1994, MINERAL MAG A, V58A, P384, DOI DOI 10.1180/MINMAG.1994.58A.1.201; HAZEN RM, 1993, NEW ALCHEMISTS; Henning T, 1998, SCIENCE, V282, P2204, DOI 10.1126/science.282.5397.2204; HERZBERG CT, 1993, EARTH PLANET SC LETT, V120, P13, DOI 10.1016/0012-821X(93)90020-A; HEYMANN D, 1994, SCIENCE, V265, P645, DOI 10.1126/science.265.5172.645; HEYMANN D, 1979, P LUNAR PLANET SCI, V10, P1943; HILDEBRAND AR, 1991, GEOLOGY, V19, P867, DOI 10.1130/0091-7613(1991)019<0867:CCAPCT>2.3.CO;2; Hill HGM, 1997, METEORIT PLANET SCI, V32, P713, DOI 10.1111/j.1945-5100.1997.tb01556.x; Hill HGM, 1998, ASTRON ASTROPHYS, V336, pL41; HOFFMAN PF, 1990, PHILOS T ROY SOC A, V331, P523, DOI 10.1098/rsta.1990.0087; Horstmann UE, 1997, J AFR EARTH SCI, V25, P115, DOI 10.1016/S0899-5362(97)00065-1; Hough RM, 1997, GEOLOGY, V25, P1019, DOI 10.1130/0091-7613(1997)025<1019:DFTIRK>2.3.CO;2; HOUGH RM, 1995, NATURE, V378, P41, DOI 10.1038/378041a0; HUSS GR, 1994, METEORITICS, V29, P791, DOI 10.1111/j.1945-5100.1994.tb01094.x; JANSE AJA, 1992, RUSS GEOL GEOPHYS, V33, P9; JAVOY M, 1986, CHEM GEOL, V57, P41, DOI 10.1016/0009-2541(86)90093-8; JOHNSON HP, 1995, GEOPHYS RES LETT, V22, P231, DOI 10.1029/94GL03051; JORDAN TH, 1988, J PETROL, P11, DOI DOI 10.1093/PETROLOGY/SPECIAL_VOLUME.1.11; JORGENSEN UG, 1988, NATURE, V332, P702, DOI 10.1038/332702a0; JURDY DM, 1995, J GEOPHYS RES-SOL EA, V100, P17965, DOI 10.1029/95JB01477; KANDA H, 1976, J MATER SCI, V11, P2336, DOI 10.1007/BF00752099; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KESSON SE, 1989, CHEM GEOL, V78, P97, DOI 10.1016/0009-2541(89)90110-1; KIRKLEY MB, 1991, APPL GEOCHEM, V6, P477, DOI 10.1016/0883-2927(91)90048-T; KIRKLEY MB, 1989, GEOL SOC AUST SPEC P, V14, P264; Koeberl C, 1997, GEOLOGY, V25, P967, DOI 10.1130/0091-7613(1997)025<0967:DFTPIS>2.3.CO;2; Kopylova MG, 1997, CONTRIB MINERAL PETR, V129, P366, DOI 10.1007/s004100050343; KRAMERS JD, 1979, EARTH PLANET SC LETT, V42, P58, DOI 10.1016/0012-821X(79)90190-0; KRONER A, 1991, TECTONOPHYSICS, V187, P393, DOI 10.1016/0040-1951(91)90478-B; Kruger D, 1996, ASTRON ASTROPHYS, V313, P891; LARSON RL, 1991, EARTH PLANET SC LETT, V107, P437, DOI 10.1016/0012-821X(91)90091-U; LARSON RL, 1991, GEOLOGY, V19, P547, DOI 10.1130/0091-7613(1991)019<0547:LPOEEF>2.3.CO;2; Levinson A.A., 1992, GEMS GEMOL, V28, P234; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; LEWIS RS, 1989, NATURE, V339, P117, DOI 10.1038/339117a0; LIPSCHUTZ ME, 1964, SCIENCE, V143, P1431, DOI 10.1126/science.143.3613.1431-a; LIPSCHUTZ ME, 1961, GEOCHIM COSMOCHIM AC, V24, P83, DOI 10.1016/0016-7037(61)90009-6; Mason B., 1962, METEORITES; McCandless T.E., 1997, RUSS GEOL GEOPHYS, V38, P394; MCCULLOCH MT, 1993, EARTH PLANET SC LETT, V115, P89, DOI 10.1016/0012-821X(93)90215-U; MENZIES MA, 1987, MANTLE METASOMATISM; Meyer H. O. A., 1987, MANTLE XENOLITHS, P501; MILLEDGE HJ, 1989, DIAMOND WORKSHOP INT, P55; Mitchell R.H., 1991, PETROLOGY LAMPROITES, DOI DOI 10.1007/978-1-4615-3788-5; Mitchell R. H., 1986, KIMBERLITES MINERALO; MOORE RO, 1985, NATURE, V318, P553, DOI 10.1038/318553a0; NASSAU K, 1993, DIAMOND FILMS COATIN, P31; NAVON O, 1988, NATURE, V335, P784, DOI 10.1038/335784a0; NISBET EG, 1984, CAN J EARTH SCI, V21, P1426, DOI 10.1139/e84-149; Nixon P.H., 1987, MANTLE XENOLITHS; NIXON PH, 1987, MANTLE XENOLITHS, P477; OHATA H, 1996, LITHOS, V37, P199; OHMOTO H, 1986, REV MINERAL, V16, P491; OReilly SY, 1996, TECTONOPHYSICS, V262, P3, DOI 10.1016/0040-1951(96)00010-8; Orlov Y.L., 1977, MINERALOGY DIAMOND; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PEARSON DG, 1989, NATURE, V338, P60, DOI 10.1038/338060a0; PEARSON DG, IN PRESS REV EC GEOL; POLET J, 1995, GEOLOGY, V23, P205, DOI 10.1130/0091-7613(1995)023<0205:DEOCAI>2.3.CO;2; POLLACK HN, 1977, TECTONOPHYSICS, V38, P279, DOI 10.1016/0040-1951(77)90215-3; Prinzhofer A, 1997, CHEM GEOL, V142, P193, DOI 10.1016/S0009-2541(97)00082-X; Revenaugh J, 1997, SCIENCE, V277, P670, DOI 10.1126/science.277.5326.670; REYNOLDS JH, 1964, J GEOPHYS RES, V69, P3263, DOI 10.1029/JZ069i015p03263; RICHARDSON SH, 1990, NATURE, V346, P54, DOI 10.1038/346054a0; Richardson SH, 1997, EARTH PLANET SC LETT, V151, P271, DOI 10.1016/S0012-821X(97)81853-5; RICHARDSON SH, 1984, NATURE, V310, P198, DOI 10.1038/310198a0; RICHARDSON SH, 1993, NATURE, V366, P256, DOI 10.1038/366256a0; RINGWOOD AE, 1992, EARTH PLANET SC LETT, V113, P521, DOI 10.1016/0012-821X(92)90129-J; Rock N.M.S., 1991, LAMPROPHYRES; Rudnick RL, 1998, CHEM GEOL, V145, P395, DOI 10.1016/S0009-2541(97)00151-4; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; RUDNICK RL, 1993, GEOLOGY, V21, P13, DOI 10.1130/0091-7613(1993)021<0013:DGHFIS>2.3.CO;2; Russell SS, 1996, METORIT PLANET SCI, V31, P343, DOI 10.1111/j.1945-5100.1996.tb02071.x; Russell SS, 1998, NATURE, V395, P325, DOI 10.1038/26348; SASLAW WC, 1969, NATURE, V221, P160, DOI 10.1038/221160b0; SAUTTER V, 1991, SCIENCE, V252, P827, DOI 10.1126/science.252.5007.827; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; Schopf JW, 1983, EARTHS EARLIEST BIOS; SCHRAUDER M, 1993, NATURE, V365, P42, DOI 10.1038/365042a0; SCLATER JG, 1970, GEOPHYS J ROY ASTR S, V20, P509, DOI 10.1111/j.1365-246X.1970.tb06089.x; SHATSKY VS, 1995, FIELD GUID BOOK 6 IN; SHELKOV D, 1995, RUSS GEOL GEOPHYS, V38, P332; Sinha SK, 1997, GEOCHIM COSMOCHIM AC, V61, P4235, DOI 10.1016/S0016-7037(97)00254-8; SMITH JV, 1985, GEOLOGY, V13, P342, DOI 10.1130/0091-7613(1985)13<342:CDAFEI>2.0.CO;2; Sobolev N.V., 1977, ANTARCT RES SER, DOI DOI 10.1029/SP011; SOBOLEV NV, 1990, NATURE, V343, P742, DOI 10.1038/343742a0; SPERA FJ, 1984, CONTRIB MINERAL PETR, V77, P56; SRINIVASAN B, 1978, SCIENCE, V201, P51, DOI 10.1126/science.201.4350.51; SUNAGAWA I, 1990, J CRYST GROWTH, V99, P1156, DOI 10.1016/S0022-0248(08)80100-5; SUZUKI A, 1995, SCIENCE, V269, P216, DOI 10.1126/science.269.5221.216; SWART PK, 1983, NATURE, V303, P793, DOI 10.1038/303793a0; SYKES LR, 1978, REV GEOPHYS, V16, P621, DOI 10.1029/RG016i004p00621; Taylor B.E., 1987, MINERALOGICAL ASS CA, V13, P337; Taylor S.R., 1985, CONTINENTAL CRUST IT; Taylor W. R., 1987, SPECIAL PUBLICATION, P121; Taylor W. R., 1995, 6 INT KIMB C NOV RUS; Taylor WR, 1996, GEOCHIM COSMOCHIM AC, V60, P4725, DOI 10.1016/S0016-7037(96)00302-X; Thiemens MH, 1999, SCIENCE, V283, P341, DOI 10.1126/science.283.5400.341; TIELENS AGGM, 1987, ASTROPHYS J, V319, pL109, DOI 10.1086/184964; VANHEERDEN LA, 1997, S AFR J GEOL, V98, P119; Verchovsky AB, 1998, SCIENCE, V281, P1165, DOI 10.1126/science.281.5380.1165; WALKER D, 1997, METEORITICS, V19, P4235; WANG W, 1997, MINERAL J, V18, P9; Wen LX, 1998, SCIENCE, V279, P1701, DOI 10.1126/science.279.5357.1701; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; Williams Q, 1998, SCIENCE, V281, P546, DOI 10.1126/science.281.5376.546; Wood BJ, 1996, PHILOS T R SOC A, V354, P1495, DOI 10.1098/rsta.1996.0060; Woolley AR, 1996, CAN MINERAL, V34, P175; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; WYLLIE PJ, 1987, GEOCHEM SOC SPEC PUB, V1, P107; WYLLIE PJ, 1989, GEOL SOC AUST SPEC P, V14, P603; XU ST, 1992, SCIENCE, V256, P80, DOI 10.1126/science.256.5053.80; Zhao XZ, 1997, NATURE, V385, P513, DOI 10.1038/385513a0; Zinner E, 1998, METEORIT PLANET SCI, V33, P549, DOI 10.1111/j.1945-5100.1998.tb01664.x	201	148	159	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					851	860		10.1126/science.285.5429.851	http://dx.doi.org/10.1126/science.285.5429.851			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436147				2022-12-28	WOS:000081860900039
J	McMurray, JE				McMurray, JE			Doctors' daughter	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	McMurray, JE (corresponding author), Univ Wisconsin, Sch Med, Dept Med, 2870 Univ Ave,Suite 106, Madison, WI 53705 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					222	224		10.7326/0003-4819-131-3-199908030-00010	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428740				2022-12-28	WOS:000081788700009
J	Winter, B; Cohen, S				Winter, B; Cohen, S			Withdrawal of treatment	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Nottingham NG7 2UH, England; UCL Hosp, London, England	University of Nottingham; University College London Hospitals NHS Foundation Trust; University of London; University College London	Winter, B (corresponding author), Univ Nottingham Hosp, Nottingham NG7 2UH, England.								0	30	32	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					306	308		10.1136/bmj.319.7205.306	http://dx.doi.org/10.1136/bmj.319.7205.306			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426751	Green Published			2022-12-28	WOS:000081909100034
J	Baldus, P; Jansen, M; Sporn, D				Baldus, P; Jansen, M; Sporn, D			Ceramic fibers for matrix composites in high-temperature engine applications	SCIENCE			English	Review								High-temperature engine applications have been limited by the performance of metal alloys and carbide fiber composites at elevated temperatures. Random inorganic networks composed of silicon, boron, nitrogen, and carbon represent a novel class of ceramics with outstanding durability at elevated temperatures. SIBN3C was synthesized by pyrolysis of a preceramic N-methylpolyborosilazane made from the single-source precursor Cl3Si-NH-BCl2. The polymer can be processed to a green fiber by melt-spinning, which then undergoes an intermediate curing step and successive pyrolysis. The ceramic fibers, which are presently produced on a semitechnical scale, combine several desired properties relevant for an application in fiber-reinforced ceramic composites: thermal stability, mechanical strength, high-temperature creep resistivity, low density, and stability against oxidation or molten silicon.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; Bayer AG, ZF MFA, D-51368 Leverkusen, Germany; Fraunhofer Inst Silicatforsch, D-97082 Wurzburg, Germany	Max Planck Society; Bayer AG; Fraunhofer Gesellschaft	Jansen, M (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.							Baldus H, 1997, ANGEW CHEM, V109, P338; Baldus H-P., 1997, ANGEW CHEM INT EDIT, V36, P328, DOI [10.1002/anie.199703281, DOI 10.1002/ANIE.199703281]; BALDUS HP, 1992, MATER RES SOC SYMP P, V271, P821, DOI 10.1557/PROC-271-821; BALDUS HP, 1997, P 1 INT C CER MET MA, P177; Chawla K. K., 1993, CERAMIC MATRIX COMPO; DICARLO JA, 1995, HDB CONTINUOUS FIBER; GORING J, 1994, P INT C SIL NITR BAS, V8991, P641; Ishikawa T, 1998, NATURE, V391, P773, DOI 10.1038/35820; Kumagawa K., 1997, CER ENG SCI P, V18, P113, DOI 10.1002/9780470294437.ch12; MANN S, 1997, J ANAL ATOM SPECTROM, V12, P995; Muhlhauser M, 1996, J PHYS CHEM-US, V100, P16551, DOI 10.1021/jp961732+; Pope DP, 1996, MRS BULL, V21, P30, DOI 10.1557/S088376940003548X; Takeda M., 1997, CERAMIC ENG SCI P, V18, P779; Tressler R. E., 1993, HIGH TEMPERATURE CER, P33; Tressler RE, 1995, CERAMIC T, V57, P141; Wilson D.M., 1995, P 19 ANN C COMPOSITE, P1005; YUN HM, 1999, IN PRESS P 23 ANN CO	17	283	310	15	289	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					699	703		10.1126/science.285.5428.699	http://dx.doi.org/10.1126/science.285.5428.699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426985				2022-12-28	WOS:000081765100044
J	Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR			Two-metal-ion catalysis in adenylyl cyclase	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA-POLYMERASE-BETA; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; GUANYLYL CYCLASES; CYTOSOLIC DOMAINS; RNA-POLYMERASE; MECHANISM; BINDING; COMPLEX	Adenylyl cyclase (AC) converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate, a ubiquitous second messenger that regulates many cellular functions. Recent structural studies have revealed much about the structure and function of mammalian AC but have not fully defined its active site or catalytic mechanism. Four crystal structures were determined of the catalytic domains of AC in complex with two different ATP analogs and various divalent metal ions. These structures provide a model for the enzyme-substrate complex and conclusively demonstrate that two metal ions bind in the active site. The similarity of the active site of AC to those of DNA polymerases suggests that the enzymes catalyze phosphoryl transfer by the same two-metal-ion mechanism and likely have evolved from a common ancestor.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Chim Bioorgan Lab, F-34095 Montpellier 5, France	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite de Montpellier	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371, DK38828] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COOPER DMF, 1998, ADV 2 MESSENGER PHOS, V32; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; LESLIE AGW, 1997, MOSFLM 5 50 IMAGE PL; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; PADMAJA N, 1991, B CHEM SOC JPN, V64, P1359, DOI 10.1246/bcsj.64.1359; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SHELDRICK WS, 1978, ACTA CRYSTALLOGR B, V34, P2324, DOI 10.1107/S0567740878008067; SHOSHANI I, UNPUB; SLABY I, 1984, BIOCHEM BIOPH RES CO, V122, P1410, DOI 10.1016/0006-291X(84)91248-8; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUNAHAVA I, UNPUB; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; VARUGHESE KI, 1982, J AM CHEM SOC, V104, P3398, DOI 10.1021/ja00376a026; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	45	268	276	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					756	760		10.1126/science.285.5428.756	http://dx.doi.org/10.1126/science.285.5428.756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427002				2022-12-28	WOS:000081765100061
J	Ballard, JO				Ballard, JO			Anticoagulant-induced thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; INDUCED SKIN NECROSIS; WARFARIN		Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, Hershey, PA 17033 USA	Geisinger Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ballard, JO (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, POB 850, Hershey, PA 17033 USA.							BAUER KA, 1987, BLOOD, V70, P343; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; FIORE L, 1995, WILLIAMS HEMATOLOGY, P1562; Greinacher A, 1999, CIRCULATION, V99, P73, DOI 10.1161/01.CIR.99.1.73; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; Sallah S, 1997, THROMB HAEMOSTASIS, V78, P785; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1	11	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					310	312		10.1001/jama.282.4.310	http://dx.doi.org/10.1001/jama.282.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432014				2022-12-28	WOS:000081596800003
J	Boulton, M; Beck, E; Walters, S; Miller, D				Boulton, M; Beck, E; Walters, S; Miller, D			General practice and the care of children with HIV infection: 6 month prospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; PRACTITIONERS; INVOLVEMENT; VIEWS; WOMEN; AIDS	Objectives To describe the use of primary care services by children infected with HIV and to explore the attitudes of their parents to the role of general practitioners in their children's care. Design A 6 month prospective study. Quantitative analysis of "contact diaries" kept by parents; qualitative analysis of face to face interviews with parents. Participants Parents of children receiving care at a regional referral centre in London. Results Twenty four families (80% response rate) were recruited to the study. In 19 families the mother was black African. Half the children had been diagnosed with symptomatic HIV infection, half with AIDS. All the children were registered with a general practitioner who knew of the child's HIV infection. In five families there had initially been tensions in their relationship with their general practitioner but by the time of the study all but one family had established at least an "acceptable" relationship Children with symptomatic HIV infection saw their general practitioner a mean of 7.5 times per patient year; for children with AIDS the figure was 5.8. Parents regarded the paediatric HIV team at the hospital as their primary source of medical care. Three factors constrained their use of general practice: their own anxieties about distinguishing "normal" symptoms from those related to HIV infection; their view that. their general practitioner did not feel competent to treat HIV infected children; and their concerns about maintaining confidentiality in the surgery. Conclusions Parents remain oriented towards. the paediatric HIV team as their primary source of medical care and use general practice largely for routine prescriptions for their children. Any further development of the general practitioner's role will need to build on existing relationships with specialist providers and take account of parents' concerns.	Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England	Imperial College London; Imperial College London	Boulton, M (corresponding author), Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England.	m.boulton@ic.ac.uk	BOULTON, Mary/X-9056-2019	BOULTON, Mary/0000-0002-2247-8318				BECK EJ, 1997, HOSP COMMUNITY SERVI; BOULTON M, 1997, EXPERIENCE FAMILIES; CLARKE AE, 1993, FAM PRACT, V10, P8, DOI 10.1093/fampra/10.1.8; *COMM DIS SURV CTR, 1998, COMMUN DIS REP CDR W, V8, P386; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; Huby G, 1998, AIDS CARE, V10, pS83, DOI 10.1080/09540129850124398; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, J ROY COLL GEN PRACT, V39, P280; Madge S, 1998, BRIT J GEN PRACT, V48, P1329; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Shaw M, 1996, BRIT MED J, V312, P1463, DOI 10.1136/bmj.312.7044.1463; SHELDON J, 1993, FAM PRACT, V10, P396, DOI 10.1093/fampra/10.4.396; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; Smith S, 1996, BRIT MED J, V312, P416, DOI 10.1136/bmj.312.7028.416	16	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					232	235		10.1136/bmj.319.7204.232	http://dx.doi.org/10.1136/bmj.319.7204.232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417088	Green Published, Bronze			2022-12-28	WOS:000081720300027
J	Stewart, J; O'Halloran, C; Harrigan, P; Spencer, JA; Barton, JR; Singleton, SJ				Stewart, J; O'Halloran, C; Harrigan, P; Spencer, JA; Barton, JR; Singleton, SJ			Identifying appropriate tasks for the preregistration year: modified Delphi technique	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOUSE OFFICERS; JUNIOR DOCTORS; WORK; REGIONS	Objectives To identify the tasks that should constitute the work of preregistration house officers to provide the basis for the development of a self evaluation instrument Design Literature review and modified Delphi technique. Setting Northern Deanery within the Northern and Yorkshire office NHS executive. Subjects 67 educational supervisors of preregistration house officers. Main outcome measures Percentage of agreement by educational supervisors to tasks identified from the literature. Results Over 61% of communication items, 70% of on call patient care items, 75% of routine patient care items, 45% of practical procedure items, and over 63% of self management items achieved over 95% agreement that they should be part of the house job of preregistration house officers. Poor agreement was found for the laboratory and clinical investigations that house officers could perform with or without supervision. Conclusions The tasks of house officers were identified but issues in using this method and in devising a universally acceptable list of tasks for preregistration house officers were apparent.	Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England; Newcastle Univ, Sch Med, Dept Primary Hlth Care, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; N Tyneside Hosp, Reg Sch Med, N Shields NE29 8NH, England	Newcastle University - UK; Newcastle University - UK	Stewart, J (corresponding author), Postgrad Inst Med & Dent, Newcastle Upon Tyne NE2 4AB, Tyne & Wear, England.	Jane.Stewart@ncl.ac.uk		O'Halloran, Catherine/0000-0002-2780-2260				*BRIT MED ASS, 1997, BMA COH STUD 1995 ME; *C POSTGR MED DEAN, 1994, PRER HOUS OFF EXP IM; CALMAN KC, 1991, MED EDUC, V25, P51, DOI 10.1111/j.1365-2923.1991.tb00026.x; Dent T, 1995, Health Trends, V27, P22; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; DORNBUSCH SM, 1975, EVALUATION EXERCISE, P71; DOWLING S, 1991, DOCTORS MAKING EXPER; Duffield C, 1988, Aust J Adv Nurs, V6, P41; ELIZABETH JE, 1986, BRIT MED J, V293, P1559, DOI 10.1136/bmj.293.6561.1559; FIRTHCOZENS J, 1989, STRESS MEDICINE, V5, P121, DOI 10.1002/smi.2460050210; General Medical Council, 1997, NEW DOCT; General Medical Council, 1993, TOM DOCT; GILLARD JH, 1993, BRIT MED J, V307, P1180, DOI 10.1136/bmj.307.6913.1180; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038; MCKEE M, 1993, J PUBLIC HEALTH MED, V15, P16, DOI 10.1093/oxfordjournals.pubmed.a042815; MITCHELL IA, 1992, PRACTICAL HOUSE OFFI; TURNBULL NB, 1990, BRIT MED J, V301, P1191, DOI 10.1136/bmj.301.6762.1191; WILLIAMS PL, 1994, J ADV NURS, V19, P180, DOI 10.1111/j.1365-2648.1994.tb01066.x	19	96	97	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					224	229		10.1136/bmj.319.7204.224	http://dx.doi.org/10.1136/bmj.319.7204.224			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417084	Bronze, Green Published, Green Accepted			2022-12-28	WOS:000081720300023
J	Williams, DDR				Williams, DDR			Personal view - Old age psychiatry in Swansea	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					267	267		10.1136/bmj.319.7204.267	http://dx.doi.org/10.1136/bmj.319.7204.267			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417119	Green Published			2022-12-28	WOS:000081720300074
J	van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D				van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D			Spo76p is a conserved chromosome morphogenesis protein that links the mitotic and meiotic programs	CELL			English	Article							SISTER-CHROMATID COHESION; SORDARIA-MACROSPORA; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; MATING-TYPE; MEIOSIS; RECOMBINATION; GENE; ORGANIZATION; CONDENSATION	Spo76p is conserved and related to the fungal proteins Pds5p and BIMD and the human AS3 prostate proliferative shutoff-associated protein. Spo76p localizes to mitotic and meiotic chromosomes, except at metaphase(s) and anaphase(s). During meiotic prophase, Spo76p assembles into strong lines in correlation with axial element formation. As inferred from spo76-1 mutant phenotypes, Spo76p is required for sister chromatid cohesiveness, chromosome axis morphogenesis, and chromatin condensation during critical transitions at mitotic prometaphase and meiotic midprophase. Spo76p is also required for meiotic interhomolog recombination, likely at postinitiation stage(s). We propose that a disruptive force coordinately promotes chromosomal axial compaction and destabilization of sister connections and that Spo76p restrains and channels the effects of this force into appropriate morphogenetic mitotic and meiotic outcomes.	Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France; Ruhr Univ Bochum, Lehrstuhl Allgemeine Bot, D-44780 Bochum, Germany	UDICE-French Research Universities; Universite Paris Saclay; Ruhr University Bochum	van Heemst, D (corresponding author), Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France.	zickler@igmors.u-psud.fr	Berteaux-Lecellier, Veronique/O-4767-2018; BERTEAUX-LECELLIER, Veronique/P-6456-2019	Berteaux-Lecellier, Veronique/0000-0003-2152-6231; BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231	NIGMS NIH HHS [R37 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bickel SE, 1997, GENETICS, V146, P1319; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAWE RK, 1994, CELL, V76, P901, DOI 10.1016/0092-8674(94)90364-6; DENISON SH, 1993, GENETICS, V134, P1085; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Geck P, 1999, J STEROID BIOCHEM, V68, P41, DOI 10.1016/S0960-0760(98)00165-4; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Holt CL, 1996, GENETICS, V142, P777; HUYNH AD, 1986, CURR GENET, V10, P545, DOI 10.1007/BF00447389; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; MOREAU PJF, 1985, MOL GEN GENET, V198, P189, DOI 10.1007/BF00382995; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; OSIEWACZ HD, 1994, CURR GENET, V26, P87, DOI 10.1007/BF00326309; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Poggeler S, 1997, GENETICS, V147, P567; PUKKILA PJ, 1995, CAN J BOT, V73, pS215; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SLONIMSKI PP, 1993, YEAST, V9, P941, DOI 10.1002/yea.320090902; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; THOMPSONCOFFE C, 1994, DEV BIOL, V165, P257, DOI 10.1006/dbio.1994.1251; TURCQ B, 1990, CURR GENET, V17, P297, DOI 10.1007/BF00314876; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619; ZICKLER D, 1992, GENETICS, V132, P135	45	104	106	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					261	271		10.1016/S0092-8674(00)81020-X	http://dx.doi.org/10.1016/S0092-8674(00)81020-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428037	Bronze			2022-12-28	WOS:000081632300015
J	Shepherd, PR; Kahn, BB				Shepherd, PR; Kahn, BB			Mechanisms of disease - Glucose transporters and insulin action - Implications for insulin resistance and diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1 PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-B; TRANSGENIC MICE; RAT ADIPOCYTES; 3T3-L1 ADIPOCYTES; IN-VITRO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE		Beth Israel Deaconess Med Ctr, Diabet Unit, Dept Med, Boston, MA 02215 USA; UCL, Dept Biochem & Mol Biol, London, England; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; University of London; University College London; Harvard University; Harvard Medical School	Kahn, BB (corresponding author), Beth Israel Deaconess Med Ctr, Diabet Unit, Dept Med, 99 Brookline Ave, Boston, MA 02215 USA.				NIDDK NIH HHS [R01 DK043051, DK43051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043051, R01DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel E. Dale, 1996, P530; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bailey C.J., 1997, CURRENT OPINION ENDO, V4, P40; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; BJORBAEK C, 1994, DIABETES, V43, P976, DOI 10.2337/diabetes.43.8.976; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bray GA, 1997, J CLIN ENDOCR METAB, V82, P3878; Bray GA, 1997, J CLIN ENDOCR METAB, V82, P2771, DOI 10.1210/jc.82.9.2771; BRICHARD SM, 1995, TRENDS PHARMACOL SCI, V16, P265, DOI 10.1016/S0165-6147(00)89043-4; BUSE JB, 1992, DIABETES, V41, P1436, DOI 10.2337/diabetes.41.11.1436; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; CAREY JO, 1995, DIABETES, V44, P682, DOI 10.2337/diabetes.44.6.682; Ciaraldi T, 1997, EUR J ENDOCRINOL, V137, P610, DOI 10.1530/eje.0.1370610; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; DeFronzo RA, 1997, DIABETES REV, V5, P177; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; FISCHER Y, 1995, ENDOCRINOLOGY, V136, P412, DOI 10.1210/en.136.2.412; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GALUSKA D, 1994, DIABETOLOGIA, V37, P826, DOI 10.1007/BF00404340; Garvey WT, 1997, DIABETES, V46, P444, DOI 10.2337/diabetes.46.3.444; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HIRSHMAN MF, 1995, BIOCHEM BIOPH RES CO, V208, P835, DOI 10.1006/bbrc.1995.1412; HOFMANN C, 1991, ENDOCRINOLOGY, V129, P1915, DOI 10.1210/endo-129-4-1915; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; LIU ML, 1992, J BIOL CHEM, V267, P11673; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MATTHAEI S, 1991, DIABETES, V40, P850, DOI 10.2337/diabetes.40.7.850; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; MULLER G, 1993, DIABETES, V42, P1852, DOI 10.2337/diabetes.42.12.1852; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; ORAHILLY S, 1992, DIABETOLOGIA, V35, P486, DOI 10.1007/BF02342449; RANDLE PJ, 1963, LANCET, V1, P785; Ranganathan S, 1998, ENDOCRINOLOGY, V139, P2509, DOI 10.1210/en.139.5.2509; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Santer R, 1998, NAT GENET, V18, P298, DOI 10.1038/ng0398-298a; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SINHA MK, 1990, AM J PHYSIOL, V258, pE534, DOI 10.1152/ajpendo.1990.258.3.E534; Sivitz WI, 1997, ENDOCRINOLOGY, V138, P3395, DOI 10.1210/en.138.8.3395; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451; YKIJARVINEN H, 1990, DIABETES, V39, P157, DOI 10.2337/diabetes.39.2.157; YkiJarvinen H, 1996, DIABETES, V45, P302, DOI 10.2337/diabetes.45.3.302; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zierath JR, 1996, DIABETOLOGIA, V39, P306; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504; ZIERATH JR, 1992, FEBS LETT, V307, P379, DOI 10.1016/0014-5793(92)80717-U; Zierath JR, 1998, DIABETES, V47, P1, DOI 10.2337/diabetes.47.1.1; ZIERATH JR, 1994, DIABETOLOGIA, V37, P270, DOI 10.1007/BF00398054	106	939	982	6	101	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					248	257		10.1056/NEJM199907223410406	http://dx.doi.org/10.1056/NEJM199907223410406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413738				2022-12-28	WOS:000081528800006
J	Ely, EW; Evans, GW; Haponik, EF				Ely, EW; Evans, GW; Haponik, EF			Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	95th International Conference of the American-Thoracic-Society	APR 23-29, 1999	SAN DIEGO, CA	Amer Thorac Soc		respiration, artificial; age factors; intensive care units; outcome and process assessment (health care); health resources	ILL HOSPITALIZED ADULTS; NEW-YORK-STATE; RESPIRATORY-FAILURE; AGE; MORTALITY; SURVIVAL; SUPPORT; IMPACT; LIFE; PREFERENCES	Background: It has been argued that life support for the elderly should be limited to conserve resources. As this population increases, so will the importance of evaluating appropriate use of mechanical ventilation in this group. Objective: To determine whether age has an independent effect on the outcomes of patients treated with mechanical ventilation after admission to an intensive care unit (ICU). Design: Prospective cohort study. Setting: University-based tertiary care medical center. Patients: 63 patients 75 years of age or older and 237 patients younger than 75 years of age enrolled from medical and coronary ICUs. Measurements: In-hospital mortality rate, duration of mechanical ventilation, lengths of stay in the ICU and in the hospital, and cost of care. Results: Median duration of mechanical ventilation was 4.2 days (interquartile range, 2.1 to 9.3 days) for patients 75 years of age or older and 6.4 days (interquartile range, 3.4 to 11.4 days) for patients younger than 75 years of age (P = 0.14). When the length of time required to "pass" a daily screening test of weaning variables was used as an indicator of recovery from respiratory failure, elderly patients passed earlier than younger patients (risk ratio, 1.58 [95% CI, 1.13 to 2.22]; P = 0.03). The cost of ICU care was lower for older ($12 822 [CI, $9821 to $26 313] than for younger ($19 316 [CI, $9699 to $39 950]) patients (P = 0.03). Median hospital costs tended to be lower in the older group ($21 292 compared with $29 049; P = 0.17). After adjustment for ethnicity, sex, and severity of illness in a multivariate logistic regression analysis, patient age of 75 years or older was predictive of 1 less day on the ventilator (CI, -2.8 to 1.2 days). Lengths of stay in the ICU (beta-coefficient, -0.5 days [CI, -3.0 to 2.7 days]) and in the hospital (beta-coefficient, 0.3 days [CI, -3.7 to 5.5 days]) did not differ for persons 75 years of age or older after these adjustments (P > 0.1). Intensive care unit and hospital costs, however, were lower for elderly persons (P = 0.02). The in-hospital mortality rate was 38.1% among elderly patients and 38.8% among younger patients (P > 0.2); Cox proportional hazards analysis confirmed that survival did not differ between the two groups (relative risk for older patients, 0.82 [CI, 0.52 to 1.29]). Conclusions: After adjustment for severity of illness, elderly patients spent similar time on mechanical ventilation and in the ICU and hospital but had a lower cost of care than younger patients. These outcomes are not explained by differences in mortality rate and suggest that mechanical ventilation should not be restricted in elderly patients with respiratory failure on the basis of chronologic age.	Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Vanderbilt University; Wake Forest University	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, 913 Oxford House, Nashville, TN 37232 USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Barrett-Connor E, 1998, JAMA-J AM MED ASSOC, V279, P622, DOI 10.1001/jama.279.8.622; Blouin AS, 1996, J NURS ADMIN, V26, P3, DOI 10.1097/00005110-199611000-00001; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Campion EW, 1998, NEW ENGL J MED, V338, P1064, DOI 10.1056/NEJM199804093381512; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DARDAINE V, 1995, AGING-CLIN EXP RES, V7, P221, DOI 10.1007/BF03324339; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; ELPERN EH, 1989, CHEST, V96, P1120, DOI 10.1378/chest.96.5.1120; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Fried TR, 1996, J GEN INTERN MED, V11, P257, DOI 10.1007/BF02598264; Giugliano RP, 1998, ARCH INTERN MED, V158, P1113, DOI 10.1001/archinte.158.10.1113; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRACEY DR, 1992, CHEST, V101, P211, DOI 10.1378/chest.101.1.211; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HEUSER MD, 1992, ARCH INTERN MED, V152, P1683, DOI 10.1001/archinte.152.8.1683; Hobbs FB, 1995, 65 PLUS US; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kurek CJ, 1998, CHEST, V114, P214, DOI 10.1378/chest.114.1.214; Kurek CJ, 1997, CRIT CARE MED, V25, P983, DOI 10.1097/00003246-199706000-00015; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, P295; PAPADAKIS MA, 1993, WESTERN J MED, V159, P659; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STAUFFER JL, 1993, CHEST, V104, P1222, DOI 10.1378/chest.104.4.1222; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; SWINBURNE AJ, 1993, ARCH INTERN MED, V153, P1657, DOI 10.1001/archinte.153.14.1657; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Yuen E J, 1995, Am J Med Qual, V10, P76, DOI 10.1177/0885713X9501000203; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	54	132	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					96	+		10.7326/0003-4819-131-2-199907200-00004	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	217QD	10419447				2022-12-28	WOS:000081509700003
J	Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP				Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP			'Green revolution' genes encode mutant gibberellin response modulators	NATURE			English	Article							WHEAT; MAIZE; TRANSDUCTION; EVOLUTION; DWARFISM; GENETICS; ALLELES; PATHWAY; DNA; SH2	World wheat grain yields increased substantially in the 1960s and 1970s because farmers rapidly adopted the new varieties and cultivation methods of the so-called 'green revolution(1-4). The new varieties are shorter, increase grain yield at the expense of straw biomass, and are more resistant to damage by wind and rain(3,4). These wheats are short because they respond abnormally to the plant growth hormone gibberellin, This reduced response to gibberellin is conferred by mutant dwarfing alleles at one of two Reduced height-1 (Rht-B1 and Rht-D1) loci(4,5), Here we show that Rht-B1/Rht-D1 and maize dwarf-8 (d8)(6,7) are orthologues of the Arabidopsis Gibberellin Insensitive (GAI) gene(8,9). These genes encode proteins that resemble nuclear transcription factors and contain an SH2-like(10) domain, indicating that phosphotyrosine may participate in gibberellin signalling. Six different orthologous dwarfing mutant alleles encode proteins that are altered in a conserved amino-terminal gibberellin signalling domain, Transgenic rice plants containing a mutant GAI allele give reduced responses to gibberellin and are dwarfed, indicating that mutant GAI orthologues could be used to increase yield in a wide range of crop species.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Harberd, NP (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk,Colney Lane, Norwich NR4 7UH, Norfolk, England.	harberd@bbsrc.ac.uk	Christou, Paul/C-8645-2011; Devos, Katrien M/B-1380-2014	Christou, Paul/0000-0001-6358-7396; Snape, john/0000-0002-9241-3931; Peng, Jinrong/0000-0002-0793-4848	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000583] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Borner A, 1996, EUPHYTICA, V89, P69, DOI 10.1007/BF00015721; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Conway G., 1997, DOUBLY GREEN REVOLUT; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVOS KM, 1995, THEOR APPL GENET, V91, P282, DOI 10.1007/BF00220890; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Dyson T, 1996, POPULATION FOOD GLOB; Evans LT., 1993, CROP EVOLUTION ADAPT; FUJIOKA S, 1988, P NATL ACAD SCI USA, V85, P9031, DOI 10.1073/pnas.85.23.9031; Futterer J, 1996, PLANT MOL BIOL, V32, P159, DOI 10.1007/BF00039382; Gale M. D., 1985, Progress in plant breeding - 1, P1; GALE MD, 1976, HEREDITY, V37, P283, DOI 10.1038/hdy.1976.88; HARBERD NP, 1989, GENETICS, V121, P827; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KURATA N, 1994, NAT GENET, V8, P365, DOI 10.1038/ng1294-365; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, PLANT PHYSIOL, V119, P1199, DOI 10.1104/pp.119.4.1199; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Sudhakar D, 1998, TRANSGENIC RES, V7, P289, DOI 10.1023/A:1008870012568; Webb SE, 1998, PHYTOCHEMISTRY, V47, P671, DOI 10.1016/S0031-9422(97)00684-5; WINKLER RG, 1994, PLANTA, V193, P341, DOI 10.1007/BF00201811; Winkler RG, 1993, MAIZE GENET COOP NEW, V67, P110	30	1381	1662	39	583	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					256	261		10.1038/22307	http://dx.doi.org/10.1038/22307			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421366				2022-12-28	WOS:000081503800042
J	Visscher, K; Schnitzer, MJ; Block, SM				Visscher, K; Schnitzer, MJ; Block, SM			Single kinesin molecules studied with a molecular force clamp	NATURE			English	Article							STOCHASTIC-MODEL; MYOSIN MOLECULE; ATP HYDROLYSIS; OPTICAL TRAPS; MOTOR; MECHANICS; KINETICS; MOVEMENT; MICROTUBULES; STEPS	Kinesin is a two-headed, ATP-driven motor protein that moves processively along microtubules in discrete steps of 8 nm, probably by advancing each of its heads alternately in sequence(1-4). Molecular details of how the chemical energy stored in ATP is coupled to mechanical displacement remain obscure. To shed light on this question, a force clamp was constructed, based on a feedback-driven optical trap capable of maintaining constant loads on single kinesin motors(5). The instrument provides unprecedented resolution of molecular motion and permits mechanochemical studies under controlled external loads. Analysis of records of kinesin motion under variable ATP concentrations and loads revealed several new features. First, kinesin stepping appears to be tightly coupled to ATP hydrolysis over a wide range of forces, with a single hydrolysis per 8-nm mechanical advance. Second, the kinesin stall force depends on the ATP concentration. Third, increased loads reduce the maximum velocity as expected, but also raise the apparent Michaelis-Menten constant. The kinesin cycle therefore contains at least one load-dependent transition affecting the rate at which ATP molecules bind and subsequently commit to hydrolysis, It is likely that at least one other load-dependent rate exists, affecting turnover number. Together, these findings will necessitate revisions to our understanding of how kinesin motors function.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Schnitzer, MJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HIGUCHI H, 1998, CELL STRUCT FUNCT S, V23, P198; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1995, BIOPHYS J, V68, pS245; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0	32	805	819	0	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					184	189		10.1038/22146	http://dx.doi.org/10.1038/22146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408448				2022-12-28	WOS:000081324900059
J	Zagrovic, B; Aldrich, R				Zagrovic, B; Aldrich, R			Neuroscience - For the latest information, tune to channel KcsA	SCIENCE			English	Article							ACTIVATION; SELECTIVITY; VOLTAGE		Stanford Univ, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Zagrovic, B (corresponding author), Stanford Univ, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.			Zagrovic, Bojan/0000-0003-3814-3675				ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; Chapman ML, 1997, BIOPHYS J, V72, P708, DOI 10.1016/S0006-3495(97)78707-1; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Hille B., 1992, IONIC CHANNELS EXCIT; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101	13	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					59	+		10.1126/science.285.5424.59	http://dx.doi.org/10.1126/science.285.5424.59			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10428704				2022-12-28	WOS:000081199800027
J	Cole, BJ; Wiernasz, DC				Cole, BJ; Wiernasz, DC			The selective advantage of low relatedness	SCIENCE			English	Article							SOCIAL INSECT COLONIES; APIS-MELLIFERA L; POGONOMYRMEX-OCCIDENTALIS; SEX DETERMINATION; MATING FREQUENCY; HONEY-BEES; EVOLUTION; ANT; HYMENOPTERA; POLYANDRY	Relatedness within colonies of social Hymenoptera is often significantly lower than the outbred population maximum of 0.75, Several hypotheses address the widespread occurrence of Low relatedness, but none have measured the covariation of colony fitness and relatedness. In a polyandrous harvester ant, Pogonomyrmex occidentalis, average within-colony relatedness in the population is Low but highly variable among colonies, and relatedness is negatively correlated with colony growth rate. Differences in growth rate strongly influence survival and the onset of reproduction, leading to a 35-fold increase in fitness of fast-growing colonies, Benefits of a genetically diverse worker population may favor polyandry in this species.	Univ Houston, Dept Biol & Biochem, Div Evolutionary Biol & Ecol, Houston, TX 77204 USA	University of Houston System; University of Houston	Cole, BJ (corresponding author), Univ Houston, Dept Biol & Biochem, Div Evolutionary Biol & Ecol, Houston, TX 77204 USA.	bcole@uh.edu	Cole, Brian/K-4268-2019					Baer B, 1999, NATURE, V397, P151, DOI 10.1038/16451; Boomsma JJ, 1996, PHILOS T R SOC B, V351, P947, DOI 10.1098/rstb.1996.0087; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; Cole BJ, 1997, BEHAV ECOL SOCIOBIOL, V40, P79, DOI 10.1007/s002650050318; COOK JM, 1993, HEREDITY, V71, P421, DOI 10.1038/hdy.1993.157; Crozier R.H., 1996, EVOLUTION SOCIAL INS; CROZIER RH, 1985, BEHAV ECOL SOCIOBIOL, V18, P105, DOI 10.1007/BF00299039; CROZIER RH, 1971, AM NAT, V105, P399, DOI 10.1086/282733; EVANS JD, 1995, P NATL ACAD SCI USA, V92, P6514, DOI 10.1073/pnas.92.14.6514; FEWELL JH, 1993, EXPERIENTIA, V49, P1106, DOI 10.1007/BF01929923; Fuchs S, 1999, BEHAV ECOL SOCIOBIOL, V45, P269, DOI 10.1007/s002650050561; KEELER KH, 1993, SOUTHWEST NAT, V38, P286, DOI 10.2307/3671438; Li C., 1975, PATH ANAL A PRIMER; Liersch S, 1998, P ROY SOC B-BIOL SCI, V265, P221, DOI 10.1098/rspb.1998.0285; MUELLER UG, 1991, SCIENCE, V254, P442, DOI 10.1126/science.254.5030.442; PAGE RE, 1989, WESTV STUD, P15; PAGE RE, 1995, BEHAV ECOL SOCIOBIOL, V36, P387, DOI 10.1007/BF00177334; PAGE RE, 1980, GENETICS, V96, P263; Pamilo P, 1997, ANNU REV ECOL SYST, V28, P1, DOI 10.1146/annurev.ecolsys.28.1.1; PAMILO P, 1984, GENETICS, V107, P307; Partridge L, 1998, SCIENCE, V281, P2003, DOI 10.1126/science.281.5385.2003; Queller David C., 1993, P132; QUELLER DC, 1993, NATURE, V365, P639, DOI 10.1038/365639a0; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; QUELLER DC, 1993, AM NAT, V142, P346, DOI 10.1086/285541; RATNIEKS FLW, 1995, AM NAT, V145, P969, DOI 10.1086/285779; ROSS KG, 1993, GENETICS, V135, P843; SCHMIDHEMPEL P, 1994, PHILOS T R SOC B, V346, P313, DOI 10.1098/rstb.1994.0148; SHERMAN PW, 1988, AM NAT, V131, P602, DOI 10.1086/284809; SHERMAN PW, 1998, PARASITES SOCIAL INS; SHYKOFF JA, 1991, P ROY SOC B-BIOL SCI, V243, P55, DOI 10.1098/rspb.1991.0009; Sokal R.R., 1995, BIOMETRY, P794; Sundstrom L, 1998, BEHAV ECOL, V9, P116, DOI 10.1093/beheco/9.2.116; SUNDSTROM L, 1994, NATURE, V367, P266, DOI 10.1038/367266a0; WADE MJ, 1985, J THEOR BIOL, V112, P109, DOI 10.1016/S0022-5193(85)80119-3; WIERNASZ DC, 1995, J ANIM ECOL, V64, P519, DOI 10.2307/5654; YOKOYAMA S, 1979, GENETICS, V91, P609; Zeh JA, 1996, P ROY SOC B-BIOL SCI, V263, P1711, DOI 10.1098/rspb.1996.0250	38	127	130	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					891	893		10.1126/science.285.5429.891	http://dx.doi.org/10.1126/science.285.5429.891			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436157				2022-12-28	WOS:000081860900049
J	Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR				Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR			Early neocortical regionalization in the absence of thalamic innervation	SCIENCE			English	Article							CEREBRAL-CORTEX; NERVOUS-SYSTEM; CALRETININ IMMUNOREACTIVITY; EXPRESSION PATTERN; CORTICAL AREAS; MUTANT MICE; FOREBRAIN; GENE; RAT; SPECIFICATION	There is a Long-standing controversy regarding the mechanisms that generate the functional subdivisions of the cerebral neocortex. One model proposes that thalamic axonal input specifies these subdivisions; the competing model postulates that patterning mechanisms intrinsic to the dorsal telencephalon generate neocortical regions. Gbx-2 mutant mice, whose thalamic differentiation is disrupted, were investigated. Despite the Lack of cortical innervation by thalamic axons, neocortical region-specific gene expression (Cadherin-6, EphA-7, Id-2, and RZR-beta) developed normally. This provides evidence that patterning mechanisms intrinsic to the neocortex specify the basic organization of its functional subdivisions.	Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; Univ Miguel Hernandez, Univ Murcia, Inst Neurosci, Fac Med,Dept Morphol Sci, Alicante, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidad Miguel Hernandez de Elche; University of Murcia	Rubenstein, JLR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926	NIMH NIH HHS [R01 MH49428-01, R01 MH51561-01A1] Funding Source: Medline; NINDS NIH HHS [NS34661-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049428, R01MH051561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034661] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acampora D, 1997, DEVELOPMENT, V124, P3639; ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BULFONE A, 1993, J NEUROSCI, V13, P3155; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P5212, DOI 10.1210/en.136.11.5212; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; FONSECA M, 1995, J COMP NEUROL, V361, P177, DOI 10.1002/cne.903610114; FRANZ T, 1994, ACTA ANAT, V150, P38; Frassoni C, 1998, NEUROSCIENCE, V83, P1203, DOI 10.1016/S0306-4522(97)00443-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GITTON Y, IN PRESS CEREB; Golden JA, 1999, P NATL ACAD SCI USA, V96, P2439, DOI 10.1073/pnas.96.5.2439; Grove EA, 1998, DEVELOPMENT, V125, P2315; HEVNER RF, UNPUB; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; MIYASHITALIN EM, UNPUB; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Nothias F, 1998, CURR BIOL, V8, P459, DOI 10.1016/S0960-9822(98)70189-7; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; Qiu MS, 1996, DEV BIOL, V178, P174, DOI 10.1006/dbio.1996.0207; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; RUBENSTEIN JLR, IN PRESS CEREB CORTE; Schaeren-Wiemers N, 1997, EUR J NEUROSCI, V9, P2687, DOI 10.1111/j.1460-9568.1997.tb01698.x; Stoykova A, 1996, DEVELOPMENT, V122, P3453; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yoshida M, 1997, DEVELOPMENT, V124, P101	36	264	269	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					906	909		10.1126/science.285.5429.906	http://dx.doi.org/10.1126/science.285.5429.906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436162				2022-12-28	WOS:000081860900054
J	Pourgourides, C				Pourgourides, C			Palestinian health care under siege	LANCET			English	Editorial Material									SW London & St Georges Mental Hlth NHS Trust, Shaftesbury Clin, London SW17 7DJ, England		Pourgourides, C (corresponding author), SW London & St Georges Mental Hlth NHS Trust, Shaftesbury Clin, London SW17 7DJ, England.								0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					420	421		10.1016/S0140-6736(99)90138-1	http://dx.doi.org/10.1016/S0140-6736(99)90138-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437889				2022-12-28	WOS:000081764900047
J	Rosner, F				Rosner, F			Can an amulet cure leukemia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		PREUSS J, 1993, BIBLICAL TALMUDIC ME, P146; Rosner F, 1999, MT SINAI J MED, V66, P102; ZIMMELS HJ, 1952, MAGICIANS THEOLOGIAN, P135	3	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					307	307		10.1001/jama.282.4.307	http://dx.doi.org/10.1001/jama.282.4.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432013				2022-12-28	WOS:000081596800001
J	Spiegel, D; Parker, RA				Spiegel, D; Parker, RA			A 43-year-old woman coping with cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METASTATIC BREAST-CANCER; STRUCTURED PSYCHIATRIC INTERVENTION; SOCIAL SUPPORT; PSYCHOLOGICAL RESPONSE; PSYCHOSOCIAL FACTORS; MALIGNANT-MELANOMA; ALAMEDA COUNTY; UNITED-STATES; SURVIVAL; WOMEN		Stanford Univ, Med Ctr, Sch Med, Stanford, CA 94305 USA	Stanford University	Spiegel, D (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med, 330 Brookline Ave,LY318, Boston, MA 02215 USA.			Spiegel, David/0000-0002-9476-9173				Benson Herbert, 1996, TIMELESS HEALING POW; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BURGESS C, 1988, J PSYCHOSOM RES, V32, P263, DOI 10.1016/0022-3999(88)90067-0; Caplan G., 1964, PRINCIPLES PREVENTIV; CARVER C, 1993, CANCER, V73, P1213; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; Classen C, 1996, HEALTH PSYCHOL, V15, P434, DOI 10.1037/0278-6133.15.6.434; COOPER CL, 1992, PSYCHOL MED, V22, P447, DOI 10.1017/S0033291700030397; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; DEROGATIS LR, 1979, JAMA-J AM MED ASSOC, V242, P1504, DOI 10.1001/jama.242.14.1504; DUNKELSCHETTER C, 1992, HEALTH PSYCHOL, V11, P79, DOI 10.1037/0278-6133.11.2.79; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ELL K, 1992, J PSYCHOSOM RES, V36, P531, DOI 10.1016/0022-3999(92)90038-4; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P729; FAWZY FI, 1995, ARCH GEN PSYCHIAT, V52, P100; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; Folkman S, 1997, SOC SCI MED, V45, P1207, DOI 10.1016/S0277-9536(97)00040-3; FUNCH DP, 1983, J PSYCHOSOM RES, V27, P77, DOI 10.1016/0022-3999(83)90112-5; GANSTER DC, 1988, BRIT J MED PSYCHOL, V61, P17, DOI 10.1111/j.2044-8341.1988.tb02763.x; GELLERT GA, 1993, J CLIN ONCOL, V11, P66, DOI 10.1200/JCO.1993.11.1.66; GLASER R, 1987, Brain Behavior and Immunity, V1, P7, DOI 10.1016/0889-1591(87)90002-X; GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125; Goodwin JS, 1996, JNCI-J NATL CANCER I, V88, P1031, DOI 10.1093/jnci/88.15.1031; Goodwin PJ, 1996, CANCER TREAT REV, V22, P91, DOI 10.1016/S0305-7372(96)90068-7; GRAHAM J, 1997, ONCOLOGY, V11, P1179; GREER S, 1991, PSYCHOL MED, V21, P43, DOI 10.1017/S003329170001463X; GREER S, 1975, J PSYCHOSOM RES, V19, P147, DOI 10.1016/0022-3999(75)90062-8; GREER S, 1979, PRACTITIONER, V222, P173; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; HISLOP TG, 1987, J CHRON DIS, V40, P729; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JOFFRES M, 1985, AM J EPIDEMIOL, V121, P488, DOI 10.1093/oxfordjournals.aje.a114027; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kabat-Zinn J., 1994, FULL CATASTROPHE LIV; KENNEDY S, 1988, BRIT J MED PSYCHOL, V61, P77, DOI 10.1111/j.2044-8341.1988.tb02766.x; Kogon MM, 1997, CANCER-AM CANCER SOC, V80, P225, DOI 10.1002/(SICI)1097-0142(19970715)80:2<225::AID-CNCR9>3.3.CO;2-A; Leszcz M, 1998, INT J GROUP PSYCHOTH, V48, P245, DOI 10.1080/00207284.1998.11491538; LIANG LP, 1990, BRIT J CANCER, V62, P1000, DOI 10.1038/bjc.1990.425; LINN MW, 1982, CANCER, V49, P1048, DOI 10.1002/1097-0142(19820301)49:5<1048::AID-CNCR2820490534>3.0.CO;2-G; Mahon S M, 1990, Oncol Nurs Forum, V17, P47; MAUNSELL E, 1995, CANCER, V76, P631, DOI 10.1002/1097-0142(19950815)76:4<631::AID-CNCR2820760414>3.0.CO;2-9; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; MOOS RH, 1990, STRESS MEDICINE, V6, P171, DOI 10.1002/smi.2460060302; Penninx BWJH, 1998, J NATL CANCER I, V90, P1888, DOI 10.1093/jnci/90.24.1888; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; REYNOLDS P, 1990, BEHAV MED, V16, P101, DOI 10.1080/08964289.1990.9934597; RICHARDSON JL, 1990, J CLIN ONCOL, V8, P356, DOI 10.1200/JCO.1990.8.2.356; RODIN J, 1986, AGING PSYCHOL CONTRO; ROWLAND J, 1990, PSYCHOONCOLOGY PSYCH, P44; SAPOLSKY RM, 1985, ENDOCRINOLOGY, V117, P662, DOI 10.1210/endo-117-2-662; SIEGEL BS, 1986, LOVE MED MIRACLES; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1993, J NATL CANCER I, V85, P1198, DOI 10.1093/jnci/85.15.1198; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; SPIEGEL D, 1990, CANCER-AM CANCER SOC, V66, P1422, DOI 10.1002/1097-0142(19900915)66:14+<1422::AID-CNCR2820661419>3.0.CO;2-L; Spiegel D, 1996, J NATL CANCER I, V88, P629, DOI 10.1093/jnci/88.10.629; SPIEGEL D, 1993, DISSOCIATION CULTURE; SPIEGEL D, IN PRESS PSYCHOONCOL; SPIEGEL D, 1998, PROLONGING CANC SURV, P674; SPIEGEL D, 1983, J PSYCHOSOC ONCOL, V1, P33, DOI DOI 10.1300/J077V01N01_04; Spiegel H., 1987, TRANCE TREATMENT CLI; STAVRAKY KM, 1988, J CLIN EPIDEMIOL, V41, P75, DOI 10.1016/0895-4356(88)90011-X; TEMOSHOK L, 1985, SOC SCI MED, V20, P833, DOI 10.1016/0277-9536(85)90338-7; WAXLERMORRISON N, 1991, SOC SCI MED, V33, P177, DOI 10.1016/0277-9536(91)90178-F; Weinerman, 1994, ANNU ROYAL COLL PHYS, V27, P93	71	19	19	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					371	378		10.1001/jama.282.4.371	http://dx.doi.org/10.1001/jama.282.4.371			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	219FG	10432035				2022-12-28	WOS:000081596800033
J	Collinge, J				Collinge, J			Variant Creutzfeldt-Jakob disease	LANCET			English	Review							BOVINE SPONGIFORM ENCEPHALOPATHY; PRION PROTEIN GENE; TRANSMISSIBLE MINK ENCEPHALOPATHY; FATAL FAMILIAL INSOMNIA; STRAIN VARIATION; TRANSGENIC MICE; PRP GENE; SCRAPIE; BSE; CATTLE	It is clear that the prion strain causing bovine spongiform encephalopathy (BSE) in cattle has infected human beings, manifesting itself as a novel human prion disease, variant Creutzfeldt-Jakob disease (CjD). Studies of the incubation periods seen in previous epidemics of human prion disease and of the effect of transmission barriers limiting spread of these diseases between species, suggest that the early variant CID cases may have been exposed during the preclinical phase of the BSE epidemic. It must therefore be considered that many cases may follow from later exposure in an epidemic that would be expected to evolve over decades. Since the number of people currently incubating this disease is unknown, there are concerns that prions might be transmitted iatrogenically via blood transfusion, tissue donation, and, since prions resist routine sterilisation, contamination of surgical instruments. Such risks remain unquantified. Although variant CJD can be diagnosed during life by tonsil biopsy, a prion-specific blood test is needed to assess and manage this potential threat to public health. The theoretical possibility that BSE prions might have transferred to other species and continue to present a risk to human health cannot be excluded at present.	St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit, London W2 1PG, England; St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, London W2 1PG, England; St Marys Hosp, Dept Neurol, London W2 1PG, England	Imperial College London; Imperial College London; Imperial College London	Collinge, J (corresponding author), St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit, Praed St, London W2 1PG, England.							Aguzzi A, 1997, LANCET, V350, P1519, DOI 10.1016/S0140-6736(05)63941-4; ALPERS M, 1987, P451; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BARLOW RM, 1990, VET REC, V126, P111; BERNOULLI C, 1977, LANCET, V1, P478; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; Brown P, 1995, Curr Opin Hematol, V2, P472; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1994, MOL MED, V1, P19; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CLOUSCARD C, 1995, J GEN VIROL, V76, P2097, DOI 10.1099/0022-1317-76-8-2097; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; Collinge J, 1996, LANCET, V347, P916, DOI 10.1016/S0140-6736(96)91407-5; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Collinge J, 1998, NAT MED, V4, P1369, DOI 10.1038/3955; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CUILLE J., 1936, Compte Rendu de l'Academie des Sciences, V203, P1552; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; Diringer H, 1998, J GEN VIROL, V79, P609, DOI 10.1099/0022-1317-79-3-609; FRSER H, 1992, PRION DIS HUMANS ANI, P308; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GHANI AC, 1999, P R SOC LOND B, V265, P2243; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HADLOW WJ, 1959, LANCET, V2, P289; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1998, NEUROSCI LETT, V255, P159, DOI 10.1016/S0304-3940(98)00736-8; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; HSIAO K, 1992, NAT GENET, V1, P68, DOI 10.1038/ng0492-68; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KLEIN M, 1998, NAT MED, V4, P1; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KLITZMAN R L, 1984, Neuroepidemiology, V3, P3, DOI 10.1159/000110837; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; OUTRAM GW, 1974, NATURE, V249, P855, DOI 10.1038/249855a0; OWEN F, 1990, NUCLEIC ACIDS RES, V18, P3103, DOI 10.1093/nar/18.10.3103; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PARCHI P, 1996, ANN NEUROL, V39, P669; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Race R, 1998, NATURE, V392, P770, DOI 10.1038/33834; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wells GAH, 1998, VET REC, V142, P103, DOI 10.1136/vr.142.5.103; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204	68	343	358	1	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					317	323		10.1016/S0140-6736(99)05128-4	http://dx.doi.org/10.1016/S0140-6736(99)05128-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440324				2022-12-28	WOS:000081646000045
J	Lev, MH; Rhea, JT; Bramson, RT				Lev, MH; Rhea, JT; Bramson, RT			Avoidance of variability and error in radiology	LANCET			English	Editorial Material									Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Lev, MH (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.							Berlin L, 1996, AM J ROENTGENOL, V167, P587, DOI 10.2214/ajr.167.3.8751657; BLUMENTHAL D, 1994, JAMA-J AM MED ASSOC, V272, P1867, DOI 10.1001/jama.272.23.1867; Brown J, 1996, BRIT MED J, V312, P809; HENDRIX RW, 1995, RADIOLOGY, V195, P578, DOI 10.1148/radiology.195.2.7724791; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Robinson PJA, 1999, BRIT J RADIOL, V72, P323, DOI 10.1259/bjr.72.856.10474490; Schriger DL, 1998, JAMA-J AM MED ASSOC, V279, P1293, DOI 10.1001/jama.279.16.1293; Wadsworth HM, 2002, MODERN METHODS QUALI	8	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					272	272		10.1016/S0140-6736(99)00145-2	http://dx.doi.org/10.1016/S0140-6736(99)00145-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440301				2022-12-28	WOS:000081646000007
J	Inouye, S; Chikkatur, AP; Stamper-Kurn, DM; Stenger, J; Pritchard, DE; Ketterle, W				Inouye, S; Chikkatur, AP; Stamper-Kurn, DM; Stenger, J; Pritchard, DE; Ketterle, W			Superradiant Rayleigh scattering from a Bose-Einstein condensate	SCIENCE			English	Article							COLLECTIVE ATOMIC RECOIL; LASER; INTERFERENCE; GAS	Rayleigh scattering off a Bose-Einstein condensate was studied. Exposing an elongated condensate to a single off-resonant laser beam resulted in the observation of highly directional scattering of light and atoms. This collective light scattering is caused by the coherent center-of-mass motion of the atoms in the condensate. A directional beam of recoiling atoms was built up by matter wave amplification.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Inouye, S (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Stamper-Kurn, Dan/B-5442-2015	Stamper-Kurn, Dan/0000-0002-4845-5835				Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Berman PR, 1999, PHYS REV A, V59, P585, DOI 10.1103/PhysRevA.59.585; BONIFACIO R, 1994, NUCL INSTRUM METH A, V341, P360, DOI 10.1016/0168-9002(94)90382-4; BONIFACIO R, 1975, PHYS REV A, V11, P1507, DOI 10.1103/PhysRevA.11.1507; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Deng L, 1999, NATURE, V398, P218, DOI 10.1038/18395; Dicke R. H., 1964, P 3 INT C QUANT EL, P35; DICKE RH, 1954, PHYS REV, V93, P99, DOI 10.1103/PhysRev.93.99; Fried DG, 1998, PHYS REV LETT, V81, P3811, DOI 10.1103/PhysRevLett.81.3811; GROSS M, 1982, PHYS REP, V93, P301, DOI 10.1016/0370-1573(82)90102-8; Hall DS, 1998, PHYS REV LETT, V81, P1543, DOI 10.1103/PhysRevLett.81.1543; JANICKE U, 1997, TOPICS ULTRACOLD ATO, V7, P38; Law CK, 1998, PHYS REV A, V58, P4791, DOI 10.1103/PhysRevA.58.4791; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; Miesner HJ, 1998, SCIENCE, V279, P1005, DOI 10.1126/science.279.5353.1005; Moore MG, 1998, PHYS REV A, V58, P3248, DOI 10.1103/PhysRevA.58.3248; Moore MG, 1999, PHYS REV A, V59, pR1754, DOI 10.1103/PhysRevA.59.R1754; MOORE MG, CONDMAT9902293; OLSHANII M, 1995, P 12 INT C LAS SPECT, P7; REHLER NE, 1971, PHYS REV A-GEN PHYS, V3, P1735, DOI 10.1103/PhysRevA.3.1735; SKRIBANO.N, 1973, PHYS REV LETT, V30, P309, DOI 10.1103/PhysRevLett.30.309; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; Vrehen QHF, 1982, TOP CURR PHYS, V27, P111; WISEMAN HM, 1995, PHYS LETT A, V202, P246, DOI 10.1016/0375-9601(95)00355-7	27	440	451	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					571	574		10.1126/science.285.5427.571	http://dx.doi.org/10.1126/science.285.5427.571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417384				2022-12-28	WOS:000081609500034
J	Hecht, FM; Wilson, IB; Wu, AW; Cook, RL; Turner, BJ				Hecht, FM; Wilson, IB; Wu, AW; Cook, RL; Turner, BJ		Soc Gen Internal Med AIDS Task Force	Optimizing care for persons with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ACUTE MYOCARDIAL-INFARCTION; US NATIONAL SURVEY; AMBULATORY CARE; SPECIALIST PHYSICIANS; HOSPITAL EXPERIENCE; TERTIARY PREVENTION; COST-EFFECTIVENESS; ISCHEMIC STROKE; VIRUS INFECTION	Treatment advances and outcomes data have raised new concerns about how to optimize care for patients with HIV infection. This paper reviews evidence on 1) the relation between experience and type of training and patient outcomes, 2) the relation between the components of primary care and patient outcomes, and 3) primary care physicians' basic HIV knowledge and skills in screening and prevention. Several studies indicate that greater experience in HIV care leads to improved patient outcomes. The relation between outcomes and type of training (subspecialist or generalist) is less clear, and studies have not distinguished between type of training and experience. Less experienced physicians may be able to provide high-quality care if appropriate consultation from expert physicians is available. Components of primary care, including accessibility, continuity, coordination, and comprehensiveness, are associated with better patient outcomes. Optimal care of HIV infection requires a combination of disease-specific expertise and primary care skills and organization. Criteria for expertise in HIV management should focus on actual patient care experience and HIV expertise rather than on subspecialty training per se. The management of HIV has become sufficiently complex that primary care physicians cannot be routinely expected to have extensive specialized knowledge in this area. However, many primary care physicians have weaknesses in the basic HIV-related skills that are needed in most settings, such as HIV test counseling and recognition of important HIV-related symptom complexes. Primary care physicians need to strengthen these basic HIV-related medical skills.	Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA; Johns Hopkins Univ, Hlth Serv Res & Dev Ctr, Baltimore, MD 21205 USA; Univ Pittsburgh, Pittsburgh, PA 15213 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Tufts Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jefferson University	Hecht, FM (corresponding author), Univ Calif San Francisco, AIDS Program, Box 0874, San Francisco, CA 94143 USA.	rhecht@sfaids.ucsf.edu	Wilson, Ira/F-9190-2016; Cook, Robert Lewis/ABI-4866-2020; Wu, Albert/AAJ-4780-2021	Wilson, Ira/0000-0002-0246-738X; Hecht, Frederick/0000-0002-5782-1171				[Anonymous], 1995, MMWR Recomm Rep, V44, P1; Ayanian JZ, 1997, ARCH INTERN MED, V157, P2570, DOI 10.1001/archinte.157.22.2570; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Chin MH, 1997, J GEN INTERN MED, V12, P523, DOI 10.1046/j.1525-1497.1997.07105.x; Cook RL, 1998, ACAD MED, V73, P342, DOI 10.1097/00001888-199803000-00026; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; Cunningham WE, 1996, J ACQ IMMUN DEF SYND, V13, P327, DOI 10.1097/00042560-199612010-00005; CUNNINGHAM WE, 1995, MED CARE, V33, P739, DOI 10.1097/00005650-199507000-00009; CURTIS JR, 1995, ARCH INTERN MED, V155, P1613, DOI 10.1001/archinte.155.15.1613; CURTIS JR, 1995, J GEN INTERN MED, V10, P395, DOI 10.1007/BF02599841; DOLAN NC, 1995, J GEN INTERN MED, V10, P515, DOI 10.1007/BF02602405; Donohoe MT, 1998, ARCH INTERN MED, V158, P1596, DOI 10.1001/archinte.158.15.1596; Evans TI, 1996, J RHEUMATOL, V23, P143; Fendrick AM, 1996, AM J GASTROENTEROL, V91, P1544; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GOLDSTEIN LB, 1995, STROKE, V26, P1607, DOI 10.1161/01.STR.26.9.1607; Goldstein LB, 1996, STROKE, V27, P1473, DOI 10.1161/01.STR.27.9.1473; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hecht F. M., 1995, JGIM, V10, P68; HECHT FM, 1990, AIDS DX RX, P92; HECHT FM, 1996, INT C AIDS, V11, P433; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hnatiuk O, 1996, J GEN INTERN MED, V11, P204, DOI 10.1007/BF02642476; Institute of Medicine, 1978, MANP POL PRIM HLTH C; JEWETT JF, 1993, JAMA-J AM MED ASSOC, V269, P1144, DOI 10.1001/jama.269.9.1144; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KNOBEL H, 1998, INT C AIDS, V12, P585; Laine C., 1996, JGIM, V11, P77; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; LOFT J, 1994, JAMA-J AM MED ASSOC, V271, P261; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MAUSKOPF J, 1994, HEALTH SERV RES, V29, P489; Mauskopf J, 1998, AM J MANAG CARE, V4, P1004; Mitchell JB, 1996, STROKE, V27, P1937, DOI 10.1161/01.STR.27.11.1937; MOORE R, 1999, 6 C RETR OPP INF, P86; Newschaffer CJ, 1998, J URBAN HEALTH, V75, P153, DOI 10.1007/BF02344936; NORQUIST G, 1995, ARCH GEN PSYCHIAT, V52, P695; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panush R S, 1995, J Clin Rheumatol, V1, P74, DOI 10.1097/00124743-199504000-00003; RISEBROUGH N, 1999, 6 C RETR OPP INF, P866; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; SAMET JH, 1994, AM J MED, V97, P347, DOI 10.1016/0002-9343(94)90301-8; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Solomon DH, 1997, ANN INTERN MED, V127, P52, DOI 10.7326/0003-4819-127-1-199707010-00009; Starfield B., 1992, PRIMARY CARE CONCEPT; STONE VE, 1995, J GEN INTERN MED, V10, P239, DOI 10.1007/BF02599878; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; TURNER B, 1996, J GEN INTERN MED, V11, P91; Turner BJ, 1996, ARCH PEDIAT ADOL MED, V150, P615, DOI 10.1001/archpedi.1996.02170310049009; TURNER BJ, 1994, MED CARE, V32, P902, DOI 10.1097/00005650-199409000-00002; TURNER BJ, 1992, J ACQ IMMUN DEF SYND, V5, P978; Wenrich MD, 1997, J GEN INTERN MED, V12, P107, DOI 10.1046/j.1525-1497.1997.00015.x; Willison DJ, 1998, ARCH INTERN MED, V158, P1778, DOI 10.1001/archinte.158.16.1778; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011	63	51	52	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					136	143		10.7326/0003-4819-131-2-199907200-00011	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419430				2022-12-28	WOS:000081509700009
J	Pauker, SG; Rothberg, M				Pauker, SG; Rothberg, M			Commentary: Resist jumping to conclusions	BRITISH MEDICAL JOURNAL			English	Editorial Material									New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Pauker, SG (corresponding author), New England Med Ctr, Box 302,750 Washington St, Boston, MA 02111 USA.							CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; GOLDRATT F, 1992, GOAL; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; 1999, ALLIANCE PRUDENT USE	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1616	1617						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428553				2022-12-28	WOS:000080913100038
J	Garcia, PM; Kalish, LA; Pitt, J; Minkoff, H; Quinn, TC; Burchett, SK; Kornegay, J; Jackson, B; Moye, J; Hanson, C; Zorrilla, C; Lew, JF				Garcia, PM; Kalish, LA; Pitt, J; Minkoff, H; Quinn, TC; Burchett, SK; Kornegay, J; Jackson, B; Moye, J; Hanson, C; Zorrilla, C; Lew, JF		Women Infants Transmision Study Grp	Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	18th Annual Meeting of the Society-of-Perinatal-Obstetricians	FEB 02-07, 1998	MIAMI, FLORIDA	Soc Perinatal Obstetricians			TO-CHILD TRANSMISSION; VIRAL LOAD; VERTICAL TRANSMISSION; ZIDOVUDINE TREATMENT; HIV TRANSMISSION; PREGNANCY; INFECTION; INFANT; AIDS; REDUCTION	Background The importance of plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA in pregnant women in relation to the other factors known to influence the risk of transmission of infection to their infants is incompletely defined. We studied the relation of maternal plasma HIV-1 RNA levels to the risk of perinatal transmission and the timing of transmission. Methods We measured plasma HIV-1 RNA serially in 552 women with HIV-1 infection who had singleton pregnancies. The status of infection in their infants was assessed by culture of blood and further classified as early (if a culture of blood obtained within the first two days of life was positive) or late (if a culture of blood obtained in the first seven days of life was negative but subsequent cultures were positive). The rates of transmission at various levels of maternal plasma HIV-1 RNA were analyzed by tests for trend, with adjustment for covariates by stratification and logistic regression. Results Increasing geometric mean levels of plasma HIV-1 RNA were associated with increasing rates of transmission: the rate was 0 percent among women with less than 1000 copies per milliliter (0 of 57), 16.6 percent among women with 1000 to 10,000 copies per milliliter (32 of 193), 21.3 percent among women with 10,001 to 50,000 copies per milliliter (39 of 183), 30.9 percent among women with 50,001 to 100,000 copies per milliliter (17 of 54), and 40.6 percent among women with more than 100,000 copies per milliliter (26 of 64, P<0.001). The treatment status of one woman was unknown. The highest rate of transmission was among women whose plasma HIV-1 RNA levels exceeded 100,000 copies per milliliter and who had not received zidovudine (19 of 30 women, 63.3 percent). Neither higher HIV-1 RNA levels early in pregnancy nor higher levels late in pregnancy were associated with the timing of infection in the infants. Conclusions In pregnant women with HIV-1 infection, the level of plasma HIV-1 RNA predicts the risk but not the timing of transmission of HIV-1 to their infants. (N Engl J Med 1999;341:394-402.) (C) 1999, Massachusetts Medical Society.	Northwestern Univ, Dept Obstet & Gynecol, Chicago, IL 60611 USA; New England Res Inst, Watertown, MA 02172 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; SUNY Hlth Sci Ctr, Dept Obstet & Gynecol, Brooklyn, NY 11203 USA; Johns Hopkins Univ, Baltimore, MD USA; NIAID, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Roche Mol Syst, Alameda, CA USA; NICHHD, Bethesda, MD 20892 USA; Baylor Coll Med, Sect Allergy & Immunol, Houston, TX 77030 USA; Univ Puerto Rico, Dept Obstet & Gynecol, San Juan, PR 00936 USA	Northwestern University; HealthCore, Inc; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School; Roche Holding; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Garcia, PM (corresponding author), Northwestern Univ, Prentice Womens Hosp, Rm 410,333 E Super St, Chicago, IL 60611 USA.		Quinn, Thomas/A-2494-2010	jackson, brooks/0000-0001-9458-135X; moye, john/0000-0001-9976-8586	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034841, ZIAAI000361, U01AI034840, U01AI034842, Z01AI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI 34840, U01 AI 34842, U01 AI 34841] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Hollinger F B., 1993, ACTG VIROLOGY MANUAL; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jackson JB, 1996, PEDIATR AIDS HIV INF, V7, P37; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mayaux MJ, 1997, J INFECT DIS, V175, P172, DOI 10.1093/infdis/175.1.172; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P287; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P315; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; Rosner B., 2010, FUNDAMENTALS BIOSTAT; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; SHEON AR, 1996, J WOMENS HEALTH, V5, P69, DOI DOI 10.1089/JWH.1996.5.69; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; 1998, MMWR MORB MORTAL WKL, V47, P151	28	520	537	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					394	402		10.1056/NEJM199908053410602	http://dx.doi.org/10.1056/NEJM199908053410602			9	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10432324				2022-12-28	WOS:000081860100002
J	Kopelman, RI; Wong, JB; Pauker, SG				Kopelman, RI; Wong, JB; Pauker, SG			A little math helps the medicine go down	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MILIARY TUBERCULOSIS; CORTICOSTEROIDS; PULMONARY; HEPATITIS; DISEASE		Tufts Univ, Sch Med, New England Med Ctr, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Pauker, SG (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Dept Med, Box 302,750 Washington St, Boston, MA 02111 USA.	stephen.pauker@es.nemc.org		Wong, John/0000-0003-4203-9010				BATEMAN ED, 1993, RESP MED, V87, P485, DOI 10.1016/0954-6111(93)90001-G; BIEHL JP, 1958, AM REV TUBERC PULM, V77, P605; BRICE EAW, 1995, CHEST, V107, P706, DOI 10.1378/chest.107.3.706; CRYSTAL RG, 1998, HARRISONS PRINCIPLES, V2, P1922; DYER RA, 1985, CRIT CARE MED, V13, P12, DOI 10.1097/00003246-198501000-00004; FANBURG BL, 1983, SARCOIDOSIS OTHER GR, P381; GEPPERT EF, 1979, ARCH INTERN MED, V139, P1381, DOI 10.1001/archinte.139.12.1381; GOTTLIEB JE, 1983, SARCOIDOSIS OTHER GR, P349; HAAS DW, 1995, PRINCIPLES PRACTICE, V2, P2213; HOUGHTON LE, 1954, LANCET, V1, P595; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; MUNT PW, 1972, MEDICINE, V51, P139, DOI 10.1097/00005792-197203000-00004; MUTHUSWAMY P, 1995, CHEST, V107, P1621, DOI 10.1378/chest.107.6.1621; Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706; Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014; PAUKER SG, 1975, NEW ENGL J MED, V293, P229, DOI 10.1056/NEJM197507312930505; RAVIGLIONE MC, 1998, HARRISONS PRINCIPLES, V1, P1004; SAHN SA, 1974, AM J MED, V56, P495, DOI 10.1016/0002-9343(74)90482-3; SENDEROVITZ T, 1994, RESP MED, V88, P561, DOI 10.1016/S0954-6111(05)80002-2; STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465; WILLCOX PA, 1986, THORAX, V41, P681, DOI 10.1136/thx.41.9.681	21	14	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					435	439		10.1056/NEJM199908053410608	http://dx.doi.org/10.1056/NEJM199908053410608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10432329				2022-12-28	WOS:000081860100008
J	Aviles-Santa, L; Sinding, J; Raskin, P				Aviles-Santa, L; Sinding, J; Raskin, P			Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						metformin; insulin; diabetes mellitus, non-insulin dependent; obesity; weight gain	OBESE; MECHANISM; EFFICACY; THERAPY; RISK	Background: Patients with type 2 diabetes are often obese and require large doses of insulin to achieve glycemic control. Weight gain often accompanies insulin therapy and results in increasing insulin requirements. Objective: To evaluate the efficacy of metformin in combination with insulin in patients with type 2 diabetes poorly controlled with insulin therapy alone. Design: Randomized, double-blind, placebo-controlled trial. Setting: Outpatient diabetes clinic at a university medical center. Patients: 43 patients with poorly controlled type 2 diabetes who were receiving insulin therapy. Intervention: Patients were randomly assigned to receive placebo or metformin in combination with insulin for 24 weeks. Results: Hemoglobin A(1c) levels decreased by 2.5 percentage points (95% CI, 1.8 to 3.1 percentage points) in the metformin group, a significantly greater change (P = 0.04) than the decrease of 1.6 percentage points in the placebo group. Average final hemoglobin A(1c) levels were 6.5% in the metformin group and 7.6% in the placebo group (difference, 11%). For patients who received placebo, the insulin dose increased 22.8 units (CI, 11 to 44 units) or 29% more than did the dose for patients who received metformin (P = 0.002); for these patients, the insulin dose decreased slightly. Patients in the placebo group gained an average of 3.2 kg of body weight (Cl, 1.2 to 5.1 kg); patients in the metformin group gained an average of 0.5 kg of body weight (P = 0.07). Total cholesterol and low-density lipoprotein cholesterol levels decreased in both groups. High-density lipoprotein cholesterol and triglyceride levels did not change. Conclusions: The addition of metformin to insulin therapy resulted in hemoglobin A(1c) concentrations that were 10% lower than those achieved by insulin therapy alone. This improvement in glycemic control occurred with the use of 29% less insulin and without significant weight gain. Metformin is an effective adjunct to insulin therapy in patients with type 2 diabetes.	Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Raskin, P (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd,G5-238, Dallas, TX 75235 USA.			Aviles-Santa, M Larissa/0000-0002-8130-0026				Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Davidson MB, 1997, AM J MED, V102, P99, DOI 10.1016/S0002-9343(96)00353-1; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; Garber AJ, 1997, AM J MED, V103, P491, DOI 10.1016/S0002-9343(97)00254-4; Genuth S, 1996, ANN INTERN MED, V124, P104, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00005; GIUGLIANO D, 1993, EUR J CLIN PHARMACOL, V44, P107, DOI 10.1007/BF00315466; HALIMI S K, 1991, American Journal of Medicine, V90, p83S, DOI 10.1016/0002-9343(91)90424-V; Johnson JL, 1996, ARCH INTERN MED, V156, P259, DOI 10.1001/archinte.156.3.259; LEFEBVRE PJ, 1995, CLIN INVEST MED, V18, P340; MCINTYRE HD, 1991, AUST NZ J MED, V21, P714; Melander A, 1996, DIABETIC MED, V13, pS143; PAGANO G, 1983, DIABETOLOGIA, V24, P351; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Scheen AJ, 1997, DRUGS, V54, P355, DOI 10.2165/00003495-199754030-00001; SCHEEN AJ, 1995, DIABETES METAB REV, V11, pS69, DOI 10.1002/dmr.5610110511; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIRTORI CR, 1994, PHARMACOL RES, V30, P187, DOI 10.1016/1043-6618(94)80104-5; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Wright A, 1998, ANN INTERN MED, V128, P165, DOI 10.7326/0003-4819-128-3-199802010-00001	21	162	165	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					182	+		10.7326/0003-4819-131-3-199908030-00004	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428734				2022-12-28	WOS:000081788700003
J	Borriello, SP				Borriello, SP			Science, medicine, and the future - Near patient microbiological tests	BRITISH MEDICAL JOURNAL			English	Review							POLYMERASE-CHAIN-REACTION; DNA; HYBRIDIZATION; CHIPS		Cent Publ Hlth Lab, PHLS, London NW9 5HT, England	Public Health England	Borriello, SP (corresponding author), Cent Publ Hlth Lab, PHLS, London NW9 5HT, England.							Bevan V M, 1999, Commun Dis Public Health, V2, P14; CAO LK, 1995, J CLIN MICROBIOL, V33, P336, DOI 10.1128/JCM.33.2.336-341.1995; Charych D, 1996, CHEM BIOL, V3, P113, DOI 10.1016/S1074-5521(96)90287-2; Cheng J, 1998, NAT BIOTECHNOL, V16, P541, DOI 10.1038/nbt0698-541; Cheng J, 1998, ANAL BIOCHEM, V257, P101, DOI 10.1006/abio.1997.2531; Greenwood J E, 1997, J Wound Care, V6, P219; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Needham CA, 1998, J CLIN MICROBIOL, V36, P3468, DOI 10.1128/JCM.36.12.3468-3473.1998; SHENA M, 1995, SCIENCE, V270, P467; Southern EM, 1996, TRENDS GENET, V12, P110, DOI 10.1016/0168-9525(96)81422-3; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wilding P, 1998, ANAL BIOCHEM, V257, P95, DOI 10.1006/abio.1997.2530	12	22	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					298	301		10.1136/bmj.319.7205.298	http://dx.doi.org/10.1136/bmj.319.7205.298			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426746	Green Published			2022-12-28	WOS:000081909100029
J	Brooksby, P; Robinson, PJ; Segal, R; Klinger, G; Pitt, B; Cowley, AJC				Brooksby, P; Robinson, PJ; Segal, R; Klinger, G; Pitt, B; Cowley, AJC		ELITE study grp	Effects of losartan and captopril on QT dispersion in elderly patients with heart failure	LANCET			English	Article							ELITE	Differences in QT dispersion (a predictor for sudden death) were observed In a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan.	Univ Nottingham Hosp, Queens Med Ctr, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Merck Res Labs, W Point, PA USA; Merck Sharpe & Dohme UK, Hoddesdon, Herts, England; Univ Michigan Hosp, Div Cardiol, Ann Arbor, MI 48109 USA	University of Nottingham; Merck & Company; Merck & Company; University of Michigan System; University of Michigan	Brooksby, P (corresponding author), Pontefract Gen Infirm, Dept Cardiol, Pontefract WF8 1PL, W Yorkshire, England.							BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; LYNCH JJ, IN PRESS J AM COLL C; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Rump LC, 1998, LANCET, V351, P644, DOI 10.1016/S0140-6736(05)78427-0; Thomas GP, 1996, J PHARMACOL EXP THER, V278, P1090	5	27	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					395	396		10.1016/S0140-6736(99)01354-9	http://dx.doi.org/10.1016/S0140-6736(99)01354-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437875				2022-12-28	WOS:000081764900021
J	Gottlieb, S				Gottlieb, S			Editor of New England Journal of Medicine departs	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					273	273		10.1136/bmj.319.7205.273	http://dx.doi.org/10.1136/bmj.319.7205.273			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426720	Green Published			2022-12-28	WOS:000081909100005
J	Bauer, S; Groh, V; Wu, J; Steinle, A; Phillips, JH; Lanier, LL; Spies, T				Bauer, S; Groh, V; Wu, J; Steinle, A; Phillips, JH; Lanier, LL; Spies, T			Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA	SCIENCE			English	Article							NATURAL-KILLER-CELLS; CLASS-I MOLECULES; INHIBITORY RECEPTOR; HLA-E; EXPRESSION; SUPERFAMILY; RECOGNITION; LYMPHOCYTES; CD94/NKG2A; ANTIGEN	Stress-inducible MICA, a distant homolog of major histocompatibility complex (MHC) class I, functions as an antigen for gamma delta T cells and is frequently expressed in epithelial tumors. A receptor for MICA was detected on most gamma delta T cells, CD8(+) alpha beta T cells, and natural killer (NK) cells and was identified as NKG2D. Effector cells from all these subsets could be stimulated by ligation of NKG2D. Engagement of NKG2D activated cytolytic responses of gamma delta T cells and NK cells against transfectants and epithelial tumor cells expressing MICA. These results define an activating immunoreceptor-MHC ligand interaction that may promote antitumor NK and T cell responses.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Fred Hutchinson Cancer Center; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Spies, T (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Steinle, Alexander/E-6131-2012; Lanier, Lewis L/E-2139-2014	Steinle, Alexander/0000-0001-5081-8503; Lanier, Lewis L/0000-0003-1308-3952; Bauer, Stefan/0000-0002-8462-1845	NCI NIH HHS [P01 CA18221] Funding Source: Medline; NIAID NIH HHS [R01 AI30581] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bauer S, 1998, ACTA CRYSTALLOGR D, V54, P451, DOI 10.1107/S0907444997015229; Bauer S., UNPUB; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brooks AG, 1997, J EXP MED, V185, P795, DOI 10.1084/jem.185.4.795; Carena I, 1997, J EXP MED, V186, P1769, DOI 10.1084/jem.186.10.1769; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Groh V., UNPUB; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Noppen C, 1998, EUR J IMMUNOL, V28, P1134, DOI 10.1002/(SICI)1521-4141(199804)28:04<1134::AID-IMMU1134>3.0.CO;2-G; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; YABE T, 1993, IMMUNOGENETICS, V37, P455; Yokoyama WM, 1998, CURR OPIN IMMUNOL, V10, P298, DOI 10.1016/S0952-7915(98)80168-4; 1996, J EXP MED, V183, P1681	27	2317	2468	10	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					727	729		10.1126/science.285.5428.727	http://dx.doi.org/10.1126/science.285.5428.727			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426993				2022-12-28	WOS:000081765100052
J	Zhitenev, NB; Brodsky, M; Ashoori, RC; Pfeiffer, LN; West, KW				Zhitenev, NB; Brodsky, M; Ashoori, RC; Pfeiffer, LN; West, KW			Localization-delocalization transition in quantum dots	SCIENCE			English	Article							2-DIMENSIONAL ELECTRON; ARTIFICIAL ATOMS; 2 DIMENSIONS; FIELD; SYSTEM; ISLAND	Single-electron capacitance spectroscopy precisely measures the energies required to add individual electrons to a quantum dot. The spatial extent of electronic wave functions is probed by investigating the dependence of these energies on changes in the dot confining potential. For low electron densities, electrons occupy distinct spatial sites localized within the dot. At higher densities, the electrons become delocalized, and all wave functions are spread over the full dot area. Near the delocalization transition, the last remaining localized states exist at the perimeter of the dot, Unexpectedly, these electrons appear to bind with electrons in the dot center.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; AT&T Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs	Ashoori, RC (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Zhitenev, Nikolai/N-1780-2014	Zhitenev, Nikolai/0000-0002-7477-6341				ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; ASHOORI RC, 1992, PHYS REV LETT, V68, P3088, DOI 10.1103/PhysRevLett.68.3088; BEDANOV VM, 1994, PHYS REV B, V49, P2667, DOI 10.1103/PhysRevB.49.2667; CHUI ST, 1995, PHYS REV LETT, V74, P458, DOI 10.1103/PhysRevLett.74.458; EDWARDS JT, 1972, J PHYS PART C SOLID, V5, P807, DOI 10.1088/0022-3719/5/8/007; EGGER R, CONDMAT9903111; EGUILUZ AG, 1983, PHYS REV B, V27, P4933, DOI 10.1103/PhysRevB.27.4933; Hanein Y, 1998, PHYS REV LETT, V80, P1288, DOI 10.1103/PhysRevLett.80.1288; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; Koulakov AA, 1998, PHYS REV B, V57, P2352, DOI 10.1103/PhysRevB.57.2352; Kravchenko SV, 1996, PHYS REV LETT, V77, P4938, DOI 10.1103/PhysRevLett.77.4938; LEVITOV LS, COMMUNICATION, P32710; MILLER DL, CONDMAT9808103; Raikh ME, 1996, PHYS REV LETT, V77, P1354, DOI 10.1103/PhysRevLett.77.1354; Thouless D.J., 1974, PHYS REP, V13, P93, DOI DOI 10.1016/0370-1573(74)90029-5; WAN Y, 1995, PHYS REV LETT, V75, P2879, DOI 10.1103/PhysRevLett.75.2879; Zhitenev NB, 1997, PHYS REV LETT, V79, P2308, DOI 10.1103/PhysRevLett.79.2308	21	40	41	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					715	718		10.1126/science.285.5428.715	http://dx.doi.org/10.1126/science.285.5428.715			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426989				2022-12-28	WOS:000081765100048
J	Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW				Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW			Genetic selection of peptide inhibitors of biological pathways	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; STAPHYLOCOCCAL NUCLEASE; RESPONSE PATHWAY; PROTEIN; KINASE; IDENTIFICATION; ACTIVATION; PHEROMONE	Genetic selections were used to find peptides that inhibit biological pathways in budding yeast. The peptides were presented inside cells as peptamers, surface loops on a highly expressed and biologically inert carrier protein, a catalytically inactive derivative of staphylococcal nuclease, Peptamers that inhibited the pheromone signaling pathway, transcriptional silencing, and the spindle checkpoint were isolated. Putative targets for the inhibitors were identified by a combination of two-hybrid analysis and genetic dissection of the target pathways. This analysis identified Ydr517w as a component of the spindle checkpoint and reinforced earlier indications that Ste50 has both positive and negative roles in pheromone signaling. Analysis of transcript arrays showed that the peptamers were highly specific in their effects, which suggests that they may be useful reagents in organisms that lack sophisticated genetics as well as for identifying components of existing biological pathways that are potential targets for drug discovery.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Rosetta Pharmaceut, Kirkland, WA 98034 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Norman, TC (corresponding author), Microbia Inc, 840 Mem Dr, Cambridge, MA 02139 USA.			Sorger, Peter/0000-0002-3364-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR11823] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; CHAMBERS A, 1988, NUCLEIC ACIDS RES, V16, P8245, DOI 10.1093/nar/16.17.8245; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; James P, 1996, GENETICS, V144, P1425; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; NORMAN TC, UNPUB; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; RAD MR, 1992, MOL GEN GENET, V236, P145; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Singer MS, 1998, GENETICS, V150, P613; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75	36	153	170	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					591	595		10.1126/science.285.5427.591	http://dx.doi.org/10.1126/science.285.5427.591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417390				2022-12-28	WOS:000081609500040
J	Weliky, M; Katz, LC				Weliky, M; Katz, LC			Correlational structure of spontaneous neuronal activity in the developing lateral geniculate nucleus in vivo	SCIENCE			English	Article							ORIENTATION PREFERENCE MAPS; OCULAR DOMINANCE COLUMNS; RETINAL GANGLION-CELLS; CAT VISUAL-CORTEX; STRIATE CORTEX; IN-VITRO; PERIGENICULATE NUCLEUS; ORDERED ARRANGEMENT; BURSTING ACTIVITY; MAMMALIAN RETINA	The properties of spontaneous activity in the developing visual pathway beyond the retina are unknown. Multielectrode recordings in the lateral geniculate nucleus (LGN) of awake behaving ferrets, before eye opening, revealed patterns of spontaneous activity that reflect a reshaping of retinal drive within higher visual stages. Significant binocular correlations were present only when corticothalamic feedback was intact. In the absence of retinal drive, cortico-thalamic feedback was required to sustain correlated LGN bursting. Activity originating from the contralateral eye drove thalamic activity far more strongly than that originating from the ipsilateral eye. Thus, in vivo patterns of LGN spontaneous activity emerge from interactions between retina, thalamus, and cortex.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Weliky, M (corresponding author), Univ Rochester, Dept Brain & Cognit Sci, Meljora Hall, Rochester, NY 14627 USA.							BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Contreras D, 1996, SCIENCE, V274, P771, DOI 10.1126/science.274.5288.771; COULTER DA, 1993, BRAIN RES, V631, P137, DOI 10.1016/0006-8993(93)91199-3; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Erwin E, 1998, J NEUROSCI, V18, P9870; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godwin DW, 1996, J NEUROSCI, V16, P8181; HOLLANDER H, 1972, BRAIN RES, V41, P464, DOI 10.1016/0006-8993(72)90516-1; Horton JC, 1996, J NEUROSCI, V16, P1791; HU B, 1989, NEUROSCIENCE, V31, P13, DOI 10.1016/0306-4522(89)90027-4; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; Kao CQ, 1997, J NEUROPHYSIOL, V77, P2661, DOI 10.1152/jn.1997.77.5.2661; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; LO FS, 1994, EXP BRAIN RES, V100, P365; LU SM, 1993, VISUAL NEUROSCI, V10, P631, DOI 10.1017/S0952523800005332; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Murphy PC, 1996, J NEUROSCI, V16, P1180; MURPHY PC, 1994, VISUAL NEUROSCI, V11, P781, DOI 10.1017/S0952523800003084; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SWINDALE NV, 1980, PROC R SOC SER B-BIO, V208, P243, DOI 10.1098/rspb.1980.0051; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	37	207	210	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					599	604		10.1126/science.285.5427.599	http://dx.doi.org/10.1126/science.285.5427.599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417392				2022-12-28	WOS:000081609500042
J	Yeomans, DK; Antreasian, PG; Cheng, A; Dunham, DW; Farquhar, RW; Gaskell, RW; Giorgini, JD; Helfrich, CE; Konopliv, AS; McAdams, JV; Miller, JK; Owen, WM; Thomas, PC; Veverka, J; Williams, BG				Yeomans, DK; Antreasian, PG; Cheng, A; Dunham, DW; Farquhar, RW; Gaskell, RW; Giorgini, JD; Helfrich, CE; Konopliv, AS; McAdams, JV; Miller, JK; Owen, WM; Thomas, PC; Veverka, J; Williams, BG			Estimating the mass of asteroid 433 Eros during the NEAR spacecraft flyby	SCIENCE			English	Article							253-MATHILDE; 433-EROS; MISSION; ORBIT	The Near Earth Asteroid Rendezvous (NEAR) spacecraft flew within 3830 kilometers of asteroid 433 Eros on 23 December 1998. The gravitational perturbation on NEAR was evident in the spacecraft tracking data. Ground-based Doppler and range tracking of the spacecraft as well as spacecraft images of the asteroid's center of figure and surface features were used to determine the mass and rotation pole of Eros. The mass of Eros is (7.2 +/- 1.8) x 10(18) grams and, coupled with a volume estimate provided by the NEAR imaging team, this mass suggests a bulk density of 2.5 +/- 0.8 grams per cubic centimeter. The rotation pole position is 15.6 (+/-3.7) degrees in right ascension and 16.4 (+/-1.8) degrees in declination, which is consistent with ground-based and NEAR imaging team observations.	CALTECH, Jet Prop Lab, Nav & Flight Mech Sect, Pasadena, CA 91109 USA; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; Cornell Univ, Ithaca, NY 14853 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Cornell University	Yeomans, DK (corresponding author), CALTECH, Jet Prop Lab, Nav & Flight Mech Sect, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.		Dunham, David W/A-5214-2014	Dunham, David W/0000-0001-7527-4207; Antreasian, Peter/0000-0001-9040-310X				BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; Chapman CR, 1996, METEORIT PLANET SCI, V31, P699, DOI 10.1111/j.1945-5100.1996.tb02107.x; Krimigis SM, 1995, J ASTRONAUT SCI, V43, P345; Miller JK, 1995, J ASTRONAUT SCI, V43, P453; MILLER JK, 1990, J GUID CONTROL DYNAM, V13, P775, DOI 10.2514/3.25402; RIEDEL JE, 1990, AM I AER ASTR AM AST; Veverka J, 1999, SCIENCE, V285, P562, DOI 10.1126/science.285.5427.562; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; Yeomans DK, 1997, SCIENCE, V278, P2106, DOI 10.1126/science.278.5346.2106; Yeomans DK, 1995, J ASTRONAUT SCI, V43, P417; ZELLNER B, 1976, ICARUS, V28, P149, DOI 10.1016/0019-1035(76)90097-X; 1997, J GEOPHYS RES, V102, P23695	12	45	46	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					560	561		10.1126/science.285.5427.560	http://dx.doi.org/10.1126/science.285.5427.560			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417380				2022-12-28	WOS:000081609500030
J	Santosh, PJ; Baird, G				Santosh, PJ; Baird, G			Psychopharmacotherapy in children and adults with intellectual disability	LANCET			English	Article							PERVASIVE DEVELOPMENTAL DISORDERS; MENTALLY-HANDICAPPED PATIENTS; SELF-INJURIOUS-BEHAVIOR; YOUNG AUTISTIC-CHILDREN; DOUBLE-BLIND; OPEN-LABEL; CLOMIPRAMINE TREATMENT; PSYCHIATRIC-DISORDERS; FLUOXETINE TREATMENT; LEARNING-DISABILITIES	The prevalence of psychiatric disorders is increased in children and adults with intellectual disability. Brain damage or dysfunction interact with social and family factors to increase susceptibility to mental illness. Psychiatric disorders in the context of genetic syndromes are commonly overlooked, and there is substantial underdiagnosis of mental disorders because of the atypical and non-specific clinical presentations, and the frequent assumption that psychiatric symptoms are an inherent part of the underlying intellectual disability. There is a strong need for evidence-based practice in the prescribing and monitoring of drugs in this population, especially since many of the drugs are unlicensed for use in children. There is an urgent need to understand and establish the pharmacokinetics, pharmacodynamics, and side-effect profiles of psychotropic medication in this population. Positive trends in pharmacotherapy include the use of atypical antipsychotics instead of the classic antipsychotics, serotonin-specific reuptake inhibitors (SSRIs) rather than tricyclic antidepressants, and newer antiepileptic drugs. Another welcome trend is the use of SSRIs instead of antipsychotics in the long-term management of challenging behaviour in this population.	Inst Psychiat, Acad Dept Child & Adolescent Psychiat, London SE5 8AF, England; Guys Hosp, Newcomen Ctr, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Santosh, PJ (corresponding author), Inst Psychiat, Acad Dept Child & Adolescent Psychiat, Denmark Hill, London SE5 8AF, England.		Santosh, Paramala/B-7303-2008	Santosh, Paramala/0000-0003-4830-5893				Aman MG, 1997, AM J MENT RETARD, V101, P521; AMAN MG, 1993, J AM ACAD CHILD PSY, V32, P851, DOI 10.1097/00004583-199307000-00022; BAUMEISTER AA, 1993, CLIN NEUROPHARMACOL, V16, P271, DOI 10.1097/00002826-199308000-00001; Berkson G., 1993, CHILDREN HANDICAPS R; Bhaumik S, 1997, HUM PSYCHOPHARM CLIN, V12, P47, DOI 10.1002/(SICI)1099-1077(199701/02)12:1<47::AID-HUP833>3.0.CO;2-6; BODFISH JW, 1993, AM J MENT RETARD, V98, P360; BRUNNER HG, 1993, AM J HUM GENET, V52, P1032; Buitelaar JK, 1998, J CLIN PSYCHIAT, V59, P56, DOI 10.4088/JCP.v59n0203; Buitelaar JK, 1996, EUR NEUROPSYCHOPHARM, V6, P13, DOI 10.1016/0924-977X(95)00049-U; BUITELAAR JK, 1992, J AM ACAD CHILD PSY, V31, P1149, DOI 10.1097/00004583-199211000-00026; CAMPBELL M, 1993, J AM ACAD CHILD PSY, V32, P1283, DOI 10.1097/00004583-199311000-00024; Campbell M, 1997, J AM ACAD CHILD PSY, V36, P835, DOI 10.1097/00004583-199706000-00022; CLARKE DJ, 1989, MED SCI LAW, V29, P136, DOI 10.1177/002580248902900209; CLARKE DJ, 1993, BRIT J PSYCHIAT, V163, P680, DOI 10.1192/bjp.163.5.680; COHEN SA, 1994, J CLIN PSYCHIAT, V55, P440; COOK EH, 1992, J AM ACAD CHILD PSY, V31, P739, DOI 10.1097/00004583-199207000-00024; CRAFT M, 1987, BRIT J PSYCHIAT, V150, P685, DOI 10.1192/bjp.150.5.685; Davanzo PA, 1998, AM J MENT RETARD, V102, P427; DEB S, 1997, J PSYCHOPHARMACOL, V11, P291; DEKONING P, 1994, INT CLIN PSYCHOPHARM, V9, P187, DOI 10.1097/00004850-199409000-00007; DeLong GR, 1998, DEV MED CHILD NEUROL, V40, P551; ERNST M, 1992, PSYCHOPHARMACOL BULL, V28, P187; FANKHAUSER MP, 1992, J CLIN PSYCHIAT, V53, P77; Findling RL, 1997, PSYCHOPHARMACOL BULL, V33, P155; FREUND LS, 1993, PEDIATRICS, V91, P321; GARBER HJ, 1992, J AM ACAD CHILD PSY, V31, P1157, DOI 10.1097/00004583-199211000-00027; GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441; Handen BL, 1997, J ABNORM CHILD PSYCH, V25, P287, DOI 10.1023/A:1025760302598; HANDEN BL, 1994, J AM ACAD CHILD PSY, V33, P1185, DOI 10.1097/00004583-199410000-00014; HANDEN BL, 1992, J AM ACAD CHILD PSY, V31, P455, DOI 10.1097/00004583-199205000-00011; Hellings JA, 1996, J CLIN PSYCHIAT, V57, P333; Horrigan JP, 1997, J AUTISM DEV DISORD, V27, P313, DOI 10.1023/A:1025854532079; HUROWITZ GI, 1993, J NEUROPSYCH CLIN N, V5, P30; Jacoby Ann, 1996, Epilepsia, V37, P202; Jan JE, 1996, J PINEAL RES, V21, P193, DOI 10.1111/j.1600-079X.1996.tb00286.x; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; Kalachnik JE, 1995, MENT RETARD, V33, P374; KENNES D, 1988, EUR J PHARMACOL, V153, P19, DOI 10.1016/0014-2999(88)90583-3; KIERNAN C, 1995, J INTELL DISABIL RES, V39, P263, DOI 10.1111/j.1365-2788.1995.tb00518.x; KOLEMAN BK, 1995, J AM ACAD CHILD ADOL, V34, P223; LEWIS MH, 1995, AM J MENT RETARD, V100, P299; Lewis MH, 1996, AM J MENT RETARD, V100, P654; Luckasson R., 1992, MENTAL RETARDATION D; MALT UF, 1995, BRIT J PSYCHIAT, V166, P374, DOI 10.1192/bjp.166.3.374; Markowitz P I, 1990, J Clin Psychopharmacol, V10, P299; MARKOWITZ PI, 1992, J CLIN PSYCHOPHARM, V12, P27; Masi G, 1997, J INTELL DISABIL RES, V41, P268, DOI 10.1111/j.1365-2788.1997.tb00707.x; McDougle CJ, 1998, J CLIN PSYCHOPHARM, V18, P62, DOI 10.1097/00004714-199802000-00010; McDougle CJ, 1998, ARCH GEN PSYCHIAT, V55, P633, DOI 10.1001/archpsyc.55.7.633; McDougle CJ, 1997, J AM ACAD CHILD PSY, V36, P685, DOI 10.1097/00004583-199705000-00020; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P993; Meins W, 1996, NERVENARZT, V67, P216; Moss S, 1997, SOC PSYCH PSYCH EPID, V32, P344, DOI 10.1007/BF00805440; Nicolson R, 1998, J AM ACAD CHILD PSY, V37, P372, DOI 10.1097/00004583-199804000-00014; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; RATEY J, 1991, J CLIN PSYCHIAT, V52, P159; RATEY JJ, 1986, J CLIN PSYCHOPHARM, V6, P103; RATEY JJ, 1989, J CLIN PSYCHIAT, V50, P382; REALMUTO GM, 1989, J CLIN PSYCHOPHARM, V9, P122, DOI 10.1097/00004714-198904000-00009; Reiss S, 1997, J INTELL DISABIL RES, V41, P448, DOI 10.1111/j.1365-2788.1997.tb00736.x; RICKETTS RW, 1994, J AM ACAD CHILD PSY, V33, P270, DOI 10.1097/00004583-199402000-00017; RUEDRICH SL, 1990, AM J MENT RETARD, V95, P110; SAJATOVIC M, 1994, COMPR PSYCHIAT, V35, P29, DOI 10.1016/0010-440X(94)90166-X; Schroeder SR, 1995, MENTAL RETARDATION D, V1, P120, DOI [DOI 10.1002/MRDD.1410010208, 10.1002/mrdd.1410010208]; SINGH I, 1992, J INTELL DISABIL RES, V36, P541; Spreat S, 1997, AM J MENT RETARD, V102, P80, DOI 10.1352/0895-8017(1997)102<0080:UOPMIO>2.0.CO;2; Steffenburg S, 1996, ARCH NEUROL-CHICAGO, V53, P904, DOI 10.1001/archneur.1996.00550090114017; Steingard RJ, 1997, J CHILD ADOL PSYCHOP, V7, P9, DOI 10.1089/cap.1997.7.9; SWIFT RG, 1991, AM J PSYCHIAT, V148, P775; Szymanski L. S., 1994, MENTAL HLTH MENTAL R, P19; TROISI A, 1995, PHARMACOPSYCHIATRY, V28, P73; TUNIER S, 1994, CURR OPIN PSYCHIATR, V7, P380; TURK J, 1992, 1992 INTERNATIONAL FRAGILE X CONFERENCE PROCEEDINGS, P195; TYRER SP, 1984, PROG NEURO-PSYCHOPH, V8, P751, DOI 10.1016/0278-5846(84)90052-6; TYRER SP, 1993, EUR NEUROPSYCHOPHARM, V3, P384; VANDENBORRE R, 1993, ACTA PSYCHIAT SCAND, V87, P167; Verhoeven WMA, 1996, J INTELL DISABIL RES, V40, P502, DOI 10.1046/j.1365-2788.1996.806806.x; VERHOEVEN WMA, IN PRESS J INTELLECT; WILLEMSENSWINKELS SHN, 1995, PSYCHIAT RES, V58, P203, DOI 10.1016/0165-1781(95)02749-M; WILLEMSENSWINKELS SHN, 1995, ARCH GEN PSYCHIAT, V52, P766; WORRALL EP, 1975, BRIT J PSYCHIAT, V126, P464, DOI 10.1192/bjp.126.5.464	82	71	71	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					233	242		10.1016/S0140-6736(98)07059-7	http://dx.doi.org/10.1016/S0140-6736(98)07059-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	217MU	10421318				2022-12-28	WOS:000081504200042
J	Stapleton, JA; Lowin, A; Russell, MAH				Stapleton, JA; Lowin, A; Russell, MAH			Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness	LANCET			English	Article							RANDOMIZED TRIAL; ADJUNCT	Background The 1998 UK government White Paper Smoking Kills emphasises that normal practice should be for general practitioners (GPs), practice nurses, and others to offer advice and support to smokers in their efforts to stop. However, GPs are not allowed to write NHS prescriptions for nicotine-replacement therapy, even though this is the only effective pharmceutical treatment available in the UK. We estimated the cost-effectiveness, for the NHS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks. Methods We used data from a randomised, placebo-controlled efficacy trial of nicotine patches and a survey of associated resource use in 30 GP surgeries in 15 English counties. We calculated the health benefit of nicotine-patch treatment in number of life years that would be saved by stopping smoking at various ages, and used an abstinence-contingent treatment model to calculate the incremental cost per life year saved by GP counselling with nicotine-patch treatment over GP counselling alone. Cost effectiveness was assessed on the basis that GPs would provide repeat NHS prescriptions for up to 12 weeks if the treatment was proving successful. Findings If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 weeks, the incremental cost per life year saved would be: pound 398 per person younger than 35 years; pound 345 for those aged 35-44 years; pound 432 for those aged 45-54 years; and pound 785 for those aged 55-65 years. Interpretation The low cost per life year saved would make GP intervention against smoking a cost-effective life-saving treatment. The priniciples of the government White Paper could be cost-effectively extended into general practice to reduce smoking and smoking-related illnesses.	Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; Univ Sydney, Ctr Hlth Econ & Evaluat, Sydney, NSW 2006, Australia	University of London; King's College London; University of London; King's College London; University of Sydney	Stapleton, JA (corresponding author), Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England.		Stapleton, John A/I-6550-2012					Akehurst R, 1994, BR J MED EC, V7, P115; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; BURKE P, 1994, BRIT MED J, V308, P1476; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; *DEP HLTH, 1995, HLTH NAT POL APPR HL; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Physical Education Teaching Materials Compilation Committee the writing group calisthenics teaching, 1990, BLOOD CHOL TEST COST, P1; Dey P, 1999, BRIT J GEN PRACT, V49, P127; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; HAM C, 1995, BR J HLTH CARE MANAG, V1, P27; JARVIS M, 1988, BRIT J ADDICT, V83, P323; JARVIS MJ, 1996, COMMUNICATION; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Mikkelsen K, 1994, J SMOK REL DIS, V5, P95; Netten A, 1998, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 1998, LIV BRIT RES 1996 GE; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PARROTS S, 1999, THORAX S5, V53, pS1; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1994, MORTALITY TOBACCO DE; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SILAGY C, 1999, COCHRANE LIBRARY; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Stapleton JA, 1998, BRIT MED J, V316, P830, DOI 10.1136/bmj.316.7134.830; Tonnesen P, 1999, EUR RESPIR J, V13, P238, DOI 10.1034/j.1399-3003.1999.13b04.x; Torrance GW, 1987, METHODS EC EVALUATIO; Wasley MA, 1997, PREV MED, V26, P264, DOI 10.1006/pmed.1996.0127; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; Yudkin PL, 1996, BRIT J GEN PRACT, V46, P145	30	64	64	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					210	215		10.1016/S0140-6736(99)90001-6	http://dx.doi.org/10.1016/S0140-6736(99)90001-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421303				2022-12-28	WOS:000081504200013
J	Vacanti, JP; Langer, R				Vacanti, JP; Langer, R			Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation	LANCET			English	Article							MASKING		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Vacanti, JP (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							BARRERA DA, 1993, J AM CHEM SOC, V115, P11010, DOI 10.1021/ja00076a077; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BISCEGLIE V., 1933, ZEITSCHR KREBSFORSCH, V40, P122; BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005; CHICK WL, 1975, SCIENCE, V187, P847, DOI 10.1126/science.187.4179.847; DIAMOND DA, 1998, AM ASS PED ANN M SAN, P176; FAUSTMAN D, 1991, SCIENCE, V252, P1700, DOI 10.1126/science.1710828; Griffith LG, 1997, ANN NY ACAD SCI, V831, P382; Isogai N, 1999, J BONE JOINT SURG AM, V81A, P306, DOI 10.2106/00004623-199903000-00002; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer RS, 1999, SCI AM, V280, P86, DOI 10.1038/scientificamerican0499-86; Lysaght MJ, 1998, TISSUE ENG, V4, P231, DOI 10.1089/ten.1998.4.231; Mayhew TA, 1998, TISSUE ENG, V4, P325, DOI 10.1089/ten.1998.4.325; Mitaka T, 1999, HEPATOLOGY, V29, P111, DOI 10.1002/hep.510290103; Mooney DJ, 1996, BIOTECHNOL BIOENG, V50, P422, DOI 10.1002/(SICI)1097-0290(19960520)50:4<422::AID-BIT9>3.0.CO;2-N; Mooney DJ, 1999, SCI AM, V280, P60, DOI 10.1038/scientificamerican0499-60; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; ORGAN GM, 1992, TRANSPLANT P, V24, P3009; PAKZABAN P, 1995, NEUROSCIENCE, V65, P983, DOI 10.1016/0306-4522(94)00626-G; Shinoka T, 1998, J THORAC CARDIOV SUR, V115, P536, DOI 10.1016/S0022-5223(98)70315-0; Shinoka T, 1996, CIRCULATION, V94, P164; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VACANTI CA, 1991, PLAST RECONSTR SURG, V88, P753, DOI 10.1097/00006534-199111000-00001; VACANTI CA, 1992, MATER RES SOC SYMP P, V252, P367, DOI 10.1557/PROC-252-367; VACANTI JP, 1988, J PEDIATR SURG, V23, P3, DOI 10.1016/S0022-3468(88)80529-3; VunjakNovakovic G, 1996, AICHE J, V42, P850, DOI 10.1002/aic.690420323; 1998, BUSINESS WEEK   0727, P61	27	687	723	3	94	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1999	354			1			SI32	SI34						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437854				2022-12-28	WOS:000081825900009
J	Moore, RY				Moore, RY			Circadian rhythms - A clock for the ages	SCIENCE			English	Editorial Material							SUPRACHIASMATIC NUCLEUS; RAT; ORGANIZATION		Univ Pittsburgh, Dept Neurol Psychiat & Neurosci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Moore, RY (corresponding author), Univ Pittsburgh, Dept Neurol Psychiat & Neurosci, Pittsburgh, PA 15213 USA.							Czeisler CA, 1999, SCIENCE, V284, P2177, DOI 10.1126/science.284.5423.2177; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Moga MM, 1997, J COMP NEUROL, V389, P508, DOI 10.1002/(SICI)1096-9861(19971222)389:3<508::AID-CNE11>3.0.CO;2-H; Moore RY, 1996, PROG BRAIN RES, V111, P103, DOI 10.1016/S0079-6123(08)60403-3; MOORE RY, 1995, J COMP NEUROL, V352, P351, DOI 10.1002/cne.903520304; RECHTSCHAFFEN A, 1989, SLEEP, V12, P68; VANDENPOL AN, 1993, NEUROSCIENCE, V56, P793, DOI 10.1016/0306-4522(93)90128-3; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Wever R.A., 1979, CIRCADIAN SYSTEM MAN	9	40	42	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2102	2103		10.1126/science.284.5423.2102	http://dx.doi.org/10.1126/science.284.5423.2102			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10409066				2022-12-28	WOS:000081099300030
J	Beecham, L				Beecham, L			GPs must get involved in walk-in health centres	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					324	324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426767				2022-12-28	WOS:000081909100065
J	Skuse, D				Skuse, D			Survival after being born too soon, but at what cost?	LANCET			English	Editorial Material							LOW-BIRTH-WEIGHT; EARLY INTERVENTION; PREMATURE-INFANTS; RISK-FACTORS; AGE; ADJUSTMENT; OUTCOMES; CHILDREN; SCHOOL		Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England	University of London; University College London	Skuse, D (corresponding author), Inst Child Hlth, Behav Sci Unit, 30 Guilford St, London WC1N 1EH, England.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BLAIR C, 1995, AM J MENT RETARD, V99, P542; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; Finnstrom O, 1998, ACTA PAEDIATR, V87, P1055, DOI 10.1080/080352598750031374; FORFAR JO, 1994, DEV MED CHILD NEUROL, V36, P1037; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; HILLE ETM, 1994, J PEDIATR-US, V125, P426, DOI 10.1016/S0022-3476(05)83290-1; Horwood LJ, 1998, ARCH DIS CHILD-FETAL, V79, pF12, DOI 10.1136/fn.79.1.F12; Kaufman A. S, 2004, KAUFMAN BRIEF INTELL; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; McCarton CM, 1997, JAMA-J AM MED ASSOC, V277, P126, DOI 10.1001/jama.277.2.126; PERLMAN M, 1995, J PEDIATR-US, V126, P75, DOI 10.1016/S0022-3476(95)70507-4; Schendel DE, 1997, AM J EPIDEMIOL, V146, P740; Sykes DH, 1997, J CHILD PSYCHOL PSYC, V38, P315, DOI 10.1111/j.1469-7610.1997.tb01516.x; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	15	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					354	355		10.1016/S0140-6736(99)00150-6	http://dx.doi.org/10.1016/S0140-6736(99)00150-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437859				2022-12-28	WOS:000081764900004
J	Baldwin, LM; Hart, LG; Oshel, RE; Fordyce, MA; Cohen, R; Rosenblatt, RA				Baldwin, LM; Hart, LG; Oshel, RE; Fordyce, MA; Cohen, R; Rosenblatt, RA			Hospital peer review and the National Practitioner Data Bank - Clinical privileges action reports	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RURAL HOSPITALS; ADVERSE EVENTS; HEALTH-CARE; QUALITY	Context The National Practitioner Data Bank (NPDB) is believed to be an important source of information for peer review activities by the majority of those who use it. However, concern has been raised that hospitals may be underreporting physicians with performance problems to the NPDB. Objective To examine variation in clinical privileges action reporting by hospitals to the NPDB, changes in reporting over time, and the association of hospital characteristics with reporting. Design Retrospective cohort study of privileges action reports to the NPDB between 1991 and 1995, linked with the 1992 and 1995 databases from the Annual Survey of Hospitals conducted by the American Hospital Association. Setting and Participants A total of 4743 short-term, nonfederal, general medical/surgical hospitals throughout the United States that were continuously open between 1991-1995 and registered with the NPDB, Main Outcome Measures (1) Reporting of 1 or more privileges actions during the 5-year study period and (2) privileges action reporting rates (numbers of actions reported per 100 000 admissions). Results Study hospitals reported 3328 privileges actions between 1991 and 1995; 34.2% reported 1 or more actions during the period. The range of privileges action reporting rates for these hospitals was 0.40 to 52.27 per 100 000 admissions, with an overall rate of 2.36 per 100 000 admissions. The proportion of hospitals reporting an action decreased from 11.6% in 1991 to 10.0% in 1995 (P = .008), After adjustment for other factors, urban hospitals had significantly higher reporting than rural hospitals (adjusted odds ratio [OR], 1.21 [95% confidence interval {CI}, 1.02-1.43]), while members of the Council of Teaching Hospitals of the Association of American Medical Colleges had significantly lower reporting than nonmembers (adjusted OR, 0.54 [95% CI, 0.40-0.73]). There were notable regional differences in reporting, with the east south Central region having the lowest rate per 100 000 admissions (1.49 [95% CI, 1.33-1.65]). Conclusions The results of this study indicate a low and declining level of hospital privileges action reporting to the NPDB. Several potential explanations exist, 1 of which is that the information reported to the NPDB is incomplete.	Univ Washington, Dept Family Med, Seattle, WA 98195 USA; Univ Washington, WWAMI Rural Hlth Res Ctr, Seattle, WA 98195 USA; US Hlth Resources & Serv Adm, Div Qual Assurance, Bur Hlth Profess, Rockville, MD 20857 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; United States Health Resources & Service Administration (HRSA)	Baldwin, LM (corresponding author), Univ Washington, Dept Family Med, Box 354696, Seattle, WA 98195 USA.				DIVISION OF LUNG DISEASES [N01HR096042] Funding Source: NIH RePORTER; NHLBI NIH HHS [103HR960427A000-000, 103HR960426P000-000] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; California Medical Association, 1977, REP MED INS FEAS STU; Coleman W O, 1992, J Okla State Med Assoc, V85, P35; EPSTEIN BH, 1994, JAMA-J AM MED ASSOC, V271, P1485, DOI 10.1001/jama.271.19.1485; Faria M A Jr, 1991, J Med Assoc Ga, V80, P477; Gale A H, 1992, Mo Med, V89, P720; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HAYWARD RA, 1993, ANN INTERN MED, V118, P550, DOI 10.7326/0003-4819-118-7-199304010-00010; Hershey N, 1990, Qual Assur Util Rev, V5, P7; Hershey N, 1990, Qual Assur Util Rev, V5, P130; Hershey N, 1992, Qual Assur Util Rev, V7, P23; Hershey N, 1990, Qual Assur Util Rev, V5, P63; JOHNSON ID, 1991, JAMA-J AM MED ASSOC, V265, P407, DOI 10.1001/jama.265.3.407; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; Larson EH, 1997, SOC SCI MED, V45, P171, DOI 10.1016/S0277-9536(96)00332-2; LARSON K, 1990, MINN MED, V73, P35; MULLAN F, 1992, JAMA-J AM MED ASSOC, V268, P73, DOI 10.1001/jama.268.1.73; Neighbor WE, 1997, AM J PUBLIC HEALTH, V87, P663, DOI 10.2105/AJPH.87.4.663; *OFF INSP GEN, 1995, PUBL US DEP HLTH HUM; Roberts C C, 1987, QRB Qual Rev Bull, V13, P205; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; RYZEN E, 1992, J LEGAL MED, V13, P409, DOI 10.1080/01947649209510892; Scheutzow SO, 1999, AM J LAW MED, V25, P7; Snelson E A, 1993, Minn Med, V76, P31; *US DEP HHS, 1996, HRSA PUBL; *US DEP HHS, 1995, NAT PRACT DAT BANK U; WAKEFIELD DS, 1995, JOINT COMM J QUAL IM, V21, P227, DOI 10.1016/S1070-3241(16)30143-2; WELCH HG, 1992, AM J PUBLIC HEALTH, V82, P407, DOI 10.2105/AJPH.82.3.407; Wingert T D, 1991, Qual Assur Util Rev, V6, P38	32	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					349	355		10.1001/jama.282.4.349	http://dx.doi.org/10.1001/jama.282.4.349			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	219FG	10432032	Bronze			2022-12-28	WOS:000081596800030
J	Bernstein, DI; Sack, DA; Rothstein, E; Reisinger, K; Smith, VE; O'Sullivan, D; Spriggs, DR; Ward, RL				Bernstein, DI; Sack, DA; Rothstein, E; Reisinger, K; Smith, VE; O'Sullivan, D; Spriggs, DR; Ward, RL			Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial	LANCET			English	Article							PROTECTION; INFECTION; SAFETY	Background Rotavirus is the most common cause of severe, dehydrating diarrhoea in infants worldwide. We assessed the safety, immunogenicity, and efficacy of a live, oral human rotavirus vaccine, 89-12, in US children in a randomised, placebo-controlled, double-blind multicentre trial. Methods 215 healthy infants were enrolled, of whom 213 were given two doses of 89-12 (containing 1x10(5) plaque-forming units) or placebo, and 213 were followed up through one rotavirus season. The frequency of side-effects was compared for 7 days after each dose of vaccine. Immune responses to rotavirus were assessed by serum and stool IgA, and by serum 89-12 neutralising titres. The primary outcome variable (protection from rotavirus disease) was evaluated by comparing the frequencies of rotavirus gastroenteritis in an intention-to-treat analysis. Findings Adverse reactions were mild. Low-grade fever (greater than or equal to 38.1 degrees C) after the first dose was the only side-effect significantly more common in the vaccine group than in the placebo group (21 [19%] vs 5 [5%], p=0.001). An immune response to vaccine was detected in 94.4% of vaccinees. Rotavirus disease occurred in 18 of 107 placebo recipients and two of 108 vaccine recipients (vaccine efficacy 89.0% [95% CI 65.4-94.5]). Ten infants in the placebo group but none in the vaccine group were presented for medical care. Interpretation The 89-12 rotavirus vaccine was safe and immunogenic and provided a high degree of protection against rotavirus disease. Further investigations of this vaccine are needed to confirm these findings in other settings.	Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA; Johns Hopkins Univ, Baltimore, MD USA; Pennridge Pediat Associates, Sellersville, PA USA; Primary Phys Res, Pittsburgh, PA USA; Avant Immunotherapeut Inc, Needham, MA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University	Bernstein, DI (corresponding author), Childrens Hosp, Med Ctr, Div Infect Dis, 3333 Burnet Ave,CH-1, Cincinnati, OH 45229 USA.							BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; Bernstein DI, 1998, VACCINE, V16, P381, DOI 10.1016/S0264-410X(97)00210-7; BERNSTEIN DI, 1991, J INFECT DIS, V164, P277, DOI 10.1093/infdis/164.2.277; BERNSTEIN DI, 1997, TXB PEDIAT INFECT DI, V2, P1901; Glass RI, 1997, NAT MED, V3, P1324, DOI 10.1038/nm1297-1324; Joensuu J, 1998, PEDIATR INFECT DIS J, V17, P334, DOI 10.1097/00006454-199804000-00013; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; KNOWLTON DR, 1991, J VIROL METHODS, V33, P127, DOI 10.1016/0166-0934(91)90013-P; Moulton LH, 1998, J INFECT DIS, V178, P1562, DOI 10.1086/314504; Rennels MB, 1996, PEDIATRICS, V97, P7; Tucker AW, 1998, JAMA-J AM MED ASSOC, V279, P1371, DOI 10.1001/jama.279.17.1371; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Ward RL, 1996, J INFECT DIS, V174, pS51, DOI 10.1093/infdis/174.Supplement_1.S51; WARD RL, 1991, J CLIN MICROBIOL, V29, P449, DOI 10.1128/JCM.29.3.449-456.1991; WARD RL, 1994, J INFECT DIS, V169, P900, DOI 10.1093/infdis/169.4.900	15	168	178	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					287	290		10.1016/S0140-6736(98)12106-2	http://dx.doi.org/10.1016/S0140-6736(98)12106-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440305				2022-12-28	WOS:000081646000011
J	Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E				Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E			Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis	CELL			English	Article							BLOOD-VESSEL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; CELL-CELL CONTACTS; BETA-CATENIN; N-CADHERIN; NEURONAL APOPTOSIS; EMBRYOS LACKING; IN-VITRO; EXPRESSION; ACTIVATION	Vascular endothelial cadherin, VE-cadherin, mediates adhesion between endothelial cells and may affect vascular morphogenesis via intracellular signaling, but the nature of these signals remains unknown. Here, targeted inactivation (VEC-/-) or truncation of the beta-catenin-binding cytosolic domain (VECdelta C/delta C) Of the VE-cadherin gene was found not to affect assembly of endothelial cells in vascular plexi, but to impair their subsequent remodeling and maturation, causing lethality at 9.5 days of gestation. Deficiency or truncation of VE-cadherin induced endothelial apoptosis and abolished transmission of the endothelial survival signal by VEGF-A to Akt kinase and Bc12 via reduced complex formation with VEGF receptor-2, beta-catenin, and phosphoinositide 3 (PI3)-kinase. Thus, VE-cadherin/beta-catenin signaling controls endothelial survival.	Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Sanofi Rech, Dept Haematol, F-31036 Toulouse, France; Leiden Univ, Med Ctr, Dept Anat & Embryol, Leiden, Netherlands; Thrombosis Res Inst, Vasc Biol Lab, Weston Expt Res Ctr, London SW3 6LR, England; Univ Insubria, Dept Clin & Biol Sci, Sch Med, Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Sanofi-Aventis; Sanofi France; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Thrombosis Research Institute; University of Insubria	Carmeliet, P (corresponding author), Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.		Lupu, Florea/AAV-3257-2021; adriana, zanetti/ABA-1189-2020; Lutgens, Esther/E-2919-2010; Lupu, Florea/C-3162-2009; Carmeliet, Peter/AAQ-5140-2020	Lupu, Florea/0000-0003-1249-9278; adriana, zanetti/0000-0002-5825-9707; Lutgens, Esther/0000-0002-2609-5744; Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411; DEJANA, ELISABETTA/0000-0002-0007-0426; Nuyens, Dieter/0000-0001-9390-3273; Lampugnani, Maria Grazia/0000-0002-4802-7064; Angelillo-Scherrer, Anne/0000-0003-2872-4863				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; CORADA M, 1999, IN PRESS P NATL ACAD; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Esser S, 1998, J CELL SCI, V111, P1853; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hogers B, 1999, CARDIOVASC RES, V41, P87, DOI 10.1016/S0008-6363(98)00218-1; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Kemler R, 1992, Semin Cell Biol, V3, P149; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MCCLANAHAN T, 1993, BLOOD, V81, P2903; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieset JE, 1997, J CELL SCI, V110, P1013; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; SALOMON D, 1992, J CELL SCI, V102, P7; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; vanMaeleFabry G, 1997, INT J DEV BIOL, V41, P365; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	40	980	1013	1	46	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					147	157		10.1016/S0092-8674(00)81010-7	http://dx.doi.org/10.1016/S0092-8674(00)81010-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428027	Bronze			2022-12-28	WOS:000081632300005
J	Finnerty, GT; Roberts, LSE; Connors, BW				Finnerty, GT; Roberts, LSE; Connors, BW			Sensory experience modifies the short-term dynamics of neocortical synapses	NATURE			English	Article							RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; BARREL CORTEX; POSTSYNAPTIC POTENTIALS; CORTICAL PLASTICITY; RELEASE PROBABILITY; SYNAPTIC PLASTICITY; REORGANIZATION; DEPRESSION; MOUSE	Many representations of sensory stimuli in the neocortex are arranged as topographic maps. These cortical maps are not fixed, but show experience-dependent plasticity(1,2). For instance, sensory deprivation causes the cortical area representing the deprived sensory input to shrink, and neighbouring spared representations to enlarge, in somatosensory(3), auditory(4) or visual cortex(5). In adolescent and adult animals, changes in cortical maps are most noticeable in the supragranular layers at the junction of deprived and spared cortex(6-9). However, the cellular mechanisms of this experience-dependent plasticity are unclear. Long-term potentiation and depression have been implicated(10-12), but have not been proven to be necessary or sufficient for cortical map reorganization. Short-term synaptic dynamics have not been considered. We developed a brain slice preparation involving rat whisker barrel cortex in vitro. Here we report that sensory deprivation alters short-term synaptic dynamics in both vertical and horizontal excitatory pathways within the supragranular cortex. Moreover, modifications of horizontal pathways amplify changes in the vertical inputs. Our findings help to explain the functional cortical reorganization that follows persistent changes of sensory experience.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.		Finnerty, Gerald/E-5292-2010; Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ARMSTRONGJAMES M, 1994, J NEUROSCI, V14, P6978; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Cash S, 1998, J NEUROSCI, V18, P10; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FOX K, 1992, J NEUROSCI, V12, P1826; Garraghty PE, 1996, J COMP NEUROL, V367, P319, DOI 10.1002/(SICI)1096-9861(19960401)367:2<319::AID-CNE12>3.0.CO;2-L; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714, DOI 10.1152/jn.1996.75.4.1714; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MASON A, 1991, J NEUROSCI, V11, P72; MCCASLAND JS, 1988, J COMP NEUROL, V278, P555, DOI 10.1002/cne.902780407; Merzbacher L., 1910, Z GESAMTE NEUROL PSY, V3, P1, DOI [10.1007/BF02893591, DOI 10.1007/BF02893591]; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; VOLGUSHEV M, 1995, EUR J NEUROSCI, V7, P1751, DOI 10.1111/j.1460-9568.1995.tb00695.x; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405	29	207	208	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					367	371		10.1038/22553	http://dx.doi.org/10.1038/22553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432115				2022-12-28	WOS:000081590000051
J	Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y				Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y			Directional guidance of neuronal migration in the olfactory system by the protein Slit	NATURE			English	Article							SUBVENTRICULAR ZONE CELLS; NEURAL CREST MIGRATION; FETAL MONKEY NEOCORTEX; POLYSIALIC ACID; NERVOUS-SYSTEM; AXON GUIDANCE; GENE ENCODES; C-ELEGANS; GLIA; PRECURSORS	Although cell migration is crucial for neural development, molecular mechanisms guiding neuronal migration have remained unclear. Here we report that the secreted protein Slit repels neuronal precursors migrating from the anterior subventricular zone in the telencephalon to the olfactory bulb. Our results provide a direct demonstration of a molecular cue whose concentration gradient guides the direction of migrating neurons. They also support a common guidance mechanism for axon projection and neuronal migration and suggest that Slit may provide a molecular tool with potential therapeutic applications in controlling and directing cell migration.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Shanghai Res Ctr Life Sci, Mol Neurobiol Lab, Shanghai, Peoples R China; Chinese Acad Sci, Natl Inst Neurosci, Shanghai, Peoples R China	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.		Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2; Getchell TV., 1991, SMELL TASTE HLTH DIS, P19; Gordon N, 1996, DEV MED CHILD NEUROL, V38, P1131; GRAY GE, 1990, EXPERIENTIA, V46, P929, DOI 10.1007/BF01939386; Hardesty I, 1904, AM J ANAT, V3, P229, DOI 10.1002/aja.1000030303; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1981, J CELL BIOL, V90, P622, DOI 10.1083/jcb.90.3.622; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HINDS JW, 1968, J COMP NEUROL, V134, P305, DOI 10.1002/cne.901340305; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Norman M, 1995, CONGENITAL MALFORMAT; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; TILNEY FREDERICK, 1933, BULL NEUROL INST NEW YORK, V3, P252; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZHU Y, IN PRESS NEURON; Zigova T, 1996, DEV BIOL, V173, P459, DOI 10.1006/dbio.1996.0040	50	451	505	3	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					331	336		10.1038/22477	http://dx.doi.org/10.1038/22477			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432110	Green Accepted			2022-12-28	WOS:000081590000040
J	Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D				Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D			The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins	NATURE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; HISTONE OCTAMER; IN-VITRO; YEAST; CDC68; REPRESSION; MUTATIONS; BINDING	The regulation of gene expression depends critically upon chromatin structure(1). Transcription of protein-coding genes can be reconstituted on naked DNA with only the general transcription factors and RNA polymerase II (ref. 2), This minimal system cannot transcribe DNA packaged into chromatin, indicating that accessory factors may facilitate access to DNA. Two classes of accessory factor, ATP-dependent chromatin-remodelling enzymes(3) and histone acetyltransferases(4), facilitate transcription initiation from chromatin templates. FACT (for facilitates chromatin transcription) is a chromatin-specific elongation factor required for transcription of chromatin templates in vitro(5,6) Here we show that FACT comprises a new human homologue of the Saccharomyces cerevisiae Spt16/Cdc68 protein and the high-mobility group-1-like protein structure-specific recognition protein-1. Yeast SPT16/CDC68 is an essential gene that has been implicated in transcription and cell-cycle regulation. Consistent with our biochemical analysis of FACT, we provide evidence that Spt16/Cdc68 is involved in transcript elongation in vivo. Moreover, FACT specifically interacts with nucleosomes and histone H2A/H2B dimers, indicating that it may work by promoting nucleosome disassembly upon transcription. In support of this model, we show that FACT activity is abrogated by covalently crosslinking nucleasomal histones.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016				BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Evans DRH, 1998, GENETICS, V150, P1393; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; PRENDERGAST JA, 1990, GENETICS, V124, P81; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XU QL, 1995, MOL CELL BIOL, V15, P6025	29	428	437	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					284	288		10.1038/22350	http://dx.doi.org/10.1038/22350			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421373				2022-12-28	WOS:000081503800049
J	Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR				Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR			Endomembrane trafficking of Ras: The CAAX motif targets proteins to the ER and Golgi	CELL			English	Article							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; MURINE SARCOMA-VIRUS; PLASMA-MEMBRANE; LOCALIZATION; GENE; CELLS; PALMITOYLATION; PURIFICATION; PROTEOLYSIS	We show that Nras is transiently localized in the Golgi prior to the plasma membrane (PM). Moreover, green fluorescent protein (GFP)-tagged Nras illuminated motile, peri-Golgi vesicles, and prolonged BFA treatment blocked PM expression. GFP-Hras colocalized with GFP-Nras, but GFP-Kras4B revealed less Golgi and no vesicular fluorescence. Whereas a secondary membrane targeting signal was required for PM expression, the CAAX motif alone was necessary and sufficient to target proteins to the endomembrane where they were methylated, a modification required for efficient membrane association. Thus, prenylated CAAX proteins do not associate directly with the PM but instead associate with the endomembrane and are subsequently transported to the PM, a process that requires a secondary targeting motif.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.			Mark, Philips/0000-0002-1179-8156	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036224, R01AI036224] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00096] Funding Source: Medline; NIAID NIH HHS [R01 AI036224, AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FLECK A, 1962, BIOCHIM BIOPHYS ACTA, V55, P571; FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GRAND RJA, 1987, ONCOGENE, V1, P305; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; PHILIPS MR, 1995, METHOD ENZYMOL, V256, P49; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Willumsen BM, 1996, ONCOGENE, V13, P1901	36	602	609	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					69	80		10.1016/S0092-8674(00)80607-8	http://dx.doi.org/10.1016/S0092-8674(00)80607-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412982	hybrid			2022-12-28	WOS:000081451000009
J	Hieter, P; Griffiths, T				Hieter, P; Griffiths, T			Genetics - Polyploidy - More is more or less	SCIENCE			English	Editorial Material									Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Univ British Columbia, Dept Bot, Vancouver, BC, Canada	University of British Columbia; University of British Columbia	Hieter, P (corresponding author), Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada.							Brodsky VYa., 1985, GENOME MULTIPLICATIO; CAVALIERSMITH T, 1978, J CELL SCI, V34, P247; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gregory TR, 1999, GENOME RES, V9, P317; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Royzman I, 1998, GENES CELLS, V3, P767, DOI 10.1046/j.1365-2443.1998.00232.x	6	41	44	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					210	211		10.1126/science.285.5425.210	http://dx.doi.org/10.1126/science.285.5425.210			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10428719				2022-12-28	WOS:000081346000028
J	Sym, M; Robinson, N; Kenyon, C				Sym, M; Robinson, N; Kenyon, C			MIG-13 positions migrating cells along the anteroposterior body axis of C. elegans	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYO; ACTIVITY GRADIENT; GENE-EXPRESSION; NERVOUS-SYSTEM; AXON OUTGROWTH; MESSENGER-RNA; LDL-RECEPTOR; PROTEINS	The C. elegans Q neuroblasts and their descendants migrate along the anteroposterior (A/P) body axis to positions that are not associated with any obvious landmarks. We find that a novel protein, MIG-13, is required to position these cells correctly. MIG-13 is a transmembrane protein whose expression is restricted to the anterior and central body regions by Hox gene activity. MIG-13 functions non-cell autonomously within these regions to promote migration toward the anterior: loss of mig-13 activity shifts the Q descendants toward the posterior, whereas increasing the level of MIG-13 shifts them anteriorly in a dose-dependent manner. Our findings suggest that MIG-13 is a component of a global A/P migration system, and that the level of MIG-13 determines where along the body axis these migrating cells stop.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Battye R, 1999, DEVELOPMENT, V126, P2475; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENNER S, 1974, GENETICS, V77, P71; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Burdine RD, 1998, DEVELOPMENT, V125, P1083; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; Harris J, 1996, DEVELOPMENT, V122, P3117; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1995, GENETICS, V141, P989; HUNTER CP, 1995, NATURE, V377, P229, DOI 10.1038/377229a0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Maloof JN, 1999, DEVELOPMENT, V126, P37; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; MITANI S, 1993, DEVELOPMENT, V119, P773; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1995, THESIS U CALIFORNIA; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1996, DEVELOPMENT, V122, P671; Wolf FW, 1998, NEURON, V20, P655, DOI 10.1016/S0896-6273(00)81006-5; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	50	57	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					25	36		10.1016/S0092-8674(00)80603-0	http://dx.doi.org/10.1016/S0092-8674(00)80603-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412978	Bronze			2022-12-28	WOS:000081451000005
J	Power, S				Power, S			An occupational hazard - A patient's choice	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					367	367		10.1136/bmj.319.7206.367	http://dx.doi.org/10.1136/bmj.319.7206.367			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435963	Green Published			2022-12-28	WOS:000082001700024
J	Cotzias, CS; Paterson-Brown, S; Fisk, NM				Cotzias, CS; Paterson-Brown, S; Fisk, NM			Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis	BRITISH MEDICAL JOURNAL			English	Article									Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England.		Fisk, Nicholas M/B-2126-2009	Fisk, Nicholas M/0000-0003-0031-7975				FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; Hilder L, 1998, BRIT J OBSTET GYNAEC, V105, P169, DOI 10.1111/j.1471-0528.1998.tb10047.x; *STAT OFF, 1996, CONF ENQ STILLB DEAT; THORNTON JG, 1989, J OBSTET GYNAECOL, V9, P283, DOI 10.3109/01443618909151065; YUDKIN PL, 1987, LANCET, V1, P1192	5	83	85	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					287	288		10.1136/bmj.319.7205.287	http://dx.doi.org/10.1136/bmj.319.7205.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426736	Bronze, Green Published			2022-12-28	WOS:000081909100020
J	Arndt, CAS; Crist, WM				Arndt, CAS; Crist, WM			Medical Progress - Common musculoskeletal tumors of childhood and adolescence	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PEDIATRIC-ONCOLOGY-GROUP; SOFT-TISSUE SARCOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; LOCALIZED EWINGS-SARCOMA; RHABDOMYOSARCOMA STUDY-I; HIGH-DOSE METHOTREXATE; CHILDRENS-CANCER-GROUP; INTERGROUP RHABDOMYOSARCOMA; NEOADJUVANT CHEMOTHERAPY; OSTEO-SARCOMA		Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Arndt, CAS (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	arndt.carola@mayo.edu			NCI NIH HHS [CA28882-19] Funding Source: Medline; NIGMS NIH HHS [GM34847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA028882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1995, CANCER RES, V55, P1321; ARAKI N, 1991, CLIN ORTHOP RELAT R, V270, P271; Arndt CAS, 1998, EUR J CANCER, V34, P1224, DOI 10.1016/S0959-8049(98)00080-X; Atra A, 1996, ANN MED, V28, P159, DOI 10.3109/07853899609092941; Bacci G, 1998, J CHEMOTHERAPY, V10, P69, DOI 10.1179/joc.1998.10.1.69; Bacci G, 1996, J CHEMOTHERAPY, V8, P70, DOI 10.1179/joc.1996.8.1.70; Bacci G, 1996, Chir Organi Mov, V81, P369; Bacci G, 1998, CANCER-AM CANCER SOC, V82, P1174, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1174::AID-CNCR24>3.0.CO;2-2; BACCI G, 1993, J CHEMOTHERAPY, V5, P247; BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C; BACCI G, 1990, CANCER, V65, P2539, DOI 10.1002/1097-0142(19900601)65:11<2539::AID-CNCR2820651125>3.0.CO;2-M; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; BURDACH S, 1993, J CLIN ONCOL, V11, P1482, DOI 10.1200/JCO.1993.11.8.1482; BURGERT EO, 1990, J CLIN ONCOL, V8, P1514, DOI 10.1200/JCO.1990.8.9.1514; CRIST W, 1995, J CLIN ONCOL, V13, P610, DOI 10.1200/JCO.1995.13.3.610; CRIST W, 1999, P AN M AM SOC CLIN, V18, pA555; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; CRIST WM, 1985, CANCER, V56, P2125, DOI 10.1002/1097-0142(19851015)56:8<2125::AID-CNCR2820560841>3.0.CO;2-D; CRIST WM, 1990, J CLIN ONCOL, V8, P443, DOI 10.1200/JCO.1990.8.3.443; DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423; DAVIS RJ, 1994, CANCER RES, V54, P2869; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, V153, P106; EPELMAN S, 1995, P AN M AM SOC CLIN, V14, P439; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; EVANS RG, 1991, J CLIN ONCOL, V9, P1173, DOI 10.1200/JCO.1991.9.7.1173; FRIEDMAN M A, 1972, Journal of Surgical Oncology, V4, P482, DOI 10.1002/jso.2930040512; GALILI N, 1994, NAT GENET, V6, P214, DOI 10.1038/ng0294-214d; Goletz T. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P475; Grier H., 1994, P AN M AM SOC CLIN, V13, P421; Grier HE, 1997, PEDIATR CLIN N AM, V44, P991, DOI 10.1016/S0031-3955(05)70541-1; HARRIS MB, 1995, MED PEDIATR ONCOL, V24, P87, DOI 10.1002/mpo.2950240205; Harris MB, 1998, J CLIN ONCOL, V16, P3641, DOI 10.1200/JCO.1998.16.11.3641; Hartmann O, 1995, ANN ONCOL, V6, P13, DOI 10.1093/annonc/6.suppl_4.S13; HAYS DM, 1982, J PEDIATR SURG, V17, P812, DOI 10.1016/S0022-3468(82)80449-1; HEYN R, 1989, J CLIN ONCOL, V7, P200, DOI 10.1200/JCO.1989.7.2.200; Horowitz Marc E., 1997, P831; HOROWITZ ME, 1993, J CLIN ONCOL, V11, P1911, DOI 10.1200/JCO.1993.11.10.1911; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; KLEINERMAN ES, 1995, HEMATOL ONCOL CLIN N, V9, P927, DOI 10.1016/S0889-8588(18)30079-0; Koscielniak E, 1997, BONE MARROW TRANSPL, V19, P227, DOI 10.1038/sj.bmt.1700628; Kruzelock RP, 1997, CANCER RES, V57, P106; KUSHNER BH, 1995, J CLIN ONCOL, V13, P2796, DOI 10.1200/JCO.1995.13.11.2796; Ladenstein R, 1996, BONE MARROW TRANSPL, V18, P675; LADENSTEIN R, 1995, BONE MARROW TRANSPL, V15, P697; LAWRENCE W, 1987, J CLIN ONCOL, V5, P46, DOI 10.1200/JCO.1987.5.1.46; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; Link Michael P., 1997, P889; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; LINK MP, 1991, CLIN ORTHOP RELAT R, V270, P8; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARINA NM, 1992, CANCER-AM CANCER SOC, V70, P2722, DOI 10.1002/1097-0142(19921201)70:11<2722::AID-CNCR2820701125>3.0.CO;2-S; MARTI C, 1985, CANCER TREAT REP, V69, P115; MAURER HM, 1993, CANCER-AM CANCER SOC, V71, P1904, DOI 10.1002/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; MAURER HM, 1997, CANC MED, V2, P3023; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031-3955(05)70540-X; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; MISER J, 1998, P AN M AM SOC CLIN, V17, pA535; Miser JS, 1996, P AN M AM SOC CLIN, V15, P467; NESBIT ME, 1990, J CLIN ONCOL, V8, P1664, DOI 10.1200/JCO.1990.8.10.1664; NEVILLE H, IN PRESS J PEDIAT SU; OBERLIN O, 1992, J CLIN ONCOL, V10, P1407, DOI 10.1200/JCO.1992.10.9.1407; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; PAPPO AS, 1999, P AN M AM SOC CLIN, V18, pA555; PASTORINO U, 1991, J CLIN ONCOL, V9, P1357, DOI 10.1200/JCO.1991.9.8.1357; PERLMAN EJ, 1994, HUM PATHOL, V25, P304, DOI 10.1016/0046-8177(94)90203-8; Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76; RANEY RB, 1983, CANCER-AM CANCER SOC, V52, P44, DOI 10.1002/1097-0142(19830701)52:1<44::AID-CNCR2820520110>3.0.CO;2-V; Ruby E, 1997, P AN M AM SOC CLIN, V16, p510a; SAETER G, 1995, CANCER-AM CANCER SOC, V75, P1084, DOI 10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F; SAGERMAN RH, 1969, AMER J ROENTGENOL RA, V105, P529, DOI 10.2214/ajr.105.3.529; SCHIMKE RN, 1974, CANCER, V34, P2077, DOI 10.1002/1097-0142(197412)34:6<2077::AID-CNCR2820340630>3.0.CO;2-A; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SNYDER CL, 1991, CLIN ORTHOP RELAT R, V270, P247; STILLER CA, 1991, BRIT J CANCER, V64, P543, DOI 10.1038/bjc.1991.347; STILLER CA, 1994, PAEDIATR PERINAT EP, V8, P107, DOI 10.1111/j.1365-3016.1994.tb00439.x; TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; UNNI KK, 1996, DAHLINS BONE TUMORS, V144, P250; WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849; WeberHall SR, 1996, CANCER RES, V56, P3220; Wexler Leonard H., 1997, P799; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; WINKLER K, 1990, CANCER, V66, P1703, DOI 10.1002/1097-0142(19901015)66:8<1703::AID-CNCR2820660809>3.0.CO;2-V; WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329; YAMAGUCHI T, 1992, CANCER RES, V52, P2419; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	101	416	436	1	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					342	352		10.1056/NEJM199907293410507	http://dx.doi.org/10.1056/NEJM199907293410507			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423470				2022-12-28	WOS:000081666900007
J	Gaffney, D; Pollock, AM; Price, D; Shaoul, J				Gaffney, D; Pollock, AM; Price, D; Shaoul, J			The private finance initiative - The politics of the private finance initiative and the new NHS	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England; Northumbria Univ, Social Welf Res Unit, Newcastle Upon Tyne NE7 7XA, Tyne & Wear, England; Univ Manchester, Dept Accounting, Manchester M13 9PL, Lancs, England	University of London; University College London; Northumbria University; University of Manchester	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				Cabinet Office, 1999, MOD GOV; CHUSSDOVSKY M, 1998, GLOBALISATION POVERT; *COMM CAR MARK NEW, 1998, LAING BUSSON NEWSLET, P9; *COMM PUBL ACC, 1999, T3 REP GETT BETT VAL; *EUR COMM, 1999, MAK MOST OP PUBL PRO; *EUR COMM, 1997, PUBL PROC EUR UN EXP; *EUR INV BANK, 1998, EIB INFORMATION, V2, P97; European Commission, 1998, GOV INV FRAM EC STRA; FAYARD A, 1999, EUR C MIN TRANSP; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Gaffney D, 1999, BRIT MED J, V319, P116, DOI 10.1136/bmj.319.7202.116; GARNER H, 1998, UNDERVALUED WORK UND; Harrington C, 1998, LANCET, V351, P1805, DOI 10.1016/S0140-6736(97)09039-9; *HM TREAS, 1998, CM4011; KINNOCK N, 1998, COMMUNICATION   0224; Kuttner R, 1996, NEW ENGL J MED, V335, P362, DOI 10.1056/NEJM199608013350524; MACFARLANE A, 1998, STAT SOC; MILBURN A, 1999, COMMUNICATION    FEB; *NAT AUD OFF, 1999, DEP SOC SEC PRIM PRO; Pollock AM, 1999, BMJ-BRIT MED J, V319, P179, DOI 10.1136/bmj.319.7203.179; POLLOCK AM, 1998, HOSP DOCT COMM G JUL, P6; POLLOCK AM, 1998, HLTH SERVICE J  0409, P28; POLLOCK AM, 1995, HLTH MATTERS, V20, P9; Royal Commission on Long Term Care, 1999, CM41921; Shaoul J., 1998, MANAGEMENT ACCOUNTIN, V9, P95; SHAOUL J, 1997, NHS TRUSTS SURPRISE; SHAOUL J, 1999, RAILPOLITIK STAKEHOL; Smith R, 1999, BRIT MED J, V318, P209; The World Bank, 1994, WORLD BANK DEV REP 1; THORNTON S, 1999, PUBLIC FINANCE  0709, P20; TOWNSEND P, 1981, AGEING SOC, V1, P1; Walker A., 1997, HLTH CHOICES FUTURE, P178	32	34	34	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					249	253		10.1136/bmj.319.7204.249	http://dx.doi.org/10.1136/bmj.319.7204.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417094	Green Published			2022-12-28	WOS:000081720300032
J	Bolton, G				Bolton, G			Stories at work: reflective writing for practitioners	LANCET			English	Editorial Material									Univ Sheffield, No Gen Hosp, Community Sci Ctr, Inst Gen Practice & Primary Care, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Bolton, G (corresponding author), Univ Sheffield, No Gen Hosp, Community Sci Ctr, Inst Gen Practice & Primary Care, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.							Abse D, 1998, LANCET, V351, P362, DOI 10.1016/S0140-6736(97)10380-4; BOLTON G, 1998, THERAPEUTIC POTENTIA; Bolton G, 1994, BRIT EDUC RES J, V20, P55, DOI DOI 10.1080/0141192940200106; BRIMACOMBE M, 1996, GP              0513; Brody H., 1987, STORIES SICKNESS; Elwyn GJ, 1997, BRIT MED J, V315, P1659, DOI 10.1136/bmj.315.7123.1659; Fox NJ., 1993, POSTMODERNISM SOCIOL; HELLER T, 1997, SERIOUS FUN ARTS PRI; HOWARD J, 1997, ED GEN PRACTICE, V8, P288; Hurwitz, 1998, NARRATIVE BASED MED; PENNEBAKER JW, 1993, BEHAV RES THER, V31, P539, DOI 10.1016/0005-7967(93)90105-4; PURDY R, 1996, MED MONITOR     0306; Sweeney B, 1998, BRIT J GEN PRACT, V48, P998	13	30	30	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					243	245		10.1016/S0140-6736(98)06443-5	http://dx.doi.org/10.1016/S0140-6736(98)06443-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421319				2022-12-28	WOS:000081504200043
J	Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L				Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L			An allele of COL9A2 associated with intervertebral disc disease	SCIENCE			English	Article							COLLAGEN TYPE-IX; CROSS-LINKING SITES; LINKAGE ANALYSIS; MOLECULAR-CLONING; LUMBAR SPINE; II COLLAGEN; CARTILAGE; DEGENERATION; CHAIN; GENE	Intervertebral disc disease is one of the most common musculoskeletal disorders. A number of environmental and anthropometric risk factors may contribute to it, and recent reports have suggested the importance of genetic factors as well. The COL9A2 gene, which codes for one of the polypeptide chains of collagen IX that is expressed in the intervertebral disc, was screened for sequence variations in individuals with intervertebral disc disease. The analysis identified a putative disease-causing sequence variation that converted a codon for glutamine to one for tryptophan in six out of the 157 individuals but in none of 174 controls. The tryptophan allele cosegregated with the disease phenotype in the four families studied, giving a lod score (Logarithm of odds ratio) for linkage of 4.5, and subsequent linkage disequilibrium analysis conditional on linkage gave an additional lod score of 7.1.	Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Biochem Med, SF-90220 Oulu, Finland; Univ Oulu, Dept Phys Med & Rehabil, SF-90220 Oulu, Finland; Univ Oulu, Dept Diagnost Radiol, SF-90220 Oulu, Finland; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Kuopio, Dept Surg, Kuopio 70211, Finland; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; MCP Hahnemann Univ, Ctr Gene Therapy, Philadelphia, PA 19102 USA	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Eastern Finland; Columbia University; Rockefeller University; Drexel University	Ala-Kokko, L (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland.	leena.ala-kokko@oulu.fi			NHGRI NIH HHS [HG00008] Funding Source: Medline; NIAMS NIH HHS [AR39740] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; Becker A, 1998, HUM HERED, V48, P49, DOI 10.1159/000022781; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022; CHOTAI J, 1984, ANN HUM GENET, V48, P359, DOI 10.1111/j.1469-1809.1984.tb00849.x; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EYRE DR, 1977, BIOCHIM BIOPHYS ACTA, V492, P29, DOI 10.1016/0005-2795(77)90211-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; GORING HHH, UNPUB; GORKING HHH, UNPUB; HELIOVAARA M, 1989, ANN MED, V21, P254, DOI 10.3109/07853898909149202; HELIOVAARA M, 1987, J EPIDEMIOL COMMUN H, V41, P251, DOI 10.1136/jech.41.3.251; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Kainulainen K, 1999, HYPERTENSION, V33, P844, DOI 10.1161/01.HYP.33.3.844; Kielty Cay M., 1993, P103; Kimura T, 1996, INT ORTHOP, V20, P177, DOI 10.1007/s002640050058; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATSUI H, 1992, SPINE, V17, P1323, DOI 10.1097/00007632-199211000-00011; MORTON NE, 1955, AM J HUM GENET, V7, P277; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; Nelson C L, 1972, Clin Orthop Relat Res, V88, P142, DOI 10.1097/00003086-197210000-00025; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PERALA M, 1994, J BIOL CHEM, V269, P5064; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; ROKOS I, 1994, MATRIX BIOL, V14, P1, DOI 10.1016/0945-053X(94)90024-8; Scapinelli R, 1993, Acta Orthop Belg, V59, P371; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Terwilliger J., 1994, HDB HUMAN GENETIC LI; TIENARI PJ, 1994, GENOMICS, V19, P320, DOI 10.1006/geno.1994.1064; URBAN JPG, 1993, MUSCULOSKELETAL SOFT-TISSUE AGING: IMPACT ON MOBILITY, P391; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VARLOTTA GP, 1991, J BONE JOINT SURG AM, V73A, P124, DOI 10.2106/00004623-199173010-00016; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Weishaupt D, 1998, RADIOLOGY, V209, P661, DOI 10.1148/radiology.209.3.9844656; WILLIAMSON JA, 1990, GENET EPIDEMIOL, V7, P309, DOI 10.1002/gepi.1370070502; WU JJ, 1992, J BIOL CHEM, V267, P23007	45	241	271	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					409	412		10.1126/science.285.5426.409	http://dx.doi.org/10.1126/science.285.5426.409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411504				2022-12-28	WOS:000081465900055
J	Collier, CP; Wong, EW; Belohradsky, M; Raymo, FM; Stoddart, JF; Kuekes, PJ; Williams, RS; Heath, JR				Collier, CP; Wong, EW; Belohradsky, M; Raymo, FM; Stoddart, JF; Kuekes, PJ; Williams, RS; Heath, JR			Electronically configurable molecular-based logic gates	SCIENCE			English	Article								Logic gates were fabricated from an array of configurable switches, each consisting of a monolayer of redox-active rotaxanes sandwiched between metal electrodes. The switches were read by monitoring current flow at reducing voltages, In the "closed" state, current flow was dominated by resonant tunneling through the electronic states of the molecules. The switches were irreversibly opened by applying an oxidizing voltage across the device. Several devices were configured together to produce AND and OR logic gates. The high and low current levels of those gates were separated by factors of 15 and 30, respectively, which is a significant enhancement over that expected for wired-logic gates.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Hewlett Packard Labs, Palo Alto, CA 94304 USA	University of California System; University of California Los Angeles; Hewlett-Packard	Heath, JR (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	heath@chem.ucla.edu	Stoddart, James Fraser/H-1518-2011; Collier, Charles/C-9206-2016; Williams, R. Stanley/A-8281-2009	Stoddart, James Fraser/0000-0003-3161-3697; Collier, Charles/0000-0002-8198-793X; Williams, R. Stanley/0000-0003-0213-4259; Raymo, Francisco/0000-0002-6163-6606				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Amabilino DB, 1998, NEW J CHEM, V22, P959, DOI 10.1039/a802784f; Amlani I, 1999, SCIENCE, V284, P289, DOI 10.1126/science.284.5412.289; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; Chen RH, 1996, APPL PHYS LETT, V68, P1954, DOI 10.1063/1.115637; Credi A, 1997, J AM CHEM SOC, V119, P2679, DOI 10.1021/ja963572l; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; FEENSTRA RM, 1987, SURF SCI, V181, P295, DOI 10.1016/0039-6028(87)90170-1; Feynman R., 1996, FEYNMAN LECT COMPUTA; Gallagher William Joseph, 1997, US Patent, Patent No. [5,640,343, 5640343]; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; HIPPS KW, 1994, J PHYS CHEM-US, V98, P5824, DOI 10.1021/j100074a005; Montemerlo M.S., 1996, TECHNOLOGIES DESIGNS; POLYMEROPOULOS EE, 1978, J CHEM PHYS, V69, P1836, DOI 10.1063/1.436844; TOUGAW PD, 1994, J APPL PHYS, V75, P1818, DOI 10.1063/1.356375; Villasenor J, 1997, SCI AM, V276, P66, DOI 10.1038/scientificamerican0697-66; Zhou C, 1997, APPL PHYS LETT, V71, P611, DOI 10.1063/1.120195	17	1339	1514	4	394	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					391	394		10.1126/science.285.5426.391	http://dx.doi.org/10.1126/science.285.5426.391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411498				2022-12-28	WOS:000081465900049
J	Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ				Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ			Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya	SCIENCE			English	Article							DIFFERENCE VEGETATION INDEX; SEA-SURFACE TEMPERATURE; NEAR-INFRARED CHANNELS; DOMESTIC-ANIMALS; EL-NINO; RAINFALL; AVHRR; CALIBRATION; AFRICA; VIRUS	All known Rift Valley fever virus outbreaks in East Africa from 1950 to May 1998, and probably earlier, followed periods of abnormally high rainfall. Analysis of this record and Pacific and Indian Ocean sea surface temperature anomalies, coupled with satellite normalized difference vegetation index data, shows that prediction of Rift Valley fever outbreaks may be made up to 5 months in advance of outbreaks in East Africa. Concurrent near-real-time monitoring with satellite normalized difference vegetation data may identify actual affected areas.	Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA; NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Centers for Disease Control & Prevention - USA	Anyamba, A (corresponding author), Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Anyamba, Assaf/0000-0003-0932-9585				Anyamba A, 1996, INT J REMOTE SENS, V17, P2533, DOI 10.1080/01431169608949091; CANE MA, 1986, ANNU REV EARTH PL SC, V14, P43, DOI 10.1146/annurev.ea.14.050186.000355; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHAGAS C, 1986, PERSISTENT METEOOCEA, P1; CHE N, 1992, REMOTE SENS ENVIRON, V41, P19, DOI 10.1016/0034-4257(92)90057-Q; Daubney R, 1931, J PATHOL BACTERIOL, V34, P545, DOI 10.1002/path.1700340418; DAVIES FG, 1985, B WORLD HEALTH ORGAN, V63, P941; FARMER G, 1988, J CLIMATOL, V8, P489, DOI 10.1002/joc.3370080505; Glantz M. H, 1991, TELECONNECTIONS LINK, P1; HOLBEN BN, 1990, INT J REMOTE SENS, V11, P1511, DOI 10.1080/01431169008955109; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; LEHOUEROU HN, 1977, J RANGE MANAGE, V30, P181; Linthicum K.J., 1994, SISTEMA TERRA, V3, P44; LINTHICUM KJ, 1985, J HYG-CAMBRIDGE, V95, P197, DOI 10.1017/S0022172400062434; LINTHICUM KJ, 1987, SCIENCE, V235, P1656, DOI 10.1126/science.3823909; LOGAN TM, 1990, J AM MOSQUITO CONTR, V6, P736; LOGAN TM, 1992, T ROY SOC TROP MED H, V86, P202, DOI 10.1016/0035-9203(92)90571-S; LOGAN TM, 1991, J MED ENTOMOL, V28, P293, DOI 10.1093/jmedent/28.2.293; LOS SO, 1993, INT J REMOTE SENS, V14, P1907, DOI 10.1080/01431169308954011; MALO AR, 1990, J ARID ENVIRON, V19, P1; Myneni RB, 1996, GEOPHYS RES LETT, V23, P729, DOI 10.1029/96GL00266; Nicholls N., 1991, TELECONNECTIONS LINK, P493; Nichols, 1991, TELECONNECTIONS LINK, P309; Nicholson SE, 1997, INT J CLIMATOL, V17, P345, DOI 10.1002/(SICI)1097-0088(19970330)17:4<345::AID-JOC127>3.0.CO;2-3; NICHOLSON SE, 1990, CLIMATIC CHANGE, V17, P209, DOI 10.1007/BF00138369; POPE KO, 1992, REMOTE SENS ENVIRON, V40, P185, DOI 10.1016/0034-4257(92)90002-2; ROPELEWSKI C. F., 1987, MON WEA REV, V115, P2352; TUCKER CJ, 1994, INT J REMOTE SENS, V15, P3547, DOI 10.1080/01431169408954344; TUCKER CJ, IN PRESS AMBIO; VERMOTE E, 1995, INT J REMOTE SENS, V16, P2317, DOI 10.1080/01431169508954561	30	402	419	4	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					397	400		10.1126/science.285.5426.397	http://dx.doi.org/10.1126/science.285.5426.397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411500				2022-12-28	WOS:000081465900051
J	Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW				Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW			Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis	SCIENCE			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ANAPHASE TRANSITION; NUCLEAR DIVISION; BUDDING YEAST; METAPHASE; COMPLEX; MITOSIS; SPINDLE; PDS1P	A vertebrate securin (vSecurin) was identified on the basis of its biochemical analogy to the Pds1p protein of budding yeast and the Cut2p protein of fission yeast. The vSecurin protein bound to a vertebrate homolog of yeast separins Esp1p and Cut1p and was degraded by proteolysis mediated by an anaphase-promoting complex in a manner dependent on a destruction motif. Furthermore, expression of a stable Xenopus securin mutant protein blocked sister-chromatid separation but did not block the embryonic cell cycle. The vSecurin proteins share extensive sequence similarity with each other but show no sequence similarity to either of their yeast counterparts. Human securin is identical to the product of the gene called pituitary tumor-transforming gene (PTTG), which is overexpressed in some tumors and exhibits transforming activity in NIH 3T3 cells. The oncogenic nature of increased expression of vSecurin may result from chromosome gain or loss, produced by errors in chromatid separation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Funabiki H, 1997, EMBO J, V16, P5977, DOI 10.1093/emboj/16.19.5977; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZOU H, UNPUB	29	655	691	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					418	422		10.1126/science.285.5426.418	http://dx.doi.org/10.1126/science.285.5426.418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411507				2022-12-28	WOS:000081465900058
J	Dalgaard, LZ; Klar, AJS				Dalgaard, LZ; Klar, AJS			Orientation of DNA replication establishes mating-type switching pattern in S-pombe	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; GENETIC-ANALYSIS; INITIATION; CELLS; TRANSPOSITION; ASYMMETRY; STRANDS; BREAKS	The fission yeast Schizosaccharomyces pombe normally has haploid cells of two mating types, which differ at the chromosomal locus mat1. After two consecutive asymmetric cell divisions, only one in four 'grand-daughter' cells undergoes a 'mating-type switch', in which genetic information is transferred to mat1 from the mat2-P or mat3-M donor loci(1-4). This switching pattern probably results from an imprinting event at mat1 that marks one sister chromatid in a strand-specific manner(3-5), and is related to a site-specific, double-stranded DNA break at mat1(6,7). Here we show that the genetic imprint is a strand-specific, alkali-labile DNA modification at mat1. The DNA break is an artefact, created from the imprint during DNA purification. We also propose and test the model that mat1 is preferentially replicated by a centromere-distal origin(s), so that the strand-specific imprint occurs only during lagging-strand synthesis. Altering the origin of replication, by inverting mat1 or introducing an origin of replication, affects the imprinting and switching efficiencies in predicted ways. Two-dimensional gel analysis confirmed that mat1 is preferentially replicated by a centromere-distal origin(s). Thus, the DNA replication machinery may confer different developmental potential to sister cells.	NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Klar, AJS (corresponding author), NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA.	klar@mail.ncifcrf.gov		Dalgaard, Jacob/0000-0001-9545-7254				Arcangioli B, 1998, EMBO J, V17, P4503, DOI 10.1093/emboj/17.15.4503; ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BRESCH C, 1968, MOL GEN GENET, V102, P301, DOI 10.1007/BF00433721; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CADDLE MS, 1994, MOL CELL BIOL, V14, P1796, DOI 10.1128/MCB.14.3.1796; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; Egel R., 1989, MOL BIOL FISSION YEA, P31; GERRING S L, 1991, P57; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KLAR AJS, 1993, COLD SPRING HARB SYM, V58, P457, DOI 10.1101/SQB.1993.058.01.052; Klar AJS, 1998, CIBA F SYMP, V214, P87; KLAR AJS, 1993, CURR OPIN GENET DEV, V3, P745, DOI 10.1016/S0959-437X(05)80093-0; KLAR AJS, 1986, CELL, V46, P725, DOI 10.1016/0092-8674(86)90348-X; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIELSEN O, 1989, EMBO J, V8, P269, DOI 10.1002/j.1460-2075.1989.tb03373.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STYRKARSDOTTIR U, 1993, CURR GENET, V23, P184, DOI 10.1007/BF00352020	24	113	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					181	184		10.1038/22139	http://dx.doi.org/10.1038/22139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408447				2022-12-28	WOS:000081324900058
J	Khan, K				Khan, K			A memorable patient - Our duty lasts until the end of life	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					343	343		10.1136/bmj.319.7206.343	http://dx.doi.org/10.1136/bmj.319.7206.343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435951	Green Published			2022-12-28	WOS:000082001700015
J	Blichert-Toft, J; Frey, FA; Albarede, F				Blichert-Toft, J; Frey, FA; Albarede, F			Hf isotope evidence for pelagic sediments in the source of Hawaiian basalts	SCIENCE			English	Article							OCEANIC BASALTS; FERROMANGANESE NODULES; HALEAKALA VOLCANO; MARINE-SEDIMENTS; MANTLE EVOLUTION; CRUST; CONSTRAINTS; GEOCHEMISTRY; LAVAS; SEAWATER	Lead, oxygen, and osmium isotopic ratios measured on Hawaiian basalts can be matched with the isotopic ratios inferred for recycled ancient oceanic crust. High-precision hafnium isotopic data for lavas from several Hawaiian volcanoes identify old pelagic sediments in their source. These observations support the recycling hypothesis, whereby the mantle source of ocean island basalts includes ancient subducted oceanic crust. Hyperbolic lead-hafnium isotopic relations among Hawaiian basalts further indicate that upper mantle material is not involved in the production of hot spot basalts.	Ecole Normale Super Lyon, F-69364 Lyon 7, France; MIT, Cambridge, MA 02139 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Massachusetts Institute of Technology (MIT)	Blichert-Toft, J (corresponding author), Ecole Normale Super Lyon, F-69364 Lyon 7, France.	jblicher@ens-lyon.f	Albarede, Francis/A-8871-2011; Blichert-Toft, Janne/C-8280-2012	Albarede, Francis/0000-0003-1994-1428; Blichert-Toft, Janne/0000-0002-4932-4079; Frey, Frederick/0000-0002-5403-5677				Abouchami W, 1997, GEOCHIM COSMOCHIM AC, V61, P3957, DOI 10.1016/S0016-7037(97)00218-4; ABOUCHAMI W, UNPUB; Albarede F, 1998, CHEM GEOL, V145, P413, DOI 10.1016/S0009-2541(97)00152-6; Albarede F, 1998, GEOPHYS RES LETT, V25, P3895, DOI 10.1029/1998GL900008; Albarede F., 1995, INTRO GEOCHEMICAL MO; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Blichert-Toft J, 1999, SCIENCE, V283, P1303, DOI 10.1126/science.283.5406.1303; Blichert-Toft J, 1999, GEOPHYS RES LETT, V26, P935, DOI 10.1029/1999GL900110; BlichertToft J, 1997, CONTRIB MINERAL PETR, V127, P248, DOI 10.1007/s004100050278; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; BLICHERTTOFT J, UNPUB; CHEN CY, 1990, CONTRIB MINERAL PETR, V105, P197, DOI 10.1007/BF00678986; CHEN CY, 1991, CONTRIB MINERAL PETR, V106, P183, DOI 10.1007/BF00306433; CHEN CY, 1996, GEOPHYS MONOGR SER, V95, P161; CHRISTENSEN UR, 1994, J GEOPHYS RES-SOL EA, V99, P19867, DOI 10.1029/93JB03403; Eiler JM, 1996, EARTH PLANET SC LETT, V144, P453, DOI 10.1016/S0012-821X(96)00170-7; Farnetani C.G., 1995, EARTH PLANET SC LETT, V136, P251, DOI DOI 10.1016/0012-821X(95)00158-9; GARCIA MA, UNPUB; Garcia MO, 1996, B VOLCANOL, V58, P359, DOI 10.1007/s004450050145; GARCIA MO, 1993, J GEOPHYS RES-SOL EA, V98, P537, DOI 10.1029/92JB01707; Godfrey LV, 1997, EARTH PLANET SC LETT, V151, P91, DOI 10.1016/S0012-821X(97)00106-4; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Hauri EH, 1996, J GEOPHYS RES-SOL EA, V101, P11793, DOI 10.1029/95JB03346; HAURI EH, 1993, EARTH PLANET SC LETT, V114, P353, DOI 10.1016/0012-821X(93)90036-9; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; Jackson MC, 1999, B VOLCANOL, V60, P381, DOI 10.1007/s004450050239; KANEOKA I, 1980, SCIENCE, V208, P1366, DOI 10.1126/science.208.4450.1366; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; Lassiter JC, 1996, J GEOPHYS RES-SOL EA, V101, P11769, DOI 10.1029/96JB00181; LEEMAN WP, 1994, CONTRIB MINERAL PETR, V116, P62, DOI 10.1007/BF00310690; MINSTER JB, 1974, GEOPHYS J ROY ASTR S, V36, P541, DOI 10.1111/j.1365-246X.1974.tb00613.x; PATCHETT PJ, 1980, GEOPHYS RES LETT, V7, P1077, DOI 10.1029/GL007i012p01077; PATCHETT PJ, 1984, EARTH PLANET SC LETT, V69, P365, DOI 10.1016/0012-821X(84)90195-X; Pietruszka AJ, 1999, J PETROL, V40, P1321, DOI 10.1093/petrology/40.8.1321; Plank T, 1998, CHEM GEOL, V145, P325, DOI 10.1016/S0009-2541(97)00150-2; RODEN MF, 1994, GEOCHIM COSMOCHIM AC, V58, P1431, DOI 10.1016/0016-7037(94)90547-9; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Sims KWW, 1997, GEOCHIM COSMOCHIM AC, V61, P765, DOI 10.1016/S0016-7037(96)00372-9; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; VANDERHILST R, 1991, NATURE, V353, P733; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; WHITE WM, 1982, NATURE, V296, P821, DOI 10.1038/296821a0; WHITE WM, 1986, EARTH PLANET SC LETT, V79, P46, DOI 10.1016/0012-821X(86)90039-7; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094; [No title captured]	50	240	244	4	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					879	882		10.1126/science.285.5429.879	http://dx.doi.org/10.1126/science.285.5429.879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436154				2022-12-28	WOS:000081860900046
J	Clay, AS				Clay, AS			The medical student as patient	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Clay, AS (corresponding author), Indiana Univ, Sch Med, Dept Med, W Bldg M200,1001 W 10th St, Indianapolis, IN 46202 USA.	alclay@iupui.edu							0	4	5	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					225	226		10.7326/0003-4819-131-3-199908030-00012	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428741				2022-12-28	WOS:000081788700010
J	O'Neill, J				O'Neill, J			A peaceful death	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					327	327		10.1136/bmj.319.7205.327	http://dx.doi.org/10.1136/bmj.319.7205.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426772	Green Published			2022-12-28	WOS:000081909100069
J	Ober, C; Karrison, T; Odem, RR; Barnes, RB; Branch, DW; Stephenson, MD; Baron, B; Walker, MA; Scott, JR; Schreiber, JR				Ober, C; Karrison, T; Odem, RR; Barnes, RB; Branch, DW; Stephenson, MD; Baron, B; Walker, MA; Scott, JR; Schreiber, JR			Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial	LANCET			English	Article							SUBSEQUENT REPRODUCTIVE-PERFORMANCE; SPONTANEOUS-ABORTION; PATERNAL CELLS; IMMUNIZATION; COUPLES; WOMEN	Background Couples with unexplained recurrent miscarriage may have an alloimmune abnormality that prevents the mother from developing immune responses essential for the survival of the genetically foreign conceptus. Immunisation with paternal mononuclear cells is used as a treatment for such alloimmune-mediated pregnancy losses. However, the published results on this treatment are conflicting. In this study (the Recurrent Miscarriage [REMIS] Study), we investigated whether paternal mononuclear cell immunisation improves the rate of successful pregnancies. Methods Women who had had three or more spontaneous abortions of unknown cause were enrolled in a double-blind, multicentre, randomised clinical trial. 91 were assigned immunisation with paternal mononuclear cells (treatment) and 92 immunisation with sterile saline (control). The primary outcomes were the inability to achieve pregnancy within 12 months of randomisation, or a pregnancy which terminated before 28 weeks of gestation (failure); and pregnancy of 28 or more weeks of gestation (success). Two analyses were done: one included all women (intention to treat), and the other included only those who became pregnant. Findings Two women in each group received no treatment, and eight (three treatment, five control) were censored after an interim analysis. in the analysis of all randomised women who completed the trial. the success rate was 31/86 (36%) in the treatment group and 41/85 (48%) in the control group (odds ratio 0.60 [95% CI 0.33-1.12], p=0.108). In the analysis of pregnant women only, the corresponding success rates were 31/68 (46%) and 41/63 (65%; odds ratio 0.45 [0.22-0.91], p=0.026). The results were unchanged after adjustment for maternal age, number of previous miscarriages, and whether or not the couple had had a previous viable pregnancy. Similar results were obtained in a subgroup analysis of 133 couples with no previous livebirth. Interpretation Immunisation with paternal mononuclear cells does not improve pregnancy outcome in women with unexplained recurrent miscarriage. This therapy should not be offered as a treatment for pregnancy loss.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC, Canada	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Washington University (WUSTL); Utah System of Higher Education; University of Utah; University of British Columbia	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 924 E 57th St, Chicago, IL 60637 USA.				NICHD NIH HHS [HD27686] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027686] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alberman E, 1988, EARLY PREGNANCY LOSS; [Anonymous], 1994, Am J Reprod Immunol, V32, P55; *ASHI, 1995, ASHI LAB MAN; BEER AE, 1981, AM J OBSTET GYNECOL, V141, P987; BEER AE, 1976, IMMUNOBIOLOGY REPROD; Branch DW, 1996, LUPUS, V5, P409, DOI 10.1177/096120339600500515; CAUCHI MN, 1991, AM J REPROD IMMUNOL, V25, P16, DOI 10.1111/j.1600-0897.1991.tb01057.x; CHEDID A, 1994, HEPATOLOGY, V20, P1465, DOI 10.1002/hep.1840200614; FAULK WP, 1980, RECENT ADV CLIN IMMU, P1; FRASER EJ, 1993, OBSTET GYNECOL, V82, P854; GATENBY PA, 1993, AM J REPROD IMMUNOL, V29, P88, DOI 10.1111/j.1600-0897.1993.tb00571.x; HARGER JH, 1983, OBSTET GYNECOL, V62, P574; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P1044, DOI 10.1016/S0002-9378(11)90589-4; HO HN, 1991, AM J REPROD IMMUNOL, V25, P10, DOI 10.1111/j.1600-0897.1991.tb01056.x; ILLENI MT, 1994, HUM REPROD, V9, P1247, DOI 10.1093/oxfordjournals.humrep.a138687; JENG GT, 1995, JAMA-J AM MED ASSOC, V274, P830, DOI 10.1001/jama.274.10.830; JORDAN J, 1994, FERTIL STERIL, V62, P54; Karrison TG, 1998, CONTROL CLIN TRIALS, V19, P430, DOI 10.1016/S0197-2456(98)00019-1; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P365, DOI 10.1016/0197-2456(88)90049-9; MOWBRAY JF, 1985, LANCET, V1, P941; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; STRAYPEDERSEN B, 1984, AM J OBSTET GYNECOL, V148, P140, DOI 10.1016/S0002-9378(84)80164-7; TAYLOR CG, 1985, J ROY SOC MED, V78, P623, DOI 10.1177/014107688507800804; THO PT, 1979, FERTIL STERIL, V32, P389; WARBURTON D, 1964, AM J HUM GENET, V16, P1; WARBURTON D, 1961, BRIT J OBSTET GYNAEC, V68, P784	26	137	146	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					365	369		10.1016/S0140-6736(98)12055-X	http://dx.doi.org/10.1016/S0140-6736(98)12055-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437864				2022-12-28	WOS:000081764900010
J	Welsh, J				Welsh, J			Sri Lanka: torture continues	LANCET			English	Editorial Material									Amnesty Int, Med Programme, London WC1X 8DJ, England		Welsh, J (corresponding author), Amnesty Int, Med Programme, London WC1X 8DJ, England.							AMERASINGHE ARB, 1995, OUR FUNDAMENTAL RIGH, P48; *AMN INT, 1999, 371099 ASA AMN INT; *UN COMM TORT, 1998, A5344 UN COMM TORT	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					420	420		10.1016/S0140-6736(99)90137-X	http://dx.doi.org/10.1016/S0140-6736(99)90137-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437888				2022-12-28	WOS:000081764900046
J	Lasker, RD; Marquis, MS				Lasker, RD; Marquis, MS			The intensity of physicians' work in patient visits - Implications for the coding of patient evaluation and management services	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Clinicians use visit codes to bill for services involving the evaluation of patients and the management of their care. The existing guidelines for coding and documenting these services, as well as proposed revisions, have been criticized as complex, clinically irrelevant, and costly. We investigated whether easily measured characteristics of physician-patient visits accurately reflect differences in the amount of work performed. Such characteristics might provide the basis for a simple and equitable physician-payment scheme. Methods We collected information about the amount of physicians' work, the time spent in encounters with patients, and characteristics of patients and visits for 19,143 physician-patient visits in the practices of 339 urologists, rheumatologists, and general internists. Physicians recorded the actual time involved in evaluating the patient and managing his or her care during each visit and estimated the work involved in relation to a standardized, hypothetical visit. We used multivariate linear regression to identify factors related to differences in the total amount of work and to calculate work and work intensity (work per minute) for different types of visits. Results The duration of the face-to-face encounter with the patient or family (encounter time) was strongly predictive of the total amount of work. Total work, however, did not increase in direct proportion to encounter time. Visits with shorter encounter times were more intense than longer ones, in part because the work involved in providing fixed services, such as review of records and entry of information, did not vary in direct proportion to the length of the face-to-face encounter. Work intensity was greater for new patients than for established patients, for patients referred by other physicians than for those who were not, and for patients with new rather than previously existing problems. Conclusions A simple coding scheme based on time spent by the physician in the face-to-face encounter and a limited set of characteristics of the visit would accurately reflect total work in actual practice. A fee structure based on these factors and the inverse relation between work per minute and encounter time would provide equitable payment while encouraging efficiency and discouraging "up-coding" of services. (N Engl J Med 1999;341:337-41.) (C) 1999, Massachusetts Medical Society.	New York Acad Med, Div Publ Hlth, New York, NY 10029 USA; Rand Corp, Washington, DC 20201 USA	New York Academy of Medicine; RAND Corporation	Lasker, RD (corresponding author), New York Acad Med, Div Publ Hlth, 1216 5th Ave,Rm 452, New York, NY 10029 USA.							American Medical Association, 1999, CURR PROC TERM CPT; Brett AS, 1998, NEW ENGL J MED, V339, P1705, DOI 10.1056/NEJM199812033392312; HSIAO WC, 1992, MED CARE, V30, pNS1, DOI 10.1097/00005650-199211001-00001; LASKER RD, 1991, SURVEY VISITS CONSUL	4	31	31	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					337	341		10.1056/NEJM199907293410506	http://dx.doi.org/10.1056/NEJM199907293410506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423469				2022-12-28	WOS:000081666900006
J	Muers, MF				Muers, MF			Quitting smoking and lungs	LANCET			English	Editorial Material							DECLINE; FEV(1)		Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Muers, MF (corresponding author), Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; CALLUM C, 1998, UK SMOKING EPIDEMIC; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; Fletcher CM, 1976, NATURAL HIST CHRONIC; GOLDING JF, 1995, SMOKING RESP MED, P531; Murray RP, 1998, J CLIN EPIDEMIOL, V51, P1317, DOI 10.1016/S0895-4356(98)00120-6; Raw M, 1998, THORAX, V53, pS1, DOI 10.1136/thx.53.2008.S1; Sherrill DL, 1996, CHEST, V109, P1001, DOI 10.1378/chest.109.4.1001; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; *U YORK NHS CTR RE, 1998, EFFECTIVENESS MATTER, V3, P1; XU X, 1994, EUR RESPIR J, V7, P1056; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345	13	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					177	178		10.1016/S0140-6736(99)90021-1	http://dx.doi.org/10.1016/S0140-6736(99)90021-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421295				2022-12-28	WOS:000081504200005
J	Streeten, DHP				Streeten, DHP			What test for hypothalamic-pituitary-adrenocortical insufficiency?	LANCET			English	Editorial Material							NORMAL CORTISOL RESPONSE; ADRENAL AXIS; CORTICOTROPIN; ACTH; CELLS		SUNY Hlth Sci Ctr, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Streeten, DHP (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.							Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Agwu JC, 1999, ARCH DIS CHILD, V80, P330, DOI 10.1136/adc.80.4.330; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; Clark PM, 1998, CLIN ENDOCRINOL, V49, P287; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; DONALD RA, 1993, CLIN ENDOCRINOL, V38, P609, DOI 10.1111/j.1365-2265.1993.tb02142.x; LANDON J, 1967, LANCET, V2, P697; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; RESCHINI E, 1982, J ENDOCRINOL INVEST, V5, P259, DOI 10.1007/BF03348333; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Streeten DHP, 1999, J CLIN ENDOCR METAB, V84, P835, DOI 10.1210/jc.84.3.835; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371	16	34	39	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					179	180		10.1016/S0140-6736(98)00318-3	http://dx.doi.org/10.1016/S0140-6736(98)00318-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421297				2022-12-28	WOS:000081504200007
J	Yoshida, M; Oshiyama, M; Fujii, H; Konishi, M				Yoshida, M; Oshiyama, M; Fujii, H; Konishi, M			Erythrocytosis and a fibroid	LANCET			English	Article									Tenri Hosp, Dept Obstet & Gynaecol, Nara 6328552, Japan	Tenri Hospital	Yoshida, M (corresponding author), Tenri Hosp, Dept Obstet & Gynaecol, 200 Mishima Cho, Nara 6328552, Japan.							Howlett T A, 1985, Spec Top Endocrinol Metab, V7, P1; LEVGUR M, 1995, OBSTET GYNECOL, V86, P1026, DOI 10.1016/0029-7844(95)00292-Y	2	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					216	216		10.1016/S0140-6736(99)02273-4	http://dx.doi.org/10.1016/S0140-6736(99)02273-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421304				2022-12-28	WOS:000081504200014
J	Somerville, C; Somerville, S				Somerville, C; Somerville, S			Plant functional genomics	SCIENCE			English	Review							RNA-DNA OLIGONUCLEOTIDE; ARABIDOPSIS-THALIANA; EXPRESSION PATTERNS; GENE-EXPRESSION; SEQUENCE; IDENTIFICATION; MUTATIONS; YEAST; SCALE	Nucleotide sequencing of the Arabidopsis genome is nearing completion, sequencing of the rice genome has begun, and Large amounts of expressed sequence tag information are being obtained for many other plants. There are many opportunities to use this wealth of sequence information to accelerate progress toward a comprehensive understanding of the genetic mechanisms that control plant growth and development and responses to the environment.	Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Somerville, C (corresponding author), Carnegie Inst Sci, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	crs@andrew2.stanford.edu						Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; Baldwin D, 1999, CURR OPIN PLANT BIOL, V2, P96, DOI 10.1016/S1369-5266(99)80020-X; Baulcombe DC, 1999, CURR OPIN PLANT BIOL, V2, P109, DOI 10.1016/S1369-5266(99)80022-3; BENNETT MD, 1991, PHILOS T R SOC B, V334, P309, DOI 10.1098/rstb.1991.0120; Bennetzen JL, 1998, P NATL ACAD SCI USA, V95, P1975, DOI 10.1073/pnas.95.5.1975; Bevan M, 1998, NATURE, V391, P485, DOI 10.1038/35140; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bouchez D, 1998, PLANT PHYSIOL, V118, P725, DOI 10.1104/pp.118.3.725; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CLOUGHS J, 1999, PLANT J, V17, P735; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; Copenhaver GP, 1999, CURR OPIN PLANT BIOL, V2, P104, DOI 10.1016/S1369-5266(99)80021-1; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Doebley J, 1998, PLANT CELL, V10, P1075, DOI 10.1105/tpc.10.7.1075; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELSEN JA, 1998, GENOME RES, V8, P163; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Goff SA, 1999, CURR OPIN PLANT BIOL, V2, P86, DOI 10.1016/S1369-5266(99)80018-1; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kehoe DM, 1999, TRENDS PLANT SCI, V4, P38, DOI 10.1016/S1360-1385(98)01354-5; Kempin SA, 1997, NATURE, V389, P802, DOI 10.1038/39770; Kjemtrup S, 1998, PLANT J, V14, P91, DOI 10.1046/j.1365-313X.1998.00101.x; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lee M, 1998, SCIENCE, V280, P915, DOI 10.1126/science.280.5365.915; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; McCouch S, 1998, P NATL ACAD SCI USA, V95, P1983, DOI 10.1073/pnas.95.5.1983; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Milborrow BV, 1998, J EXP BOT, V49, P1063, DOI 10.1093/jexbot/49.324.1063; MONTANA M, 1996, SCIENCE, V274, P1537; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Pennisi E, 1998, SCIENCE, V282, P652, DOI 10.1126/science.282.5389.652; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Rounsley S, 1998, CURR OPIN PLANT BIOL, V1, P136, DOI 10.1016/S1369-5266(98)80015-0; Rounsley SD, 1996, PLANT PHYSIOL, V112, P1177, DOI 10.1104/pp.112.3.1177; Ruan Y, 1998, PLANT J, V15, P821, DOI 10.1046/j.1365-313X.1998.00254.x; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Sasaki T, 1998, P NATL ACAD SCI USA, V95, P2027, DOI 10.1073/pnas.95.5.2027; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Service RF, 1999, SCIENCE, V284, P80; TISSLER AF, IN PRESS PLANT CELL; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Winkler RG, 1998, PLANT PHYSIOL, V118, P743, DOI 10.1104/pp.118.3.743; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	58	185	213	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					380	383		10.1126/science.285.5426.380	http://dx.doi.org/10.1126/science.285.5426.380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411495				2022-12-28	WOS:000081465900046
J	Payre, F; Vincent, A; Carreno, S				Payre, F; Vincent, A; Carreno, S			Ovo/svb integrates Wingless and DER pathways to control epidermis differentiation	NATURE			English	Article							DROSOPHILA EGF RECEPTOR; OVO GENE; ARMADILLO; EXPRESSION; PROTEIN; ROLES; MORPHOGENESIS; SHAVENBABY; ENCODES; CUTICLE	In Drosophila, as in mammals, epidermal differentiation is controlled by signalling cascades' that include Wnt proteins(2,3) and the ovo/shavenbaby (svb) family of zinc-finger transcription factor(4-6) Ovo/svb is a complex gene with two genetic functions corresponding to separate control regions: ovo is required for female germline development and svb for epidermal morphogenesis(7,8). In the Drosophila embryo, the ventral epidermis consists of the segmental alternance of two major cell types that produce either naked cuticle or cytoplasmic extrusions known as denticles. Wingless signalling specifies smooth cells that produce naked cuticle(9), whereas the activation of the Drosophila epidermal growth factor (EGF) receptor (DER) leads to the production of denticles(10). Here we show that expression of the ovo/svb gene controls the choice between these cell fates. We find that svb is a key selector gene that, cell autonomously, directs cytoskeletal modifications producing the denticle. The DER pathway promotes denticle formation by activating svb expression. Conversely, Wingless promotes the smooth cell fate through the transcriptional repression of svb by the bipartite nuclear factor Armadillo/dTcf. Ou data indicate that transcriptional regulation of svb integrates inputs fi om the Wingless and DER pathways and controls epidermal differentiation.	Ctr Dev Biol, F-31062 Toulouse, France		Payre, F (corresponding author), Ctr Dev Biol, UMR5547,Bat IVR3,118 Route Narbonne, F-31062 Toulouse, France.		Vincent, Alain/AAE-4712-2019	PAYRE, Francois/0000-0002-8144-6711; Carreno, Sebastien/0000-0002-5839-2102				Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Dai X, 1998, GENE DEV, V12, P3452, DOI 10.1101/gad.12.21.3452; Dickinson WJ, 1997, CELL MOTIL CYTOSKEL, V38, P9; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GARFINKEL MD, 1994, MOL CELL BIOL, V14, P6809, DOI 10.1128/MCB.14.10.6809; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Lee T, 1996, DEVELOPMENT, V122, P409; Lu JN, 1998, DEV GENES EVOL, V208, P213, DOI 10.1007/s004270050175; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; MEVELNINIO M, 1995, MECH DEVELOP, V49, P83, DOI 10.1016/0925-4773(94)00305-7; MevelNinio M, 1996, DEVELOPMENT, V122, P4131; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Szuts D, 1997, DEVELOPMENT, V124, P3209; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	30	171	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					271	275		10.1038/22330	http://dx.doi.org/10.1038/22330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421370				2022-12-28	WOS:000081503800046
J	Nichol, KL; Mendelman, PM; Mallon, KP; Jackson, LA; Gorse, GJ; Belshe, RB; Glezen, WP; Wittes, J				Nichol, KL; Mendelman, PM; Mallon, KP; Jackson, LA; Gorse, GJ; Belshe, RB; Glezen, WP; Wittes, J		Live Attenuated Influenza Virus Vaccine Hlth	Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							A VIRUS; INACTIVATED VACCINES; VOLUNTEERS; RESISTANCE; INFECTION; EFFICACY	Context Influenza virus is a major cause of illness, disruption to daily life, and increased use of health care in ail age groups. Objective To assess the safety and effectiveness of intranasally administered trivalent, live, attenuated influenza virus (LAIV) vaccine for reducing illness, absenteeism, and health care use among healthy, working adults. Design Randomized, double-blind, placebo-controlled trial conducted from September 1997 through March 1998. Setting Thirteen centers across the United States. Participants A total of 4561 healthy, working adults aged 18 to 64 years recruited through health insurance plans, at work sites, and from the general population. Intervention Participants were randomized 2:1 to receive intranasally administered trivalent LAIV vaccine (n = 3041) or placebo (n = 1520) in the fall of 1997. Main Outcome Measures Episodes of febrile illness, severe febrile illness, febrile upper respiratory tract illness, work loss, and health care use during the peak and total influenza outbreak periods, and adverse events. Results Recipients of LAIV vaccine were as likely to experience 1 or more febrile illnesses as placebo recipients during peak outbreak periods (13.2% for vaccine vs 14.6% for placebo; P=.19). However, vaccination significantly reduced the numbers of severe febrile illnesses (18.8% reduction; 95% confidence interval [CI], 7.4%-28.8%) and febrile upper respiratory tract illnesses (23.6% reduction; 95% CI, 12.7%-33.2%). Vaccination also led to fewer days of illness across all illness syndromes (22.9% reduction for febrile illnesses, 27.3% reduction for severe febrile illnesses), fewer days of work lost (17.9% reduction for severe febrile illnesses; 28.4% reduction for febrile upper respiratory tract illnesses), and fewer days with health care provider visits (24.8% reduction for severe febrile illnesses; 40.9% reduction for febrile upper respiratory tract illnesses). Use of prescription antibiotics and over-the-counter medications was also reduced across all illness syndromes. Vaccine recipients were more likely to experience runny nose or sore throat during the first 7 days after vaccination, but serious adverse events between the groups were not significantly different. The match between the type A(H3N2) vaccine strain and the predominant circulating virus strain (A/Sydney/05/97[H3N2]) for the 1997-1998 season was poor, suggesting that LAIV provided substantial cross-protection against this variant influenza A virus strain. Conclusion Intranasal trivalent LAIV vaccine was safe and effective in healthy, working adults in a year in which a drifted influenza A virus predominated.	Vet Adm Med Ctr, Med Serv 111, Minneapolis, MN 55417 USA; Univ Minnesota, Minneapolis, MN USA; Aviron, Mountain View, CA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Immunizat Studies Program, Seattle, WA 98101 USA; Vet Adm Med Ctr, Med Serv, St Louis, MO 63125 USA; St Louis Univ, Dept Med, St Louis, MO 63103 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Stat Collaborat, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; Group Health Cooperative; US Department of Veterans Affairs; Veterans Health Administration (VHA); Saint Louis University; Baylor College of Medicine	Nichol, KL (corresponding author), Vet Adm Med Ctr, Med Serv 111, 1 Vet Dr, Minneapolis, MN 55417 USA.							[Anonymous], 1999, MMWR Recomm Rep, V48, P1; BATEY D, 1995, WORK GROUP M IMPR PE; BELSHE R, 1998, 38 INT C ANT AG CHEM; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; BRIDGES CB, 1998, INF DIS SOC AM 36 AN; *CDCP, 1998, MMWR-MORBID MORTAL W, V46, P325; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P280; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P196; CLEMENTS ML, 1984, LANCET, V1, P705; CLEMENTS ML, 1983, INFECT IMMUN, V40, P1044, DOI 10.1128/IAI.40.3.1044-1051.1983; CLEMENTS ML, 1984, J INFECT DIS, V149, P814, DOI 10.1093/infdis/149.5.814; CLEMENTS ML, 1990, J INFECT DIS, V161, P869, DOI 10.1093/infdis/161.5.869; CLOVER RD, 1991, J INFECT DIS, V163, P300, DOI 10.1093/infdis/163.2.300; COUCH RB, 1993, ANN NY ACAD SCI, V685, P803, DOI 10.1111/j.1749-6632.1993.tb35946.x; EDMONDSON KW, 1970, MED J AUSTRALIA, V2, P6, DOI 10.5694/j.1326-5377.1970.tb84667.x; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; EDWARDS KM, 1994, J INFECT DIS, V169, P68, DOI 10.1093/infdis/169.1.68; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Gorse GJ, 1996, J INFECT DIS, V173, P285, DOI 10.1093/infdis/173.2.285; GORSE GJ, 1991, CHEST, V100, P977, DOI 10.1378/chest.100.4.977; GORSE GJ, 1995, J INFECT DIS, V172, P1, DOI 10.1093/infdis/172.1.1; GRUBER W, 1998, CLIN INFECT DIS, V27, P933; Leighton L, 1996, OCCUP MED-OXFORD, V46, P146, DOI 10.1093/occmed/46.2.146; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; Orts K, 1995, J BEHAV MED, V18, P517, DOI 10.1007/BF01857893; PIEDRA PA, 1991, SEMIN PEDIAT INFECT, V2, P140; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; SMITH JWG, 1979, J HYG-CAMBRIDGE, V83, P157, DOI 10.1017/S0022172400025936; SULLIVAN KM, 1993, AM J PUBLIC HEALTH, V83, P1712, DOI 10.2105/AJPH.83.12.1712; TREANOR JJ, 1993, J INFECT DIS, V168, P455, DOI 10.1093/infdis/168.2.455; TREANOR JJ, IN PRESS VACCINE; WILDE MA, 1999, JAMA-J AM MED ASSOC, V281, P908; ZEIGLER BL, 1998, P 4 WORKSH INT VOIC	34	308	367	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					137	144		10.1001/jama.282.2.137	http://dx.doi.org/10.1001/jama.282.2.137			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411194				2022-12-28	WOS:000081376800030
J	Maisonneuve, P; Agodoa, L; Gellert, R; Stewart, JH; Buccianti, G; Lowenfels, AB; Wolfe, RA; Jones, E; Disney, APS; Briggs, D; McCredie, M; Boyle, P				Maisonneuve, P; Agodoa, L; Gellert, R; Stewart, JH; Buccianti, G; Lowenfels, AB; Wolfe, RA; Jones, E; Disney, APS; Briggs, D; McCredie, M; Boyle, P			Cancer in patients on dialysis for end-stage renal disease: an international collaborative study	LANCET			English	Article							CELL CARCINOMA; TRANSPLANT RECIPIENTS; HEMODIALYSIS-PATIENTS; KIDNEY-DISEASE; INFECTION; RISK; REGISTRY	Background Previous studies have suggested that the frequency of cancer is higher in patients with end-stage renal disease (ESRD) than in the general population, but have not established whether this increase is confined to certain cancers or to certain categories of ESRD patients. The aim of this study was to examine the risk of cancer in a large cohort of patients treated by dialysis but not transplantation. Methods We assembled a cohort of 831 804 patients who received dialysis during the period 1980-94 for ESRD in the USA, Europe, Australia, or New Zealand. We compared the observed frequency ol: cancer among these patients during 2 045 035 person-years of follow-up with the frequency of cancer in the respective background populations. Findings During average follow-up of 2.5 years, 25 044 (3%) of 831 804 patients developed cancer compared with an expected number of 21 185 (standardised incidence ratio 1.18 [95% CI 1.17-1.20]). We observed a higher risk of cancer in patients younger than 35 years (3.68 [3.39-3.99]), and the risk gradually decreased with increasing age. High risks were observed for cancer of the kidney (3.60 [3.45-3.76]), bladder (1.50 [1.42-1.57]), and thyroid and other endocrine organs (2.28 [2.03-2.54]). Excess cancers appeared in several organs for which viruses have been suspected as causative agents, whereas cancers of the lung, colorectum, prostate. breast, and stomach were not consistently increased. Interpretation The overall risk of cancer is increased in patients with ESRD, and the distribution of tumour types resembles the pattern seen after transplantation (although we have no data to make the comparison with skin cancer). The excess risk can largely be ascribed to effects df underlying renal or urinary-tract disease, or of loss of renal function, on the kidney and bladder, and to increased susceptibility to viral carcinogenesis. The relative risk, which is especially high in younger patients, gradually diminishes with age.	European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy; NIDDKD, Div Kidney Urol & Hematol Dis, Bethesda, MD 20892 USA; CSK AM Banacha, Dept Internal Med & Nephrol, Warsaw, Poland; Univ Otago, Dept Med, Dunedin, New Zealand; Hosp E Bassini San Gerardo, Dept Nephrol & Dialysis, Monza, Italy; New York Med Coll, Valhalla, NY 10595 USA; Univ Michigan, USRDS Coordinating Ctr, Ann Arbor, MI 48109 USA; ERA EDTA Registry, London, England; ANZDATA Registry, Adelaide, SA, Australia; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Otago; New York Medical College; University of Michigan System; University of Michigan; University of Otago; Cancer Council New South Wales	Maisonneuve, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, Via Ripamonti 435, I-20141 Milan, Italy.	pmaison@ieo.it	Gellert, Ryszard/F-4604-2010; Boyle, Peter/A-4380-2014; Maisonneuve, Patrick/U-9789-2018; Lowenfels, Albert/ABD-8388-2021	Boyle, Peter/0000-0001-6251-0610; Maisonneuve, Patrick/0000-0002-5309-4704; Gellert, Ryszard/0000-0001-9382-0734				Adami HO, 1996, J NATL CANCER I, V88, P1472, DOI 10.1093/jnci/88.20.1472; Beutner Karl R., 1997, American Journal of Medicine, V102, P9; BRUNNER FP, 1995, NEPHROL DIAL TRANSPL, V10, P74, DOI 10.1093/ndt/10.supp1.74; Buccianti G, 1996, INT J CANCER, V66, P591, DOI 10.1002/(SICI)1097-0215(19960529)66:5<591::AID-IJC1>3.3.CO;2-W; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Cuckovic C, 1996, NEPHRON, V73, P710; DEVILLIERS EM, 1985, INT J CANCER, V36, P575, DOI 10.1002/ijc.2910360510; DISNEY APS, ANZDATA REGISTRY REP; Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407; Flattery M P, 1998, J Transpl Coord, V8, P105; INAMOTO H, 1991, NEPHRON, V59, P611, DOI 10.1159/000186652; ISEKI K, 1993, AM J KIDNEY DIS, V22, P308, DOI 10.1016/S0272-6386(12)70323-2; ISHIKAWA I, 1990, AM J KIDNEY DIS, V16, P452, DOI 10.1016/S0272-6386(12)80058-8; KANTOR AF, 1987, AM J EPIDEMIOL, V126, P370, DOI 10.1093/oxfordjournals.aje.a114668; KEITH DS, 1994, J AM SOC NEPHROL, V4, P1661; LEVINE E, 1992, UROL RADIOL, V13, P203; LORNOY W, 1986, LANCET, V1, P1271; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MARPLE JT, 1994, J AM SOC NEPHROL, V4, P1951; *NCI, 1997, SURV EP END RES; NIU MT, 1993, AM J KIDNEY DIS, V22, P568, DOI 10.1016/S0272-6386(12)80930-9; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; PECQUEUX JC, 1990, UROL INT, V45, P290, DOI 10.1159/000281722; Penn I, 1994, Clin Transpl, P99; POPE JC, 1994, UROLOGY, V44, P497, DOI 10.1016/S0090-4295(94)80046-4; PORT FK, 1989, AM J KIDNEY DIS, V14, P119, DOI 10.1016/S0272-6386(89)80187-8; RAGHEB NE, 1991, SEMIN DIALYSIS, V4, P253, DOI 10.1111/j.1525-139X.1991.tb00104.x; SHEIL AGR, 1985, TRANSPLANT P, V17, P1685; *USRDS, 1997, NIH PUBL; Vamvakas S, 1998, AM J NEPHROL, V18, P89, DOI 10.1159/000013314; Winkelspecht B, 1997, NEPHROL DIAL TRANSPL, V12, P2099, DOI 10.1093/ndt/12.10.2099; YAMAMOTO T, 1995, NEPHRON, V70, P449, DOI 10.1159/000188644	32	624	646	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1999	354	9173					93	99		10.1016/S0140-6736(99)06154-1	http://dx.doi.org/10.1016/S0140-6736(99)06154-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408483				2022-12-28	WOS:000081377100010
J	Wong, V; Goodenough, DA				Wong, V; Goodenough, DA			Cell biology - Paracellular channels!	SCIENCE			English	Article									Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Wong, V (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.							DIAMOND JM, 1969, ANNU REV PHYSIOL, V31, P581, DOI 10.1146/annurev.ph.31.030169.003053; DISTEFANO A, 1993, RENAL PHYSIOL BIOCH, V16, P157; FROMTER E, 1972, NATURE-NEW BIOL, V235, P9, DOI 10.1038/newbio235009a0; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103	7	42	42	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					62	62		10.1126/science.285.5424.62	http://dx.doi.org/10.1126/science.285.5424.62			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10428705				2022-12-28	WOS:000081199800028
J	Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP				Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP			Galileo imaging of atmospheric emissions from Io	SCIENCE			English	Article							PLASMA TORUS; ELECTRON-IMPACT; ULTRAVIOLET; JUPITER; TEMPERATURE; VOLCANISM; SO2	The Galileo spacecraft has detected diffuse optical emissions from to in high-resolution images acquired while the satellite was eclipsed by Jupiter. Three distinct components make up lo's visible emissions. Bright blue glows of more than 300 kilorayleighs emanate from volcanic plumes, probably due to electron impact on molecular sulfur dioxide. Weaker red emissions, possibly due to atomic oxygen, are seen along the Limbs, brighter on the pole closest to the plasma torus. A faint green glow appears concentrated on the night side of to, possibly produced by atomic sodium. to's disk-averaged emission diminishes with time after entering eclipse, whereas the localized blue glows brighten instead.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Natl Cent Univ, Astron Inst, Chungli 320, Taiwan; Natl Opt Astron Observ, Tucson, AZ 85719 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	University of Arizona; National Central University; National Optical Astronomy Observatory; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Atmospheric & Environmental Research; California Institute of Technology	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.							AJELLO JM, 1992, J GEOPHYS RES-SPACE, V97, P10501, DOI 10.1029/92JA00295; AUSTIN JV, 1998, B AM ASTRON SOC, V30, P1121; BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; BALLESTER GE, 1997, B AM ASTRON SOC, V29, P980; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BRENEMAN H, 1993, D5880 JET PROP LAB; BROWN MA, UNPUB; Brown R. A., 1974, EXPLORATION PLANETAR, P527; BROWN RA, 1981, ASTROPHYS J, V244, P1072, DOI 10.1086/158777; CLARK REH, 1982, ASTROPHYS J, V254, P412, DOI 10.1086/159746; CLARKE JT, 1994, J GEOPHYS RES-PLANET, V99, P8387, DOI 10.1029/93JE02547; Combi MR, 1998, J GEOPHYS RES-SPACE, V103, P9071, DOI 10.1029/98JA00073; COOK AF, 1981, SCIENCE, V211, P1419, DOI 10.1126/science.211.4489.1419; DURRANCE ST, 1983, ASTROPHYS J, V267, pL125, DOI 10.1086/184016; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; Gold T, 1979, Science, V206, P1071, DOI 10.1126/science.206.4422.1071; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; Gurnett DA, 1996, SCIENCE, V274, P391, DOI 10.1126/science.274.5286.391; Hendrix AR, 1999, J GEOPHYS RES-PLANET, V104, P11817, DOI 10.1029/1999JE900009; Ingersoll AP, 1998, ICARUS, V135, P251, DOI 10.1006/icar.1998.5971; Klaasen KP, 1997, OPT ENG, V36, P3001, DOI 10.1117/1.601525; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; Linker JA, 1998, J GEOPHYS RES-PLANET, V103, P19867, DOI 10.1029/98JE00632; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MILLER K, 1987, CAN J PHYS, V65, P530, DOI 10.1139/p87-074; PEARL J, 1979, NATURE, V280, P757; PERATT AL, 1988, ASTROPHYS SPACE SCI, V144, P451; Roesler FL, 1999, SCIENCE, V283, P353, DOI 10.1126/science.283.5400.353; SAUER J, IN PRESS J GEOPHYS R; SCHERB F, 1993, J GEOPHYS RES-PLANET, V98, P18729, DOI 10.1029/93JE00539; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STROM RG, 1982, SATELLITES JUPITER, pCH16; TRAFTON L, 1975, NATURE, V258, P690, DOI 10.1038/258690a0; TRAUGER JT, 1976, B AM ASTRON SOC, V8, P468; TRAUGER JT, 1997, B AM ASTRON SOC, V29, P1002; Volwerk M, 1997, GEOPHYS RES LETT, V24, P1147, DOI 10.1029/97GL00966; WONG MC, 1998, B AM ASTRON SOC, V30, P1117	38	64	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					870	874		10.1126/science.285.5429.870	http://dx.doi.org/10.1126/science.285.5429.870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436151				2022-12-28	WOS:000081860900043
J	Pagani, M; Freeman, KH; Arthur, MA				Pagani, M; Freeman, KH; Arthur, MA			Late Miocene atmospheric CO2 concentrations and the expansion of C-4 grasses	SCIENCE			English	Article							ISOTOPIC EVIDENCE; NORTHERN-HEMISPHERE; EOLIAN DEPOSITION; CARBON ISOTOPES; ORGANIC-CARBON; NEOGENE; FRACTIONATION; AMERICA; CLIMATE; RECORD	The global expansion of C-4 grasslands in the late Miocene has been attributed to a large-scale decrease in atmospheric carbon dioxide (CO,) concentrations. This triggering mechanism is controversial, in part because of a lack of direct evidence for change in the partial pressure of CO2 (pCO(2)) and because other factors are also important determinants in controlling plant-type distributions. Alkenone-based pCO(2) estimates for the Late Miocene indicate that pCO(2) increased from 14 to 9 million years ago and stabilized at preindustrial values by 9 million years ago. The estimates presented here provide no evidence for major changes in pCO(2) during the Late Miocene. Thus, C-4 plant expansion was Likely driven by additional factors, possibly a tectonically related episode of enhanced Low-latitude aridity or changes in seasonal precipitation patterns on a global scale (or both).	Penn State Univ, Dept Geosci, University Pk, PA 16872 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pagani, M (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.		Arthur, Michael A/E-2872-2014; Freeman, Katherine H/H-5140-2011; Pagani, Mark/B-3233-2008	Arthur, Michael A/0000-0002-3028-6279; Freeman, Katherine H/0000-0002-3350-7671; 				AXELROD DI, 1985, BOT REV, V51, P163, DOI 10.1007/BF02861083; BARTON CE, 1986, INITIAL REP DEEP SEA, V90, P1273, DOI 10.2973/dsdp.proc.90.136.1986; Bernor R.L., 1996, P449; Bidigare RR, 1999, GLOBAL BIOGEOCHEM CY, V13, P251, DOI 10.1029/1998GB900011; Bidigare RR, 1997, GLOBAL BIOGEOCHEM CY, V11, P279, DOI 10.1029/96GB03939; BLACK CC, 1994, REGULATION CO2 O2 PH, P159; CANDE SC, 1992, J GEOPHYS RES-SOL EA, V97, P13917, DOI 10.1029/92JB01202; Cerling T. E., 1990, Chemical Geology, V84, P164, DOI 10.1016/0009-2541(90)90200-Q; CERLING TE, 1993, NATURE, V361, P344, DOI 10.1038/361344a0; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; CONTE MH, 1994, HAPTOPHYTE ALGAE, P351; CREPET WL, 1991, AM J BOT, V78, P1010, DOI 10.2307/2445181; DAVIES TA, 1977, SCIENCE, V197, P53, DOI 10.1126/science.197.4298.53; Deines P, 1980, HDB ENV ISOTOPE GEOC, DOI DOI 10.1016/B978-0-444-41780-0.50015-8; EREZ J, 1983, GEOCHIM COSMOCHIM AC, V47, P1025, DOI 10.1016/0016-7037(83)90232-6; FILIPPELLI GM, 1994, PALEOCEANOGRAPHY, V9, P643, DOI 10.1029/94PA01453; FLYNN LJ, 1982, PALAEOGEOGR PALAEOCL, V38, P129, DOI 10.1016/0031-0182(82)90067-0; FRANCELANORD C, 1994, GEOCHIM COSMOCHIM AC, V58, P4809, DOI 10.1016/0016-7037(94)90210-0; HAQ BU, 1987, SCIENCE, V235, P1156, DOI 10.1126/science.235.4793.1156; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; Hattersley P. W., 1992, Desertified grasslands: their biology and management. Papers presented at an International Symposium, London, 27, 28 February and 1 March 1991., P181; HATTERSLEY PW, 1983, OECOLOGIA, V57, P113, DOI 10.1007/BF00379569; HODELL DA, 1994, PALEOCEANOGRAPHY, V9, P405, DOI 10.1029/94PA00292; JASPER JP, 1990, NATURE, V347, P462, DOI 10.1038/347462a0; JASPER JP, 1994, PALEOCEANOGRAPHY, V9, P781, DOI 10.1029/94PA02116; Kellogg E. A., 1999, C4 PLANT BIOL, P411, DOI DOI 10.1016/B978-012614440-6/50013-6; KINGSTON JD, 1994, SCIENCE, V264, P955, DOI 10.1126/science.264.5161.955; KOCH PL, 1990, ANN REP DIR GEOPHYS, P163; Kurschner WM, 1996, MAR MICROPALEONTOL, V27, P299, DOI 10.1016/0377-8398(95)00067-4; Kuypers MMM, 1999, NATURE, V399, P342, DOI 10.1038/20659; Latorre C, 1997, EARTH PLANET SC LETT, V146, P83, DOI 10.1016/S0012-821X(96)00231-2; LEETHORP JA, 1989, J ARCHAEOL SCI, V16, P585, DOI 10.1016/0305-4403(89)90024-1; LINDER H P, 1987, Kew Bulletin, V42, P297, DOI 10.2307/4109686; MACFADDEN BJ, 1994, PALAEOGEOGR PALAEOCL, V107, P257, DOI 10.1016/0031-0182(94)90098-1; MILLER KG, 1995, GEOLOGY, V23, P747, DOI 10.1130/0091-7613(1995)023<0747:CMSION>2.3.CO;2; MILLER KG, 1991, J GEOPHYS RES-SOLID, V96, P6829, DOI 10.1029/90JB02015; MOOK WG, 1974, EARTH PLANET SC LETT, V22, P169, DOI 10.1016/0012-821X(74)90078-8; MORGAN ME, 1994, NATURE, V367, P162, DOI 10.1038/367162a0; Pagani M, 1999, PALEOCEANOGRAPHY, V14, P273, DOI 10.1029/1999PA900006; PAGANI M, IN PRESS GEOCHIM COS; PAGANI M, 1998, THESIS PENNSYLVANIA; Patzkowsky ME, 1995, PALEOBIOLOGY, V21, P440, DOI 10.1017/S0094837300013476; PEARCY RW, 1984, PLANT CELL ENVIRON, V7, P1, DOI 10.1111/j.1365-3040.1984.tb01194.x; Popp BN, 1998, PALEOCEANOGRAPHY, V13, P35, DOI 10.1029/97PA02594; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; POPP BN, IN PRESS RECONSTRUCT; QUADE J, 1994, PALAEOGEOGR PALAEOCL, V108, P41, DOI 10.1016/0031-0182(94)90021-3; QUADE J, 1989, NATURE, V342, P163, DOI 10.1038/342163a0; RAYMO ME, 1994, PALEOCEANOGRAPHY, V9, P399, DOI 10.1029/94PA00289; Rea D.K., 1992, SYNTHESIS RESULTS SC, V70, P387, DOI DOI 10.1029/GM070P0387; Rea DK, 1998, PALEOCEANOGRAPHY, V13, P215, DOI 10.1029/98PA00123; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; Retallack GJ, 1997, PALAIOS, V12, P380, DOI 10.2307/3515337; ROMANEK CS, 1992, GEOCHIM COSMOCHIM AC, V56, P41; Ruddiman W.F., 1997, TECTONIC UPLIFT CLIM, P204; RUDDIMAN WF, 1989, J GEOPHYS RES-ATMOS, V94, P18409, DOI 10.1029/JD094iD15p18409; Shackleton N.J., 1975, INITIAL REPORTS DEEP, V29, P743, DOI [DOI 10.2973/DSDP.PROC.29.117.1975, 10.2973/DSDP.PROC.29.117.1975]; Shemesh A, 1989, PALEOCEANOGRAPHY, V4, P221, DOI 10.1029/PA004i003p00221; TEERI JA, 1979, TOPICS PLANT POPULAT, P357; THUNELL R, 1982, MICROPALEONTOLOGY, V28, P381, DOI 10.2307/1485451; van Zinderen Bakker E. M., 1986, Palaeogeography, Palaeoclimatology, Palaeoecology, V56, P217, DOI 10.1016/0031-0182(86)90095-7; VANDERBURGH J, 1993, SCIENCE, V260, P1788, DOI 10.1126/science.260.5115.1788; Vincent E., 1985, CARBON CYCLE ATMOSPH, P455, DOI 10.1029/GM032p0455; WANG Y, 1994, PALAEOGEOGR PALAEOCL, V107, P269, DOI 10.1016/0031-0182(94)90099-X; Webb SD, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P91; Wei KY, 1986, PALEOCEANOGRAPHY, V1, P67, DOI 10.1029/PA001i001p00067; Weiss R.F., 1974, MAR CHEM, V2, P203, DOI DOI 10.1016/0304-4203(74)90015-2; Wolfe J.A., 1985, CARBON CYCLE ATMOSPH, V32, P357, DOI [10.1029/GM032p0357, DOI 10.1029/GM032P0357]; Woodruff F, 1989, PALEOCEANOGRAPHY, V4, P87, DOI 10.1029/PA004i001p00087; Wright JD, 1992, PALEOCEANOGRAPHY, V7, P357, DOI 10.1029/92PA00760; Wright JD, 1996, PALEOCEANOGRAPHY, V11, P157, DOI 10.1029/95PA03696	71	358	393	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					876	879		10.1126/science.285.5429.876	http://dx.doi.org/10.1126/science.285.5429.876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436153				2022-12-28	WOS:000081860900045
J	Beecham, L				Beecham, L			BMA sets up audit committee	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					324	324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426767				2022-12-28	WOS:000081909100064
J	Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J				Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J			Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USERS; VIRUS-INFECTION; RISK		Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London	Best, D (corresponding author), Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Best, David/0000-0002-6792-916X				Crofts N, 1997, ADDICTION, V92, P999, DOI 10.1111/j.1360-0443.1997.tb02979.x; DOW BC, 1993, J MED VIROL, V41, P215, DOI 10.1002/jmv.1890410309; MAJID A, 1995, J MED VIROL, V46, P48, DOI 10.1002/jmv.1890460111; Rhodes T, 1996, ADDICTION, V91, P1457, DOI 10.1111/j.1360-0443.1996.tb02250.x; Serfaty MA, 1997, DRUG ALCOHOL REV, V16, P339, DOI 10.1080/09595239700186721	5	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					290	291		10.1136/bmj.319.7205.290	http://dx.doi.org/10.1136/bmj.319.7205.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224QE	10426739	Bronze, Green Published			2022-12-28	WOS:000081909100023
J	Blogg, CE				Blogg, CE			A lesson learnt - Patient controlled hallucinations	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					301	301		10.1136/bmj.319.7205.301	http://dx.doi.org/10.1136/bmj.319.7205.301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426747	Green Published			2022-12-28	WOS:000081909100030
J	Hankey, GJ; Eikelboom, JW				Hankey, GJ; Eikelboom, JW			Homocysteine and vascular disease	LANCET			English	Review							CORONARY-ARTERY DISEASE; PLASMA TOTAL HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; RISK FACTOR; HEART-DISEASE; MYOCARDIAL-INFARCTION; FOLIC-ACID; ATHEROSCLEROTIC DISEASE; VITAMIN SUPPLEMENTATION; CARDIOVASCULAR-DISEASE	For more than 20 years, moderately raised concentrations of total homocysteine (tHcy) have been associated with an increased risk of atherothrombotic vascular events but only recently has evidence mounted to suggest that the association may be causal. The association is independent of other factors, it is fairly consistent across many studies, it is strong and dose-related, and it is biologically plausible. However, the evidence needs to be strengthened by a systematic review of all comparable studies and the demonstration, in randomised trials, that lowering tHcy is followed by a significant reduction in atherothrombotic vascular disease, in addition, the measurement of tHcy needs to be standardised. If these can be achieved then tHcy measurement will become another useful marker of vascular risk, multivitamin therapy will be another therapeutic option for people at risk of atherothrombotic vascular disease, and fortification of food with folic acid will rise high on the political and public health agenda.	Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6001, Australia; Univ Western Australia, Dept Med, Nedlands, WA 6009, Australia; McMaster Univ, Prevent Cardiol & Therapeut Program, Hamilton, ON, Canada	Royal Perth Hospital; University of Western Australia; University of Western Australia; McMaster University	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Stroke Unit, Wellington St, Perth, WA 6001, Australia.	gjhankey@cyilene.uwa.edu.au	Eikelboom, John/AAG-6117-2019; Hankey, Graeme J/H-4968-2014	Eikelboom, John/0000-0003-4126-1285; Hankey, Graeme J/0000-0002-6044-7328				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Blom HJ, 1998, EUR J PEDIATR, V157, pS131, DOI 10.1007/PL00014297; Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; de Baulny HO, 1998, EUR J PEDIATR, V157, pS77, DOI 10.1007/PL00014307; den Heijer M, 1998, ARTERIOSCL THROM VAS, V18, P356, DOI 10.1161/01.ATV.18.3.356; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P1253, DOI 10.1161/01.ATV.13.9.1253; Dudman NPB, 1996, CLIN CHEM, V42, P2028; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Frantzen F, 1998, CLIN CHEM, V44, P311; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Garg UC, 1997, CLIN CHEM, V43, P141; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; HOPKINS PN, 1995, ARTERIOSCL THROM VAS, V15, P1314, DOI 10.1161/01.ATV.15.9.1314; KANG SS, 1988, AM J HUM GENET, V43, P414; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; Konecky N, 1997, AM HEART J, V133, P534, DOI 10.1016/S0002-8703(97)70148-0; Krans JP, 1998, EUR J PEDIATR, V157, pS50, DOI 10.1007/PL00014304; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Malik R, 1996, AUST VET PRACT, V26, P27; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Malinow MR, 1997, ARTERIOSCL THROM VAS, V17, P1157, DOI 10.1161/01.ATV.17.6.1157; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Markus HS, 1997, STROKE, V28, P1739, DOI 10.1161/01.STR.28.9.1739; MCCULLY KS, 1969, AM J PATHOL, V56, P111; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; Montalescot G, 1997, INT J CARDIOL, V60, P295, DOI 10.1016/S0167-5273(97)00099-5; MUDD SH, 1985, AM J HUM GENET, V37, P1; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Rasmussen K, 1996, CLIN CHEM, V42, P630; Ray JG, 1998, ARCH INTERN MED, V158, P2101, DOI 10.1001/archinte.158.19.2101; Refsum H, 1997, J INHERIT METAB DIS, V20, P286, DOI 10.1023/A:1005321225893; Ridker PM, 1997, CIRCULATION, V95, P1777; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; Savage D.G., 1995, FOLATE HLTH DIS, V1st, P237; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Still RA, 1998, J CLIN PATHOL, V51, P183, DOI 10.1136/jcp.51.3.183; UELAND PM, 1995, CLIN CHEM, V41, P340; vandenBerg M, 1996, ARTERIOSCL THROM VAS, V16, P165, DOI 10.1161/01.ATV.16.1.165; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1997, ARTERIOSCL THROM VAS, V17, P989, DOI 10.1161/01.ATV.17.5.989; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Welch GN, 1997, ANN NY ACAD SCI, V811, P48, DOI 10.1111/j.1749-6632.1997.tb51988.x; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350	66	765	812	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					407	413		10.1016/S0140-6736(98)11058-9	http://dx.doi.org/10.1016/S0140-6736(98)11058-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437885				2022-12-28	WOS:000081764900043
J	McKee, M; Britton, A; Black, N; McPherson, K; Sanderson, C; Bain, C				McKee, M; Britton, A; Black, N; McPherson, K; Sanderson, C; Bain, C			Interpreting the evidence: choosing between randomised and non-randomised studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONRANDOMIZED CLINICAL-TRIALS; DESIGN AFFECTS OUTCOMES; ARTERY BYPASS-SURGERY; EFFICACY; MORTALITY; THERAPY; METAANALYSIS; SELECTION; CHILDREN; DISEASE		Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Queensland, Sch Med, Brisbane, Qld 4006, Australia	University of London; London School of Hygiene & Tropical Medicine; University of Queensland	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	m.mckee@lshtm.ac.uk	Sanderson, Colin F/O-9877-2014; Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; Sanderson, Colin/0000-0002-4838-6112				[Anonymous], 1994, Am J Reprod Immunol, V32, P55; [Anonymous], 1984, J AM COLL CARDIOL, V3, P114; ANTMAN K, 1985, J CLIN ONCOL, V3, P1142, DOI 10.1200/JCO.1985.3.8.1142; Barofsky I., 1979, AM J CLIN ONCOL-CANC, V2, P237; Black N, 1996, BRIT MED J, V312, P1215; Britton A, 1998, HLTH TECHNOL ASSESS, V2; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DAVIES G, 1994, BRIT MED J, V309, P1553, DOI 10.1136/bmj.309.6968.1553; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; GARENNE M, 1993, AM J EPIDEMIOL, V138, P182, DOI 10.1093/oxfordjournals.aje.a116844; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HARTZ AJ, 1992, AM J CARDIOL, V70, P179, DOI 10.1016/0002-9149(92)91272-6; HAYNES RB, 1987, CONTROL CLIN TRIALS, V8, P12, DOI 10.1016/0197-2456(87)90021-3; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; HOLME I, 1995, AM J CARDIOL, V76, pC10, DOI 10.1016/S0002-9149(99)80465-2; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; HUNNINGHAKE DB, 1987, CONTROL CLIN TRIALS, V8, pS6; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; Jones RH, 1996, J THORAC CARDIOV SUR, V111, P1013, DOI 10.1016/S0022-5223(96)70378-1; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; MCKAY JR, 1995, J CONSULT CLIN PSYCH, V63, P70, DOI 10.1037/0022-006X.63.1.70; McPherson K, 1997, J ROY SOC MED, V90, P652, DOI 10.1177/014107689709001205; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; MILLER JN, 1989, STAT MED, V8, P455, DOI 10.1002/sim.4780080409; NICOLAIDES K, 1994, LANCET, V344, P435, DOI 10.1016/S0140-6736(94)91769-8; PARADISE JL, 1984, NEW ENGL J MED, V310, P674, DOI 10.1056/NEJM198403153101102; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; PYORALA S, 1995, J CLIN ENDOCR METAB, V80, P2795, DOI 10.1210/jc.80.9.2795; REIMOLD SC, 1992, AM HEART J, V124, P924, DOI 10.1016/0002-8703(92)90974-Z; Schmoor C, 1996, STAT MED, V15, P263, DOI 10.1002/(SICI)1097-0258(19960215)15:3<263::AID-SIM165>3.0.CO;2-K; Shapiro C L, 1994, J Natl Cancer Inst Monogr, P101; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; Stukenborg GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826, DOI 10.1001/archneur.1997.00550190018009; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; WATSON A, 1994, FERTIL STERIL, V61, P470; YAMAMOTO H, 1992, MAYO CLIN PROC, V67, P228, DOI 10.1016/S0025-6196(12)60097-4; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114	39	248	252	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	1999	319	7205					312	315		10.1136/bmj.319.7205.312	http://dx.doi.org/10.1136/bmj.319.7205.312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426754	Green Submitted, Green Published			2022-12-28	WOS:000081909100037
J	Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A				Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A			Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; SYNTHETIC LIPOPEPTIDE ANALOGS; TREPONEMA-PALLIDUM; CYTOKINE PRODUCTION; PATHWAY DISTINCT; MONOCYTIC CELLS; LIPOPOLYSACCHARIDE; GENE; FAMILY	Apoptosis is implicated in the generation and resolution of inflammation in response to bacterial pathogens. All bacterial pathogens produce lipoproteins (BLPs), which trigger the innate immune response. BLPs were found to induce apoptosis in THP-1 monocytic cells through human Toll-like receptor-2 (hTLR2). BLPs also initiated apoptosis in an epithelial cell line transfected with hTLR2. In addition, BLPs stimulated nuclear factor-kappa B, a transcriptional activator of multiple host defense genes, and activated the respiratory burst through hTLR2. Thus, hTLR2 is a molecular link between microbial products, apoptosis, and host defense mechanisms.	NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Genentech Inc, Antibody Technol Grp, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	New York University; New York University; Roche Holding; Genentech; Roche Holding; Genentech; University of Connecticut; University of Texas System; University of Texas Medical Branch Galveston	Zychlinsky, A (corresponding author), NYU, Sch Med, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714	NIAID NIH HHS [AI 37720-04, AI-38894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIPRANTIS AO, UNPUB; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bessler WG, 1997, INT J IMMUNOPHARMACO, V19, P547, DOI 10.1016/S0192-0561(97)00054-4; BESSLER WG, 1985, J IMMUNOL, V135, P1900; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Moss JE, 1999, INT REV CYTOL, V187, P203, DOI 10.1016/S0074-7696(08)62419-5; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Vidal V, 1998, NAT MED, V4, P1416, DOI 10.1038/4007; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG RG, UNPUB; Zhang HW, 1997, J IMMUNOL, V159, P4868; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	29	1228	1287	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					736	739		10.1126/science.285.5428.736	http://dx.doi.org/10.1126/science.285.5428.736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426996				2022-12-28	WOS:000081765100055
J	Shah, A; Torres, P; Tscharner, R; Wyrsch, N; Keppner, H				Shah, A; Torres, P; Tscharner, R; Wyrsch, N; Keppner, H			Photovoltaic technology: The case for thin-film solar cells	SCIENCE			English	Review							EFFICIENCY; SI; DEPOSITION; CONVERSION	The advantages and limitations of photovoltaic solar modules for energy generation are reviewed with their operation principles and physical efficiency limits. Although the main materials currently used or investigated and the associated fabrication technologies are individually described, emphasis is on silicon-based solar cells. Wafer-based crystalline silicon solar modules dominate in terms of production, but amorphous silicon solar cells have the potential to undercut costs owing, for example, to the roll-to-roll production possibilities for modules. Recent developments suggest that thin-film crystalline silicon (especially microcrystalline silicon) is becoming a prime candidate for future photovoltaics.	Univ Neuchatel, Inst Microtechnol, CH-2000 Neuchatel, Switzerland; Univ Appl Sci, CH-2400 Le Lode, Switzerland	University of Neuchatel	Torres, P (corresponding author), Univ Neuchatel, Inst Microtechnol, Rue AL Breguet 2, CH-2000 Neuchatel, Switzerland.		Wyrsch, Nicoals/N-5005-2014	Wyrsch, Nicolas/0000-0002-4588-0166				BARNETT AM, 1988, P 8 EUR PHOT SOL EN, P149; Basol B. M., 1994, AIP C SERIES, V306, P79; Bergmann R. B., 1999, 5 INT C SOL EN STOR; Bergmann RB, 1998, APPL PHYS LETT, V72, P2996, DOI 10.1063/1.121519; BRENDEL R, 1995, P 13 EUR PHOT SOL EN, P432; CARNANI M, 1997, P 14 EUR COMM PHOT S, P709; CHMIEL G, 1998, P 2 WORLD C EXH PHOT, P53; Chu T. L., 1992, P 11 EUR COMM PHOT S, P988; CONTRERAS M, IN PRESS PROG PV; CRANDALL R, 1995, PROG PHOTOVOLTAICS, V3, P315, DOI 10.1002/pip.4670030506; CURTINS H, 1987, PLASMA CHEM PLASMA P, V7, P267, DOI 10.1007/BF01016517; Dimmler B., 1998, P 2 WORLD C PHOT EN, P419; Folsch J, 1995, MRS S P, V377, P517; FORD DH, 1998, P 2 WORLD C PHOT SOL, P1205; FRIEDLMEIER TM, 1998, P 2 WORLD C PHOT SOL, P1117; FTHENAKIS VM, 1995, PROG PHOTOVOLTAICS, V3, P295, DOI 10.1002/pip.4670030504; Fuhs W., 1998, P 2 WORLD C PHOT SOL, P381; GIROULTMATIAKOW.G, 1998, P 2 WORLD C PV SOL E, P3403; Green M.A., 1982, SOLAR CELLS OPERATIN; Green MA, 1998, PROG PHOTOVOLTAICS, V6, P35, DOI 10.1002/(SICI)1099-159X(199801/02)6:1<35::AID-PIP205>3.0.CO;2-5; GREEN MA, 1994, APPL PHYS LETT, V65, P2907, DOI 10.1063/1.112526; GUHA S, 1981, J APPL PHYS, V52, P859, DOI 10.1063/1.328849; GUHA S, 1996, P 25 IEEE PVSC, P1017; HAGEDORN G, 1992, KUMLIERTER ENERGIEAU; HEBLING C, 1997, P 26 IEEE PHOT SPEC, P623; *INT EN AG, 1998, 106 PVPS INT EN AG; Kalejs J.P., 1998, P 2 WORLD C PV SOL E, P1822; KIESS H, 1995, SOL ENERG MAT SOL C, V38, P45, DOI 10.1016/0927-0248(94)00214-2; Loffl A., 1997, P 14 EUR PHOT SOL EN, P2089; Meier J, 1998, MATER RES SOC SYMP P, V507, P139, DOI 10.1557/PROC-507-139; Meier J, 1998, J NON-CRYST SOLIDS, V227, P1250, DOI 10.1016/S0022-3093(98)00352-4; MERTEN J, 1997, P 14 EUR PHOT SOL EN, P260; MORIMOTO H, 1984, JPN ANNU REV ELECTR, V16, P212; NAZEERUDDIN MK, 1993, J AM CHEM SOC, V115, P6382, DOI 10.1021/ja00067a063; Ohyama H., 1997, P 26 IEEE PHOT SPEC, P343; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; *PAC SOL PTY, 1998, ANN REV; RICCAUD A, 1994, P 12 EUR COMM PHOT S, P7; RIJNBERG JMK, 1998, P 2 WORLD C PV SOL E, P47; SAITO K, 1998, P 2 WORLD C PHOT SOL, P351; SAWADA T, 1994, P 1 WORLD C PHOT EN, P1219; SHAH AV, 1995, SOL ENERG MAT SOL C, V38, P501, DOI 10.1016/0927-0248(94)00241-X; STAEBLER DL, 1977, APPL PHYS LETT, V31, P292, DOI 10.1063/1.89674; Takahama T., 1992, P 11 EC PVSEC MONTR, P1057; Tayanaka H, 1998, P 2 WORLD C PHOT SOL, P1272; TORRES P, 1997, P 26 IEEE PHOT SPEC, P711; TORRES P, 1994, P 12 EUR COMM PHOT S, P132; TSUO YS, 1998, P 2 WORLD C PV SOL E, P119; ULLAL HS, 1997, P 26 IEEE PHOT SPEC, P1161; Wagemann H. -G., 1994, GRUNDLAGEN PHOTOVOLT; Wallace R. L., 1998, P 2 WCPVEC VIENN, P1818; WALLACE RL, 1997, P 26 IEEE PHOT SPEC, P99; WENHAM SR, 1994, P 1 WORLD C PHOT EN, P1234; Wennerberg J., 1998, P 2 WORLD C PHOT SOL, P1161; WITT CE, 1994, P 1 WORLD C PHOT EN, P2262; WOLFE PR, 1998, P 2 WORLD C PV SOL E, P1901; Yamamoto K, 1998, MATER RES SOC SYMP P, V507, P131, DOI 10.1557/PROC-507-131; Yang J, 1997, APPL PHYS LETT, V70, P2975, DOI 10.1063/1.118761; Zhao J., 1995, P 13 EUR PHOT SOL EN, P1566; Zhao JH, 1998, APPL PHYS LETT, V73, P1991, DOI 10.1063/1.122345	60	1006	1049	20	914	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					692	698		10.1126/science.285.5428.692	http://dx.doi.org/10.1126/science.285.5428.692			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426984	Green Submitted			2022-12-28	WOS:000081765100043
J	Edmonds, ME				Edmonds, ME			Progress in care of the diabetic foot	LANCET			English	Editorial Material							ULCERS		Univ London Kings Coll Hosp, Kings Diabet Ctr, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Edmonds, ME (corresponding author), Univ London Kings Coll Hosp, Kings Diabet Ctr, Denmark Hill, London SE5 9RS, England.							APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong D G, 1998, Clin Podiatr Med Surg, V15, P95; Edmonds M, 1994, FOOT DIABETES; EMBONDS M, 1996, DIABET MED S4, V13, pS27; Eneroth M, 1997, FOOT ANKLE INT, V18, P716, DOI 10.1177/107110079701801107; LARSSON J, 1995, DIABETIC MED, V12, P770, DOI 10.1111/j.1464-5491.1995.tb02078.x; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; Naughton G, 1997, ARTIF ORGANS, V21, P1203; PAPA J, 1993, J BONE JOINT SURG AM, V75A, P1056, DOI 10.2106/00004623-199307000-00012; POMPOSELLI FB, 1995, J VASC SURG, V21, P375, DOI 10.1016/S0741-5214(95)70279-2; Wieman TJ, 1998, AM J SURG, V176, P436, DOI 10.1016/S0002-9610(98)00235-9	11	35	35	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					270	272		10.1016/S0140-6736(99)90012-0	http://dx.doi.org/10.1016/S0140-6736(99)90012-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440300				2022-12-28	WOS:000081646000006
J	Vogt, T; Hasler, P				Vogt, T; Hasler, P			A woman with panic attacks and double vision who liked cheese	LANCET			English	Article							NEUROBRUCELLOSIS; BRUCELLOSIS		Univ Basel, Rheumatol Klin, Felix Platter Spital, CH-4012 Basel, Switzerland	University of Basel	Hasler, P (corresponding author), Univ Basel, Rheumatol Klin, Felix Platter Spital, CH-4012 Basel, Switzerland.		Telch, Michael J/E-7027-2010					ALDEEB SM, 1989, NEUROLOGY, V39, P498, DOI 10.1212/WNL.39.4.498; Krystkowiak P, 1997, REV NEUROL, V153, P781; MILLER DH, 1987, NEURORADIOLOGY, V29, P226, DOI 10.1007/BF00451758; Oliveri RL, 1996, CLIN INFECT DIS, V23, P833, DOI 10.1093/clinids/23.4.833; Solera J, 1997, DRUGS, V53, P245, DOI 10.2165/00003495-199753020-00005	5	4	4	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					300	300		10.1016/S0140-6736(99)04040-4	http://dx.doi.org/10.1016/S0140-6736(99)04040-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440308				2022-12-28	WOS:000081646000014
J	Rial, JA				Rial, JA			Pacemaking the ice ages by frequency modulation of Earth's orbital eccentricity	SCIENCE			English	Article							CLIMATE	Evidence from power spectra of deep-sea oxygen isotope time series suggests that the climate system of Earth responds nonlinearly to astronomical forcing by frequency modulating eccentricity-related variations in insolation. With the help of a simple model, it is shown that frequency modulation of the approximate 100,000-year eccentricity cycles by the 413,000-year component accounts for the variable duration of the ice ages, the multiple-peak character of the time series spectra, and the notorious absence of significant spectral amplitude at the 413,000-year period. The observed spectra are consistent with the classic Milankovitch theories of insolation, so that climate forcing by 100,000-year variations in orbital inclination that cause periodic dust accretion appear unnecessary.	Univ N Carolina, Dept Geol Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Wave Propagat Lab, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rial, JA (corresponding author), Univ N Carolina, Dept Geol Sci, Chapel Hill, NC 27599 USA.							BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BERGER A, 1978, CONTRIBUTION U CATHO, V35; BERGER WH, 1994, GEOLOGY, V22, P463, DOI 10.1130/0091-7613(1994)022<0463:QTSFTO>2.3.CO;2; BERGER WH, 1993, P OCEAN DRILLING PRO, V0130; GHIL M, 1987, TOPICS GEOPHYSICAL F; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; HUND A, 1942, FREQUENCY MODULATION; IMBRIE J, 1980, SCIENCE, V207, P943, DOI 10.1126/science.207.4434.943; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; KALLEN E, 1979, J ATMOS SCI, V36, P2292, DOI 10.1175/1520-0469(1979)036<2292:FOIACM>2.0.CO;2; LATHI BP, 1998, MODERN DIGITAL ANALO; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Milankovitch M., 1941, ROYAL SERBIAN ACAD S, V132; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P371, DOI 10.2973/odp.proc.sr.138.120.1995; Mix A.C., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V138, P839, DOI 10.2973/odp.proc.sr.138.160.1995; MULIN T, 1993, NATURE CHAOS; Muller RA, 1997, SCIENCE, V277, P215, DOI 10.1126/science.277.5323.215; PARK J, 1993, J GEOPHYS RES-SOL EA, V98, P447, DOI 10.1029/92JB01815; PIPES LA, 1970, APPL MATH ENG PHYSIC; Raymo ME, 1997, PALEOCEANOGRAPHY, V12, P577, DOI 10.1029/97PA01169; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782	21	83	95	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					564	568		10.1126/science.285.5427.564	http://dx.doi.org/10.1126/science.285.5427.564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417382				2022-12-28	WOS:000081609500032
J	Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E				Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E			Integrators of the cytoskeleton that stabilize microtubules	CELL			English	Article							NEUROLOGIC DEGENERATION; INTERMEDIATE FILAMENTS; NERVOUS-SYSTEM; LIVING CELLS; MUTANT MICE; TAU-PROTEIN; ORGANIZATION; GENE; EXPRESSION; PLECTIN	Sensory neurodegeneration occurs in mice defective in BPAG1, a gene encoding cytoskeletal linker proteins capable of anchoring neuronal intermediate filaments to actin cytoskeleton. While BPAG1 null mice fail to anchor neurofilaments (NFs), BPAG1/NF null mice still degenerate in the absence of NFs. We report a novel neural splice form that lacks the actin-binding domain and instead binds and stabilizes microtubules. This interaction is functionally important; in mice and in vitro, neurons lacking BPAG1 display short, disorganized, and unstable microtubules defective in axonal transport. Ironically, BPAG1 neural isoforms represent microtubule-associated proteins that when absent lead to devastating consequences. Moreover, BPAG1 can functionally account for the extraordinary stability of axonal microtubules necessary for transport over long distances. Its isoforms interconnect all three cytoskeletal networks, a feature apparently central to neuronal survival.	Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Neurol, Chicago, IL 60637 USA; McGill Univ, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago; McGill University	Fuchs, E (corresponding author), Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR27883] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; BAAS PW, 1994, J CELL SCI, V107, P135; BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; Bernier G, 1995, MOL CELL NEUROSCI, V6, P509, DOI 10.1006/mcne.1995.0003; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dalpe G, 1998, MOL CELL NEUROSCI, V10, P243, DOI 10.1006/mcne.1997.0660; Dowling J, 1997, DEV BIOL, V187, P131, DOI 10.1006/dbio.1997.8567; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Eyer J, 1998, NATURE, V391, P584, DOI 10.1038/35378; Gimona M, 1998, CURR BIOL, V8, pR674; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MORRIS JR, 1982, J CELL BIOL, V92, P192, DOI 10.1083/jcb.92.1.192; NAGELE RG, 1988, BRAIN RES, V474, P279, DOI 10.1016/0006-8993(88)90441-6; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	36	157	162	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					229	238		10.1016/S0092-8674(00)81017-X	http://dx.doi.org/10.1016/S0092-8674(00)81017-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428034	Bronze			2022-12-28	WOS:000081632300012
J	Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK				Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK			Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; MAMMALIAN LIPOXYGENASES; PERITONEAL-MACROPHAGES; HUMAN 15-LIPOXYGENASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; OXIDIZED LDL; CD36; FIBROBLASTS	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-dependent nuclear receptor that has been implicated in the modulation of critical aspects of development and homeostasis, including adipocyte differentiation(1), glucose metabolism(2,3) and macrophage development and function(4-6). PPAR-gamma is activated by a range of synthetic and naturally occurring substances, including antidiabetic thiazolidinediones(2,3), polyunsaturated fatty acids(7), 15-deoxy-Delta(12,14)prostaglandin J(2) (refs 8, 9) and components of oxidized low-density lipoprotein, such as 13-hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatetraenoic acid (15-HETE)(10), However, the identities of endogenous ligands for PPAR-gamma and their means of production in vivo have not been established. In monocytes and macrophages, 13-HODE and 15-HETE can be generated from linoleic and arachidonic acids, respectively, by a 12/15-lipoxygenase that is upregulated by the T(H)2-derived cytokine interleukin-4 (ref. 11). Here we show that interleukin-4 also induces the expression of PPAR-gamma and provide evidence that the coordinate induction of PPAR-gamma and 12/15-lipoxygenase mediates interleukin-4-dependent transcription of the CD36 gene in macrophages. These findings reveal a physiological role of 12/15-lipoxygenase in the generation of endogenous ligands for PPAR-gamma, and suggest a paradigm for the regulation of nuclear receptor function by cytokines.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Nephrol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline; University of Pennsylvania	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Ricote, Mercedes/L-4615-2014; Glass, Christopher/AAI-3933-2021; Funk, Colin D/A-9518-2010; feinstein, doug/M-9414-2019	Ricote, Mercedes/0000-0002-8090-8902; Glass, Christopher/0000-0003-4344-3592; Binder, Christoph J./0000-0001-8313-7050; Funk, Colin/0000-0001-7029-4233				BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KILEWER SA, 1995, CELL, V83, P813; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; RANKIN SM, 1991, J LIPID RES, V32, P449; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	30	740	774	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					378	382		10.1038/22572	http://dx.doi.org/10.1038/22572			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432118				2022-12-28	WOS:000081590000054
J	Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL				Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL			Therapy of tuberculosis in mice by DNA vaccination	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; INTERLEUKIN-12; EXPRESSION; INFECTION; IMMUNITY; IL-12; RESISTANCE; ANTIGEN; MPT70	Mycobacterium tuberculosis continues to kill about 3 million people every year(1), more than any other single infectious agent, This is attributed primarily to an inadequate immune response towards infecting bacteria, which suffer growth inhibition rather than death and subsequently multiply catastrophically. Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has major limitations as a preventative measure(2), In addition, effective treatment requires that patients take large doses of antibacterial drug combinations for at least 6 months after diagnosis(3), which is difficult to achieve in many parts of the world and is further restricted by the emergence of multidrug-resistant strains of M. tuberculosis, In these circumstances, immunotherapy to boost the efficiency of the immune system in infected patients could be a valuable adjunct to antibacterial chemotherapy(4), Here we show in mice that DNA vaccines, initially designed to prevent infection, can also have a pronounced therapeutic action, In heavily infected mice, DNA vaccinations can switch the immune response from one that is relatively inefficient and gives bacterial stasis to one that kills bacteria, Application of such immunotherapy in conjunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certain cure of the disease in humans.	Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, BR-14049900 Ribeirao Preto, SP, Brazil; Natl Inst Med Res, Mycobacteriol Res Lab, London NW7 1AA, England; Cent Vet Lab, Addlestone KT15 3NB, Surrey, England; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Universidade de Sao Paulo; Universidade de Sao Paulo; MRC National Institute for Medical Research; University of Zurich	Silva, CL (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil.	clsilva@beverly.fmrp.usp.br	Hewinson, Glyn/AAA-2364-2019; Silva, Celio/C-4639-2012; Hewinson, Glyn/J-1902-2014; Lowrie, Douglas/B-8151-2013; Hewinson, Glyn/F-7077-2010; Lucia, Faccioli/G-8976-2015; de Lima, Valéria M.F./B-7867-2013; Bonato, Vania LD/C-3509-2015; Faccioli, Lúcia Helena/AGH-5297-2022	Silva, Celio/0000-0002-0043-4568; Lowrie, Douglas/0000-0003-2689-9627; Lucia, Faccioli/0000-0002-4999-8305; de Lima, Valéria M.F./0000-0002-0954-5045; Bonato, Vania LD/0000-0003-4189-2685; Faccioli, Lúcia Helena/0000-0002-4999-8305; Hewinson, Glyn/0000-0002-5517-4281				ALLAN WGL, 1982, TUBERCLE, V63, P89; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Bloom Barry R., 1994, P531; Bonato VLD, 1998, INFECT IMMUN, V66, P169, DOI 10.1128/IAI.66.1.169-175.1998; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; de Jong R, 1998, SCIENCE, V280, P1435; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FLYNN JL, 1995, J IMMUNOL, V155, P2515; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Johnston SA, 1997, VACCINE, V15, P808, DOI 10.1016/S0264-410X(96)00276-9; KOCHI A, 1994, LANCET, V344, P608; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lai WC, 1997, J IMMUNOL, V158, P2513; Lowrie DB, 1997, VACCINE, V15, P834, DOI 10.1016/S0264-410X(97)00073-X; MATSUMOTO S, 1995, SCAND J IMMUNOL, V41, P281, DOI 10.1111/j.1365-3083.1995.tb03565.x; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; ORME IM, 1993, J IMMUNOL, V151, P518; SCHULTZ J, IN PRESS HUM GENE TH; Smith P. G., 1994, P47; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tascon RE, 1997, NATO ADV SCI I A-LIF, V293, P181; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; WIEGESHAUS E, 1989, INFECT IMMUN, V57, P3671, DOI 10.1128/IAI.57.12.3671-3676.1989; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; ZHANG M, 1995, INFECT IMMUN, V63, P3231, DOI 10.1128/IAI.63.8.3231-3234.1995; Zhu XJ, 1997, J IMMUNOL, V158, P5921	30	372	425	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					269	271		10.1038/22326	http://dx.doi.org/10.1038/22326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421369				2022-12-28	WOS:000081503800045
J	Smith, JM				Smith, JM			Too good to be true	NATURE			English	Editorial Material									Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Smith, JM (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.							CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; CRICK FHC, 1957, P NATL ACAD SCI USA, V43, P416, DOI 10.1073/pnas.43.5.416	2	2	2	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					223	223		10.1038/22238	http://dx.doi.org/10.1038/22238			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421359	Bronze			2022-12-28	WOS:000081503800030
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1962: Francis Harry Compton Crick (b 1916); James Dewey Watson (b 1928); Maurice Hugh Frederick Wilkins (b 1916)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	1	1	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					171	171		10.1016/S0140-6736(05)75311-3	http://dx.doi.org/10.1016/S0140-6736(05)75311-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408525				2022-12-28	WOS:000081377100072
J	Todd, JA				Todd, JA			Interpretation of results from genetic studies of multifactorial diseases	LANCET			English	Article							ALZHEIMER-DISEASE; INSULIN GENE		Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England	University of Cambridge	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust-MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Todd, John/A-3542-2010	Todd, John/0000-0003-2740-8148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altshuler D, 1998, NEW ENGL J MED, V338, P1626, DOI 10.1056/NEJM199805283382214; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Blacker D, 1998, ARCH NEUROL-CHICAGO, V55, P294, DOI 10.1001/archneur.55.3.294; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bonn D, 1999, LANCET, V353, P1684, DOI 10.1016/S0140-6736(05)76995-6; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; CUCCA F, 1996, HLA MHC GENES MOL FU, P3483; DAY N, IN PRESS BR J CANC S; Dow DJ, 1999, NAT GENET, V22, P16, DOI 10.1038/8724; Golding J, 1990, West Engl Med J, V105, P80; Rogaeva EA, 1999, NAT GENET, V22, P19, DOI 10.1038/8729; Rudrasingham V, 1999, NAT GENET, V22, P17, DOI 10.1038/8726; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; TODD JA, IN PRESS METABOLIC M; 1999, NAT GENET, V22, P1	17	21	21	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI15	SI16						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437850				2022-12-28	WOS:000081825900005
J	Rennie, AC; McGregor-Schuerman, M; Dale, IM; Robinson, C; McWilliam, R				Rennie, AC; McGregor-Schuerman, M; Dale, IM; Robinson, C; McWilliam, R			Mercury poisoning after spillage at home from a sphygmomanometer on loan from hospital	BRITISH MEDICAL JOURNAL			English	Article									Yorkhill NHS Trust, Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland; Law Hosp, Carluke ML8 5ER, Lanark, Scotland; Glasgow Occupat Hlth, Glasgow G1 1JA, Lanark, Scotland	University of Glasgow	Rennie, AC (corresponding author), Yorkhill NHS Trust, Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland.							Bonhomme C, 1996, LANCET, V347, P115, DOI 10.1016/S0140-6736(96)90239-1; CLOAREC S, 1995, ARCH PEDIATRIE, V2, P43, DOI 10.1016/0929-693X(96)89808-3; McClanahan MA, 1996, LANCET, V347, P1044, DOI 10.1016/S0140-6736(96)90182-8; MCNEIL NI, 1984, LANCET, V1, P269; SWAIMAN KF, 1971, PEDIATRICS, V48, P639	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					366	367		10.1136/bmj.319.7206.366	http://dx.doi.org/10.1136/bmj.319.7206.366			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435962	Green Published			2022-12-28	WOS:000082001700023
J	Nakariakov, VM; Ofman, L; DeLuca, EE; Roberts, B; Davila, JM				Nakariakov, VM; Ofman, L; DeLuca, EE; Roberts, B; Davila, JM			TRACE observation of damped coronal loop oscillations: Implications for coronal heating	SCIENCE			English	Article							RESONANT ABSORPTION; ALFVEN WAVES; SOLAR CORONA; SCALING LAWS; DRIVEN	The imaging telescope on board the Transition Region and Coronal Explorer (TRACE) spacecraft observed the decaying transversal oscillations of a Long [(130 +/- 6) x 10(6) meters], thin [diameter (2.0 +/- 0.36) x 10(6) meters], bright coronal Loop in the 171 angstrom Fe-IX emission line. The oscillations were excited by a solar flare in the adjacent active region. The decay time of the oscillations is 14.5 +/- 2.7 minutes for an oscillation with a frequency 3.90 +/- 0.13 millihertz, The coronal dissipation coefficient is estimated to be eight to nine orders of magnitude Larger than the theoretically predicted classical value. The larger dissipation coefficient may solve existing difficulties with wave heating and reconnection theories.	NASA, Goddard Space Flight Ctr, Raytheon ITSS, Greenbelt, MD 20771 USA; Univ St Andrews, Sch Math & Computat Sci, St Andrews KY16 9SS, Fife, Scotland; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of St Andrews; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Ofman, L (corresponding author), NASA, Goddard Space Flight Ctr, Raytheon ITSS, 682, Greenbelt, MD 20771 USA.		Nakariakov, Valery/S-7760-2019; Nakariakov, Valery M/E-2375-2013; DeLuca, Edward E/L-7534-2013	Nakariakov, Valery/0000-0001-6423-8286; Nakariakov, Valery M/0000-0001-6423-8286; DeLuca, Edward E/0000-0001-7416-2895; Ofman, Leon/0000-0003-0602-6693				ASCHWANDEN MJ, IN PRESS ASTROPHYS J; BERGHMANS D, 1995, ASTROPHYS J, V453, P495, DOI 10.1086/176410; DAVILA JM, 1987, ASTROPHYS J, V317, P514, DOI 10.1086/165295; EDWIN PM, 1983, SOL PHYS, V88, P179, DOI 10.1007/BF00196186; GOLUB L, 1997, SOLAR CORONA, P219; GOLUB L, IN PRESS REV PLASMA; Handy BN, 1998, SOL PHYS, V183, P29, DOI 10.1023/A:1005079622620; HEYVAERTS J, 1983, ASTRON ASTROPHYS, V117, P220; HOLLWEG JV, 1988, J GEOPHYS RES, V93, P5423, DOI 10.1029/JA093iA06p05423; IONSON JA, 1978, ASTROPHYS J, V226, P650, DOI 10.1086/156648; KAPPRAFF JM, 1977, J PLASMA PHYS, V18, P209, DOI 10.1017/S0022377800021012; KARPEN JT, 1994, ASTROPHYS J, V421, P372, DOI 10.1086/173655; Leontovich M., 1965, REV PLASMA PHYS; OFMAN L, 1995, ASTROPHYS J, V444, P471, DOI 10.1086/175621; OFMAN L, 1995, J GEOPHYS RES-SPACE, V100, P23427, DOI 10.1029/95JA01907; OFMAN L, 1994, GEOPHYS RES LETT, V21, P2259, DOI 10.1029/94GL01416; OFMAN L, 1994, ASTROPHYS J, V421, P360, DOI 10.1086/173654; Ofman L, 1996, ASTRON ASTROPHYS, V308, P631; PARKER EN, 1983, ASTROPHYS J, V264, P642, DOI 10.1086/160637; POEDTS S, 1991, PHYS REV LETT, V66, P2871, DOI 10.1103/PhysRevLett.66.2871; ROBERTS B, 1983, NATURE, V305, P688, DOI 10.1038/305688a0; ROBERTS B, 1984, ASTROPHYS J, V279, P857, DOI 10.1086/161956; SCHRIJVER CJ, IN PRESS SOL PHYS; SPITZER L, 1962, PHYSICS FULLY IONIZE; STEINOLFSON RS, 1993, ASTROPHYS J, V415, P354, DOI 10.1086/173169; Tirry WJ, 1996, ASTROPHYS J, V471, P501, DOI 10.1086/177986	26	761	769	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					862	864		10.1126/science.285.5429.862	http://dx.doi.org/10.1126/science.285.5429.862			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436148				2022-12-28	WOS:000081860900040
J	Sort, P; Navasa, M; Arroyo, V; Aldeguer, X; Planas, R; Ruiz-del-Arbol, L; Castells, L; Vargas, V; Soriano, G; Guevara, M; Gines, P; Rodes, J				Sort, P; Navasa, M; Arroyo, V; Aldeguer, X; Planas, R; Ruiz-del-Arbol, L; Castells, L; Vargas, V; Soriano, G; Guevara, M; Gines, P; Rodes, J			Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENIN-ANGIOTENSIN SYSTEM; HEPATORENAL-SYNDROME; REFRACTORY ASCITES; PREDICTIVE FACTORS; SEPTIC SHOCK; CEFOTAXIME; PARACENTESIS; LIVER; INTERLEUKIN-6; HEMODYNAMICS	Background In patients with cirrhosis and spontaneous bacterial peritonitis, renal function frequently becomes impaired. This impairment is probably related to a reduction in effective arterial blood volume and is associated with a high mortality rate. We conducted a study to determine whether plasma volume expansion with intravenous albumin prevents renal impairment and reduces mortality in these patients. Methods We randomly assigned 126 patients with cirrhosis and spontaneous bacterial peritonitis to treatment with intravenous cefotaxime (63 patients) or cefotaxime and intravenous albumin (63 patients). Cefotaxime was given daily in doses that varied according to the serum creatinine level, and albumin was given at a dose of 1.5 g per kilogram of body weight at the time of diagnosis, followed by 1 g per kilogram on day 3. Renal impairment was defined as nonreversible deterioration of renal function during hospitalization. Results The infection resolved in 59 patients in the cefotaxime group (94 percent) and 62 in the cefotaxime-plus-albumin group (98 percent) (P=0.36). Renal impairment developed in 21 patients in the cefotaxime group (33 percent) and 6 in the cefotaxime-plus-albumin group (10 percent) (P=0.002). Eighteen patients (29 percent) in the cefotaxime group died in the hospital, as compared with 6(10 percent) in the cefotaxime-plus-albumin group (P=0.01); at three months, the mortality rates were 41 percent (a total of 26 deaths) and 22 percent (a total of 14 deaths), respectively (P=0.03). Patients treated with cefotaxime had higher levels of plasma renin activity than those treated with cefotaxime and albumin; patients with renal impairment had the highest values. Conclusions In patients with cirrhosis and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an antibiotic reduces the incidence of renal impairment and death in comparison with treatment with an antibiotic alone. (N Engl J Med 1999;341:403-9.) (C) 1999, Massachusetts Medical Society.	Hosp Clin Barcelona, Inst Malalties Digest, Liver Unit, E-08036 Barcelona, Catalunya, Spain; Inst Invest Biomed August Pi Sunyer, Barcelona, Spain; Hosp Badalona Germans Trias & Pujol, Gastroenterol Unit, Badalona, Spain; Hosp Ramon & Cajal, Gastroenterol Unit, E-28034 Madrid, Spain; Hosp Gen Valle Hebron, Liver Unit, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Gastroenterol Unit, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Germans Trias i Pujol; Hospital Universitario Ramon y Cajal; Hospital Universitari Vall d'Hebron; Hospital of Santa Creu i Sant Pau	Arroyo, V (corresponding author), Hosp Clin Barcelona, Inst Malalties Digest, Liver Unit, Villarroel 170, E-08036 Barcelona, Catalunya, Spain.	arroyo@medicina.ub.es	Ginès, Pere/C-7730-2014; Navasa, Miquel/G-7958-2016; Arroyo, Vicente/F-9189-2015; Guevara, Monica/GSI-9124-2022; Vargas, Victor/AAD-3303-2020; Vargas Blasco, Victor Manuel/C-9711-2018	Ginès, Pere/0000-0003-4657-4504; Navasa, Miquel/0000-0002-3130-9604; Arroyo, Vicente/0000-0002-2728-1848; Vargas Blasco, Victor Manuel/0000-0002-7190-6948; castells, lluis/0000-0002-6672-5931; Soriano, German/0000-0002-9267-6811				[Anonymous], 1983, HEPATIC COMA SYNDROM; Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1053/jhep.1996.v23.ajhep0230164; ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; Arroyo V, 1999, OXFORD TXB CLIN HEPA, P733; ASBERT M, 1992, J HEPATOL, V15, P179, DOI 10.1016/0168-8278(92)90033-L; Bataller R, 1997, SEMIN LIVER DIS, V17, P233, DOI 10.1055/s-2007-1007201; BHATHAL PS, 1985, J HEPATOL, V1, P325, DOI 10.1016/S0168-8278(85)80770-4; FELISART J, 1985, HEPATOLOGY, V5, P457, DOI 10.1002/hep.1840050319; FOLLO A, 1994, HEPATOLOGY, V20, P1495, DOI 10.1002/hep.1840200619; GARCIATSAO G, 1993, HEPATOLOGY, V17, P1081, DOI 10.1016/0270-9139(93)90126-8; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; GINES P, 1990, HEPATOLOGY, V12, P716, DOI 10.1002/hep.1840120416; GRANGE JD, 1990, HEPATOLOGY, V11, P360, DOI 10.1002/hep.1840110305; LEMOINE O, 1994, J HEPATOL, V20, P819; Llovet JM, 1998, J HEPATOL, V28, P307, DOI 10.1016/0168-8278(88)80018-7; MOORE K, 1992, NEW ENGL J MED, V327, P1774, DOI 10.1056/NEJM199212173272502; Navasa M, 1996, GASTROENTEROLOGY, V111, P1011, DOI 10.1016/S0016-5085(96)70069-0; Navasa M, 1998, HEPATOLOGY, V27, P1227, DOI 10.1002/hep.510270507; Navasa W, 1999, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE, P538; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PELLETIER G, 1990, J HEPATOL, V10, P327, DOI 10.1016/0168-8278(90)90140-M; PINZANI M, 1992, J CLIN INVEST, V90, P642, DOI 10.1172/JCI115905; RIMOLA A, 1995, HEPATOLOGY, V21, P674, DOI 10.1002/hep.1840210312; RuizdelArbol L, 1997, GASTROENTEROLOGY, V113, P579, DOI 10.1053/gast.1997.v113.pm9247479; RUNYON BA, 1991, GASTROENTEROLOGY, V100, P1737, DOI 10.1016/0016-5085(91)90677-D; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; Such J, 1999, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE, P99; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TOLEDO C, 1993, HEPATOLOGY, V17, P251, DOI 10.1016/0270-9139(93)90085-2; VOERMAN HJ, 1992, CRIT CARE MED, V20, P1097, DOI 10.1097/00003246-199208000-00005; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624	33	1008	1059	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					403	409		10.1056/NEJM199908053410603	http://dx.doi.org/10.1056/NEJM199908053410603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10432325				2022-12-28	WOS:000081860100003
J	Essex, C				Essex, C			The pen is mightier than the sword	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					305	305		10.1136/bmj.319.7205.305	http://dx.doi.org/10.1136/bmj.319.7205.305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426750	Green Published			2022-12-28	WOS:000081909100033
J	Garfield, R				Garfield, R			Malaria control in Nicaragua: social and political influences on disease transmission and control activities	LANCET			English	Article							HEALTH	Throughout Central America, a traditional malaria control strategy (depending on heavy use of organic pesticides) became less effective during the 1970s. In Nicaragua, an alternative strategy, based on frequent local epidemiological assessments and community participation, was developed in the 1980s. Despite war-related social instability, and continuing vector resistance, this approach was highly successful. By the end of the contra wart there finally existed organisational and ecological conditions that favoured improved malaria control. Yet the expected improvements did not occur. In the 1990s, Nicaragua experienced its worst recorded malaria epidemics. This situation was partly caused by the country's macroeconomic structural adjustment programme. Volunteers now take fewer slides and provide less treatment, malaria control workers are less motivated by the spirit of public service, and some malaria control stations charge for diagnosis or treatment. To "roll back malaria", In Nicaragua at least, will require the roll-back of some erroneous aspects of structural adjustment.	Columbia Univ, Sch Nursing, New York, NY 10032 USA	Columbia University	Garfield, R (corresponding author), Columbia Univ, Sch Nursing, Box 6,630 W 168th St, New York, NY 10032 USA.							BRUCECHWATT LJ, 1966, B WORLD HEALTH ORGAN, V35, P405; BRUCECHWATT LJ, 1983, LANCET, V2, P688; Curtis E, 1998, LANCET, V352, P1622, DOI 10.1016/S0140-6736(98)03248-6; GABALDON A, 1978, AM J TROP MED HYG, V24, P653; GARFIELD R, 1993, JAMA-J AM MED ASSOC, V270, P989, DOI 10.1001/jama.270.8.989; GARFIELD RM, 1983, LANCET, V2, P500; GARFIELD RM, 1987, AM J PUBLIC HEALTH, V77, P615, DOI 10.2105/AJPH.77.5.615; GARFIELD RM, 1984, AM J PUBLIC HEALTH, V74, P1138, DOI 10.2105/AJPH.74.10.1138; GARFIELD RM, 1986, SOC SCI MED, V8, P869; GEORGHIOU GP, 1972, AM J TROP MED HYG, V21, P797, DOI 10.4269/ajtmh.1972.21.797; Harrison G, 1978, MOSQUITOES MALARIA M; MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743; *MIN SAL, 1982, EV IMP MOV NAC ANT N; *PAN AM HLTH ORG, 1985, STAT MAL CONTR PROGR; WERNSDORFER WH, 1980, MALARIA, V1; WHO, 1973, WHO TECH REP SER, V529; *WHO, 1974, WHO TECH REP SER, V537	17	26	27	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					414	418		10.1016/S0140-6736(99)02226-6	http://dx.doi.org/10.1016/S0140-6736(99)02226-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222CB	10437886	hybrid			2022-12-28	WOS:000081764900044
J	Samanta, A; Beardsley, J				Samanta, A; Beardsley, J			Sciatica: which intervention?	BRITISH MEDICAL JOURNAL			English	Review									Leicester Royal Infirm NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England		Samanta, A (corresponding author), Leicester Royal Infirm NHS Trust, Dept Rheumatol, Leicester LE1 5WW, Leics, England.							Carette S, 1997, NEW ENGL J MED, V336, P1634, DOI 10.1056/NEJM199706053362303; McCulloch JA, 1996, SPINE, V21, pS45, DOI 10.1097/00007632-199612151-00005; Nordby EJ, 1996, SPINE, V21, P1102, DOI 10.1097/00007632-199605010-00023; Saal JA, 1996, SPINE, V21, pS2, DOI 10.1097/00007632-199612151-00002; Sackett D. L., 1997, EVIDENCE BASED MED P; WATTS RW, 1995, ANAESTH INTENS CARE, V23, P564, DOI 10.1177/0310057X9502300506	6	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					302	303		10.1136/bmj.319.7205.302	http://dx.doi.org/10.1136/bmj.319.7205.302			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426748	Green Published			2022-12-28	WOS:000081909100031
J	Melville, M; Brown, N; Gray, D; Young, T; Hampton, J				Melville, M; Brown, N; Gray, D; Young, T; Hampton, J			Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Univ Nottingham, Dept Math, British Heart Fdn, Cardiovasc Stat Unit, Nottingham NG7 2RH, England	University of Nottingham; University of Nottingham	Melville, M (corresponding author), Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England.		Young, Tracey A/A-4543-2010	Young, Tracey/0000-0001-8467-0471				*BRIT CARD SOC, 1998, STRAT PLANN CARD SER; DEBONO DP, 1994, J ROY COLL PHYS LOND, V28, P312; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GREENWOOD D, 1995, SOC SCI MED, V40, P639, DOI 10.1016/0277-9536(94)00147-L; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					230	231		10.1136/bmj.319.7204.230	http://dx.doi.org/10.1136/bmj.319.7204.230			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	221HB	10417086	Bronze, Green Published			2022-12-28	WOS:000081720300025
J	Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP				Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP			Engrailed and hedgehog make the range of wingless asymmetric in Drosophila embryos	CELL			English	Article							MORPHOGEN GRADIENT; GENE-EXPRESSION; CELL FATE; EPIDERMIS; PROTEIN; ARMADILLO; EMBRYOGENESIS; BOUNDARIES; SECRETION; INDUCTION	In many instances, remote signaling involves the transport of secreted molecules. Here, we examine the spread of Wingless within the embryonic epidermis of Drosophila. Using two assays for Wingless activity (specification of naked cuticle and repression of rhomboid transcription), we found that Wingless acts at a different range in the anterior and posterior directions. We show that this asymmetry follows in part from differential distribution of the Wingless protein. Transport or stability is reduced within engrailed-expressing cells, and farther posteriorward Wingless movement is blocked at the presumptive segment boundary and perhaps beyond. We demonstrate the role of hedgehog in the formation of this barrier.	Natl Inst Med Res, London NW7 1AA, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, LMB, Cambridge CB2 2QH, England	MRC National Institute for Medical Research; University of Cambridge; MRC Laboratory Molecular Biology	Vincent, JP (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	jp.vincent@nimr.mrc.ac.uk		Sanson, Benedicte/0000-0002-2782-4195				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; Dierick HA, 1998, DEVELOPMENT, V125, P4729; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jowett T., 1997, TISSUE IN SITU HYBRI; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Martinez Arias Alfonso, 1993, P517; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PAYRE F, 1999, IN PRESS NATURE; PFEIFFER S, 1999, IN PRESS SEMIN DEV B; Pignoni F, 1997, DEVELOPMENT, V124, P271; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Szuts D, 1997, DEVELOPMENT, V124, P3209; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	67	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					207	216		10.1016/S0092-8674(00)81015-6	http://dx.doi.org/10.1016/S0092-8674(00)81015-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428032	Bronze			2022-12-28	WOS:000081632300010
J	Gubler, JGH; Kuster, M; Dutly, F; Bannwart, F; Krause, M; Vogelin, HP; Garzoli, G; Altwegg, M				Gubler, JGH; Kuster, M; Dutly, F; Bannwart, F; Krause, M; Vogelin, HP; Garzoli, G; Altwegg, M			Whipple endocarditis without overt gastrointestinal disease: Report of four cases	ANNALS OF INTERNAL MEDICINE			English	Article							TROPHERYMA-WHIPPELII; VALVE-REPLACEMENT; IDENTIFICATION; BACILLUS	Background: Cardiac manifestations of Whipple disease are rarely diagnosed before death. Objective: To describe four patients with endocarditis caused by Tropheryma whippelii who did not have overt gastrointestinal disease. Design: Case series. Setting: Five hospitals in eastern Switzerland. Patients: Three men and one woman undergoing replacement of insufficient heart valves. Measurements: Histologic characteristics of heart valves and intestinal biopsy; broad-range and specific polymerase chain reaction for T. whippelii. Results: Tropheryma whippelii was found in the heart valves (three aortic valves and one mitral valve) of four patients with culture-negative endocarditis necessitating valve replacement. All patients had arthralgia for different lengths of time. Only one patient had mild gastrointestinal symptoms. Histologic characteristics of intestinal mucosa were normal in all patients, and polymerase chain reaction on intestinal biopsy was positive for T. whippelii in only one patient, who did not have diarrhea, In all patients, arthralgia resolved promptly after institution of antibiotic therapy. Disease did not recur in any patient after prolonged antibiotic therapy with cotrimoxazole. Conclusion: In patients with culture-negative endocarditis, the absence of clinical, microscopic, or microbiological evidence of gastrointestinal disease did not rule out T, whippelii.	Stadtspital Triemli, Dept Med, CH-8063 Zurich, Switzerland; Univ Zurich, Dept Med Microbiol, CH-8028 Zurich, Switzerland; Kantonsspital, Dept Med, CH-8596 Munsterlingen, Switzerland; Kreisspital, Dept Med, CH-8180 Bulach, Switzerland; Schwerpunktspital Zimmerberg, CH-8820 Wadenswil, Switzerland; Stadtspital Triemli, Dept Pathol, CH-8063 Zurich, Switzerland	Triemli Hospital; University of Zurich; Kantonsspital Aarau AG (KSA); Triemli Hospital	Gubler, JGH (corresponding author), Stadtspital Triemli, Dept Med, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.							Altwegg M, 1996, SCHWEIZ MED WSCHR, V126, P1495; Dauga C, 1997, J MED MICROBIOL, V46, P340, DOI 10.1099/00222615-46-4-340; DETAKATS PG, 1995, POSTGRAD MED J, V71, P236, DOI 10.1136/pgmj.71.834.236; Durand DV, 1997, MEDICINE, V76, P170, DOI 10.1097/00005792-199705000-00003; ECTORS N, 1992, HISTOPATHOLOGY, V21, P1; Ehrbar HU, 1998, GASTROENTEROLOGY, V114, pA365, DOI 10.1016/S0016-5085(98)81479-0; FEURLE GE, 1979, NEW ENGL J MED, V300, P907, DOI 10.1056/NEJM197904193001607; Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733, DOI 10.1128/JCM.35.11.2733-2739.1997; HOEN B, 1995, CLIN INFECT DIS, V20, P501, DOI 10.1093/clinids/20.3.501; Jeserich M, 1997, ANN INTERN MED, V126, P920, DOI 10.7326/0003-4819-126-11-199706010-00029; Maiwald M, 1998, APPL ENVIRON MICROB, V64, P760; MCALLISTER HA, 1975, CIRCULATION, V52, P152, DOI 10.1161/01.CIR.52.1.152; Misbah SA, 1997, QJM-MON J ASSOC PHYS, V90, P765; Nishimura JK, 1998, AM J OPHTHALMOL, V126, P130, DOI 10.1016/S0002-9394(98)00084-1; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schneider T, 1998, INFECTION, V26, P178, DOI 10.1007/BF02771847; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; Silvestry FE, 1997, ANN INTERN MED, V126, P214, DOI 10.7326/0003-4819-126-3-199702010-00006; WENDLER D, 1995, EUR HEART J, V16, P424, DOI 10.1093/oxfordjournals.eurheartj.a060928; WRIGHT CB, 1978, ANN THORAC SURG, V25, P466, DOI 10.1016/S0003-4975(10)63589-8	20	80	83	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					112	116		10.7326/0003-4819-131-2-199907200-00007	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419427				2022-12-28	WOS:000081509700006
J	Onyebujoh, PC; Levin, JB; Fourie, FB; Garhiram, V; Tembe, LC; Phili, NP; Mthiyane, TCP; Moniwa, T; Bayer, G; Ramajoe, IM; Mncwabe, TAB; Mallisar, LGM; Saul, TNM; Levin, JB; Jackson, THFG; Suparsad, S; Fine, PEM; Pendlebury, DJS; Fine, E; Houghton, I; Clyde, J; Vos, HP; Padayatchi, N; Pala, A; Ramjee, A; Ramjee, M; Ramdeen, J; Masters, IH; Osbourne, G; Naidu, K; Bamba, S; Mazur, B; Czarnocki, R; Landers, K; Ndlovu, G; Maphumulo, N; Garhiram, V; Sturm, AW; Moodley, J; Pillay, C; Roux, L; Moodley, R; Sarawan, A; Jali, T; Manickam, F; Smith, A; Gopaul; Durosanmi, T; Moonsammy, R; Wyld, P; McCallum, J; Fulton, C; Bisset, K; Henderson, S; Stewart, D; Nticinka, O; Watson, D; Tuckwell, N; Kennard, D; Stanford, JL; Rook, GA; Grange, JM; Zumla, AA; Bateman, E; Hopwell, P; Darbyshire, J; Geiter, L; Nunn, A; Weyer, K				Onyebujoh, PC; Levin, JB; Fourie, FB; Garhiram, V; Tembe, LC; Phili, NP; Mthiyane, TCP; Moniwa, T; Bayer, G; Ramajoe, IM; Mncwabe, TAB; Mallisar, LGM; Saul, TNM; Levin, JB; Jackson, THFG; Suparsad, S; Fine, PEM; Pendlebury, DJS; Fine, E; Houghton, I; Clyde, J; Vos, HP; Padayatchi, N; Pala, A; Ramjee, A; Ramjee, M; Ramdeen, J; Masters, IH; Osbourne, G; Naidu, K; Bamba, S; Mazur, B; Czarnocki, R; Landers, K; Ndlovu, G; Maphumulo, N; Garhiram, V; Sturm, AW; Moodley, J; Pillay, C; Roux, L; Moodley, R; Sarawan, A; Jali, T; Manickam, F; Smith, A; Gopaul; Durosanmi, T; Moonsammy, R; Wyld, P; McCallum, J; Fulton, C; Bisset, K; Henderson, S; Stewart, D; Nticinka, O; Watson, D; Tuckwell, N; Kennard, D; Stanford, JL; Rook, GA; Grange, JM; Zumla, AA; Bateman, E; Hopwell, P; Darbyshire, J; Geiter, L; Nunn, A; Weyer, K		Durban Immunotherapy Trial Grp	Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial	LANCET			English	Article							CHEMOTHERAPY	Background Mycobacterium vaccae, an environmental saprophyte, has immunogenic properties that enhance the host immune response. Immunotherapy with M vaccae has been suggested to shorten short-course antituberculosis chemotherapy. We tested the hypothesis that the addition of M vaccae to standard short-course antituberculosis chemotherapy would decrease the time to achieve a negative sputum culture. Methods Patients with newly diagnosed tuberculosis were randomly assigned an injection of saline (placebo) or M vaccae on day 8. All patients received antituberculosis chemotherapy with rifampicin, isoniazid, pyrazinamide, and ethambutol. Sputum samples were checked by microscopy and culture every week for the first 8 weeks and monthly until the end of chemotherapy at 6 months. The primary outcome was the time to a negative sputum culture in the first 8 weeks. Intention-to-treat analysis was used and time to sputum clearance was assessed by log-rank test and Cox's proportional-hazards regression. Findings 172 patients received M vaccae and 175 patients received placebo. At 8 weeks, 70 patients in the M vaccae group and 65 patients in the placebo group had a negative culture; there was no difference between groups in the time to a negative culture (p=0.83). There was no interaction between HIV status and treatment. Interpretation M vaccae immunotherapy has no benefit when added to standard antituberculosis chemotherapy.	Reg Off, Durban, South Africa; London Sch Hyg & Trop Med, London WC1, England; King George V Mem Hosp, Durban, South Africa; Univ KwaZulu Natal, Sch Med, ZA-4001 Durban, South Africa; King Edward VIII Hosp, Durban, South Africa; Inveresk Clin Res, Edinburgh, Midlothian, Scotland; Stanford Rook Ltd, London, England; UCL, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Kwazulu Natal; University of London; University College London	Onyebujoh, PC (corresponding author), MRC, Natl TB Res Programme, Private Bag X385, ZA-0001 Pretoria, South Africa.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				[Anonymous], 1986, Am Rev Respir Dis, V134, P355; BAHR GM, 1990, TUBERCLE, V71, P259, DOI 10.1016/0041-3879(90)90038-A; BALASUBRAMANIAN R, 1990, TUBERCLE, V71, P253, DOI 10.1016/0041-3879(90)90037-9; Corlan E, 1997, RESP MED, V91, P13, DOI 10.1016/S0954-6111(97)90132-3; ETEMADI A, 1992, LANCET, V340, P1360, DOI 10.1016/0140-6736(92)92551-P; GRANGE JM, 1992, TUBERCLE LUNG DIS, V73, P249, DOI 10.1016/0962-8479(92)90128-7; KLEEBERG HH, 1985, B INT UNION TUBERC, V60, P147; KLEEBERG HH, 1980, LAB MANUAL TUBERCULO; MITCHISON DA, 1992, J ANTIMICROB CHEMOTH, V29, P477, DOI 10.1093/jac/29.5.477; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; ONYEBUJOH PC, 1995, RESP MED, V89, P199, DOI 10.1016/0954-6111(95)90248-1; POZIAK A, 1987, B IUALD, V62, P39; Ravioli, 1987, HLTH COOPERATION PAP, V7, P201; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; STANFORD JL, 1990, VACCINE, V8, P525, DOI 10.1016/0264-410X(90)90002-4; STANFORD JL, 1993, B IUTLD, V65, P27	16	70	71	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1999	354	9173					116	119						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408487				2022-12-28	WOS:000081377100014
J	Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW				Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW			Generation of GTP-bound Ran by RCC1 is required for chromatin-induced mitotic spindle formation	NATURE			English	Article							XENOPUS EGG EXTRACTS; MICROTUBULE-ASSOCIATED PROTEIN; SELF-ORGANIZATION; RESPECTIVE ROLES; IMPORT; CENTROSOMES; TRANSPORT; RANGAP1; NUCLEUS; MUTANTS	Chromosomes are segregated by two antiparallel arrays of microtubules arranged to form the spindle apparatus. During cell division, the nucleation of cytosolic microtubules is prevented and spindle microtubules nucleate from centrosomes (in mitotic animal cells) or around chromosomes (in plants and some meiotic cells)(1,2). The molecular mechanism by which chromosomes induce local microtubule nucleation in the absence of centrosomes is unknown(3-5), but it can be studied by adding chromatin beads to Xenopus egg extracts(6). The beads nucleate microtubules that eventually reorganize into a bipolar spindle. RCC1, the guanine-nucleotide-exchange factor for the GTPase protein Ran, is a component of chromatin. Using the chromatin bead assay, we show here that the activity of chromosome-associated RCC1 protein is required for spindle formation. Ran itself, when in the GTP-bound state (Ran-GTP), induces microtubule nucleation and spindle-like structures in M-phase extract. We propose that RCC1 generates a high local concentration of Ran-GTP around chromatin which in turn induces the local nucleation of microtubules.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Segref, Alexandra/C-8325-2011	Carazo-Salas, Rafael E/0000-0002-5943-3981; Segref, Alexandra/0000-0001-8095-4469; Mattaj, Iain/0000-0002-5537-8284				Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DOMINGUEZ JE, 1994, J CELL SCI, V107, P601; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Hyman A, 1998, J CELL SCI, V111, P2077; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LEPAULT J, 1986, METHOD ENZYMOL, V127, P719; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pu RT, 1997, MOL BIOL CELL, V8, P1955, DOI 10.1091/mbc.8.10.1955; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673	30	386	392	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					178	181		10.1038/22133	http://dx.doi.org/10.1038/22133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408446				2022-12-28	WOS:000081324900057
J	Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A				Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A			Chlorophyll b and phycobilins in the common ancestor of cyanobacteria and chloroplasts	NATURE			English	Article							MULTIPLE EVOLUTIONARY ORIGINS; A/B; PROCHLOROPHYTES; PROTEINS; PLANTS; ANTENNA; ALGA	Photosynthetic organisms have a variety of accessory pigments, on which their classification has been based. Despite this variation, it is generally accepted that all chloroplasts are derived from a single cyanobacterial ancestor(1-3). How the pigment diversity has arisen is the key to revealing their evolutionary history. Prochlorophytes are prokaryotes which perform oxygenic photosynthesis using chlorophyll b, like land plants and green algae (Chlorophyta), and were proposed to be the ancestors of chlorophyte chloroplasts(4,5). However, three known prochlorophytes (Prochloron didemni, Prochlorothrix hollandica and Prochlorococcus marinus) have been shown to be not the specific ancestors of chloroplasts, but only diverged members of the cyanobacteria, which contain phycobilins but lack chlorophyll b(6,7). Consequently it has been proposed that the ability to synthesize chlorophyll b developed independently several times in prochlorophytes and in the ancestor of chlorophytes. Here we have isolated the chlorophyll b synthesis genes (chlorophyll a oxygenase)(8) from two prochlorophytes and from major groups of chlorophytes. Phylogenetic analyses show that these genes share a common evolutionary origin. This indicates that the progenitors of oxygenic photosynthetic bacteria, including the ancestor of chloroplasts, had both chlorophyll b and phycobilins.	Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan; Kamaishi Labs, Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan; Univ Amsterdam, Dept Microbiol, NL-1018 WS Amsterdam, Netherlands; Kyoto Univ, Kyoto Univ Museum, Kyoto 6068502, Japan	Kyoto University; Hokkaido University; Kyoto University; University of Amsterdam; Kyoto University	Tomitani, A (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan.	tomitani@terra.kueps.kyoto-u.ac.jp	Matthijs, Hans/B-4503-2009; Tanaka, Ayumi/D-9003-2012					Adachi J., 1996, COMPUTER SCI MONOGRA, V28; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BHATTACHARYYA A, 1995, PHYS ESSAYS, V8, P3, DOI 10.4006/1.3036517; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; DELWICHE CF, 1997, ORIGINS ALGAE THEIR, P53; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; Hess WR, 1996, P NATL ACAD SCI USA, V93, P11126, DOI 10.1073/pnas.93.20.11126; Kaneko T, 1996, DNA Res, V3, P109; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LEWIN RA, 1975, NATURE, V256, P735, DOI 10.1038/256735a0; LEWIN RA, 1976, NATURE, V261, P697, DOI 10.1038/261697b0; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; Rudiger W, 1999, NATO ASI 3 HIGH TECH, V64, P185; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Tan S, 1997, PLANT MOL BIOL, V33, P157, DOI 10.1023/A:1005715528297; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0; WOLFE GR, 1994, NATURE, V367, P566, DOI 10.1038/367566a0	25	154	172	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					159	162		10.1038/22101	http://dx.doi.org/10.1038/22101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408441				2022-12-28	WOS:000081324900052
J	Kaltiala-Heino, R; Rimpela, M; Marttunen, M; Rimpela, A; Rantanen, P				Kaltiala-Heino, R; Rimpela, M; Marttunen, M; Rimpela, A; Rantanen, P			Bullying, depression, and suicidal ideation in Finnish adolescents: school survey	BRITISH MEDICAL JOURNAL			English	Article							VICTIM PROBLEMS; CHILDREN; MIDDLE; INVENTORY; STABILITY; BULLIES	Objective To assess the relation between being bullied or being a bully at school, depression, and severe suicidal ideation. Design A school based survey of health, health behaviour, and behaviour in school which included questions about bullying and the Beck depression inventory, which includes items asking about suicidal ideation. Setting Secondary schools in two regions of Finland. Participants 16 410 adolescents aged 14-16. Results There was an increased prevalence of depression and severe suicidal ideation among both those who were bullied and those who were bullies. Depression was equally likely to occur among those who were bullied and those who were bullies. It was most common among those students who were both bullied by others and who were also bullies themselves. When symptoms of depression were controlled for, suicidal ideation occurred most often among adolescents who were bullies. Conclusion Adolescents who are being bullied and those who are bullies are at an increased risk of depression and suicide. The need for psychiatric intervention should be considered not only for victims of bullying but also for bullies.	Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, Helsinki 00531, Finland; Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, SF-00300 Helsinki, Finland; Tampere Univ Hosp, Dept Adolescent Psychiat, Tampere 33521, Finland	Tampere University; Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital	Kaltiala-Heino, R (corresponding author), Univ Tampere, Tampere Sch Publ Hlth, Box 607, FIN-33101 Tampere, Finland.		Rimpela, Arja/J-3910-2014; Kaltiala, Riittakerttu/T-9411-2019	Kaltiala, Riittakerttu/0000-0002-2783-3892				BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BECK AT, 1974, PSYCHOL REP, V34, P1184; Bennett DS, 1997, J AFFECT DISORDERS, V45, P127, DOI 10.1016/S0165-0327(97)00045-1; BOULTON MJ, 1994, BRIT J DEV PSYCHOL, V12, P315, DOI 10.1111/j.2044-835X.1994.tb00637.x; BOULTON MJ, 1992, BRIT J EDUC PSYCHOL, V62, P73, DOI 10.1111/j.2044-8279.1992.tb01000.x; BOWERS L, 1994, J SOC PERS RELAT, V11, P215, DOI 10.1177/0265407594112004; BYRNE BJ, 1994, IRISH J PSYCHOL, V15, P574, DOI 10.1080/03033910.1994.10558031; CHARMAN T, 1994, J AFFECT DISORDERS, V30, P109, DOI 10.1016/0165-0327(94)90038-8; KALTIALAHEINO R, IN PRESS NORD J PSYC; King A, 1996, EUROPEAN SERIES; KUMPULAINEN K, IN PRESS CHILD ABUSE; PERRY DG, 1988, DEV PSYCHOL, V24, P807, DOI 10.1037/0012-1649.24.6.807; Raitasalo R, 1995, ELAMANHALLINTA SOSIA; Rapoport J.I., 1994, CHILD ADOLESCENT PSY; REINHERZ HZ, 1995, J AM ACAD CHILD PSY, V34, P599, DOI 10.1097/00004583-199505000-00012; RIGBY K, 1993, J SOC PSYCHOL, V133, P33, DOI 10.1080/00224545.1993.9712116; RUTTERM, 1995, PSYCHOSOCIAL DISTURB; SALMIVALLI C, 1998, NOT ONLY BULLIES VIC; Salmon G, 1998, BRIT MED J, V317, P924; SLEE PT, 1993, CHILD PSYCHIAT HUM D, V23, P273, DOI 10.1007/BF00707680; Slee PT., 1995, INT J ADOLESCENCE YO, V5, P215, DOI [DOI 10.1080/02673843.1995.9747767, 10.1080/02673843.1995.9747767]; WHITNEY I, 1993, EDUC RES, V35, P3, DOI 10.1080/0013188930350101; Williams K, 1996, BRIT MED J, V313, P17, DOI 10.1136/bmj.313.7048.17	23	452	469	6	118	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					348	351		10.1136/bmj.319.7206.348	http://dx.doi.org/10.1136/bmj.319.7206.348			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	226CA	10435954	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000082001700017
J	Moszynski, P				Moszynski, P			United Nations estimates of HIV prevalence in Zambia under attack	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					338	338		10.1136/bmj.319.7206.338	http://dx.doi.org/10.1136/bmj.319.7206.338			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435948	Green Published			2022-12-28	WOS:000082001700012
J	Farrell, Z; O'Neill, D				Farrell, Z; O'Neill, D			Towards better screening and assessment of oropharyngeal swallow disorders in the general hospital	LANCET			English	Editorial Material							ASPIRATION; STROKE		Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland; Adelaide & Meath Hosp Dublin, Dept Age Related Hlth Care, Dublin 24, Ireland	Trinity College Dublin; Trinity College Dublin	Farrell, Z (corresponding author), Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				*AG HLTH CAR POL R, 1999, 99E023 ACHPR AG HLTH; Bastian Robert W., 1993, Dysphagia, V8, P359, DOI 10.1007/BF01321780; COLLINS DR, 1996, CLIN INTENSIVE CARE, V7, P315; Collins MJ, 1997, STROKE, V28, P1773, DOI 10.1161/01.STR.28.9.1773; DEPIPPO KL, 1994, ARCH PHYS MED REHAB, V75, P1284; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; Leder SB, 1997, DYSPHAGIA, V12, P21, DOI 10.1007/PL00009514; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann J., 1997, EVALUATION TREATMENT; *SCOTT INT GUID NE, 1997, MAN PAT STROK 3; Selley W. G., 1994, Dysphagia, V9, P162, DOI 10.1007/BF00341260; Smith D., 1997, ROMANI CULTURE IDENT, P7; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; STROUD A, 1997, DYSPHAGIA, V12, P106; ZENNER PM, 1995, DYSPHAGIA, V10, P27, DOI 10.1007/BF00261276	15	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					355	356		10.1016/S0140-6736(98)90085-X	http://dx.doi.org/10.1016/S0140-6736(98)90085-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437860				2022-12-28	WOS:000081764900005
J	Goodman, CA; Coleman, PG; Mills, AJ				Goodman, CA; Coleman, PG; Mills, AJ			Cost-effectiveness of malaria control in sub-Saharan Africa	LANCET			English	Article							CHILDREN; HEALTH; CHEMOPROPHYLAXIS; CHLOROQUINE; STRATEGIES; MORBIDITY; EFFICACY; PROGRAM; WOMEN	Background Information on the cost-effectiveness of malaria control is needed for the WHO Roll Back Malaria campaign, but is sparse. We used mathematical models to calculate cost-effectiveness ratios for the main prevention and treatment interventions in sub-Saharan Africa. Methods We analysed interventions to prevent malaria in childhood (insecticide-treated nets, residual spraying of houses, and chemoprophylaxis) and pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and to improve malaria treatment (improved compliance, improved availability of second-line and third-line drugs, and changes in first-line drug). We developed models that included probabilistic sensitivity analysis to calculate ranges for the cost per disability-adjusted life year (DALY) averted for each intervention in three economic strata. Data were obtained from published and unpublished sources, and consultations with researchers and programme managers. Findings In a very-low-income country, for insecticide treatment of existing nets, the cost-effectiveness range was US$4-10 per DALY averted; for provision of nets and insecticide treatment $19-85; for residual spraying (two rounds per year) $32-58; for chemoprophylaxis for children $3-12 (assuming an existing delivery system); for intermittent treatment of pregnant women $4-29; and for improvement in case management $1-8. Although some interventions are inexpensive, achieving high coverage with an intervention to prevent childhood malaria would use a high proportion of current health-care expenditure. Interpretation Cost-effective interventions are available. A package of interventions:to decrease the bulk of the malaria burden is not, however, affordable in very-low-income countries. Coverage of the most vulnerable groups in Africa will require substantial assistance from external donors.	London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Goodman, CA (corresponding author), London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England.			Goodman, Catherine/0000-0002-2241-3485; Mills, Anne/0000-0001-9863-9950				[Anonymous], DECADE PROGR MALARIA; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Barat LM, 1998, TROP MED INT HEALTH, V3, P535, DOI 10.1046/j.1365-3156.1998.00271.x; Barendregt JJ, 1996, B WORLD HEALTH ORGAN, V74, P439; Bloland PB, 1998, TROP MED INT HEALTH, V3, P543; BRINKMANN U, 1991, TROP MED PARASITOL, V42, P204; Coleman PG, 1999, TROP MED INT HEALTH, V4, P175, DOI 10.1046/j.1365-3156.1999.43382.x; Curtis CF, 1998, PHILOS T ROY SOC B, V353, P1769, DOI 10.1098/rstb.1998.0329; Curtis CF, 1998, TROP MED INT HEALTH, V3, P619, DOI 10.1046/j.1365-3156.1998.00281.x; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Eurostat, 2022, LIF TABL EUR COUNTR; Gilson L, 1998, SOC SCI MED, V47, P1891; GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q; GREENWOOD BM, 1988, LANCET, V1, P1121; GULMEZOGLU AM, 1998, COCHRANE COLLABORATI; HILL JA, 1996, APPROACHES MALARIA 1; JAMISON DT, 1993, DIS CONTROL PRIORIRI; LENGELER C, 1998, COCHRANE LIB; *MAN SCI HLTH, 1996, INT DRUG PRIC IND GU; MCDERMOTT JM, 1996, AM J TROP MED HYG S1, V55, P1; MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L; MOLINEAUX L, 1985, HLTH POLICY SOCIAL P, P13; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7; Phillips MA., 1993, PEEM GUIDELINES SERI, V3; SCHAPIRA A, 1993, PARASITOL TODAY, V9, P168, DOI 10.1016/0169-4758(93)90140-B; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Steketee RW, 1996, AM J TROP MED HYG, V55, P95, DOI 10.4269/ajtmh.1996.55.95; WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, V2, P1765; *WHO, 1998, ROLL BACK MAL GLOB P; *WHO, 1996, TDRGEN961 WHO; *WHO TDR, 1997, TDR NEWS, V54, P5; *WORLD BANK, 1994, TANZ ROL GOV PUBL EX, V1; World Bank, 1997, WORLD DEV REP STAT C	36	182	183	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					378	385		10.1016/S0140-6736(99)02141-8	http://dx.doi.org/10.1016/S0140-6736(99)02141-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437867				2022-12-28	WOS:000081764900013
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 69-year-old man with chronic dizziness, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Drachman DA, 1998, JAMA-J AM MED ASSOC, V280, P2111, DOI 10.1001/jama.280.24.2111	1	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					378	378		10.1001/jama.282.4.378	http://dx.doi.org/10.1001/jama.282.4.378			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432036				2022-12-28	WOS:000081596800034
J	Lucas, A; Fewtrell, MS; Cole, TJ				Lucas, A; Fewtrell, MS; Cole, TJ			Education and debate - Fetal origins of adult disease - the hypothesis revisited	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; BIRTH-WEIGHT; GLUCOSE-TOLERANCE; HEART-DISEASE; IN-UTERO; GROWTH; SIZE; INSULIN; LIFE; CHILDREN		Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London; University of London; University College London	Lucas, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline; MRC [G9827821] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANGELBECK JH, 1983, BRAIN RES, V264, P277, DOI 10.1016/0006-8993(83)90825-9; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; Dobbing J., 1981, MOL BASIS NEUROPATHO, P221; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Fall C. H. D., 1995, Archives of Disease in Childhood, V73, P287; Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.0.CO;2-O; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; FORRESTER TE, 1996, BRIT MED J, V312, P56; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; LANGLEYEVANS SC, 1994, CLIN NUTR, V13, P319, DOI 10.1016/0261-5614(94)90056-6; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1998, EUR J CLIN NUTR, V52, pS72; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LEWIS DS, 1986, J CLIN INVEST, V78, P899, DOI 10.1172/JCI112678; LEWIS DS, 1988, ARTERIOSCLEROSIS, V8, P274, DOI 10.1161/01.ATV.8.3.274; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LUCAS A, 1991, CIBA F SYMP, V156, P38; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; McCance RA, 1962, LANCET, V280, P271; MOTT GE, 1991, CIBA F SYMP, V156, P56; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SMART JL, 1986, P 13 C NUTR, P74; Spalding D.A., 1873, MACMILLANS MAGAZINE, V27, P282; Taylor SJC, 1997, BRIT MED J, V314, P475, DOI 10.1136/bmj.314.7079.475; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; VIJAYAKUMAR M, 1995, BRIT HEART J, V73, P363; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	35	586	607	2	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					245	249		10.1136/bmj.319.7204.245	http://dx.doi.org/10.1136/bmj.319.7204.245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417093	Green Published, Green Submitted			2022-12-28	WOS:000081720300031
J	Warren, G; Mellman, I				Warren, G; Mellman, I			Bulk flow redux?	CELL			English	Review							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; PROTEINS; CELLS; COPII		Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University	Warren, G (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Mellman, Ira/ABG-5896-2020					CASE RM, 1978, BIOL REV, V53, P211, DOI 10.1111/j.1469-185X.1978.tb01437.x; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; SHIMA DT, 1999, IN PRESS CURR BIOL; THORNER J, 1981, MOL BIOL YEAST SACCH, P143; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	14	44	45	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					125	127		10.1016/S0092-8674(00)81006-5	http://dx.doi.org/10.1016/S0092-8674(00)81006-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428023	hybrid			2022-12-28	WOS:000081632300001
J	van Oijen, AM; Ketelaars, M; Kohler, J; Aartsma, TJ; Schmidt, J				van Oijen, AM; Ketelaars, M; Kohler, J; Aartsma, TJ; Schmidt, J			Unraveling the electronic structure of individual photosynthetic pigment-protein complexes	SCIENCE			English	Article							LH2 ANTENNA COMPLEX; RHODOPSEUDOMONAS-ACIDOPHILA; RHODOBACTER-SPHAEROIDES; ENERGY-TRANSFER; PURPLE BACTERIA; BACTERIOCHLOROPHYLL; DYNAMICS; B850	Low-temperature single-molecule spectroscopic techniques were applied to a Light-harvesting pigment-protein complex (LH2) from purple photosynthetic bacteria. The properties of the electronically excited states of the two circular assemblies (B800 and B850) of bacteriochlorophyll a (BChl a) pigment molecules in the individual complexes were revealed, without ensemble averaging. The results show that the excited states of the B800 ring of pigments are mainly Localized on individual BChl a molecules. In contrast, the absorption of a photon by the B850 ring can be consistently described in terms of an excitation that is completely delocalized over the ring. This property may contribute to the high efficiency of energy transfer in these photosynthetic complexes.	Leiden Univ, Ctr Study Excited States Mol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Huygens Lab, Dept Biophys, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	van Oijen, AM (corresponding author), Leiden Univ, Ctr Study Excited States Mol, POB 9504, NL-2300 RA Leiden, Netherlands.		van Oijen, Antoine/I-3167-2014; Köhler, Jürgen/AAC-3030-2019	van Oijen, Antoine/0000-0002-1794-5161; Köhler, Jürgen/0000-0002-4214-4008				Alden RG, 1997, J PHYS CHEM B, V101, P4667, DOI 10.1021/jp970005r; Basche T., 1997, SINGLE MOL OPTICAL D; Bopp MA, 1997, P NATL ACAD SCI USA, V94, P10630, DOI 10.1073/pnas.94.20.10630; Chachisvilis M, 1997, J PHYS CHEM B, V101, P7275, DOI 10.1021/jp963360a; Jimenez R, 1996, J PHYS CHEM-US, V100, P6825, DOI 10.1021/jp953074j; Kennis JTM, 1997, J PHYS CHEM B, V101, P8369, DOI 10.1021/jp971497a; Leegwater JA, 1996, J PHYS CHEM-US, V100, P14403, DOI 10.1021/jp961448i; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; MONSHOUWER R, 1995, CHEM PHYS LETT, V246, P341, DOI 10.1016/0009-2614(95)01104-H; Nagarajan V, 1997, BIOCHEMISTRY-US, V36, P2300, DOI 10.1021/bi962534b; Papiz MZ, 1996, TRENDS PLANT SCI, V1, P198, DOI 10.1016/1360-1385(96)20005-6; Sauer K, 1996, PHOTOCHEM PHOTOBIOL, V64, P564, DOI 10.1111/j.1751-1097.1996.tb03106.x; van Oijen AM, 1998, J PHYS CHEM B, V102, P9363, DOI 10.1021/jp9830629; VANOIJEN AM, IN PRESS CHEM PHYS; Vulto SIE, 1999, J PHYS CHEM B, V103, P878, DOI 10.1021/jp9825415; Wu HM, 1996, J PHYS CHEM-US, V100, P12022, DOI 10.1021/jp9608178	16	422	432	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					400	402		10.1126/science.285.5426.400	http://dx.doi.org/10.1126/science.285.5426.400			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411501	Green Submitted			2022-12-28	WOS:000081465900052
J	Reichman, LB				Reichman, LB			Whither Mycobacterium vaccae?	LANCET			English	Editorial Material									New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reichman, LB (corresponding author), New Jersey Med Sch, Natl TB Ctr, Newark, NJ 07107 USA.							[Anonymous], 1993, World Health Forum, V14, P438; AYVAZIAN LF, 1993, TUBERCULOSIS COMPREH, P1; GRANGE JM, 1994, J ROY SOC MED, V87, P272; Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P451; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; STANFORD JL, 1991, LANCET, V338, P557, DOI 10.1016/0140-6736(91)91113-9; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; 1948, BMJ, V2, P780	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					90	90		10.1016/S0140-6736(99)90049-1	http://dx.doi.org/10.1016/S0140-6736(99)90049-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408480				2022-12-28	WOS:000081377100006
J	Pickard, BG; Beachy, RN				Pickard, BG; Beachy, RN			Intercellular connections are developmentally controlled to help move molecules through the plant	CELL			English	Review							PLASMODESMATA; TRAFFICKING; PROTEINS		Washington Univ, Dept Biol, St Louis, MO 63130 USA; Donald Danforth Plant Sci Ctr, St Louis, MO 63105 USA	Washington University (WUSTL); Donald Danforth Plant Science Center	Pickard, BG (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.							Blackman LM, 1998, PLANT J, V14, P733, DOI 10.1046/j.1365-313x.1998.00161.x; Boevink P, 1998, PLANT J, V15, P441, DOI 10.1046/j.1365-313X.1998.00208.x; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Itaya A, 1998, PLANT PHYSIOL, V118, P373, DOI 10.1104/pp.118.2.373; Kragler F, 1998, PLANT J, V15, P367, DOI 10.1046/j.1365-313X.1998.00219.x; Lazarowitz SG, 1999, PLANT CELL, V11, P535, DOI 10.1105/tpc.11.4.535; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1999, PLANT CELL, V11, P739, DOI 10.1105/tpc.11.4.739; Oparka KJ, 1999, CELL, V97, P743, DOI 10.1016/S0092-8674(00)80786-2; Reuzeau C, 1997, PROTOPLASMA, V199, P173, DOI 10.1007/BF01294505; Taiz L., 1998, PLANT PHYSIOL, P251	12	20	21	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					5	8		10.1016/S0092-8674(00)80600-5	http://dx.doi.org/10.1016/S0092-8674(00)80600-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412975	Bronze			2022-12-28	WOS:000081451000002
J	Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K				Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K			Distortion of proximodistal information causes JNK-dependent apoptosis in Drosophila wing	NATURE			English	Article							LONG-RANGE ACTION; DECAPENTAPLEGIC GENE; MORPHOGEN GRADIENT; IMAGINAL DISKS; EXPRESSION; MELANOGASTER; SURVIVAL; COMPLEX; AXIS; HID	Distinct and evolutionarily conserved signal-transduction cascades mediate the survival or death of cells during development. The c-Jun amino-terminal kinases (JNKs) of the mitogen-activated protein kinase superfamily are involved in apoptotic signalling in various cultured cells(1), However, the role of the JNK pathway in development is less well understood In Drosophila, Decapentaplegic (Dpp; a homologue of transforming growth factor-beta) and Wingless (Wg; a Wnt homologue) proteins are secretory morphogens that act cooperatively to induce formation of the proximodistal axis of appendages(2-7). Here we show that either decreased Dpp signalling in the distal wing cells or increased Dpp signalling in the proximal wing cells causes apoptosis, Inappropriate levels of Dpp signalling lead to aberrant morphogenesis in the respective wing zones, and these apoptotic zones are also determined by the strength of the Wg signal. Our results indicate that distortion of the positional information determined by Dpp and Wg signalling gradients leads to activation of the JNK apoptotic pathway, and the consequent induction of cell death thereby maintains normal morphogenesis.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Adachi-Yamada, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Tsai, Yu-Chen/B-5852-2008	Kamada, Konomi/0000-0002-2186-8728				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deCelis JF, 1997, DEVELOPMENT, V124, P1007; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 1997, DEVELOPMENT, V124, P761; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TERRAS V, 1994, SLAVIC E EUR J, V38, P165, DOI 10.2307/308553; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	27	243	245	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					166	169		10.1038/22112	http://dx.doi.org/10.1038/22112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408443				2022-12-28	WOS:000081324900054
J	Lawrence, S; Giles, CL				Lawrence, S; Giles, CL			Accessibility of information on the web	NATURE			English	Editorial Material									NEC Res Inst, Princeton, NJ 08540 USA	NEC Corporation	Lawrence, S (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.			Giles, C Lee/0000-0002-1931-585X				CORE D, 1999, DUBLIN CORE SIMPLE C; *GRAPH VIS US CTR, 1998, GVUS 10 WWW US SURV; Huberman B. A., 1999, EVOLUTIONARY DYNAMIC; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; LAWRENCE S, 1999, IEEE COMPUTER, V32; SELBERG E, 1997, IEEE EXPERT      JAN, P11	6	792	851	1	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					107	109		10.1038/21987	http://dx.doi.org/10.1038/21987			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10428673	Bronze			2022-12-28	WOS:000081324900023
J	Barker, DJP				Barker, DJP			Intrauterine nutrition may be important - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							ACHESON ED, 1986, P NUTR SOC, V45, P131, DOI 10.1079/PNS19860047; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Barker DJP, 1998, MOTHERS BABIES HLTH; Dwork, 1987, WAR IS GOOD BABIES O; Fogel R., 1991, NUTR POVERTY	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1477	1478						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419294				2022-12-28	WOS:000080668200030
J	Kirsch, JD; Cedeno, MA				Kirsch, JD; Cedeno, MA			Informed consent for family planning for poor women in Chiapas, Mexico	LANCET			English	Editorial Material									Univ Minnesota, Sch Med, Minneapolis, MN 55406 USA; Defensoria Derecho Salud, San Cristobal De Las Cas, Chiapas, Mexico	University of Minnesota System; University of Minnesota Twin Cities	Kirsch, JD (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55406 USA.		Kirsch, Jonathan D/AGB-3147-2022	Kirsch, Jonathan D/0000-0003-0185-8001				*CTR REPR LAW POL, 1997, WOM REPR RIGHTS MEX, P12; NazarBeutelspacher A, 1996, SALUD PUBLICA MEXICO, V38, P13; *PHYS HUM RIGHTS, 1999, HLTH CAR HELD HOST H, P29; Physicians for Human Rights & Human Rights Watch, 1994, WAIT JUST CHIAP; 1996, TRIBUNAL DERECHOS RE; 1992, DIRECCION GEN SALUD	6	7	8	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					419	420		10.1016/S0140-6736(99)90136-8	http://dx.doi.org/10.1016/S0140-6736(99)90136-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437887				2022-12-28	WOS:000081764900045
J	Saunderson, EM; Ridsdale, L				Saunderson, EM; Ridsdale, L			General practitioners' beliefs and attitudes about how to respond to death and bereavement: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GRIEVING ADULT; PRIMARY-CARE; 2 PARTS	Objectives To investigate the perceptions of general practitioners when they are notified or hear of a death or bereavement in their practice; to explore doctors' accounts of their relationships with their patients in the context of bereavement; and to explore the concerns of general practitioners in managing themselves and bereaved patients. Design Semistructured interviews followed by qualitative content analysis. Setting London borough of Redbridge. Participants 25 general practitioners. Results Almost all the doctors had felt guilty about issues relating to the death of patients. These feelings were based on their expectations of not making mistakes and diagnostic precision. They described a culture gap existing between hospital and general practice and a need to develop new models and methods to explain and manage the causes of illness presented to them. In the absence of useful teaching on bereavement, many devised strategies which relied more on their personal experiences. General practitioners used various methods to contact bereaved patients, especially if they had been involved in the terminal care or if the death was particularly shocking. The doctor was also bereaved by the death of well known patients and sometimes needed to grieve and express emotion. Conclusion General practitioners may need support and learning methods to manage their own and their patients' bereavement.	N St Med Care, Romford RM11 2TH, Essex, England; Guys Kings & St Thomas Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England	University of London; King's College London	Saunderson, EM (corresponding author), N St Med Care, 274 North St, Romford RM11 2TH, Essex, England.	E.Saunderson@btinternet.com						Bateman B, 1996, Aust Fam Physician, V25, P1687; BERLIN A, 1993, BRIT J GEN PRACT, V43, P70; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BYRNE GJA, 1994, PSYCHOL MED, V24, P411, DOI 10.1017/S0033291700027380; CHARLTON R, 1995, BRIT J GEN PRACT, V45, P427; CLAYTON PJ, 1974, ARCH GEN PSYCHIAT, V30, P747; Dangler L A, 1996, Fam Med, V28, P694; DEVAUL RA, 1979, PRIMARY CARE, V6, P391; ESTOK P, 1983, BIRTH-ISS PERINAT C, V10, P17, DOI 10.1111/j.1523-536X.1983.tb01394.x; Harris T, 1998, BRIT J GEN PRACT, V48, P1560; HOWELL J, 1992, STRESS MED PROFESSIO; Lindemann E, 1944, AM J PSYCHIAT, V101, P141, DOI 10.1176/ajp.101.2.141; Muhr, 1991, QUALITATIVE SOCIOLOG, V14, P349, DOI DOI 10.1007/BF00989645; PARKES CM, 1964, BRIT MED J, V2, P274, DOI 10.1136/bmj.2.5404.274; PASNAU RO, 1987, PSYCHIAT CLIN N AM, V10, P109; REES WD, 1967, BRIT MED J, V4, P13, DOI 10.1136/bmj.4.5570.13; Rout U, 1996, BRIT J GEN PRACT, V46, P157; Stacy R, 1998, BRIT J GEN PRACT, V48, P1739; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; Tudiver F, 1991, Fam Med, V23, P501; Wadlands W, 1988, FAM SYSTEMS MED, V6, P176, DOI DOI 10.1037/H0089743; Woof W R, 1997, Eur J Cancer Care (Engl), V6, P133; Woof WR, 1997, BRIT J GEN PRACT, V47, P509; Woof WR, 1997, BRIT J GEN PRACT, V47, P443	24	36	38	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	1999	319	7205					293	296		10.1136/bmj.319.7205.293	http://dx.doi.org/10.1136/bmj.319.7205.293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426743	Green Published, Bronze			2022-12-28	WOS:000081909100025
J	Nadeau, RM; McEvilly, TV				Nadeau, RM; McEvilly, TV			Fault slip rates at depth from recurrence intervals of repeating microearthquakes	SCIENCE			English	Article							SAN-ANDREAS FAULT; PARKFIELD; CALIFORNIA; EARTHQUAKES; PARAMETERS; FRICTION; ZONE	Unique attributes in sequences of recurring, similar microearthquakes at Parkfield, California, provide a means for inferring slip rate at depth throughout the active fault surface from the time intervals between sequence events. Application of the method using an 11-year microseismicity record revealed systematic spatial and temporal changes in the slip rate that were synchronous with earthquake activity and other independent measures of fault-zone slip. If this phenomenon is found to be generally common behavior in active faults, it forms the basis for a method to monitor the changing strain field throughout a seismogenic fault zone.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Nadeau, RM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA.		Nadeau, Robert/G-1884-2017	Nadeau, Robert/0000-0003-1255-0643				BAKUN WH, 1985, SCIENCE, V229, P619, DOI 10.1126/science.229.4714.619; Burgmann R, 1998, GEOLOGY, V26, P559, DOI 10.1130/0091-7613(1998)026<0559:SATHFC>2.3.CO;2; DIETERICH JH, 1972, J GEOPHYS RES, V77, P3690, DOI 10.1029/JB077i020p03690; Ellsworth W.L., 1995, URBAN DISASTER MITIG; Fletcher JB, 1998, J GEOPHYS RES-SOL EA, V103, P835, DOI 10.1029/97JB01797; HARRIS RA, 1987, J GEOPHYS RES-SOLID, V92, P7945, DOI 10.1029/JB092iB08p07945; Karageorgi E, 1997, B SEISMOL SOC AM, V87, P39; LANGBEIN J, IN PRESS GEOPHYS RES; LANGBEIN J, UNPUB; LANGBEIN JO, 1990, J GEOPHYS RES-SOLID, V95, P2533, DOI 10.1029/JB095iB03p02533; Nadeau RM, 1997, B SEISMOL SOC AM, V87, P1463; Nadeau RM, 1998, B SEISMOL SOC AM, V88, P790; NADEAU RM, 1995, SCIENCE, V267, P503, DOI 10.1126/science.267.5197.503; Quilty EG, 1997, B SEISMOL SOC AM, V87, P310; Schaff DP, 1998, GEOPHYS RES LETT, V25, P4549, DOI 10.1029/1998GL900192; SCHOLZ C, 1972, J GEOPHYS RES, V77, P6382; SCHOLZ CH, 1976, INT J ROCK MECH MIN, V13, P149, DOI 10.1016/0148-9062(76)90819-6	17	250	272	4	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					718	721		10.1126/science.285.5428.718	http://dx.doi.org/10.1126/science.285.5428.718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426990				2022-12-28	WOS:000081765100049
J	Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH				Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH			Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response	SCIENCE			English	Article							BREAST-CANCER; PROTEIN; IDENTIFICATION; REPAIR; RAD50	BRCA1 encodes a tumor suppressor that is mutated in familiar breast and ovarian cancers. Here, it is shown that BRCA1 interacts in vitro and in vivo with hRad50, which forms a complex with hMre11 and p95/nibrin. Upon irradiation, BRCA1 was detected in discrete foci in the nucleus, which colocalize with hRad50. Formation of irradiation-induced foci positive for BRCA1, hRad50, hMre11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wild-type BRCA1. Ectopic expression of wild-type, but not mutated, BRCA1 in these cells rendered them less sensitive to the DNA damage agent, methyl methanesulfonate. These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the hRad50-hMre11-p95 complex.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022; LI, SHANG/HII-4989-2022	Zhong, Qing/0000-0001-6979-955X; LI, SHANG/0000-0002-6226-3362; Chen, Chi-Fen/0000-0002-6391-821X	NCI NIH HHS [CA 30195, CA 58183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1997, CANCER RES, V57, P4225	15	502	525	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					747	750		10.1126/science.285.5428.747	http://dx.doi.org/10.1126/science.285.5428.747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426999				2022-12-28	WOS:000081765100058
J	Ralph, SG; Rutherford, AJ; Wilson, JD				Ralph, SG; Rutherford, AJ; Wilson, JD			Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study	BRITISH MEDICAL JOURNAL			English	Article							PRETERM DELIVERY; GENITAL-TRACT; PREGNANCY; WOMEN; ENDOMETRITIS; ASSOCIATION; HORMONE; BIRTH	Objectives To assess whether bacterial vaginosis affects the rates of conception and miscarriage in the first trimester. Design Cohort study. Setting Assisted conception unit of a teaching hospital in Leeds. Participants 867 consecutive women undergoing in vitro fertilisation. Interventions Screening for bacterial vaginosis with a Gram stained vaginal smear before egg collection. Main outcome measures The presence of bacterial vaginosis or normal vaginal flora, and the rate of conception and miscarriage in the first trimester. Results 190 of 771 (24.6%) women had bacterial vaginosis. No difference in conception rate was found between those women with bacterial vaginosis and those with normal vaginal flora: 61 women (32.1%) and 146 of 493 women (29.6%) respectively (relative risk 1.08, 95% confidence interval 0.85 to 1.39; odds ratio 1.12, 0.77 to 1.64). However, 22 women (31.6%) with bacterial vaginosis who conceived had a significantly increased risk of miscarriage in the first trimester compared with 27 women (18.5%) with normal vaginal flora (crude relative risk 1.95, 1.11 to 3.42; crude odds ratio: 2.49; 1.21 to 5.12). This increased risk remained significant after adjustment for factors known to increase the rate of miscarriage: increasing maternal age, smoking, history of three or more miscarriages, no precious live birth and polycystic ovaries (adjusted relative risk 2.03, 1.09 to 3.78; adjusted odds ratio 2.67, 1.26 to 5.63). Conclusions Bacterial vaginosis does not affect conception but is associated with an increased risk of miscarriage in the first trimester in women undergoing in vitro fertilisation, independent of other risk factors.	Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England; Gen Infirm, Reprod Med Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; Leeds General Infirmary	Wilson, JD (corresponding author), Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England.							ASHKENAZI J, 1994, FERTIL STERIL, V61, P526; Curtis P, 1992, HUM REPROD, V7, P625; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HOWE RS, 1988, FERTIL STERIL, V49, P726; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KURKI T, 1992, OBSTET GYNECOL, V80, P173; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; RUTHERFORD AJ, 1988, BRIT MED J, V296, P1765, DOI 10.1136/bmj.296.6639.1765; SAUER MV, 1992, AM J OBSTET GYNECOL, V166, P148, DOI 10.1016/0002-9378(92)91850-A; STENMAN UH, 1987, J CLIN ENDOCR METAB, V64, P730, DOI 10.1210/jcem-64-4-730; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	15	164	174	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					220	223		10.1136/bmj.319.7204.220	http://dx.doi.org/10.1136/bmj.319.7204.220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417083	Green Published, Bronze			2022-12-28	WOS:000081720300022
J	Robinson, WC; Lee, MK; Hill, K; Burnham, GM				Robinson, WC; Lee, MK; Hill, K; Burnham, GM			Mortality in North Korean migrant households: a retrospective study	LANCET			English	Article								Background A deteriorating economy, coupled with a series of natural disasters in 1995-97, led to a severe food crisis in North Korea. Although the country has received substantial international aid since 1996, demographic assessments of crisis impact have been limited. We assessed mortality trends in North Korea since 1995. Methods At 15 randomly selected sites in China, 440 North Korean adult migrants were interviewed during July-September, 1998. Respondents were asked about births, deaths, and migration patterns in their households between mid-1994 and mid-1998, and about household food sources. The respondents also provided basic demographic information about the households of their relatives. We compared mortality rates from migrant households with data from the 1993 census and with data about households of non-migrant relatives. Findings Households that included a recent migrant to China showed increasing mortality: crude death rates rose from 28.9 per 1000 in 1995, to 45.6 per 1000 in 1996, and to 56.0 per 1000 in 1997 (p=0.0001), with a 3-year average rate of 42.8 per 1000. The crude 3-year birth rate was 11.0 per 1000. Average household size declined from 4.0 at the beginning of 1995 to 3.4 at the end of 1997 (p=0.0002). Among 259 households of non-migrant relatives, the crude death rate was 43.2 per 1000 and the crude birth rate was 8.8 per 1000. In these households, the 3-year trend of increasing mortality was significant (p=0.001), as was the decline in average household size from 4.3 at the beginning of 1995 to 3.7 at the end of 1997(p=0.0001). Interpretation Among North Korean households that include a recent migrant to China, mortality has increased and household size has declined since 1995. This trend raises concern about the state of the general population, at least in the province of North Hamkyong, from where most of the migrants originated.	Johns Hopkins Sch Hyg & Publ Hlth, Ctr Refugee & Disaster Studies, Baltimore, MD 21205 USA	Johns Hopkins University	Robinson, WC (corresponding author), Johns Hopkins Sch Hyg & Publ Hlth, Ctr Refugee & Disaster Studies, 615 N Wolfe St, Baltimore, MD 21205 USA.	wcrobinson@hotmail.com						*CDC, 1997, MMWR-MORBID MORTAL W, V46, P24; *CHIN STAT STAT BU, 1998, STAT YB YANB; *DPRK CENTR BUR ST, 1993, UNPUB POP LOC HOUS 1; DYSON T, 1991, POPULATION STUDIES, V45, P18; Eberstadt N, 1998, ASIAN SURV, V38, P203, DOI 10.1525/as.1998.38.3.01p0337x; EBERSTADT N, 1992, POPULATION N KOREA, P18; *EM NUTR NETW, 1998, FIELD EXCHANGE   JAN; *EUR UN UNICEF WOR, 1998, NUTR SURV DEM PEOPL; Katona-Apte J, 1998, J NUTR, V128, P1315, DOI 10.1093/jn/128.8.1315; LEE CJ, 1986, CHINAS KOREAN  MINOR; *UN DE EC SOC AFF, 1998, 1996 DEM YB, P136; *UN DEP HUM AFF, 1995, 1 UN DHA DPR; United Nations Children's Fund World Health Organization World Bank Group, 2021, LEVELS TRENDS CHILD; *WORLD FOOD PROGR, 1997, KNIF EDG MAJ FAM; YOUNG H, 1997, DISASTERS, V19, P2; 1998, INT HEARLD TRIB 1223; 1999, NY TIMES        0323	17	31	31	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					291	295		10.1016/S0140-6736(99)02266-7	http://dx.doi.org/10.1016/S0140-6736(99)02266-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440306	hybrid			2022-12-28	WOS:000081646000012
J	Houghton, RA; Hackler, JL; Lawrence, KT				Houghton, RA; Hackler, JL; Lawrence, KT			The US carbon budget: Contributions from land-use change	SCIENCE			English	Article							TEXAS SAVANNAS; UNITED-STATES; FOREST; INVASION; FIRE; MANAGEMENT; HISTORY; STORAGE; DIOXIDE	The rates at which lands in the United States were cleared for agriculture, abandoned, harvested for wood, and burned were reconstructed from historical data for the period 1700-1990 and used in a terrestrial carbon model to calculate annual changes in the amount of carbon stored in terrestrial ecosystems, including wood products. Changes in land use released 27 +/- 6 petagrams of carbon to the atmosphere before 1945 and accumulated 2 +/- 2 petagrams of carbon after 1945, Largely as a result of fire suppression and forest growth on abandoned farmlands. During the 1980s, the net flux of carbon attributable to land management offset 10 to 30 percent of U.S. fossil fuel emissions.	Woods Hole Res Ctr, Woods Hole, MA 02543 USA	Woods Hole Research Center	Houghton, RA (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.	rhoughton@whrc.org	Noojipady, Praveen/B-2511-2010					AJTAY GL, 1979, GLOBAL CARBON CYCLE, P129; Andres R.J., 1999, GLOBAL REGIONAL NATL; [Anonymous], 1994, COASTAL WILDERNESS F; ARCHER S, 1989, AM NAT, V134, P545, DOI 10.1086/284996; Bailey RG, 1995, DESCRIPTION ECOREGIO; Birdsey R.A., 1992, CARBON STORAGE ACCUM, V59, DOI [10.1016/j.ecoleng.2016.10.006, DOI 10.1016/J.ECOLENG.2016.10.006]; BIRDSEY RA, 1993, FOREST ECOL MANAG, V58, P33, DOI 10.1016/0378-1127(93)90129-B; BIRDSEY RA, 1995, PRODUCTIVITY AM FORE, P56; Brown S, 1997, FOREST ECOL MANAG, V96, P37, DOI 10.1016/S0378-1127(97)00044-3; BURKHARDT JW, 1976, ECOLOGY, V57, P472, DOI 10.2307/1936432; CANNELL RQ, 1994, SOIL TILL RES, V30, P245, DOI 10.1016/0167-1987(94)90007-8; CIAIS P, 1995, J GEOPHYS RES-ATMOS, V100, P5051, DOI 10.1029/94JD02847; COUPLAND RT, 1961, J ECOL, V49, P135, DOI 10.2307/2257431; COVINGTON WW, 1994, J FOREST, V92, P39; CUTTER BE, 1994, AM MIDL NAT, V132, P393, DOI 10.2307/2426595; DONIGIAN AS, 1995, ADV SOIL SCI SOIL MA, P121; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Fule PZ, 1997, ECOL APPL, V7, P895, DOI 10.1890/1051-0761(1997)007[0895:DRCFEM]2.0.CO;2; GAUDINSKI J, IN PRESS BIOGEOCHEMI; GEBHART DL, 1994, J SOIL WATER CONSERV, V49, P488; Goulden ML, 1996, SCIENCE, V271, P1576, DOI 10.1126/science.271.5255.1576; GROVER HD, 1990, CLIMATIC CHANGE, V17, P305, DOI 10.1007/BF00138373; GRUELL GE, 1985, NORTHWEST SCI, V59, P97; GUYETTE R, 1982, Transactions of the Missouri Academy of Science, V16, P85; Harmon ME, 1996, ECOL APPL, V6, P641, DOI 10.2307/2269398; HOUGHTON RA, IN PRESS GLOBAL ECOL; HOUGHTON RA, 1995, ORNLCDIAC79; HOUGHTON RA, IN PRESS GLOBAL EC B; JOHNSON DW, 1992, WATER AIR SOIL POLL, V64, P83, DOI 10.1007/BF00477097; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Knapp PA, 1998, GLOBAL CHANGE BIOL, V4, P347, DOI 10.1046/j.1365-2486.1998.00160.x; Kurz WA, 1999, ECOL APPL, V9, P526, DOI 10.1890/1051-0761(1999)009[0526:AYRAOC]2.0.CO;2; Mast JN, 1997, FOREST ECOL MANAG, V93, P181, DOI 10.1016/S0378-1127(96)03954-0; MOONEY HA, 1981, WO26 USDA FOR SERV; Olson J., 1983, TR004 US DEP EN; Phillips W.S., 1963, VEGETATIONAL CHANGES; Pyne SJ., 1982, FIRE AM CULTURAL HIS; PYNE SJ, 1984, INTRO WIDLAND FIRE F; Reichle D.E., 1981, DYNAMIC PROPERTIES F; Schlesinger WH, 1998, BIOGEOCHEMISTRY, V42, P169, DOI 10.1023/A:1005939924434; Schroeder P, 1997, FOREST SCI, V43, P424; SHARROW SH, 1977, J RANGE MANAGE, V30, P266, DOI 10.2307/3897302; Smith P, 1998, GLOB CHANGE BIOL, V4, P679, DOI 10.1046/j.1365-2486.1998.00185.x; Stallard RF, 1998, GLOBAL BIOGEOCHEM CY, V12, P231, DOI 10.1029/98GB00741; STEINAUER EM, 1987, AM MIDL NAT, V118, P358, DOI 10.2307/2425792; STRENG DR, 1982, AM MIDL NAT, V108, P278, DOI 10.2307/2425488; Swetnam TW, 1998, J CLIMATE, V11, P3128, DOI 10.1175/1520-0442(1998)011<3128:MDAERT>2.0.CO;2; SWETNAM TW, 1993, SCIENCE, V262, P885, DOI 10.1126/science.262.5135.885; TIAN H, IN PRESS TELLUS; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033; *US BUR CENS, 1977, HIST STAT US COL TIM; *USDA, 1926, FOR SERV COOP FIR PR; *USDA EC RES SERV, 1996, 89003 USDA EC RES SE; *USDA FOR SERV, 1993, FOR TYP GROUPS US; *USDA FOR SERV, 1992, FOR SERV RES INV OV; Wernick I.K., 1997, J IND ECOL, V1, P125, DOI [10.1162/jiec.1997.1.3.125, DOI 10.1162/JIEC.1997.1.3.125]	56	755	923	23	294	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					574	578		10.1126/science.285.5427.574	http://dx.doi.org/10.1126/science.285.5427.574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417385				2022-12-28	WOS:000081609500035
J	Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ				Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ			Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein	SCIENCE			English	Article							FOCAL CEREBRAL-ISCHEMIA; P-SELECTIN; RECEPTOR TYPE-1; NEUTROPHIL ADHESION; ALZHEIMERS-DISEASE; INFARCT VOLUME; BRAIN; REPERFUSION; C1Q; PLATELET	Glycoprotein adhesion receptors such as selectins contribute to tissue injury in stroke. Ischemic neurons strongly expressed C1q, which may target them for complement-mediated attack or C1qRp-mediated clearance. A hybrid molecule was used to simultaneously inhibit both complement activation and selectin-mediated adhesion. The extracellular domain of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLe(x)) to inhibit complement activation and endothelial-platelet-Leukocyte interactions. sCR1 and sCR1sLe(x) colocalized to ischemic cerebral microvessels and C1q-expressing neurons, inhibited neutrophil and platelet accumulation, and reduced cerebral infarct volumes. Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sCR1 molecule.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Avant Immunotherapeut Inc, Needham, MA 02494 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Columbia University; University of California System; University of California Irvine	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Kim, Louis/F-1781-2011	Marsh, Henry/0000-0001-5637-6013; Huang, Judy/0000-0002-0675-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035144] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL59488, R01 HL55397] Funding Source: Medline; NINDS NIH HHS [R01 NS35144] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Diacovo TG, 1996, BLOOD, V88, P146; Frijns CJM, 1997, STROKE, V28, P2214, DOI 10.1161/01.STR.28.11.2214; Fruchterman TM, 1998, SURGERY, V124, P782, DOI 10.1067/msy.1998.91489; FURIE B, 1995, THROMB HAEMOSTASIS, V74, P224; GILLINOV AM, 1993, ANN THORAC SURG, V55, P619, DOI 10.1016/0003-4975(93)90264-I; Haring HP, 1996, STROKE, V27, P1386, DOI 10.1161/01.STR.27.8.1386; HILL J, 1992, J IMMUNOL, V149, P1723; HUANG J, IN PRESS NEUROSURGER; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; KOROTZER AR, 1995, EXP NEUROL, V134, P214, DOI 10.1006/exnr.1995.1051; Kuijper PHM, 1996, BLOOD, V87, P3271, DOI 10.1182/blood.V87.8.3271.bloodjournal8783271; Lazar HL, 1998, ANN THORAC SURG, V65, P973, DOI 10.1016/S0003-4975(98)00021-6; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; PETRY F, 1991, J IMMUNOL, V147, P3988; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rittershaus CW, 1999, J BIOL CHEM, V274, P11237, DOI 10.1074/jbc.274.16.11237; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TENNER AJ, 1981, J IMMUNOL, V127, P648; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YOUNG KR, 1991, J IMMUNOL, V146, P3356	32	278	295	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					595	599		10.1126/science.285.5427.595	http://dx.doi.org/10.1126/science.285.5427.595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417391				2022-12-28	WOS:000081609500041
J	Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D				Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D			Squid hnRNP protein promotes apical cytoplasmic transport and localization of Drosophila pair-rule transcripts	CELL			English	Article							MESSENGER-RNA LOCALIZATION; CIS-ACTING SEQUENCES; BINDING PROTEIN; XENOPUS OOCYTES; FUSHI-TARAZU; BICOID RNA; ASYMMETRIC LOCALIZATION; EARLY EMBRYOGENESIS; NUCLEAR EXPORT; GENE	Drosophila melanogaster pair-rule segmentation gene transcripts localize apically of nuclei in blastoderm embryos. This might occur by asymmetric (vectorial) export from one side of the nucleus or by transport within the cytoplasm. We have followed fluorescently labeled pair-rule transcripts postinjection into Drosophila embryos. Naked, microinjected fushi tarazu (ftz) transcripts do not localize in blastoderm embryos, indicating that cytoplasmic mechanisms alone are insufficient for epical targeting. However, prior exposure of ftz to Drosophila or human embryonic nuclear extract leads to rapid, specific, microtubule-dependent transport, arguing against vectorial export. We present evidence that ftz transcript localization involves the Squid (Hrp40) hnRNP protein and that the activity of hnRNP proteins in promoting transcript localization is evolutionarily conserved. We propose that cytoplasmic localization machineries recognize transcripts in the context of nuclear partner proteins.	Imperial Canc Res Fund, Dev Genet Lab, London WC2A 3PX, England; Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Cancer Research UK; Howard Hughes Medical Institute; Princeton University	Ish-Horowicz, D (corresponding author), Imperial Canc Res Fund, Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England.			Ish-Horowicz, David/0000-0001-5684-7129				AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EDGAR BA, 1986, CELL, V47, P747, DOI 10.1016/0092-8674(86)90517-9; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FOE VE, 1983, J CELL SCI, V61, P31; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Litman P, 1996, DEV BIOL, V176, P86, DOI 10.1006/dbio.1996.9992; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Wallace CS, 1998, J NEUROSCI, V18, P26; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	61	71	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					171	180		10.1016/S0092-8674(00)81012-0	http://dx.doi.org/10.1016/S0092-8674(00)81012-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428029	Bronze			2022-12-28	WOS:000081632300007
J	Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM				Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM		Natl Registry Myocardial Infarction 2 Participa	Sex-based differences in early mortality after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; THROMBOLYTIC THERAPY; UNITED-STATES; CASE-FATALITY; SHORT-TERM; INTERVENTION REGISTRY; NATIONAL REGISTRY; DIABETES-MELLITUS; CLINICAL OUTCOMES; BYPASS-SURGERY	Background There is conflicting information about whether short-term mortality after myocardial infarction is higher among women than among men after adjustment for age and other prognostic factors. We hypothesized that younger, but not older, women have higher mortality rates during hospitalization than their male peers. Methods We analyzed data on 384,878 patients (155,565 women and 229,313 men) who were 30 to 89 years of age and who had been enrolled in the National Registry of Myocardial Infarction 2 between June 1994 and January 1998. Patients who had been transferred from or to other hospitals were excluded. Results The overall mortality rate during hospitalization was 16.7 percent among the women and 11.5 percent among the men. Sex-based differences in the rates varied according to age. Among patients less than 50 years of age, the mortality rate for the women was more than twice that for the men. The difference in the rates decreased with increasing age and was no longer significant after the age of 74 (P < 0.001 for the interaction between sex and age). Logistic-regression analysis showed that the odds of death were 11.1 percent greater for women than for men with every five-year decrease in age (95 percent confidence interval, 10.1 to 12.1 percent). Differences in medical history, the clinical severity of the infarction, and early management accounted for only about one third of the difference in the risk. After adjustment for these factors, women still had a higher risk of death for every five years of decreasing age (increase in the odds of death, 7.0 percent; 95 percent confidence interval, 5.9 to 8.1 percent). Conclusions After myocardial infarction, younger women, but not older women, have higher rates of death during hospitalization than men of the same age. The younger the age of the patients, the higher the risk of death among women relative to men. Younger women with myocardial infarction represent a high-risk group deserving of special study. (N Engl J Med 1999;341:217-25.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med Cardiol, New Haven, CT 06520 USA; Univ Washington, Sch Med, Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Field Program, Seattle, WA USA; Univ Washington, Sch Med, Div Cardiol, Cardiovasc Outcomes Res Ctr, Seattle, WA USA; Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA; Genentech Inc, Div Med Affairs, San Francisco, CA 94080 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Roche Holding; Genentech; Yale University	Vaccarino, V (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					ABBOT RD, 1989, JAMA-J AM MED ASSOC, V261, P1884; ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Albert CM, 1996, CIRCULATION, V93, P1170, DOI 10.1161/01.CIR.93.6.1170; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P3249; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Barron HV, 1998, J AM COLL CARDIOL, V32, P360, DOI 10.1016/S0735-1097(98)00225-3; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BERGLUND U, 1988, THROMB HAEMOSTASIS, V60, P21; Breslow NE, 1980, IARC SCI PUBL, V32; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; Burke AP, 1998, CIRCULATION, V97, P2110, DOI 10.1161/01.CIR.97.21.2110; Chambless L, 1997, CIRCULATION, V96, P3849; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; CIRAULO DA, 1983, CHEST, V2, P196; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; Cox DR., 1989, ANAL BINARY DATA; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HAMMAR N, 1992, INT J EPIDEMIOL, V21, P1090, DOI 10.1093/ije/21.6.1090; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman B, 1997, EUR HEART J, V18, P963; HERRINGTON DM, 1997, WOMEN HEART DIS, P243; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KILLIP T, 1967, AM J CARDIOL, V20, P467; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; MARRUGAT J, 1998, NEW ENGL J MED, V338, P8; Maynard C, 1997, ARCH INTERN MED, V157, P1379, DOI 10.1001/archinte.157.12.1379; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1993, CARDIOL ELDER, V1, P121; Nohria Anju, 1998, Cardiology Clinics, V16, P45, DOI 10.1016/S0733-8651(05)70383-0; PETER T, 1978, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1978.tb107829.x; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; Sonke GS, 1996, BRIT MED J, V313, P853; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Vaccarino V, 1996, J AM GERIATR SOC, V44, P1174, DOI 10.1111/j.1532-5415.1996.tb01366.x; Vaccarino V, 1998, ARCH INTERN MED, V158, P2054, DOI 10.1001/archinte.158.18.2054; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4	63	930	967	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					217	225		10.1056/NEJM199907223410401	http://dx.doi.org/10.1056/NEJM199907223410401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413733				2022-12-28	WOS:000081528800001
J	Wolter, T				Wolter, T			If the fates allow	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Family Hlth Associates, Chippewa Falls, WI 54729 USA		Wolter, T (corresponding author), Family Hlth Associates, 2449 Cty Highway 1, Chippewa Falls, WI 54729 USA.	taran@execpc.com							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					148	149		10.7326/0003-4819-131-2-199907200-00014	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419433				2022-12-28	WOS:000081509700012
J	Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC				Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC			Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study	LANCET			English	Article							BONE-MARROW MICROMETASTASES; EPITHELIAL MEMBRANE ANTIGEN; MAMMARY-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROGNOSTIC-SIGNIFICANCE; MICRO-METASTESES; TUMOR-CELLS; METASTASES	Background Bone-marrow micrometastases have been found in patients with primary breast cancer. We report long-term follow-up of women with primary breast cancer, diagnosed between 1981 and 1986, who had multiple aspirates taken at the time of initial surgery. Methods 350 women with primary breast cancer were examined immunocytochemically with antibody to epithelial membrane antigen. We investigated associations with various prognostic factors as well as the effect of micrometastases on relapse-free survival and overall survival. Findings At median follow-up of 12.5 years, 151 patients had metastatic disease and 136 patients had died from breast cancer. 10-year relapse-free and overall survival were 43.9% (95% CI 33.4-54.7) and 44.9% (34.2-55.9) in patients with micrometastases, and 62.7% (56.5-68.6) and 65.7% (59.4-71.5) in patients without micrometastases at presentation (p<0.001). For relapse-free survival acid overall survival, allowing for tumour size, lymph-node Status, and vascular invasion, the effect of micrometastases decreased and was no longer significant, with a hazard ratio of 1.09 (0.74-1.61) for relapse-free survival and 1.21 (0.84-1.75) for overall survival. Interpretation The presence of bone-marrow micrometastases in patients with primary breast cancer is associated with a shorter relapse-free survival and overall survival, but is not all independent prognostic factor. This immunocytochemical technique may be of value in patients for whom pathological tumour size and lymph-node status are unavailable tie, patients receiving primary medical treatment).	Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England; Inst Canc Res, Surrey, England; Univ London St Georges Hosp, Dept Surg, London SW17 0QT, England; Charing Cross Hosp, Dept Oncol, London, England	St Georges University London; University of London; Institute of Cancer Research - UK; St Georges University London; Imperial College London	Mansi, JL (corresponding author), Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England.			Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100				BERGER U, 1988, AM J CLIN PATHOL, V90, P1; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COTE RJ, 1988, AM J SURG PATHOL, V12, P333, DOI 10.1097/00000478-198805000-00001; COTE RJ, 1991, DIAGN ONCOL, V1, P37; DEARNALEY DP, 1983, J ROY SOC MED, V76, P359, DOI 10.1177/014107688307600506; DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152; DIEL IJ, 1992, J CLIN ONCOL, V10, P1534, DOI 10.1200/JCO.1992.10.10.1534; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; ELLIS G, 1989, CANCER, V63, P2509, DOI 10.1002/1097-0142(19890615)63:12<2509::AID-CNCR2820631225>3.0.CO;2-K; Fields KK, 1996, J CLIN ONCOL, V14, P1868, DOI 10.1200/JCO.1996.14.6.1868; HARBECK N, 1994, BRIT J CANCER, V69, P566, DOI 10.1038/bjc.1994.103; HARBECK N, 1990, Journal of Cancer Research and Clinical Oncology, V116, P49; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; MANSI JL, 1988, J UROLOGY, V139, P545, DOI 10.1016/S0022-5347(17)42516-X; MANSI JL, 1989, J CLIN ONCOL, V7, P445, DOI 10.1200/JCO.1989.7.4.445; MANSI JL, 1991, EUR J CANCER, V27, P1552, DOI 10.1016/0277-5379(91)90413-8; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; PASSOSCOELHO J, 1994, CANCER RES, V54, P2366; PINKUS GS, 1985, HUM PATHOL, V16, P929, DOI 10.1016/S0046-8177(85)80132-5; PORRO G, 1988, CANCER, V61, P2407, DOI 10.1002/1097-0142(19880615)61:12<2407::AID-CNCR2820611202>3.0.CO;2-G; REDDING WH, 1983, LANCET, V2, P1271; SHARP JG, 1992, INT J CELL CLONING, V10, P92, DOI 10.1002/stem.5530100731; THOMAS P, 1987, HUM PATHOL, V18, P728, DOI 10.1016/S0046-8177(87)80244-7; THOR A, 1988, BREAST CANCER RES TR, V11, P133, DOI 10.1007/BF01805837	26	233	245	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					197	202		10.1016/S0140-6736(98)10175-7	http://dx.doi.org/10.1016/S0140-6736(98)10175-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421301				2022-12-28	WOS:000081504200011
J	Ishige, I; Usui, Y; Takemura, T; Eishi, Y				Ishige, I; Usui, Y; Takemura, T; Eishi, Y			Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis	LANCET			English	Article							POLYMERASE CHAIN-REACTION; TUBERCULOSIS	Background The causes of sarcoidosis are not known. The DNA of Mycobacterium tuberculosis has been detected in some sarcoid lesions. In Japan, Propionibacterium acnes has been isolated from such lesions, but whether this indigenous bacterium is related to the disease is unclear. We used PCR to estimate the number of genomes of these bacteria in sarcoid lesions, to identify any link between sarcoidosis and these two bacterial species. Methods We examined formalin-fixed and paraffin-embedded sections of biopsy and surgical samples from lymph nodes of 15 patients with sarcoidosis, 15 patients with tuberculosis, and 15 patients with gastric cancer (controls). Quantitative PCR was done to amplify segments of 16 S ribosomal RNA of P acnes and P granulosum and of insertion sequence 6110 of M tuberculosis. PCR products were identified and the quantities of the products were estimated in terms of the fluorescence of oligonucleotide reporter probes. The numbers of bacterial genomes in samples were estimated from standard curves of serially diluted bacterial DNA. Findings Genomes of M tuberculosis were found in samples from all 15 patients with tuberculosis, from three patients with sarcoidosis, and in one control sample. Genomes of P acnes were found in 12 of the 15 patients with sarcoidosis, in two tuberculosis patients, and three controls. The difference in the estimated number of P acnes genomes between individuals with and without sarcoidosis was similar to that in the number of M tuberculosis between people with and without tuberculosis. There were 5x10(5) P acnes genomes in sarcoidosis and 3x10(6) M tuberculosis genomes in tuberculosis, respectively, on average per mu g of total DNA. The three patients with sarcoidosis but without P acnes all had P granulosum DNA in their biopsy samples; the number of genomes of the bacterium was 5x10(5). Interpretation These findings suggest that propionibacteria had resided or proliferated ectopically in the sarcoid lesions, whether there was a connection with the disease or not. Propionibacteria are a more likely cause than mycobacteria of sarcoidosis.	Tokyo Med & Dent Univ, Fac Med, Dept Pathol, Bunkyo Ku, Tokyo 1138519, Japan; Japanese Red Cross Med Ctr, Dept Pathol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japanese Red Cross Medical Center; University of Tokyo	Eishi, Y (corresponding author), Tokyo Med & Dent Univ, Fac Med, Dept Pathol, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138519, Japan.		Eishi, Yoshinobu/N-3602-2017	Eishi, Yoshinobu/0000-0002-0521-1670				ABE C, 1984, ZBL BAKT-INT J MED M, V256, P541, DOI 10.1016/S0174-3031(84)80032-3; ALBERTI LD, 1997, LANCET, V350, P1655; BAESS I, 1984, ACTA PATH MICRO IM B, V92, P209; BOCART D, 1992, AM REV RESPIR DIS, V145, P1142, DOI 10.1164/ajrccm/145.5.1142; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; JAMES DG, 1994, SARCOIDOSIS, V11, P43; POPPER HH, 1994, AM J CLIN PATHOL, V101, P738, DOI 10.1093/ajcp/101.6.738; SABOOR SA, 1992, LANCET, V339, P1012, DOI 10.1016/0140-6736(92)90535-B; SUZUKI S, 1975, REPORTS BASIC STUDIE; Vokurka M, 1997, AM J RESP CRIT CARE, V156, P1000, DOI 10.1164/ajrccm.156.3.9612035; WALKER DA, 1992, THORAX, V47, P690, DOI 10.1136/thx.47.9.690; Yi ES, 1996, AM J PATHOL, V149, P1303	12	217	221	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					120	123		10.1016/S0140-6736(98)12310-3	http://dx.doi.org/10.1016/S0140-6736(98)12310-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408488				2022-12-28	WOS:000081377100015
J	Shekelle, P; Roland, M				Shekelle, P; Roland, M			Nurse-led telephone-advice lines	LANCET			English	Editorial Material							EMERGENCY		Rand Corp, Santa Monica, CA 90407 USA; Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	RAND Corporation; University of Manchester	Shekelle, P (corresponding author), Rand Corp, Santa Monica, CA 90407 USA.							BROWN A, 1995, BRIT J GEN PRACT, V45, P673; Foster J, 1999, BRIT J GEN PRACT, V49, P111; Gallagher M, 1998, BRIT J GEN PRACT, V48, P1141; HALLAM L, 1999, HLTH TECHNOLOGY ASSE, V3; ISAACMAN DJ, 1992, PEDIATRICS, V89, P35; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; MUNRO J, 1998, EVALUATION NHS DIREC; VERDILE VP, 1989, ANN EMERG MED, V18, P278, DOI 10.1016/S0196-0644(89)80414-7	8	27	27	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					88	89		10.1016/S0140-6736(98)00159-7	http://dx.doi.org/10.1016/S0140-6736(98)00159-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408478				2022-12-28	WOS:000081377100004
J	Hemminki, E; Hailey, D; Koivusalo, M				Hemminki, E; Hailey, D; Koivusalo, M			Health care policy - The courts - A challenge to health technology assessment	SCIENCE			English	Editorial Material							DRUG		Natl Res & Dev Ctr Welf & Hlth, Helsinki 00531, Finland; Alberta Heritage Fdn Med Res, Edmonton, AB T5J 3S4, Canada		Hemminki, E (corresponding author), Natl Res & Dev Ctr Welf & Hlth, POB 220, Helsinki 00531, Finland.			Hailey, David/0000-0003-0797-9090				Abraham J, 1998, LANCET, V352, P480, DOI 10.1016/S0140-6736(97)11282-X; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; KRISTIANSEN IS, COMMUNICATION; MINTZES B, 1993, HER SKIN; Ollila E, 1996, Int J Risk Saf Med, V9, P161, DOI 10.3233/JRS-1996-9306; Ollila E, 1997, INT J HEALTH SERV, V27, P309, DOI 10.2190/D4TX-HQ5J-B095-7WEY; OLLILA E, COMMUNICATION; PORRAS C, 1997, HMG COA REDUCTASE IN; Roberts I, 1998, LANCET, V352, P726, DOI 10.1016/S0140-6736(98)07600-4; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V280, P683, DOI 10.1001/jama.280.8.683; SKRIBELAND NO, 1997, NYTT LEGEMIDLER, V6, P123; *WHO EX BOARD, 1998, SCRIP           0403, P16; *WTO, 1998, EUR COMM MEAS AFF AS; *WTO PAN, 1997, EC MEAS MEAT MEAT PR; 1998, ETHYL NEWS      0720; 1996, INT J RISK SAFETY ME, V9, P131	16	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					203	204		10.1126/science.285.5425.203	http://dx.doi.org/10.1126/science.285.5425.203			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10428717				2022-12-28	WOS:000081346000023
J	Malissen, B				Malissen, B			Immunology - Dancing the immunological two-step	SCIENCE			English	Editorial Material							ADHESION; RECEPTORS; AFFINITY; CD2		CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Malissen, B (corresponding author), CNRS Marseille Luminy, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 9, France.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342				Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Malissen B, 1998, SCIENCE, V281, P528, DOI 10.1126/science.281.5376.528; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354	9	15	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					207	208		10.1126/science.285.5425.207	http://dx.doi.org/10.1126/science.285.5425.207			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10428718				2022-12-28	WOS:000081346000026
J	Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB				Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB			Fas ligand: A sensor for DNA damage critical in skin cancer etiology	SCIENCE			English	Article							P53 MUTATIONS; INDUCED APOPTOSIS; CELL CARCINOMA; MOUSE SKIN; ULTRAVIOLET; LYMPHOCYTES; ACTIVATION; SUNLIGHT; TUMORS; MICE	DNA-damaged cells can either repair the DNA or be eliminated through a homeostatic control mechanism termed "cellular proofreading." Elimination of DNA-damaged cells after ultraviolet radiation (UVR) through sunburn cell (apoptotic keratinocyte) formation is thought to be pivotal for the removal of precancerous skin cells. Sunburn cell formation was found to be dependent on Fas ligand (FasL), a pro-apoptotic protein induced by DNA damage. Chronic exposure to UVR caused 14 of 20 (70 percent) FasL-deficient mice and 1 of 20 (5 percent) wild-type mice to accumulate p53 mutations in the epidermis, Thus, Fast-mediated apoptosis is important for skin homeostasis, suggesting that the dysregulation of Fas-FasL interactions may be central to the development of skin cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Owen-Schaub, LB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	lowensch@mdanderson.org			NCI NIH HHS [CA52457, CA45623] Funding Source: Medline; NIAID NIH HHS [F32 AI09351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hill LL, 1999, J EXP MED, V189, P1285, DOI 10.1084/jem.189.8.1285; HILL LL, UNPUB; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KANJILAL S, 1993, CANCER RES, V53, P2961; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	20	206	207	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					898	900		10.1126/science.285.5429.898	http://dx.doi.org/10.1126/science.285.5429.898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436160				2022-12-28	WOS:000081860900052
J	Horton, R				Horton, R			An unwilling exit from the NEJM	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							FRANKEL M, 1999, TIMES MY LIFE, P410; HAZLITT W, 1991, SELECTED WRITINGS, P41; Horton R, 1999, LANCET, V353, P252, DOI 10.1016/S0140-6736(99)00019-7; Kassirer JP, 1999, NEW ENGL J MED, V340, P1671, DOI 10.1056/NEJM199905273402109; Kassirer JP, 1997, NEW ENGL J MED, V337, P700, DOI 10.1056/NEJM199709043371008; Kassirer JP, 1999, NEW ENGL J MED, V340, P466, DOI 10.1056/NEJM199902113400609; TYE L, 1999, BOSTON GLOBE    0727, P1; 1999, JAMA, V281, P2240	8	10	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					358	358		10.1016/S0140-6736(99)00250-0	http://dx.doi.org/10.1016/S0140-6736(99)00250-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437862				2022-12-28	WOS:000081764900007
J	Spargias, KS; Hall, AS; Ball, SG				Spargias, KS; Hall, AS; Ball, SG			Safety concerns about digoxin after acute myocardial infarction	LANCET			English	Article								We examined clinical outcomes associated with non-randomised digoxin therapy in a postmyocardial infarction population with clinical heart failure (AIRE study). Our results raise concern about the safety of digoxin in this population.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hall, AS (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.		Hall, Alistair/K-1953-2019	Hall, Alistair/0000-0003-0306-7887				*AIRE STUD INV, 1993, LANCET, V343, P821; GHEORGHIADE M, 1992, AM J CARDIOL, V69, pG1; IESAKA Y, 1983, J AM COLL CARDIOL, V2, P45, DOI 10.1016/S0735-1097(83)80375-1; MCCLEMENTS BM, 1993, J AM COLL CARDIOL, V21, P1419, DOI 10.1016/0735-1097(93)90319-V; Perry G, 1997, NEW ENGL J MED, V336, P525	5	26	28	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					391	392		10.1016/S0140-6736(99)01429-4	http://dx.doi.org/10.1016/S0140-6736(99)01429-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437870				2022-12-28	WOS:000081764900016
J	Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA				Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA			Light-dependent sequestration of TIMELESS by CRYPTOCHROME	SCIENCE			English	Article							DROSOPHILA CLOCK GENE; CIRCADIAN CLOCK; PROTEIN; PERIOD; TIM; PHOTORECEPTORS; TRANSCRIPTION; MELANOGASTER; ENTRAINMENT; HOMOLOG	Most organisms have circadian clocks consisting of negative feedback Loops of gene regulation that facilitate adaptation to cycles of light and darkness. In this study, CRYPTOCHROME (CRY), a protein involved in circadian photoperception in Drosophila, is shown to block the function of PERIOD/TIMELESS (PER/TIM) heterodimeric complexes in a light-dependent fashion. TIM degradation does not occur under these conditions: thus, TIM degradation is uncoupled from abrogation of its function by light, CRY and TIM are part of the same complex and directly interact in yeast in a light-dependent fashion. PER/TIM and CRY influence the subcellular distribution of these protein complexes, which reside primarily in the nucleus after the perception of a light signal. Thus, CRY acts as a circadian photoreceptor by directly interacting with core components of the circadian clock.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011; Mas, Paloma/B-8215-2016	Kay, Steve A/0000-0002-0402-2878; Mas, Paloma/0000-0002-3780-8041; Ceriani, Maria/0000-0001-8945-3070	NIMH NIH HHS [MH-59943, MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059943, R01MH051573] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CERIANI MF, UNPUB; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Egan ES, 1999, J NEUROSCI, V19, P3665; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; STAKNIS D, UNPUB; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323	36	431	446	4	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					553	556		10.1126/science.285.5427.553	http://dx.doi.org/10.1126/science.285.5427.553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417378				2022-12-28	WOS:000081609500028
J	Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT				Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT			Temporal dissociation of parallel processing in the human subcortical outputs	NATURE			English	Article							BASAL GANGLIA; WORKING-MEMORY; MOTOR CONTROL; HUMAN BRAIN; DATA SETS; CEREBELLUM; CHANNELS	Many tasks require rapid and fine-tuned adjustment of motor performance based on incoming sensory information. This process of sensorimotor adaptation engages two parallel subcortico-cortical neural circuits, involving the cerebellum and basal ganglia, respectively(1-10), How these distributed circuits are functionally coordinated has not been shown in humans. The cerebellum and basal ganglia show very similar convergence of input-output organization(11,12), which presents an ideal neuroimaging model for the study of parallel processing at a systems level(13). Here we used functional magnetic resonance imaging to measure the temporal coherence of brain activity during a tactile discrimination task. We found that, whereas the prefrontal cortex maintained a high level of activation, output activities in the cerebellum and basal ganglia showed different phasic patterns. Moreover, cerebellar activity significantly correlated with the activity of the supplementary motor area but not with that of the primary motor cortex; in contrast, basal ganglia activity was more strongly associated with the activity of the primary motor cortex than with that of the supplementary motor area. These results demonstrate temporally partitioned activity in the cerebellum and basal ganglia, implicating functional independence in the parallel subcortical outputs. This further supports the idea of task-related dynamic reconfiguration of large-scale neural networks(14,15).	Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, YY (corresponding author), Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Fox, Peter/B-4725-2010; anand, amit/A-7222-2009	Fox, Peter/0000-0002-0465-2028; LIOTTI, MARIO/0000-0003-3375-5488				ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BRESSLER SL, 1995, BRAIN RES REV, V20, P288, DOI 10.1016/0165-0173(94)00016-I; CHURCHLAND PS, 1988, SCIENCE, V242, P741, DOI 10.1126/science.3055294; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; FOX EM, 1995, PAC RIM L POLY J, V4, P1; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; Ghez C, 1991, PRINCIPLES NEURAL SC, P609; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; Hoover JE, 1999, J NEUROSCI, V19, P1446; Houk JC, 1997, PROG BRAIN RES, V114, P543; HOUK JC, 1993, TRENDS NEUROSCI, V16, P27, DOI 10.1016/0166-2236(93)90049-R; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LIU Y, 1998, P INT SOC MAGN RESON, V6, P110; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Middleton FA, 1997, PROG BRAIN RES, V114, P553; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; ROLAND PE, 1988, EUR J NEUROSCI, V1, P3; Rouiller Eric M., 1996, P99, DOI 10.1016/B978-012759440-8/50009-8; Van Essen D. C., 1994, LARGE SCALE NEURONAL, P271; Voogd J, 1997, PROG BRAIN RES, V114, P21; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	28	61	65	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					364	367		10.1038/22547	http://dx.doi.org/10.1038/22547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432114				2022-12-28	WOS:000081590000050
J	Verma, R; Freeman, I				Verma, R; Freeman, I			Rupture of papillary muscle during acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Nassau Cty Med Ctr, E Meadow, NY 11554 USA		Verma, R (corresponding author), Nassau Cty Med Ctr, E Meadow, NY 11554 USA.								0	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					247	247		10.1056/NEJM199907223410405	http://dx.doi.org/10.1056/NEJM199907223410405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413737				2022-12-28	WOS:000081528800005
J	Dierkes, J; Westphal, S; Luley, C				Dierkes, J; Westphal, S; Luley, C			Serum homocysteine increases after therapy with fenofibrate or bezafibrate	LANCET			English	Article								A 44% and 17.5% increase of homocysteine occurred in patients treated either with fenofibrate or bezafibrate. The increase was not explained by changes in vitamin concentrations but may be related to renal function.	Univ Magdeburg, Inst Clin Chem, D-39120 Magdeburg, Germany	Otto von Guericke University	Dierkes, J (corresponding author), Univ Magdeburg, Inst Clin Chem, Leipziger Str 44, D-39120 Magdeburg, Germany.							de Lorgeril M, 1999, LANCET, V353, P209, DOI 10.1016/S0140-6736(05)77220-2; Dennis VW, 1996, KIDNEY INT, V50, pS11; DEVUYST O, 1993, LANCET, V341, P840, DOI 10.1016/0140-6736(93)90625-Q; LIPKIN GW, 1993, LANCET, V341, P371, DOI 10.1016/0140-6736(93)90170-L; Norlund L, 1998, CLIN CHEM LAB MED, V36, P175, DOI 10.1515/CCLM.1998.032	5	113	113	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					219	220		10.1016/S0140-6736(99)02153-4	http://dx.doi.org/10.1016/S0140-6736(99)02153-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421307				2022-12-28	WOS:000081504200017
J	Mitchell, P				Mitchell, P			Alleged unlicensed gene-therapy trial comes to light	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					225	225		10.1016/S0140-6736(99)00125-7	http://dx.doi.org/10.1016/S0140-6736(99)00125-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421314				2022-12-28	WOS:000081504200024
J	Gaskell, G; Bauer, MW; Durant, J; Allum, NC				Gaskell, G; Bauer, MW; Durant, J; Allum, NC			Worlds apart? The reception of genetically modified foods in Europe and the US	SCIENCE			English	Review								Recent controversies about genetically modified foods in the United Kingdom and several other European countries highlight the apparent differences that exist in public opinion on this subject across the Atlantic. Why are people in the United States seemingly untroubled by a technology that causes Europeans so many difficulties? The results of survey research on public perceptions of biotechnology in Europe and the United States during 1996-1997, together with an analysis of press coverage and policy formation from 1984 to 1996, can help to answer this question.	London Sch Econ, Methodol Inst, London WC2A 2AE, England; London Sch Econ, Dept Social Psychol, London WC2A 2AE, England; Sci Museum London, London SW7 2DD, England	University of London; London School Economics & Political Science; University of London; London School Economics & Political Science	Gaskell, G (corresponding author), London Sch Econ, Methodol Inst, London WC2A 2AE, England.							Converse P., 1964, IDEOLOGY DISCONTENT, P206; DURANT J, 1998, BIOTECHNOLOGY PUBLIC; Jasanoff Sheila., 1995, RESISTANCE NEW TECHN, P311, DOI [10.1017/CBO9780511563706.016, DOI 10.1017/CBO9780511563706.016]; LEAHY PJ, 1980, SOC STUD SCI, V10, P259, DOI 10.1177/030631278001000301; LUHMANN Niklas, 1979, TRUST POWER; SCHUMANN H, 1981, QUESTIONS ANSWERS AT	6	345	356	1	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					384	387		10.1126/science.285.5426.384	http://dx.doi.org/10.1126/science.285.5426.384			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411496				2022-12-28	WOS:000081465900047
J	Palmer, JS; Kaplan, WE; Firlit, CF				Palmer, JS; Kaplan, WE; Firlit, CF			Erectile dysfunction in spina bifida is treatable	LANCET			English	Article								We undertook a prospective, blinded, randomised, placebo-controlled, dose escalation, crossover study that showed that erectile dysfunction in spina bifida is medically treatable, specifically with sildenafil citrate.	Northwestern Univ, Childrens Mem Hosp, Sch Med, Div Urol, Chicago, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Palmer, JS (corresponding author), Northwestern Univ, Childrens Mem Hosp, Sch Med, Div Urol, 2300 Childrens Plaza,24, Chicago, IL 60614 USA.							DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Joyner BD, 1998, EUR J PEDIATR SURG, V8, P29, DOI 10.1055/s-2008-1071115; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; YEN IH, 1992, AM J DIS CHILD, V146, P857, DOI 10.1001/archpedi.1992.02160190089028	5	29	29	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					125	126		10.1016/S0140-6736(99)02480-0	http://dx.doi.org/10.1016/S0140-6736(99)02480-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408490				2022-12-28	WOS:000081377100017
J	Weinberg, JR; Duerden, BI				Weinberg, JR; Duerden, BI			Commentary: A matter of good clinical practice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, London NW9 5EQ, England	Public Health England	Duerden, BI (corresponding author), Publ Hlth Lab Serv, London NW9 5EQ, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1617	1618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428554				2022-12-28	WOS:000080913100039
J	Dowdney, L; Wilson, R; Maughan, B; Allerton, M; Schofield, P; Skuse, D				Dowdney, L; Wilson, R; Maughan, B; Allerton, M; Schofield, P; Skuse, D			Psychological disturbance and service provision in parentally bereaved children: prospective case-control study	BRITISH MEDICAL JOURNAL			English	Article							SCHOOL-AGE-CHILDREN; CHILDHOOD BEREAVEMENT; DEATH; DEPRESSION; DISORDER	Objectives To identify whether psychiatric disturbance in parentally bereaved children and surviving parents is related to service prevision. Design Prospective case-control study Setting Two adjacent outer London health authorities. Participants 45 bereaved families with children aged 2 to 16 years. Main outcome measures Psychological disturbance in parentally bereaved children and surviving parents, and statistical associations between sample characteristics and service provision. Results Parentally bereaved children and surviving parents showed higher than expected levels of psychiatric difficulties. Boys were more affected than girls, and bereaved mothers had more mental health difficulties than bereaved fathers. Levels of psychiatric difficulties man bereaved fathers. Levels of psychiatric disturbance in children were higher when parents showed probable psychiatric disorder. Service provision related to the age of the children and the manner of parental death. Children under 5 years of age were less likely to be offered services than older children even though their parents desired it. Children were significantly more likely to be offered services when the parent had committed suicide or when the death was expected. Children least likely to receive service support were those who were not in touch with services before parental death. Conclusions Service provision was not significantly related to parental wishes or to level of psychiatric disturbance in parents or children. There is a role for general practitioners and primary care workers in identifying psychologically distressed surviving parents whose children may be psychiatrically disturbed, and referring them to appropriate services.	Sutton Hosp, Child Psychol Serv, Surrey SM5 2NF, England; Sutton Hosp, Dept Child Psychol, Surrey, England; Kingston Gen Hosp, Surrey KT2 7QB, England; Inst Psychiat, MRC, Child Psychiat Unit, London SE5 8AF, England; Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England	University of London; King's College London; University of London; University College London	Dowdney, L (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 5XH, Surrey, England.							Achenbach T. M., 1992, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; [Anonymous], 1991, MANUAL CHILD BEHAV C; BLACK D, 1992, PSYCHOTHER PSYCHOSOM, V57, P152, DOI 10.1159/000288592; Black D, 1996, BRIT MED J, V312, P1496, DOI 10.1136/bmj.312.7045.1496; Black D, 1998, BMJ-BRIT MED J, V316, P931, DOI 10.1136/bmj.316.7135.931; CHEIFETZ PN, 1989, CAN J PSYCHIAT, V34, P688, DOI 10.1177/070674378903400711; FRISTAD MA, 1993, AM J PSYCHIAT, V150, P511; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GERSTEN JC, 1991, AM J COMMUN PSYCHOL, V19, P481, DOI 10.1007/BF00937988; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Harrington R, 1996, BRIT MED J, V313, P822; HARRIS T, 1986, PSYCHOL MED, V16, P641, DOI 10.1017/S0033291700010394; KRANZLER EM, 1990, J AM ACAD CHILD PSY, V29, P513, DOI 10.1097/00004583-199007000-00002; PANTELL R, 1992, PEDIATRICS, V89, P516; PARK SW, 1995, POLYM-KOREA, V19, P1; Sanchez L, 1994, Ann Clin Psychiatry, V6, P39, DOI 10.3109/10401239409148838; SILVERMAN PR, 1992, AM J ORTHOPSYCHIAT, V62, P93, DOI 10.1037/h0079304; SOOD B, 1992, COMPREHENSIVE MENTAL, V2, P17; VANEERDEWEGH MM, 1982, BRIT J PSYCHIAT, V140, P23, DOI 10.1192/bjp.140.1.23; WELLER RA, 1991, AM J PSYCHIAT, V148, P1536; Worden JW, 1996, OMEGA-J DEATH DYING, V33, P91, DOI 10.2190/P77L-F6F6-5W06-NHBX; WORDEN JW, 1993, OMEGA-J DEATH DYING, V27, P251, DOI 10.2190/XMHJ-F977-P8GV-4W07; [No title captured]	24	42	42	1	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					354	357		10.1136/bmj.319.7206.354	http://dx.doi.org/10.1136/bmj.319.7206.354			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435957	Bronze, Green Published			2022-12-28	WOS:000082001700020
J	Balint, JA				Balint, JA			Brief encounters: Speaking with patients	ANNALS OF INTERNAL MEDICINE			English	Article							MODEL		Albany Med Ctr, Ctr Med Eth Educ & Res, Albany, NY 12208 USA	Albany Medical College	Balint, JA (corresponding author), Albany Med Ctr, Ctr Med Eth Educ & Res, Mail Code 153,47 New Scotland Ave, Albany, NY 12208 USA.							BALINT M, 1964, DOCT HIS PATIENT ILL; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; Coulehan John L., 1987, MED INTERVIEW PRIMER; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Lipkin MJ, 1995, MED INTERVIEW CLIN C; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Stoeckle J, 1987, ENCOUNTERS PATIENTS; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; TUMULTY PA, 1970, NEW ENGL J MED, V283, P20, DOI 10.1056/NEJM197007022830105; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204	11	4	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					231	234		10.7326/0003-4819-131-3-199908030-00023	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428750				2022-12-28	WOS:000081788700021
J	Bethune, CA; Gompels, MM; Spickett, GP				Bethune, CA; Gompels, MM; Spickett, GP			Physiological effects of starvation interpreted as food allergy	BRITISH MEDICAL JOURNAL			English	Article									Royal Victoria Infirm, Reg Dept Immunol, Newcastle Upon Tyne NE1 3LP, Tyne & Wear, England; Southmead Gen Hosp, Dept Immunol, Bristol BS10 5NB, Avon, England	Newcastle University - UK; Southmead Hospital	Bethune, CA (corresponding author), Royal Victoria Infirm, Reg Dept Immunol, Newcastle Upon Tyne NE1 3LP, Tyne & Wear, England.							HALES CN, 1963, LANCET, V1, P790; PERMUTT MA, 1976, J CLIN ENDOCR METAB, V43, P1088, DOI 10.1210/jcem-43-5-1088; *ROYAL COLL PHYS, 1992, ALL CONV ALT CONC; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					304	305		10.1136/bmj.319.7205.304	http://dx.doi.org/10.1136/bmj.319.7205.304			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426749	Green Published			2022-12-28	WOS:000081909100032
J	Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI				Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI			Long-term outcome in children after antenatal intervention for obstructive uropathies	LANCET			English	Article							POSTERIOR URETHRAL VALVES; CONGENITAL HYDRONEPHROSIS INUTERO; FETAL RENAL-FUNCTION; PRUNE BELLY SYNDROME; PULMONARY HYPOPLASIA; GROWTH; BLADDER; OLIGOHYDRAMNIOS; BIOCHEMISTRY; THERAPY	Background Antenatal intervention has been done for fetal obstructive uropathy far over a decade, yet little is known about long-term outcomes. To assess the long-term implications of fetal intervention, we reviewed the outcomes of children who underwent vesicoamniotic shunt placement. Methods We reviewed the clinical outcomes of 14 children who underwent vesicoamniotic shunt placement at our institution and who survived beyond 2 years of age. Findings In 1987-96, 34 patients underwent vesicoamniotic shunt placement. 13 died and 21 survived, of whom 17 are now more than 2 years old. Three survivors were lost to follow-up. Mean age at follow-up was 54.3 months (range 25-114). Final diagnoses included prune belly syndrome (seven cases), posterior urethral valves (four), urethral atresia (one), vesicoureteral reflux (one), and megacystis (one). Height was below the 25th percentile in 12 (86%) with seven (50%) below the 5th percentile. Five (36%) had renal failure and had successful transplantation, three (21%) have renal insufficiency, and six (43%) have normal renal function. Seven (50%) are acceptably continent, five (36%) have not yet begun toilet-training, and two (14%) are incontinent. Three of four children with valves needed bladder augmentation. Interpretation Antenatal intervention may help those fetuses with the most severe forms of obstructive uropathy, usually associated with a fatal neonatal course. intervention achieves outcomes similar to less severe cases that are usually diagnosed postnatally.	Childrens Hosp Michigan, Dept Paediat Urol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynaecol, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Mol Med & Geriatr, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Pathol, Detroit, MI USA	Children's Hospital of Michigan; Wayne State University; Wayne State University; Wayne State University	Freedman, AL (corresponding author), 100 UCLA Med Plaza,Suite 690, Los Angeles, CA 90095 USA.							BAUER SB, 1979, J UROLOGY, V121, P769, DOI 10.1016/S0022-5347(17)56985-2; CAMPAIOLA JM, 1985, J UROLOGY, V134, P708, DOI 10.1016/S0022-5347(17)47400-3; CONNOR JP, 1990, J UROLOGY, V144, P1209, DOI 10.1016/S0022-5347(17)39695-7; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1990, J UROLOGY, V144, P574, DOI 10.1016/S0022-5347(17)39526-5; ELDER JS, 1987, LANCET, V2, P1007; FREEDMAN AL, 1997, J UROLOGY, V157, pA10; GEARY DF, 1986, J UROLOGY, V135, P324, DOI 10.1016/S0022-5347(17)45627-8; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; GLICK PL, 1984, J PEDIATR SURG, V19, P649, DOI 10.1016/S0022-3468(84)80348-6; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1983, J PEDIATR SURG, V18, P247, DOI 10.1016/S0022-3468(83)80094-3; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; JOHNSON MP, 1995, AM J OBSTET GYNECOL, V173, P59, DOI 10.1016/0002-9378(95)90170-1; KRUEGER RP, 1980, UROL CLIN N AM, V7, P265; LIPITZ S, 1993, AM J OBSTET GYNECOL, V168, P174, DOI 10.1016/S0002-9378(12)90909-6; MANDELBROT L, 1991, J PERINAT MED, V19, P283; MANNING FA, 1986, NEW ENGL J MED, V315, P336, DOI 10.1056/NEJM198607313150532; MERGUERIAN PA, 1992, J UROLOGY, V148, P1499, DOI 10.1016/S0022-5347(17)36949-5; Mitchell M., 1982, DIAL PEDIAT UROL, V5, P8; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NICOLAIDES KH, 1992, AM J OBSTET GYNECOL, V166, P932, DOI 10.1016/0002-9378(92)91367-J; PETERS CA, 1991, J UROLOGY, V146, P597, DOI 10.1016/S0022-5347(17)37865-5; PETERS CA, 1990, J UROLOGY, V144, P122, DOI 10.1016/S0022-5347(17)39388-6; PETERS CA, 1991, J UROLOGY, V146, P1178, DOI 10.1016/S0022-5347(17)38035-7; REINBERG Y, 1992, J UROLOGY, V148, P125, DOI 10.1016/S0022-5347(17)36532-1; REINBERG Y, 1992, J UROLOGY, V148, P532, DOI 10.1016/S0022-5347(17)36645-4; REINBERG Y, 1991, J UROLOGY, V145, P1017, DOI 10.1016/S0022-5347(17)38518-X; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; WARSHAW BL, 1985, J UROLOGY, V133, P240, DOI 10.1016/S0022-5347(17)48899-9	31	128	131	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					374	377		10.1016/S0140-6736(98)11006-1	http://dx.doi.org/10.1016/S0140-6736(98)11006-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437866				2022-12-28	WOS:000081764900012
J	Jones, EA				Jones, EA			Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy	LANCET			English	Article							PROLONGED EXERCISE	A woman with chronic hepatitis C and profound fatigue became symptomfree when treated long-term with ondansetron 4 mg twice daily. Altered central serotoninergic neurotransmission may contribute to fatigue complicating chronic liver disease.	Acad Med Ctr, Dept Gastrointestinal & Liver Dis, NL-1105 AZ Amsterdam ZO, Netherlands		Jones, EA (corresponding author), Acad Med Ctr, Dept Gastrointestinal & Liver Dis, NL-1105 AZ Amsterdam ZO, Netherlands.							BAILEY SP, 1993, J APPL PHYSIOL, V74, P3006, DOI 10.1152/jappl.1993.74.6.3006; JALAN R, 1996, GUT, V39, pA30; Jones EA, 1997, HEPATOLOGY, V25, P492; WILSON WM, 1992, EXP PHYSIOL, V77, P921, DOI 10.1113/expphysiol.1992.sp003660	4	50	51	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					397	397		10.1016/S0140-6736(99)02936-0	http://dx.doi.org/10.1016/S0140-6736(99)02936-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437877				2022-12-28	WOS:000081764900023
J	Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T				Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T			Near patient testing for respiratory syncytial virus in paediatric accident and emergency: prospective pilot study	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS; DIAGNOSIS		City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland		Hallam, N (corresponding author), City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland.							*JOINT WORK GROUP, 1999, GUID NEAR PAT POINT; Langley JM, 1997, PEDIATRICS, V100, P943, DOI 10.1542/peds.100.6.943; TODD SJ, 1995, J CLIN MICROBIOL, V33, P1650, DOI 10.1128/JCM.33.6.1650-1651.1995; Wendt C H, 1995, Semin Respir Infect, V10, P224; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					289	290		10.1136/bmj.319.7205.289	http://dx.doi.org/10.1136/bmj.319.7205.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426738	Bronze, Green Published			2022-12-28	WOS:000081909100022
J	Wijnhoven, BPL; Pignatelli, M				Wijnhoven, BPL; Pignatelli, M			E-cadherin-catenin: more than a "sticky" molecular complex	LANCET			English	Editorial Material							ALPHA-CATENIN; BETA-CATENIN; EXPRESSION; CANCER		Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Wijnhoven, BPL (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England.		Wijnhoven, Bas/AAF-4838-2020; Pignatelli, Massimo/ABA-2672-2020	Pignatelli, Massimo/0000-0001-9257-3567				Bailey T, 1998, AM J PATHOL, V152, P135; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; GUMBINER BM, 1993, J CELL SCI, P155; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; Krishnadath KK, 1997, J PATHOL, V182, P331; Liu D, 1997, LAB INVEST, V77, P557; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Richmond PJM, 1997, CANCER RES, V57, P3189; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Valizadeh A, 1997, AM J PATHOL, V150, P1977	15	37	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					356	357		10.1016/S0140-6736(99)90055-7	http://dx.doi.org/10.1016/S0140-6736(99)90055-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437861				2022-12-28	WOS:000081764900006
J	Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG				Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG			Embryonic stem cell-derived glial precursors: A source of myelinating transplants	SCIENCE			English	Article							IN-VITRO DIFFERENTIATION; CENTRAL-NERVOUS-SYSTEM; NEURAL PRECURSORS; TARGETED MUTATION; PROGENITOR CELLS; NEURONS; BRAIN; ESTABLISHMENT; ASTROCYTE; LETHALITY	Self-renewing, totipotent embryonic stem (ES) cells may provide a virtually unlimited donor source for transplantation. A protocol that permits the in vitro generation of precursors for oligodendrocytes and astrocytes from ES cells was devised. Transplantation in a rat model of a human myelin disease shows that these ES cell-derived precursors interact with host neurons and efficiently myelinate axons in brain and spinal cord. Thus, ES cells can serve as a valuable source of cell type-specific somatic precursors for neural transplantation.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA	University of Bonn; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison	Brustle, O (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.				NINDS NIH HHS [NS33710] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033710] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BLAKEMORE WF, 1995, BRAIN PATHOL, V5, P443, DOI 10.1111/j.1750-3639.1995.tb00623.x; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; BRUSTLE O, UNPUB; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1996, J NEUROSCI, V16, P1056; FISHELL G, 1995, DEVELOPMENT, V121, P803; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; HODES ME, 1993, DEV NEUROSCI-BASEL, V15, P383, DOI 10.1159/000111361; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LACHAPELLE F, 1995, BRAIN PATHOL, V5, P289, DOI 10.1111/j.1750-3639.1995.tb00606.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	32	737	852	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					754	756		10.1126/science.285.5428.754	http://dx.doi.org/10.1126/science.285.5428.754			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427001				2022-12-28	WOS:000081765100060
J	Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP				Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP			Peptide antagonists of the human estrogen receptor	SCIENCE			English	Article							HUMAN PROGESTERONE; ANTIESTROGENS; TAMOXIFEN; IDENTIFICATION; ACTIVATION; YEAST	Estrogen receptor a transcriptional activity is regulated by distinct conformational states that are the result of ligand binding. Phage display was used to identify peptides that interact specifically with either estradiol- or tamoxifen-activated estrogen receptor alpha. When these peptides were coexpressed with estrogen receptor alpha in cells, they functioned as ligand-specific antagonists, indicating that estradiol-agonist and tamoxifen-partial agonist activities do not occur by the same mechanism. The ability to regulate estrogen receptor a transcriptional activity by targeting sites outside of the ligand-binding pocket has implications for the development of estrogen receptor a antagonists for the treatment of tamoxifen-refractory breast cancers.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Novalon Pharmaceut Corp, Durham, NC 27703 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Hamilton, Paul/0000-0003-4028-424X; Norris, John/0000-0001-6553-8053	NIDDK NIH HHS [DK48807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048807, R01DK048807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang C. H., UNPUB; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; NORRIS JR, UNPUB; Osborne CK, 1996, SCI MED, V3, P32; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	15	307	342	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					744	746		10.1126/science.285.5428.744	http://dx.doi.org/10.1126/science.285.5428.744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426998				2022-12-28	WOS:000081765100057
J	Cormack, BP; Ghori, N; Falkow, S				Cormack, BP; Ghori, N; Falkow, S			An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ANTIFUNGAL SUSCEPTIBILITY; ALBICANS GENE; RECEPTORS; EXPRESSION; VIRULENCE; INFECTION; PROTEINS; CLONING; VECTORS	Candida glabrata is an important fungal pathogen of humans that is responsible for about 15 percent of mucosal and systemic candidiasis. Candida glabrata adhered avidly to human epithelial cells in culture. By means of a genetic approach and a strategy allowing parallel screening of mutants, it was possible to clone a lectin from a Candida species. Deletion of this adhesin reduced adherence of C. glabrata to human epithelial cells by 95 percent. The adhesin, encoded by the EPA1 gene, is likely a glucan-cross-linked cell-wall protein and binds to host-cell carbohydrate, specifically recognizing asialo-lactosyl-containing carbohydrates.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Prot Design Labs, Fremont, CA 94555 USA	Stanford University	Cormack, BP (corresponding author), Johns Hopkins Med Inst, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	bcormack@jhmi.edu						Calderone R A, 1993, Arch Med Res, V24, P275; Cameron BJ, 1996, INFECT IMMUN, V64, P891, DOI 10.1128/IAI.64.3.891-896.1996; CLEMONS KV, 1994, J INFECT DIS, V169, P859, DOI 10.1093/infdis/169.4.859; Cormack BP, 1999, GENETICS, V151, P979; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P637; Fidel PL, 1996, J INFECT DIS, V173, P425, DOI 10.1093/infdis/173.2.425; FONZI WA, 1993, GENETICS, V134, P717; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gaur NK, 1997, INFECT IMMUN, V65, P5289, DOI 10.1128/IAI.65.12.5289-5294.1997; *GENB, AF149048 GENB; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0; PASCOPELLA L, 1995, INFECT IMMUN, V63, P4329, DOI 10.1128/IAI.63.11.4329-4335.1995; PENDRAK ML, 1995, FEMS MICROBIOL LETT, V129, P103, DOI 10.1111/j.1574-6968.1995.tb07566.x; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V33, P217, DOI 10.1016/S0732-8893(98)00160-6; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P289, DOI 10.1016/S0732-8893(97)00245-9; SCHABERG DR, 1991, AM J MED S3B, V91, P725; Schuman P, 1998, CLIN INFECT DIS, V27, P1161, DOI 10.1086/514979; Sherman F., 1986, METHODS YEAST GENETI; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STGEME JW, 1994, INFECT IMMUN, V62, P3881, DOI 10.1128/IAI.62.9.3881-3889.1994; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; TEUNISSEN AWRH, 1993, YEAST, V9, P423, DOI 10.1002/yea.320090413; TOSH FD, 1992, INFECT IMMUN, V60, P4734, DOI 10.1128/IAI.60.11.4734-4739.1992; WATARI J, 1994, YEAST, V10, P211, DOI 10.1002/yea.320100208; WHELAN WL, 1987, CRC CR REV MICROBIOL, V14, P99, DOI 10.3109/10408418709104437; YU L, 1994, INFECT IMMUN, V62, P2843, DOI 10.1128/IAI.62.7.2843-2848.1994; YU L, 1994, INFECT IMMUN, V62, P5213, DOI 10.1128/IAI.62.12.5213-5219.1994	35	287	296	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					578	582		10.1126/science.285.5427.578	http://dx.doi.org/10.1126/science.285.5427.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417386				2022-12-28	WOS:000081609500036
J	Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z				Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z			The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis	CELL			English	Article							TRANSGENIC MICE; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; JUVENILE POLYPOSIS; TUMOR PROGRESSION; STROMELYSIN-1	Matrix metalloproteinases (MMPs) are invariably upregulated in the stromal compartment of epithelial cancers and appear to promote invasion and metastasis. Here we report that phenotypically normal mammary epithelial cells with tetracycline-regulated expression of MMP3/stromelysin-1 (Str1) form epithelial glandular structures in vivo without Str1 but form invasive mesenchymal-like tumors with Str1. Once initiated, the tumors become independent of continued Str1 expression. Str1 also promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice. These changes are blocked by coexpression of a TIMP1 transgene. The premalignant and malignant lesions have stereotyped genomic changes unlike those seen in other murine mammary cancer models. These data indicate that Str1 influences tumor initiation and alters neoplastic risk.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Canc Genet Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Sternlicht, MD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.				NCI NIH HHS [R01 CA057621, CA72006, P01 CA072006-020003, R01 CA064786-04A1, R37 CA064786, R01 CA064786, CA57621, P01 CA072006, CA64786, R01 CA057621-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621, R01CA064786, R37CA064786, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; Ahmad A, 1998, AM J PATHOL, V152, P721; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Bachman KE, 1999, CANCER RES, V59, P798; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Birchmeier C, 1996, ACTA ANAT, V156, P217; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chin JR, 1997, DEVELOPMENT, V124, P1519; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DEOME KB, 1959, CANCER RES, V19, P515; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GACK S, 1994, J BIOL CHEM, V269, P10363; GILLES C, 1996, BREAST J, V2, P83; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hsieh CJ, 1998, CANCER RES, V58, P3942; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; Kim KS, 1998, EXP CELL RES, V245, P79, DOI 10.1006/excr.1998.4238; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; Martorana AM, 1998, CANCER RES, V58, P4970; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; Mehindate K, 1996, LAB INVEST, V75, P529; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Noe V, 1999, J CELL SCI, V112, P127; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ritland SR, 1997, CANCER RES, V57, P3520; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Rutter JL, 1998, CANCER RES, V58, P5321; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Squartini F, 1994, IARC Sci Publ, P47; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sun DZ, 1998, INT J DEV BIOL, V42, P733; SUNDARRAJ N, 1992, CELL TISSUE RES, V267, P347, DOI 10.1007/BF00302973; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; SYMPSON CJ, 1996, J CELL BIOL, V132; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; TISTY TD, 1998, CURR OPIN CELL BIOL, V10, P647; WARGOTZ ES, 1989, HUM PATHOL, V20, P628, DOI 10.1016/0046-8177(89)90149-4; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055	62	711	728	3	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					137	146		10.1016/S0092-8674(00)81009-0	http://dx.doi.org/10.1016/S0092-8674(00)81009-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428026	Bronze, Green Accepted			2022-12-28	WOS:000081632300004
J	Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM				Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM		Global Use Strategies Open Occluded Coronary Ar	Sex, clinical presentation, and outcome in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; INTERVENTION REGISTRY; GENDER DIFFERENCES; HEART-DISEASE; RISK-FACTORS; SHORT-TERM; WOMEN; MEN; MORTALITY	Background Studies have reported that women with acute myocardial infarction have in-hospital and long-term outcomes that are worse than those of men. Methods To assess sex-based differences in presentation and outcome, we examined data from the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb study, which enrolled 12,142 patients (3662 women and 8480 men) with acute coronary syndromes, including infarction with ST-segment elevation, infarction with no ST-segment elevation, and unstable angina. Results Overall, the women were older than the men and had significantly higher rates of diabetes, hypertension, and prior congestive heart failure. They had significantly lower rates of prior myocardial infarction and were less likely ever to have smoked. A smaller percentage of women than men had infarction with ST elevation (27.2 percent vs. 37.0 percent, P<0.001), and of the patients who presented with no ST elevation (those with myocardial infarction or unstable angina), fewer women than men had myocardial infarction (36.6 percent vs. 47.6 percent, P<0.001). Women had more complications than men during hospitalization and a higher mortality rate at 30 days (6.0 percent vs. 4.0 percent, P<0.001) but had similar rates of reinfarction at 30 days after presentation. However, there was a significant interaction between sex and the type of coronary syndrome at presentation (P=0.001). After stratification according to coronary syndrome and adjustment for base-line variables, there was a nonsignificant trend toward an increased risk of death or reinfarction among women as compared with men only in the group with infarction and ST elevation (odds ratio, 1.27; 95 percent confidence interval, 0.98 to 1.63; P=0.07). Among patients with unstable angina, female sex was associated with an independent protective effect (odds ratio for infarction or death, 0.65; 95 percent confidence interval, 0.49 to 0.87; P=0.003). Conclusions Women and men with acute coronary syndromes had different clinical profiles, presentation, and outcomes. These differences could not be entirely accounted for by differences in base-line characteristics and may reflect pathophysiologic and anatomical differences between men and women. (N Engl J Med 1999;341:226-32.) (C) 1999, Massachusetts Medical Society.	St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; Duke Clin Res Inst, Durham, NC USA; Henry Ford Heart & Vasc Inst, Detroit, MI USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Flinders Med Ctr, Adelaide, SA, Australia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Duke University; Henry Ford Health System; KU Leuven; University Hospital Leuven; Flinders Medical Centre; Cleveland Clinic Foundation	Hochman, JS (corresponding author), St Lukes Roosevelt Hosp Ctr, 1111 Amsterdam Ave, New York, NY 10025 USA.			Aylward, Philip/0000-0002-5358-8552; Hochman, Judith/0000-0002-5889-5981				BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BEHAR S, 1994, AM J CARDIOL, V73, P438, DOI 10.1016/0002-9149(94)90672-6; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; Cucuianu M., 1993, Revue Roumaine de Medecine Interne, V31, P183; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HARRELL FE, 1996, TRANSCAN S FUNCTION; HE J, 1994, AM J EPIDEMIOL, V139, P693, DOI 10.1093/oxfordjournals.aje.a117059; Hochman JS, 1997, J AM COLL CARDIOL, V30, P141, DOI 10.1016/S0735-1097(97)00107-1; HOCHMAN JS, IN PRESS AM HEART J; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; STEGNAR M, 1993, THROMB RES, V69, P81, DOI 10.1016/0049-3848(93)90005-9; STEGNAR M, 1993, THROMB RES, V72, P173, DOI 10.1016/0049-3848(93)90219-E; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Tracy R P, 1992, Ann Epidemiol, V2, P509; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; VACEK JL, 1993, AM HEART J, V126, P521, DOI 10.1016/0002-8703(93)90399-T; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097	40	607	638	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					226	232		10.1056/NEJM199907223410402	http://dx.doi.org/10.1056/NEJM199907223410402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413734				2022-12-28	WOS:000081528800002
J	Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R				Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R			Low-density lipoprotein cholesterol and the risk of dementia with stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTHERN MANHATTAN STROKE; CARDIOVASCULAR-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; VASCULAR DEMENTIA; ISCHEMIC STROKE; E POLYMORPHISM; HEART-DISEASE; POPULATION; INFARCTION	Context Next to Alzheimer disease; vascular dementia is the second most common form of dementia in the elderly, yet few specific risk factors have been identified. Objective To investigate the relationship of plasma lipids and lipoproteins to dementia with stroke. Design and Setting Prospective longitudinal community-based study over a 7-year period (1991-1998). Participants A total of 1111 nondemented participants (mean [SD] age, 75.0 [5.9] years) were followed up for an average of 2.1 years (range, 1-7.8 years). Main Outcome Measure Incident dementia with stroke according to standardized criteria, by baseline levels of total plasma cholesterol and triglycerides, low-density lipoprotein (LDL)cholesterol, LDL levels corrected for lipoprotein(a), high-density lipoprotein cholesterol, lipoprotein(a), and apolipoprotein E genotype. Results Two hundred eighty-six (25.7%) of the 1111 subjects developed dementia during follow-up; 61 (21.3%) were classified as having dementia with stroke and 225 (78.7%) as having probable Alzheimer disease. Levels of LDC cholesterol were significantly associated with an increased risk of dementia with stroke. Compared with the lowest quartile, the highest quartile of LDL cholesterol was associated with an approximately 3-fold increase in risk of dementia with stroke, adjusting for vascular risk factors and demographic variables (relative risk [RR], 3.1; 95% confidence interval [CI], 1.5-6.1). Levels of LDL corrected for lipoprotein(a) were an even stronger predictor of dementia with stroke in the adjusted multivariate analysis. Compared with the lowest quartile, the RR of dementia with stroke for the highest quartile of lipoprotein(a)-corrected LDL cholesterol was 4.1 (95% CI, 1.8-9.6) after adjusting for vascular factors and demographic variables. Lipid or lipoprotein levels were not associated with the development of Alzheimer disease in-our cohort. Conclusions Elevated levels of LDL cholesterol were associated with the risk of dementia with stroke in elderly patients. Further study is needed to determine whether treatment of elevated LDL cholesterol levels will reduce the risk of dementia with stroke.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Mayeux, R (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Mayeux, Richard/E-9788-2013	Mayeux, Richard/0000-0001-6519-9696; Berglund, Lars/0000-0001-6705-1791; Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07232, AG 10963] Funding Source: Medline; NINDS NIH HHS [K08 NS 02051] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fujiwara Y, 1997, J Atheroscler Thromb, V4, P90; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; HIXSON J, 1991, J LIPID RES, V31, P545; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029; Kalmijn S, 1996, STROKE, V27, P2230, DOI 10.1161/01.STR.27.12.2230; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; NAUCK M, 1995, CLIN CHEM, V41, P1761; Pablos-Mendez A, 1997, ARTERIOSCL THROM VAS, V17, P3534, DOI 10.1161/01.ATV.17.12.3534; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; SACCO RL, 1994, NEUROLOGY, V44, P626, DOI 10.1212/WNL.44.4.626; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; TATEMICHI TK, 1995, J NEUROL NEUROSUR PS, V58, P633, DOI 10.1136/jnnp.58.5.633; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; Tuck CH, 1997, ARTERIOSCL THROM VAS, V17, P1822, DOI 10.1161/01.ATV.17.9.1822; *US BUR CENS, 1991, CENS POP HOUS SUMM T; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416	40	152	161	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					254	260		10.1001/jama.282.3.254	http://dx.doi.org/10.1001/jama.282.3.254			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422994	Bronze, Green Published			2022-12-28	WOS:000081504400031
J	Ustun, TB; Rehm, J; Chatterji, S; Saxena, S; Trotter, R; Room, R; Bickenbach, J				Ustun, TB; Rehm, J; Chatterji, S; Saxena, S; Trotter, R; Room, R; Bickenbach, J		WHO NIH Joint Project CAR Study Grp	Multiple-informant ranking of the disabling effects of different health conditions in 14 countries	LANCET			English	Article							GLOBAL BURDEN; DISEASE; DISABILITY	Background The Global Burden of Disease study provided international statistics on the burden of diseases, combining mortality and disability, that can be used for priority setting and policy making. However, there are concerns about the universality of the disability weights used, We undertook a study to investigate the stability of such weighting in different countries and informant groups. Methods 241 key informants (health professionals, policy makers, people with disabilities, and their carers) from 14 countries were asked to rank 17 health conditions from most disabling to least disabling. Kruskal-Wallis ANOVA was used to test for differences in ranking between countries or informant groups and Kendall tau-B correlations to measure association between different rank orders. Findings For 13 of 17 health conditions, there were significant (p<0.05) differences in ranking between countries; in the comparison of informant groups, there were significant differences for five of the 17 health conditions. The overall rank order in the present study was, however, almost identical to the ranking of the Global Burden of Disease study, which used a different method, Most. of the rank correlations between countries were between 0.50 and 0.70 (average 0.61 [95% CI 0.59-0.64]). The average correlation of rank orders between different informant groups was 0.76. Interpretation Rank order of disabling effects of health conditions is relatively stable across countries, informant groups, and methods. However, the differences are large enough to cast doubt: on the assumption of universality of experts' judgments at,out disability weights. Further studies are needed because disability weights are central to the calculation of disability-adjusted life years.	WHO, Assessment Classificat & Epidemiol Grp, CH-1211 Geneva 27, Switzerland; Addict Res Fdn, Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; No Arizona Univ, Dept Anthropol, Flagstaff, AZ 86011 USA; Natl Inst Alcohol & Drug Res, Oslo, Norway; Queens Univ, Kingston, ON, Canada	World Health Organization; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Northern Arizona University; Queens University - Canada	Ustun, TB (corresponding author), WHO, Assessment Classificat & Epidemiol Grp, CH-1211 Geneva 27, Switzerland.		Rehm, Jürgen/K-2147-2012; CHATTERJI, Somnath/ABE-6832-2020; Rem, Jürgen/H-1309-2011; Room, Robin/ABH-8505-2020; Room, Robin/ABF-7460-2021	Rehm, Jürgen/0000-0001-5665-0385; Room, Robin/0000-0002-5618-385X	NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH035883] Funding Source: NIH RePORTER; NIMH NIH HHS [UO1MH35883] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ad Hoc Cabinet Committee on Training and Employment, 1987, FURTH ED TRAIN WHO S; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Field M, 1998, SUMMARISING POPULATI; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P345, DOI 10.1016/0895-4356(89)90039-5; Hays W. L., 1973, STAT SOCIAL SCI, V2nd; Hyder AA, 1998, AM J PUBLIC HEALTH, V88, P196, DOI 10.2105/AJPH.88.2.196; MAKELA K, 1981, ALCOHOL SOC STATE, V1; Mehrez A, 1992, Pharmacoeconomics, V1, P338; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NORD E, 1995, MED DECIS MAKING, V15, P201, DOI 10.1177/0272989X9501500302; Rehm J.T., 1990, INTUITIVE PREDICTION; Single E, 1997, DRUG-EDUC PREV POLIC, V4, P7, DOI 10.3109/09687639709035758; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TROTTER RT, IN PRESS HUM ORG; USTUN TB, 1998, INT J METH PSYCH RES, V7, P79; *WHO, 1997, INT CLASS IMP ACT PA; World Health Organization, 1980, INT CLASS IMP DIS HA	18	145	153	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					111	115		10.1016/S0140-6736(98)07507-2	http://dx.doi.org/10.1016/S0140-6736(98)07507-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	215HW	10408486				2022-12-28	WOS:000081377100013
J	Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE				Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE			Stabilization of chromatin structure by PRC1, a polycomb complex	CELL			English	Article							POLYMERASE-II TRANSCRIPTION; DROSOPHILA BITHORAX COMPLEX; CHROMOSOME-BINDING-SITES; HOMEOTIC GENE-EXPRESSION; GROUP PROTEINS; CAENORHABDITIS-ELEGANS; MEDIATED REPRESSION; GROUP PRODUCTS; MELANOGASTER; DOMAIN	The Polycomb group (PcG) genes are required for maintenance of homeotic gene repression during development. Mutations in these genes can be suppressed by mutations in genes of the SWI/SNF family. We have purified a complex, termed PRC1 (Polycomb repressive complex 1), that contains the products of the PcG genes Polycomb, Posterior sex combs, polyhomeotic, Sex combs on midleg, and several other proteins. Preincubation of PRC1 with nucleosomal arrays blocked the ability of these arrays to be remodeled by SWI/SNF. Addition of PRC1 to arrays at the same time as SWI/SNF did not block remodeling. Thus, PRC1 and SWI/SNF might compete with each other for the nucleosomal template. Several different types of repressive complexes, including deacetylases, interact with histone tails. In contrast, PRC1 was active on nucleosomal arrays formed with tailless histones.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Raible, Florian/G-6019-2011	Raible, Florian/0000-0002-4515-6485				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHIANG A, 1995, DEVELOPMENT, V121, P1681; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hodgson JW, 1997, MECH DEVELOP, V66, P69, DOI 10.1016/S0925-4773(97)00091-9; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KOGIE C, 1999, BIOCHEMISTRY-US, V38, P2514; Korf I, 1998, DEVELOPMENT, V125, P2469; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; LONIE A, 1994, DEVELOPMENT, V120, P2629; MARTIN EC, 1993, DEVELOPMENT, V117, P641; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tie F, 1998, DEVELOPMENT, V125, P3483; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU CT, 1995, GENETICS, V140, P139; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	53	648	666	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					37	46		10.1016/S0092-8674(00)80604-2	http://dx.doi.org/10.1016/S0092-8674(00)80604-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412979	Bronze			2022-12-28	WOS:000081451000006
J	McKendrick, O				McKendrick, O			The ladder of truth - The story of a mother and her son	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					371	371		10.1136/bmj.319.7206.371	http://dx.doi.org/10.1136/bmj.319.7206.371			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435965	Green Published			2022-12-28	WOS:000082001700026
J	Ferriman, A				Ferriman, A			Dobson defends use of the PFI for hospital building	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					275	275		10.1136/bmj.319.7205.275	http://dx.doi.org/10.1136/bmj.319.7205.275			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426725	Green Published			2022-12-28	WOS:000081909100009
J	Bains, S; Corfield, RM; Norris, RD				Bains, S; Corfield, RM; Norris, RD			Mechanisms of climate warming at the end of the Paleocene	SCIENCE			English	Article							STABLE-ISOTOPE STRATIGRAPHY; CIRCUM-CARIBBEAN VOLCANISM; OCEANIC METHANE HYDRATE; HIGH-RESOLUTION RECORDS; THERMAL MAXIMUM; LATEST PALEOCENE; BIGHORN BASIN; PLANKTONIC-FORAMINIFERA; EARLY EOCENE; CAUSAL LINK	An abrupt episode of global warming marked the end of the Paleocene epoch. Oxygen and carbon isotope records from two widely separated sites support the notion that degassing of biogenic methane hydrate may have been an important factor in altering Earth's climate. The data show evidence for multiple injections of methane, separated by intervals in which the carbon cycle was in stasis. Correlations between the two sites suggest that even these small-scale events were global in nature.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA	University of Oxford; Woods Hole Oceanographic Institution	Bains, S (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.	Santo.Bains@earth.ox.ac.uk						BAINS S, UNPUB; BERGER WH, 1986, GEOL RUNDSCH, V75, P249, DOI 10.1007/BF01770192; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; BERGGREN WA, 1996, CORRELATION EARLY PA, P309; Booth JS, 1998, GEOL SOC SPEC PUBL, V137, P113, DOI 10.1144/GSL.SP.1998.137.01.08; Bralower TJ, 1998, GEOLOGY, V26, P671; Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; BRALOWER TJ, 1995, PALEOCEANOGRAPHY, V10, P841, DOI 10.1029/95PA01143; Clyde WC, 1998, GEOLOGY, V26, P1011, DOI 10.1130/0091-7613(1998)026<1011:MCRTTL>2.3.CO;2; Corfield RM, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P124; CORFIELD RM, 1992, TERRA NOVA, V4, P443, DOI 10.1111/j.1365-3121.1992.tb00579.x; CORFIELD RM, 1994, EARTH-SCI REV, V37, P225, DOI 10.1016/0012-8252(94)90030-2; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; Dickens GR, 1998, GEOLOGY, V26, P670, DOI 10.1130/0091-7613(1998)026<0670:HRROTL>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; ELDHOLM O, 1993, EARTH PLANET SC LETT, V117, P319, DOI 10.1016/0012-821X(93)90087-P; GINSBURG GD, 1998, GAS HYDRATES, P61; Haq BU, 1998, GEOL SOC SPEC PUBL, V137, P303, DOI 10.1144/GSL.SP.1998.137.01.24; Hooker J.J., 1996, Geological Society Special Publication, V101, P205, DOI 10.1144/GSL.SP.1996.101.01.13; Kelly DC, 1998, PALAEOGEOGR PALAEOCL, V141, P139, DOI 10.1016/S0031-0182(98)00017-0; Kelly DC, 1996, GEOLOGY, V24, P423; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KOCH PL, 1995, PALAEOGEOGR PALAEOCL, V115, P61, DOI 10.1016/0031-0182(94)00107-J; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; KVENVOLDEN KA, 1988, CHEM GEOL, V71, P41, DOI 10.1016/0009-2541(88)90104-0; KYENVOLDEN KA, 1998, GAS HYDRATES, P9; LU G, 1995, PALAEOGEOGR PALAEOCL, V117, P211, DOI 10.1016/0031-0182(94)00125-R; LU GY, 1993, MAR MICROPALEONTOL, V21, P101, DOI 10.1016/0377-8398(93)90012-M; MAAS MC, 1995, PALAEOGEOGR PALAEOCL, V115, P181, DOI 10.1016/0031-0182(94)00111-K; Pak DK, 1992, PALEOCEANOGRAPHY, V7, P405, DOI 10.1029/92PA01234; SHACKLETON NJ, 1993, PALEOCEANOGRAPHY, V8, P141, DOI 10.1029/93PA00123; SHACKLETON NJ, 1984, FOSSILS CLIMATE, P27; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; STOTT LD, 1996, CORRELATIONS EARLY P, P381; Thomas E., 1990, Proceedings of the Ocean Drilling Program Scientific Results, V113, P571, DOI 10.2973/odp.proc.sr.113.123.1990; THOMAS E, 1996, CORRELATION EARLY PA, P401; WING SL, 1995, PALAEOGEOGR PALAEOCL, V115, P117, DOI 10.1016/0031-0182(94)00109-L; ZACHOS JC, 1993, J GEOL, V101, P191, DOI 10.1086/648216; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	39	267	300	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					724	727		10.1126/science.285.5428.724	http://dx.doi.org/10.1126/science.285.5428.724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426992				2022-12-28	WOS:000081765100051
J	Fitzpatrick, MO; Gan, P				Fitzpatrick, MO; Gan, P			Lesson of the week - Contrast enhanced computed tomography in the early diagnosis of cerebral abscess	BRITISH MEDICAL JOURNAL			English	Article							BRAIN ABSCESSES		So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Fitzpatrick, MO (corresponding author), So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.							HEINEMAN HS, 1971, J AMER MED ASSOC, V218, P1542, DOI 10.1001/jama.218.10.1542; Miller E S, 1988, Br J Neurosurg, V2, P439, DOI 10.3109/02688698809029597; MILLER JD, 1987, NORTHFIELDS SURG CEN, P502; ROSENBLUM ML, 1978, J NEUROSURG, V49, P658, DOI 10.3171/jns.1978.49.5.0658; SALEH J, 1988, BRIT J NEUROSURG, V2, P514; SALZMAN C, 1987, ARCH INTERN MED, V147, P951, DOI 10.1001/archinte.147.5.951; STEPHANOV S, 1988, NEUROSURGERY, V22, P724, DOI 10.1227/00006123-198804000-00017	7	4	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					239	240		10.1136/bmj.319.7204.239	http://dx.doi.org/10.1136/bmj.319.7204.239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417091	Green Published			2022-12-28	WOS:000081720300029
J	Greenberg, PD; Riddell, SR				Greenberg, PD; Riddell, SR			Immunology - Deficient cellular immunity - Finding and fixing the defects	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; BONE-MARROW TRANSPLANTATION; EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; ADENOSINE-DEAMINASE DEFICIENCY; ACTIVE ANTIRETROVIRAL THERAPY; HYPER-IGM SYNDROME; ADOPTIVE TRANSFER; HIV-1 INFECTION; IN-VITRO	The critical role of cellular immunity in resistance to infectious diseases is glaringly revealed by life-threatening infections if T cell function is disrupted by an inherited or acquired immunodeficiency. Although treatment has historically focused on infectious complications, understanding of the cellular and molecular basis of immunodeficiency and technologies useful for enhancing cellular immunity have both been rapidly; evolving. A new era of molecular and cellular therapy is emerging as approaches to correct abnormal genes, the loss of T cell subpopulations, and aberrant T cell homeostasis make the transition from bench to bedside.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Greenberg, PD (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.	pgreen@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA033084, R37CA033084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041754, P30AI027757] Funding Source: NIH RePORTER; NCI NIH HHS [CA33084] Funding Source: Medline; NIAID NIH HHS [AI27757, AI41754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1992, AIDS RES HUM RETROV, V8, P581, DOI 10.1089/aid.1992.8.581; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bolotin E, 1996, BLOOD, V88, P1887; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CHATILA T, 1990, P NATL ACAD SCI USA, V87, P10033, DOI 10.1073/pnas.87.24.10033; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Clegg CH, 1996, NATURE, V384, P261, DOI 10.1038/384261a0; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971; Davis CM, 1997, J CLIN IMMUNOL, V17, P167, DOI 10.1023/A:1027382600143; de Jong R, 1998, SCIENCE, V280, P1435; De Paoli P, 1997, J CLIN INVEST, V100, P2737, DOI 10.1172/JCI119819; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; Fischer A, 1997, ANNU REV IMMUNOL, V15, P93, DOI 10.1146/annurev.immunol.15.1.93; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; Garcia-Ojeda ME, 1998, J EXP MED, V187, P1813, DOI 10.1084/jem.187.11.1813; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; GORSKI J, 1994, J IMMUNOL, V152, P5109; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Gunthard HF, 1998, J VIROL, V72, P2422; Heitger A, 1997, BLOOD, V90, P850, DOI 10.1182/blood.V90.2.850.850_850_857; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hershfield MS, 1998, SEMIN HEMATOL, V35, P291; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hong R, 1998, SEMIN HEMATOL, V35, P282; Jabado N, 1996, PEDIATRICS, V98, P420; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kourtis AP, 1996, NEW ENGL J MED, V335, P1431, DOI 10.1056/NEJM199611073351904; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LEE SW, 1994, J VIROL, V68, P8254, DOI 10.1128/JVI.68.12.8254-8264.1994; Levine BL, 1997, J IMMUNOL, V159, P5921; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIEBOWITZ D, 1998, BLOOD S, V92, P57; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P8000, DOI 10.1073/pnas.90.17.8000; Lucas KG, 1996, BLOOD, V87, P2594, DOI 10.1182/blood.V87.6.2594.bloodjournal8762594; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1996, J IMMUNOL, V156, P4609; Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707; Mackall Crystal L., 1993, Blood, V82, P2585; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Masuko K, 1996, BLOOD, V87, P789, DOI 10.1182/blood.V87.2.789.bloodjournal872789; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; MIMICHAEL A, 1998, J EXP MED, V187, P1367; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL S, UNPUB; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIDDELL SR, 1992, SCIENCE, V257, P238; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Roux E, 1996, BLOOD, V87, P3984, DOI 10.1182/blood.V87.9.3984.bloodjournal8793984; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SATO K, 1995, J EXP MED, V182, P759, DOI 10.1084/jem.182.3.759; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; SOIFFER RJ, 1990, BLOOD, V75, P2076; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; Subauste CS, 1999, J IMMUNOL, V162, P6690; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tangye SG, 1999, J IMMUNOL, V162, P6981; Volberding PA, 1998, JAMA-J AM MED ASSOC, V279, P1343, DOI 10.1001/jama.279.17.1343; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Watanabe N, 1998, AIDS RES HUM RETROV, V14, P393, DOI 10.1089/aid.1998.14.393; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WithersWard ES, 1997, NAT MED, V3, P1102, DOI 10.1038/nm1097-1102; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154; ZHOU C, 1994, GENE, V149, P33	118	78	104	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					546	551		10.1126/science.285.5427.546	http://dx.doi.org/10.1126/science.285.5427.546			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417377				2022-12-28	WOS:000081609500027
J	Serafini, T				Serafini, T			Finding a partner in a crowd: Neuronal diversity and synaptogenesis	CELL			English	Review							CADHERINS; PROTOCADHERIN; EXPRESSION; SUBTYPES; FAMILY; CELLS		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Serafini, T (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.							Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; OBATA S, 1995, J CELL SCI, V108, P3765; Obata S, 1998, CELL ADHES COMMUN, V6, P323, DOI 10.3109/15419069809010791; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; RAMON CS, 1995, HISTOLOGY NERVOUS SY, V2; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Serafini T, 1997, TRENDS NEUROSCI, V20, P322; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Stevens CF, 1998, CURR BIOL, V8, pR708, DOI 10.1016/S0960-9822(98)70454-3; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	20	64	65	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					133	136		10.1016/S0092-8674(00)81008-9	http://dx.doi.org/10.1016/S0092-8674(00)81008-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428025	Bronze			2022-12-28	WOS:000081632300003
J	Shankar, AH; Genton, B; Semba, RD; Baisor, M; Paino, J; Tamja, S; Adiguma, T; Wu, L; Rare, L; Tielsch, JM; Alpers, MP; West, KP				Shankar, AH; Genton, B; Semba, RD; Baisor, M; Paino, J; Tamja, S; Adiguma, T; Wu, L; Rare, L; Tielsch, JM; Alpers, MP; West, KP			Effect of vitamin A supplementation on morbidity due to Plasmodium falciparum in young children in Papua New Guinea: a randomised trial	LANCET			English	Article							EAST SEPIK PROVINCE; A-DEFICIENCY; MALARIAL ATTACKS; IMMUNE FUNCTION; NORTHERN GHANA; VACCINE TRIALS; WOSERA AREA; MORTALITY; RETINOL; EPIDEMIOLOGY	Background Many individuals at risk of malaria also have micronutrient deficiencies that may hamper protective immunity. Vitamin A is central to normal immune function, and supplementation has been shown to lower the morbidity of some infectious diseases. We investigated the effect of vitamin A supplementation on malaria morbidity. Methods This randomised double-blind placebo-controlled trial of vitamin A supplementation took place in a P falciparum endemic area of Papua New Guinea. Of 520 potentially eligible children aged 6-60 months, 480 were randomly assigned high-dose vitamin A (n=239) or placebo (n=241), every 3 months for 13 months. Malaria morbidity was assessed through weekly community-based case detection and surveillance of patients who self-reported to the health centre. Cross-sectional surveys were also done at the beginning, middle, and end of the study to assess malariometric indicators. Analyses were by intention to treat. Findings The number of P falciparum febrile episodes (temperature greater than or equal to 37.5 degrees C with a parasite count of at least 8000/mu L) was 30% lower in the vitamin A group than in the placebo group (178 vs 249 episodes; relative risk 0.70 [95% CI 0.57-0.87], p=0.0013). At the end of the study P falciparum geometric mean density was lower in the vitamin A than the placebo group (1300 [907-1863] vs 2039 [1408-2951]) as was the proportion with spleen enlargement (125/196 [64%] vs 148/207 [71%]); neither difference was significant (p=0.093 and p=0.075). Children aged 12-36 months benefited most, having 35% fewer febrile episodes (89 vs 141; relative risk 0.65 [14-50], p=0.0023), 26% fewer enlarged spleens (46/79 [58%] vs 67/90 [74%], p=0.0045), and a 68% lower parasite density (1160 [95% CI 665-2022] vs 3569 [2080-6124], p=0.0054). Vitamin A had no consistent effect on cross-sectional indices of proportion infected or with anaemia. Interpretation Vitamin A supplementation may be an effective low-cost strategy to lower morbidity due to P falciparum in young children. The findings suggest that clinical episodes, spleen enlargement, and parasite density are influenced by different immunological mechanisms from infection and anaemia.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; Johns Hopkins Univ Hosp, Wilmer Inst, Div Ocular Immunol, Baltimore, MD 21287 USA; Papua New Guinea Inst Med Res, Goroka, Papua N Guinea	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; PNG Institute Of Medical Research	Shankar, AH (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Div Human Nutr, Room 2041,615 N Wolfe St, Baltimore, MD 21205 USA.	ashankar@jhsph.edu	; Shankar, Anuraj/U-3764-2018	Tielsch, James/0000-0002-1151-060X; Shankar, Anuraj/0000-0001-7268-6708				ALLEN S, 1995, LANCET, V346, P1555; ALYAMAN F, 1994, PAPUA NEW GUINEA MED, V37, P54; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BINKA FN, 1995, AM J CLIN NUTR, V61, P853, DOI 10.1093/ajcn/61.4.853; Craft NE, 1996, FASEB J, V10, P3039; Davis TME, 1998, ACTA TROP, V69, P111, DOI 10.1016/S0001-706X(97)00129-0; FILTEAU SM, 1993, AM J CLIN NUTR, V58, P192, DOI 10.1093/ajcn/58.2.192; Foote SJ, 1997, NAT GENET, V17, P380, DOI 10.1038/ng1297-380; Friis H, 1997, AM J CLIN NUTR, V66, P665, DOI 10.1093/ajcn/66.3.665; GALAN P, 1990, INT J VITAM NUTR RES, V60, P224; GENTON B, 1995, ANN TROP MED PARASIT, V89, P377, DOI 10.1080/00034983.1995.11812966; GENTON B, 1995, ANN TROP MED PARASIT, V89, P359, DOI 10.1080/00034983.1995.11812965; GILLES HM, 1985, BRUCE CHWATTS ESSENT, P73; Graves P, 1998, PARASITOL TODAY, V14, P218, DOI 10.1016/S0169-4758(98)01242-3; Graves PM, 1998, ANN TROP MED PARASIT, V92, P399, DOI 10.1080/00034989859384; Krishna S, 1999, LANCET, V353, P546, DOI 10.1016/S0140-6736(98)06316-8; KRISHNAN S, 1976, J NUTR, V106, P784, DOI 10.1093/jn/106.6.784; Krogstad DJ, 1996, EPIDEMIOL REV, V18, P77, DOI 10.1093/oxfordjournals.epirev.a017918; LENGELER C, 1998, COCHRANE LIBRARY; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; ROSS AC, 1993, J NUTR, V123, P346, DOI 10.1093/jn/123.suppl_2.346; SAMBA D, 1989, GASTROEN CLIN BIOL, V13, pA288; SAMBA DC, 1992, INT J VITAM NUTR RES, V62, P99; SCHELLENBERG JRMA, 1994, PARASITOL TODAY, V10, P439, DOI 10.1016/0169-4758(94)90179-1; Semba RD, 1998, NUTR REV, V56, pS38, DOI 10.1111/j.1753-4887.1998.tb01643.x; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; SHANKAR AH, 1995, AM J CLIN NUTR, V62, P842; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; STOLTZFUS RJ, 1989, J NUTR, V119, P2030, DOI 10.1093/jn/119.12.2030; STURCHLER D, 1987, ACTA TROP, V44, P213; TABONE MD, 1992, IMMUNOLOGY, V75, P553; THURNHAM DI, 1991, T ROY SOC TROP MED H, V85, P194, DOI 10.1016/0035-9203(91)90017-S; Underwood BA, 1996, FASEB J, V10, P1040, DOI 10.1096/fasebj.10.9.8801165; West K, 1996, VITAMIN A DEFICIENCY; WEST KP, 1995, AM J CLIN NUTR, V62, P143, DOI 10.1093/ajcn/62.1.143; 1993, STANDARD TREATMENT C	39	154	161	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					203	209		10.1016/S0140-6736(98)08293-2	http://dx.doi.org/10.1016/S0140-6736(98)08293-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421302	hybrid			2022-12-28	WOS:000081504200012
J	Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ				Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ			Different trajectories of parallel evolution during viral adaptation	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANCE MUTATIONS; BENEFICIAL MUTATIONS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SELECTION; FITNESS; POPULATION; DRUG; DNA	The molecular basis of adaptation is a major focus of evolutionary biology, yet the dynamic process of adaptation has been explored only piecemeal. Experimental evolution of two bacteriophage lines under strong selection led to over a dozen nucleotide changes genomewide in each replicate. At Least 96 percent of the amino acid substitutions appeared to be adaptive, and half the changes in one line also occurred in the other. However, the order of these changes differed between replicates, and parallel substitutions did not reflect the changes with the largest beneficial effects or indicate a common trajectory of adaptation.	Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Idaho; University of Idaho; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Wichman, HA (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA.	hwichman@uidaho.edu			NIGMS NIH HHS [GM57755, R01 GM057756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057756, R01GM057755] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; Boyd EF, 1998, J MOL EVOL, V47, P258, DOI 10.1007/PL00006383; Bull JJ, 1997, GENETICS, V147, P1497; Canica MMM, 1997, J MOL EVOL, V44, P57, DOI 10.1007/PL00006121; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Elena SF, 1996, GENETICS, V142, P673; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; HOLLAND JJ, 1979, CELL, V16, P495, DOI 10.1016/0092-8674(79)90024-2; KELLAM P, 1994, J GEN VIROL, V75, P341, DOI 10.1099/0022-1317-75-2-341; LAU PCK, 1985, GENE, V40, P273, DOI 10.1016/0378-1119(85)90050-2; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Li W. H, 1997, MOL EVOLUTION; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Nijhuis M, 1998, P NATL ACAD SCI USA, V95, P14441, DOI 10.1073/pnas.95.24.14441; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SPENCER JH, 1978, SINGLE STRANDED DNA, P87; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; WARNER JC, 1978, SINGLE STRANDED DNA, P417	28	273	274	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					422	424		10.1126/science.285.5426.422	http://dx.doi.org/10.1126/science.285.5426.422			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411508				2022-12-28	WOS:000081465900059
J	Sherwood, T; Horton, R				Sherwood, T; Horton, R			Ombudsman's third report	LANCET			English	Editorial Material																		Karlawish J, 1997, LANCET, V350, P1833, DOI 10.1016/S0140-6736(97)11309-5; Loefler IJP, 1996, LANCET, V348, P1703, DOI 10.1016/S0140-6736(96)12006-7; Power L, 1998, LANCET, V352, P1999, DOI 10.1016/S0140-6736(98)11283-7	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					91	92		10.1016/S0140-6736(99)00229-9	http://dx.doi.org/10.1016/S0140-6736(99)00229-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408482				2022-12-28	WOS:000081377100008
J	Smith, AE				Smith, AE			Gene therapy - where are we?	LANCET			English	Article							CELLULAR IMMUNE-RESPONSES; IN-VIVO; ADENOVIRUS VECTORS; CYSTIC-FIBROSIS; RETROVIRAL VECTOR; EXPRESSION; REPLICATION; MUSCLE; AIRWAY; VIRUS		Genzyme Corp, Framingham, MA 01701 USA	Sanofi-Aventis; Genzyme Corporation	Smith, AE (corresponding author), Genzyme Corp, POB 9322,1 Mtn Rd, Framingham, MA 01701 USA.							Alton EWFW, 1999, LANCET, V353, P947, DOI 10.1016/S0140-6736(98)06532-5; Anderson WF, 1998, NATURE, V392, P25; Armentano D, 1997, J VIROL, V71, P2408, DOI 10.1128/JVI.71.3.2408-2416.1997; Boucher RC, 1996, TRENDS GENET, V12, P81, DOI 10.1016/0168-9525(96)81410-7; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kaptein LCM, 1997, HUM GENE THER, V8, P1605, DOI 10.1089/hum.1997.8.13-1605; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P8000, DOI 10.1073/pnas.90.17.8000; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Mack CA, 1998, J VASC SURG, V27, P699, DOI 10.1016/S0741-5214(98)70236-8; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Mullen CA, 1996, HUM GENE THER, V7, P1123, DOI 10.1089/hum.1996.7.9-1123; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Rigg A, 1997, MOL MED TODAY, V3, P359, DOI 10.1016/S1357-4310(97)01082-4; Rosenberg SA, 1998, J NATL CANCER I, V90, P1894, DOI 10.1093/jnci/90.24.1894; Scaria A, 1997, GENE THER, V4, P611, DOI 10.1038/sj.gt.3300431; Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180; Simons JW, 1997, CANCER RES, V57, P1537; SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807; TOLSTOSHEV P, 1992, BONE MARROW TRANSPL, V9, P148; Tseng WC, 1998, PHARM SCI TECHNOL TO, V1, P206, DOI 10.1016/S1461-5347(98)00054-6; VERMA IM, 1990, SCI AM, V263, P66; Ye XH, 1998, HUM GENE THER, V9, P2135, DOI 10.1089/hum.1998.9.14-2135; YEI SP, 1994, GENE THER, V1, P192; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	29	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI1	SI4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437847				2022-12-28	WOS:000081825900002
J	Cranford, RE				Cranford, RE			Policy should be balanced with concern for the family	BRITISH MEDICAL JOURNAL			English	Article									Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA	Hennepin County Medical Center	Cranford, RE (corresponding author), Hennepin Cty Med Ctr, Dept Neurol, 701 Pk Ave, Minneapolis, MN 55415 USA.							Youngner S., 1999, DEFINITION DEATH CON	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1754	1755						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428563				2022-12-28	WOS:000081216900040
J	Myers, EB; Ralph, DC; Katine, JA; Louie, RN; Buhrman, RA				Myers, EB; Ralph, DC; Katine, JA; Louie, RN; Buhrman, RA			Current-induced switching of domains in magnetic multilayer devices	SCIENCE			English	Article							GIANT MAGNETORESISTANCE; EXCITATION	Current-induced switching in the orientation of magnetic moments is observed in cobalt/copper/cobalt sandwich structures, for currents flowing perpendicularly through the Layers. Magnetic domains in adjacent cobalt layers can be manipulated controllably between stable parallel and antiparallel configurations by applying current pulses of the appropriate sign. The observations are in accord with predictions that a spin-polarized current exerts a torque at the interface between a magnetic and nonmagnetic metal, due to Local exchange interactions between conduction electrons and the magnetic moments.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University; Cornell University	Ralph, DC (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.		Ralph, Daniel C/G-3251-2010; Myers, Edward/AAM-6628-2021					Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; EGROWE JE, 1999, EUROPHYS LETT, V45, P626; Gijs MAM, 1997, ADV PHYS, V46, P285, DOI 10.1080/00018739700101518; JANSEN AGM, 1980, J PHYS C SOLID STATE, V13, P6073, DOI 10.1088/0022-3719/13/33/009; LOUIE RN, 1997, THESIS CORNELL U ITH; RALLS KS, 1989, APPL PHYS LETT, V55, P2459, DOI 10.1063/1.102001; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Slonczewski JC, 1999, J MAGN MAGN MATER, V195, pL261, DOI 10.1016/S0304-8853(99)00043-8; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Tsoi M, 1998, PHYS REV LETT, V81, P493, DOI 10.1103/PhysRevLett.81.493; Tsoi M, 1998, PHYS REV LETT, V80, P4281, DOI 10.1103/PhysRevLett.80.4281; Tsoi MV, 1997, J APPL PHYS, V81, P5530, DOI 10.1063/1.364944; [No title captured]; 1998, IBM J RES DEV, V42	14	1119	1152	4	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					867	870		10.1126/science.285.5429.867	http://dx.doi.org/10.1126/science.285.5429.867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436150				2022-12-28	WOS:000081860900042
J	Weinberg, DS; Newschaffer, CJ; Topham, A				Weinberg, DS; Newschaffer, CJ; Topham, A			Risk for colorectal cancer after gynecologic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							OVARIAN-CANCER; COLON-CANCER; RECTUM; WOMEN; CARE	Background. Studies have suggested that women with previous diagnoses of gynecologic cancer (cervical, endometrial, or ovarian) have an increased risk for colorectal cancer. Objective: To quantify risk for colorectal cancer after gynecologic cancer, both overall and for subgroups defined by age at diagnosis, cancer stage at diagnosis, ethnicity, and duration of follow-up. Design: Retrospective cohort analysis of the Surveillance, Epidemiology, and End Results (SEER) program database from 1974 through 1995. Setting: U.S. cancer registry. Patients: 21 222 patients with cervical cancer, 51 680 patients with endometrial cancer, and 28 832 patients with ovarian cancer. Measurements: Standardized incidence ratios (SIRs) were calculated for each gynecologic cancer site and for subgroups to represent the relative risk for colorectal cancer in women with previously diagnosed gynecologic cancer compared with women without gynecologic cancer. Poisson regression methods adjusting simultaneously for all study variables were used to estimate relative risks for colorectal cancer across subgroups with each gynecologic cancer. Results: Overall, risk for colorectal cancer was elevated among women with previous ovarian cancer (SIR, 1.36 [95% CI, 1.21 to 1.53]). Risk was greatest in women who received a diagnosis before 50 years of age (SIR, 3.67 [CI, 2.74 to 4.80]) but was also elevated in women who received a diagnosis between 50 and 64 years of age (SIR, 1.52 [CI, 1.25 to 1.83]). The risk for colorectal cancer after endometrial cancer was also elevated substantially if endometrial cancer was diagnosed before the age of 50 (SIR, 3.39 [CI, 2.73 to 4.17]). No apparent risk elevation was associated with previous cervical cancer. Conclusions: Previous endometrial or ovarian cancer, particularly when diagnosed at an early age, increases subsequent risk for colorectal cancer. Greater emphasis on colorectal cancer screening in these populations may be necessary.	Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA	Jefferson University	Weinberg, DS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, 480 Main Bldg,132 S 10th St, Philadelphia, PA 19107 USA.	david.weinberg@mail.tju.edu						BERGFELDT K, 1995, ACTA ONCOL, V34, P771, DOI 10.3109/02841869509127185; Boice J D Jr, 1985, Natl Cancer Inst Monogr, V68, P3; BOMAN B, 1999, P AM ASS CANC RES PH, V40, pA278; BRESLOW N, 1986, NATL CANC I MONOGR, V67, P149; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Easton DF, 1996, INT J CANCER, V65, P284, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;284::AID-IJC2&gt;3.0.CO;2-W; Fontana SA, 1997, AM J PUBLIC HEALTH, V87, P1190, DOI 10.2105/AJPH.87.7.1190; HENDERSON B, 1997, CANC MED, V1, P277; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lynch HT, 1998, SEMIN ONCOL, V25, P265; McCredie M, 1997, CANCER EPIDEM BIOMAR, V6, P155; NELSON CL, 1993, GENET EPIDEMIOL, V10, P235, DOI 10.1002/gepi.1370100404; Potter J, 1996, PREVENTION EARLY DET; SANDLER RS, 1983, GASTROENTEROLOGY, V84, P51; *SEER CANC STAT RE, 1993, NIH PUBL; Travis LB, 1996, CANCER RES, V56, P1564; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; ZUMOFF B, 1982, CANCER RES, V42, P3289	20	42	42	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					189	193		10.7326/0003-4819-131-3-199908030-00005	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428735				2022-12-28	WOS:000081788700004
J	Adler, M				Adler, M			STD outreach by taxi	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					296	296		10.1136/bmj.319.7205.296	http://dx.doi.org/10.1136/bmj.319.7205.296			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426744	Green Published			2022-12-28	WOS:000081909100027
J	Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS				Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS			Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model	BRITISH MEDICAL JOURNAL			English	Article									Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen NV, Denmark; Gentofte Hosp, Dept Neurol, DK-2900 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Jorgensen, HS (corresponding author), Bispebjerg Hosp, Dept Neurol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.							Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JORGENSEN HS, 1994, LANCET, V344, P156; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401	4	32	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					288	289		10.1136/bmj.319.7205.288	http://dx.doi.org/10.1136/bmj.319.7205.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426737	Bronze, Green Published			2022-12-28	WOS:000081909100021
J	Corey, L; Langenberg, AGM; Ashley, R; Sekulovich, RE; Izu, AE; Douglas, JM; Handsfield, HH; Warren, T; Marr, L; Tyring, S; DiCarlo, R; Adimora, AA; Leone, P; Dekker, CL; Burke, RL; Leong, WP; Straus, SE				Corey, L; Langenberg, AGM; Ashley, R; Sekulovich, RE; Izu, AE; Douglas, JM; Handsfield, HH; Warren, T; Marr, L; Tyring, S; DiCarlo, R; Adimora, AA; Leone, P; Dekker, CL; Burke, RL; Leong, WP; Straus, SE		Chiron HSV Vaccine Study Grp	Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	37th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 28-OCT 03, 1997	TORONTO, CANADA	S African Med Res Council, Harry Crossley Fdn, Univ Stellenbosch			HERPES-SIMPLEX VIRUS; WESTERN IMMUNOBLOT; GUINEA-PIGS; TYPE-2; RISK; ACQUISITION; PROTECTION; ANTIBODY; AIDS; PREGNANCY	Context In the last 3 decades, herpes simplex virus type 2 (HSV-2) infection seroprevalence and neonatal herpes have increased substantially. An effective vaccine for the prevention of genital herpes could help control this epidemic. Objective To evaluate the efficacy of a vaccine for prevention of HSV-2 infection. Design Two randomized, double-blind, placebo-controlled multicenter trials of a recombinant subunit vaccine containing 30 mu g each of 2 major HSV-2 surface glycoproteins (gB(2) and gD(2)) against which neutralizing antibodies are directed, administered at months 0, 1, and 6. Control subjects were given a citrate buffer vehicle. Participants were followed up for 1 year after the third immunization. Setting and Participants We enrolled 2393 persons from December 10, 1993, to April 4, 1995, who were HSV-2 and human immunodeficiency virus seronegative. One trial with 18 centers enrolled 531 HSV-2-seronegative partners of HSV-2-infected persons; the other, with 22 centers, enrolled 1862 persons attending sexually transmitted disease clinics. A total of 2268 (94.8%) met inclusion criteria and were included in the analysis with 1135 randomized to placebo and 2012 to vaccine. Main Outcome Measure Time to acquisition of HSV-2 infection, defined by seroconversion or isolation of HSV-2 in culture during the study period by randomization group. Results Time-to-event curves indicated a 50% lower acquisition rate among vaccine vs placebo recipients during the initial 5 months of the trial; however, overall vaccine efficacy was 9% (95% confidence interval, -29% to 36%). Acquisition rates of HSV-2 were 4.6 and 4.2 per 100 patient-years in the placebo and vaccine recipients, respectively (P = .58). Follow-up of vaccine recipients acquiring HSV-2 infection showed vaccination had no significant influence on duration of clinical first genital HSV-2 episodes (vaccine, median of 7.1 days; placebo, 6.5 days; P > .10) or subsequent frequency of reactivation (median monthly recurrence rate with vaccine, 0.2; with placebo, 0.3; P > .10). The vaccine induced high levels of HSV-2-specific neutralizing antibodies in vaccinated persons who did and did not develop genital herpes. Conclusions Efficient and sustained protection from sexual acquisition of HSV-2 infection will require more than high titers of specific neutralizing antibodies. Protection against sexually transmitted viruses involving exposure over a prolonged period will require a higher degree of vaccine efficacy than that achieved in this study.	Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA USA; Denver Dis Control Serv, Denver, CO USA; Westover Hts Clin, Portland, OR USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Louisiana State Univ, New Orleans, LA USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Wake Cty Hlth Dept, Raleigh, NC USA; NIH, Bethesda, MD 20892 USA; Chiron Corp, HSV Vaccine Study Grp, Emeryville, CA 94608 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Texas System; University of Texas Medical Branch Galveston; Louisiana State University System; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; Novartis	Corey, L (corresponding author), 1100 Fairview Ave E,D3-100,POB 19024, Seattle, WA 98109 USA.		Leong, Wai Yie/J-8181-2017; Warren, Terri/AAJ-1650-2021; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER D, 1996, EUR INT C HERP VIR G; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY R, 1995, DIAGNOSTIC PROCEDURE, P375; BALACHANDRAN N, 1982, INFECT IMMUN, V37, P1132, DOI 10.1128/IAI.37.3.1132-1137.1982; Bernstein D., 1978, Journal of Statistical Computation and Simulation, V8, P65, DOI 10.1080/00949657808810249; Brown ZA, 1997, NEW ENGL J MED, V337, P509, DOI 10.1056/NEJM199708213370801; BROWN ZA, 1987, NEW ENGL J MED, V317, P1246, DOI 10.1056/NEJM198711123172002; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; BURKE RL, 1992, CURR TOP MICROBIOL, V179, P137; BYARS NE, 1994, VACCINE, V12, P200, DOI 10.1016/0264-410X(94)90195-3; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AL, 1993, MED J AUSTRALIA, V158, P525, DOI 10.5694/j.1326-5377.1993.tb121867.x; DALESSIO J, 1992, J CLIN MICROBIOL, V30, P1005, DOI 10.1128/JCM.30.4.1005-1007.1992; DIX RD, 1981, INFECT IMMUN, V34, P192, DOI 10.1128/IAI.34.1.192-199.1981; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Fleming TR, 1991, COUNTING PROCESSES S; FORSGREN M, 1990, SCAND J INFECT DIS, P37; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kleibaum D., 1988, APPL REGRESSION ANAL; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; LAKEMAN AD, 1986, SEX TRANSM DIS, V13, P61, DOI 10.1097/00007435-198604000-00001; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; SAFRIN S, 1992, J CLIN MICROBIOL, V30, P1312, DOI 10.1128/JCM.30.5.1312-1314.1992; *SAS I INC, 1985, SAC US GUID STAT; Schacker T, 1998, JAMA-J AM MED ASSOC, V280, P61, DOI 10.1001/jama.280.1.61; SCHMIDT OW, 1984, J INFECT DIS, V149, P645, DOI 10.1093/infdis/149.4.645; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; SULLENDER WM, 1987, J INFECT DIS, V155, P28, DOI 10.1093/infdis/155.1.28; Terhune SS, 1998, J INFECT DIS, V178, P8, DOI 10.1086/515590; WACHSMAN M, 1987, J INFECT DIS, V155, P1188, DOI 10.1093/infdis/155.6.1188; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd; YEAGER AS, 1980, INFECT IMMUN, V29, P532	45	367	396	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					331	340		10.1001/jama.282.4.331	http://dx.doi.org/10.1001/jama.282.4.331			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	219FG	10432030	Bronze			2022-12-28	WOS:000081596800028
J	Bisgaard, H; Moller, H				Bisgaard, H; Moller, H			Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-93	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Bisgaard, H (corresponding author), Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark.	Bisgaard@RH.DK	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Moller, Henrik/0000-0001-8200-5929	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bisgaard H, 1997, PEDIATR PULM, P27; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Warner JO, 1998, PEDIATR PULM, V25, P1	4	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					229	230		10.1136/bmj.319.7204.229	http://dx.doi.org/10.1136/bmj.319.7204.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417085	Bronze, Green Published			2022-12-28	WOS:000081720300024
J	Colman, E				Colman, E			The first English medical journal: Medicina Curiosa	LANCET			English	Article									US FDA, Div Metab & Endocrine Drug Prod, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Colman, E (corresponding author), US FDA, Div Metab & Endocrine Drug Prod, HFD-510 5600 Fishers Lane, Rockville, MD 20857 USA.	colmane@cder.fda.gov						BEIER LM, 1987, HEALERS SUFFERS EXPE; Cressy David, 1980, LITERACY SOCIAL ORDE; Garrison, 1922, INTRO HIST MED, V15, P335; GARRISON FH, 1934, B I HIST MED, V5, P285; JOHNSTONSAINT P, 1939, MED PRESS CIRCULAR, V25, P117; King H, 1995, Clio Med, V30, P184; Kronick D., 1976, HIST SCI TECHNICAL P, V2; KRONICK DA, 1990, LIBR CULTURE, V25, P243; KRONICK DA, 1960, B CLEVELAND MED LIB, V7, P47; Locke J., 1990, ESSAY HUMAN UNDERSTA; Merton Robert K., 1938, OSIRIS, V4, P360; Nagy Doreen G., 1988, POPULAR MED 17 CENTU; Osler W, 1900, LANCET, V2, P73; Pelling M, 1995, Clio Med, V30, P250; PLOMeR H.R., 1907, DICT BOOKSELLERS PRI; Porter R, 1992, MED J MED KNOWLEDGE; Porter R., 1997, GREATEST BENEFIT MAN; Porter Roy, 1992, POPULARIZATION MED 1; POYNTER F N L, 1948, Br Med J, V2, P307; POYNTER FNL, 1962, J HIST MED, V17, P155; Thornton John L., 1966, MED BOOKS LIB COLLEC; Webster Charles, 1974, INTELLECTUAL REVOLUT; Webster Charles, 1975, GREAT INSTAURATION S, P384; *WELLC UN HIST MED, 1984, MED CUR VAR NEW COMM; Williams Dawson, 1928, Glasgow Med J, V109, P105	25	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					324	326		10.1016/S0140-6736(98)11102-9	http://dx.doi.org/10.1016/S0140-6736(98)11102-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440325				2022-12-28	WOS:000081646000046
J	Barish, MA; Yucel, EK; Ferrucci, JT				Barish, MA; Yucel, EK; Ferrucci, JT			Current concepts - Magnetic resonance cholangiopancreatography	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; SPIN-ECHO TECHNIQUE; MR-CHOLANGIOPANCREATOGRAPHY; DUCT OBSTRUCTION; PANCREATIC DUCT; CHOLANGIOGRAPHY; CHOLEDOCHOLITHIASIS; DIAGNOSIS; ERCP		Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA	Boston University	Barish, MA (corresponding author), Boston Univ, Med Ctr, Dept Radiol, 1 Boston Med Ctr Pl, Boston, MA 02118 USA.			Barish, Matthew/0000-0002-7521-8878				BARISH MA, 1995, AM J ROENTGENOL, V165, P295, DOI 10.2214/ajr.165.2.7618543; BARON RL, 1983, AM J ROENTGENOL, V140, P1173, DOI 10.2214/ajr.140.6.1173; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; Bret PM, 1996, RADIOLOGY, V199, P99, DOI 10.1148/radiology.199.1.8633179; Chan YL, 1996, RADIOLOGY, V200, P85, DOI 10.1148/radiology.200.1.8657949; CRANLEY B, 1989, BRIT J SURG, V67, P869; CRONAN JJ, 1983, RADIOLOGY, V146, P467, DOI 10.1148/radiology.146.2.6849096; CUNNINGHAM JT, 1990, ADV THERAPEUTIC ENDO, P193; David V, 1998, AM J ROENTGENOL, V170, P1055, DOI 10.2214/ajr.170.4.9530058; DOWSETT JF, 1990, GUT, V31, P905, DOI 10.1136/gut.31.8.905; Ernst O, 1997, AM J ROENTGENOL, V168, P1115, DOI 10.2214/ajr.168.4.9124131; Ernst O, 1998, AM J ROENTGENOL, V171, P1027, DOI 10.2214/ajr.171.4.9762990; FORBES A, 1984, GUT, V25, P971, DOI 10.1136/gut.25.9.971; Fulcher AS, 1998, RADIOLOGY, V207, P21, DOI 10.1148/radiology.207.1.9530295; GROSS BH, 1983, RADIOLOGY, V146, P471, DOI 10.1148/radiology.146.2.6849097; Guibaud L, 1998, AM J ROENTGENOL, V170, P27, DOI 10.2214/ajr.170.1.9423592; GUIBAUD L, 1994, AM J ROENTGENOL, V163, P847, DOI 10.2214/ajr.163.4.8092021; GUIBAUD L, 1995, RADIOLOGY, V197, P109, DOI 10.1148/radiology.197.1.7568807; HAMILTON I, 1983, CLIN RADIOL, V34, P543, DOI 10.1016/S0009-9260(83)80156-1; JEFFREY RB, 1983, AM J ROENTGENOL, V140, P1179, DOI 10.2214/ajr.140.6.1179; Koito K, 1998, RADIOLOGY, V208, P231, DOI 10.1148/radiology.208.1.9646818; LAING FC, 1983, RADIOLOGY, V146, P475, DOI 10.1148/radiology.146.2.6849098; Lee MG, 1997, RADIOLOGY, V202, P663, DOI 10.1148/radiology.202.3.9051013; Lehman G A, 1995, Gastrointest Endosc Clin N Am, V5, P145; MACAULAY SE, 1995, RADIOLOGY, V196, P227, DOI 10.1148/radiology.196.1.7784572; Matos C, 1997, RADIOLOGY, V203, P435, DOI 10.1148/radiology.203.2.9114101; Onaya H, 1998, AM J ROENTGENOL, V171, P171, DOI 10.2214/ajr.171.1.9648782; OSNES M, 1986, GUT, V27, P1193, DOI 10.1136/gut.27.10.1193; PAVONE P, 1995, RADIOLOGY, V197, P312; PHILLIPS EH, 1994, SURG CLIN N AM, V74, P931, DOI 10.1016/S0039-6109(16)46395-4; Regan F, 1996, AM J ROENTGENOL, V167, P1441, DOI 10.2214/ajr.167.6.8956574; RIEGER R, 1995, GASTROINTEST ENDOSC, V42, P6, DOI 10.1016/S0016-5107(95)70235-0; SILVIS SE, 1985, BOCKUS GASTROENTEROL, V6, P3569; Soto JA, 1996, RADIOLOGY, V199, P91, DOI 10.1148/radiology.199.1.8633178; SOTO JA, 1995, RADIOLOGY, V196, P459, DOI 10.1148/radiology.196.2.7617861; Soto JA, 1996, GASTROENTEROLOGY, V110, P589, DOI 10.1053/gast.1996.v110.pm8566608; TAKEHARA Y, 1994, RADIOLOGY, V192, P73, DOI 10.1148/radiology.192.1.8208969; THOENI RF, 1990, GASTROINTEST RADIOL, V15, P291, DOI 10.1007/BF01888800; WALLNER BK, 1991, RADIOLOGY, V181, P805, DOI 10.1148/radiology.181.3.1947101; Yamataka A, 1997, J PEDIATR SURG, V32, P1560, DOI 10.1016/S0022-3468(97)90452-8	40	143	149	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					258	264		10.1056/NEJM199907223410407	http://dx.doi.org/10.1056/NEJM199907223410407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413739				2022-12-28	WOS:000081528800007
J	Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF				Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF			Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lymphoma, mucosa-associated lymphoid tissue; Helicobacter pylori; Helicobacter infections; antibiotics; neoplasm staging	HELICOBACTER-PYLORI INFECTION; MANTLE CELL LYMPHOMA; MALT LYMPHOMA; MALIGNANT-LYMPHOMA; CLASSIFICATION; REGRESSION; ERADICATION; THERAPY; SYSTEM; CURE	Background: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth. Objective: To determine the response of gastric MALT lymphoma to antibiotic treatment. Design: Prospective, uncontrolled treatment trial. Setting: University hospital referral center and three collaborating university and community hospitals. Patients: 34 patients with stage I or stage II N1 gastric MALT lymphoma. Intervention: Two of three oral antibiotic regimens-1) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2) tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily-were administered sequentially (usually in the order written) for 21 days at baseline and at 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate. Measurements: Complete remission was defined as the absence of histopathologic evidence of lymphoma on endoscopic biopsy. Partial remission was defined as a reduction in endoscopic tumor stage or 50% reduction in the size of large tumors. Results: 34 patients were followed for a mean (+/-SD) of 41 +/- 16 months (range, 18 to 70 months) after antibiotic treatment. Of 28 H. pylori-positive patients, 14 (50% [95% CI, 31% to 69%]) achieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of the 8), and 10 (36% [CI, 19% to 56%]) did not respond to treatment. Treatment failed in all 6 (100% [CI, 54% to 100%]) H. pylori-negative patients. Patients with endoscopic appearance of gastritis (stage I T1 disease) were most likely to achieve complete remission within 18 months. Tumors in the distal stomach were associated with more favorable response than tumors in the proximal stomach. Conclusions: A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respond to antibiotics. The likelihood of: early complete remission seems to be greatest for superficial and distal tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Steinbach, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Box 78,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsteihb@aol.com	Graham, David/AAL-2165-2021	Shen, Yu/0000-0002-3899-7868; Steinbach, Gideon/0000-0001-7597-0544; Cabanillas, Fernando/0000-0001-9234-7893	NCI NIH HHS [CA-16672, R01 CA67540-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067540, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BLACKLEDGE G, 1979, CLIN ONCOL, V5, P209; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CHAN JKC, 1990, AM J PATHOL, V136, P1153; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; GREINER A, 1994, LAB INVEST, V70, P572; HARRIS NL, 1994, BLOOD, V84, P1361; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; LUTHRA R, 1995, DIAGN MOL PATHOL, V4, P4, DOI 10.1097/00019606-199503000-00003; McLaughlin P, 1996, ANN ONCOL, V7, P211; MONTALBAN C, 1995, ANN ONCOL, V6, P355, DOI 10.1093/oxfordjournals.annonc.a059184; MOUTSOPOULOS HM, 1994, CLIN IMMUNOL IMMUNOP, V72, P162, DOI 10.1006/clin.1994.1123; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NAKAMURA S, 1995, CANCER, V76, P1313, DOI 10.1002/1097-0142(19951015)76:8<1313::AID-CNCR2820760804>3.0.CO;2-1; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; Neubauer A, 1997, JNCI-J NATL CANCER I, V89, P1350, DOI 10.1093/jnci/89.18.1350; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Sackmann M, 1997, GASTROENTEROLOGY, V113, P1087, DOI 10.1053/gast.1997.v113.pm9322502; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; STEINBACH G, 1995, GASTROENTEROLOGY, V108, pA541; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	33	170	178	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					88	+		10.7326/0003-4819-131-2-199907200-00003	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419446				2022-12-28	WOS:000081509700002
J	Attia, J; Hatala, R; Cook, DJ; Wong, JG				Attia, J; Hatala, R; Cook, DJ; Wong, JG			Does this adult patient have acute meningitis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE BACTERIAL-MENINGITIS; NERVOUS-SYSTEM INFECTIONS; ELDERLY PATIENTS	Context Early clinical recognition of meningitis is imperative to allow clinicians to efficiently complete further tests and initiate appropriate therapy. Objective To review the accuracy and precision of the clinical examination in the diagnosis of adult meningitis, Data Sources A comprehensive review of English- and French-language literature was conducted by searching MEDLINE for 1966 to July 1997, using a structured search strategy, Additional references were identified by reviewing reference lists of pertinent articles. Study Selection The search yielded 139 potentially relevant studies, which were reviewed by the first author, Studies were included if they described the clinical examination in the diagnosis of objectively confirmed bacterial or viral meningitis. Studies were excluded if they enrolled predominantly children or immunocompromised adults or focused only on metastatic meningitis or meningitis of a single microbial origin. A total of 10 studies met the criteria and were included in the analysis. Data Extraction Validity of the studies was assessed by a critical appraisal of several components of the study design. These components included an assessment of the reference standard used to diagnose meningitis (lumbar puncture or autopsy), the completeness of patient ascertainment, and whether the clinical examination was described in sufficient detail to be reproducible. Data Synthesis Individual items of the clinical history have low accuracy for the diagnosis of meningitis in adults (pooled sensitivity for headache, 50% [95% confidence interval {CI} 32%-68%]; for nausea/vomiting, 30% [95% CI, 22%-38%]). On physical examination, the absence of fever, neck stiffness, and altered mental status effectively eliminates meningitis (sensitivity, 99%-100% for the presence of 1 of these findings), Of the classic signs of meningeal irritation, only 1 study has assessed Kernig sign; no studies subsequent to the original report have evaluated Brudzinski sign. Among patients with fever and headache, jolt accentuation of headache is a useful adjunctive maneuver, with a sensitivity of 100%, specificity of 54%, positive likelihood ratio of 2.2, and negative likelihood ratio of 0 for the diagnosis of meningitis, Conclusions Among adults with a clinical presentation that is low risk for meningitis, the clinical examination aids in excluding the diagnosis. However, given the seriousness of this infection, clinicians frequently need to proceed directly to lumbar puncture in high-risk patients, Many of the signs and symptoms of meningitis have been inadequately studied, and further prospective research is needed.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Washington Univ, Sch Med, Div Gen Med Med Sci, St Louis, MO USA	McMaster University; McMaster University; Washington University (WUSTL)	Hatala, R (corresponding author), Henderson Gen Hosp, 4th Floor,McMaster Bldg,711 Concess St, Hamilton, ON L8V 1C3, Canada.		Attia, John R/F-5376-2013	Attia, John R/0000-0001-9800-1308				Aronin SI, 1998, ANN INTERN MED, V129, P862, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00004; BEHRMAN RE, 1989, ARCH INTERN MED, V149, P1596; BERGER JR, 1994, CURR OPIN NEUROL, V7, P191, DOI 10.1097/00019052-199406000-00004; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; BRODY IA, 1969, ARCH NEUROL-CHICAGO, V21, P215, DOI 10.1001/archneur.1969.00480140115012; Brudzinski J., 1909, ARCH MED ENFANTS, V12, P745; BRYAN JP, 1990, REV INFECT DIS, V12, P128; DOMINGO P, 1990, ARCH INTERN MED, V150, P1546, DOI 10.1001/archinte.1990.00390190176035; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Genton B, 1988, Rev Med Suisse Romande, V108, P795; GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603; Harvey AM, 1988, PRINCIPLES PRACTICE; Kernig W, 1884, BERLIN KLIN WSCHR, V21, P829; LEWIN S, 1981, ARCH INTERN MED, V141, P920, DOI 10.1001/archinte.141.7.920; LINDSAY K, 1991, NEUROLOGY NEUROSURGE; Magnussen C R, 1980, N Y State J Med, V80, P901; MASSANARI RM, 1977, GERIATRICS, V32, P55; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; OCONNELL JEA, 1946, BRAIN, V69, P9, DOI 10.1093/brain/69.1.9; PUXTY JAH, 1983, J AM GERIATR SOC, V31, P590, DOI 10.1111/j.1532-5415.1983.tb04599.x; RASMUSSEN HH, 1992, AGE AGEING, V21, P216, DOI 10.1093/ageing/21.3.216; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHELD WM, 1990, TROPICAL GEOGRAPHICA, P798; Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425; SPANOS A, 1989, JAMA-J AM MED ASSOC, V262, P2700, DOI 10.1001/jama.262.19.2700; Sprengell C, 1735, APHORISMS HIPPOCRATE; TUNKEL AR, 1993, CLIN MICROBIOL REV, V6, P118, DOI 10.1128/CMR.6.2.118-136.1993; UCHIHARA T, 1991, HEADACHE, V31, P167, DOI 10.1111/j.1526-4610.1991.hed3103167.x	29	145	147	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					175	181		10.1001/jama.282.2.175	http://dx.doi.org/10.1001/jama.282.2.175			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411200				2022-12-28	WOS:000081376800036
J	Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A				Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A			The mPer2 gene encodes a functional component of the mammalian circadian clock	NATURE			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION; LIGHT; RHYTHMS; TIMELESS; HOMOLOG; PAS; REGULATORS; EXPRESSION	Circadian rhythms are driven by endogenous biological clocks that regulate many biochemical, physiological and behavioural professes in a wide range of life forms'. In mammals, there is a master circadian clock in the suprachiasmatic nucleus of the anterior hypothalamus. Three putative mammalian homologues (mPer1, mPer2 and mPer3) of the Drosophila circadian clock gene period (per) have been identified(2-8). The mPer genes share a conserved PAS domain (a dimerization domain found in Per, Amt and Sim) and show a circadian expression pattern in the suprachiasmatic nucleus. To assess the in vivo function of mPer2, we generated and characterized a deletion mutation in the PAS domain of the mouse mPer2 gene. Here we show that mice homozygous for this mutation display a shorter circadian period followed by a loss of circadian rhythmicity in constant darkness. The mutation also diminishes the oscillating expression of both mPer1 and mPer2 in the suprachiasmatic nucleus, indicating that mPer2 may regulate mPer1 in vivo. These data provide evidence that an mPer gene functions in the circadian clock, and define mPer2 as a component of the mammalian circadian oscillator.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	ching@bcm.tmc.edu	Albrecht, Urs/A-9831-2011; Sun, Zhongsheng/AAS-4883-2020	Albrecht, Urs/0000-0002-0663-8676; Sun, Zhongsheng/0000-0002-7640-5026; Bradley, Allan/0000-0002-2349-8839				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Aschoff J, 1981, HDB BEHAVIORAL NEURO, P3, DOI DOI 10.1007/978-1-4615-6552-9_1; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bracewell R. N., 1986, HARTLEY TRANSFORM; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; IBUKA N, 1977, BRAIN RES, V122, P33, DOI 10.1016/0006-8993(77)90660-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	30	565	579	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					169	173		10.1038/22118	http://dx.doi.org/10.1038/22118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408444				2022-12-28	WOS:000081324900055
J	Thies, C; Tscharntke, T				Thies, C; Tscharntke, T			Landscape structure and biological control in agroecosystems	SCIENCE			English	Article							PARASITISM; DYNAMICS	Biological pest control has primarily relied on local improvements in populations of natural enemies, but landscape structure may also be important. This is shown here with experiments at different spatial scales using the rape pollen beetle (Meligethes aeneus), an important pest on oilseed rape (Brassica napus). The presence of old field margin strips along rape fields was associated with increased mortality of pollen beetles resulting from parasitism and adjacent, Large, old fallow habitats had an even greater effect. In structurally complex Landscapes, parasitism was higher and crop damage was lower than in simple Landscapes with a high percentage of agricultural use.	Univ Gottingen, Dept Agroecol, D-37073 Gottingen, Germany	University of Gottingen	Thies, C (corresponding author), Univ Gottingen, Dept Agroecol, Waldweg 26, D-37073 Gottingen, Germany.		Tscharntke, Teja/N-5123-2014					BORNER C, 1920, MITT BIOL REICHSANST, V18, P91; Eber S, 1996, J ANIM ECOL, V65, P621, DOI 10.2307/5741; Hansson L., 1995, MOSAIC LANDSCAPES EC; HAWKINS BA, 1994, SCIENCE, V266, P1886, DOI 10.1126/science.266.5192.1886; HOKKANEN H, 1988, ANN AGR FENN, V27, P281; Jourdheuil P., 1960, ANN EPIPHYT, V11, P445; KAREIVA P, 1990, PHILOS T R SOC B, V330, P175, DOI 10.1098/rstb.1990.0191; KREUSS A, 1994, SCIENCE, V264, P1581; Marino PC, 1996, ECOL APPL, V6, P276, DOI 10.2307/2269571; Menalled FD, 1999, ECOL APPL, V9, P634, DOI 10.1890/1051-0761(1999)009[0634:DALSAP]2.0.CO;2; NILSSON C, 1985, Z ANGEW ENTOMOL, V100, P302; *PFLANZ HANN, 1998, EMPF PFLANZ; Powell W., 1986, P319; Roland J, 1997, NATURE, V386, P710, DOI 10.1038/386710a0; Tscharntke Teja, 1999, P190, DOI 10.1017/CBO9780511542077.015; Van Driesche R. G., 1996, BIOL CONTROL	16	516	562	4	282	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					893	895		10.1126/science.285.5429.893	http://dx.doi.org/10.1126/science.285.5429.893			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436158				2022-12-28	WOS:000081860900050
J	Summerfield, D				Summerfield, D			The politics of apology	LANCET			English	Editorial Material									Med Fdn Care Victims Torture, London NW5 3EJ, England		Summerfield, D (corresponding author), Med Fdn Care Victims Torture, London NW5 3EJ, England.								0	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					421	421		10.1016/S0140-6736(99)90139-3	http://dx.doi.org/10.1016/S0140-6736(99)90139-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437890				2022-12-28	WOS:000081764900048
J	Freifeld, A; Marchigiani, D; Walsh, T; Chanock, S; Lewis, L; Hiemenz, J; Hiemenz, S; Hicks, JE; Gill, V; Steinberg, SM; Pizzo, PP				Freifeld, A; Marchigiani, D; Walsh, T; Chanock, S; Lewis, L; Hiemenz, J; Hiemenz, S; Hicks, JE; Gill, V; Steinberg, SM; Pizzo, PP			A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; FEVER; MANAGEMENT; CIPROFLOXACIN; CEFTAZIDIME; EPISODES	Background Among patients with fever and neutropenia during cancer chemotherapy who have a low risk of complications, oral administration of empirical broad-spectrum antibiotics may be an acceptable alternative to intravenous treatment. Methods We conducted a randomized, double-blind, placebo-controlled study of patients (age, 5 to 74 years) who had fever and neutropenia during chemotherapy for cancer. Neutropenia was expected to be present for no more than 10 days in these patients, and they had to have no other underlying conditions. Patients were assigned to receive either oral ciprofloxacin plus amoxicillin-clavulanate or intravenous ceftazidime. They were hospitalized until fever and neutropenia resolved. Results A total of 116 episodes were included in each group (84 patients in the oral-therapy group and 79 patients in the intravenous-therapy group). The mean neutrophil counts at admission were 81 per cubic millimeter and 84 per cubic millimeter, respectively; the mean duration of neutropenia was 3.4 and 3.8 days, respectively. Treatment was successful without the need for modifications in 71 percent of episodes in the oral-therapy group and 67 percent of episodes in the intravenous-therapy group (difference between groups, 3 percent; 95 percent confidence interval, -8 percent to 15 percent; P=0.48). Treatment was considered to have failed because of the need for modifications in the regimen in 13 percent and 32 percent of episodes, respectively (P<0.001) and because of the patient's inability to tolerate the regimen in 16 percent and 1 percent of episodes, respectively (P<0.001). There were no deaths. The incidence of intolerance of the oral antibiotics was 16 percent, as compared with 8 percent for placebo (P=0.07). Conclusions In hospitalized low-risk patients who have fever and neutropenia during cancer chemotherapy, empirical therapy with oral ciprofloxacin and amoxicillin-clavulanate is safe and effective. (N Engl J Med 1999;341:305-11.) (C) 1999, Massachusetts Medical Society.	NCI, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Freifeld, A (corresponding author), Univ Nebraska, Med Ctr, Infect Dis Sect, 985400 Nebraska Med Ctr, Omaha, NE 68198 USA.		Lee, Yee Mei/H-1143-2011		NATIONAL CANCER INSTITUTE [Z01SC007202, ZIDSC007202] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; CAMP AV, 1971, ORTHOPAEDICS OXFORD, V4, P39; *CANC THER EV PROG, 1998, COMM TOX CRIT CTC V2; FREIFELD AG, 1995, J CLIN ONCOL, V13, P165, DOI 10.1200/JCO.1995.13.1.165; GARDEMBASPAIN M, 1991, ANN ONCOL, V2, P485, DOI 10.1093/oxfordjournals.annonc.a057996; GOUGH A, 1979, TOXICOL APPL PHARM, V51, P177, DOI 10.1016/0041-008X(79)90020-6; LAU RC, 1994, PEDIATR HEMAT ONCOL, V11, P417, DOI 10.3109/08880019409140541; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MALIK I, 1992, LANCET, V340, P128; MALIK IA, 1994, CLIN INFECT DIS, V19, P522, DOI 10.1093/clinids/19.3.522; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; PIZZO PA, 1982, MEDICINE, V61, P153, DOI 10.1097/00005792-198205000-00003; RITCHIE DM, 1968, Q J MED, V37, P393; RUBENSTEIN EB, 1995, EUR J CANCER, V31A, P2, DOI 10.1016/0959-8049(94)00456-F; RUBENSTEIN EB, 1993, CANCER-AM CANCER SOC, V71, P3640, DOI 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H; RUBIN M, 1988, CANCER INVEST, V6, P167, DOI 10.3109/07357908809077045; SCHAAD UB, 1991, PEDIATR INFECT DIS J, V10, P723; TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316; Vallejo C, 1997, HEMATOL CELL THER, V39, P223, DOI 10.1007/s00282-997-0223-0; Warren RW, 1997, PEDIATR INFECT DIS J, V16, P118, DOI 10.1097/00006454-199701000-00034	23	296	307	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					305	311		10.1056/NEJM199907293410501	http://dx.doi.org/10.1056/NEJM199907293410501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423464				2022-12-28	WOS:000081666900001
J	Busch, MA; Bomblies, K; Weigel, D				Busch, MA; Bomblies, K; Weigel, D			Activation of a floral homeotic gene in Arabidopsis	SCIENCE			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; MERISTEM IDENTITY; EXPRESSION; LEAFY; PLANTS; ANTIRRHINUM; FLORICAULA; TRANSCRIPTION; MORPHOGENESIS	The patterned expression of floral homeotic genes in Arabidopsis depends on the earlier action of meristem-identity genes such as LEAFY, which encodes a transcription factor that determines whether a meristem will generate flowers instead of Leaves and shoots. The LEAFY protein, which is expressed throughout the flower, participates in the activation of homeotic genes, which are expressed in specific regions of the flower. Analysis of a LEAFY-responsive enhancer in the homeotic gene AGAMOUS indicates that direct interaction of LEAFY with this enhancer is required for its activity in plants. Thus, LEAFY is a direct upstream regulator of floral homeotic genes.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Bomblies, Kirsten/0000-0002-2434-3863				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Busch M., UNPUB; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HANTKE SS, 1995, DEVELOPMENT, V121, P27; Hofer J, 1997, CURR BIOL, V7, P581, DOI 10.1016/S0960-9822(06)00257-0; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; LIU ZC, 1995, DEVELOPMENT, V121, P975; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McSteen PCM, 1998, DEVELOPMENT, V125, P2359; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Motte P, 1998, DEVELOPMENT, V125, P71; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PARCY F, UNPUB; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1998, DEVELOPMENT, V125, P733; Southerton SG, 1998, PLANT MOL BIOL, V37, P897, DOI 10.1023/A:1006056014079; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	36	290	336	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					585	587		10.1126/science.285.5427.585	http://dx.doi.org/10.1126/science.285.5427.585			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417388				2022-12-28	WOS:000081609500038
J	Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF				Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF			Fetal anemia and apoptosis of red cell progenitors in Stat5a(-/-)5b(-/-) mice: A direct role for Stat5 in Bcl-X-L induction	CELL			English	Article							GENE-EXPRESSION; ERYTHROID PROGENITORS; ERYTHROPOIETIN RECEPTOR; SEQUENCE SIMILARITY; FORMING-UNITS; S-PHASE; PROLIFERATION; ACTIVATION; DEATH; DIFFERENTIATION	The erythropoietin receptor (EpoR) is essential for production of red blood cells; a principal function of EpoR is to rescue committed erythroid progenitors from apoptosis. Stat5 is rapidly activated following EpoR stimulation, but its function in erythropoiesis has been unclear since adult Stat5a(-/-)5b(-/-) mice have normal steady-state hematocrit. Here we show that Stat5 is essential for the high erythropoietic rate during fetal development. Stat5a(-/-)5b(-/-) embryos are severely anemic; erythroid progenitors are present in low numbers, show higher levels of apoptosis, and are less responsive to Epo. These findings are explained by a crucial role for Stat5 in EpoR's antiapoptotic signaling: it mediates the immediate-early induction of Bcl-X-L in erythroid cells through direct binding to the Bcl-X promoter.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Socolovsky, Merav/0000-0001-6747-7960	NHLBI NIH HHS [HL 32262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; CROIZAT H, 1990, BLOOD, V75, P1006; Erslev AF, 1995, WILLIAMS HEMATOLOGY, P441; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; GREGORY T, 1999, IN PRESS BLOOD; Grillot DAM, 1997, J IMMUNOL, V158, P4750; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LANDSCHULZ KT, 1992, BLOOD, V79, P2749; LIN EY, 1993, J IMMUNOL, V151, P1979; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RUSSELL ELIZABETH S., 1966, P351; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	42	593	606	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					181	191		10.1016/S0092-8674(00)81013-2	http://dx.doi.org/10.1016/S0092-8674(00)81013-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428030	Bronze			2022-12-28	WOS:000081632300008
J	Vevers, J				Vevers, J			Time is such a precious thing	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					391	391		10.1136/bmj.319.7206.391	http://dx.doi.org/10.1136/bmj.319.7206.391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435988	Green Published			2022-12-28	WOS:000082001700066
J	de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC				de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC			Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behaviour concerning use of folic acid: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Netherlands Org Appl Sci Res TNO Prevent & Hlth, NL-2301 CE Leiden, Netherlands; Groningen Inst Drug Studies, NL-9713 AW Groningen, Netherlands; Midden Brabent, Gemeenschappelylie Gezondheids dienst, NL-5003 DA Tilburg, Netherlands; GGD Reg Achterhock, NL-7005 AZ Doetinchem, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; University of Groningen	Cornel, MC (corresponding author), Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands.		Cornel, Martina/AAE-8955-2020; Schouten, Johannes S.A.G./M-9376-2016	Cornel, Martina/0000-0002-5397-5544; Schouten, Johannes S.A.G./0000-0001-6495-7758				de Jong-van den Berg LTW, 1998, EUR J CLIN PHARMACOL, V54, P329, DOI 10.1007/s002280050468; GEERTS A, 1995, VOEDINGSMAGAZINE, V8, P3	2	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					291	292		10.1136/bmj.319.7205.291	http://dx.doi.org/10.1136/bmj.319.7205.291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426740	Green Published, Bronze			2022-12-28	WOS:000081909100024
J	Lincoff, AM; Califf, RM; Moliterno, DJ; Ellis, SG; Ducas, J; Kramer, JH; Kleiman, NS; Cohen, EA; Booth, JE; Sapp, SK; Cabot, CF; Topol, EJ				Lincoff, AM; Califf, RM; Moliterno, DJ; Ellis, SG; Ducas, J; Kramer, JH; Kleiman, NS; Cohen, EA; Booth, JE; Sapp, SK; Cabot, CF; Topol, EJ		Evaluation Platelet IIb IIIa Inhibition Stentin	Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; INTRAVASCULAR ULTRASOUND; DIABETES-MELLITUS; RANDOMIZED TRIAL; RESTENOSIS; IMPLANTATION; DISEASE; INTERVENTION; INTEGRIN	Background Inhibition of the platelet glycoprotein Ilb/IIIa receptor with the monoclonal-antibody fragment abciximab reduces the acute ischemic complications associated with percutaneous coronary revascularization, whereas coronary-stent implantation reduces restenosis. We conducted a trial to determine the efficacy of abciximab and stent implantation in improving long-term outcome. Methods A total of 2399 patients were randomly assigned to stent implantation and placebo, stent implantation and abciximab, or balloon angioplasty and abciximab. The patients were followed for six months. Results At six months, the incidence of the composite end point of death or myocardial infarction was 11.4 percent in the group that received ai stent and placebo, as compared with 5.6 percent in the group that received a stent and abciximab (hazard ratio, 0.47; 95 percent confidence interval, 0.33 to 0.68; P<0.001) and 7.8 percent in the group assigned to balloon angioplasty and abciximab (hazard ratio, 0.67; 95 percent confidence interval, 0.49 to 0.92; P=0.01). The hazard ratio for stenting plus abciximab as compared with angioplasty plus abciximab was 0.70 (95 percent confidence interval, 0.48 to 1.04; P=0.07). The rate of repeated revascularization of the target vessel was 10.6 percent in the stent-plus-placebo group, as compared with 8.7 percent in the stent-plus-abciximab group (hazard ratio, 0.82; 95 percent confidence interval, 0.59 to 1.13; P=0.22) and 15.4 percent in the angioplasty-plus-abciximab group (hazard ratio, 1.49; 95 percent confidence interval, 1.13 to 1.97; P=0.005). The hazard ratio for stenting plus abciximab as compared with angioplasty plus abciximab was 0.55 (95 percent confidence interval, 0.41 to 0.74; P<0.001). Among patients with diabetes, the combination of abciximab and stenting was associated with a lower rate of repeated target-vessel revascularization (8.1 percent) than was stenting and placebo (16.6 percent, P=0.02) or angioplasty and abciximab (18.4 percent, P=0.008). Conclusions For coronary revascularization, abciximab and stent implantation confer complementary long-term clinical benefits. (N Engl J Med 1999;341: 319-27.) (C) 1999. Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Duke Univ, Duke Clin Res Inst, Dept Med, Durham, NC USA; Univ Manitoba, Winnipeg, MB, Canada; Our Lady Lourdes Med Ctr, Cherry Hill, NJ USA; Baylor Coll Med, Houston, TX 77030 USA; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Centocor, Malvern, PA USA; Univ Arkansas, Little Rock, AR 72204 USA; Toronto Hosp, Toronto, ON M5T 2S8, Canada; Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; Moses Cone Mem Hosp, Greensboro, NC USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Duke University; University of Manitoba; Baylor College of Medicine; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alberta; Moses Cone Memorial Hospital	Lincoff, AM (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Desk F25, Cleveland, OH 44195 USA.			Ducas, John/0000-0001-5953-3352; Topol, Eric/0000-0002-1478-4729				CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; *CAPTURE INV, 1997, LANCET, V350, P744; CARROZZA JP, 1993, ANN INTERN MED, V118, P344, DOI 10.7326/0003-4819-118-5-199303010-00004; Erbel R, 1998, NEW ENGL J MED, V339, P1672, DOI 10.1056/NEJM199812033392304; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Kornowski R, 1997, CIRCULATION, V95, P1366; Lau KW, 1996, CORONARY ARTERY DIS, V7, P327, DOI 10.1097/00019501-199604000-00010; Lincoff AM, 1999, CIRCULATION, V99, P1951, DOI 10.1161/01.CIR.99.15.1951; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; MANCINI GBJ, 1987, CIRCULATION, V75, P1199; Mintz GS, 1996, AM J CARDIOL, V78, P18, DOI 10.1016/S0002-9149(96)00493-6; Prineas R., 1982, MINNESOTA CODE MANUA; Serruys P, 1998, LANCET, V352, P1478; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Simoons ML, 1997, LANCET, V349, P1429; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; WONG SC, 1995, J AM COLL CARDIOL, V26, P704, DOI 10.1016/0735-1097(95)00217-R	22	294	304	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					319	327		10.1056/NEJM199907293410503	http://dx.doi.org/10.1056/NEJM199907293410503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423466				2022-12-28	WOS:000081666900003
J	Koshiya, N; Smith, JC				Koshiya, N; Smith, JC			Neuronal pacemaker for breathing visualized in vitro	NATURE			English	Article							RESPIRATORY RHYTHM GENERATION; PRE-BOTZINGER COMPLEX; SPINAL-CORD; MEDULLARY SLICES; MAMMALIAN BRAIN; MECHANISMS; CIRCUITRY; NETWORK; MOTOR; RAT	Breathing movements in mammals arise from a rhythmic pattern of neural activity, thought to originate in the pre-Botzinger complex(1) in the lower brainstem. The mechanisms generating the neural rhythm in this region are unknown(2-5). The central question is whether the rhythm is generated by a network of bursting pacemaker neurons coupled by excitatory synapses that synchronize pacemaker activity. Here we visualized the activity of inspiratory pacemaker neurons at single-cell and population levels with calcium-sensitive dye. We developed methods to label these neurons retrogradely with the dye in neonatal rodent brainstem slices that retain the rhythmically active respiratory network We simultaneously used infrared structural imaging to allow patch-damp recording from the identified neurons, After we pharmacologically blocked glutamatergic synaptic transmission, a subpopulation of inspiratory neurons continued to burst rhythmically but asynchronously. The intrinsic bursting frequency of these pacemaker neurons depended on the baseline membrane potential, providing a cellular mechanism for respiratory frequency control. These results provide evidence that the neuronal kernel for rhythm generation consists of a network of synaptically-coupled pacemaker neurons.	NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Koshiya, N (corresponding author), NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA.	koshiya@nih.gov	Koshiya, Naohiro/ABA-8628-2020	Koshiya, Naohiro/0000-0002-2952-8779				BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; DODT HU, 1994, TRENDS NEUROSCI, V17, P453, DOI 10.1016/0166-2236(94)90130-9; FETCHO JR, 1995, J NEUROPHYSIOL, V73, P399, DOI 10.1152/jn.1995.73.1.399; FOSKETT JK, 1988, AM J PHYSIOL       S, pC566; FRIEDLANDER ML, 1992, INT J GYNECOL CANCER, V2, P2; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; Inoue S., 1997, VIDEO MICROSCOPY FUN; JOHNSON SM, 1994, J NEUROPHYSIOL, V72, P2598, DOI 10.1152/jn.1994.72.6.2598; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N., 1997, Society for Neuroscience Abstracts, V23, P1252; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; ODONOVAN M, 1994, J NEUROSCI, V14, P6354; Ramirez JM, 1996, CURR OPIN NEUROBIOL, V6, P817, DOI 10.1016/S0959-4388(96)80033-X; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Ramirez JM, 1996, J PHYSIOL-LONDON, V491, P799, DOI 10.1113/jphysiol.1996.sp021258; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; SCHWARZACHER SW, 1995, J NEUROPHYSIOL, V73, P1452, DOI 10.1152/jn.1995.73.4.1452; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; SMITH JC, 1995, LUNG BIOL HEALTH DIS, V82, P463; SMITH JC, 1997, NEURONS NETWORKS MOT, P97; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; WILSON CG, 1998, SOC NEUR ABSTR, V23, P875	30	353	358	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					360	363		10.1038/22540	http://dx.doi.org/10.1038/22540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432113				2022-12-28	WOS:000081590000049
J	Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ				Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ			Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; US MALE PHYSICIANS; MYOCARDIAL-INFARCTION; INSULIN SENSITIVITY; 4-YEAR INCIDENCE; SHAPED CURVE; BRITISH MEN; CONSUMPTION; WISCONSIN; RETINOPATHY	Context Despite nutrition information and guidelines that advise against depriving diabetic patients of the potential benefit of moderate alcohol intake against cardiovascular events, the association between alcohol consumption and risk of cardiovascular outcomes in diabetic individuals has not been determined. Objective To examine the relationship between alcohol intake and coronary heart disease (CHD) mortality in persons with older-onset diabetes. Design Population-based, prospective cohort study conducted from 1984 through 1996, with a follow-up of up to 12.3 years. Setting and Participants A total of 983 older-onset diabetic individuals (mean [SD] age, 68.6 [11.0] years; 45.2% male; 98.5% white) were interviewed about their past-year intake of alcoholic beverages during the 1984-1986 follow-up examination of a population-based study of diabetic persons in southern Wisconsin. Main Outcome Measure Time to mortality from CHD by category alcohol intake. Results Alcohol use was inversely associated with risk of CHD mortality in older-onset diabetic subjects. The CHD mortality rates for never and former drinkers were 43.9 and 38.5 per 1000 person-years, respectively, while the rates for those with alcohol intakes of less than 2, 2 to 13, and 14 or more g/d were 25.3, 20.8, and 10.0 per 1000 person-years, respectively. Compared with never drinkers and controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-peptide level, history of angina or myocardial infarction, digoxin use, and the presence and severity of diabetic retinopathy, former drinkers had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.43-1.12); for those who drank less than 2 g/d (less frequent than 1 drink a week), the RR was 0.54 (95% CI, 0.33-0.90); for 2 to 13 g/d, it was 0.44 (95% CI, 0.23-0.84); and for 14 or more g/d (about 1 drink or more a day), it was 0.21 (95% CI, 0.09-0.48). Further adjustments for blood pressure, body mass index, education, physical activity, diabetes duration, hypertension history, overt nephropathy, peripheral neuropathy, lipid measures, or intake of medications such as aspirin and antihypertensive agents did not change the associations observed. Conclusion Our results suggest an overall beneficial effect of alcohol consumption in decreasing the risk of death due to CHD in people with older-onset diabetes.	Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Klein, R (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,WARF 460, Madison, WI 53705 USA.	kleinr@epi.ophth.wisc.edu			NEI NIH HHS [EY03083] Funding Source: Medline; NHLBI NIH HHS [HL59259] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059259] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; *AM DIAB ASS, 1998, MED MAN TYP 2 DIAB, P48; Amer Diabet Assoc, 1999, DIABETES CARE, V22, pS42; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1995, DIABETES AM; Bell DSH, 1996, DIABETES CARE, V19, P509, DOI 10.2337/diacare.19.5.509; Camargo CA, 1997, ANN INTERN MED, V126, P372, DOI 10.7326/0003-4819-126-5-199703010-00005; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FABER OK, 1978, DIABETES, V27, P170, DOI 10.2337/diab.27.1.S170; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HULLEY SB, 1981, CIRCULATION, V64, P57; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; Kiechl S, 1996, BRIT MED J, V313, P1040; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kitamura A, 1998, AM J EPIDEMIOL, V147, P59; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, AM J EPIDEMIOL, V119, P54, DOI 10.1093/oxfordjournals.aje.a113725; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; Malin H, 1983, DHHS PUBLICATION PHS, P490; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MOSS SE, 1988, J CLIN EPIDEMIOL, V41, P645, DOI 10.1016/0895-4356(88)90116-3; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SHAPER AG, 1988, LANCET, V2, P1267; The hypertension detection and follow-up program. Hypertension detetection and follow-up program cooperative group, 1976, PREV MED, V5, P207; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; *USDA, 1995, NUTR YOUR HLTH DIET, P40; Wannamethee SG, 1997, INT J EPIDEMIOL, V26, P523, DOI 10.1093/ije/26.3.523; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WIEBE DA, 1984, CLIN CHEM, V30, P352; World Health Organization, 1977, INT CLASS DIS	55	117	117	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					239	246		10.1001/jama.282.3.239	http://dx.doi.org/10.1001/jama.282.3.239			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422992	Bronze			2022-12-28	WOS:000081504400029
J	Suh-Burgmann, EJ; Goodman, A				Suh-Burgmann, EJ; Goodman, A			Surveillance for endometrial cancer in women receiving tamoxifen	ANNALS OF INTERNAL MEDICINE			English	Review							NONPOLYPOSIS COLORECTAL-CANCER; SURGICAL-ADJUVANT-BREAST; POSTMENOPAUSAL WOMEN; ULTRASONOGRAPHIC EVALUATION; VAGINAL EPITHELIUM; CERVICAL CYTOLOGY; TREATED PATIENTS; CARCINOMA; THERAPY; TRIAL	Recent studies showing a protective effect of tamoxifen in women at high risk for breast cancer have expanded the indications of the drug. While acting as an estrogen antagonist in the breast, tamoxifen can have estrogenic effects on the endometrium; consensus opinion is that tamoxifen increases the risk for endometrial cancer. Because an increasing number of women are taking tamoxifen, a strategy for gynecologic surveillance is needed. Studies examining the relation between risk for endometrial cancer and tamoxifen use have conflicting results. However, because of an overall interpretation that tamoxifen use slightly increases risk for endometrial cancer, some researchers advocate routine ultrasonography and endometrial biopsy for screening asymptomatic women receiving tamoxifen. This paper reviews the literature on endometrial cancer in women taking tamoxifen and the usefulness of various screening methods in this setting. Risk factors and screening criteria for endometrial cancer in the general population are discussed, and a strategy for surveillance of women taking tamoxifen is proposed. Patients should be screened for signs or symptoms of endometrial abnormality before taking tamoxifen. This evaluation, which should include a careful history, pelvic examination, and Papanicolaou smear, should be repeated annually while the patient is receiving tamoxifen. Although transvaginal ultrasonography is not recommended for routine screening, it is indicated if an adequate pelvic examination cannot be performed or if additional risk factors are present. The likelihood of abnormality is greater for patients who have abnormal bleeding, discharge, abnormal glandular cells on Papanicolaou smear, or an endometrial measurement on ultrasonography of more than 8 mm; these findings should prompt an aggressive evaluation of the endometrium.	Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Goodman, A (corresponding author), Massachusetts Gen Hosp, Wang ACC 2, Boston, MA 02114 USA.	goodman.annekathryn@mgh.harvard.edu		Suh-Burgmann, Betty/0000-0003-4732-1453				ACHIRON R, 1995, ULTRASOUND OBST GYN, V6, P116, DOI 10.1046/j.1469-0705.1995.06020116.x; ACHIRON R, 1995, J ULTRAS MED, V14, P685; ADAMI HO, 1987, BRIT J CANCER, V55, P77, DOI 10.1038/bjc.1987.16; American Cancer Society, 1998, CANC FACTS FIG 1998; ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; [Anonymous], 1996, INT J GYNECOL OBSTET, V53, P197; [Anonymous], 1994, Gynecol Oncol, V55, pS4; [Anonymous], 1992, Lancet, V339, P1; ANZAI Y, 1989, CANCER RES, V49, P2362; ARMENIA CS, 1967, OBSTET GYNECOL, V30, P524; Assikis VJ, 1996, EUR J CANCER, V32A, P1464, DOI 10.1016/0959-8049(96)00184-0; BARAKAT RR, 1994, GYNECOL ONCOL, V55, P164, DOI 10.1006/gyno.1994.1271; BAUM M, 1988, BRIT J CANCER, V57, P608; Berliere M, 1998, OBSTET GYNECOL, V91, P40, DOI 10.1016/S0029-7844(97)00591-7; Bertelli G, 1998, BREAST CANCER RES TR, V47, P41, DOI 10.1023/A:1005820115535; BOCCARDO F, 1990, J CLIN ONCOL, V8, P1310, DOI 10.1200/JCO.1990.8.8.1310; BOCCARDO F, 1981, ONCOLOGY, V38, P281, DOI 10.1159/000225571; BOCCARDO F, 1984, TUMORI, V70, P61, DOI 10.1177/030089168407000110; BonillaMusoles F, 1997, GYNECOL ONCOL, V65, P245, DOI 10.1006/gyno.1997.4678; BORNSTEIN J, 1994, J REPROD MED, V39, P674; BRINTON LA, 1992, AM J OBSTET GYNECOL, V167, P1317, DOI 10.1016/S0002-9378(11)91709-8; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Cecchini S, 1996, GYNECOL ONCOL, V60, P409, DOI 10.1006/gyno.1996.0064; Chang J, 1998, BREAST CANCER RES TR, V48, P81, DOI 10.1023/A:1005999008736; Cheng WF, 1997, GYNECOL ONCOL, V66, P233, DOI 10.1006/gyno.1997.4739; Cohen I, 1997, GYNECOL OBSTET INVES, V43, P60, DOI 10.1159/000291821; COHEN I, 1993, J ULTRAS MED, V12, P275, DOI 10.7863/jum.1993.12.5.275; COOK LS, 1995, J NATL CANCER I, V87, P1359, DOI 10.1093/jnci/87.18.1359; COULAM CB, 1983, OBSTET GYNECOL, V61, P403; Cuenca RE, 1996, CANCER, V77, P2058, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2058::AID-CNCR14>3.0.CO;2-U; Curtis R E, 1985, Natl Cancer Inst Monogr, V68, P113; Curtis RE, 1996, J NATL CANCER I, V88, P832, DOI 10.1093/jnci/88.12.832; Decensi A, 1996, J CLIN ONCOL, V14, P434, DOI 10.1200/JCO.1996.14.2.434; DEMUYLDER X, 1991, INT J GYNECOL OBSTET, V36, P127, DOI 10.1016/0020-7292(91)90767-Y; Duska LR, 1998, OBSTET GYNECOL, V91, P278, DOI 10.1016/S0029-7844(97)00659-5; Exacoustos C, 1995, ULTRASOUND OBST GYN, V6, P435, DOI 10.1046/j.1469-0705.1995.06060435.x; FERRAZZI E, 1977, BRIT MED J, V1, P1351, DOI 10.1136/bmj.1.6072.1351-e; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; FORNANDER T, 1991, J CLIN ONCOL, V9, P1740, DOI 10.1200/JCO.1991.9.10.1740; GOLDSTEIN SR, 1994, AM J OBSTET GYNECOL, V170, P447, DOI 10.1016/S0002-9378(94)70209-8; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Hann LE, 1997, AM J ROENTGENOL, V168, P657, DOI 10.2214/ajr.168.3.9057510; HARDELL L, 1990, CANCER, V66, P1661, DOI 10.1002/1097-0142(19901001)66:7<1661::AID-CNCR2820660735>3.0.CO;2-N; KANGAS L, 1992, ACTA ONCOL, V31, P143, DOI 10.3109/02841869209088894; KARLSSON B, 1995, AM J OBSTET GYNECOL, V172, P1488, DOI 10.1016/0002-9378(95)90483-2; Katase K, 1998, CANCER, V82, P1698, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.3.CO;2-K; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KOSS LG, 1984, OBSTET GYNECOL, V64, P1; KURJAK A, 1993, AM J OBSTET GYNECOL, V169, P1597, DOI 10.1016/0002-9378(93)90443-M; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MACMAHON B, 1974, Gynecologic Oncology, V2, P122, DOI 10.1016/0090-8258(74)90003-1; MACMAHON B, 1997, SEMIN ONCOL S1, V24; MAGRIPLES U, 1993, J CLIN ONCOL, V11, P485, DOI 10.1200/JCO.1993.11.3.485; MALFETANO JH, 1990, GYNECOL ONCOL, V39, P82, DOI 10.1016/0090-8258(90)90404-9; Marconi D, 1997, J AM ASSOC GYN LAP, V4, P331, DOI 10.1016/S1074-3804(05)80224-5; MATHEW A, 1990, NEW YORK STATE J MED, V90, P207; MEREDITH RF, 1986, CANCER, V58, P2003, DOI 10.1002/1097-0142(19861101)58:9<2003::AID-CNCR2820580908>3.0.CO;2-2; PARAZZINI F, 1991, GYNECOL ONCOL, V41, P1, DOI 10.1016/0090-8258(91)90246-2; PETERSON WF, 1956, OBSTET GYNECOL, V8, P40; POWLES TJ, 1994, BREAST CANCER RES TR, V31, P73, DOI 10.1007/BF00689678; RIBEIRO G, 1988, BRIT J CANCER, V57, P601, DOI 10.1038/bjc.1988.136; ROBINSON DC, 1995, GYNECOL ONCOL, V59, P186; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; RYDEN S, 1992, ACTA ONCOL, V31, P271, DOI 10.3109/02841869209088914; Saidi MH, 1997, J ULTRAS MED, V16, P587; SCHAPIRA DV, 1990, BREAST CANCER RES TR, V17, P3, DOI 10.1007/BF01812678; Schwartz LB, 1998, ULTRASOUND OBST GYN, V11, P48, DOI 10.1046/j.1469-0705.1998.11010048.x; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; SEOUD MAF, 1993, OBSTET GYNECOL, V82, P165; Stewart H J, 1992, J Natl Cancer Inst Monogr, P117; STEWART HJ, 1987, LANCET, V2, P171; TEPPER R, 1994, J ULTRAS MED, V13, P635; Tepper R, 1997, GYNECOL ONCOL, V64, P386, DOI 10.1006/gyno.1996.4568; Timmerman D, 1998, AM J OBSTET GYNECOL, V179, P62, DOI 10.1016/S0002-9378(98)70294-7; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; VASEN HFA, 1994, ANTICANCER RES, V14, P1675; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; WYNDER EL, 1966, CANCER, V19, P489, DOI 10.1002/1097-0142(196604)19:4<489::AID-CNCR2820190406>3.0.CO;2-W; YANCEY M, 1990, OBSTET GYNECOL, V76, P1000; 1989, LANCET, V1, P375	87	51	52	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					127	135		10.7326/0003-4819-131-2-199907200-00009	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419429				2022-12-28	WOS:000081509700008
J	Epstein, PR				Epstein, PR			Perspectives: Medicine - Climate and health	SCIENCE			English	Editorial Material							TEMPERATURE; OCEAN		Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Epstein, PR (corresponding author), Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA 02115 USA.	paul_epstein@hms.harvard.edu						ABRAMOVITZ JN, 1998, RECORD YEAR WEATHER; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Binder S, 1999, SCIENCE, V284, P1311, DOI 10.1126/science.284.5418.1311; BINDOFF NL, 1992, NATURE, V357, P59, DOI 10.1038/357059a0; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; Coley PD, 1999, SCIENCE, V284, P2098, DOI 10.1126/science.284.5423.2098; Dai A, 1998, GEOPHYS RES LETT, V25, P3367, DOI 10.1029/98GL52511; Daily G.C, 1997, NATURES SERVICE SOC; Diaz HF, 1996, NATURE, V383, P152, DOI 10.1038/383152a0; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Epstein P.R., 1997, BIODIVERSITY HUMAN H, P60; Epstein P.R., 1998, MARINE ECOSYSTEMS EM; EPSTEIN PR, 1993, LANCET, V342, P1216, DOI 10.1016/0140-6736(93)92191-U; Epstein PR, 1998, B AM METEOROL SOC, V79, P409, DOI 10.1175/1520-0477(1998)079<0409:BAPSOC>2.0.CO;2; EPSTEIN PR, 1992, AM J PREV MED, V8, P263, DOI 10.1016/S0749-3797(18)30815-8; EPSTEIN PR, 1999, EXTREME WEATHER EVEN; EPSTEIN PR, 1994, AM J PUBLIC HEALTH, V85, P168; FAJER ED, 1991, OECOLOGIA, V87, P37, DOI 10.1007/BF00323777; GILL C. A., 1920, Indian Journal of Medical Research, V7, P618; Hellin J, 1999, NATURE, V399, P316, DOI 10.1038/20577; Institute of Medicine, 1992, EM INF MICR THREATS; *INT FED RED CROSS, 1998, WORLD DIS REP 1998, P198; KARL TR, 1997, SCI AM           MAY, P8; Krabill W, 1999, SCIENCE, V283, P1522, DOI 10.1126/science.283.5407.1522; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; MAYEWSKI P, COMMUNICATION; McMichael A.J., 1996, CLIMATE CHANGE HUMAN; PARRILLA G, 1994, NATURE, V369, P48, DOI 10.1038/369048a0; Pimentel D., 1997, TECHNIQUES REDUCING, P1; REGALADO A, 1995, SCIENCE, V268, P1436, DOI 10.1126/science.268.5216.1436; Rind D, 1998, SCIENCE, V281, P1152, DOI 10.1126/science.281.5380.1152; Rosenzweig C., 1998, CLIMATE CHANGE GLOBA, P101; Stern Paul C., 1999, MAKING CLIMATE FOREC; Taylor K, 1999, AM SCI, V87, P320, DOI 10.1511/1999.4.320; THOMPSON LG, 1993, GLOBAL PLANET CHANGE, V7, P145, DOI 10.1016/0921-8181(93)90046-Q; TRAVIS J, 1994, SCIENCE, V266, P1947, DOI 10.1126/science.266.5193.1947; Trenberth KE, 1995, CLIMATE CHANGE 1995: THE SCIENCE OF CLIMATE CHANGE, P51; TRENBERTH KE, 1998, CLIMATIC CHANGE, V36, P1; WAYNE PW, UNPUB; Wilf P, 1999, SCIENCE, V284, P2153, DOI 10.1126/science.284.5423.2153; *WORLD HLTH REP 19, 1996, FIGHT DIS FOST DEV	44	122	126	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					347	348		10.1126/science.285.5426.347	http://dx.doi.org/10.1126/science.285.5426.347			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438299				2022-12-28	WOS:000081465900031
J	Lin, XH; Perrimon, N				Lin, XH; Perrimon, N			Daily cooperates with Drosophila Frizzled 2 to transduce Wingless signalling	NATURE			English	Article							LONG-RANGE ACTION; EXPRESSION; GENE; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MORPHOGEN; POLARITY	The Drosophila wingless gene (wg) encodes a protein of the Wnt family and is a critical regulator in many developmental processes(1). Biochemical studies have indicated that heparan sulphate proteoglycans, consisting of a protein core to which heparan sulphate glycosaminoglycans are attached(2), are important for Wg function(3). Here we show that, consistent with these findings, the Drosophila gene sulfateless (sfl), which encodes a homologue of vertebrate heparan sulphate N-deacetylase/N-sulphotransferase (an enzyme needed for the modification of heparan sulphate) is essential for Wg signalling. We have identified the product of division abnormally delayed (dally), a glycosyl-phosphatidyl inositol (GPI)-linked glypican, as a heparan sulphate proteoglycan molecule involved in Wg signalling, Our results indicate that Daily may act as a co-receptor for Wg, and that Daily, together with Drosophila Frizzled 2, modulates both short- and long-range activities of Wg.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CADIGAN KM, 1998, DEVELOPMENT, V125, P3075; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HAECKER U, 1997, DEVELOPMENT, V124, P3565; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PERRIMON N, 1996, GENETICS, V144, P168; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	20	396	401	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					281	284		10.1038/22343	http://dx.doi.org/10.1038/22343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421372				2022-12-28	WOS:000081503800048
J	Cheasty, T; Said, B; Threlfall, EJ				Cheasty, T; Said, B; Threlfall, EJ			V cholerae non-01: Implications for man?	LANCET			English	Editorial Material							VIBRIO-CHOLERAE; EPIDEMIOLOGY; HEMOLYSINS		PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England		Threlfall, EJ (corresponding author), PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England.							ALDOVA E, 1968, J INFECT DIS, V118, P25, DOI 10.1093/infdis/118.1.25; ARITA M, 1986, INFECT IMMUN, V52, P45, DOI 10.1128/IAI.52.1.45-49.1986; BOOTH BA, 1986, J INFECT DIS, V154, P183, DOI 10.1093/infdis/154.1.183; DAKIN WPH, 1974, MED J AUSTRALIA, V2, P487, DOI 10.5694/j.1326-5377.1974.tb70935.x; DATTAROY K, 1986, APPL ENVIRON MICROB, V52, P875, DOI 10.1128/AEM.52.4.875-879.1986; KAMAL AM, 1971, J EGYPT PUBLIC HLTH, V46, P125; KAPER JB, 1986, J CLIN MICROBIOL, V23, P652, DOI 10.1128/JCM.23.3.652-654.1986; MORRIS JG, 1990, EPIDEMIOL REV, V12, P179, DOI 10.1093/oxfordjournals.epirev.a036052; MORRIS JG, 1990, J CLIN INVEST, V85, P679; RHODES JB, 1985, J CLIN MICROBIOL, V22, P572, DOI 10.1128/JCM.22.4.572-575.1985; ROBERTS D, 1979, J HYG-CAMBRIDGE, V82, P123, DOI 10.1017/S0022172400025547; SANYAL SC, 1974, J INFECT DIS, V130, P575, DOI 10.1093/infdis/130.6.575; SHIMADA T, 1993, LANCET, V341, P1347; Visser IJR, 1999, VET REC, V144, P451, DOI 10.1136/vr.144.16.451; YAMAMOTO K, 1986, INFECT IMMUN, V51, P927, DOI 10.1128/IAI.51.3.927-931.1986	15	11	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					89	90		10.1016/S0140-6736(99)00151-8	http://dx.doi.org/10.1016/S0140-6736(99)00151-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408479				2022-12-28	WOS:000081377100005
J	Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH				Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH			Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; ROD DARK-ADAPTATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; GENE ABCR; RETINITIS-PIGMENTOSA; FUNDUS FLAVIMACULATUS; MACULAR DEGENERATION; FATTY-ACIDS; LIGHT ADAPTATION; OUTER SEGMENTS	Rim protein (RmP) is an ABC transporter of unknown function in rod outer segment discs. The human gene for RmP (ABCR) is affected in several recessive retinal degenerations. Here, we characterize the ocular phenotype in abcr knockout mice. Mice lacking RmP show delayed dark adaptation, increased all-trans-retinaldehyde (all-trans-RAL) following light exposure, elevated phosphatidylethanolamine (PE) in outer segments, accumulation of the protonated Schiff base complex of all-trans-RAL and PE (N-retinylidene-PE), and striking deposition of a major lipofuscin fluorophore (A2-E) in retinal pigment epithelium (RPE). These data suggest that RmP functions as an outwardly directed flippase for N-retinylidene-PE. Delayed dark adaptation is likely due to accumulation in discs of the noncovalent complex between opsin and all-trans-RAL. Finally, ABCR-mediated retinal degeneration may result from "poisoning" of the RPE due to A2-E accumulation, with secondary photoreceptor degeneration due to loss of the RPE support role.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Retina Fdn SW, Dallas, TX 75231 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Retina Foundation of the Southwest	Travis, GH (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	travis@utsw.swmed.edu	Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Birch, David/0000-0002-6594-2897; Tzekov, Radouil/0000-0002-3662-9818				ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BERGSMA DR, 1977, NATURE, V265, P66, DOI 10.1038/265066a0; Birch DG, 1995, DEGENERATIVE DISEASES OF THE RETINA, P359; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN HM, 1992, J CHROMATOGR-BIOMED, V578, P124, DOI 10.1016/0378-4347(92)80234-H; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DAEMEN FJM, 1969, NATURE, V222, P879, DOI 10.1038/222879a0; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005; Dogra S, 1999, YEAST, V15, P111, DOI 10.1002/(SICI)1097-0061(19990130)15:2&lt;111::AID-YEA350&gt;3.0.CO;2-E; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; FISHMAN GA, 1994, AM J OPHTHALMOL, V118, P362, DOI 10.1016/S0002-9394(14)72961-7; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GRANIT R, 1947, SENSORY MECHANISM RE; GROENENDIJK GWT, 1984, VISION RES, V24, P1623, DOI 10.1016/0042-6989(84)90320-1; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; HOOD DC, 1993, VISUAL NEUROSCI, V10, P857, DOI 10.1017/S0952523800006076; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JIN J, 1994, VISUAL NEUROSCI, V11, P389, DOI 10.1017/S0952523800001735; JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769; Kedzierski W, 1999, J NEUROCHEM, V72, P430, DOI 10.1046/j.1471-4159.1999.0720430.x; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487; Lee BL, 1999, RETINA VITREOUS MACU, P978; Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pepperberg DR, 1997, VISUAL NEUROSCI, V14, P73, DOI 10.1017/S0952523800008774; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SUZUKI T, 1986, VISION RES, V26, P425, DOI 10.1016/0042-6989(86)90185-9; TAMURA T, 1989, SCIENCE, V245, P755, DOI 10.1126/science.2772634; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	68	678	711	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					13	23		10.1016/S0092-8674(00)80602-9	http://dx.doi.org/10.1016/S0092-8674(00)80602-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412977	Bronze			2022-12-28	WOS:000081451000004
J	Mackenbach, JP; Kunst, AE				Mackenbach, JP; Kunst, AE			Heterogeneity of populations should be taken into account - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Mackenbach, JP (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Kunst, Anton/0000-0002-3313-5273				Cavelaars A E, 1997, J Health Psychol, V2, P353, DOI 10.1177/135910539700200306; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kunst AE, 1999, AM J PUBLIC HEALTH, V89, P47, DOI 10.2105/AJPH.89.1.47; MANCIA G, 1988, AM HEART J, V115, P240, DOI 10.1016/0002-8703(88)90643-6; *WHO, 1997, WHO REG UBL EUR SER, V75	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1478	1479						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419295				2022-12-28	WOS:000080668200031
J	Ostro, SJ; Pravec, P; Benner, LAM; Hudson, RS; Sarounova, L; Hicks, MD; Rabinowitz, DL; Scotti, JV; Tholen, DJ; Wolf, M; Jurgens, RF; Thomas, ML; Giorgini, JD; Chodas, PW; Yeomans, DK; Rose, R; Frye, R; Rosema, KD; Winkler, R; Slade, MA				Ostro, SJ; Pravec, P; Benner, LAM; Hudson, RS; Sarounova, L; Hicks, MD; Rabinowitz, DL; Scotti, JV; Tholen, DJ; Wolf, M; Jurgens, RF; Thomas, ML; Giorgini, JD; Chodas, PW; Yeomans, DK; Rose, R; Frye, R; Rosema, KD; Winkler, R; Slade, MA			Radar and optical observations of asteroid 1998 KY26	SCIENCE			English	Article							NEAR-EARTH ASTEROIDS; DISRUPTION; FRAGMENTS; IMPACT; SHAPE	Observations of near-Earth asteroid 1998 KY26 shortly after its discovery reveal a slightly elongated spheroid with a diameter of about 30 meters, a composition analogous to carbonaceous chondritic meteorites, and a rotation period of 10.7 minutes. which is an order of magnitude shorter than that measured for any other solar system object. The rotation is too rapid for 1998 KY26 to consist of multiple components bound together just by their mutual gravitational attraction. This monolithic object probably is a fragment derived from cratering or collisional destruction of a much larger asteroid.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Acad Sci Czech Republ, Inst Astron, CZ-25165 Ondrejov, Czech Republic; Washington State Univ, Sch Elect Engn & Comp Sci, Pullman, WA 99164 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Charles Univ, Astron Inst, CZ-18000 Prague, Czech Republic	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Czech Academy of Sciences; Astronomical Institute of the Czech Academy of Sciences; Washington State University; University of Arizona; University of Hawaii System; Charles University Prague	Ostro, SJ (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.		Pravec, Petr/AAE-2695-2019; Wolf, Marek/Q-1687-2017; Pravec, Petr/G-9037-2014	Pravec, Petr/0000-0001-8434-9776; Wolf, Marek/0000-0002-4387-6358; 				ANDREWS AK, 1995, OPT LETT, V20, P2327, DOI 10.1364/OL.20.002327; Asphaug E, 1998, NATURE, V393, P437, DOI 10.1038/30911; Benner LAM, 1999, ICARUS, V137, P247, DOI 10.1006/icar.1999.6044; Benner LAM, 1997, ICARUS, V130, P296, DOI 10.1006/icar.1997.5834; BESSELL MS, 1990, PUBL ASTRON SOC PAC, V102, P1181, DOI 10.1086/132749; Bottke WF, 1998, PLANET SPACE SCI, V46, P311, DOI 10.1016/S0032-0633(97)00035-4; BRITT DT, 1999, ENCY SOLAR SYSTEM, P585; Farinella P, 1998, ICARUS, V132, P378, DOI 10.1006/icar.1997.5872; FUJIWARA A, 1981, ICARUS, V48, P329, DOI 10.1016/0019-1035(81)90113-5; GARVIN JB, 1985, J GEOPHYS RES-SOLID, V90, P6859, DOI 10.1029/JB090iB08p06859; Gault DE., 1972, GEOCHIM COSMOCHIM AC, V3, P2713; Giblin I, 1997, ICARUS, V127, P424, DOI 10.1006/icar.1996.5671; GREENBERG R, 1994, ICARUS, V107, P84, DOI 10.1006/icar.1994.1008; Greenberg R, 1996, ICARUS, V120, P106, DOI 10.1006/icar.1996.0040; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; Harris A.W., 1996, LUNAR PLANET SCI, V27, P493; HARRIS AW, 1994, ICARUS, V107, P209, DOI 10.1006/icar.1994.1017; HARRIS AW, 1989, ICARUS, V77, P171, DOI 10.1016/0019-1035(89)90015-8; HUDSON RS, 1995, SCIENCE, V270, P84, DOI 10.1126/science.270.5233.84; LEWIS JS, 1997, PHYSICS CHEM SOLAR S; Love SG, 1996, ICARUS, V124, P141, DOI 10.1006/icar.1996.0195; Lupishko DF, 1998, PLANET SPACE SCI, V46, P47, DOI 10.1016/S0032-0633(97)00132-3; MAGRI C, IN PRESS ICARUS; McKay D.S., 1989, ASTEROIDS, VII, P617; Mitchell DL, 1998, ICARUS, V131, P4, DOI 10.1006/icar.1997.5815; Pravec P, 1996, ICARUS, V124, P471, DOI 10.1006/icar.1996.0223; RABINOWITZ DL, 1993, NATURE, V363, P704, DOI 10.1038/363704a0; Rabinowitz DL, 1998, ICARUS, V134, P342, DOI 10.1006/icar.1998.5951; Ryan EV, 1998, ICARUS, V133, P1, DOI 10.1006/icar.1998.5915; Shoemaker E. M, 1978, NASA C PUBLICATION, V2053, P245; Steel DI, 1997, PLANET SPACE SCI, V45, P1091, DOI 10.1016/S0032-0633(97)00063-9; SUPPE J, 1985, PRINCIPLES STRUCTURA, P155; TEDESCO EF, 1992, PLTR922049; Tholen D.J., 1989, ASTEROIDS, VII, P298; TURCOTTE DL, 1982, GEODYNAMICS APPL CON, P85; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; WILLIAMS GV, 1998, 1998LO2 MIN PLAN EL; [No title captured]	38	49	50	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					557	559		10.1126/science.285.5427.557	http://dx.doi.org/10.1126/science.285.5427.557			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417379				2022-12-28	WOS:000081609500029
J	Grumbach, K; Selby, JV; Damberg, C; Bindman, AB; Quesenberry, C; Truman, A; Uratsu, C				Grumbach, K; Selby, JV; Damberg, C; Bindman, AB; Quesenberry, C; Truman, A; Uratsu, C			Resolving the gatekeeper conundrum - What patients value in primary care and referrals to specialists	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN AVOID CONFLICT; ORGANIZATION; SATISFACTION; BACKLASH; OUTCOMES; ACCESS; TRUST; VIEW	Context Few data are available regarding how patients view the role of primary care physicians as "gatekeepers" in managed care systems. Objective To determine the extent to which patients value the role of their primary care physicians as first-contact care providers and coordinators of referrals, whether patients perceive that their primary care physicians impede access to specialists, and whether problems in gaining access to specialists are associated with a reduction in patients' trust and confidence in their primary care physicians. Design, Setting, and Patients Cross-sectional survey mailed in the fall of 1997 to 12 707 adult patients who were members of managed care plans and received care from 10 large physician groups in California. The response rate among eligible patients was 71%. A total of 7718 patients (mean age, 66.7 years; 32% female) were eligible for analysis. Main Outcome Measures Questionnaire items addressed 3 main topics: (1) patient attitudes toward the first-contact and coordinating role of their primary care physicians, (2) patients' ratings of their primary care physicians (trust and confidence in and satisfaction with), and (3) patient perceptions of barriers to specialty referrals. Referral barriers were analyzed as predictors of patients' ratings of their physicians. Results Almost all patients valued the role of a primary care physician as a source of first-contact care (94%) and coordinator of referrals (89%). Depending on the specific medical problem, 75% to 91% of patients preferred to seek care initially from their primary care physicians rather than specialists. Twenty-three percent reported that their primary care physicians or medical groups interfered with their ability to see specialists. Patients who had difficulty obtaining referrals were more likely to report low trust (adjusted odds ratio [OR], 2.7; 95% confidence interval [CI], 2.1-3.5), low confidence (OR, 2.2; 95% CI, 1.6-2.9), and low satisfaction (OR, 3.3; 95% CI, 2.6-4.2) with their primary care physicians. Conclusions Patients value the first-contact and coordinating role of primary care physicians. However, managed care policies that emphasize primary care physicians as gatekeepers impeding access to specialists undermine patients' trust and confidence in their primary care physicians.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Primary Care Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Calif Hlth Workforce Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; Kaiser Permanente Med Care Program No Calif, Div Res, Oakland, CA USA; Pacific Business Grp Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	Grumbach, K (corresponding author), San Francisco Gen Hosp, Dept Family & Community Med, 1001 Potrero Ave,Ward 83, San Francisco, CA 94110 USA.		Grumbach, Kevin/L-9222-2016		AHRQ HHS [R01 HS08269] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; Bindman AB, 1996, J GEN INTERN MED, V11, P269, DOI 10.1007/BF02598266; Blendon RJ, 1998, HEALTH AFFAIR, V17, P80, DOI 10.1377/hlthaff.17.4.80; Bodenheimer T, 1999, JAMA-J AM MED ASSOC, V281, P2045, DOI 10.1001/jama.281.21.2045; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Donaldson M, 1996, PRIMARY CARE AM HLTH; ELLSBURY KE, 1989, J FAM PRACTICE, V28, P698; ELLSBURY KE, 1987, J FAM PRACTICE, V25, P616; Flocke SA, 1997, J FAM PRACTICE, V45, P64; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P160; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; Halm EA, 1997, JAMA-J AM MED ASSOC, V278, P1677, DOI 10.1001/jama.278.20.1677; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kapsner P E, 1994, Med Group Manage J, V41, ppassim; KAPSNER PE, 1994, MED GROUP MANAGE J, V41, P56; KAPSNER PE, 1994, MED GROUP MANAGE J, V41, P54; Kerr EA, 1998, MED CARE RES REV, V55, P59, DOI 10.1177/107755879805500104; Kuttner R, 1998, NEW ENGL J MED, V338, P1635, DOI 10.1056/NEJM199805283382221; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LINN MW, 1982, MED CARE, V20, P606, DOI 10.1097/00005650-198206000-00006; Mullan F, 1998, HEALTH AFFAIR, V17, P118, DOI 10.1377/hlthaff.17.2.118; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; Safran DG, 1998, J FAM PRACTICE, V47, P213; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Starfield B., 1992, PRIMARY CARE CONCEPT; STEPHENS GG, 1989, J FAM PRACTICE, V28, P701; Stewart AL, 1997, J FAM PRACTICE, V44, P177; STPETER RF, 1997, CTR STUDYING HLTH SY, V7; TAYLOR TR, 1989, BRIT MED J, V299, P1323, DOI 10.1136/bmj.299.6711.1323; Thom DH, 1999, MED CARE, V37, P510, DOI 10.1097/00005650-199905000-00010; Thom DH, 1997, J FAM PRACTICE, V44, P169	34	225	226	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					261	266		10.1001/jama.282.3.261	http://dx.doi.org/10.1001/jama.282.3.261			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	217MW	10422995	Bronze			2022-12-28	WOS:000081504400032
J	Leape, LL; Cullen, DJ; Clapp, MD; Burdick, E; Demonaco, HJ; Erickson, JI; Bates, DW				Leape, LL; Cullen, DJ; Clapp, MD; Burdick, E; Demonaco, HJ; Erickson, JI; Bates, DW			Pharmacist participation on physician rounds and adverse drug events in the intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; PREVENTION; COSTS	Context Pharmacist review of medication orders in the intensive care unit (ICU) has been shown to prevent errors, and pharmacist consultation has reduced drug costs. However, whether pharmacist participation in the ICU at the time of drug prescribing reduces adverse events has not been studied. Objective To measure the effect bf pharmacist participation on medical rounds in the ICU on the rate of preventable adverse drug events (ADEs) caused by ordering errors. Design Before-after comparison between phase 1 (baseline) and phase 2 (after intervention implemented) and phase 2 comparison with a control unit that did not receive the intervention. Setting A medical ICU (study unit) and a coronary care unit (control unit) in a large urban teaching hospital. Patients Seventy-five patients randomly selected from each of 3 groups: all admissions to the study unit from February 1, 1993, through July 31, 1993 (baseline) and all admissions to the study unit (postintervention) and control unit from October 1, 1994, through July 7, 1995. In addition, 50 patients were selected at random from the control unit during the baseline period. Intervention A senior pharmacist made rounds with the ICU team and remained in the ICU for consultation in the morning, and was available on call throughout the day. Main Outcome Measures Preventable ADEs due to ordering (prescribing) errors and the number, type, and acceptance of interventions made by the pharmacist. Preventable ADEs were identified by review of medical records of the randomly selected patients during both preintervention and postintervention phases. Pharmacists recorded all recommendations, which were then analyzed by type and acceptance. Results The rate of preventable ordering ADEs decreased by 66% from 10.4 per 1000 patient-days (95% confidence interval [CI], 7-14) before the intervention to 3.5 (95% CI, 1-5, P<.001) after the Intervention. In the control unit, the rate was essentially unchanged during the same time periods: 10.9 (95% CI, 6-16) and 12.4 (95% CI, 8-17) per 1000 patient-days. The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) were accepted by physicians. Conclusions The presence of a. pharmacist on rounds as a full member of the patient care team in a medical ICU was associated with a substantially lower rate of ADEs caused by prescribing errors. Nearly all the changes were readily accepted by physicians.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Anesthesia, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Nursing, Boston, MA 02114 USA; Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROYLES JE, 1991, DICP ANN PHARMAC, V25, P119, DOI 10.1177/106002809102500201; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; FOLLI HL, 1987, PEDIATRICS, V79, P718; Kilroy R A, 1993, Crit Care Nurs Clin North Am, V5, P221; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; MONTAZERI M, 1994, CRIT CARE MED, V22, P1044, DOI 10.1097/00003246-199406000-00027; SAS Institute Inc, 1988, SAS PROC GUID REL 6	13	951	993	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					267	270		10.1001/jama.282.3.267	http://dx.doi.org/10.1001/jama.282.3.267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422996	Bronze			2022-12-28	WOS:000081504400033
J	Rattner, DW				Rattner, DW			Inguinal herniorrhaphy: for surgical specialists only?	LANCET			English	Editorial Material							HERNIA REPAIR		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Rattner, DW (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.							DEVLIN HB, 1986, BRIT J SURG, V73, P123, DOI 10.1002/bjs.1800730217; Juul P, 1999, BRIT J SURG, V86, P316, DOI 10.1046/j.1365-2168.1999.01053.x; Kozol R, 1997, ARCH SURG-CHICAGO, V132, P292; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; PAYNE JH, 1994, ARCH SURG-CHICAGO, V129, P973	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					175	176		10.1016/S0140-6736(99)90103-4	http://dx.doi.org/10.1016/S0140-6736(99)90103-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421293				2022-12-28	WOS:000081504200003
J	Stoddard, PK				Stoddard, PK			Predation enhances complexity in the evolution of electric fish signals	NATURE			English	Article							ORDER GYMNOTIFORMES; ELECTRORECEPTION; LEPIDOPTERA; COURTSHIP; ARCTIIDAE	Theories of sexual selection assume that predation is a restrictive, simplifying force in the evolution of animal display characters' and many empirical studies have shown that predation opposes excessive elaboration of sexually selected traits(2). In an unexpected turnaround, I show here that predation pressure on neotropical, weakly electric fish (order Gymnotiformes) seems to have selected for greater signal complexity, by favouring characters that have enabled further signal elaboration by sexual selection. Most gymnotiform fish demonstrate adaptations that lower detectability of their electrolocation/communication signals by key predators. A second wave phase added to the ancestral monophasic signal shifts the emitted spectrum above the most sensitive frequencies of electroreceptive predators. By using playback trials with the predatory electric eel (Electrophorus electricus), I show that these biphasic signals are less detectable than the primitive monophasic signals. But sexually mature males of many species in the family Hypopomidae extend the duration of the second phase of their electric signal pulses(3) and further amplify this sexual dimorphism nightly during the peak hours of reproduction(4). Thus a signal element that evolved for crypsis has itself been modified by sexual selection.	Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA	State University System of Florida; Florida International University	Stoddard, PK (corresponding author), Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA.	stoddard@fiu.edu	Stoddard, Philip K/AAY-4188-2020					Albert JS, 1996, COPEIA, P85; ALVESGOMES JA, 1995, MOL BIOL EVOL, V12, P298; Andersson Malte, 1994; BENNETT LA, 1971, J RES CRIME DELINQ, V8, P1, DOI 10.1177/002242787100800101; BENNETT MV, 1961, ANN NY ACAD SCI, V94, P458, DOI 10.1111/j.1749-6632.1961.tb35555.x; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Crampton William G. R., 1998, Anais da Academia Brasileira de Ciencias, V70, P805; Darwin C., 1871, DESCENT MAN SELECTIO; DUNNING BB, 1973, THESIS U MINNESOTA; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; Franchina CR, 1998, J COMP PHYSIOL A, V183, P759, DOI 10.1007/s003590050299; HAGEDORN M, 1988, COPEIA, P324; Hopkins C.D., 1986, P527; HOPKINS CD, 1990, BRAIN BEHAV EVOLUT, V35, P350, DOI 10.1159/000115880; HOPKINS CD, 1978, BEHAV ECOL SOCIOBIOL, V3, P113, DOI 10.1007/BF00294985; HOPKINS CD, 1976, J COMP PHYSIOL, V111, P171, DOI 10.1007/BF00605531; KIRSCHBAUM F, 1995, ELECT FISHES HIST BE, P267; LISSMANN HW, 1958, J EXP BIOL, V35, P156; MCCREERY DB, 1977, J COMP PHYSIOL, V113, P317, DOI 10.1007/BF00620405; MERRON GS, 1993, J FISH BIOL, V43, P575; MILLER RR, 1966, COPEIA, P773, DOI 10.2307/1441406; Moller P., 1995, ELECT FISHES HIST BE; PETERS RC, 1972, J COMP PHYSIOL, V79, P29, DOI 10.1007/BF00693616; REID S, 1983, REV UNELLEZ CIENC TE, V0001, P00013; SANDERFORD MV, 1995, J INSECT BEHAV, V8, P19, DOI 10.1007/BF01990967; SHUMWAY CA, 1988, J COMP PHYSIOL A, V163, P465, DOI 10.1007/BF00604901; Simmons RB, 1996, J INSECT BEHAV, V9, P909, DOI 10.1007/BF02208978; SULLIVAN JP, 1997, THESIS DUKE U; Szabo T., 1974, P59; WESTBY GWM, 1988, BEHAV ECOL SOCIOBIOL, V22, P341	30	129	135	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					254	256		10.1038/22301	http://dx.doi.org/10.1038/22301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421365				2022-12-28	WOS:000081503800041
J	Struhl, K				Struhl, K			Fundamentally different logic of gene regulation in eukaryotes and prokaryotes	CELL			English	Review							IN-VIVO; TRANSCRIPTION; RECRUITMENT; ACTIVATION		Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; Geanacopoulos M, 1999, GENE DEV, V13, P1251, DOI 10.1101/gad.13.10.1251; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hochschild A, 1998, CELL, V92, P597, DOI 10.1016/S0092-8674(00)81126-5; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kingston RE, 1999, NATURE, V399, P199, DOI 10.1038/20302; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	18	345	354	1	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					1	4		10.1016/S0092-8674(00)80599-1	http://dx.doi.org/10.1016/S0092-8674(00)80599-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412974	Bronze			2022-12-28	WOS:000081451000001
J	Torgerson, DJ; Roberts, C				Torgerson, DJ; Roberts, C			Understanding controlled trials - Randomisation methods: concealment	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of York - UK; University of Manchester	Torgerson, DJ (corresponding author), Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO1 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				Kennedy A, 1997, CONTROLLED CLIN T S3, V18, pS77, DOI DOI 10.1016/S0197-2456(97)91044-8; POCOCK SJ, 1988, CLIN TRIALS PRACTICA; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	4	71	83	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					375	376		10.1136/bmj.319.7206.375	http://dx.doi.org/10.1136/bmj.319.7206.375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435967	Green Published			2022-12-28	WOS:000082001700032
J	Rufe, E; Hochella, MF				Rufe, E; Hochella, MF			Quantitative assessment of reactive surface area of phlogopite during acid dissolution	SCIENCE			English	Article							BIOTITE DISSOLUTION; KINETICS; TEMPERATURE; ADSORPTION; PH	The reactive surface area of a dissolving sheet silicate, phlogopite, was quantitatively assessed in experiments performed in the fluid cell of an atomic force microscope at room temperature and pH values of 2 and 5.7, Additional assessment was provided by surface chemical analysis and electron diffraction. Dissolution rates of phlogopite (hkO) edges are in the range of 10(-10) moles per square meters per second, two orders of magnitude faster than bulk rates for this mineral. The basal (001) surfaces also show distinct reactivity, although it is short-lived before they become relatively inert. These basal surfaces are shown to Leach, hydrate, and expand to an amorphous silica-enriched film.	Virginia Polytech Inst & State Univ, Dept Geol Sci, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Rufe, E (corresponding author), Virginia Polytech Inst & State Univ, Dept Geol Sci, Blacksburg, VA 24061 USA.							ACKER JG, 1992, GEOCHIM COSMOCHIM AC, V56, P3073, DOI 10.1016/0016-7037(92)90290-Y; BOSBACH D, UNPUB; BRANTLEY SL, 1995, REV MINERALOGY, V31, pCH4; CASEY WH, 1988, GEOCHIM COSMOCHIM AC, V52, P1545, DOI 10.1016/0016-7037(88)90224-4; CASEY WH, 1990, REV MINERALOGY, V23, pCH10; DREVER JI, 1995, REV MINERALOGY, V31, pCH10; HOCELLA MF, 1988, SURF SCI, V197, pL260; HOCHELLA MF, 1995, REV MINERALOGY, V31, pCH8; HOCHELLA MF, 1998, ACS SYM SER, V715, P37; HOCHELLA MF, 1995, MINERALOGICAL SOC SE, V5, pCH2; Jordan G, 1996, GEOCHIM COSMOCHIM AC, V60, P5055, DOI 10.1016/S0016-7037(96)00309-2; Kalinowski BE, 1996, GEOCHIM COSMOCHIM AC, V60, P367, DOI 10.1016/0016-7037(95)00411-4; KAVIRATNA H, 1994, CLAY CLAY MINER, V42, P717, DOI 10.1346/CCMN.1994.0420607; Koretsky CM, 1998, AM J SCI, V298, P349, DOI 10.2475/ajs.298.5.349; Liang Y, 1996, GEOCHIM COSMOCHIM AC, V60, P4883, DOI 10.1016/S0016-7037(96)00337-7; Malmstrom M, 1997, GEOCHIM COSMOCHIM AC, V61, P2779, DOI 10.1016/S0016-7037(97)00093-8; Nagy K.L, 1995, REV MINERAL, V31, pCh; NONAKA A, 1984, J COLLOID INTERF SCI, V99, P335, DOI 10.1016/0021-9797(84)90120-6; PUTNIS A, 1995, GEOCHIM COSMOCHIM AC, V59, P4623, DOI 10.1016/0016-7037(95)00324-X; Russ J. C., 2016, IMAGE PROCESSING HDB, V7th; TURPAULT MP, 1994, GEOCHIM COSMOCHIM AC, V58, P2761, DOI 10.1016/0016-7037(94)90112-0; WHITE AF, 1990, ACS S SERIES, V416, pCH35	22	92	94	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					874	876		10.1126/science.285.5429.874	http://dx.doi.org/10.1126/science.285.5429.874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436152				2022-12-28	WOS:000081860900044
J	Faderl, S; Talpaz, M; Estrov, Z; Kantarjian, HM				Faderl, S; Talpaz, M; Estrov, Z; Kantarjian, HM			Chronic myelogenous leukemia: Biology and therapy	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC MYELOID-LEUKEMIA; BONE-MARROW TRANSPLANTATION; IN-SITU HYBRIDIZATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; RECOMBINANT INTERFERON-ALPHA; CHRONIC MYELOCYTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; ABL-POSITIVE CELLS; LATE CHRONIC PHASE	Chronic myelogenous leukemia is a myeloproliferative disorder. It is characterized by a biphasic or triphasic clinical course in which a benign chronic phase is followed by transformation into an accelerated and blastic phase. On a cytogenetic and molecular level, most patients with chronic myelogenous leukemia demonstrate BCR-ABL fusion genes in hematopoietic progenitor cells, which result from a reciprocal translocation between chromosomes 9 and 22; this translocation leads to a shortened chromosome 22, called the Philadelphia chromosome. Translation of the fusion products yields chimeric proteins of variable size that have increased tyrosine kinase activity. Conventional chemotherapy with hydroxyurea or busulfan can achieve hematologic control but cannot modify the natural disease course, which inevitably terminates in a rapidly fatal blastic phase. Since its introduction in the 1980s, allogeneic stem-cell transplantation has provided the groundwork for a cure of chronic myelogenous leukemia. However, few patients are eligible for this treatment because of donor availability and age restrictions. Therapy with interferon-ol alone or in combination with cytarabine suppresses the leukemic clone, produces cytogenetic remissions, and prolongs survival. It is an effective alternative first-line treatment for patients ineligible for transplantation. New drugs active against chronic myelogenous leukemia may show increased activity in the transformed phases of the disease. Novel therapies and concepts are developing rapidly; targeted molecules are tyrosine kinases, ras, and messenger RNA through antisense oligonucleotides. Alternative transplantation options, such as stem cells from autologous sources and matched unrelated donors, are expanding. Immunomodulation by adoptive immunotherapy and vaccine strategies hold significant promise for the cure of chronic myelogenous leukemia.	Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kantarjian, HM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA.		ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Talpaz, Moshe/0000-0003-3361-3981				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALIMENA G, 1988, BLOOD, V72, P642; ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ALLAN NC, 1996, INT J HEMATOL S1, V64, pS68; Ansari H., 1997, Journal of Molecular Medicine (Berlin), V75, pB243; ARCESE W, 1993, BLOOD, V82, P3211; ARTHUR CK, 1993, ACTA HAEMATOL-BASEL, V89, P15; BACCARANI M, 1984, CANCER, V54, P333, DOI 10.1002/1097-0142(19840715)54:2<333::AID-CNCR2820540226>3.0.CO;2-1; BARANOVSKY A, 1986, CA-CANCER J CLIN, V36, P26, DOI 10.3322/canjclin.36.1.26; Beelen DW, 1999, BLOOD, V93, P1779, DOI 10.1182/blood.V93.5.1779.405a39b_1779_1781; BEELEN DW, 1995, BLOOD, V85, P2981, DOI 10.1182/blood.V85.10.2981.bloodjournal85102981; Beran M, 1998, CLIN CANCER RES, V4, P1661; BIERNAUX C, 1995, BLOOD, V86, P3118; BOLIN RW, 1982, CANCER-AM CANCER SOC, V50, P1683, DOI 10.1002/1097-0142(19821101)50:9<1683::AID-CNCR2820500904>3.0.CO;2-X; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Bouvet M, 1997, SURGERY, V122, P20, DOI 10.1016/S0039-6060(97)90259-2; BRINCKER H, 1982, SCAND J HAEMATOL, V29, P241; CANNISTRA S, 1990, BLOOD, V76, pA259; CARELLA AM, 1993, LEUKEMIA LYMPHOMA, V9, P477, DOI 10.3109/10428199309145754; Carella AM, 1997, HAEMATOLOGICA, V82, P478; Choudhury A, 1997, BLOOD, V89, P1133, DOI 10.1182/blood.V89.4.1133; Clift RA, 1996, BONE MARROW TRANSPL, V17, pS1; CLIFT RA, 1993, BLOOD, V82, P1954; Clift RA, 1997, BAILLIERE CLIN HAEM, V10, P319, DOI 10.1016/S0950-3536(97)80010-8; CLIFT RA, 1994, BLOOD, V84, P2036, DOI 10.1182/blood.V84.6.2036.2036; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Cuneo A, 1998, LEUKEMIA, V12, P1718, DOI 10.1038/sj.leu.2401163; Daoud MS, 1997, J AM ACAD DERMATOL, V36, P178, DOI 10.1016/S0190-9622(97)70276-7; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; De Simone C, 1998, EUR J DERMATOL, V8, P114; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Delannoy A, 1997, J NATL CANCER I, V89, P1616; DERDERIAN PM, 1993, AM J MED, V94, P69, DOI 10.1016/0002-9343(93)90122-6; Devergie A, 1997, BONE MARROW TRANSPL, V20, P11, DOI 10.1038/sj.bmt.1700844; Dewald GW, 1998, BLOOD, V91, P3357, DOI 10.1182/blood.V91.9.3357.3357_3357_3365; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; DRUKER BJ, 1999, P AN M AM SOC CLIN, V18, P72; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Gajewski J, 1997, Biol Blood Marrow Transplant, V3, P76; GALTON DAG, 1953, LANCET, V264, P208; GAMIS AS, 1993, J CLIN ONCOL, V11, P834, DOI 10.1200/JCO.1993.11.5.834; GIRALT SA, 1993, J CLIN ONCOL, V11, P1055, DOI 10.1200/JCO.1993.11.6.1055; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; Grand FH, 1998, GENE CHROMOSOME CANC, V23, P109, DOI 10.1002/(SICI)1098-2264(199810)23:2<109::AID-GCC3>3.0.CO;2-6; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; GRIFFIN JD, 1983, BLOOD, V61, P85; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; GUO JQ, 1991, CANCER RES, V51, P3048; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; HIGANO CS, 1992, BLOOD, V80, P1437; Hochhaus A, 1998, RECENT RESULTS CANC, V144, P36; HOCHHAUS A, 1995, BRIT J HAEMATOL, V91, P126, DOI 10.1111/j.1365-2141.1995.tb05257.x; Hochhaus A, 1998, BLOOD, V92, p495A; Horowitz M. M., 1996, Blood, V88, p682A; Horowitz MM, 1996, BONE MARROW TRANSPL, V17, pS5; Horowitz MM, 1996, EXP HEMATOL, V24, P649; Ishikura H, 1997, LEUKEMIA LYMPHOMA, V25, P573; Issa JPJ, 1997, LEUKEMIA, V11, pS7; KANTARJIAN HM, 1995, J CLIN ONCOL, V13, P553, DOI 10.1200/JCO.1995.13.3.553; KANTARJIAN HM, 1991, CANCER-AM CANCER SOC, V68, P1201, DOI 10.1002/1097-0142(19910915)68:6<1201::AID-CNCR2820680604>3.0.CO;2-1; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KANTARJIAN HM, 1992, J CLIN ONCOL, V10, P772, DOI 10.1200/JCO.1992.10.5.772; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kantarjian HM, 1997, LEUKEMIA, V11, pS35; Kantarjian HM, 1999, J CLIN ONCOL, V17, P284, DOI 10.1200/JCO.1999.17.1.284; Kantarjian HM, 1998, HEMATOL ONCOL CLIN N, V12, P31, DOI 10.1016/S0889-8588(05)70496-2; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P192, DOI 10.1200/JCO.1985.3.2.192; Kantarjian HM, 1996, BLOOD, V87, P3069, DOI 10.1182/blood.V87.8.3069.bloodjournal8783069; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; Kantarjian HM, 1997, LEUKEMIA, V11, P1617, DOI 10.1038/sj.leu.2400796; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KENNEDY BJ, 1972, CANCER-AM CANCER SOC, V29, P1052, DOI 10.1002/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Kurzrock R, 1998, J CLIN ONCOL, V16, P1526, DOI 10.1200/JCO.1998.16.4.1526; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lim SH, 1997, AM J HEMATOL, V54, P61, DOI 10.1002/(SICI)1096-8652(199701)54:1<61::AID-AJH9>3.0.CO;2-2; LISSAUER H, 1865, KLIN WOCHENSCHR, V2, P403; Mahon FX, 1998, BLOOD, V92, P4059, DOI 10.1182/blood.V92.11.4059.423k34_4059_4065; MAHON FX, 1994, BLOOD, V84, P3592; Maran A, 1998, BLOOD, V92, P4336, DOI 10.1182/blood.V92.11.4336.423a06_4336_4343; Marasca R, 1996, LEUKEMIA LYMPHOMA, V24, P175, DOI 10.3109/10428199609045726; MCGLAVE P, 1993, BLOOD, V81, P543; MELO JV, 1994, LEUKEMIA, V8, P208; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MITELMAN F, 1993, LEUKEMIA LYMPHOMA, V11, P11, DOI 10.3109/10428199309047856; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Morton AJ, 1998, BLOOD, V92, P394, DOI 10.1182/blood.V92.2.394.414k42_394_401; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; Muhlmann J, 1998, GENE CHROMOSOME CANC, V21, P90, DOI 10.1002/(SICI)1098-2264(199802)21:2<90::AID-GCC3>3.0.CO;2-2; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien S, 1999, BLOOD, V93, P4149, DOI 10.1182/blood.V93.12.4149.412k10_4149_4153; O'Brien S, 1998, BLOOD, V92, p251A; OBRIEN S, 1995, BLOOD, V86, P3322, DOI 10.1182/blood.V86.9.3322.bloodjournal8693322; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; Pigneux A, 1998, BLOOD, V92, p495A; Pusey WA, 1902, J AMER MED ASSOC, V38, P911; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Ravandi-Kashani F, 1998, BLOOD, V92, p94A; REIFFERS J, 1994, BONE MARROW TRANSPL, V14, P407; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sacchi S, 1997, LEUKEMIA, V11, P1610, DOI 10.1038/sj.leu.2400791; Savage DG, 1997, BRIT J HAEMATOL, V96, P111, DOI 10.1046/j.1365-2141.1997.d01-1982.x; Savage DG, 1997, BRIT J HAEMATOL, V99, P30, DOI 10.1046/j.1365-2141.1997.3453159.x; SEONG DC, 1995, BLOOD, V86, P2343, DOI 10.1182/blood.V86.6.2343.bloodjournal8662343; SERRA A, 1993, LEUKEMIA LYMPHOMA, V11, P25, DOI 10.3109/10428199309047858; Shepherd P, 1995, BLOOD, V86, P363; Shepherd PCA, 1996, BONE MARROW TRANSPL, V17, pS15; Silver R. T., 1996, Blood, V88, p638A; Simonsson B, 1996, BONE MARROW TRANSPL, V17, pS63; Smit WM, 1997, HUM IMMUNOL, V53, P216, DOI 10.1016/S0198-8859(96)00285-6; SOKAL J, 1986, BLOOD, V68, pA233; SOKAL JE, 1987, CANCER, V59, P197, DOI 10.1002/1097-0142(19870101)59:1<197::AID-CNCR2820590137>3.0.CO;2-8; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SPECCHIA G, 1995, LEUKEMIA LYMPHOMA, V18, P37, DOI 10.3109/10428199509075301; Straetmans N, 1996, HEMATOPATHOL MOL HEM, V10, P213; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; TALPAZ M, 1994, J CLIN INVEST, V94, P1383, DOI 10.1172/JCI117473; Talpaz M, 1998, BLOOD, V92, p251A; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1995, BLOOD, V85, P3257, DOI 10.1182/blood.V85.11.3257.bloodjournal85113257; Thaler J, 1997, LEUKEMIA RES, V21, P75, DOI 10.1016/S0145-2126(96)00084-7; Thomas D, 1998, BLOOD, V92, p251A; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; Tomas JF, 1998, BONE MARROW TRANSPL, V22, P47, DOI 10.1038/sj.bmt.1701288; Tura S, 1998, BLOOD, V92, p317A; TURA S, 1994, NEW ENGL J MED, V330, P820; Tura S, 1998, BLOOD, V92, P1541; vanRhee F, 1997, BONE MARROW TRANSPL, V20, P553, DOI 10.1038/sj.bmt.1700933; Weinlich G, 1998, J AM ACAD DERMATOL, V39, P372, DOI 10.1016/S0190-9622(98)70394-9; Wilhelm M, 1998, LEUKEMIA, V12, P65, DOI 10.1038/sj.leu.2400885; Zuffa E, 1998, HAEMATOLOGICA, V83, P231; ZUFFA E, 1995, BONE MARROW TRANS S2, V15, pS18	144	329	347	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					207	219		10.7326/0003-4819-131-3-199908030-00008	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428738				2022-12-28	WOS:000081788700007
J	Beecham, L				Beecham, L			Consultant bodies should have strong voice in trusts	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					324	324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426767				2022-12-28	WOS:000081909100066
J	Margolis, RM; Kammen, DM				Margolis, RM; Kammen, DM			Underinvestment: The energy technology and R&D policy challenge	SCIENCE			English	Editorial Material							EMISSIONS; NATIONS	This Viewpoint examines data on international trends in energy research and development (R&D) funding, patterns of U.S. energy technology patents and R&D funding, and U.S. R&D intensities across selected sectors. The data present a disturbing picture: (i) Energy technology funding Levels have declined significantly during the past two decades throughout the industrial world; (ii) U.S. R&D spending and patents. both overall and in the energy sector, have been highly correlated during the past two decades; and (iii) the R&D intensity of the U.S. energy sector is extremely Low. It is argued that recent cutbacks in energy R&D are Likely to reduce the capacity of the energy sector to innovate. The trends are particularly troubling given the need for increased international capacity to respond to emerging risks such as global climate change.	Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Sci Technol & Environm Policy Program, Princeton, NJ 08544 USA; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA	Princeton University; University of California System; University of California Berkeley	Margolis, RM (corresponding author), Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Sci Technol & Environm Policy Program, Princeton, NJ 08544 USA.							Cohen L. R., 2002, TECHNOLOGY PORK BARR; *COMM CRIT FED SUP, 1995, ALL FUNDS SCI TECHN; Dooley JJ, 1998, ENERG POLICY, V26, P547, DOI 10.1016/S0301-4215(97)00166-3; *EN RES DEV PAN PR, 1997, FED EN RES DEV CHALL; EVENSON RE, 1979, SCIENCE, V205, P1101, DOI 10.1126/science.205.4411.1101; GRILICHES Z, 1987, SCIENCE, V237, P31, DOI 10.1126/science.237.4810.31; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; *HOUS COMM SCI, 1998, UNCL OUR FUT NEW NAT; *INT EN AG ORG EC, 1997, IEA EN TECHN R D STA; Kinzig AP, 1998, GLOBAL ENVIRON CHANG, V8, P183, DOI 10.1016/S0959-3780(98)00013-2; MANSFIELD E, 1972, SCIENCE, V175, P477, DOI 10.1126/science.175.4021.477; MARGOLIS RM, IN PRESS ENERGY POLI; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; May RM, 1998, SCIENCE, V281, P49, DOI 10.1126/science.281.5373.49; Morgan MG, 1998, ISSUES SCI TECHNOL, V15, P81; Nadiri M. I., 1993, 4423 NBER; NAKICENOVIC N, 1993, ENERGY, V18, P401, DOI 10.1016/0360-5442(93)90019-A; Parson EA, 1998, SCIENCE, V282, P1053, DOI 10.1126/science.282.5391.1053; Reddy A, 1997, ENERGY RIO PROSPECTS; Stokes D. E., 1997, PASTEURS QUADRANT BA; STOKEY NL, 1995, REV ECON STUD, V62, P469, DOI 10.2307/2298038; *US DEP EN, 1997, STAT EN PRIC EXP REP; *US GEN ACC OFF, 1996, GAORCED96203; Watson R.T., 1996, CLIMATE CHANGE 1995	24	102	105	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					690	692		10.1126/science.285.5428.690	http://dx.doi.org/10.1126/science.285.5428.690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426983				2022-12-28	WOS:000081765100042
J	Ramamoorthy, S; Blakely, RD				Ramamoorthy, S; Blakely, RD			Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants	SCIENCE			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; IMIPRAMINE BINDING-SITES; TRITIATED IMIPRAMINE; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; STRIATAL SYNAPTOSOMES; FUNCTIONAL REGULATION; SURFACE EXPRESSION; XENOPUS-OOCYTES	Many psychotropic drugs interfere with the reuptake of dopamine, norepinephrine, and serotonin. Transport capacity is regulated by kinase-linked pathways, particularly those involving protein kinase C (PKC), resulting in transporter phosphorylation and sequestration. Phosphorylation and sequestration of the serotonin transporter (SERT) were substantially impacted by ligand occupancy. Ligands that can permeate the transporter, such as serotonin or the amphetamines, prevented PKC-dependent SERT phosphorylation. Nontransported SERT antagonists such as cocaine and antidepressants were permissive for SERT phosphorylation but blocked serotonin effects. PKC-dependent SEPT sequestration was also blocked by serotonin. These findings reveal activity-dependent modulation of neurotransmitter reuptake and identify previously unknown consequences of amphetamine, cocaine, and antidepressant action.	Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA.	randy.blakely@mcmail.vanderbilt.edu			NIDA NIH HHS [DA07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; APPARSUNDARAM S, 1996, SOC NEUR ABSTR, V22; Barker Eric L., 1995, P321; BAUMAN AL, 1998, SOC NEUR ABSTR, V24; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; BERGER UV, 1992, EUR J PHARMACOL, V215, P153, DOI 10.1016/0014-2999(92)90023-W; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bonisch H, 1998, Adv Pharmacol, V42, P183; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Cinquanta M, 1997, NEUROPHARMACOLOGY, V36, P803, DOI 10.1016/S0028-3908(97)00064-6; Cook EH, 1997, MOL PSYCHIATR, V2, P247; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; CORNEZA J, 1991, BIOCHEM J, V275, P435; Crespi D, 1997, BRIT J PHARMACOL, V121, P1735, DOI 10.1038/sj.bjp.0701325; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Fozzard J., 1989, PERIPHERAL ACTIONS 5; FULLER RW, 1994, LIFE SCI, V55, P163, DOI 10.1016/0024-3205(94)00876-0; FULLER RW, 1990, ANN N Y ACAD SCI, V600, P68; Furlong RA, 1998, AM J MED GENET, V81, P58, DOI 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.0.CO;2-V; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Huff RA, 1997, J NEUROCHEM, V68, P225; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; Jones SR, 1998, J NEUROSCI, V18, P1979; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Little KY, 1998, AM J PSYCHIAT, V155, P207; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MARCUSSON JO, 1989, PSYCHOPHARMACOLOGY, V99, P17, DOI 10.1007/BF00634446; MELTZER HY, 1981, ARCH GEN PSYCHIAT, V38, P1322; MELTZER HY, 1990, ANN NY ACAD SCI, V600, P486; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Morgan AE, 1997, EUR J PHARMACOL, V331, pR1, DOI 10.1016/S0014-2999(97)01035-2; MYERS CL, 1988, J APPL PHYSIOL, V65, P377, DOI 10.1152/jappl.1988.65.1.377; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P919; NISHIO H, 1995, EUR J PHARM-MOLEC PH, V288, P149, DOI 10.1016/0922-4106(95)90189-2; OWENS MJ, 1994, CLIN CHEM, V40, P288; PAUL SM, 1981, ARCH GEN PSYCHIAT, V38, P1315; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; RAMAMOORTHY S, UNPUB; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; ROSS SB, 1964, ACTA PHARMACOL TOX, V21, P226; ROSS SB, 1982, BIOL SEROTONERGIC TR, P160; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Sakai N, 1997, J NEUROCHEM, V68, P2618; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; STANLEY M, 1982, SCIENCE, V216, P1337, DOI 10.1126/science.7079769; SULZER D, 1993, J NEUROCHEM, V60, P527, DOI 10.1111/j.1471-4159.1993.tb03181.x; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Weiger WA, 1997, BIOL REV, V72, P61, DOI 10.1017/S0006323196004975; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105; Yura A, 1996, BRAIN RES, V738, P96, DOI 10.1016/0006-8993(96)00762-7; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	79	292	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					763	766		10.1126/science.285.5428.763	http://dx.doi.org/10.1126/science.285.5428.763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427004				2022-12-28	WOS:000081765100063
J	Mills, JL; DerSimonian, R; Raymond, E; Morrow, JD; Roberts, LJ; Clemens, JD; Hauth, JC; Catalano, P; Sibai, B; Curet, LB; Levine, RJ				Mills, JL; DerSimonian, R; Raymond, E; Morrow, JD; Roberts, LJ; Clemens, JD; Hauth, JC; Catalano, P; Sibai, B; Curet, LB; Levine, RJ			Prostacyclin and thromboxane changes predating clinical onset of preeclampsia - A multicenter prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DOSE ASPIRIN; CHROMATOGRAPHY MASS-SPECTROMETRY; PREVENT PREECLAMPSIA; POSTPARTUM PERIOD; RANDOMIZED TRIAL; PREGNANT-WOMEN; QUANTIFICATION; HYPERTENSION; METABOLITES; DELIVERY	Context An imbalance in vasodilating (prostacyclin [PGI(2)]) and vasoconstricting (thromboxane A(2) [TxA(2)]) eicosanoids may be important in preeclampsia, but prospective data from large studies needed to resolve this issue are lacking. Because most trials using aspirin to reduce TxA(2) production have failed to prevent preeclampsia, it is critical to determine whether eicosanoid changes occur before the onset of clinical disease or are secondary to clinical manifestations of preeclampsia, Objective To determine whether PGI(2) or TxA(2) changes occur before onset of clinical signs of preeclampsia. Design, Setting, and Participants Multicenter prospective study from 1992 to 1995 of subjects from the placebo arm of the Calcium for Preeclampsia Prevention Trial. Women who developed preeclampsia (n =134) were compared with matched normotensive control women (n = 139), Main Outcome Measures Excretion of urinary metabolites of PGI(2) (PGI-M) and TxA(2) (Tx-M) as measured from timed urine collections obtained prospectively before 22 weeks', between 26 and 29 weeks', and at 36 weeks' gestation. Results Women who developed preeclampsia had significantly lower PCI-M levels throughout pregnancy, even at 13 to 16 weeks' gestation (long before the onset of clinical disease); their gestational age-adjusted levels were 17% lower than those of controls (95% confidence interval [CI], 6%-27%; P = 005). The Tx-M levels of preeclamptic women were not significantly higher overall (9% higher than those of controls; 95% CI, -3% to 23%; P = .14). The ratio of Tx-M to PGI-M, used to express relative vasoconstricting vs vasodilating effects, was 24% higher (95% CI, 6% -45%) n preeclamptic women throughout pregnancy (P = .007). Conclusions Our results show that reduced PGI(2) production, but not increased TxA(2) production, occurs many months before clinical onset of preeclampsia, Aspirin trials may have failed because an increase in thromboxane production is not the initial anomaly. Future interventions should make correcting prostacyclin deficiency a major part of the strategy to balance the abnormal vasoconstrictor-vasodilator ratio present in preeclampsia.	NICHHD, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; NICHHD, Biometry & Stat Branch, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; Family Hlth Int, Clin Trials Div, Durham, NC USA; Vanderbilt Univ, Dept Clin Pharmacol, Nashville, TN USA; Vanderbilt Univ, Dept Med, Nashville, TN USA; Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; Metrohlth Med Ctr, Dept Obstet & Gynecol, Cleveland, OH USA; Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA; Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vanderbilt University; Vanderbilt University; University of Alabama System; University of Alabama Birmingham; MetroHealth System; University of Tennessee System; University of Tennessee Health Science Center; University of New Mexico	Mills, JL (corresponding author), NICHD, Pediat Epidemiol Sect, DESPR, NIH, 6100 Execut Blvd,Room 7B03, Bethesda, MD 20892 USA.		Catalano, Patrick/GVR-9069-2022	Mills, James/0000-0003-4496-332X	NICHD NIH HHS [N01-HD-3121, N01-HD-3122, N01-HD-3123] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Barden A, 1994, Blood Press, V3, P38, DOI 10.3109/08037059409101520; BEROYZ G, 1994, LANCET, V343, P619; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; DANIEL VC, 1994, J CHROMATOGR B, V653, P117, DOI 10.1016/0378-4347(93)E0432-P; Diggle PJ, 1994, ANAL LONGITUDINAL DA; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; GOESCHEN K, 1993, J PERINAT MED, V21, P481, DOI 10.1515/jpme.1993.21.6.481; Golding J, 1998, BRIT J OBSTET GYNAEC, V105, P293, DOI 10.1111/j.1471-0528.1998.tb10089.x; HAUTH JC, 1993, AM J OBSTET GYNECOL, V168, P1083, DOI 10.1016/0002-9378(93)90351-I; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; KAAJA R, 1995, OBSTET GYNECOL, V85, P353, DOI 10.1016/0029-7844(94)00380-V; Levine RJ, 1996, CONTROL CLIN TRIALS, V17, P442, DOI 10.1016/S0197-2456(96)00106-7; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; MORROW JD, 1993, J CHROMATOGR-BIOMED, V612, P179, DOI 10.1016/0378-4347(93)80161-V; Rotchell YE, 1998, BRIT J OBSTET GYNAEC, V105, P286, DOI 10.1111/j.1471-0528.1998.tb10088.x; *SAS I INC, 1997, SAS STAT SOFTW CHANG, P571; Sibai BM, 1997, AM J OBSTET GYNECOL, V177, P1003, DOI 10.1016/S0002-9378(97)70004-8; SMITH AJ, 1995, BRIT J OBSTET GYNAEC, V102, P900, DOI 10.1111/j.1471-0528.1995.tb10879.x; Sulaiman S., 1995, Singapore Medical Journal, V36, P637; YAMAGUCHI M, 1985, AM J OBSTET GYNECOL, V151, P121, DOI 10.1016/0002-9378(85)90437-5; YLIKORKALA O, 1986, J CLIN ENDOCR METAB, V63, P1307, DOI 10.1210/jcem-63-6-1307	23	119	133	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					356	362		10.1001/jama.282.4.356	http://dx.doi.org/10.1001/jama.282.4.356			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432033	Bronze			2022-12-28	WOS:000081596800031
J	Dill, KA				Dill, KA			Strengthening biomedicine's roots	NATURE			English	Editorial Material							SCIENCE		Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Dill, KA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.							Borman S, 1998, CHEM ENG NEWS, V76, P39, DOI 10.1021/cen-v076n002.p039; Garwin L, 1999, NATURE, V397, P3, DOI 10.1038/16091; Pennisi E, 1998, SCIENCE, V279, P978, DOI 10.1126/science.279.5353.978; Pennisi E, 1998, SCIENCE, V282, P1972, DOI 10.1126/science.282.5396.1972; Service RF, 1999, SCIENCE, V284, P80; Stephan PE, 1996, J ECON LIT, V34, P1199; STUDT T, 1999, DRUG DISCOVERY D JAN, P62; VARMUS H, 1998, AAAS PLEN LECT 13 FE	8	29	30	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					309	310		10.1038/22415	http://dx.doi.org/10.1038/22415			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432104				2022-12-28	WOS:000081590000023
J	Krishnan, B; Dryer, SE; Hardin, PE				Krishnan, B; Dryer, SE; Hardin, PE			Circadian rhythms in olfactory responses of Drosophila melanogaster	NATURE			English	Article							MUTANTS; PHYSIOLOGY; EXPRESSION; CLOCK; LIGHT; FLY	The core mechanism of circadian timekeeping in arthropods and vertebrates consists of feedback loops involving several clock genes, including period (per) and timeless (tim)(1,2). In the fruitfly Drosophila, circadian oscillations in per expression occur in chemosensory cells of the antennae, even when the antennae are excised and maintained in isolated organ culture(3). Here we demonstrate a robust circadian rhythm in Drosophila in electrophysiological responses to two classes of olfactory stimuli. These rhythms are observed in wild-type flies during light-dark cycles and in constant darkness, but are abolished in per or tim null-mutant flies (per(01) and tim(01)) which lack rhythms in adult emergence and locomotor behaviour. Olfactory rhythms are also abolished in the per 7.2:2 transgenic line in which per expression is restricted to the lateral neurons of the optic lobe(4). Because per 7.2:2 flies do not express per in peripheral oscillators, our results provide evidence that peripheral circadian oscillators are necessary for circadian rhythms in olfactory responses. As olfaction is essential for food acquisition, social interactions and predator avoidance in many animals, circadian regulation of olfactory systems could have profound effects on the behaviour of organisms that rely on this sensory modality.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Dryer, SE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.		Krishnan, Balaji/M-9914-2019; Krishnan, Balaji/C-7572-2009	Krishnan, Balaji/0000-0003-2074-4165; Hardin, Paul/0000-0002-3370-9011				ALCORTA E, 1991, J NEUROPHYSIOL, V65, P702, DOI 10.1152/jn.1991.65.3.702; Anholt RRH, 1996, GENETICS, V143, P293; AYER RK, 1992, J NEUROBIOL, V23, P965, DOI 10.1002/neu.480230804; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DUBIN AE, 1995, J NEUROBIOL, V28, P214, DOI 10.1002/neu.480280208; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Hardin PE, 1998, CURR OPIN NEUROBIOL, V8, P642, DOI 10.1016/S0959-4388(98)80093-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033	16	239	243	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					375	378		10.1038/22566	http://dx.doi.org/10.1038/22566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432117				2022-12-28	WOS:000081590000053
J	Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA				Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA			Older persons' preferences for site of terminal care	ANNALS OF INTERNAL MEDICINE			English	Article							PALLIATIVE CARE; DEATH; PLACE; HOME; TEAM; LIFE; END	Background: Little is known about patients' preferences for site of terminal care, Objective: To describe older persons' preferences for home or hospital as the site of terminal care and to explore potential reasons for their preferences. Design: Cross-sectional quantitative and qualitative interviews. Setting: Participants' homes. Patients: Community-dwelling persons 65 years of age or older who were recently hospitalized with congestive heart failure, chronic obstructive pulmonary disease, or pneumonia and were not selected according to life expectancy; 246 patients participated in quantitative interviews and 29 participated in qualitative interviews. Measurements: Preference for site of terminal care and the reasons for that preference. Results: In quantitative interviews, 118 patients (48%) preferred terminal care in the hospital, 106 (43%) preferred home, and 22 (9%) did not know. One third changed their preference when asked about their preference in the event of a nonterminal illness. Reasons for preference identified during qualitative interviews included the desire to be with family members and concerns about burden to family members and their ability to provide necessary care. Concern about long-term care needs resulted in preference for a nursing home when choice was not constrained to home and hospital. Conclusions: Preference for home as the site of care for terminal illness exceeds existing practice. However, the current debate about home versus hospital as the ideal site for end-of-life care may ignore an important issue to older persons-namely, the care of disabilities that precede death.	Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, West Haven, CT 06516 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale Univ, Program Aging, New Haven, CT 06511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gilbar O, 1996, Hosp J, V11, P31, DOI 10.1300/J011v11n01_03; Glaser B.G., 1965, AWARENESS DYING; GROTHJUNCKER A, 1983, J AM GERIATR SOC, V31, P457, DOI 10.1111/j.1532-5415.1983.tb05116.x; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; MCWHINNEY IR, 1995, CAN MED ASSOC J, V152, P361; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; *NAT CTR HLTH STAT, 1990, VIT STAT US  A, V2; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415	13	108	110	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					109	112		10.7326/0003-4819-131-2-199907200-00006	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419426				2022-12-28	WOS:000081509700005
J	Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE				Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE			Bacterial photoreceptor with similarity to photoactive yellow protein and plant phytochromes	SCIENCE			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOCYCLE INTERMEDIATE; SIGNAL-TRANSDUCTION; HISTIDINE KINASE; QUANTUM YIELD; GENE; CHROMOPHORE; RHODOPSIN; KINETICS	A phytochrome-like protein called Ppr was discovered in the purple photosynthetic bacterium Rhodospirillum centenum, Ppr has a photoactive yellow protein (PYP) amino-terminal domain, a central domain with similarity to phytochrome, and a carboxyl-terminal histidine kinase domain. Reconstitution experiments demonstrate that Ppr covalently attaches the blue light-absorbing chromophore p-hydroxycinnamic acid and that it has a photocycle that is spectrally similar to, but kinetically slower than, that of PYP. Ppr also regulates chalcone synthase gene expression in response to blue light with autophosphorylation inhibited in vitro by blue light. Phylogenetic analysis demonstrates that R. centenum Ppr may be ancestral to cyanobacterial and plant phytochromes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	Indiana University System; Indiana University Bloomington; University of Arizona	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, R01GM040941, R01GM053940, R37GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053940, GM 40941, R01 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Devanathan S, 1997, ARCH BIOCHEM BIOPHYS, V340, P83, DOI 10.1006/abbi.1997.9902; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; *GENB, AF121274 GENB; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang Z., UNPUB; Jiang ZY, 1997, J BACTERIOL, V179, P5720, DOI 10.1128/jb.179.18.5720-5727.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; MARTIN CR, 1993, INT REV CYTOL, V147, P233, DOI 10.1016/S0074-7696(08)60770-6; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Meyer TE, 1998, SCIENCE, V281, P1964; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RAGATZ L, 1995, ARCH MICROBIOL, V163, P1; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	29	150	156	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					406	409		10.1126/science.285.5426.406	http://dx.doi.org/10.1126/science.285.5426.406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411503				2022-12-28	WOS:000081465900054
J	Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM				Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM			Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1	NATURE			English	Article							RAT-BRAIN; GENE; PEPTIDES; NEUROPEPTIDES; EXPRESSION; CLONING; BINDING; FAMILY; ACID	The underlying causes of obesity are poorly understood but probably involve complex interactions between many neurotransmitter and neuropeptide systems involved in the regulation of food intake and energy balance. Three pieces of evidence indicate that the neuropeptide melanin-concentrating hormone (MCH) is an important component of this system. First, MCH stimulates feeding when injected directly into rat brains(1,2); second, the messenger RNA for the MCH precursor is upregulated in the hypothalamus of genetically obese mice and in fasted animals'; and third, mice lacking MCH eat less and are lean(3). MCH antagonists might, therefore, provide a treatment for obesity. However, the development of such molecules has been hampered because the identity of the MCH receptor has been unknown until now. Here we show that the 353-amino-acid human orphan G-protein-coupled receptor SLC-1 (ref, 4) expressed in HEK293 cells binds MCH with sub-nanomolar affinity, and is stimulated by MCH to mobilize intracellular Ca2+ and reduce forskolin-elevated cyclic AMP levels. We also show that SLC-1 messenger RNA and protein is expressed in the ventromedial and dorsomedial nuclei of the hypothalamus, consistent with a role for SLC-1 in mediating the effects of MCH on feeding.	SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Renal Pharmaceut, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Chambers, J (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, New Frontier Sci Pk,So Way, Harlow CM19 5AW, Essex, England.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; Burgaud JL, 1997, BIOCHEM BIOPH RES CO, V241, P622, DOI 10.1006/bbrc.1997.7849; DROZDZ R, 1995, FEBS LETT, V359, P199, DOI 10.1016/0014-5793(95)00043-9; Fitzgerald LW, 1998, J PHARMACOL EXP THER, V287, P448; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; Hervieu G, 1998, NEUROSCIENCE, V85, P1263, DOI 10.1016/S0306-4522(98)00024-4; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Kolakowski LF, 1996, FEBS LETT, V398, P253, DOI 10.1016/S0014-5793(96)01160-X; Lakaye B, 1998, BBA-MOL CELL RES, V1401, P216, DOI 10.1016/S0167-4889(97)00135-3; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; Miller CL, 1998, BRAIN RES, V803, P86, DOI 10.1016/S0006-8993(98)00626-X; MORO O, 1993, J BIOL CHEM, V268, P22273; PRESSE F, 1990, MOL ENDOCRINOL, V4, P632, DOI 10.1210/mend-4-4-632; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; Tritos NA, 1998, DIABETES, V47, P1687, DOI 10.2337/diabetes.47.11.1687	25	418	450	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					261	265		10.1038/22313	http://dx.doi.org/10.1038/22313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421367				2022-12-28	WOS:000081503800043
J	Colleoni, M; Price, KN; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A				Colleoni, M; Price, KN; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A		Int Breast Canc Study Grp	Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil	LANCET			English	Article								Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials.	European Inst Oncol, Div Med Oncol, I-20141 Milan, Italy; IBCSG Stat Ctr, Boston, MA USA; Frontier Sci & Technol Res Fdn, Boston, MA USA; IBCSG Coordinating Ctr, Bern, Switzerland; Australian New Zealand Breast Canc Trials Grp, Sydney, NSW, Australia; Australian Canc Soc, Sydney, NSW, Australia; Osped Civico, Lugano, Switzerland	IRCCS European Institute of Oncology (IEO); Frontier Science Foundation	Colleoni, M (corresponding author), European Inst Oncol, Div Med Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Colleoni, Marco/AAN-8647-2020	Colleoni, Marco/0000-0002-5743-3013				Abe O, 1998, LANCET, V352, P930; GOLDHIRSCH A, 1994, CANCER, V74, P1139, DOI 10.1002/1097-0142(19940801)74:3+<1139::AID-CNCR2820741524>3.0.CO;2-K; Goldhirsch A, 1998, ANN ONCOL, V9, P489, DOI 10.1023/A:1008236502420; Hurny C, 1996, LANCET, V347, P1279; OSBORNE CK, 1996, DIS BREAST, P548	5	31	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					130	131		10.1016/S0140-6736(99)02015-2	http://dx.doi.org/10.1016/S0140-6736(99)02015-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408495				2022-12-28	WOS:000081377100022
J	[Anonymous]				[Anonymous]			Injury surveillance programmes, ethics, and the Data Protection Act	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	1999	319	7206					372	372						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435966				2022-12-28	WOS:000082001700028
J	Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J				Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J			Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, ILLINOIS	Soc Epidemiol Res			CORONARY HEART-DISEASE; Q-FEVER ENDOCARDITIS; HELICOBACTER-PYLORI SEROPOSITIVITY; ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; ATHEROSCLEROTIC PLAQUES; AORTIC-ANEURYSMS; RISK FACTOR; WALLS; TWAR	Objective To evaluate the range of long term vascular manifestations of Coxiella burnetii infection. Design Cohort study in Switzerland of people affected in 1983 by the largest reported outbreak of Q fever and who were followed up 12 rears later. Follow up information about possible vascular disease and endocarditis was obtained through a mailed questionnaire and death certificates. Setting Val de Bagnes, a rural Alpine valley in Switzerland. Participants 2044 (87%) of 2355 people who had serum testing for Coxiella burnetii infection in 1983: 1247 were classed as not hating been infected, 411 were classed as having been acutely infected, and 386 were classed as having been infected before 1983. Main outcome measures Relative risk controlled for age and sex and 12 year risk of vascular diseases and endocarditis among infected participants as compared with those who had never been infected. Results The 12 year risk of endocarditis or venous thromboembolic disease was not increased among those who had been acutely infected. The 12 rear risk of arterial disease was significantly higher among those who had been acutely infected (7%) as compared with those who had never been infected (4%) (relative risk 2.2, 95% confidence interval 1.4 to 3.6). Specifically, there was an increased risk of developing a cerebrovascular accident (relative risk 3.7, 1.6 to 8.4) and cardiac ischaemia (relative risk 1.9, 1.04 to 3.4). 12 year mortality was significantly higher among the 411 people who had been acutely infected in 1983 (9.7%; age adjusted relative risk 1.8, 1.2 to 2.6) when compared with the 1247 participants who had remained serologically negative in 1983 (7.0%) Conclusions Coxiella burnetii infection may cause long term complications including vascular disease.	Univ Hosp Geneva, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; Hop Valaisans, Inst Cent, Div Infect Dis & Immunol, CH-1951 Sion, Switzerland; Hop Reg, Serv Med Interne, CH-1920 Martigny, Switzerland; Etat Valais, CH-1950 Sion, Switzerland	University of Geneva; University of Geneva	Lovey, PY (corresponding author), Univ Hosp Geneva, Dept Internal Med, Rue Micheli Crest 24, CH-1211 Geneva 14, Switzerland.							BACA OG, 1983, MICROBIOL REV, V47, P127, DOI 10.1128/MMBR.47.2.127-149.1983; Blasi F, 1996, J CLIN MICROBIOL, V34, P2766, DOI 10.1128/JCM.34.11.2766-2769.1996; BROUQUI P, 1993, ARCH INTERN MED, V153, P642, DOI 10.1001/archinte.153.5.642; COYLE PV, 1985, J CLIN PATHOL, V38, P743, DOI 10.1136/jcp.38.7.743; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DUPUIS G, 1985, J CLIN MICROBIOL, V22, P484, DOI 10.1128/JCM.22.4.484-487.1985; DUPUIS G, 1987, INT J EPIDEMIOL, V16, P282, DOI 10.1093/ije/16.2.282; ELLIS ME, 1983, Q J MED, V52, P54; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FERNANDEZGUERRERO ML, 1988, ANN INTERN MED, V108, P209, DOI 10.7326/0003-4819-108-2-209; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; GILBERT A, 1889, CR HEBD ACAD SCI, V6, P583; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HACKSTADT T, 1986, INFECT IMMUN, V52, P337, DOI 10.1128/IAI.52.1.337-340.1986; HALDANE EV, 1983, J INFECT DIS, V148, P978, DOI 10.1093/infdis/148.6.978; HENDRIX LR, 1991, J GEN MICROBIOL, V137, P269, DOI 10.1099/00221287-137-2-269; Juvonen JJ, 1997, J VASC SURG, V25, P499, DOI 10.1016/S0741-5214(97)70260-X; Kuo CC, 1997, J VASC SURG, V26, P29, DOI 10.1016/S0741-5214(97)70143-5; Libby P, 1997, CIRCULATION, V96, P4095; MALLAVIA LP, 1991, EUR J EPIDEMIOL, V7, P213, DOI 10.1007/BF00145669; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; PETER O, 1985, EUR J CLIN MICROBIOL, V4, P394, DOI 10.1007/BF02148690; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; REIMER LG, 1993, CLIN MICROBIOL REV, V6, P193, DOI 10.1128/CMR.6.3.193-198.1993; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMUEL JE, 1985, INFECT IMMUN, V49, P775, DOI 10.1128/IAI.49.3.775-779.1985; SiegmanIgra Y, 1997, SCAND J INFECT DIS, V29, P41, DOI 10.3109/00365549709008663; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680	30	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					284	286		10.1136/bmj.319.7205.284	http://dx.doi.org/10.1136/bmj.319.7205.284			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426735	Bronze, Green Published			2022-12-28	WOS:000081909100019
J	Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL				Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL			Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS INFECTION; SYNTHETIC LIPOPEPTIDE ANALOGS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TREPONEMA-PALLIDUM; BACTERIAL LIPOPROTEIN; LEISHMANIA-MAJOR; INTERFERON-GAMMA	The generation of cell-mediated immunity against many infectious pathogens involves the production of interleukin-12 (IL-12), a key signal of the innate immune system. Yet, for many pathogens, the molecules that induce IL-12 production by macrophages and the mechanisms by which they do so remain undefined. Here it is shown that microbial lipoproteins are potent stimulators of IL-12 production by human macrophages, and that induction is mediated by Toll-like receptors (TLRs). Several lipoproteins stimulated TLR-dependent transcription of inducible nitric oxide synthase and the production of nitric oxide, a powerful microbicidal pathway. Activation of TLRs by microbial lipoproteins may initiate innate defense mechanisms against infectious pathogens.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; CUNY Mt Sinai Sch Med, Ctr Immunol, New York, NY 10029 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech; Colorado State University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Belisle, John T/B-8944-2017; Modlin, Robert L/M-7941-2014; Yang, Ruey-Bing/O-1494-2018	Belisle, John T/0000-0002-2539-2798; Modlin, Robert L/0000-0003-4720-031X; Yang, Ruey-Bing/0000-0003-3017-3714				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; ASHBRIDGE KR, 1989, NUCLEIC ACIDS RES, V17, P1249, DOI 10.1093/nar/17.3.1249; BESSLER WG, 1977, BIOCHEM BIOPH RES CO, V76, P239, DOI 10.1016/0006-291X(77)90717-3; BESSLER WG, 1985, J IMMUNOL, V135, P1900; BIESERT L, 1987, EUR J BIOCHEM, V162, P651, DOI 10.1111/j.1432-1033.1987.tb10687.x; BRAUN V, 1974, ANNU REV BIOCHEM, V43, P89, DOI 10.1146/annurev.bi.43.070174.000513; BRICKER TM, 1988, INFECT IMMUN, V56, P295, DOI 10.1128/IAI.56.2.295-301.1988; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COOPER AM, 1995, IMMUNOLOGY, V84, P423; de Jong R, 1998, SCIENCE, V280, P1435; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; FLYNN JL, 1995, J IMMUNOL, V155, P2515; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUSCHILDT S, 1990, EUR J IMMUNOL, V20, P63, DOI 10.1002/eji.1830200110; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Libraty DH, 1997, J CLIN INVEST, V99, P336, DOI 10.1172/JCI119162; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MAILLARD J, 1972, J EXP MED, V136, P185, DOI 10.1084/jem.136.1.185; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; NORGARD MV, 1995, INFECT IMMUN, V63, P1507, DOI 10.1128/IAI.63.4.1507-1515.1995; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIELING PA, 1994, J IMMUNOL, V153, P3639; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Vogel SN, 1999, J IMMUNOL, V162, P5666; WALLIS RS, 1990, P NATL ACAD SCI USA, V87, P3348, DOI 10.1073/pnas.87.9.3348; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; Wooten RM, 1998, J IMMUNOL, V160, P5485; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	52	1327	1392	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					732	736		10.1126/science.285.5428.732	http://dx.doi.org/10.1126/science.285.5428.732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426995				2022-12-28	WOS:000081765100054
J	Alam, NH; Majumder, RN; Fuchs, GJ				Alam, NH; Majumder, RN; Fuchs, GJ		CHOICE Study Grp	Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double blind clinical trial	LANCET			English	Article							DIARRHEA; GLUCOSE	Background The effects of oral rehydration solution (ORS) with reduced osmolarity on children with acute watery diarrhoea are known, but little is known about the effects of such ORS on adults with cholera. We aimed to compare the efficacy and safety of an ORS with reduced osmolarity with that of standard WHO ORS in adults with cholera. Methods We undertook a double-blind, controlled clinical trial In adults with severe cholera at the International Centre for Diarrhoeal Disease Research, Bangladesh. Our primary outcomes were mean stool output in the 24 h after randomisation. proportion of patients who needed unscheduled intravenous therapy, and proportion of patients with biochemical hyponatraemia 24 h randomisation, unscheduled randomisation. Findings 147 patients received ORS with reduced osmolarity and 153 received standard WHO ORS. There was no significant difference between the two groups in terms of main outcome variables: mean initial 24 h and total stool output (reduced osmolarity vs standard WHO ORS 212 [SE 8] vs 207 [8] and 284 [13] vs 273 [13] g/kg respectively), duration of diarrhoea (46 [1.5] vs 43 [1.5]). The proportion of patients vomiting during the first 24 h and the proportion who received unscheduled intravenous infusion during the first 24 h was similar between groups. More patients on reduced osmolarity ORS than on standard WHO ORS developed hyponatraemia during the first 24 h, defined as serum sodium concentration below 130 mmol/L (29 of 142 vs 16 of 150; odds ratio 2.1[95% CI 1.1-4.1]). However, all hyponatraemic patients in both groups were symptom-free and the proportion of patients with serum sodium concentration below 125 mmol/L was similar between groups. Interpretation There was no difference in clinical outcome between cholera patients treated with reduced osmolarity ORS solution and those treated with standard WHO ORS. The risk of increased incidence of symptom-free hyponatraemia in patients with cholera treated with an ORS with reduced osmolarity should be further assessed by meta-analysis. The risk should be taken Into account when choice of ORS is made in areas in which cholera is endemic.	Int Ctr Diarrhoeal Dis Res, Bangladesh ICDDR B, Dhaka, Bangladesh; Louisiana State Univ, Sch Med, New Orleans, LA USA	International Centre for Diarrhoeal Disease Research (ICDDR); Louisiana State University System	Alam, NH (corresponding author), Int Ctr Diarrhoeal Dis Res, Bangladesh ICDDR B, GPO Box 128, Dhaka, Bangladesh.		Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				ALAM NH, 1992, GUT, V33, P560, DOI 10.1136/gut.33.4.560; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Faruque ASG, 1996, SCAND J INFECT DIS, V28, P87, DOI 10.3109/00365549609027156; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; International Study Group on Reduced-Osmolality ORS Solutions, 1995, LANCET, V346, P282; MAHALANABIS D, 1995, ACTA PAEDIATR, V84, P289, DOI 10.1111/j.1651-2227.1995.tb13630.x; Rabbani G.H., 1990, TXB SECRETORY DIARRH, P233; Santosham M, 1996, J PEDIATR-US, V128, P45, DOI 10.1016/S0022-3476(96)70426-2; SARKER SA, 1995, ACTA PAEDIATR, V84, P775, DOI 10.1111/j.1651-2227.1995.tb13755.x; *WHO DIV DIARRH AC, 1994, JOINT WHO ICDDR B CO	10	46	47	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					296	299		10.1016/S0140-6736(98)09332-5	http://dx.doi.org/10.1016/S0140-6736(98)09332-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440307				2022-12-28	WOS:000081646000013
J	Feighery, C				Feighery, C			Fortnightly review - Coeliac disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ADULT CELIAC-DISEASE; TISSUE TRANSGLUTAMINASE; PREVALENCE; DEFICIENCY; ENDOMYSIUM; ANTIBODIES; OATS		St James Hosp, Dept Immunol, Dublin 8, Ireland	Trinity College Dublin	Feighery, C (corresponding author), St James Hosp, Dept Immunol, Dublin 8, Ireland.	con.feighery@tcd.ie						AURICCHIO S, 1992, COMMON FOOD TOLERANC, V1; BurginWolff A, 1997, LANCET, V349, P1843, DOI 10.1016/S0140-6736(05)61732-1; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Catassi C, 1997, COELIAC DISEASE, P23; CHORZELSKI TP, 1983, ANN NY ACAD SCI, V420, P325, DOI 10.1111/j.1749-6632.1983.tb22220.x; COLLIN P, 1994, GUT, V35, P1215, DOI 10.1136/gut.35.9.1215; CONIN CC, 1998, Q J MED, V91, P303; CORRAO G, 1994, GUT, V35, P771, DOI 10.1136/gut.35.6.771; Cronin CC, 1997, LANCET, V349, P1096, DOI 10.1016/S0140-6736(96)09153-2; Dicke W.K., 1950, THESIS U UTRECHT NET; Dieterich W, 1998, GASTROENTEROLOGY, V115, P1317, DOI 10.1016/S0016-5085(98)70007-1; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Fasano A, 1996, ACTA PAEDIATR, V85, P20, DOI 10.1111/j.1651-2227.1996.tb14242.x; FEIGHERY C, 1991, EUR J GASTROEN HEPAT, V3, P119; Feighery C, 1998, EUR J GASTROEN HEPAT, V10, P919; FEIGHERY C, 1994, P 6INT S COEL DIS DU; Fry L, 1997, COELIAC DISEASE, P67; Greco L, 1997, COELIAC DISEASE, P9; Greco L., 1992, COMMON FOOD INTOLERA, P25; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; KAGNOFF MF, 1992, COELIAC DIS, P215; Kelly C P, 1990, Adv Intern Med, V35, P341; Kingham JGC, 1998, GUT, V42, P120, DOI 10.1136/gut.42.1.120; KUMAR PJ, 1990, COELIAC DIS 100 YEAR; LINDH E, 1992, J INTERN MED, V231, P403, DOI 10.1111/j.1365-2796.1992.tb00951.x; Logan RFA, 1992, COELIAC DIS, P192; MAKI M, 1997, COELIAC DIS; Marsh M.N., 1992, COELIAC DIS, P136; McMillan SA, 1996, GUT, V39, P43, DOI 10.1136/gut.39.1.43; MIDHAGEN G, 1988, SCAND J GASTROENTERO, V23, P1000, DOI 10.3109/00365528809090160; Schroeder HW, 1998, MOL MED, V4, P72, DOI 10.1007/BF03401731; SHREWRY PR, 1992, COELIAC DIS, P305; Srinivasan U, 1996, BRIT MED J, V313, P1300, DOI 10.1136/bmj.313.7068.1300; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; Visakorpi JK, 1997, COELIAC DISEASE, P1; WALTERS JRF, 1995, GUT, V37, P220, DOI 10.1136/gut.37.2.220; [No title captured]	40	192	199	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					236	239		10.1136/bmj.319.7204.236	http://dx.doi.org/10.1136/bmj.319.7204.236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417090	Green Published			2022-12-28	WOS:000081720300028
J	Blat, Y; Kleckner, N				Blat, Y; Kleckner, N			Cohesins bind to preferential sites along yeast chromosome III, with differential regulation along arms versus the centric region	CELL			English	Article							SISTER-CHROMATID COHESION; SMC PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; NUCLEAR SCAFFOLD; S-PHASE; DYNAMICS; CONDENSATION; MITOSIS; MEIOSIS	Sister chromatid cohesion is mediated by evolutionary conserved chromosomal proteins, termed "cohesins." Using an extension of chromatin immunoprecipitation, we have analyzed the distribution of cohesins Mcd1/Scc1 and Smc1 along yeast chromosome III. Both proteins occur preferentially at the same similar to 23 positions. Sites in a similar to 50 kb region around the centromere give especially intense signals. Prominent centric region binding appears to emerge from a more even distribution, probably by differential loss of cohesins along the chromosome arms. Cohesin binding peaks correspond closely to peaks of high local AT composition, a base composition periodicity of similar to 15 kb that is distinct from the similar to 50 kb periodicity of base composition isochores, consistent with axis association of cohesins. The methodology described can be used to analyze the distribution of any DNA-binding protein and, via microchips, along entire genomes.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Blat, Y (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Biggins S, 1998, CURR OPIN CELL BIOL, V10, P769, DOI 10.1016/S0955-0674(98)80120-8; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Furuya K, 1998, GENE DEV, V12, P3408, DOI 10.1101/gad.12.21.3408; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1995, J HERED, V86, P330, DOI 10.1093/oxfordjournals.jhered.a111600; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLEBAJER J, 1958, CHROMOSOMA, V9, P322; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; SAITOH Y, 1993, COLD SPRING HARB SYM, V58, P755, DOI 10.1101/SQB.1993.058.01.083; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUMNER AT, 1991, CHROMOSOMA, V100, P36; SUROSKY RT, 1986, P NATL ACAD SCI USA, V83, P414, DOI 10.1073/pnas.83.2.414; Swedlow JR, 1996, CURR BIOL, V6, P544, DOI 10.1016/S0960-9822(02)00538-9; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	45	331	339	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					249	259		10.1016/S0092-8674(00)81019-3	http://dx.doi.org/10.1016/S0092-8674(00)81019-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428036	Bronze			2022-12-28	WOS:000081632300014
J	Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P				Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P			Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist	NATURE			English	Article							NUCLEUS-ACCUMBENS; RAT; LESIONS; REINFORCEMENT; MODULATION; DEPENDENCE; ACTIVATION; SCHEDULES; ADDICTION; CIRCUITS	Environmental stimuli that are reliably associated with the effects of many abused drugs, especially stimulants such as cocaine, can produce craving and relapse in abstinent human substance abusers(1-4). In animals, such cues can induce and maintain drug-seeking behaviour and also reinstate drug-seeking after extinction(5-7). Reducing the motivational effects of drug-related cues might therefore be useful in the treatment of addiction(3). Converging pharmacological(8,9), human post-mortem(10) and genetic(11) studies implicate the dopamine D-3 receptor(12) in drug addiction. Here we have designed BP 897, the first D-3-receptor-selective agonist, as assessed in vitro with recombinant receptors and in vivo with mice bearing disrupted D-3-receptor genes. BP 897 is a partial agonist in vitro and acts in vivo as either an agonist or an antagonist. We show that BP 897 inhibits cocaine-seeking behaviour that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects. Our data indicate that compounds like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Lab Bioprojet, F-75002 Paris, France; Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Fac Pharm, CNRS, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch, France	University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Everitt, BJ (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.			Everitt, Barry/0000-0003-4431-6536	Medical Research Council [G9537855] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774; Bordet R, 1997, P NATL ACAD SCI USA, V94, P3363, DOI 10.1073/pnas.94.7.3363; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BEHAV PHARMACOL, V6, P333; Caine SB, 1997, NEUROREPORT, V8, P2373, DOI 10.1097/00001756-199707070-00054; COSTA T, 1992, MOL PHARMACOL, V41, P549; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; Di Ciano P, 1998, EUR J NEUROSCI, V10, P1121, DOI 10.1046/j.1460-9568.1998.00125.x; Duaux E, 1998, MOL PSYCHIATR, V3, P333, DOI 10.1038/sj.mp.4000409; EVERITT B J, 1992, P401; FONTANA DJ, 1993, BRAIN RES, V629, P31, DOI 10.1016/0006-8993(93)90477-5; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Grech DM, 1996, PSYCHOPHARMACOLOGY, V125, P97, DOI 10.1007/BF02249407; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X; OBRIEN CP, 1992, RES P ARNMD, V70, P157; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; PULVIRENTI L, 1994, TRENDS PHARMACOL SCI, V15, P374, DOI 10.1016/0165-6147(94)90158-9; Ridray S, 1998, EUR J NEUROSCI, V10, P1676, DOI 10.1046/j.1460-9568.1998.00173.x; Sautel F, 1995, J PHARMACOL EXP THER, V275, P1239; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Staley JK, 1996, J NEUROSCI, V16, P6100; Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447; Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; Xu M, 1999, SYNAPSE, V31, P210, DOI 10.1002/(SICI)1098-2396(19990301)31:3<210::AID-SYN6>3.3.CO;2-S	30	512	535	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					371	375		10.1038/43944	http://dx.doi.org/10.1038/43944			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432116				2022-12-28	WOS:000081590000052
J	Schwartz, LM; Woloshin, S; Welch, HG				Schwartz, LM; Woloshin, S; Welch, HG			Misunderstandings about the effects of race and sex on physicians' referrals for cardiac catheterization	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OUTCOMES		VA Outcomes Grp, White River Junction, VT 05009 USA	VA Outcomes Group	Schwartz, LM (corresponding author), VA Outcomes Grp, White River Junction, VT 05009 USA.							Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; FEINSTEIN AR, 1986, J CHRON DIS, V39, P485, DOI 10.1016/0021-9681(86)90116-5; Fisher ES, 1999, JAMA-J AM MED ASSOC, V281, P446, DOI 10.1001/jama.281.5.446; GOLDSTEIN A, 1999, WASH POST       1228, pA1; Hennekens C.H., 1987, EPIDEMIOLOGY MED; RUBIN R, 1999, US TODAY        0225, pA1; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; WELCH HG, 1995, NEW ENGL J MED, V332, P396; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; 1999, ECONOMIST       0227, P28; 1999, LOS ANGELES TIM 0225, P12; 1999, WALL STREET J   0226, pB6; 1999, NY TIMES        0225, pA23; 1999, NIGHTLINE       0224	18	134	136	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					279	283		10.1056/NEJM199907223410411	http://dx.doi.org/10.1056/NEJM199907223410411			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413743				2022-12-28	WOS:000081528800011
J	Linebarger, HV				Linebarger, HV			The blue drape	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					216	216		10.1001/jama.282.3.216	http://dx.doi.org/10.1001/jama.282.3.216			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422974				2022-12-28	WOS:000081504400001
J	Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE				Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE			Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer - Implications for clinical predisposition testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISMATCH REPAIR GENES; COLON-CANCER; MICROSATELLITE INSTABILITY; MLH1 MUTATIONS; HMSH2 MUTATIONS; HNPCC FAMILIES; HMLH1 GENES; HOMOLOG; MSH2; CARCINOMA	Context Genetic testing for cancer predisposition is evolving from purely research applications to affecting clinical management. Objective To determine how often genetic lest results for hereditary nonpolyposis colorectal cancer (HNPCC) can be definitively interpreted and used to guide clinical management. Design Case-series study conducted in 1996 to 1998 in which a complete sequence analysis of hMSH2 and hMLH1 coding sequence and flanking intronic regions was performed. Mutations were categorized as protein truncating and missense. In the case of missense alterations, additional analyses were performed in an effort to assess pathogenicity. Setting and Participants Families were identified by self-referral or health care provider referral to a cancer genetics program. Participants and kindreds were classified into 1 of 4 categories: (1) Amsterdam criteria for HNPCC, (2) modified Amsterdam criteria for HNPCC, (3) young age at onset, or (4) HNPCC-variant. In addition, each proband was classified according to the Bethesda guidelines for identification of individuals with HNPCC. Main Outcome Measure Alterations of hMSH2 and hMLH1 genes. Results Twenty-seven alterations of hMSH2 and hMLH1 were found in 24 of 70 families (34.3 %), Of these, deleterious mutations that could be used with confidence in clinical management were identified in 25.7% (18/70) of families. The rates of definitive results for families fulfilling Amsterdam criteria, modified Amsterdam criteria, young age at onset, HNPCC-variant, and Bethesda guidelines were 27 (39.3%), 13 (18.2%), 12 (16.7%), 11 (15.8%), and 21 (30.4%), respectively. The prevalence of missense mutations, genetic heterogeneity of the syndrome, and limited availability of validated functional assays present a challenge in the interpretation of genetic test results of HNPCC families. Conclusions The identification of pathogenic mutations in a significant subset of families for whom the results may have marked clinical importance makes genetic testing an important option for HNPCC and HNPCC-like kindreds. However, for the majority of individuals in whom sequence analysis of hMSH2 and hMLH1 does not give a definitive result, intensive follow-up is still warranted.	Dana Farber Canc Inst, Dept Populat Sci, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Ludwig Inst Canc Res, La Jolla, CA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research	Garber, JE (corresponding author), Dana Farber Canc Inst, Dept Populat Sci, 44 Binney St,Smith 208, Boston, MA 02115 USA.	judy_garber@dfci.harvard.edu		Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bellacosa A, 1996, AM J MED GENET, V62, P353, DOI 10.1002/(SICI)1096-8628(19960424)62:4<353::AID-AJMG7>3.0.CO;2-S; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Cotton RGH, 1998, HUM MUTAT, V12, P1, DOI 10.1002/(SICI)1098-1004(1998)12:1<1::AID-HUMU1>3.0.CO;2-M; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROGGATT NJ, 1995, LANCET, V345, P727, DOI 10.1016/S0140-6736(95)90900-1; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Hackman P, 1997, NAT GENET, V17, P135, DOI 10.1038/ng1097-135; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; Holtzman NA., 1998, PROMOTING SAFE EFFEC; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLBERG R, 1994, J NIH RES, V6, P37; KOLODNER RD, 1995, CANCER RES, V55, P242; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Maliaka YK, 1996, HUM GENET, V97, P251, DOI 10.1007/BF02265276; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARY JL, 1994, HUM MOL GENET, V3, P2067; MAUILLON JL, 1996, CANCER RES, V56, P242; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Offit K, 1998, CLINICAL CANCER GENETICS, P1; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; Risinger JI, 1996, CANCER, V77, P1836, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1836::AID-CNCR12>3.0.CO;2-0; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; TANNERGARD P, 1995, CANCER RES, V55, P6092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	53	97	110	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					247	253		10.1001/jama.282.3.247	http://dx.doi.org/10.1001/jama.282.3.247			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422993				2022-12-28	WOS:000081504400030
J	Dart, J				Dart, J			Extended-wear contact lenses, microbial keratitis, and public health	LANCET			English	Editorial Material									Moorfields Eye Hosp, Corneal & External Dis Serv, London EC1V 2PD, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Dart, J (corresponding author), Moorfields Eye Hosp, Corneal & External Dis Serv, City Rd, London EC1V 2PD, England.		Dart, John Kenneth/GZM-7807-2022					Alvord L, 1998, OPTOMETRY VISION SCI, V75, P30, DOI 10.1097/00006324-199801000-00022; Brennan NA, 1997, OPTOMETRY VISION SCI, V74, P609, DOI 10.1097/00006324-199708000-00022; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; DART JKG, 1996, DUANES FDN CLIN OPTH, V2, P1; HOLDEN BA, 1985, INVEST OPHTH VIS SCI, V26, P1489; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; Radford CF, 1998, BRIT J OPHTHALMOL, V82, P1272, DOI 10.1136/bjo.82.11.1272	7	20	20	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					174	175		10.1016/S0140-6736(99)90104-6	http://dx.doi.org/10.1016/S0140-6736(99)90104-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421292				2022-12-28	WOS:000081504200002
J	DellaPenna, D				DellaPenna, D			Nutritional genomics: Manipulating plant micronutrients to improve human health	SCIENCE			English	Review							CANCER PREVENTION; GENE-EXPRESSION; BETA-CAROTENE; FOLIC-ACID; VITAMIN-C; ARABIDOPSIS; BIOSYNTHESIS; VEGETABLES; DEFICIENT; FRUIT	The nutritional health and well-being of humans are entirely dependent on plant foods either directly or indirectly when plants are consumed by animals. Plant foods provide almost all essential vitamins and minerals and a number of other health-promoting phytochemicals. Because micronutrient concentrations are often low in staple crops, research is under way to understand and manipulate synthesis of micronutrients in order to improve crop nutritional quality. Genome sequencing projects are providing novel approaches for identifying plant biosynthetic genes of nutritional importance. The term "nutritional genomics" is used to describe work at the interface of plant biochemistry, genomics, and human nutrition.	Univ Nevada, Dept Biochem MS200, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	DellaPenna, D (corresponding author), Univ Nevada, Dept Biochem MS200, Reno, NV 89557 USA.	della_d@med.unr.edu						*AIFCR WORLD CANC, 1997, FOOD NUTR PREV CANC; Arnaud C.D., 1996, PRESENT KNOWLEDGE NU, V7th, P245; Baldet P, 1997, FEBS LETT, V419, P206, DOI 10.1016/S0014-5793(97)01458-0; Belanger FC, 1995, PLANT MOL BIOL, V29, P809, DOI 10.1007/BF00041170; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Buring JE, 1997, NUTR REV, V55, pS53, DOI [10.1111/j.1753-4887.1997.tb06103.x, NO_DOI]; Butterworth CE, 1996, ANNU REV NUTR, V16, P73, DOI [10.1146/annurev.nutr.16.1.73, 10.1146/annurev.nu.16.070196.000445]; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Calloway DH, 1995, HUMAN NUTR FOOD MICR; Charleux JL, 1996, NUTR REV, V54, pS109, DOI 10.1111/j.1753-4887.1996.tb03829.x; Conklin PL, 1997, PLANT PHYSIOL, V115, P1277, DOI 10.1104/pp.115.3.1277; Conn EE, 1995, CUR TOP PL, V15, P1; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; DELANGE F, 1994, THYROID, V4, P107, DOI 10.1089/thy.1994.4.107; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desprez T, 1998, PLANT J, V14, P643, DOI 10.1046/j.1365-313X.1998.00160.x; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Food and Nutrition Board NRC, 1989, REC DIET ALL; Grusak MA, 1996, J AM SOC HORTIC SCI, V121, P656, DOI 10.21273/JASHS.121.4.656; Harborne J. B., 1993, INTRO ECOLOGICAL BIO, V4th; HARPER AE, 1987, ANNU REV NUTR, V7, P509, DOI 10.1146/annurev.nu.07.070187.002453; HECHT SS, 1995, J CELL BIOCHEM, P195; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kaneko T, 1996, DNA Res, V3, P109; KEHRER JP, 1994, FREE RADICALS BIOL S, V2; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Lachance PA, 1998, NUTR REV, V56, pS34; Mertz W, 1997, NUTR REV, V55, P44, DOI 10.1111/j.1753-4887.1997.tb01594.x; Mock DM., 1996, PRESENT KNOWLEDGE NU, V7th ed, P220; Norris SR, 1995, PLANT CELL, V7, P2139, DOI 10.1105/tpc.7.12.2139; Norris SR, 1998, PLANT PHYSIOL, V117, P1317, DOI 10.1104/pp.117.4.1317; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5; Ruan Y, 1998, PLANT J, V15, P821, DOI 10.1046/j.1365-313X.1998.00254.x; SAUBERLICH HE, 1994, ANNU REV NUTR, V14, P371, DOI 10.1146/annurev.nu.14.070194.002103; Schonhof I, 1996, GARTENBAUWISSENSCHAF, V61, P281; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; SHIRLEY BW, 1995, PLANT J, V8, P659, DOI 10.1046/j.1365-313X.1995.08050659.x; SIMON PW, 1989, HORTSCIENCE, V24, P174; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Sterky F, 1998, P NATL ACAD SCI USA, V95, P13330, DOI 10.1073/pnas.95.22.13330; STOMMEL JR, 1994, J HERED, V85, P401, DOI 10.1093/oxfordjournals.jhered.a111486; Talalay P, 1996, BIOCHEM SOC T, V24, P806, DOI 10.1042/bst0240806; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; Underwood B. A., 1998, Nutrition Today, V33, P121, DOI 10.1097/00017285-199805000-00013; Wang M, 1996, J AM SOC HORTIC SCI, V121, P1040, DOI 10.21273/JASHS.121.6.1040; Winzerling JJ, 1997, ANNU REV NUTR, V17, P501, DOI 10.1146/annurev.nutr.17.1.501; Yamamoto K, 1997, PLANT MOL BIOL, V35, P135, DOI 10.1023/A:1005735322577; Ziegler E.E., 1996, PRESENT KNOWLEDGE NU; [No title captured]; [No title captured]	51	216	238	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					375	379		10.1126/science.285.5426.375	http://dx.doi.org/10.1126/science.285.5426.375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411494				2022-12-28	WOS:000081465900045
J	Tallis, R				Tallis, R			Commentary: Leave well alone	BRITISH MEDICAL JOURNAL			English	Article									Hope Hosp, Dept Geriatr Med, Salford M6 8HD, Lancs, England		Tallis, R (corresponding author), Hope Hosp, Dept Geriatr Med, Salford M6 8HD, Lancs, England.								0	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1757	1758						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428565				2022-12-28	WOS:000081216900044
J	Back, CH; Allenspach, R; Weber, W; Parkin, SSP; Weller, D; Garwin, EL; Siegmann, HC				Back, CH; Allenspach, R; Weber, W; Parkin, SSP; Weller, D; Garwin, EL; Siegmann, HC			Minimum field strength in precessional magnetization reversal	SCIENCE			English	Article							THIN-FILMS; PHOTOEMISSION; MAGNETISM; PARTICLES; DYNAMICS; PULSES	Ultrafast magnetic field pulses as short as 2 picoseconds are able to reverse the magnetization in thin, in-plane, magnetized cobalt films. The field pulses are applied in the plane of the film, and their direction encompasses all angles with the magnetization. At a right angle to the magnetization, maximum torque is exerted on the spins. In this geometry, a precessional magnetization reversal can be triggered by fields as small as 184 kiloamperes per meter. Applications in future ultrafast magnetic recording schemes can be foreseen.	ETH Zurich, Festkorperphys Lab, CH-8093 Zurich, Switzerland; IBM Corp, Div Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland; IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA; Stanford Univ, Stanford Linear Accelerator Ctr, Stanford, CA 94305 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; International Business Machines (IBM); International Business Machines (IBM); Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Back, CH (corresponding author), ETH Zurich, Festkorperphys Lab, CH-8093 Zurich, Switzerland.		Back, Christian/A-8969-2012; Back, Christian/AAD-7824-2021; Parkin, Stuart/D-2521-2012	Back, Christian/0000-0003-3840-0993; Back, Christian/0000-0003-3840-0993; Parkin, Stuart/0000-0003-4702-6139				ADOLPHSON C, 1996, ZEROTH ORDER DESIGN; ALLENSPACH R, 1994, J MAGN MAGN MATER, V129, P160, DOI 10.1016/0304-8853(94)90108-2; Back CH, 1998, PHYS REV LETT, V81, P3251, DOI 10.1103/PhysRevLett.81.3251; Chou SY, 1996, J APPL PHYS, V79, P6101, DOI 10.1063/1.362440; DOYLE WD, 1998, J MAGN SOC JPN, V22, P91; Hiebert WK, 1997, PHYS REV LETT, V79, P1134, DOI 10.1103/PhysRevLett.79.1134; Koch RH, 1998, PHYS REV LETT, V81, P4512, DOI 10.1103/PhysRevLett.81.4512; LEDERMAN M, 1994, PHYS REV LETT, V73, P1986, DOI 10.1103/PhysRevLett.73.1986; Lyberatos A, 1997, J PHYS-CONDENS MAT, V9, P2623, DOI 10.1088/0953-8984/9/12/010; NAKANISHI T, 1998, P LE 98 ST PET RUSS; Oberli D, 1998, PHYS REV LETT, V81, P4228, DOI 10.1103/PhysRevLett.81.4228; Scholl A, 1997, PHYS REV LETT, V79, P5146, DOI 10.1103/PhysRevLett.79.5146; SIEGMANN HC, 1995, J MAGN MAGN MATER, V151, pL8, DOI 10.1016/0304-8853(95)00602-8; Silva TJ, 1999, J APPL PHYS, V85, P7849, DOI 10.1063/1.370596; Stamm C, 1998, SCIENCE, V282, P449, DOI 10.1126/science.282.5388.449; VATERLAUS A, 1992, PHYS REV B, V46, P5280, DOI 10.1103/PhysRevB.46.5280; Wernsdorfer W, 1997, PHYS REV LETT, V78, P1791, DOI 10.1103/PhysRevLett.78.1791	17	249	257	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					864	867		10.1126/science.285.5429.864	http://dx.doi.org/10.1126/science.285.5429.864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436149				2022-12-28	WOS:000081860900041
J	Silverman, EM; Skinner, JS; Fisher, ES				Silverman, EM; Skinner, JS; Fisher, ES			The association between for-profit hospital ownership and increased Medicare spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; COLUMBIA/HCA; COST	Background and Methods The rare of conversion to for-profit ownership of hospitals has recently increased in the United States, with uncertain implications for health care costs. We compared total per capita Medicare spending in areas served by for-profit and not-for-profit hospitals. We used American Hospital Association data to categorize U.S. hospital service areas as for-profit (meaning that all beds in the area were in for-profit hospitals), not-for-profit (all beds were in not-for-profit hospitals), or mixed in 1989, 1992, and 1995. We then used data from the Continuous Medicare History Sample to calculate the 1989, 1992, and 1995 spending rates in each area; adjusting for other characteristics known to influence spending: age, sex, race,region of the United States, percentage of population living in urban areas, Medicare mortality rate, number of hospital's, number of physicians per capita, percentage of beds in hospitals affiliated with medical schools, percentage of beds in hospitals belonging to hospital chains, and percentage of Medicare beneficiaries enrolled in health maintenance organizations. Results Adjusted total per capita Medicare spending in the 208 areas where all hospitals remained under for-profit ownership during the study years was greater than in the 2860 areas where all hospitals remained under not-for-profit ownership ($4,006 vs. $3,554 in 1989, $4,243 vs. $3,841 in 1992, and $5,172 vs. $4,440 in 1995; P<0.001 for each comparison). Mixed areas had intermediate spending rates. Spending in for-profit areas was greater than in not-for-profit areas in each category of service examined: hospital services, physicians' services, home health care, and services at other facilities. The greatest increases in per capita spending between 1989 and 1995 were for hospital services (a mean increase of $395 in for-profit areas and $283 in not-for-profit areas, P=0.03 for the comparison between for-profit and not-for-profit areas) and home health care (an increase of $457 in for-profit areas and $324 in not-for-profit areas, P<0.001). Between 1989 and 1995, spending in the 33 areas where all hospitals converted from not-for-profit to for-profit ownership grew more rapidly than in the 2860 areas where all hospitals remained under not-for-profit ownership ($1,295 vs. $866, P=0.03). Conclusions Both the rates of per capita Medicare spending and the increases in spending rates were greater in areas served by for-profit hospitals than in areas served by nor-for-profit hospitals. (N Engl J Med 1999;341:420-6.) (C) 1999, Massachusetts Medical Society.	Dartmouth Coll, Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; Dept Vet Affairs, Vet Affairs Outcomes Grp, White River Junction, VT USA; Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Dartmouth College; Dartmouth College; National Bureau of Economic Research	Fisher, ES (corresponding author), Dartmouth Coll, Sch Med, Ctr Evaluat Clin Sci, HB7251, Hanover, NH 03755 USA.							BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; Claxton G, 1997, HEALTH AFFAIR, V16, P9, DOI 10.1377/hlthaff.16.2.9; *COUNC EC ADV, 1998, EC REP PRES; CUTLER D, IN PRESS NOT PROFIT; EICHENWALD K, 1997, NY TIMES        0401, pD2; *GEN ACC OFF, 1997, PUBL GEN ACC OFF; Gray BH, 1997, HEALTH AFFAIR, V16, P29, DOI 10.1377/hlthaff.16.2.29; GRAY BH, 1986, NEW ENGL J MED, V314, P1523, DOI 10.1056/NEJM198606053142335; GREENE W, 1993, ECONOMETRIC ANAL, P487; GRIFFITH JR, 1985, HEALTH SERV RES, V20, P131; Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; *HCFA, 1996, HCFA PUBL; Kleinke JD, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.2.7; Kuttner R, 1996, NEW ENGL J MED, V335, P362, DOI 10.1056/NEJM199608013350524; Kuttner R, 1996, NEW ENGL J MED, V335, P531; LAGNADO L, 1997, WALL STREET J   0530, pA6; Manning DL, 1997, HEALTH AFFAIR, V16, P108, DOI 10.1377/hlthaff.16.2.108; Menke TJ, 1997, HEALTH SERV RES, V32, P177; MOREY RC, 1995, MED CARE, V33, P531, DOI 10.1097/00005650-199505000-00007; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; NORTON EC, 1994, RAND J ECON, V25, P171, DOI 10.2307/2555860; PAGANO M, 1993, PRINCIPLES BIOSTATIS; POPE GC, 1989, HEALTH AFFAIR, V8, P117, DOI 10.1377/hlthaff.8.3.117; Reinhardt UE, 1996, HEALTH AFFAIR, V15, P145, DOI 10.1377/hlthaff.15.2.145; Reinhardt UE, 1998, HEALTH AFFAIR, V17, P30, DOI 10.1377/hlthaff.17.2.30; SHACTMAN D, 1996, CONVERSION HOSPITALS; SLOAN FA, 1998, 6706 NAT BUR EC RES; *STAT STAT SOFTW, 1997, REL 5 0 REF MAN, P376; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG J, 1996, DARTMOUTH ATLAS HLTH, P251; Woolhandler S, 1997, NEW ENGL J MED, V337, P1783; ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644	33	78	79	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					420	426		10.1056/NEJM199908053410606	http://dx.doi.org/10.1056/NEJM199908053410606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	223UN	10432327				2022-12-28	WOS:000081860100006
J	Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL				Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL			Detection of Alloiococcus otitis in mixed bacterial populations from middle-ear effusions of patients with otitis media	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PCR; IDENTIFICATION; PERSISTENT; PATHOGENS; CHILDREN; RNA; DNA	Background Otitis media is a potentially serious disorder, since there is a risk of permanent hearing loss. Culture methods are not useful in characterisation of populations of bacteria in the middle ear. We have used a PCR-based method that does not depend on prior knowledge of the bacteria identified by culture. Methods Middle-ear effusion fluid was obtained from 12 patients with chronic otitis media with effusion. Total DNA was extracted from the samples, and the hypervariable regions of bacterial 16S rRNA genes were amplified by means of broad-range PCR primers. Individual PCR products were segregated by cloning to allow analysis of mixed bacterial populations. Findings Many bacterial species were detected by PCR, whereas with culture-based approaches, no bacterial growth was detected for ten of the 12 patients. The gram-positive bacterium Alloiococcus otitis (A otitidis) was detected by 16S rDNA amplification in six of the twelve samples, but not by culture techniques. Interpretation The method may have general usefulness in characterising bacterial populations at the site of infection and may indicate, from small sample numbers, organisms that are candidates for further investigation.	Univ Birmingham, Sch Biol Sci, Birmingham, W Midlands, England; City Hosp NHS Trust, Hosp Infect Res Lab, Birmingham, W Midlands, England; City Hosp NHS Trust, Dept Otorhinolaryngol, Birmingham, W Midlands, England	University of Birmingham	Beswich, AJ (corresponding author), Hlth & Safety Lab, Broad Lane, Sheffield S3 7HQ, S Yorkshire, England.	alan.beswick@hsl.gov.uk						AGUIRRE M, 1992, INT J SYST BACTERIOL, V42, P79, DOI 10.1099/00207713-42-1-79; ALVAREZ AJ, 1994, APPL ENVIRON MICROB, V60, P374, DOI 10.1128/AEM.60.1.374-376.1994; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; Hinton A, 1996, CLIN OTOLARYNGOL, V21, P158, DOI 10.1111/j.1365-2273.1996.tb01322.x; HOTOMI M, 1993, INT J PEDIATR OTORHI, V27, P119, DOI 10.1016/0165-5876(93)90127-O; HOWIE VM, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430016006; Jero J, 1997, ACTA OTO-LARYNGOL, P22; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; Liederman EM, 1998, ANN OTO RHINOL LARYN, V107, P10; Matar GM, 1998, J CLIN MICROBIOL, V36, P1185, DOI 10.1128/JCM.36.5.1185-1188.1998; Ohtani H, 1998, NEPHROL DIAL TRANSPL, V13, P177, DOI 10.1093/ndt/13.1.177; PICHICHERO ME, 1995, PEDIATR INFECT DIS J, V14, P178, DOI 10.1097/00006454-199503000-00002; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Saffer M, 1996, ACTA OTO-LARYNGOL, V116, P836, DOI 10.3109/00016489609137936; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stackebrandt E, 1996, MICROBIAL DIVERSITY IN TIME AND SPACE, P19, DOI 10.1007/978-0-585-34046-3_3; TEBBE CC, 1993, APPL ENVIRON MICROB, V59, P2657, DOI 10.1128/AEM.59.8.2657-2665.1993; Wilbrink B, 1998, ARTHRITIS RHEUM-US, V41, P535, DOI 10.1002/1529-0131(199803)41:3<535::AID-ART20>3.0.CO;2-4	22	39	45	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					386	389		10.1016/S0140-6736(98)09295-2	http://dx.doi.org/10.1016/S0140-6736(98)09295-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437868				2022-12-28	WOS:000081764900014
J	Khunti, K; Sorrie, R; Jennings, S; Farooqi, A				Khunti, K; Sorrie, R; Jennings, S; Farooqi, A			Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Leicester, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Leicester LE5 4PW, Leics, England; Leicester Gen Hosp, Leicestershire Primary Care Audit Grp, Leicester LE5 4PW, Leics, England; Leicestershire Area Hlth Author, Leicester LE5 4QF, Leics, England	University of Leicester; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Khunti, K (corresponding author), Univ Leicester, Dept Gen Practice & Primary Hlth Care, Clin Governance Res & Dev Unit, Leicester LE5 4PW, Leics, England.	kk22@le.ac.uk	/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Bradley F, 1997, FAM PRACT, V14, P220, DOI 10.1093/fampra/14.3.220; Chambers R, 1996, QUAL HEALTH CARE, V5, P13, DOI 10.1136/qshc.5.1.13; *SECR STAT HLTH, 1997, CM3807; WHITFORD DL, 1994, BMJ-BRIT MED J, V309, P1268, DOI 10.1136/bmj.309.6964.1268	5	12	12	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	1999	319	7205					297	297		10.1136/bmj.319.7205.297	http://dx.doi.org/10.1136/bmj.319.7205.297			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426745	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000081909100028
J	Smith, R				Smith, R			Another editor bites the dust	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Davies HTO, 1999, JAMA-J AM MED ASSOC, V281, P2344, DOI 10.1001/jama.281.24.2344; Ferriman A, 1999, BRIT MED J, V318, P1645, DOI 10.1136/bmj.318.7199.1645; Kassirer JP, 1998, NEW ENGL J MED, V339, P397, DOI 10.1056/NEJM199808063390608; Kassirer JP, 1999, NEW ENGL J MED, V340, P1671, DOI 10.1056/NEJM199905273402109; KASSIRER JP, 1999, NEW ENGL J MED, V340, P36; Rosenberg RN, 1999, JAMA-J AM MED ASSOC, V281, P2239, DOI 10.1001/jama.281.23.2239; Sabin JE, 1998, BRIT MED J, V317, P1002; Smith R, 1999, BRIT MED J, V318, P210; TYE L, 1999, BOSTON GLOBE    0726	9	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					272	272		10.1136/bmj.319.7205.272	http://dx.doi.org/10.1136/bmj.319.7205.272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426719	Green Published			2022-12-28	WOS:000081909100004
J	Kern, WV; Cometta, A; de Rock, R; Langenaeken, J; Paesmans, M; Gaya, H				Kern, WV; Cometta, A; de Rock, R; Langenaeken, J; Paesmans, M; Gaya, H		European Org Res Treatment Canc	Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEBRILE NEUTROPENIC PATIENTS; CEFTAZIDIME PLUS AMIKACIN; EARLY HOSPITAL DISCHARGE; 400 MG IV; LOW-RISK; ANTIBIOTIC-THERAPY; CLINICAL-TRIALS; COMPARATIVE PHARMACOKINETICS; ESCHERICHIA-COLI; RANDOMIZED TRIAL	Background Intravenously administered antimicrobial agents have been the standard choice for the empirical management of fever in patients with cancer and granulocytopenia. If orally administered empirical therapy is as effective as intravenous therapy, it would offer advantages such as improved quality of life and lower cost. Methods In a prospective, open-label, multicenter trial, we randomly assigned febrile patients with cancer who had granulocytopenia that was expected to resolve within 10 days to receive empirical therapy with either oral ciprofloxacin (750 mg twice daily) plus amoxicillin-clavulanate (625 mg three times daily) or standard daily doses of intravenous ceftriaxone plus amikacin. All patients were hospitalized until their fever resolved. The primary objective of the study was to determine whether there was equivalence between the regimens, defined as an absolute difference in the rates of success of 10 percent or less. Results Equivalence was demonstrated at the second interim analysis, and the trial was terminated after the enrollment of 353 patients. In the analysis of the 312 patients who were treated according to the protocol and who could be evaluated, treatment was successful in 86 percent of the patients in the oral-therapy group (95 percent confidence interval, 80 to 91 percent) and 84 percent of those in the intravenous-therapy group (95 percent confidence interval, 78 to 90 percent; P=0.02). The results were similar in the intention-to-treat analysis (80 percent and 77 percent, respectively; P=0.03), as were the duration of fever, the time to a change in the regimen, the reasons for such a change, the duration of therapy, and survival. The types of adverse events differed slightly between the groups but were similar in frequency. Conclusions In low-risk patients with cancer who have fever and granulocytopenia, oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy. (N Engl J Med 1999; 341:312-8.) (C) 1999, Massachusetts Medical Society.	Univ Ulm, Med Klin & Poliklin, Sekt Infect & Klin Immunol, D-89070 Ulm, Germany; CHU Vaudois, CH-1011 Lausanne, Switzerland; Allgemeen Ziekenhuis Middleheim, Antwerp, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Royal Brompton Hosp, London SW3 6LY, England; Patras Univ Hosp, Patras, Greece; Brown Univ, Providence, RI 02912 USA; Natl Inst Canc Res, Genoa, Italy; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; Kingston Reg Canc Ctr, Kingston, ON, Canada	Ulm University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Institut Jules Bordet; Royal Brompton Hospital; University of Patras; Brown University; University of Genoa; IRCCS AOU San Martino IST; Hebrew University of Jerusalem	Kern, WV (corresponding author), Univ Ulm, Med Klin & Poliklin, Sekt Infect & Klin Immunol, D-89070 Ulm, Germany.	winfried.kern@medizin.uni-ulm.de	Calandra, Thierry/D-9017-2015; Sanz, Miguel/F-7485-2018	Calandra, Thierry/0000-0003-3051-1285; Sanz, Miguel/0000-0003-1489-1177				Ball P, 1997, J CHEMOTHERAPY, V9, P167, DOI 10.1179/joc.1997.9.3.167; BASH RO, 1994, CANCER, V74, P189, DOI 10.1002/1097-0142(19940701)74:1<189::AID-CNCR2820740130>3.0.CO;2-7; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRUNIER H, 1993, PEST 3 PLANNING EVAL; CALANDRA T, 1993, ANN INTERN MED, V119, P584, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00006; CATCHPOLE C, 1994, J ANTIMICROB CHEMOTH, V33, P103, DOI 10.1093/jac/33.1.103; COMETTA A, 1994, NEW ENGL J MED, V330, P1240, DOI 10.1056/NEJM199404283301717; COMETTA A, 1995, ANTIMICROB AGENTS CH, V39, P445, DOI 10.1128/AAC.39.2.445; Cometta AF, 1996, ANTIMICROB AGENTS CH, V40, P1108, DOI 10.1128/AAC.40.5.1108; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; Elting LS, 1997, CLIN INFECT DIS, V25, P247, DOI 10.1086/514550; GARDEMBASPAIN M, 1991, ANN ONCOL, V2, P485, DOI 10.1093/oxfordjournals.annonc.a057996; Hann I, 1997, BRIT J HAEMATOL, V99, P580, DOI 10.1046/j.1365-2141.1997.4453255.x; Hidalgo M, 1999, CANCER, V85, P213, DOI 10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D; Horowitz HW, 1996, LEUKEMIA LYMPHOMA, V23, P159, DOI 10.3109/10428199609054816; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; HUGHES WT, 1990, J INFECT DIS, V161, P1316; KERN WV, 1994, ANTIMICROB AGENTS CH, V38, P681, DOI 10.1128/AAC.38.4.681; LAN KKG, 1989, BIOMETRICS, V45, P1017, DOI 10.2307/2531701; LAN KKG, 1993, STAT MED, V12, P753, DOI 10.1002/sim.4780120804; LIM SH, 1990, BRIT J HAEMATOL, V76, P41, DOI 10.1111/j.1365-2141.1990.tb07935.x; Lucas KG, 1996, CANCER, V77, P791, DOI 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.3.CO;2-B; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MALIK IA, 1992, LANCET, V339, P1092, DOI 10.1016/0140-6736(92)90674-R; MALIK IA, 1995, AM J MED, V98, P224, DOI 10.1016/S0002-9343(99)80367-2; MEROPOL NJ, 1994, EUR J CANCER, V30A, P1595, DOI 10.1016/0959-8049(94)90069-8; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; MULLEN CA, 1990, J CLIN ONCOL, V8, P1998, DOI 10.1200/JCO.1990.8.12.1998; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P142; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; ROSSINI F, 1994, SUPPORT CARE CANCER, V2, P259, DOI 10.1007/BF00365733; RUBENSTEIN EB, 1993, CANCER-AM CANCER SOC, V71, P3640, DOI 10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H; RUBIN M, 1988, CANCER INVEST, V6, P167, DOI 10.3109/07357908809077045; SHAH A, 1994, J ANTIMICROB CHEMOTH, V33, P795, DOI 10.1093/jac/33.4.795; TALCOTT JA, 1994, J CLIN ONCOL, V12, P107, DOI 10.1200/JCO.1994.12.1.107; TALCOTT JA, 1992, J CLIN ONCOL, V10, P316, DOI 10.1200/JCO.1992.10.2.316; VELASCO E, 1995, AM J CLIN ONCOL-CANC, V18, P429, DOI 10.1097/00000421-199510000-00014	39	250	259	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					312	318		10.1056/NEJM199907293410502	http://dx.doi.org/10.1056/NEJM199907293410502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423465	Bronze			2022-12-28	WOS:000081666900002
J	Caparros-Lefebvre, D; Elbaz, A				Caparros-Lefebvre, D; Elbaz, A		Caribbean Parkinsonism Study Grp	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study	LANCET			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRESSIVE SUPRANUCLEAR PALSY; DOPAMINE TRANSPORTER; DEMENTIA COMPLEX; ENDOGENOUS AMINE; ANNONA-MURICATA; DISEASE; GUAM; DERIVATIVES; ACCURACY	Background In Europe and North America, Parkinson's disease is the major form of parkinsonism; less than 4% of cases are progressive supranuclear palsy (PSP) and about 20% are atypical parkinsonism. The distribution of these subgroups is different in the French West Indies. We aimed to define the clinical and demographic specificity of these disorders in Guadeloupe and to investigate a postulated link with consumption of herbal tea and fruits from the Annonaceae family (Annona muricata and Annona squamosa), which contain neurotoxic benzyltetrahydroisoquinoline alkaloids. Methods Between September, 1996, and August, 1998, 87 consecutive patients with parkinsonism were referred to the single neurological department in Guadeloupe. After detailed clinical, neurophysiological, cognitive, and neuroradiological assessment, they were classified by generally accepted criteria as having Parkinson's disease, PSP, or atypical parkinsonism. We compared the amount of tropical fruits and herbal tea consumed by the various parkinsonian subgroups and by frequency-matched controls (patients with benign symptoms and no neurodegenerative disease). Findings Of the 87 patients, 22 had Parkinson's disease, 31 had PSP, 30 had atypical parkinsonism, and four had atypical parkinsonism associated with motor neuron disease, 44 of the patients with PSP or atypical parkinsonism were male. The patients with atypical parkinsonism had symmetrical rigidity and bradykinesia, and no levodopa peak-dose dyskinesias. Patients with PSP differed from those with atypical parkinsonism because they had supranuclear vertical down-gaze palsy, severe gait and balance problems, and frontal-lobe syndrome. 29 Patients with PSP reported regular consumption of pawpaw fruit, and 26 drank herbal tea. 30 patients with atypical parkinsonism reported regular consumption of pawpaw fruit, and 24 drank herbal tea. Both of these groups consumed significantly more fruit and herbal tea than patients with Parkinson's disease (fruit: odds ratio 23.6; herbal tea: 28.2); and controls (fruit: 20.7; herbal tea: 6.48). Both of these groups and herbal tea than Interpretation Our study confirms the over-representation of atypical parkinsonism and PSP in patients with parkinsonism in the French West Indies. Chronic exposure to neurotoxic alkaloids could be an important aetiological factor because these compounds induce parkinsonism in animals. A larger epidemiological study, to clarify the link between these fruits with atypical parkinsonism and PSP, is proposed.	CHU Antilles & Guyane, Dept Neurol, F-97159 Pointe A Pitre, Guadeloupe, France; Hop La Pitie Salpetriere, INSERM, U360, F-75013 Paris, France	CHU Guadeloupe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Caparros-Lefebvre, D (corresponding author), CHU Antilles & Guyane, Dept Neurol, Route de Chauvel, F-97159 Pointe A Pitre, Guadeloupe, France.	lefebvdo@ais.gp	Elbaz, Alexis/F-8952-2017	Elbaz, Alexis/0000-0001-9724-5490				AMARENCO P, 1991, J NEUROL NEUROSUR PS, V54, P1121, DOI 10.1136/jnnp.54.12.1121-a; BOOTH RG, 1989, NEUROSCI LETT, V100, P306, DOI 10.1016/0304-3940(89)90704-0; BRUNETON J, 1993, TECHNIQUE DOCUMENTAT, P707; Cabedo N, 1998, J NAT PROD, V61, P709, DOI 10.1021/np980008a; CHAUDHURI KR, 1996, MOV DISORD S1, V11, P534; Coleman T, 1996, J PHARMACOL EXP THER, V277, P685; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; ELIZAN TS, 1966, ARCH NEUROL-CHICAGO, V14, P356, DOI 10.1001/archneur.1966.00470100012002; ESTEGUY M, 1985, REV NEUROL, V141, P413; Fahn S., 1987, RECENT DEV PARKINSON, P153; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; Hasrat JA, 1997, J PHARM PHARMACOL, V49, P1145, DOI 10.1111/j.2042-7158.1997.tb06058.x; Hasrat JA, 1997, PHYTOMEDICINE, V4, P133, DOI 10.1016/S0944-7113(97)80059-1; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; HOF PR, 1994, ACTA NEUROPATHOL, V88, P397; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JOSEPH H, 1983, THESIS U MONTPELLIER; Kawai H, 1998, J NEUROCHEM, V70, P745; KOTAKE Y, 1995, J NEUROCHEM, V65, P2633; Kotake Y, 1996, NEUROSCI LETT, V217, P69; KOVAR J, 1983, ARCH BIOCHEM BIOPHYS, V221, P271, DOI 10.1016/0003-9861(83)90144-3; LEBOEUF M, 1981, PLANTA MED, V42, P37, DOI 10.1055/s-2007-971543; Litvan I, 1996, NEUROLOGY, V46, P922, DOI 10.1212/WNL.46.4.922; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; MARTIN RO, 1967, BIOCHEMISTRY-US, V6, P2355, DOI 10.1021/bi00860a010; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Nagatsu T, 1997, NEUROSCI RES, V29, P99, DOI 10.1016/S0168-0102(97)00083-7; Okada T, 1998, NEUROSCI RES, V30, P87, DOI 10.1016/S0168-0102(97)00121-1; OYANAGI K, 1994, ACTA NEUROPATHOL, V88, P405; REED D, 1987, AM J EPIDEMIOL, V125, P92, DOI 10.1093/oxfordjournals.aje.a114515; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Uitti R J, 1995, Parkinsonism Relat Disord, V1, P21, DOI 10.1016/1353-8020(95)00004-P; WU YC, 1989, PLANTA MED, P163, DOI 10.1055/s-2006-961913	35	165	172	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					281	286		10.1016/S0140-6736(98)10166-6	http://dx.doi.org/10.1016/S0140-6736(98)10166-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440304				2022-12-28	WOS:000081646000010
J	Reynolds, T				Reynolds, T			A memorable patient - "Now I can be remembered"	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					231	231		10.1136/bmj.319.7204.231	http://dx.doi.org/10.1136/bmj.319.7204.231			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417087	Green Published			2022-12-28	WOS:000081720300026
J	Bendor, R				Bendor, R			Arthritis and I	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					150	152		10.7326/0003-4819-131-2-199907200-00015	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419434				2022-12-28	WOS:000081509700013
J	Orr-Weaver, TL				Orr-Weaver, TL			Perspectives: Cell cycle - The difficulty in separating sisters	SCIENCE			English	Editorial Material							CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; ANAPHASE; YEAST		Whitehead Inst, Cambridge, MA 02142 USA; MIT, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Orr-Weaver, TL (corresponding author), Whitehead Inst, Cambridge, MA 02142 USA.							Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	15	11	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					344	345						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438298				2022-12-28	WOS:000081465900030
J	van Ommen, GJB; Bakker, E; den Dunnen, JT				van Ommen, GJB; Bakker, E; den Dunnen, JT			The human genome project and the future of diagnostics, treatment, and prevention	LANCET			English	Article							POLYMERASE CHAIN-REACTION; NONPOLYPOSIS COLORECTAL-CANCER; MUTATION DETECTION; BREAST-CANCER; OLIGONUCLEOTIDE ARRAYS; GENETIC-HETEROGENEITY; CYSTIC-FIBROSIS; DNA ANALYSIS; BETA-GLOBIN; BRCA1		Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Ommen, GJB (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands.	gvanomme@ruly46.medfac.leidenuniv.nl	dunnen, johan den/ABH-4228-2020; Bakker, Egbert/D-3525-2009	dunnen, johan den/0000-0002-6304-1710; Bakker, Egbert/0000-0002-2843-7357				Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Becker J, 1996, AM J HUM GENET, V58, P657; COTTON R, 1997, MUTATION DETECTION; COTTON RGH, 1991, METHOD MOL BIOL, P39; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; de Wert G, 1998, PATIENT EDUC COUNS, V35, P43, DOI 10.1016/S0738-3991(98)00082-2; DEKNIJFF P, 1994, HUM MUTAT, V4, P178, DOI 10.1002/humu.1380040303; DENDUNNEN JT, IN PRESS HUM MUTAT; DudokdeWit AC, 1998, J MED GENET, V35, P745, DOI 10.1136/jmg.35.9.745; Farrell PM, 1997, NEW ENGL J MED, V337, P963, DOI 10.1056/NEJM199710023371403; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gieser L, 1998, AM J HUM GENET, V63, P1439, DOI 10.1086/302121; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Jin L., 1995, American Journal of Human Genetics, V57, pA26; KALAYDJIEVA L, 1991, J MED GENET, V28, P686, DOI 10.1136/jmg.28.10.686; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; Lambrinakos A, 1999, NUCLEIC ACIDS RES, V27, P1866, DOI 10.1093/nar/27.8.1866; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lynch HT, 1997, CANCER EPIDEM BIOMAR, V6, P987; Monforte JA, 1997, NAT MED, V3, P360, DOI 10.1038/nm0397-360; Nilsson M, 1997, NAT GENET, V16, P252, DOI 10.1038/ng0797-252; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Roest PAM, 1999, LANCET, V353, P727, DOI 10.1016/S0140-6736(98)05471-3; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Sandoval N, 1999, HUM MOL GENET, V8, P69, DOI 10.1093/hmg/8.1.69; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; Syvanen AC, 1999, HUM MUTAT, V13, P1; Turner G, 1996, AM J MED GENET, V64, P196, DOI 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; van Orsouw NJ, 1998, NUCLEIC ACIDS RES, V26, P2398, DOI 10.1093/nar/26.10.2398; vanderLuijt RB, 1997, HUM MUTAT, V9, P7, DOI 10.1002/(SICI)1098-1004(1997)9:1<7::AID-HUMU2>3.0.CO;2-8; Watnick TJ, 1997, HUM MOL GENET, V6, P1473, DOI 10.1093/hmg/6.9.1473; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Youil R, 1996, GENOMICS, V32, P431, DOI 10.1006/geno.1996.0138; [No title captured]	49	29	31	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1999	354			1			SI5	SI10						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437848				2022-12-28	WOS:000081825900003
J	Tanne, JH				Tanne, JH			US National Institutes of Health updates peer review system	BRITISH MEDICAL JOURNAL			English	News Item																		Alberts BM, 1999, SCIENCE, V285, P666, DOI 10.1126/science.285.5428.666	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					336	336		10.1136/bmj.319.7206.336	http://dx.doi.org/10.1136/bmj.319.7206.336			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435943	Green Published			2022-12-28	WOS:000082001700008
J	Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H				Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H			Molecular identification of a eukaryotic, stretch-activated nonselective cation channel	SCIENCE			English	Article							MECHANOSENSITIVE ION-CHANNEL; EPITHELIAL NA+ CHANNEL; BALB/C 3T3 CELLS; PLASMA-MEMBRANE; PROTEIN; CD20; EXPRESSION; INFLUX; GENE	Calcium-permeable, stretch-activated nonselective cation (SA Cat) channels mediate cellular responses to mechanical stimuli. However, genes encoding such channels have not been identified in eukaryotes. The yeast MID1 gene product (Mid1) is required for calcium influx in the yeast Saccharomyces cerevisiae. Functional expression of Midi in Chinese hamster ovary cells conferred sensitivity to mechanical stress that resulted in increases in both calcium conductance and the concentration of cytosolic free calcium. These increases were dependent on the presence of extracellular calcium and were reduced by gadolinium, a blocker of SA Cat channels. Single-channel analyses with cell-attached patches revealed that Midi acts as a calcium-permeable, cation-selective stretch-activated channel with a conductance of 32 picosiemens at 150 millimolar cesium chloride in the pipette. Thus, Midi appears to be a eukaryotic, SA Cat channel.	Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan; Nagoya Univ, Sch Med, Dept Physiol, Aichi 4668550, Japan; Electrotech Lab, Supermol Sci Div, Tsukuba, Ibaraki 3058568, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Cell Biol Lab, Gunma 3718510, Japan	Tokyo Gakugei University; Nagoya University; National Institute of Advanced Industrial Science & Technology (AIST); Gunma University	Iida, H (corresponding author), Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan.	iida@u-gakugei.ac.jp	NARUSE, Keiji/B-1620-2011; Iida, Hidetoshi/AAO-5506-2020; Sato, Chikara/M-7183-2016; Sokabe, Masahiro/I-1565-2012; Kanzaki, Makoto/H-6680-2017	Sato, Chikara/0000-0001-5543-4496; Kanzaki, Makoto/0000-0002-6884-2955; naruse, keiji/0000-0003-4100-6444				Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Drummond HA, 1998, NEURON, V21, P1435, DOI 10.1016/S0896-6273(00)80661-3; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KANZAKI M, UNPUB; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Naruse K, 1998, AM J PHYSIOL-HEART C, V274, pH1532; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; TASAKA Y, UNPUB; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	27	171	178	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					882	886		10.1126/science.285.5429.882	http://dx.doi.org/10.1126/science.285.5429.882			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436155				2022-12-28	WOS:000081860900047
J	Adams, ME				Adams, ME			Hype about glucosamine	LANCET			English	Editorial Material							INSULIN-RESISTANCE; OSTEOARTHRITIS		Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada	University of Calgary	Adams, ME (corresponding author), Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada.							ADAMS ME, 1994, OSTEOARTHR CARTILAGE, P45; Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bassleer C, 1998, OSTEOARTHR CARTILAGE, V6, P427, DOI 10.1053/joca.1998.0146; MALEMUD CJ, 1992, BIOL REGULATION CHON, P295; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MATYAS JR, 1995, ARTHRITIS RHEUM, V38, P420, DOI 10.1002/art.1780380320; McAlindon TE, 1998, ARTHRITIS RHEUM, V41, pS198; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Muller-Fassbender H, 1994, Osteoarthritis Cartilage, V2, P61, DOI 10.1016/S1063-4584(05)80007-X; Noack W, 1994, Osteoarthritis Cartilage, V2, P51, DOI 10.1016/S1063-4584(05)80006-8; POOS MD, 1998, P ASS AM PHYS, V110, P422; *QUACKW, 1999, GLUC ARTHR; REICHELT A, 1994, ARZNEIMITTELFORSCH, V44-1, P75; Roos MD, 1996, AM J PHYSIOL-CELL PH, V270, pC803, DOI 10.1152/ajpcell.1996.270.3.C803; SEMIKAR I, 1986, ARZNEIMITTELFORSGUNG, V36, P729	16	46	48	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					353	354		10.1016/S0140-6736(99)90040-5	http://dx.doi.org/10.1016/S0140-6736(99)90040-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437858				2022-12-28	WOS:000081764900003
J	Hodgkin, P				Hodgkin, P			Keith Hodgkin - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		HODGKIN K, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					323	323		10.1136/bmj.319.7205.323	http://dx.doi.org/10.1136/bmj.319.7205.323			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426766	Green Published			2022-12-28	WOS:000081909100063
J	Gunning, K; Rowan, K				Gunning, K; Rowan, K			ABC of intensive care - Outcome data and scoring systems	BRITISH MEDICAL JOURNAL			English	Article									Addenbrookes Hosp, John Farman Intens Care Unit, Cambridge, England; Intens Care Natl Audit Res Ctr, London, England; UCL, Bloomsbury Inst Intens Care Med, London WC1E 6BT, England; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Intensive Care National Audit & Research Centre; University of London; University College London; University of Edinburgh	Gunning, K (corresponding author), Addenbrookes Hosp, John Farman Intens Care Unit, Cambridge, England.								0	89	96	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					241	244		10.1136/bmj.319.7204.241	http://dx.doi.org/10.1136/bmj.319.7204.241			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417092	Green Published			2022-12-28	WOS:000081720300030
J	Nicod, LP				Nicod, LP			Pirfenidone in idiopathic pulmonary fibrosis	LANCET			English	Editorial Material							LUNG FIBROSIS; PREDNISONE		Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland	University of Geneva	Nicod, LP (corresponding author), Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland.		Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X				Cain WC, 1998, INT J IMMUNOPHARMACO, V20, P685, DOI 10.1016/S0192-0561(98)00042-3; Douglas WW, 1998, AM J RESP CRIT CARE, V158, P220, DOI 10.1164/ajrccm.158.1.9709089; GANESH R, 1999, AM J RESP CRIT CARE, V159, P1061; Iyer SN, 1998, EXP LUNG RES, V24, P119, DOI 10.3109/01902149809046058; Kaneko M, 1998, CLIN EXP IMMUNOL, V113, P72, DOI 10.1046/j.1365-2249.1998.00618.x; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Lee BS, 1998, J CLIN ENDOCR METAB, V83, P219, DOI 10.1210/jc.83.1.219; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; MCANULTY RJ, 1995, EXP NEPHROL, V3, P96; MEIERSYDOW J, 1979, PRAX KLIN PNEUMOL, V33, P680; Nicod LP, 1998, DRUGS, V55, P555, DOI 10.2165/00003495-199855040-00006; RAGHU G, 1991, AM REV RESPIR DIS, V144, P191; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077	13	15	17	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					268	269		10.1016/S0140-6736(99)00178-6	http://dx.doi.org/10.1016/S0140-6736(99)00178-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440298				2022-12-28	WOS:000081646000004
J	Nishimura, D				Nishimura, D			GeneTool 1.0	SCIENCE			English	Software Review									Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	University of Iowa	Nishimura, D (corresponding author), Univ Iowa, Dept Pediat, 440G EMRB, Iowa City, IA 52242 USA.							Basham B, 1999, SCIENCE, V283, P1132, DOI 10.1126/science.283.5405.1132; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687	2	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					355	356		10.1126/science.285.5426.355	http://dx.doi.org/10.1126/science.285.5426.355			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438300				2022-12-28	WOS:000081465900036
J	Serageldin, I				Serageldin, I			Biotechnology and food security in the 21st century	SCIENCE			English	Editorial Material								Biotechnology can contribute to future food security if it benefits sustainable small-farm agriculture in developing countries. Presently, agrobiotechnology research cites ethical, safety, and intellectual property rights issues. Protection of intellectual property rights encourages private sector investment in agrobiotechnology, but in developing countries the needs of smallholder farmers and environmental conservation are unlikely to attract private funds. Public investment will be needed, and new and imaginative public-private collaboration can make the gene revolution beneficial to developing countries. This is crucial for the well-being of today's hungry people and future generations.	World Bank, Consultat Grp Int Agr Res, Washington, DC 20433 USA; World Bank, Special Programs, Washington, DC 20433 USA	The World Bank; The World Bank	Serageldin, I (corresponding author), World Bank, Consultat Grp Int Agr Res, 1818 H St NW, Washington, DC 20433 USA.							BORGSTROM G, 1973, FOOD PEOPLE DILEMMA; *CGIAR, 1998, SHAP CGIARS FUT SUMM, P52; CONWAY G, 1998, DOUBLY GREEN REVOLUT, P44; Eckholm EP, 1976, LOSING GROUND; Hayenga M., 1998, AGBIOFORUM, V1; HAZELL PBR, 1998, AGR ENV PERSPECTIVES; IFPRI, 1995, 2020 VIS FOOD AGR EN; JOHNSON B, 1999, COMMUNICATION   0326; KENDALL H, 1999, BIOTECHNOLOGY BIOSAF, P1; Leisinger K.M., 1995, 2 INT FOOD POL RES I; PINSTRUPANDERSE.PP, 1997, WORLD FOOD SITUATION; Rifkin Jeremy, 1998, BIOTECH CENTURY; SERAGELDIN I, 1997, RURAL WELL BEING VIS, P43; *UN DEV PROGR, 1998, HUM DEV REP 1998, P19; *UN POP DIV, 1999, WORLD POP PROSP 1998; WRIGHT BD, 1996, 19 INT FOOD POL RES; [No title captured]	17	88	106	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					387	389		10.1126/science.285.5426.387	http://dx.doi.org/10.1126/science.285.5426.387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411497				2022-12-28	WOS:000081465900048
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Tolerating differences	SCIENCE			English	Article																		Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					357	358						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438301				2022-12-28	WOS:000081465900038
J	Feher, VA; Cavanagh, J				Feher, VA; Cavanagh, J			Millisecond-timescale motions contribute to the function of the bacterial response regulator protein Spo0F	NATURE			English	Article							N-15 NMR RELAXATION; HIGH-RESOLUTION NMR; BACKBONE DYNAMICS; BACILLUS-SUBTILIS; STAPHYLOCOCCAL NUCLEASE; MOLECULAR RECOGNITION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; DOMAIN; SPECTROSCOPY	Protein backbones and side chains display varying degrees of flexibility, which allows many slightly different but related conformational substates to occur(1). Such fluctuations are known to differ in both timescale and magnitude, from rotation of methyl groups (nanoseconds) to the flipping of buried tyrosine rings (seconds)(2,3), Because many mechanisms for protein function require conformational change, it has been proposed that some of these ground-state fluctuations are related to protein function(4). But exactly which aspects of motion are functionally relevant remains to be determined. Only a few examples so far exist where function can be correlated to structural fluctuations with known magnitude and timescale(5,6). As part of an investigation of the mechanism of action of the Bacillus subtilis response regulator Spo0F, we have explored the relationship between the motional characteristics and protein-protein interactions. Here we use a set of nuclear magnetic resonance N-15 relaxation measurements to determine the relative timescales of Spo0F backbone fluctuations on the picosecond-to-millisecond timescale, We show that regions having motion on the millisecond timescale correlate with residues and surfaces that are known to be critical for protein-protein interactions.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Cavanagh, J (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.	johnc@wadsworth.org						AKKE M, 1994, J MAGN RESON SER B, V104, P298, DOI 10.1006/jmrb.1994.1090; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Gryk MR, 1996, PROTEIN SCI, V5, P1195; Jiang MY, 1997, J BIOL CHEM, V272, P11850, DOI 10.1074/jbc.272.18.11850; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; KAYL E, 1998, NAT STRUCT BIOL, V5, P156; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LEE UK, 1987, B KOR CHEM SOC, V8, P1; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; Tzeng YL, 1998, BIOCHEMISTRY-US, V37, P16538, DOI 10.1021/bi981340o; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7; Wyss DF, 1997, PROTEIN SCI, V6, P534; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	30	196	197	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					289	293		10.1038/22357	http://dx.doi.org/10.1038/22357			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421374				2022-12-28	WOS:000081503800050
J	Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I				Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I			Prevalence of carpal tunnel syndrome in a general population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NERVE-CONDUCTION; WORK DISABILITY	Context Carpal tunnel syndrome (CTS) is a cause of pain, numbness, and tingling in the hands and is an important cause of work disability. Although high prevalence rates of CTS in certain occupations have been reported, little is known about its prevalence in the general population. Objective To estimate the prevalence of CTS in a general population. Design General health mail survey sent in February 1997, inquiring about symptoms of pain, numbness, and tingling in any part of the body, followed 2 months later by clinical examination and nerve conduction testing of responders reporting symptoms in the median nerve distribution in the hands, as well as of a sample of those not reporting these symptoms (controls). Setting A region in southern Sweden with a population of 170 000. Participants A sex- and age-stratified sample of 3000 subjects (age range, 25-74 years) was randomly selected from the general population register and sent the survey, with a response rate of 83% (n = 2466; 46% men). Of the symptomatic responders, 81% underwent clinical examination. Main Outcome Measures Population prevalence rates, calculated as the number of symptomatic responders diagnosed on examination as having clinically certain CTS and/or electrophysiological median neuropathy divided by the total number of responders. Results Of the 2466 responders, 354 reported pain, numbness, and/or tingling in the median nerve distribution in the hands (prevalence, 14.4%; 95% confidence interval [CI], 13.0%-15.8%). On clinical examination, 94 symptomatic subjects were diagnosed as having clinically certain CTS (prevalence, 3.8%; 95% CI, 3.1%-4.6%). Nerve conduction testing showed median neuropathy at the carpal tunnel in 120 symptomatic subjects (prevalence, 4.9%; 95% CI, 4.1%-5.8%), Sixty-six symptomatic subjects had clinically and electrophysiologically confirmed CTS (prevalence, 2.7%; 95% CI, 2.1%-3.4%). Of 125 control subjects clinically examined, electrophysiological median neuropathy was found in 23 (18.4%; 95% CI, 12.0%-26.3%). Conclusion Symptoms of pain, numbness, and tingling in the hands are common in the general population. Based on our data, 1 in 5 symptomatic subjects would be expected to have CTS based on clinical examination and electrophysiologic testing.	Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden; Univ Lund, Lund, Sweden; Univ Lund Hosp, Dept Orthoped, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Clin Neurosci, Div Clin Neurophysiol, S-22185 Lund, Sweden; Malmo Univ, Dept Hlth & Soc, Malmo, Sweden	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Malmo University	Atroshi, I (corresponding author), Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden.		Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				Altman D.G., 1991, PRACTICAL STAT MED R; Bingham RC, 1996, AM J IND MED, V30, P355, DOI 10.1002/(SICI)1097-0274(199609)30:3<355::AID-AJIM15>3.0.CO;2-V; DAWSON DM, 1993, NEW ENGL J MED, V329, P2013, DOI 10.1056/NEJM199312303292707; DEKROM MCTFM, 1992, J CLIN EPIDEMIOL, V45, P373, DOI 10.1016/0895-4356(92)90038-O; Feuerstein M, 1998, J OCCUP ENVIRON MED, V40, P546, DOI 10.1097/00043764-199806000-00007; HAGBERG M, 1992, SCAND J WORK ENV HEA, V18, P337, DOI 10.5271/sjweh.1564; JABLECKI CK, 1993, MUSCLE NERVE, V16, P1392; Katz JN, 1998, AM J IND MED, V33, P543, DOI 10.1002/(SICI)1097-0274(199806)33:6<543::AID-AJIM4>3.0.CO;2-R; KATZ JN, 1990, ANN INTERN MED, V112, P321, DOI 10.7326/0003-4819-112-5-321; KIMURA J, 1989, ELECTRODIAGNOSIS DIS, P105; Rempel D, 1998, AM J PUBLIC HEALTH, V88, P1447, DOI 10.2105/AJPH.88.10.1447; ROSEN I, 1993, SCAND J PLAST RECONS, V27, P95, DOI 10.3109/02844319309079790; ROSENBERG JH, 1993, NEUROLOGY, V43, P2404; Salerno DF, 1998, MUSCLE NERVE, V21, P999, DOI 10.1002/(SICI)1097-4598(199808)21:8<999::AID-MUS3>3.0.CO;2-0; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; *STAT SWED, 1999, OFF STAT SWED POP ST; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Werner RA, 1998, AM J IND MED, V33, P374, DOI 10.1002/(SICI)1097-0274(199804)33:4<374::AID-AJIM7>3.0.CO;2-U; Yassi A, 1997, LANCET, V349, P943, DOI 10.1016/S0140-6736(96)07221-2; 1985, LANCET, V1, P854	21	1074	1133	4	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					153	158		10.1001/jama.282.2.153	http://dx.doi.org/10.1001/jama.282.2.153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411196				2022-12-28	WOS:000081376800032
J	Pantilat, SZ; Alpers, A; Wachter, RM				Pantilat, SZ; Alpers, A; Wachter, RM			A new doctor in the house - Ethical issues in hospitalist systems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; IMPACT	The traditional patient-primary care physician (PCP) relationship provides many ethical protections for patients, including confidentiality, shared medical decision making, and respect for patient autonomy. Hospitalist models, which introduce a purposeful discontinuity of care, threaten these protections and raise certain ethical concerns. We analyze 2 cases that explore ethical issues arising in hospitalist systems and suggest ways to ensure ethical protection for patients. The first case examines how hospitalization can disrupt the patient-PCP relationship and raise ethical issues regarding confidentiality. In the second case, we discuss decision making when the patient's goals and preferences for care change as a result of hospitalization. Effective hospitalist systems provide a model for a trusting patient-physician relationship. Although the hospitalist must take responsibility for inpatient management, the PCP has a key role in addressing important issues in the hospital and providing care after discharge. As hospitalists assume control of inpatient care, they must also provide ethical protections to patients to supplement those currently vested in the patient-PCP relationship. An approach that keeps the patient's best interests foremost, defines a clear role for the PCP, and takes advantage of the expertise and availability of hospitalists will best serve patients and physicians.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Aids Prevent Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pantilat, SZ (corresponding author), Univ Calif San Francisco, Program Med Eth, 521 Parnassus Ave,Suite C-126, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459-06] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P418; Bellet PS, 1999, PEDIATRICS, V103, P473, DOI 10.1542/peds.103.2.473; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LINDENAUER PK, 1997, NEW MED, V1, P245; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1995, RESOLVING ETHICAL DI, P44; Manian FA, 1999, NEW ENGL J MED, V340, P1362, DOI 10.1056/NEJM199904293401712; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MITCHELL C, 1988, BIOETHICS, P63; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	18	41	41	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					171	174		10.1001/jama.282.2.171	http://dx.doi.org/10.1001/jama.282.2.171			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411199				2022-12-28	WOS:000081376800035
J	Rosanio, S; Tocchi, M; Cutler, D; Uretsky, BF; Stouffer, GA; deFilippi, CR; MacInerney, EJ; Runge, SR; Aaron, J; Otero, J; Garg, S; Runge, MS				Rosanio, S; Tocchi, M; Cutler, D; Uretsky, BF; Stouffer, GA; deFilippi, CR; MacInerney, EJ; Runge, SR; Aaron, J; Otero, J; Garg, S; Runge, MS			Queuing for coronary angiography during severe supply-demand mismatch in a US public hospital - Analysis of a waiting list registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; QUALITY-OF-LIFE; CARDIAC-CATHETERIZATION; CONSECUTIVE PATIENTS; ANGINA-PECTORIS; GRAFT-SURGERY; ANGIOPLASTY; REVASCULARIZATION; RISK; CONSEQUENCES	Context Adverse cardiac events have been reported in patients waiting for either coronary surgery or angioplasty. However, data on the risk of adverse events while awaiting coronary angiography are limited, and none are available from a US population. Objective To quantify cardiac outcomes in patients waiting for elective coronary angiography. Design, Setting, and Participants Observational cohort study of 381 adult outpatients (mean [SD] age, 55 [12] years; 64% male; 61% white) on a waiting list for coronary angiography at a US tertiary care public teaching hospital during 1993-1994. Main Outcome Measures Rates of cardiac death, nonfatal myocardial infarction, and hospitalizations for unstable angina or heart failure as a function of amount of time spent on a waiting list. Results Sixty-six patients were dropped from the waiting list but were included in the study analysis. During a mean (SD) follow-up of 8.4 (6.5) months, cardiac death, myocardial infarction, and hospitalization occurred in 6 (1.6%), 4 (1.0%), and 26 (6.8%) patients, respectively. The probability of events was minimal in the first 2 weeks and increased steadily between 3 and 13 weeks. By Cox multivariate analysis, 2 variables independently identified an increased risk of adverse events: a strongly positive treadmill exercise electrocardiogram or positive stress imaging result at referral (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.22-4.16; P=.01) and the use of 2 to 3 anti-ischemic medications (OR, 1.98; 95% CI, 1.19-3.96; P=.04). Among 311 patients who ultimately underwent angiography, those with adverse events had a higher prevalence of coronary disease (96% vs 60%; P<.001), more frequently required revascularization (93% vs 53%; P<.001), and had longer hospital stays (mean [SD], 6.2 [4.3] vs 1.3 [0.7] days; P=.001). Conclusion Our data suggest that in a cohort referred for coronary angiography, delaying the procedure places some patients at risk for death, myocardial infarction, unplanned hospitalization, a longer hospital stay, and, potentially, a poorer prognosis. Waits longer than 2 weeks should be avoided, and patients with strongly positive stress test results and those who require 2 to 3 anti-ischemic medications should be prioritized for early intervention.	Univ Texas, Med Branch, Dept Internal Med, Div Cardiol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Runge, MS (corresponding author), Univ Texas, Med Branch, John Sealy Hosp 5 106, Div Cardiol, 301 Univ Blvd, Galveston, TX 77555 USA.	mrunge@utmb.edu	Stouffer, George/AAK-4763-2021					BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; Bengtson A, 1996, EUR HEART J, V17, P1846; BENGTSON A, 1994, J INTERN MED, V235, P263, DOI 10.1111/j.1365-2796.1994.tb01070.x; BENNEFIELD RL, 1997, CURRENT POPULATIONS, P60; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Califf RM, 1996, J AM COLL CARDIOL, V27, P1007, DOI 10.1016/0735-1097(96)87733-3; CARROLL RJ, 1995, J AM COLL CARDIOL, V25, P557, DOI 10.1016/0735-1097(94)00442-S; CHESTER M, 1995, BRIT HEART J, V73, P216; CONTI CR, 1992, J AM COLL CARDIOL, V19, P1486, DOI 10.1016/0735-1097(92)90608-P; Cox JL, 1996, J AM COLL CARDIOL, V27, P1365, DOI 10.1016/0735-1097(96)00028-9; DEFEYTER PJ, 1994, TXB INTERVENTIONAL C, P274; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P324, DOI 10.1001/jama.272.4.324; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; GLASER WA, 1993, JAMA-J AM MED ASSOC, V270, P980, DOI 10.1001/jama.270.8.980; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; Graves E J, 1991, Vital Health Stat 13, P1; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HIGGINSON LAJ, 1992, CAN MED ASSOC J, V146, P921; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; JOHNSON LW, 1993, CATHETER CARDIO DIAG, V28, P219, DOI 10.1002/ccd.1810280305; KASKI JC, 1995, CIRCULATION, V92, P2058, DOI 10.1161/01.CIR.92.8.2058; Lange RA, 1998, NEW ENGL J MED, V338, P1838, DOI 10.1056/NEJM199806183382509; Morgan CD, 1998, HEART, V79, P345, DOI 10.1136/hrt.79.4.345; MORRIS AL, 1990, MED CARE, V28, P784, DOI 10.1097/00005650-199009000-00008; *NAT ASS PUBL HOSP, 1991, AM SAF NET HOSP FDN, P26; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NAYLOR CD, 1995, LANCET, V346, P1605, DOI 10.1016/S0140-6736(95)91934-1; NWASOKWA ON, 1991, ANN INTERN MED, V114, P1035, DOI 10.7326/0003-4819-114-12-1035; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; Silber S, 1996, HERZ, V21, P389; STRAUSS WE, 1995, CIRCULATION, V92, P1710, DOI 10.1161/01.CIR.92.7.1710; SUTTORP MJ, 1992, EUR HEART J, V13, P238, DOI 10.1093/oxfordjournals.eurheartj.a060153; Teo KKT, 1998, CIRCULATION, V98, pII29; TEOH KH, 1987, J THORAC CARDIOV SUR, V93, P291; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WEISSMAN JS, 1998, J AM COLL CARDIOL, V31, P1474	39	24	24	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					145	152		10.1001/jama.282.2.145	http://dx.doi.org/10.1001/jama.282.2.145			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411195				2022-12-28	WOS:000081376800031
J	Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP				Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP			Early Lung Cancer Action Project: overall design and findings from baseline screening	LANCET			English	Article							SURGICAL-TREATMENT; PULMONARY NODULE; STAGE-I; SURVIVAL; CT	Background The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung cancer. We report the baseline experience. Methods ELCAP has enrolled 1000 symptom-free volunteers, aged 60 years or older, with at least 10 pack years of cigarette smoking and no previous cancer, who were medically fit to undergo thoracic surgery. After a structured interview and informed consent, chest radiographs and low-dose CT were done for each participant. The diagnostic investigation of screen-detected non-calcified pulmonary nodules was guided by ELCAP recommendations, which included short-term high-resolution CT follow-up for the smallest non-calcified nodules. Findings Non-calcified nodules were detected in 233 (23% [95%; CI 21-26]) participants by low-dose CT at baseline, compared with 68 (7% [5-9]) by chest radiography. Malignant disease was detected in 27 (2.7% [1.8-3.8]) by CT and seven (0.7% [0.3-1.3]) by chest radiography, and stage malignant disease in 23 (2.3% [1.5-3.3]) and four (0.4% [0.1-0.9]), respectively. Of the 27 CT-detected cancers, 26 were resectable. Biopsies were done on 28 of the 233 participants with non-calcified nodules; 27 had malignant non-calcified nodules and one had a benign nodule. Another three individuals underwent biopsy against the ELCAP recommendations; all had benign non-calcified nodules. No participant had thoracotomy for a benign nodule. Interpretation low-dose CT can greatly improve the likelihood of detection of small non-calcified nodules, and thus of lung cancer at an earlier and potentially more curable stage. Although false-positive CT results are common. they can be managed with little use of invasive diagnostic procedures.	New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY USA; NYU Med Ctr, New York, NY 10016 USA; McGill Univ, Montreal, PQ, Canada	Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York University; McGill University	Henschke, CI (corresponding author), New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, 525 E 68th St, New York, NY 10021 USA.			McGuinness, Georgeann/0000-0002-5326-9180; naidich, david/0000-0003-3751-5836	NATIONAL CANCER INSTITUTE [R01CA063393] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-63393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUCKSHEE N, 1999, ALA ATS INT C SAN DI; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS VP, 1956, AMER J ROENTGENOL RA, V76, P988; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FLEHINGER BJ, 1993, CANCER, V72, P1573, DOI 10.1002/1097-0142(19930901)72:5<1573::AID-CNCR2820720514>3.0.CO;2-9; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FONTANA RS, 1998, INT C PREV EARL DIAG, P15; HENSCHKE CI, 1994, CLIN IMAG, V18, P6; Inoue K, 1998, J THORAC CARDIOV SUR, V116, P407, DOI 10.1016/S0022-5223(98)70006-6; KANEKO M, 1998, INT C PREV EARL DIAG, P144; KANEKO M, IN PRESS CANCER; LAIRD AK, 1965, BRIT J CANCER, V19, P278, DOI 10.1038/bjc.1965.32; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LIBBY DM, 1995, AM J MED, V99, P491, DOI 10.1016/S0002-9343(99)80225-3; MELAMED MR, 1987, SURG CLIN N AM, V67, P909; MIETTINEN OS, IN PRESS CANCER; MIETTINEN OS, 1998, INT C PREV EARL DIAG, P98; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAIDICH DP, 1990, RADIOLOGY, V175, P729, DOI 10.1148/radiology.175.3.2343122; NATHAN MH, 1962, RADIOLOGY, V79, P221, DOI 10.1148/79.2.221; NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L; Shah R, 1996, J CARDIOVASC SURG, V37, P169; SOBUE T, 1992, CANCER, V69, P685, DOI 10.1002/1097-0142(19920201)69:3<685::AID-CNCR2820690315>3.0.CO;2-W; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Yankelevitz DF, 1997, CLIN IMAG, V21, P107, DOI 10.1016/S0899-7071(96)00011-3; YANKELEVITZ DF, IN PRESS RADIOLOGY; ZERHOUNI EA, 1986, RADIOLOGY, V160, P319, DOI 10.1148/radiology.160.2.3726107	29	1825	1911	2	120	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					99	105		10.1016/S0140-6736(99)06093-6	http://dx.doi.org/10.1016/S0140-6736(99)06093-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408484	hybrid			2022-12-28	WOS:000081377100011
J	Wang, J; Zheng, LX; Lobito, A; Chan, FKM; Dale, J; Sneller, M; Yao, X; Puck, JM; Straus, SE; Lenardo, MJ				Wang, J; Zheng, LX; Lobito, A; Chan, FKM; Dale, J; Sneller, M; Yao, X; Puck, JM; Straus, SE; Lenardo, MJ			Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FAS GENE-MUTATIONS; FADD-DEPENDENT APOPTOSIS; MATURE T-CELLS; NF-KAPPA-B; INTERLEUKIN-1-BETA-CONVERTING ENZYME; TNF RECEPTOR; LIGAND TRAIL; APO-2 LIGAND; IN-VIVO	Caspases are cysteine proteases that mediate programmed cell death in phylogenetically diverse multicellular organisms. We report here two kindreds with autoimmune lymphoproliferative syndrome (ALPS) type II, characterized by abnormal lymphocyte and dendritic cell homeostasis and immune regulatory defects, that harbor independent missense mutations in Caspase 10. These encode amino acid substitutions that decrease caspase activity and interfere with death receptor-induced apoptosis, particularly that stimulated by Pas ligand and TRAIL. These results provide evidence that inherited nonlethal caspase abnormalities cause pleiotropic apoptosis defects underlying autoimmunity in ALPS type II.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.	lenardo@nih.gov	Chan, Francis/ABB-1895-2021; Chan, Francis Ka-Ming/E-9647-2014	Chan, Francis Ka-Ming/0000-0002-4803-8353; Wang, Jin/0000-0002-3116-0838; Wang, Jin/0000-0002-7882-1699	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000769, Z01AI000732, ZIAAI000732, ZIAAI000769] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Dianzani U, 1997, BLOOD, V89, P2871, DOI 10.1182/blood.V89.8.2871; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FINER MH, 1994, BLOOD, V83, P43; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jackson CE, 1999, AM J HUM GENET, V64, P1002, DOI 10.1086/302333; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasahara Y, 1998, INT IMMUNOL, V10, P195, DOI 10.1093/intimm/10.2.195; Kotze MJ, 1997, CLIN GENET, V51, P394; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Lenardo MJ, 1996, J EXP MED, V183, P721, DOI 10.1084/jem.183.3.721; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Thomas WD, 1998, J IMMUNOL, V161, P2195; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAIHNAW AK, 1999, J CLIN INVEST, V103, P355; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang J, 1997, J EXP MED, V186, P1171, DOI 10.1084/jem.186.7.1171; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	65	473	490	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					47	58		10.1016/S0092-8674(00)80605-4	http://dx.doi.org/10.1016/S0092-8674(00)80605-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412980	Bronze			2022-12-28	WOS:000081451000007
J	Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ				Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ			Improved auditory spatial tuning in blind humans	NATURE			English	Article							CONGENITALLY DEAF ADULTS; SIGHTED SUBJECTS; VISUAL-CORTEX; PLASTICITY; POTENTIALS; ACTIVATION; ATTENTION	Despite reports of improved auditory discrimination capabilities in blind humans(1-3) and visually deprived animals(4), there is no general agreement as to the nature or pervasiveness of such compensatory sensory enhancements(5). Neuroimaging studies have pointed out differences in cerebral organization between blind and sighted humans(6-12), but the relationship between these altered cortical activation patterns and auditory sensory acuity remains unclear. Here we compare behavioural and electrophysiological indices of spatial tuning within central and peripheral auditory space in congenitally blind and normally sighted but blindfolded adults to test the hypothesis (raised by earlier studies of the effects of auditory deprivation on visual processing(13,14)) that the effects of visual deprivation might be more pronounced for processing peripheral sounds. We find that blind participants displayed localization abilities that were superior to those of sighted controls, but only when attending to sounds in peripheral auditory space. Electrophysiological recordings obtained at the same time revealed sharper tuning of early spatial attention mechanisms in the blind subjects. Differences in the scalp distribution of brain electrical activity between the two groups suggest a compensatory reorganization of brain areas in the blind that may contribute to the improved spatial resolution for peripheral sound sources.	Univ Marburg, Dept Psychol, D-35037 Marburg, Germany; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; Univ Oregon, Dept Psychol, Eugene, OR 97403 USA	Philipps University Marburg; University of California System; University of California San Diego; University of Konstanz; University of Oregon	Roder, B (corresponding author), Univ Marburg, Dept Psychol, Gutenbergstr 18, D-35037 Marburg, Germany.		Roeder, Brigitte/A-4652-2009					Ashmead DH, 1998, PERCEPTION, V27, P105, DOI 10.1068/p270105; Brainard MS, 1998, J NEUROSCI, V18, P3929; Clark V.P., 1994, HUMAN BRAIN MAPPING, V2, P170, DOI [10.1002/hbm.460020306, DOI 10.1002/HBM.460020306]; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Downing C. J., 1985, ATTENTION PERFORM, P171; Hillyard Steven A., 1995, P665; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; HYVARINEN J, 1981, EXP BRAIN RES, V42, P1; Knudsen EI, 1998, SCIENCE, V279, P1531, DOI 10.1126/science.279.5356.1531; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Lessard N, 1998, NATURE, V395, P278, DOI 10.1038/26228; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MILLER L, 1992, J VISUAL IMPAIR BLIN, V86, P206; MILLS AW, 1972, FDN MODERN AUDITORY, P303; MONDOR TA, 1995, J EXP PSYCHOL HUMAN, V21, P387, DOI 10.1037/0096-1523.21.2.387; MORRONGIELLO BA, 1994, DEV INTERSENSORY PER, P235; MUCHNIK C, 1991, SCAND AUDIOL, V20, P19, DOI 10.3109/01050399109070785; Naatanen R., 2018, ATTENTION BRAIN FUNC; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; NEVILLE HJ, 1983, BRAIN RES, V266, P127, DOI 10.1016/0006-8993(83)91314-8; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; RAUSCHECKER JP, 1983, EXP BRAIN RES, V50, P63; RICE C, 1970, AM F BLIND RES B, V22, P1, DOI DOI 10.3758/S13414-011-0160-4; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Roder B, 1997, PSYCHOPHYSIOLOGY, V34, P292, DOI 10.1111/j.1469-8986.1997.tb02400.x; ROSLER F, 1993, COGNITIVE BRAIN RES, V1, P145, DOI 10.1016/0926-6410(93)90022-W; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Teder-Salejarvi WA, 1998, PERCEPT PSYCHOPHYS, V60, P1228, DOI 10.3758/BF03206172; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7	30	457	463	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					162	166		10.1038/22106	http://dx.doi.org/10.1038/22106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	214JM	10408442				2022-12-28	WOS:000081324900053
J	Zhang, ZD; Green, BR; Cavalier-Smith, T				Zhang, ZD; Green, BR; Cavalier-Smith, T			Single gene circles in dinoflagellate chloroplast genomes	NATURE			English	Article							DNA-REPLICATION; SEQUENCE; RUBISCO; ORIGIN	Photosynthetic dinoflagellates are important aquatic primary producers and notorious causes of toxic 'red tides: Typical dinoflagellate chloroplasts differ from all other plastids in having a combination of three envelope membranes' and peridinin-chlorophyll ale light-harvesting pigments'. Despite evidence of a dinoflagellete satellite DNA containing chloroplast genes(3), previous attempts to obtain chloroplast gene sequences have been uniformly unsuccessful. Here we show that the dinoflagellate chloroplast DNA genome structure is unique. Complete sequences of chloroplast ribosomal RNA genes and seven chloroplast protein genes from the dinoflagellate Heterocapsa triquetra reveal that each is located alone on a separate minicircular chromosome:'one gene-one circle: The genes are the most divergent known from chloroplast genomes. Each circle has an unusual tripartite non-coding region (putative replicon origin), which is highly conserved among the nine circles through extensive gene conversion, but is very divergent between species. Several other dinoflagellate species have minicircular chloroplast genes, indicating that this type of genomic organization may have evolved in ancestral peridinean dinoflagellates. Phylogenetic analysis indicates that dinoflagellate chloroplasts are related to chromistan and red algal chloroplasts and supports their origin by Secondary symbiogenesis(4-6)	Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada	Canadian Institute for Advanced Research (CIFAR); University of British Columbia	Green, BR (corresponding author), Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada.	brgreen@interchange.ubc.ca	Green, Beverley R./AAJ-5199-2021	Green, Beverley R./0000-0002-4021-9387				Backert S, 1997, TRENDS PLANT SCI, V2, P477, DOI 10.1016/S1360-1385(97)01148-5; BOCZAR BA, 1991, PLANT PHYSIOL, V97, P613, DOI 10.1104/pp.97.2.613; BOORE JL, 1994, GENETICS, V138, P423; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CAVALIERSMITH T, 1995, BIODIVERSITY EVOLUTI, P75; DODGE J D, 1975, Phycologia, V14, P253, DOI 10.2216/i0031-8884-14-4-253.1; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; JACOBS JD, 1992, MOL GEN GENET, V233, P302, DOI 10.1007/BF00587592; JEFFREY SW, 1975, J PHYCOL, V11, P374, DOI 10.1111/j.1529-8817.1975.tb02799.x; La Claire JW, 1998, CURR GENET, V34, P204, DOI 10.1007/s002940050387; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; MORSE D, 1995, SCIENCE, V268, P1622, DOI 10.1126/science.7777861; Palmer J.D., 1998, MOL SYSTEMATICS PLAN, P375, DOI [10.1007/978-1-4615-5419-6_13, DOI 10.1007/978-1-4615-5419-6_13]; Rowan R, 1996, PLANT CELL, V8, P539, DOI 10.1105/tpc.8.3.539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saunders GW, 1997, PLANT SYST EVOL, P237; SCHLUNEGGER B, 1984, CURR GENET, V8, P629, DOI 10.1007/BF00395709; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WU M, 1986, P NATL ACAD SCI USA, V83, P6761, DOI 10.1073/pnas.83.18.6761	25	267	288	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					155	159		10.1038/22099	http://dx.doi.org/10.1038/22099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408440				2022-12-28	WOS:000081324900051
J	Motulsky, AG				Motulsky, AG			If I had a gene test, what would I have and who would I tell?	LANCET			English	Editorial Material							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; POPULATION; MUTATIONS; RISKS		Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Motulsky, AG (corresponding author), Univ Washington, Dept Med, Box 356723, Seattle, WA 98195 USA.							Baron H, 1996, NAT BIOTECHNOL, V14, P1279, DOI 10.1038/nbt1096-1279; Bernstein T, 1994, RADON RENTAL HOUSING; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P95, DOI 10.1006/bcmd.1997.0125; BOTHWELL TH, 1995, METABOLIC MOL BASES; Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182; BURKE W, 1998, JAMA-J AM MED ASSOC, V280, P173; Devilee P, 1999, AM J HUM GENET, V64, P943, DOI 10.1086/302350; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Gryfe R, 1999, AM J HUM GENET, V64, P378, DOI 10.1086/302262; Hartge P, 1999, AM J HUM GENET, V64, P963, DOI 10.1086/302320; HERRERA VLM, 1994, J HYPERTENS, V12, pS47; Levy-Lahad E, 1998, J GERIATR PSYCH NEUR, V11, P42, DOI 10.1177/089198879801100202; Lynch HT, 1998, AM J HUM GENET, V62, P1288, DOI 10.1086/301890; MOTULSKY AG, 1992, GENETIC BASIS COMMON, P150; Poirier J, 1999, J PSYCHIATR NEUROSCI, V24, P147; Powell SM, 1998, METH MOL B, V92, P251; Reilly PR, 1998, AM J HUM GENET, V63, P682, DOI 10.1086/302028; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; Sachse C, 1997, AM J HUM GENET, V60, P284; Salomon O, 1999, ARTERIOSCL THROM VAS, V19, P511, DOI 10.1161/01.ATV.19.3.511; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804	24	17	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI35	SI37						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437855				2022-12-28	WOS:000081825900010
J	Jennett, B				Jennett, B			Brain stem death defines death in law	BMJ-BRITISH MEDICAL JOURNAL			English	Article									So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Jennett, B (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.							BLACK D, 1995, J ROY COLL PHYS LOND, V29, P381; *HLTH DEP GREAT BR, 1983, CAD ORG TRANSPL COD; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; SPRUNG CL, 1995, CRIT CARE MED, V23, P618, DOI 10.1097/00003246-199504000-00004	4	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1755	1755						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428564				2022-12-28	WOS:000081216900041
J	Stampfer, M; Rimm, E				Stampfer, M; Rimm, E			Alcohol and other dietary factors may be important - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; NUT CONSUMPTION; RISK; FOLATE; WOMEN; FIBER; MEN; PREVENTION; COHORT		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Stampfer, M (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.	meir.stampfer@channing.harvard.edu						DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; HU FB, IN PRESS AM J CLIN N; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; Liu S, 1998, FASEB J, V12, pA260; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Parodi PW, 1997, MED HYPOTHESES, V49, P313, DOI 10.1016/S0306-9877(97)90197-3; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472	14	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	1999	318	7196					1476	1477						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419293				2022-12-28	WOS:000080668200029
J	Forero, R; McLellan, L; Rissel, C; Bauman, A				Forero, R; McLellan, L; Rissel, C; Bauman, A			Bullying behaviour and psychosocial health among school students in New South Wales, Australia: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							VICTIM PROBLEMS; CHILDREN; MIDDLE; ASSOCIATION; DIMENSIONS; DEPRESSION	Objectives To examine the prevalence of bullying behaviours in schoolchildren and the association of bullying with psychological and psychosomatic health. Design Cross sectional survey. Setting Government and non-government schools in New South Wales, Australia. Participants 3918 schoolchildren attending year 6 (mean age 11.88 years), year 8 (13.96), and year 10 (15.97) classes from 115 schools. Main outcome measures Self reported bullying behaviours and psychological and psychosomatic symptoms. Results Almost a quarter of students (23.7%) bullied other students, 12.7% were bullied, 21.5% were both bullied and bullied others on one or more occasions in the last term of school, and 42.4% were neither bullied nor bullied others. More boys than girls reported bullying others and being victims of bullying: Bullying behaviour was associated with increased psychosomatic symptoms. Bullies tended to be unhappy with school; students who were bullied tended to like school and to feel alone. Students who both bullied and were bullied had the greatest number of psychological and psychosomatic symptoms. Conclusions Being bullied seems to be widespread in schools in New South Wales and is associated with increased psychosomatic symptoms and poor mental health. Health practitioners evaluating students with common psychological and psychosomatic symptoms should consider bullying and the student's school environment as potential causes.	Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Newtown, NSW 2042, Australia; Liverpool Hosp, Hlth Promot Unit, Liverpool, NSW 2070, Australia; Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia	Liverpool Hospital; University of New South Wales Sydney	Rissel, C (corresponding author), Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Newtown, NSW 2042, Australia.		Rissel, Chris/AAH-2423-2019; Forero, Roberto/I-2164-2019	Rissel, Chris/0000-0002-2156-8581				Bauman A., 1998, HLTH BEHAV NEW S WAL; BOULTON MJ, 1994, BRIT J DEV PSYCHOL, V12, P315, DOI 10.1111/j.2044-835X.1994.tb00637.x; BOULTON MJ, 1992, BRIT J EDUC PSYCHOL, V62, P73, DOI 10.1111/j.2044-8279.1992.tb01000.x; DAWKINS J, 1995, BRIT MED J, V310, P274, DOI 10.1136/bmj.310.6975.274; Eltinge J., 1997, STATA STAT B, V40, P39; Jessor R., 1977, PROBLEM BEHAV PSYCHO; King A., 1996, WHO REGIONAL PUBLICA, V69; Mynard H, 1997, BRIT J EDUC PSYCHOL, V67, P51, DOI 10.1111/j.2044-8279.1997.tb01226.x; NEARY A, 1994, PERS INDIV DIFFER, V16, P183, DOI 10.1016/0191-8869(94)90122-8; NUTBEAM D, 1993, J PAEDIAT CHILD H S1, V29, P25; Oliver R., 1994, SCH COUNSELOR, V41, P199; OLWEUS D, 1994, J CHILD PSYCHOL PSYC, V35, P1171, DOI 10.1111/j.1469-7610.1994.tb01229.x; Olweus D., 1993, BULLYING SCH; RIGBY K, 1993, J SOC PSYCHOL, V133, P33, DOI 10.1080/00224545.1993.9712116; RIGBY K, 1969, BULLYING AUSTR SCH W; Rigby K., 1997, CHILDREN AUSTR, V22, P28; RIGBY K, 1998, YOUTH STUDIES AUSTR, V17, P13; Salmon G, 1998, BRIT MED J, V317, P924; Smith PK, 1994, SCH BULLYING INSIGHT; WHITNEY I, 1993, EDUC RES, V35, P3, DOI 10.1080/0013188930350101; Williams K, 1996, BRIT MED J, V313, P17, DOI 10.1136/bmj.313.7048.17; Zubrick S. R., 1997, W AUSTR CHILD HLTH S	22	243	252	2	43	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					344	348		10.1136/bmj.319.7206.344	http://dx.doi.org/10.1136/bmj.319.7206.344			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	226CA	10435953	Bronze, Green Published			2022-12-28	WOS:000082001700016
J	Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD				Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD			Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3	SCIENCE			English	Article							MITOTIC CHROMOSOME CONDENSATION; PROTEIN; TRANSCRIPTION; PP90(RSK); KINASES; SIGNAL; CBP; MAP; ACETYLTRANSFERASE; HYPERACETYLATION	During the immediate-early response of mammalian cells to mitogens, histone H3 is rapidly and transiently phosphorylated by one or more unidentified kinases. Rsk-2, a member of the pp90(rsk) family of kinases implicated in growth control, was required for epidermal growth factor (EGF)-stimulated phosphorylation of H3. RSK-2 mutations in humans are Linked to Coffin-Lowry syndrome (CLS). Fibroblasts derived from a CLS patient failed to exhibit EGF-stimulated phosphorylation of H3, although H3 was phosphorylated during mitosis. Introduction of the wild-type RSK-2 gene restored EGF-stimulated phosphorylation of H3 in CLS cells. In addition, disruption of the RSK-2 gene by homologous recombination in murine embryonic stem cells abolished EGF-stimulated phosphorylation of H3. H3 appears to be a direct or indirect target of Rsk-2, suggesting that chromatin remodeling might contribute to mitogen-activated protein kinase-regulated gene expression.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Strasbourg, France; Univ Virginia, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Virginia	Sassone-Corsi, P (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Strasbourg, France.		Monaco, Lucia/A-4031-2010; Sassone-Corsi, Paolo/H-6182-2011		NIGMS NIH HHS [GM40922] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALLIS CD, UNPUB; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHADEE DN, IN PRESS J BIOL CHEM; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; SASSONECORSI P, UNPUB; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wolffe AP, 1997, BIOCHEM SOC T, V25, P354, DOI 10.1042/bst0250354; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	29	405	418	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					886	891		10.1126/science.285.5429.886	http://dx.doi.org/10.1126/science.285.5429.886			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436156				2022-12-28	WOS:000081860900048
J	Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW				Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW			Functional characterization of the S-cerevisiae genome by gene deletion and parallel analysis	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST GENOME; DNA-SEQUENCE; PROTEIN; IDENTIFICATION; DISRUPTION; EXPRESSION; LOCALIZATION; REDUCTASE	The functions of many open reading frames (ORFs) identified in genome-sequencing projects are unknown. New, whole-genome approaches are required to systematically determine their function. A total of 6925 Saccharomyces cerevisiae strains were constructed, by a high-throughput strategy, each with a precise deletion of one of 2026 ORFs (more than one-third of the ORFs in the genome). Of the deleted ORFs, 17 percent were essential for viability in rich medium. The phenotypes of more than 500 deletion strains were assayed in parallel. Of the deletion strains, 40 percent showed quantitative growth defects in either rich or minimal medium.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Rosetta Inpharmat Inc, Kirkland, WA 98034 USA; Free Univ Brussels, Lab Physiol Cellulaire & Genet Levures, Brussels, Belgium; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Salamanca, Dipartimento Microbiol & Genet, Edificio Dept 323, CSIC, E-37007 Salamanca, Spain; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4003 Basel, Switzerland; ULB, IRMW, B-1070 Brussels, Belgium; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Affymetrix, Santa Clara, CA 95051 USA; Inst Microbiol, D-40225 Dusseldorf, Germany; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium	Stanford University; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Yale University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Johns Hopkins University; McGill University; University of Basel; Universite Libre de Bruxelles; Universite Catholique Louvain; Affymetrix; Washington University (WUSTL); KU Leuven	Davis, RW (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	dbowe@cmgm.stanford.edu	Johnston, Mark/R-6156-2019; BENITO, ROCIO/B-4271-2017; Lucau-Danila, Anca/AAE-7674-2021; Revuelta, Jose L/C-2324-2012; Winzeler, Elizabeth/AAP-6752-2020; André, Bruno/D-1725-2010; Revuelta, Jose Luis/ABG-1502-2020; Zhang, Ning/F-1387-2014; Johnston, Mark/K-3543-2019; Storms, Reginald/B-2405-2013	BENITO, ROCIO/0000-0001-9781-4198; Revuelta, Jose L/0000-0001-7838-5308; Winzeler, Elizabeth/0000-0002-4049-2113; Revuelta, Jose Luis/0000-0001-7838-5308; Johnston, Mark/0000-0002-4932-7229; Wysocki, Robert/0000-0002-3274-2629; Menard, Patrice/0000-0001-8844-3727; Snyder, Michael/0000-0003-0784-7987; Gentalen, Erik/0000-0002-7982-2431; LUCAU-DANILA, Anca/0000-0002-9379-6241	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001633, R01HG001627] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01627, HG01633, HG00185-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baganz F, 1998, YEAST, V14, P1417, DOI 10.1002/(SICI)1097-0061(199811)14:15<1417::AID-YEA334>3.0.CO;2-N; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brachmann CB, 1998, YEAST, V14, P115; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CHOW TYK, 1992, J CELL SCI, V101, P709; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; KASAHARA S, 1994, J BACTERIOL, V176, P1488, DOI 10.1128/jb.176.5.1488-1499.1994; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; NIEDENTHAL R, IN PRESS YEAST; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Rad MR, 1997, YEAST, V13, P281; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Storms RK, 1997, GENOME, V40, P151, DOI 10.1139/g97-022; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	37	3050	3192	3	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					901	906		10.1126/science.285.5429.901	http://dx.doi.org/10.1126/science.285.5429.901			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436161				2022-12-28	WOS:000081860900053
J	Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M				Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M		IHIT Study Grp	Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; carcinoma, hepatocellular; interferon; liver cirrhosis; alanine aminotransferase	POLYMERASE CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; NON-B-HEPATITIS; VIRUS-RNA; NON-A; SUSTAINED RESPONSE; LIVER-DISEASE; ALFA THERAPY; DOUBLE-BLIND; EFFICACY	Background: Previous studies on the effect of interferon therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for hepatocellular carcinoma. Objective: To evaluate the effect of interferon therapy on incidence of hepatocellular carcinoma, adjusting for risk factors, including the degree of liver fibrosis. Design: Retrospective cohort study. Setting: Seven university hospitals and one regional core hospital in Japan. Patients: 2890 patients with chronic hepatitis C who had undergone liver biopsy since 1986. Of these patients, 2400 received interferon and 490 were untreated. Measurements: The degree of liver fibrosis was assessed from stage F0 (no fibrosis) to stage F4 (cirrhosis). Response to interferon was determined virologically and biochemically. Screening for development of hepatocellular carcinoma was performed periodically during an average follow-up of 4.3 years. Effect of interferon therapy on the risk for hepatocellular carcinoma was analyzed by using Cox proportional hazards regression. Results: Hepatocellular carcinoma developed in 89 interferon-treated patients and in 59 untreated patients. Among untreated patients, the annual incidence of hepatocellular carcinoma increased with the degree of liver fibrosis, from 0.5% among patients with stage F0 or F1 fibrosis to 7.9% among patients with stage F4 fibrosis. The cumulative incidence in treated and untreated patients differed significantly for patients with stage F2 fibrosis (P = 0.0128) and for those with stage F3 fibrosis (P = 0.0011). In multivariate analysis, interferon therapy was associated with a reduced risk for hepatocellular carcinoma (adjusted risk ratio, 0.516 [95% CI, 0.358 to 0.742]; P < 0.001), especially among patients with sustained virologic response (risk ratio, 0.197 [CI, 0.099 to 0.392]), among those with persistently normal serum alanine aminotransferase levels (risk ratio, 0.197 [CI, 0.104 to 0.375]), and among those with alanine aminotransferase levels less than two times the upper limit of normal (risk ratio, 0.358 [CI, 0.206 to 0.622]). Conclusions: Interferon therapy significantly reduces the risk for hepatocellular carcinoma, especially among virologic or biochemical responders.	Univ Tokyo, Dept Gastroenterol, Tokyo 1138655, Japan; Univ Tokyo, Dept Gastroenterol, Tokyo 113, Japan; Nihon Univ, Dept Internal Med 3, Tokyo 173, Japan; Kurume Univ, Dept Internal Med 2, Fukuoka 830, Japan; Nagasaki Chuo Natl Hosp, Dept Clin Res, Nagasaki 856, Japan; Kumamoto Univ, Dept Internal Med 3, Kumamoto 860, Japan; Osaka City Univ, Dept Internal Med 3, Osaka 545, Japan; Chiba Univ, Dept Internal Med 1, Chiba 260, Japan; Kawasaki Med Sch, Ctr Liver, Okayama 700, Japan	University of Tokyo; University of Tokyo; Nihon University; Kurume University; Kumamoto University; Osaka Metropolitan University; Chiba University; Kawasaki Medical School	Yoshida, H (corresponding author), Univ Tokyo, Dept Gastroenterol, Hongo 7-3-1, Tokyo 1138655, Japan.	yoshida-2im@h.u-tokyo.ac.jp						Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KATO Y, 1994, CANCER, V74, P2234, DOI 10.1002/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6; KAWANO SI, 1994, J GASTROEN HEPATOL, V9, P217, DOI 10.1111/j.1440-1746.1994.tb01712.x; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OMATA M, 1991, DIGEST DIS SCI, V36, P1217, DOI 10.1007/BF01307512; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1996, HEPATOLOGY, V24, P778; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiratori Y, 1997, GASTROENTEROLOGY, V113, P558, DOI 10.1053/gast.1997.v113.pm9247476; Shiratori Y, 1996, J GASTROEN HEPATOL, V11, P705, DOI 10.1111/j.1440-1746.1996.tb00318.x; Silini E, 1996, GASTROENTEROLOGY, V111, P199, DOI 10.1053/gast.1996.v111.pm8698200; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; TAKANO S, 1995, HEPATOLOGY, V21, P650; TAKEDA T, 1993, GASTROENTEROL JPN, V28, P104, DOI 10.1007/BF02989218; TANAKA E, 1995, J GASTROEN HEPATOL, V10, P538, DOI 10.1111/j.1440-1746.1995.tb01344.x; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; Tarao K, 1997, CANCER, V79, P688, DOI 10.1002/(SICI)1097-0142(19970215)79:4<688::AID-CNCR5>3.0.CO;2-A; YAMADA G, 1993, GUT, V34, pS133, DOI 10.1136/gut.34.2_Suppl.S133; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; YOKOSUKA O, 1995, GUT, V37, P721, DOI 10.1136/gut.37.5.721; Yoshida H, 1996, RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, P543	36	900	931	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					174	+		10.7326/0003-4819-131-3-199908030-00003	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428733				2022-12-28	WOS:000081788700002
J	Turner, NJ; Haward, RA; Mulley, GP; Selby, PJ				Turner, NJ; Haward, RA; Mulley, GP; Selby, PJ			Cancer in old age - is it inadequately investigated and treated?	BRITISH MEDICAL JOURNAL			English	Article							CELL LUNG-CANCER; BREAST-CANCER; ELDERLY PATIENTS; THERAPY; CARE; RADIOTHERAPY; TOXICITY; MEDICINE; TRIALS; PEOPLE		St James Univ Hosp, Dept Med Elderly, Leeds LS9 7TF, W Yorkshire, England; Cookridge Hosp, Yorkshire Canc Org, Ctr Canc Res, Res Sch Med, Leeds LS16 6QB, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Ctr Canc Res,Res Sch Med, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; Cookridge Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Turner, NJ (corresponding author), St James Univ Hosp, Dept Med Elderly, Leeds LS9 7TF, W Yorkshire, England.							*AG, 1995, NOT MY AG WHY PRES B; Balducci L, 1997, EUR J CANCER, V33, P1720, DOI 10.1016/S0959-8049(97)00297-9; BALDUCCI L, 1992, GERIATRIC ONCOLOGY, P169; BEGG CB, 1983, CANCER, V52, P1986, DOI 10.1002/1097-0142(19831201)52:11<1986::AID-CNCR2820521103>3.0.CO;2-7; Bufalari A, 1996, BRIT J SURG, V83, P1783, DOI 10.1002/bjs.1800831239; Busch E, 1996, CANCER, V78, P101, DOI 10.1002/(SICI)1097-0142(19960701)78:1<101::AID-CNCR15>3.0.CO;2-3; Calman K., 1995, POLICY FRAMEWORK COM; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Cleary JF, 1997, CANCER, V80, P1335, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1335::AID-CNCR21>3.3.CO;2-5; Coebergh JWW, 1996, EUR J CANCER, V32A, P569, DOI 10.1016/0959-8049(96)00001-9; EVANS WK, 1995, AM J CLIN ONCOL-CANC, V18, P149, DOI 10.1097/00000421-199504000-00011; Farrow DC, 1996, J AM GERIATR SOC, V44, P559, DOI 10.1111/j.1532-5415.1996.tb01442.x; Fentiman IS, 1996, ANN ONCOL, V7, P657; FLETCHER A, 1990, LANCET, V335, P97, DOI 10.1016/0140-6736(90)90552-G; FORMAN D, 1996, YORKSHIRE CANC REGIS; GIVEN CW, 1994, CANCER, V74, P2128, DOI 10.1002/1097-0142(19941001)74:7+<2128::AID-CNCR2820741721>3.0.CO;2-J; GOODWIN JS, 1993, CANCER-AM CANCER SOC, V72, P594, DOI 10.1002/1097-0142(19930715)72:2<594::AID-CNCR2820720243>3.0.CO;2-#; GUADAGNOLI E, 1990, ARCH INTERN MED, V150, P1485, DOI 10.1001/archinte.150.7.1485; Haigney E, 1997, BRIT MED J, V315, P1058, DOI 10.1136/bmj.315.7115.1058; Hazzard WR, 1997, J AM GERIATR SOC, V45, P638, DOI 10.1111/j.1532-5415.1997.tb03102.x; Mead GE, 1997, J AM GERIATR SOC, V45, P1409, DOI 10.1111/j.1532-5415.1997.tb02948.x; Monfardini S, 1996, EUR J CANCER, V32A, P12, DOI 10.1016/0959-8049(95)00580-3; Morandi U, 1997, EUR J CARDIO-THORAC, V11, P432, DOI 10.1016/S1010-7940(96)01084-6; NEWCOMB PA, 1993, J NATL CANCER I, V85, P1580, DOI 10.1093/jnci/85.19.1580; Olmi Patrizia, 1997, Rays (Rome), V22, P53; PEARLMAN RA, 1988, J GERONTOL, V43, pM25, DOI 10.1093/geronj/43.2.M25; Pignon T, 1997, RADIOTHER ONCOL, V42, P107, DOI 10.1016/S0167-8140(96)01861-0; Pignon T, 1998, RADIOTHER ONCOL, V46, P239, DOI 10.1016/S0167-8140(97)00188-6; RIES LAG, 1993, CANCER-AM CANCER SOC, V71, P524; ROBERTSON JFR, 1988, BRIT MED J, V297, P511, DOI 10.1136/bmj.297.6647.511; ROSTOM AY, 1987, INT J RADIAT ONCOL, V13, P551, DOI 10.1016/0360-3016(87)90070-8; SAINSBURY R, 1995, BRIT J CANCER, V71, P1275, DOI 10.1038/bjc.1995.246; SAMET J, 1986, JAMA-J AM MED ASSOC, V255, P3385, DOI 10.1001/jama.255.24.3385; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8; SHANK WA, 1992, J AM GERIATR SOC, V40, P151, DOI 10.1111/j.1532-5415.1992.tb01936.x; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; VanDijck JAAM, 1996, INT J CANCER, V66, P727, DOI 10.1002/(SICI)1097-0215(19960611)66:6<727::AID-IJC3>3.0.CO;2-1; WEINRICH SP, 1986, CANC NURS, V9, P30; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; YELLEN SB, 1994, J NATL CANCER I, V86, P1766, DOI 10.1093/jnci/86.23.1766	40	91	91	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					309	312		10.1136/bmj.319.7205.309	http://dx.doi.org/10.1136/bmj.319.7205.309			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426753	Green Published			2022-12-28	WOS:000081909100036
J	Berger, AK; Schulman, KA; Gersh, BJ; Pirzada, S; Breall, JA; Johnson, AE; Every, NR				Berger, AK; Schulman, KA; Gersh, BJ; Pirzada, S; Breall, JA; Johnson, AE; Every, NR			Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; THERAPY; EXPERIENCE; HOSPITALS; MEDICARE; VOLUME	Context Despite evidence from randomized trials that, compared with early thrombolysis, primary percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction (AMI) reduces mortality in middle-aged adults, whether elderly patients with AMI are more likely to benefit from PTCA or early thrombolysis is not known. Objective To determine survival after primary PTCA vs thrombolysis in elderly patients, Design The Cooperative Cardiovascular Project, a retrospective cohort study using data from medical charts and administrative files. Setting Acute care hospitals in the United States. Patients A total of 20 683 Medicare beneficiaries, who arrived within 12 hours of the onset of symptoms, were admitted between January 1994 and February 1996 with a principal discharge diagnosis of AMI, and were eligible for reperfusion therapy. Main Outcome Measures Thirty-day and 1-year survival. Results A total of 80 356 eligible patients had an AMI at hospital arrival and met the inclusion criteria, of whom 23.2% received thrombolysis and 2.5% underwent primary PTCA within 6 hours of hospital arrival, Patients undergoing primary PTCA had lower 30-day (8.7% vs 11.9%, P=.001) and 1-year mortality (14.4% vs 17.6%, P=.001). After adjusting for baseline cardiac risk factors and admission and hospital characteristics, primary PTCA was associated with improved 30-day (hazard ratio [HR] of death, 0.74; 95% confidence interval [CI], 0.63-0.88) and 1-year (HR, 0.88; 95% CI, 0.73-0.94) survival. The benefits of primary coronary angioplasty persisted when stratified by hospitals' AMI volume and the presence of on-site angiography. In patients classified as ideal for reperfusion therapy, the mortality benefit of primary PTCA was not significant at 1-year follow-up (HR, 0.92; 95% CI, 0.78-1.08). Conclusion In elderly patients who present with AMI, primary PTCA is associated with modestly lower short- and long-term mortality rates, In the subgroup of patients who were classified as ideal for reperfusion therapy, the observed benefit of primary PTCA was no longer significant.	Georgetown Univ, Med Ctr, Clin Econ Res Unit, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Inst Cardiovasc Sci, Div Cardiol, Washington, DC 20007 USA; Delmarva Fdn Med Care Inc, Easton, MD USA; Univ Washington, NW Hlth Serv Res & Dev Field Program, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98195 USA; Univ Washington, Div Cardiol, Seattle, WA 98195 USA; Univ Washington, Cardiovasc Outcomes Res Ctr, Seattle, WA 98195 USA	Georgetown University; Georgetown University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Schulman, KA (corresponding author), Georgetown Univ, Med Ctr, Clin Econ Res Unit, 2233 Wisconsin Ave NW,Suite 440, Washington, DC 20007 USA.	schulmak@gunet.georgetown.edu						*AM HOSP ASS, 1994, ANN SURV HOSP; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Betriu A, 1997, NEW ENGL J MED, V336, P1621; COX DR, 1972, J R STAT SOC B, V34, P187; Ellis SG, 1997, CIRCULATION, V95, P2479, DOI 10.1161/01.CIR.95.11.2479; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; HOCHMAN JS, 1998, TXB CARDIOVASCULAR M, P437; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Kahn HA, 1989, STAT METHODS EPIDEMI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MARC, 1998, JAMA-J AM MED ASSOC, V279, P1351; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; *SAS I, 1996, SAS SYST WIND COMP P; Stone Gregg W., 1993, Journal of the American College of Cardiology, V21, p330A; Thiemann DR, 1997, CIRCULATION, V96, P3146; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; VOGEL RA, 1994, CLIN CARDIOL, V17, P354, DOI 10.1002/clc.4960170703; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093	23	130	137	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					341	348		10.1001/jama.282.4.341	http://dx.doi.org/10.1001/jama.282.4.341			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432031				2022-12-28	WOS:000081596800029
J	Kondrashov, AS; Kondrashov, FA				Kondrashov, AS; Kondrashov, FA			Interactions among quantitative traits in the course of sympatric speciation	NATURE			English	Article							SEXUAL SELECTION; LAKE-VICTORIA; MODEL; EVOLUTION; CICHLIDS; BARBS	Sympatric speciation, the origin of two or more species from a single local population, has almost certainly been involved in formation of several species flocks(1-4), and may be fairly common in nature(5). The most straightforward scenario for sympatric speciation requires disruptive selection favouring two substantially different phenotypes, and consists of the evolution of reproductive isolation between them followed by the elimination of all intermediate phenotypes(6). Here we use the hypergeometric phenotypic model(7-10) to show that sympatric speciation is possible even when fitness and mate choice depend on different quantitative traits, so that speciation must involve formation of covariance between these traits. The increase in the number of variable loci affecting fitness facilitates sympatric speciation, whereas the increase in the number of variable loci affecting mate choice has the opposite effect. These predictions may enable more cases of sympatric speciation to be identified.	Simons Rock Coll, Great Barrington, MA 01230 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Kondrashov, FA (corresponding author), Simons Rock Coll, 84 Alford Rd, Great Barrington, MA 01230 USA.		Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694				[Anonymous], 1861, ORIGIN SPECIES MEANS; AXELROD HR, 1996, MOST COMPLETE COLORE; BARTON NH, 1992, EVOLUTION, V46, P551, DOI 10.1111/j.1558-5646.1992.tb02058.x; Berrebi P, 1998, BIOL J LINN SOC, V64, P369; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Galis F, 1998, TRENDS ECOL EVOL, V13, P1, DOI 10.1016/S0169-5347(97)01239-1; Johnson TC, 1996, SCIENCE, V273, P1091, DOI 10.1126/science.273.5278.1091; KARLIN S, 1975, THEOR POPUL BIOL, V7, P364, DOI 10.1016/0040-5809(75)90025-8; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; KONDRASHOV AS, 1986, BIOL J LINN SOC, V27, P201, DOI 10.1111/j.1095-8312.1986.tb01734.x; KONDRASHOV AS, 1984, GENETIKA+, V20, P408; Kondrashov AS, 1998, ENDLESS FORMS, P90; Lewontin RC, 1966, SYST ZOOL, V15, P141, DOI DOI 10.2307/2411632; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mina MV, 1996, J FISH BIOL, V48, P383, DOI 10.1111/j.1095-8649.1996.tb01435.x; RICE WR, 1984, EVOLUTION, V38, P1251, DOI 10.1111/j.1558-5646.1984.tb05647.x; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Ritchie MG, 1998, ENDLESS FORMS, P291; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; Shpak M, 1999, EVOLUTION, V53, P600, DOI 10.1111/j.1558-5646.1999.tb03794.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; van Doorn GS, 1998, P ROY SOC B-BIOL SCI, V265, P1915, DOI 10.1098/rspb.1998.0520; Wallace A.R., 1989, DARWINISM	27	418	431	3	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					351	354		10.1038/22514	http://dx.doi.org/10.1038/22514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432111				2022-12-28	WOS:000081590000046
J	Ghose, RP; Hall, PM; Bravo, EL				Ghose, RP; Hall, PM; Bravo, EL			Medical management of aldosterone-producing adenomas	ANNALS OF INTERNAL MEDICINE			English	Article						aldosterone; adenoma; hypertension; potassium; aldosteronism	DIAGNOSIS	Background: No data are available on the long-term medical management of aldosterone-producing adenomas. Objective: To demonstrate the efficacy of medical management of aldosterone-producing adenomas in terms of blood pressure and serum potassium concentration and to discuss morbidity associated with medical management. Design: Retrospective cohort study. Setting: Large tertiary care referral center. Patients: 24 patients with documented aldosterone-producing adenomas who were treated medically for at least 5 years. Measurements: Aldosterone excretion rate, plasma renin activity, and size and location of adenomas (by computed tomography). Blood pressure and serum electrolytes were measured at the time of diagnosis and last follow-up. Results: From the time of diagnosis to the time of last follow-up, systolic blood pressure decreased from 175 mm Hg to 129 mm Hg (95% CI for difference, 37.1 to 53.8 mm Hg) and diastolic blood pressure decreased from 106 mm Hg to 79 mm Hg (CI for difference, 20.8 to 33.9 mm Hg). Serum potassium concentration increased from 3.0 mmol/L to 4.3 mmol/L (CI for difference, 1.1 to 1.5 mmol/L). Conclusions: Medical management of aldosterone-producing adenomas is a viable option for controlling blood pressure and serum potassium concentration.	Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hall, PM (corresponding author), Cleveland Clin Fdn, Dept Hypertens & Nephrol, 9500 Euclid Ave,Desk A101, Cleveland, OH 44195 USA.	hallpm@ccf.org						BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1993, CLEV CLIN J MED, V60, P379; BRAVO EL, 1988, HYPERTENSION, V11, P207; CONN JN, 1965, J LAB CLIN MED, V45, P3; LITCHFIELD WR, 1995, ENDOCRIN METAB CLIN, V24, P593, DOI 10.1016/S0889-8529(18)30033-1; Lo CY, 1996, ANN SURG, V224, P125, DOI 10.1097/00000658-199608000-00003; Quarmby CJ, 1995, S AFR MED J, V85, P1353; YOUNG WF, 1990, MAYO CLIN PROC, V65, P96, DOI 10.1016/S0025-6196(12)62114-4	8	88	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					105	+		10.7326/0003-4819-131-2-199907200-00005	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419425				2022-12-28	WOS:000081509700004
J	Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A				Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A			Generation of a widespread Drosophila inversion by a transposable element	SCIENCE			English	Article							EVOLUTIONARY HISTORY; MOLECULAR CHARACTERIZATION; CHROMOSOME REARRANGEMENTS; BODY-SIZE; MELANOGASTER; BUZZATII; POPULATIONS; HOBO; RECOMBINATION; BREAKPOINTS	Although polymorphic inversions in Drosophila are very common, the origin of these chromosomal rearrangements is unclear. The breakpoints of the cosmopolitan inversion 2j of D. buzzatii were cloned and sequenced. Both breakpoints contain large insertions corresponding to a transposable element. It appears that the two pairs of target site duplications generated upon insertion were exchanged during the inversion event, and that the inversion arose by ectopic recombination between two copies of the transposon that were in opposite orientations. This is apparently the mechanism by which transposable elements generate natural inversions in Drosophila.	Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	Autonomous University of Barcelona; University of Chicago	Caceres, M (corresponding author), Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.		Barbadilla, Antonio/A-6915-2017; Ruiz, Alfredo/ABH-2402-2020; Cáceres, Mario/A-6379-2009; jose, ranz/A-5432-2008	Barbadilla, Antonio/0000-0002-0374-1475; Cáceres, Mario/0000-0002-7736-3251; 				[Anonymous], 1992, DROSOPHILA INVERSION; BARKER JSF, 1994, GENETICA, V92, P165, DOI 10.1007/BF00132535; Betran E, 1998, EVOLUTION, V52, P144, DOI [10.2307/2410929, 10.1111/j.1558-5646.1998.tb05147.x]; BRAND S, 1993, NUCLEIC ACIDS RES, V21, P3699, DOI 10.1093/nar/21.16.3699; BUSSEAU I, 1989, MOL GEN GENET, V218, P222, DOI 10.1007/BF00331272; CAPY P, 1998, DYNAMICS EVOLUTION T; CIRERA S, 1995, GENETICS, V139, P321; Daveran-Mingot ML, 1998, J BACTERIOL, V180, P4834, DOI 10.1128/JB.180.18.4834-4842.1998; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Eggleston WB, 1996, GENETICS, V144, P647; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FONTDEVILA A, 1981, EVOLUTION, V35, P148, DOI 10.1111/j.1558-5646.1981.tb04867.x; HASSON E, 1995, J EVOLUTION BIOL, V8, P369, DOI 10.1046/j.1420-9101.1995.8030369.x; KOMODA Y, 1991, GENETICS, V129, P639; Ladeveze V, 1998, P ROY SOC B-BIOL SCI, V265, P1157, DOI 10.1098/rspb.1998.0412; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LIM JK, 1994, BIOESSAYS, V16, P269, DOI 10.1002/bies.950160410; LYTTLE TW, 1992, GENETICA, V86, P113, DOI 10.1007/BF00133715; MARIN I, 1995, MOL GEN GENET, V248, P423, DOI 10.1007/BF02191642; Mathiopoulos KD, 1998, P NATL ACAD SCI USA, V95, P12444, DOI 10.1073/pnas.95.21.12444; MONTGOMERY EA, 1991, GENETICS, V129, P1085; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; Nei M., 1987, MOL EVOLUTIONARY GEN; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; Powell J. R., 1997, PROGR PROSPECTS EVOL; Ranz JM, 1999, CHROMOSOMA, V108, P32; Ranz JM, 1997, GENETICS, V145, P281; ROEDER GS, 1983, MOBILE GENETIC ELEME, P299; Rost A.K., 1995, QUANTITATION MRNA PO, P93; RUIZ A, 1991, GENETICS, V128, P739; RUIZ A, 1993, HEREDITY, V70, P582, DOI 10.1038/hdy.1993.85; Ruiz A., 1984, Genetica Iberica, V36, P13; SAWRUK E, 1990, FEBS LETT, V273, P177, DOI 10.1016/0014-5793(90)81078-3; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; STRECK RD, 1986, EMBO J, V5, P3615, DOI 10.1002/j.1460-2075.1986.tb04690.x; TAKASUISHIKAWA E, 1992, MOL GEN GENET, V232, P17, DOI 10.1007/BF00299132; WESLEY CS, 1994, P NATL ACAD SCI USA, V91, P3132, DOI 10.1073/pnas.91.8.3132; WOJTAS KM, 1992, GENETICS, V132, P789	44	163	166	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					415	418		10.1126/science.285.5426.415	http://dx.doi.org/10.1126/science.285.5426.415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411506				2022-12-28	WOS:000081465900057
J	Blendon, RJ; Benson, JM; Brodie, M; Altman, DE; James, M; Hugick, L				Blendon, RJ; Benson, JM; Brodie, M; Altman, DE; James, M; Hugick, L			Voters and health care in the 1998 election	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Henry J Kaiser Family Fdn, Menlo Park, CA USA; Princeton Survey Res Associates, Princeton, NJ USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.							Blendon RJ, 1997, JAMA-J AM MED ASSOC, V277, P1253, DOI 10.1001/jama.277.15.1253; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V268, P3371, DOI 10.1001/jama.268.23.3371; BLENDON RJ, 1995, JAMA-J AM MED ASSOC, V273, P671, DOI 10.1001/jama.273.8.671; *HJ KAIS FAM FDN H, 1995, L HARR ASS POLL; *HJ KAIS FAM FDN H, 1998, ICR POLL; *HJ KAIS FAM FDN S, 1998, PRINC SURV RES ASS P; *L HARR ASS, 1999, HARR POLL; *L HARR ASS, 1998, HARR POLL; LADD EC, 1999, AM POLLS 1998; *PEW RES CTR PEOPL, 1998, PRINC SURV RES ASS P; *QW AYR ASS, 1998, AM ASS HLTH PLANS PO; *ROP CTR PUBL OP R, 1998, ZOGB INT POLL; *ROP CTR PUBL OP R, 1998, WIRTHL WORLDW POLL; *ROP CTR PUBL OP R, 1998, VOT NEWS SERV NAT EL; *ROP CTR PUBL OP R, 1992, VOT RES SURV NAT EL; WALL STREET J   0725; 1998, WASHINGTON POST 0729; 1998, WASHINGTON POST 0709; 1998, TIME            0630; 1998, NEWSWEEK        0917; 1998, WALL STREET J   0618	21	13	13	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					189	194		10.1001/jama.282.2.189	http://dx.doi.org/10.1001/jama.282.2.189			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411204				2022-12-28	WOS:000081376800041
J	Newstead, CG				Newstead, CG			Cancer risk in patients on dialysis	LANCET			English	Editorial Material							STAGE RENAL-DISEASE; TRANSPLANTATION; CARCINOMA		St James Univ Hosp, Renal Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Newstead, CG (corresponding author), St James Univ Hosp, Renal Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.							Bukvic D, 1996, Srp Arh Celok Lek, V124 Suppl 1, P181; CHANTREL, 1999, NEPHROL DIAL TRANSPL, V14, P129; Chertow GM, 1996, ARCH INTERN MED, V156, P1345, DOI 10.1001/archinte.156.12.1345; Curtis J J, 1998, J Am Soc Nephrol, V9, pS137; Kliem V, 1996, TRANSPLANT INT, V9, P231, DOI 10.1111/j.1432-2277.1996.tb00885.x; Levine E, 1996, RADIOL CLIN N AM, V34, P947; Newstead CG, 1998, LANCET, V351, P610, DOI 10.1016/S0140-6736(98)22009-5; RAINE AEG, 1992, NEPHROL DIAL TRANSPL, V7, P7; SMITH PK, 1989, DRUGS KIDNEY, P1; Swindle P, 1998, BRIT J UROL, V81, P229; TAYLOR JS, 1972, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1972.tb106534.x; Vamvakas S, 1997, SCHWEIZ MED WSCHR, V127, P597	12	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					90	91		10.1016/S0140-6736(99)00207-X	http://dx.doi.org/10.1016/S0140-6736(99)00207-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408481				2022-12-28	WOS:000081377100007
J	Thomeer, M; Van Bleyenbergh, P; Nemery, B; Demedts, M				Thomeer, M; Van Bleyenbergh, P; Nemery, B; Demedts, M			A breathless accountant who blew up balloons	LANCET			English	Article							TALC		Univ Hosp Gasthuisberg, Div Pulm Dis, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Demedts, M (corresponding author), UZ Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.		Thomeer, Michiel/AAK-7772-2020; Nemery, Benoit/D-1224-2013; Nemery, Benoit/N-3155-2019	Thomeer, Michiel/0000-0001-5627-0323; Nemery, Benoit/0000-0003-0571-4689				*AM C GOV IND HYG, 1997, THRESH LIM VAL CHEM; FARBER HW, 1982, AM REV RESPIR DIS, V125, P258; Gysbrechts C, 1998, EUR RESPIR J, V11, P1412, DOI 10.1183/09031936.98.11061412; JONES RN, 1994, OCCUPATIONAL LUNG DI, P536	4	6	6	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					124	124		10.1016/S0140-6736(99)03184-0	http://dx.doi.org/10.1016/S0140-6736(99)03184-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408489				2022-12-28	WOS:000081377100016
J	Chinnery, PF; Turnbull, DM				Chinnery, PF; Turnbull, DM			Mitochondrial DNA and disease	LANCET			English	Article							HEREDITARY OPTIC NEUROPATHY; MATERNAL INHERITANCE; SKELETAL-MUSCLE; MUTATION LOAD; MELAS; MTDNA; ENCEPHALOMYOPATHY; THERAPY; MERRF		Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Turnbull, DM (corresponding author), Newcastle Univ, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	D.M.Turnbull@ncl.ac.uk		Chinnery, Patrick/0000-0002-7065-6617	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CHEN X, 1995, AM J HUM GENET, V57, P239; Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889; Chinnery PF, 1997, LANCET, V350, P560, DOI 10.1016/S0140-6736(97)05005-8; Chinnery PF, 1999, J MED GENET, V36, P425; Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559; Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713; Chinnery PF, 1998, J INHERIT METAB DIS, V21, P321, DOI 10.1023/A:1005357221101; Chinnery PF, 1998, AM J HUM GENET, V63, P1908, DOI 10.1086/302157; Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222; Dahl HHM, 1998, AM J HUM GENET, V63, P1594, DOI 10.1086/302169; DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883; Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HARDING AE, 1995, AM J HUM GENET, V57, P77; Howell N, 1997, J BIOENERG BIOMEMBR, V29, P165, DOI 10.1023/A:1022690030664; Howell N, 1999, INT REV CYTOL, V186, P49; JOHNSON MA, 1996, HDB MUSCLE DIS; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Maassen JA, 1996, DIABETOLOGIA, V39, P375; Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; POULTON J, 1998, AM J HUM GENET, V2, P52; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; SERVIDEI S, 1999, NEUROMUSCULAR DISORD, V9, P15; Shitara H, 1998, GENETICS, V148, P851; Shoffner JM, 1996, LANCET, V348, P1283, DOI 10.1016/S0140-6736(96)09138-6; Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047; Taivassalo T, 1997, NEUROLOGY, V48, P28003; Taylor RW, 1997, J BIOENERG BIOMEMBR, V29, P195, DOI 10.1023/A:1022646215643; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; WALLACE DC, 1995, AM J HUM GENET, V57, P201; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WHITE SL, IN PRESS AM J HUM GE	38	59	61	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1999	354			1			SI17	SI21						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437851				2022-12-28	WOS:000081825900006
J	Drickamer, MA				Drickamer, MA			Commentary: Honesty is the best policy	BRITISH MEDICAL JOURNAL			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06504 USA	Yale University	Drickamer, MA (corresponding author), Yale Univ, Sch Med, 20 York St, New Haven, CT 06504 USA.							Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1618	1618						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428555				2022-12-28	WOS:000080913100040
J	James, D; Driver, L				James, D; Driver, L			Ethnic and sex differences in selection for admission to Nottingham University Medical School	BRITISH MEDICAL JOURNAL			English	Article							STUDENTS; APPLICANTS		Queens Med Ctr, Fac Med, Nottingham NG7 2UH, England	University of Nottingham	James, D (corresponding author), Queens Med Ctr, Fac Med, Nottingham NG7 2UH, England.							COLLIER J, 1986, MED EDUC, V20, P86, DOI 10.1111/j.1365-2923.1986.tb01052.x; McManus IC, 1998, BRIT MED J, V317, P1111; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; MCMANUS IC, 1986, BRIT MED J, V293, P124, DOI 10.1136/bmj.293.6539.124; Powis D, 1998, BRIT MED J, V317, P1149	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					351	352		10.1136/bmj.319.7206.351	http://dx.doi.org/10.1136/bmj.319.7206.351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435955	Green Published, Bronze			2022-12-28	WOS:000082001700018
J	Walker, MF; Gladman, JRF; Lincoln, NB; Siemonsma, P; Whiteley, T				Walker, MF; Gladman, JRF; Lincoln, NB; Siemonsma, P; Whiteley, T			Occupational therapy for stroke patients not admitted to hospital: a randomised controlled trial	LANCET			English	Article							REHABILITATION; SCALE	Background Patients who have a stroke are not always admitted to hospital, and 22-60% remain in the community, frequently without coordinated rehabilitation. We aimed to assess the efficacy of an occupational therapy intervention for patients with stroke who were not admitted to hospital. Methods In this single-blind randomised controlled trial, consecutive stroke patients on a UK community register in Nottingham and Derbyshire were allocated randomly to up to 5 months of occupational therapy at home or to no intervention (control group) 1 month after their stroke. The aim of the occupational therapy was to encourage independence in personal and instrumental activities of daily living. Patients were assessed on outcome measures at baseline (before randomisation) and at 6 months. The primary outcome measure was the score on the extended activities of daily living (EADL) scale at 6 months. Other outcome measures included the Barthel index, the general health questionnaire 28, the carer strain index, and the London handicap scale. All assessments were done by an independent assessor who was unaware of treatment allocation. The analysis included only data from completed questionnaires. Findings 185 patients were included: 94 in the occupational therapy group and 91 in the control group. 22 patients were not assessed at 6 months. At follow-up, patients who had occupational therapy had significantly higher median scores than the controls on: the EADL scale (16 vs 12, p<0.01, estimated difference 3 [95% CI 1 to 41); the Barthel index (20 vs 18, p<0.01, difference 1, [0-1]); the carer strain index (1 vs 3, p<0.05, difference 1[0 to 2]); and the London handicap scale (76 vs 65, p<0.05, difference 7, [0 3 to 13.5]). There were no significant differences on the general health questionnaire between the patient or carer. Interpretation Occupational therapy significantly reduced disability and handicap in patients with stroke who were not admitted to hospital.	City Hosp NHS Trust, Div Stroke Med, Nottingham NG5 1PB, England; Univ Nottingham, Dept Psychol, Nottingham NG7 2RD, England; Univ Nottingham, Div Rehabil & Ageing, Nottingham NG7 2RD, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham	Walker, MF (corresponding author), City Hosp NHS Trust, Div Stroke Med, Nottingham NG5 1PB, England.		Lincoln, Nadina B/B-9149-2009; Gladman, John/M-7429-2015	Walker, Marion/0000-0002-3534-591X; Gladman, John/0000-0002-8506-7786				BAMFORD J, 1986, BRIT MED J, V292, P1329; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Drummond A, 1995, CLIN REHABIL, V9, P283, DOI DOI 10.1177/026921559500900402; GLADMAN JRF, 1993, AGE AGEING, V22, P419, DOI 10.1093/ageing/22.6.419; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HARWOOD RH, 1994, J NEUROL NEUROSUR PS, V57, P825, DOI 10.1136/jnnp.57.7.825; HEWER RL, 1976, P 9 PFIZ INT S ED CH; Juby LC, 1996, CEREBROVASC DIS, V6, P106, DOI 10.1159/000108005; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lincoln NB, 1998, DISABIL REHABIL, V20, P457, DOI 10.3109/09638289809166110; LINCOLN NB, 1976, PHYSIOTHERAPY, V65, P48; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; MAHONEY F I, 1965, Md State Med J, V14, P61; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; Noad R, 1998, BR J THER REHABIL, V5, P578; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Siemonsma PC, 1997, CLIN REHABIL, V11, P273, DOI 10.1177/026921559701100402; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; WOLFE CDA, 1993, J EPIDEMIOL COMMUN H, V47, P144, DOI 10.1136/jech.47.2.144	22	111	112	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					278	280		10.1016/S0140-6736(98)11128-5	http://dx.doi.org/10.1016/S0140-6736(98)11128-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440303				2022-12-28	WOS:000081646000009
J	Seder, RA; Gurunathan, S				Seder, RA; Gurunathan, S			DNA vaccines - Designer vaccines for the 21st Century	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LYMPHOCYTES		NIAID, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476	5	42	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					277	278		10.1056/NEJM199907223410410	http://dx.doi.org/10.1056/NEJM199907223410410			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413742				2022-12-28	WOS:000081528800010
J	Poulin, JF; Sekaly, RP				Poulin, JF; Sekaly, RP			Function of the thymus in HIV-infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Clin Res Inst Montreal, Immunol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Poulin, JF (corresponding author), Clin Res Inst Montreal, Immunol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FRANCIS IR, 1985, AM J ROENTGENOL, V145, P249, DOI 10.2214/ajr.145.2.249; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; PICKER LJ, 1993, J IMMUNOL, V150, P1105; STEINMANN GG, 1986, HUMAN THYMUS HISTOPA, P43; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	7	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					219	219		10.1001/jama.282.3.219	http://dx.doi.org/10.1001/jama.282.3.219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422975				2022-12-28	WOS:000081504400002
J	Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P				Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P			Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse	NATURE			English	Article							PRECURSOR PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; IN-VIVO; PRESENILIN-1; DEPOSITION; PEPTIDE	Amyloid-beta peptide (A beta) seems to have a central role in the neuropathology of Alzheimer's disease (AD)(1). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes(2,3). Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (A beta(42))(4-8), which is the predominant form found in the amyloid plaques of Alzheimer's disease(9,10). The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner(11,12). In the present study, transgenic animals were immunized with A beta(42), either before the onset of AD-type neuropathologies (at 6 weeks of age) or at an older age (11 months), when amyloid-beta deposition and several of the subsequent neuropathological changes were well established. We report that immunization of the young animals essentially prevented the development of beta-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-beta may be effective in preventing and treating Alzheimer's disease.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Schenk, D (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; Hyman BT, 1998, ARCH NEUROL-CHICAGO, V55, P1174, DOI 10.1001/archneur.55.9.1174; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; Lippa CF, 1998, LANCET, V352, P1117, DOI 10.1016/S0140-6736(05)79757-9; McGeer EG, 1997, MOVEMENT DISORD, V12, P855, DOI 10.1002/mds.870120604; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016	16	2596	2986	3	322	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					173	177		10.1038/22124	http://dx.doi.org/10.1038/22124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408445				2022-12-28	WOS:000081324900056
J	Aguzzi, A; Brandner, S				Aguzzi, A; Brandner, S			The genetics of prions - a contradiction in terms?	LANCET			English	Article							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; GERSTMANN-STRAUSSLER SYNDROME; TRANSGENIC MICE; PRP GENE; CELLULAR PRP; PROTEIN GENE; SCRAPIE; VARIANT; BSE		Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8001 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Aguzzi, A (corresponding author), Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, Schmelzbergstr 12, CH-8001 Zurich, Switzerland.		Brandner, Sebastian/J-4562-2014; Aguzzi, Adriano/A-3351-2008	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 1996, NATURE, V383, P666, DOI 10.1038/383666a0; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BRUCE ME, 1985, J NEUROPATH EXP NEUR, V44, P285, DOI 10.1097/00005072-198505000-00006; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARP RI, 1986, INTERVIROLOGY, V26, P85, DOI 10.1159/000149685; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAPLANCHE JL, 1990, NUCLEIC ACIDS RES, V18, P6745, DOI 10.1093/nar/18.22.6745; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Mabbott NA, 1998, IMMUNOL TODAY, V19, P201, DOI 10.1016/S0167-5699(98)01253-5; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Moore RC, 1998, NAT GENET, V18, P118, DOI 10.1038/ng0298-118; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, NUCLEIC ACIDS RES, V18, P3103, DOI 10.1093/nar/18.10.3103; OWEN F, 1990, AM J HUM GENET, V46, P1215; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; Scott MR, 1997, P NATL ACAD SCI USA, V94, P14279, DOI 10.1073/pnas.94.26.14279; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Weissmann C, 1997, CURR OPIN NEUROBIOL, V7, P695, DOI 10.1016/S0959-4388(97)80091-8; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; WILL R, 1999, LANCET, V353, P9157	45	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1999	354			1			SI22	SI25						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437852				2022-12-28	WOS:000081825900007
J	Rubins, HB; Robins, SJ; Collins, D; Fye, CL; Anderson, JW; Elam, MB; Faas, FH; Linares, E; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J				Rubins, HB; Robins, SJ; Collins, D; Fye, CL; Anderson, JW; Elam, MB; Faas, FH; Linares, E; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J		Vet Affairs High-Density Lipoprotein Chole	Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY DISEASE; RISK-FACTORS; HYPERCHOLESTEROLEMIC PATIENTS; CARDIOVASCULAR-DISEASE; CLINICAL IMPLICATIONS; INTERVENTION TRIAL; HDL CHOLESTEROL; FOLLOW-UP; PRAVASTATIN; MORTALITY	Background Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose primary lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol. Methods We conducted a double-blind trial comparing gemfibrozil (1200 mg per clay) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. The primary study outcome was nonfatal myocardial infarction or death from coronary causes. Results The median follow-up was 5.1 years. At one year, the mean HDL cholesterol level was 6 percent higher, the mean triglyceride level was 31 percent lower, and the mean total cholesterol level was 4 percent lower in the gemfibrozil group than in the placebo group. LDL cholesterol levels did not differ significantly between the groups. A primary event occurred in 275 of the 1267 patients assigned to placebo (21.7 percent) and in 219 of the 1264 patients assigned to gemfibrozil (17.3 percent). The overall reduction in the risk of an event was 4.4 percentage points, and the reduction in relative risk was 22 percent (95 percent confidence interval, 7 to 35 percent; P=0.006). We observed a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, and stroke (P<0.001). There were no significant differences in the rates of coronary revascularization, hospitalization for unstable angina, death from any cause, and cancer. Conclusions Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level. The findings suggest that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels. (N Engl J Med 1999;341:410-8.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Sect Gen Internal Med 111O, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Dept Vet Affairs, Cooperat Studies Program, Coordinating Ctr, West Haven, CT USA; Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA; Vet Affairs Med Ctr, Med Serv, Lexington, KY USA; Vet Affairs Med Ctr, Med Serv, Memphis, TN USA; Vet Affairs Med Ctr, Med Serv, Little Rock, AR USA; Vet Affairs Med Ctr, Med Serv, San Juan, PR USA; Tufts Univ, Sch Med, Lipid Res Lab, Boston, MA 02111 USA; Vet Affairs Med Ctr, Med Serv, Milwaukee, WI USA; Stat Collaborat, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rubins, HB (corresponding author), Vet Affairs Med Ctr, Sect Gen Internal Med 111O, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA.	bloom013@tc.umn.edu		bloomfield, hanna/0000-0002-0756-7064; Robins, Sander/0000-0002-3735-8415				BHATNAGAR D, 1992, ATHEROSCLEROSIS, V92, P49, DOI 10.1016/0021-9150(92)90009-6; COX DR, 1972, J R STAT SOC B, V34, P187; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENEST JJ, 1991, AM J CARDIOL, V67, P1185, DOI 10.1016/0002-9149(91)90924-A; Ginsberg HN, 1997, ANN INTERN MED, V126, P912, DOI 10.7326/0003-4819-126-11-199706010-00012; Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Grundy SM, 1998, CIRCULATION, V97, P1436; Grundy SM, 1997, CIRCULATION, V95, P1, DOI 10.1161/01.CIR.95.1.1; Hill SA, 1997, CLIN BIOCHEM, V30, P517, DOI 10.1016/S0009-9120(97)00098-2; HUTTUNEN JK, 1994, J INTERN MED, V235, P31, DOI 10.1111/j.1365-2796.1994.tb01029.x; Iwane MK, 1999, J CLIN EPIDEMIOL, V52, P685, DOI 10.1016/S0895-4356(99)00031-1; LAKATOS E, 1986, CONTROL CLIN TRIALS, V7, P189, DOI 10.1016/0197-2456(86)90047-4; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Miller DB, 1997, ARCH INTERN MED, V157, P2045, DOI 10.1001/archinte.157.18.2045; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; Prineas R., 1982, MINNESOTA CODE MANUA; Rubins HB, 1996, AM J CARDIOL, V78, P572, DOI 10.1016/S0002-9149(96)00369-4; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; RUBINS HB, 1993, AM J CARDIOL, V71, P45, DOI 10.1016/0002-9149(93)90708-K; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schaefer EJ, 1996, ATHEROSCLEROSIS, V127, P113, DOI 10.1016/S0021-9150(96)05941-2; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; YUAN JN, 1994, ATHEROSCLEROSIS, V110, P1, DOI 10.1016/0021-9150(94)90062-0; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	37	2468	2609	1	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1999	341	6					410	418		10.1056/NEJM199908053410604	http://dx.doi.org/10.1056/NEJM199908053410604			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223UN	10438259				2022-12-28	WOS:000081860100004
J	Beecham, L				Beecham, L			Junior doctors rebut government claims	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					324	324						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426767				2022-12-28	WOS:000081909100067
J	Iranpour, R; Stenstrom, MK; Tchobanoglous, G; Miller, D; Wright, J; Vossoughi, M				Iranpour, R; Stenstrom, MK; Tchobanoglous, G; Miller, D; Wright, J; Vossoughi, M			Environmental engineering: Energy value of replacing waste disposal with resource recovery	SCIENCE			English	Review							WATER RECLAMATION; ULTRAVIOLET DISINFECTION; MEMBRANE AERATION; HYDRODYNAMICS; PERFORMANCE; CALIFORNIA; SCALE	Although in the past, environmental engineering has been primarily concerned with waste disposal, the focus of the field is now shifting toward viewing wastes as potential resources. Because reclamation usually consumes Less energy than producing new materials, increasing reclamation not only reduces pollution but saves energy. Technological innovations contributing to this shift are summarized here, and are variously classified as emerging technologies or research topics, as either new departures or incremental improvements, and as opportunistic innovations, or examples of a unifying strategy. Both liquid and solid waste examples are given, such as a recent discovery of effects in disinfecting microfiltered reclaimed wastewater with ultraviolet light. In addition to its value in reducing pollution and conserving energy, this reorientation of environmental engineering could contribute to a more general shift toward greater cooperation among organizations dealing with the environment.	Los Angeles Sanitat, Hyper Treatment Plant, Appl Res Grp, Santa Monica, CA 90402 USA; Univ Calif Los Angeles, Dept Civil & Environm Engn, Los Angeles, CA 90095 USA; Univ Calif Davis, Dept Civil & Environm Engn, Davis, CA 95616 USA; Tech Res, Los Angeles, CA 90034 USA; Purdue Univ, Dept Civil Engn, W Lafayette, IN 47907 USA; Sharif Univ Technol, Biochem & Bioengn Res Ctr, Tehran, Iran	University of California System; University of California Los Angeles; University of California System; University of California Davis; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sharif University of Technology	Iranpour, R (corresponding author), Los Angeles Sanitat, Hyper Treatment Plant, Appl Res Grp, 229 21st St, Santa Monica, CA 90402 USA.	rezairanpo@aol.com	Stenstrom, Michael K/A-3177-2008	Stenstrom, Michael K/0000-0001-6157-0718				AHMED T, 1992, J MEMBRANE SCI, V69, P11, DOI 10.1016/0376-7388(92)80163-E; AHMED T, 1992, J MEMBRANE SCI, V69, P1, DOI 10.1016/0376-7388(92)80162-D; ALLBAUGH T, 1985, AERATIONS YSTEM DESI; *AN CORP, 1996, WHAT YOU SHOULD KNOW; ANDERSON J, 1995, HYDRAULIC CHARACTERI; [Anonymous], 1992, STAND METH AN WAT WA; AQUINO JT, 1997, WASTE AGE, V28, P167; Bastian R. K., 1997, WATER ENV TECHNOL, V9, P45; BELL J, 1993, WATER ENVIRON RES, V65, P708, DOI 10.2175/WER.65.6.2; Blackwell D. D., 1992, GEOTHERMAL MAP N AM; Blatchley ER, 1996, WATER ENVIRON RES, V68, P194, DOI 10.2175/106143096X127389; BLATCHLEY ER, 1994, WATER SCI TECHNOL, V30, P115, DOI 10.2166/wst.1994.0171; BLATCHLEY ER, 1995, J ENVIRON ENG-ASCE, V121, P258; BLATCHLEY ER, 1998, WATER RES, V31, P9; BLUMER M, 1976, SCI AM, V234, P35; Brindle K, 1998, J MEMBRANE SCI, V144, P197, DOI 10.1016/S0376-7388(98)00047-7; CAMPBELL JH, 1982, P WORKSH AER SYST DE, P345; *CENTR KAG CORP, 1994, NISSIN BOD RAP MEAS; CORSI RL, 1989, THESIS CALIFORNIA DA; *COS INSTR CORP, 1994, BIOX 1010 BOD AN US; Currie I.G, 1974, FUNDAMENTAL MECH FLU; DARBY JL, 1993, WATER ENVIRON RES, V65, P169, DOI 10.2175/WER.65.2.10; Drzyzga O, 1996, APPL ENVIRON MICROB, V62, P1710, DOI 10.1128/AEM.62.5.1710-1716.1996; DUFFIELD A, 1994, 1125 US GEOL SURV; EWING L, 1982, P SEM WORKSH AER U W, P410; GENTER RE, 1996, FINAL REPORT MICROFI; GHOSH S, 1995, WATER ENVIRON RES, V67, P206, DOI 10.2175/106143095X131367; Grady D, 1996, SCIENCE, V274, P1081, DOI 10.1126/science.274.5290.1081; Graham CM, 1997, WATER ENVIRON RES, V69, P620, DOI 10.2175/106143097X134902; HEDZIK KJ, 1990, WASTE AGE, V21, P66; HIKUMA M, 1979, EUR J APPL MICROBIOL, V8, P289, DOI 10.1007/BF00508793; Hung YT, 1997, WATER ENVIRON RES, V69, P613, DOI 10.2175/106143097X134894; HURST W, 1981, ADV PETROLEUM ENG; IRANPOUR, 1988, WATER EVN RES, V70, P1099; Iranpour R, 1997, J ENVIRON ENG-ASCE, V123, P154, DOI 10.1061/(ASCE)0733-9372(1997)123:2(154); Iranpour R, 1998, WATER ENVIRON RES, V70, P1198, DOI 10.2175/106143098X123534; Iranpour R, 1999, WATER RES, V33, P595; Iranpour R, 1999, WATER ENVIRON RES, V71, P114, DOI 10.2175/106143099X121607; Iranpour R, 1998, WATER RES, V32, P3500; Iranpour R, 1997, J ENVIRON ENG-ASCE, V123, P521, DOI 10.1061/(ASCE)0733-9372(1997)123:5(521.2); IRANPOUR R, 1998, WEFTECH 98, P183; IRANPOUR R, 1998, WEFTECH 98; IRANPOUR R, 1997, ASSESSMENT AERATION; IRANPOUR R, 1998, DISINFECTION 98 LAST, P183; IRANPOUR R, 1998, CALIF WATER ENV ASS; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Jolis D, 1996, WATER SCI TECHNOL, V33, P181, DOI 10.1016/0273-1223(96)00419-2; JOLIS D, 1993, MICROFILTRATION ULTR; LARSON RW, 1996, SOLAR HEAT TECHNOLOG, V10; LEWIS MF, 1975, P NAT C MUN SLUDG MA; Loge FJ, 1996, WATER ENVIRON RES, V68, P900, DOI 10.2175/106143096X127910; LOVINS A, 1977, SOFT ENERGY PATHS DU, P34; Madireddi K, 1997, WATER ENVIRON RES, V69, P350, DOI 10.2175/106143097X125551; *MEMT AM CORP, 1995, MEMC CONT FILTR SYST; *METC EDD INC, 1991, WAST ENG TREATM DISP, pCH16; NAZIRUDDIN M, 1995, WATER ENVIRON RES, V67, P151, DOI 10.2175/106143095X131295; Norton B, 1992, SOLAR ENERGY THERMAL; OLEARY P, 1991, WASTE AGE, V22; OPPENHEIMER JA, 1993, P WEF SPEC C SER PLA; PoggiVaraldo HM, 1997, WATER ENVIRON RES, V69, P575, DOI 10.2175/106143097X134876; REDMON D, 1983, J WATER POLLUT CON F, V55, P1338; Reis J., 1996, ENV CONTROL PETROLEU; REYNOLDS TD, 1996, UNIT OPERATIONS PROC, P511; RICHMAN M, 1997, WATER ENV TECHNOL, V9, P14; RIEDEL K, 1985, 202 LANG GMBH BERL; RIEGLER G, 1987, INTECH, V34, P45; SEVERIN BF, 1980, J WATER POLLUT CON F, V52, P2007; SMARGON AJ, GLOBALPERSPECTIVES S; STENSTROM M, 1991, OFFGAS TEST REPORTS; STENSTROM MK, 1989, FINE BUBBLE DIFFUSER; Tansel B, 1997, WATER ENVIRON RES, V69, P603, DOI 10.2175/106143097X134885; *TROJ TECHN INC, 1989, UV TROJ TECHN MAN; WADA F, 1990, CAL WAT POLL CONTR A; Wampler T.P., 1995, APPL PYROLYSIS HDB; YAGHMAEI Y, UNPUB; ZIMMERMAN PR, 1982, SCIENCE, V218, P563, DOI 10.1126/science.218.4572.563	76	43	55	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					706	711		10.1126/science.285.5428.706	http://dx.doi.org/10.1126/science.285.5428.706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426987				2022-12-28	WOS:000081765100046
J	Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K				Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K			Genetic mechanisms of age regulation of human blood coagulation factor IX	SCIENCE			English	Article							GLASGOW MONICA SURVEY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; ACTIVATION MARKERS; BINDING MOTIF; FACTOR-VIII; ETS-DOMAIN; SEX; L1; EXPRESSION	Blood coagulation capacity increases with age in healthy individuals. Through extensive Longitudinal analyses of human factor IX gene expression in transgenic mice, two essential age-regulatory elements, AE5' and AE3', have been identified. These elements are required and together are sufficient for normal age regulation of factor IX expression. AE5', a PEA-3 related element present in the 5' upstream region of the gene encoding factor IX, is responsible for age-stable expression of the gene. AE3', in the middle of the 3' untranslated region, is responsible for age-associated elevation in messenger RNA Levels. In a concerted manner, AE5' and AE3' recapitulate natural patterns of the advancing age-associated increase in factor IX gene expression.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kurachi, K (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644, R01HL053713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013283] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53713, HL38644] Funding Source: Medline; NIA NIH HHS [AG13283] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREW M, 1988, BLOOD, V72, P1651; ANDREW M, 1987, BLOOD, V70, P165, DOI 10.1182/blood.V70.1.165.165; ANDREW M, 1992, BLOOD, V80, P1998, DOI 10.1182/blood.V80.8.1998.1998; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CONLON MG, 1994, THROMB HAEMOSTASIS, V72, P551; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1993, P NATL ACAD SCI USA, V90, P6513, DOI 10.1073/pnas.90.14.6513; FISHER RJ, 1991, ONCOGENE, V6, P2249; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HOGAN F, 1994, MANIPULATING MOUSE E; HSU WK, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONKEL DA, 1978, CELL, V15, P1125, DOI 10.1016/0092-8674(78)90040-5; KURACHI K, 1993, BLOOD COAGUL FIBRIN, V4, P953, DOI 10.1097/00001721-199304060-00013; Kurachi S, 1996, THROMB HAEMOSTASIS, V76, P965; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; KURACHI S, 1998, BIOCHEMICA, V3, P43; KURACHI S, UNPUB; Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; RODE JJ, 1996, NAT MED, V2, P293; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAITO H, 1991, DISORDERS HEMOSTASIS, P18; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SWEENEY JD, 1993, AM J CLIN PATHOL, V99, P687, DOI 10.1093/ajcp/99.6.687; Woodward M, 1997, BRIT J HAEMATOL, V97, P785, DOI 10.1046/j.1365-2141.1997.1232935.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAO SN, 1991, THROMB HAEMOSTASIS, V65, P52; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	36	41	45	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					739	743		10.1126/science.285.5428.739	http://dx.doi.org/10.1126/science.285.5428.739			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426997				2022-12-28	WOS:000081765100056
J	Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D			Detecting protein function and protein-protein interactions from genome sequences	SCIENCE			English	Article							ESCHERICHIA-COLI; DNA; ASSOCIATION; STABILITY; SRC	A computational method is proposed for inferring protein interactions from genome sequences on the basis of the observation that some pairs of interacting proteins have homologs in another organism fused into a single protein chain. Searching sequences from many genomes revealed 6809 such putative protein-protein interactions in Escherichia coli and 45,502 in yeast. Many members of these pairs were confirmed as functionally related; computational filtering further enriches for interactions. Some proteins have links to several other proteins; these coupled links appear to represent functional interactions such as complexes or pathways. Experimentally confirmed interacting pairs are documented in a Database of interacting Proteins.	Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Box 951570, Los Angeles, CA 90095 USA.		Ng, Ho Leung/E-3419-2010	Ng, Ho Leung/0000-0002-6415-1938; Yeates, Todd/0000-0001-5709-9839; Pellegrini, Matteo/0000-0001-9355-9564; Marcotte, Edward/0000-0001-8808-180X; Rice, Danny/0000-0002-1123-4617	NIGMS NIH HHS [P01 GM 31299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1994, MOL BIOL CELL; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; FIELDS S, 1989, NATURE, V340, P243; HORTON N, 1992, PROTEIN SCI, V1, P169; Lodish H., 1995, MOL CELL BIOL; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P5929, DOI 10.1073/pnas.95.11.5929; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; Tsai CJ, 1996, J MOL BIOL, V260, P604, DOI 10.1006/jmbi.1996.0424; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEH WK, 1981, J BIOL CHEM, V256, P1565	21	1242	1307	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					751	753		10.1126/science.285.5428.751	http://dx.doi.org/10.1126/science.285.5428.751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427000	Green Submitted			2022-12-28	WOS:000081765100059
J	Nakajima, T; Nashimoto, A; Kitamura, M; Kito, T; Iwanaga, T; Okabayashi, K; Goto, M				Nakajima, T; Nashimoto, A; Kitamura, M; Kito, T; Iwanaga, T; Okabayashi, K; Goto, M		Gastric Canc Surg Study Grp	Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial	LANCET			English	Article							CYTOSINE-ARABINOSIDE; CURATIVE RESECTION; CHEMOTHERAPY; 5-FLUOROURACIL; THERAPY; DOXORUBICIN; CARCINOMA; COMBINATION; 5-FU	Background To study the survival benefit of adjuvant chemotherapy in gastric cancer, seven cancer centres in Japan carried out a phase III clinical trial of adjuvant chemotherapy after curative gastrectomy for macroscopically serosa-negative gastric cancer. Methods 579 patients were enrolled in the study, stratified by disease stage (T1, n=188; T2, n=323), and allocated randomly adjuvant chemotherapy or no further treatment, 285 of 288 cases in the treatment group and 288 of 291 in the control group were eligible, Six cases were excluded because they did not fulfil the entry criteria. The treatment group had intravenous mitomycin (1.4 mg/m(2)) and fluorouracil (166.7 mg/m(2)) twice weekly for 3 weeks after surgery, and oral UFT (uracil plus tegafur, 300 mg daily) for 18 months. Analyses were by intention to treat. Findings No serious toxic effects were observed in the treatment group. At median follow-up of 72 months, 59 patients in the control group and 47 in the treatment group had died. There was no significant difference in survival between the groups (5-year survival 82.9% control vs 85.8% treated; hazard ratio 0.738 [95% CI 0.498-1.093]). 5-year survival of patients with T1 (mucosal or submucosal) cancer in the control and treatment groups was 94.9% versus 92.0%, and that of patients with T2 (muscularis propria or subserosa) cancer was 76.9% versus 83.0%. However, a test for heterogeneity and interaction over T1 and T2 subgroups revealed no significant difference in terms of drug response. Interpretation There was no survival benefit with this adjuvant therapy regimen for patients with macroscopically serosa-negative gastric cancer (T1 and T2) after curative gastrectomy. Patients with T1 cancer can be excluded from future trials, because curative surgery alone yielded a very good survival rate and there seemed no need for adjuvant therapy.	Canc Inst Hosp, Dept Surg, Toshima Ku, Tokyo 170, Japan; Niigata Canc Ctr, Dept Surg, Niigata, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo, Japan; Aichi Canc Ctr, Dept Surg, Nagoya, Aichi 464, Japan; Ctr Adult Dis, Dept Surg, Osaka 537, Japan; Natl Canc Ctr, Dept Surg, Tokyo 104, Japan; Hokkaido Canc Ctr, Dept Surg, Sapporo, Hokkaido, Japan; Osaka Univ, Dept Informat & Math Sci, Osaka, Japan	Japanese Foundation for Cancer Research; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Aichi Cancer Center; National Cancer Center - Japan; Osaka University	Nakajima, T (corresponding author), Canc Inst Hosp, Dept Surg, Toshima Ku, 1-37-1 Kamilkebukuro, Tokyo 170, Japan.							AJANI JA, 1990, J CLIN ONCOL, V8, P1231, DOI 10.1200/JCO.1990.8.7.1231; ALLUM WH, 1989, BRIT J CANCER, V60, P739, DOI 10.1038/bjc.1989.350; BLAKE JRS, 1981, CLIN ONCOL, V7, P13; BLOKHINA NG, 1972, NEOPLASMA, V19, P351; COCCONI G, 1982, CANCER TREAT REP, V66, P1263; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; COPPIN CML, 1987, SEMIN ONCOL, V14, P34; DIXON WJ, 1971, ANN SURG, V173, P26, DOI 10.1097/00000658-197101000-00004; DOUGLASS H, 1981, P AN M AM SOC CLIN, V17, P430; ENGSTROM PF, 1985, CANCER-AM CANCER SOC, V55, P1868, DOI 10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B; ENGSTROM PF, 1984, ADJUVANT THERAPY CAN, V4, P449; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; HIGGINS GA, 1983, CANCER, V52, P1105, DOI 10.1002/1097-0142(19830915)52:6<1105::AID-CNCR2820520629>3.0.CO;2-Z; HUGIER PF, 1980, AM J SURG, V139, P197; KAJITANI T, 1981, JPN J SURG, V11, P127; Kelsen D, 1996, J CLIN ONCOL, V14, P1818, DOI 10.1200/JCO.1996.14.6.1818; KLEIN H O, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P84; KROOK JE, 1991, CANCER, V67, P2454, DOI 10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2; LISE M, 1995, J CLIN ONCOL, V13, P2757, DOI 10.1200/JCO.1995.13.11.2757; NAKAJIMA T, 1995, WORLD J SURG, V19, P570, DOI 10.1007/BF00294725; NAKAJIMA T, 1984, J CLIN ONCOL, V2, P1366, DOI 10.1200/JCO.1984.2.12.1366; Nakajima T, 1997, ANN SURG ONCOL, V4, P203, DOI 10.1007/BF02306611; NAKAJIMA T, 1980, JPN J CLIN ONCOL, V10, P187; NAKAJIMA T, 1989, ONCOLOGIA, V22, P100; NAKAJIMA T, 1988, GASTRIC CANC, P125; NAKAJIMA T, 1994, JPN J CANC CHEMOTHER, V21, P1813; Nakajima Toshifusa, 1994, Journal of Japan Society for Cancer Therapy, V29, P654; OTA K, 1972, CANCER CHEMOTH REP 1, V56, P373; SCHREML W, 1984, ADJUVANT THERAPY CAN, V4, P441; SERLIN O, 1977, CANCER, V40, P1318, DOI 10.1002/1097-0142(197709)40:3<1318::AID-CNCR2820400349>3.0.CO;2-9; WILKE H, 1990, SEMIN ONCOL, V17, P61; WILS JA, 1991, J CLIN ONCOL, V9, P827, DOI 10.1200/JCO.1991.9.5.827	32	132	143	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					273	277		10.1016/S0140-6736(99)01048-X	http://dx.doi.org/10.1016/S0140-6736(99)01048-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440302				2022-12-28	WOS:000081646000008
J	Chen, DK; McGeer, A; de Azavedo, JC; Low, DE				Chen, DK; McGeer, A; de Azavedo, JC; Low, DE		Canadian Bacterial Surveillance Network	Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PENICILLIN-RESISTANT PNEUMOCOCCI; ANTIMICROBIAL RESISTANCE; DNA GYRASE; IN-VITRO; CIPROFLOXACIN RESISTANCE; RESPIRATORY PATHOGENS; MULTIRESISTANT CLONE; TOPOISOMERASE-IV; UNITED-STATES; OTITIS-MEDIA	Background Fluoroquinolones are now recommended for the treatment of respiratory tract infections due to Streptococcus pneumoniae, particularly when the isolates are resistant to beta-lactam antibiotics. Although pneumococci with reduced susceptibility to fluoroquinolones have been identified, their prevalence has not been determined in a defined population. Methods We performed susceptibility testing on 7551 isolates of S. pneumoniae obtained from surveillance in Canada in 1988 and from 1993 to 1998. Pneumococci with reduced susceptibility to fluoroquinolones (defined as a minimal inhibitory concentration of ciprofloxacin of at least 4 mu g per milliliter) were further characterized. We also examined antibiotic prescriptions dispensed in Canadian retail pharmacies, Results Between 1988 and 1997 fluoroquinolone prescriptions increased from 0.8 to 5.5 per 100 persons per year. The prevalence of pneumococci with reduced susceptibility to fluoroquinolones increased from 0 percent in 1993 to 1.7 percent in 1997 and 1998 (P=0.01). Among adults, the prevalence increased from 1.5 percent in 1993 and 1994 combined to 2.9 percent in 1997 and 1998 combined. The prevalence was higher in isolates from older patients (2.6 percent among those 65 years of age or older vs. 1.0 percent among those 15 to 64 years of age, P<0.001) and among those from Ontario (1.5 percent, vs. 0.4 percent among those from the rest of Canada; P<0.001). Fluoroquinolone use was greatest among the elderly and in Ontario, The 75 isolates (17 serotypes) of pneumococci with reduced susceptibility to fluoroquinolones were submitted by 40 laboratories in eight provinces. Reduced susceptibility to fluoroquinolones was associated with resistance to penicillin. Conclusions The prevalence of pneumococci with reduced susceptibility to fluoroquinolones is increasing in Canada, probably as a result of selective pressure from the increased use of fluoroquinolones, (N Engl J Med 1999;341:233-9.) (C) 1999 Massachusetts Medical Society.	Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Toronto Hosp, Dept Microbiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Low, DE (corresponding author), Mt Sinai Hosp, Dept Microbiol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		McGeer, Allison/AAB-6885-2020; Low, Donald/B-1726-2012; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Ballow CH, 1997, DIAGN MICR INFEC DIS, V29, P173, DOI 10.1016/S0732-8893(97)81807-X; Barry AL, 1996, J ANTIMICROB CHEMOTH, V37, P365, DOI 10.1093/jac/37.2.365; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Brook I, 1996, CLIN INFECT DIS, V22, P143, DOI 10.1093/clinids/22.1.143; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Campbell GD, 1999, CHEST, V115, p14S, DOI 10.1378/chest.115.suppl_1.14S; Chodosh S, 1998, CLIN INFECT DIS, V27, P730, DOI 10.1086/514934; Coffey TJ, 1996, MICROBIOL-UK, V142, P2747, DOI 10.1099/13500872-142-10-2747; DALHOFF A, 1998, 8 INT C INF DIS BOST, P124; Doern GV, 1998, CLIN INFECT DIS, V27, P764, DOI 10.1086/514953; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; DOUIDAR SM, 1989, REV INFECT DIS, V11, P878; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Fuchs PC, 1997, J ANTIMICROB CHEMOTH, V39, P671, DOI 10.1093/jac/39.5.671; Goldsmith CE, 1998, J ANTIMICROB CHEMOTH, V41, P420, DOI 10.1093/jac/41.3.420; Goldsmith CE, 1997, J ANTIMICROB CHEMOTH, V40, P11, DOI 10.1093/jac/40.suppl_1.11; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; Gruneberg RN, 1996, DIAGN MICR INFEC DIS, V25, P169, DOI 10.1016/S0732-8893(96)00135-6; Hall LMC, 1998, J CLIN PATHOL, V51, P270, DOI 10.1136/jcp.51.4.270; Hooper DC, 1998, ANN INTERN MED, V129, P908, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00015; JANOIR C, 1998, CLIN INFECT DIS   S1, V27, pS54; KAM KM, 1995, ANTIMICROB AGENTS CH, V39, P2667, DOI 10.1128/AAC.39.12.2667; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; LEE BL, 1991, NEW ENGL J MED, V325, P520; LOVGREN M, 1998, CMAJ, V158, P27; MARCHESE A, 1995, J ANTIMICROB CHEMOTH, V36, P833, DOI 10.1093/jac/36.5.833; Mittermayer H, 1996, EUR J CLIN MICROBIOL, V15, P817, DOI 10.1007/BF01701526; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1991, J CLIN MICROBIOL, V29, P418; *NAT COMM CLIN LAB, 1998, M100SB NCCLS; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Rahal K, 1997, CLIN INFECT DIS, V24, pS169, DOI 10.1093/clinids/24.Supplement_1.S169; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Richard MP, 1998, J ANTIMICROB CHEMOTH, V41, P207, DOI 10.1093/jac/41.2.207; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Setchanova L, 1995, MICROB DRUG RESIST, V1, P79, DOI 10.1089/mdr.1995.1.79; Simor AE, 1996, ANTIMICROB AGENTS CH, V40, P2190, DOI 10.1128/AAC.40.9.2190; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SREEDHARAN S, 1991, ANTIMICROB AGENTS CH, V35, P2151, DOI 10.1128/AAC.35.10.2151; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; Tankovic J, 1996, ANTIMICROB AGENTS CH, V40, P2505, DOI 10.1128/AAC.40.11.2505; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Thornsberry C, 1997, DIAGN MICR INFEC DIS, V29, P249, DOI 10.1016/S0732-8893(97)00195-8; Wang EEL, 1998, CAN FAM PHYSICIAN, V44, P1881; Wise R, 1996, LANCET, V348, P1660, DOI 10.1016/S0140-6736(05)65724-8; Wise R, 1997, J ANTIMICROB CHEMOTH, V40, P27, DOI 10.1093/jac/40.suppl_1.27; YOSHIDA R, 1995, ANTIMICROB AGENTS CH, V39, P1196, DOI 10.1128/AAC.39.5.1196; Zhao XL, 1997, P NATL ACAD SCI USA, V94, P13991, DOI 10.1073/pnas.94.25.13991	51	843	867	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					233	239		10.1056/NEJM199907223410403	http://dx.doi.org/10.1056/NEJM199907223410403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413735				2022-12-28	WOS:000081528800003
J	Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI				Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI			Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCUTANEOUS ADIPOSE-TISSUE; SKELETAL-MUSCLE; SYNTHASE ACTIVITY; HEXOKINASE-II; BETA-CELL; NIDDM; RESISTANCE; MELLITUS; PHOSPHORYLATION; DEFICIENCY	Background Insulin resistance, a major factor in the pathogenesis of type 2 diabetes mellitus, is due mostly to decreased stimulation of glycogen synthesis in muscle by insulin. The primary rate-controlling step responsible for the decrease in muscle glycogen synthesis is not known, although hexokinase activity and glucose transport have been implicated. Methods We used a novel nuclear magnetic resonance approach with carbon-13 and phosphorus-31 to measure intramuscular glucose, glucose-6-phosphate, and glycogen concentrations under hyperglycemic conditions (plasma glucose concentration, approximately 180 mg per deciliter [10 mmol per liter]) and hyperinsulinemic conditions in six patients with type 2 diabetes and seven normal subjects. In vivo microdialysis of muscle tissue was used to determine the gradient between plasma and interstitial-fluid glucose concentrations, and open-flow microperfusion was used to determine the concentrations of insulin in interstitial fluid. Results The time course and concentration of insulin in interstitial fluid were similar in the patients with diabetes and the normal subjects. The rates of whole-body glucose metabolism and muscle glycogen synthesis and the glucose-6-phosphate concentrations in muscle were approximately 80 percent lower in the patients with diabetes than in the normal subjects under conditions of matched plasma insulin concentrations. The mean (+/-SD) intracellular glucose concentration was 2.0+/-8.2 mg per deciliter (0.11+/-0.46 mmol per liter) in the normal subjects. In the patients with diabetes, the intracellular glucose concentration was 4.3+/-4.9 mg per deciliter (0.24+/-0.27 mmol per liter), a value that was 1/25 of what it would be if hexokinase were the rate-controlling enzyme in glucose metabolism. Conclusions Impaired insulin-stimulated glucose transport is responsible for the reduced rate of insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes mellitus. (N Engl J Med 1999;341:240-6.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, POB 9812, New Haven, CT 06536 USA.		Krssak, Martin/AAU-8183-2020; Trajanoski, Zlatko/AAT-6703-2021; Shulman, Gerald I./P-7176-2019; Inzucchi, Silvio/ABF-4121-2021	Krssak, Martin/0000-0001-9717-803X; Shulman, Gerald I./0000-0003-1529-5668; 	NCRR NIH HHS [MO1 RR-00125] Funding Source: Medline; NIDDK NIH HHS [R01 DK-49230, P30 DK-45735] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK049230] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; CAHILL GF, 1988, NEW ENGL J MED, V318, P1268, DOI 10.1056/NEJM198805123181909; Cline GW, 1999, DIABETES, V48, pA273; Cline GW, 1998, AM J PHYSIOL-ENDOC M, V274, pE381, DOI 10.1152/ajpendo.1998.274.2.E381; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; HAFFNER SM, 1990, METABOLISM, V39, P842, DOI 10.1016/0026-0495(90)90130-5; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; Moberg E, 1997, DIABETOLOGIA, V40, P1320, DOI 10.1007/s001250050827; *NAT DIS DAT GROUP, 1995, NIH PUBL; Nolan JJ, 1997, DIABETES, V46, P994, DOI 10.2337/diabetes.46.6.994; REAVEN GM, 1976, AM J MED, V60, P80, DOI 10.1016/0002-9343(76)90536-2; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Saccomani MP, 1996, AM J PHYSIOL-ENDOC M, V270, pE170, DOI 10.1152/ajpendo.1996.270.1.E170; Shen J, 1996, J MAGN RESON SER B, V112, P131, DOI 10.1006/jmrb.1996.0123; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Trajanoski Z, 1997, DIABETES CARE, V20, P1114, DOI 10.2337/diacare.20.7.1114; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YANG YJ, 1989, J CLIN INVEST, V84, P1620, DOI 10.1172/JCI114339; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	30	464	479	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					240	246		10.1056/NEJM199907223410404	http://dx.doi.org/10.1056/NEJM199907223410404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413736				2022-12-28	WOS:000081528800004
J	Iglehart, JK				Iglehart, JK			Support for academic medical centers - Revisiting the 1997 Balanced Budget Act	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Blumenthal D, 1997, NEW ENGL J MED, V337, P1550, DOI 10.1056/NEJM199711203372113; *CONGR BUDG OFF, 1999, AN PRES BUDG PROP FI; Gardner J, 1999, Mod Healthc, V29, P12; *GEN ACC OFF, 1999, HEHS99120 GAO; GUSMANO M, 1998, SOCIAL ROLES MED; Iglehart JK, 1998, NEW ENGL J MED, V338, P402, DOI 10.1056/NEJM199802053380620; Iglehart JK, 1999, NEW ENGL J MED, V340, P327, DOI 10.1056/NEJM199901283400424; Lagnado L., 1999, WALL STREET J, pB1; MCGINLEY L, 1999, WALL STREET J   0426, pB1; *NAT AC SOC INS, 1999, MED AM SOC CONTR FIN; ROSS MN, 1999, PUTTING FINANCIAL PR; Vladeck BC, 1999, NEW ENGL J MED, V340, P1503, DOI 10.1056/NEJM199905133401911; 1999, NY TIMES        0531, pA18	13	52	52	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					299	304		10.1056/NEJM199907223410424	http://dx.doi.org/10.1056/NEJM199907223410424			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413745				2022-12-28	WOS:000081528800032
J	Wade, D				Wade, D			Rehabilitation therapy after stroke	LANCET			English	Editorial Material									Rivermead Rehabil Ctr, Oxford OX1 4XD, England		Wade, D (corresponding author), Rivermead Rehabil Ctr, Oxford OX1 4XD, England.			Wade, Derick/0000-0002-1188-8442				Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Lord SE, 1998, CLIN REHABIL, V12, P477, DOI 10.1191/026921598675863454; Nelson DL, 1996, AM J OCCUP THER, V50, P639, DOI 10.5014/ajot.50.8.639; Tinson D J, 1989, Int Disabil Stud, V11, P45; Wade DT, 1998, CLIN REHABIL, V12, P363, DOI 10.1191/026921598666679396	7	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					176	177		10.1016/S0140-6736(99)90064-8	http://dx.doi.org/10.1016/S0140-6736(99)90064-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421294				2022-12-28	WOS:000081504200004
J	Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB				Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB			The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila	NATURE			English	Article							SEGMENT POLARITY GENES; NERVOUS-SYSTEM; EMBRYO; PROTEIN; GLYCOSAMINOGLYCANS; TRANSCRIPTION; MELANOGASTER; BIOSYNTHESIS; EXPRESSION; SECRETION	Wingless (Wg) is a member of the Wnt family of growth factors, secreted proteins that control proliferation and differentiation during development. Studies in Drosophila have shown that responses to Wg require cell-surface heparan sulphate, a glycosaminoglycan component of proteoglycans(1-4). These findings suggest that a cell-surface proteoglycan is a component of a Wg/Wnt receptor complex. We demonstrate here that the protein encoded by the division abnormally delayed (dally) gene is a cell-surface, heparan-sulphate-modified proteoglycan(5,6). dally partial loss-of-function mutations compromise Wg-directed events, and disruption of daily function with RNA interference produces phenotypes comparable to those found with RNA interference of wg or frizzled (fz)/Dfz2 (ref. 7). Ectopic expression of Daily potentiates Wg signalling without altering levels of Wg and can rescue a wg partial loss-of-function mutant, We also show that dally a regulator of Decapentaplegic (DFP) signalling during post-embryonic development, has tissue-specific effects on Wg and Dpp signalling. Daily can therefore differentially influence signalling mediated by two growth factors, and may form a regulatory component of both Wg and Dpp receptor complexes.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo, Japan; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Novartis Inc, Res Triangle Pk, NC 27709 USA	University of Arizona; University of Arizona; Tokyo Metropolitan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Novartis	Selleck, SB (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.			Archer, Michael/0000-0002-0304-4039				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Binari RC, 1997, DEVELOPMENT, V124, P2623; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Emerald BS, 1998, DEV GENES EVOL, V208, P504, DOI 10.1007/s004270050209; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1993, DEVELOPMENT, V117, P283; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PEIFER M, 1994, DEVELOPMENT, V120, P369; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	333	343	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					276	280		10.1038/22336	http://dx.doi.org/10.1038/22336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421371				2022-12-28	WOS:000081503800047
J	Himmelstein, DU; Woolhandler, S; Hellander, I; Wolfe, SM				Himmelstein, DU; Woolhandler, S; Hellander, I; Wolfe, SM			Quality of care in investor-owned vs not-for-profit HMOs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; HEALTH-CARE; MEDICAL OUTCOMES; 2 PARTS; GO BAD; SERVICE; PREPAID; PLANS; SYSTEMS; VIEWS	Context The proportion of health maintenance organization (HMO) members enrolled in investor-owned plans has increased sharply, yet little is known about the quality of these plans compared with not-for-profit HMOs. Objective To compare quality-of-care measures for investor-owned and not-for-profit HMOs, Design, Setting, and Participants Analysis of the Health Plan Employer Data and Information Set (HEDIS) Version 3.0 from the National Committee for Quality Assurance's Quality Compass 1997, which included 1996 quality-of-care data for 329 HMO plans (248 investor-owned and 81 not-for-profit), representing 56% of the total HMO enrollment in the United States. Main Outcome Measures Rates for 14 HEDIS quality-of-care indicators. Results Compared with not-for-profit HMOs, investor-owned plans had lower rates for all 14 quality-of-care indicators. Among patients discharged from the hospital after myocardial infarction, 59.2% of members in investor-owned HMOs vs 70.6% in not-for-profit plans received a beta-blocker (P<.001); 35.1% of patients with diabetes mellitus in investor-owned plans vs 47.9% in not-for-profit plans had annual eye examinations (P<.001). Investor-owned plans had lower rates than not-for-profit plans of immunization (63.9% vs 72.3%; P<.001), mammography (69.4% vs 75.1%; P<.001), Papanicolaou tests (69.2% vs 77.1%; P<.001), and psychiatric hospitalization (70.5% vs 77.1%; P<.001). Quality scores were highest for staff- and group-model HMOs. In multivariate analyses, investor ownership was consistently associated with lower quality after controlling for model type, geographic region, and the method each HMO used to collect data. Conclusions Investor-owned HMOs deliver lower quality of care than not-for-profit plans.	Harvard Univ, Sch Med, Cambridge Hosp, Ctr Natl Hlth Program Studies,Dept Med, Cambridge, MA 02138 USA; Publ Citizen Hlth Res Grp, Natl Hlth Program, Washington, DC USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital	Himmelstein, DU (corresponding author), 1493 Cambridge St, Cambridge, MA 02139 USA.							Adler G S, 1995, Health Care Financ Rev, V16, P175; Born P, 1998, J Health Care Finance, V24, P65; Borowsky SJ, 1997, JAMA-J AM MED ASSOC, V278, P917, DOI 10.1001/jama.278.11.917; BRINK S, 1997, US NEWS WORLD R 1013, P60; COLLINS KS, 1997, COMMONWEALTH FUND SU; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; Donelan K, 1997, HEALTH AFFAIR, V16, P139, DOI 10.1377/hlthaff.16.5.139; DONELAN K, 1996, HLTH AFF MILLWOOD, V15, P256; *FAM US FDN, 1997, COMP MED HMOS DO THE; FARLEY D, 1998, ASSESSING QUALITY MA; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; Hellinger FJ, 1998, ARCH INTERN MED, V158, P833, DOI 10.1001/archinte.158.8.833; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; KRAUS N, 1991, INTERSTUDY EDGE MANA; Kuhlthau K, 1998, HEALTH AFFAIR, V17, P42, DOI 10.1377/hlthaff.17.4.42; Kuttner R, 1998, NEW ENGL J MED, V338, P1635, DOI 10.1056/NEJM199805283382221; Kuttner R, 1998, NEW ENGL J MED, V338, P1558, DOI 10.1056/NEJM199805213382123; LEEFELDSTEIN A, 1994, JAMA-J AM MED ASSOC, V271, P1163, DOI 10.1001/jama.271.15.1163; Mark T, 1996, HEALTH AFFAIR, V15, P81, DOI 10.1377/hlthaff.15.4.81; *MED HEDIS DAT, 1999, 1996 AUD; Miller RH, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.5.7; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; *NAT COMM QUAL ASS, 1997, NCQAS QUAL COMP DAT; *NAT COMM QUAL ASS, 1997, HEDIS 3 0, V2; Neuman P, 1998, HEALTH AFFAIR, V17, P132, DOI 10.1377/hlthaff.17.4.132; *PHYS PAYM REV COM, 1996, ANN REP C 1996; PORELL FW, 1992, M HLTH CAR FIN ADM J; Retchin SM, 1997, JAMA-J AM MED ASSOC, V278, P119; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; *SAS I, 1987, SAS SOFTW VERS 6 04; SCHIFF GD, 1994, JAMA-J AM MED ASSOC, V272, P803, DOI 10.1001/jama.272.10.803; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P187; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; WARE JE, 1986, LANCET, V1, P1017; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Yelin EH, 1996, JAMA-J AM MED ASSOC, V276, P1048, DOI 10.1001/jama.276.13.1048; 1997, INT COMP EDG 7 1; 1999, INT COMP EDG 9 1 2; 1998, MMWR MORB MORTAL WKL, V47, P613; 1995, PUBLIC CITIZEN HLTH, V11, P1; 1996, CONSUMER REPORTS AUG, P26	42	162	162	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					159	163		10.1001/jama.282.2.159	http://dx.doi.org/10.1001/jama.282.2.159			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	215HT	10411197	Green Published, Bronze			2022-12-28	WOS:000081376800033
J	Vamecq, J; Latruffe, N				Vamecq, J; Latruffe, N			Medical significance of peroxisome proliferator-activated receptors	LANCET			English	Review							GAMMA PPAR-GAMMA; GENE-EXPRESSION; HORMONE-RECEPTOR; FATTY-ACIDS; INSULIN-RESISTANCE; LIPID-METABOLISM; BETA-OXIDATION; OXIDIZED LDL; CROSS-TALK; IN-VITRO	Peroxisome proliferator-activated receptors (PPAR) were discovered in 1990, ending 25 years of uncertainty about the molecular mechanisms of peroxisome proliferation. Subsequently, PPARs have improved our understanding of adipocyte differentiation. But there is more to PPARs than solving a puzzle about an organelle (the peroxisome) long considered an oddity, and their medical significance goes beyond obesity too. Enhanced PPAR type a: expression protects against cardiovascular disorders though the role of enhanced PPAR gamma expression seems less favourable. PPAR mechanisms, mainly via induction of more differentiated cell phenotypes, protect against some cancers. The differentiation of many cell types (hepatocyte, fibroblast, adipocyte, keratinocyte, myocyte, and monocyte/macrophege) involves PPARs, and these nuclear receptors are now attracting the attention of many medical specialties;and the pharmaceutical industry.	CHU Lille, INSERM, Neuropaediat Dept Prof Jean Pierre Nuyts, F-59037 Lille, France; Univ Burgundy, Fac Sci Gabriel, Lab Mol & Cell Biol, Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Bourgogne	Vamecq, J (corresponding author), CHU Lille, INSERM, Neuropaediat Dept Prof Jean Pierre Nuyts, 2 Ave Oscar Lambret, F-59037 Lille, France.	lvallee@chru-lille.fr	Vamecq, Joseph/M-4953-2018	Vamecq, Joseph/0000-0002-4089-7663				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Auwerx J, 1998, LANCET, V351, P737, DOI 10.1016/S0140-6736(97)06348-4; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chevalier S, 1998, ONCOL REP, V5, P1319; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; ELTSTNER E, 1998, P NATL ACAD SCI USA, V95, P8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Grossman S L, 1997, Expert Opin Investig Drugs, V6, P1025, DOI 10.1517/13543784.6.8.1025; Heimburger M, 1998, BIOCHEM BIOPH RES CO, V249, P371, DOI 10.1006/bbrc.1998.9157; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISTOW M, 1998, NEW ENGL J MED, V339, P953; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kubota T, 1998, CANCER RES, V58, P3344; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1997, J BIOL CHEM, V79, P81; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Plant NJ, 1998, CARCINOGENESIS, V19, P925, DOI 10.1093/carcin/19.5.925; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1996, J LIPID RES, V37, P907; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shimaya A, 1998, HORM METAB RES, V30, P543, DOI 10.1055/s-2007-978929; Spencer CM, 1997, DRUGS, V54, P89, DOI 10.2165/00003495-199754010-00010; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STRINGER DA, 1992, ECETOC MONOGR, V17; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vamecq J, 1989, Essays Biochem, V24, P115; VAMECQ J, 1993, BIOCHIM BIOPHYS ACTA, V1170, P151, DOI 10.1016/0005-2760(93)90065-H; VAMECQ J, 1987, PEROXISOMES BIOL MED, P364; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Winrow CJ, 1998, J BIOL CHEM, V273, P31442, DOI 10.1074/jbc.273.47.31442; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116	66	392	445	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	1999	354	9173					141	148		10.1016/S0140-6736(98)10364-1	http://dx.doi.org/10.1016/S0140-6736(98)10364-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408502				2022-12-28	WOS:000081377100044
J	Wingrove, JA; O'Farrell, PH				Wingrove, JA; O'Farrell, PH			Nitric oxide contributes to behavioral, cellular, and developmental responses to low oxygen in Drosophila	CELL			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; DEPENDENT PROTEIN-KINASE; GUANYLATE-CYCLASE; RIBONUCLEOTIDE REDUCTASE; RELAXING FACTOR; GENE ENCODES; CELLS; GROWTH; MELANOGASTER; SYNTHASE	A nitric oxide (NO)/cyclic GMP (cGMP) signaling pathway is thought to play an important role in mammalian vasodilation during hypoxia. We show that Drosophila utilizes components of this pathway to respond to hypoxia. Hypoxic exposure rapidly induced exploratory behavior in larvae and arrested the cell cycle. These behavioral and cellular responses were diminished by an inhibitor of NO synthase and by a polymorphism affecting a form of cGMP-dependent protein kinase. Conversely, these responses were induced by ectopic expression of NO synthase. Perturbing components of the NO/cGMP pathway altered both tracheal development and survival during prolonged hypoxia. These results indicate that NO and protein kinase G contribute to Drosophila's ability to respond to oxygen deprivation.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Farrell, PH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193, R01 GM037193-10, R01 GM037193-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; DEBELLE JS, 1989, GENETICS, V123, P157; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1989, DEVELOPMENT, V107, P1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishida A, 1997, J BIOL CHEM, V272, P10050; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Kantrow SP, 1997, AM J PHYSIOL-LUNG C, V272, pL1167, DOI 10.1152/ajplung.1997.272.6.L1167; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Manning Gerards, 1993, P609; MEULEMANS A, 1994, NEUROSCI LETT, V171, P89, DOI 10.1016/0304-3940(94)90612-2; Millar Timothy M., 1997, Biochemical Society Transactions, V25, p528S; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Truman JW, 1996, DEVELOPMENT, V122, P3949; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; Wildemann B, 1999, J NEUROBIOL, V38, P1, DOI 10.1002/(SICI)1097-4695(199901)38:1<1::AID-NEU1>3.0.CO;2-L; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; [No title captured]	45	206	222	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					105	114		10.1016/S0092-8674(00)80610-8	http://dx.doi.org/10.1016/S0092-8674(00)80610-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412985	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000081451000012
J	Wallace, PGM; Ridley, SA				Wallace, PGM; Ridley, SA			ABC of intensive care - Transport of critically ill patients	BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England	University of Glasgow; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Wallace, PGM (corresponding author), Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland.								0	44	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					368	371		10.1136/bmj.319.7206.368	http://dx.doi.org/10.1136/bmj.319.7206.368			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435964	Green Published			2022-12-28	WOS:000082001700025
J	Imtiaz, KE; Vora, JP				Imtiaz, KE; Vora, JP			Dancing eyes-dancing feet	LANCET			English	Article							OPSOCLONUS-MYOCLONUS SYNDROME		Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Imtiaz, KE (corresponding author), Halton Gen Hosp, Block 2, Runcorn WA7 2DA, Cheshire, England.							Adamolekun B, 1998, E AFR MED J, V75, P120; CAVINESS JN, 1995, MOVEMENT DISORD, V10, P22, DOI 10.1002/mds.870100106; Pranzatelli MR, 1996, CLIN NEUROPHARMACOL, V19, P1, DOI 10.1097/00002826-199619010-00001; Shapiro B, 1994, J Nucl Biol Med, V38, P545; Tabarki B, 1998, J NEUROL NEUROSUR PS, V64, P406	5	8	8	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					390	390		10.1016/S0140-6736(99)05250-2	http://dx.doi.org/10.1016/S0140-6736(99)05250-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437869				2022-12-28	WOS:000081764900015
J	Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL				Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL			Measurement of the urinary lactate : creatinine ratio for the early identification of newborn infants at risk for hypoxic-ischemic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROSPINAL-FLUID; BIRTH ASPHYXIA; PERINATAL ASPHYXIA; MAGNETIC-RESONANCE; TERM INFANTS; ORGANIC-ACID; EXCRETION; PROGNOSIS; SYSTEM; BRAIN	Background Newborn infants with perinatal asphyxia are prone to the development of hypoxic-ischemic encephalopathy. There are no reliable methods For identifying infants at risk for this disorder. Methods We measured the ratio of lactate to creatinine in urine by proton nuclear magnetic resonance spectroscopy within 6 hours and again 48 to 72 hours after birth in 58 normal infants and 40 infants with asphyxia. The results were correlated with the subsequent presence or absence of hypoxic-ischemic encephalopathy. Results Hypoxic-ischemic encephalopathy did not develop in any of the normal newborns but did develop in 16 of the 40 newborns with asphyxia. Within six hours after birth, the mean (+/-SD) ratio of urinary lactate to creatinine was 16.75+/-27.38 in the infants who subsequently had hypoxic-ischemic encephalopathy, as compared with 0.09+/-0.02 in the normal infants (P<0.001) and 0.19+/-0.12 in the infants with asphyxia in whom hypoxic-ischemic encephalopathy did not develop (P<0.001). A ratio of 0.64 or higher within six hours after birth had a sensitivity of 94 percent and a specificity of 100 percent for predicting the development of hypoxic-ischemic encephalopathy. The sensitivity and specificity of measurements obtained 48 to 72 hours after birth were much lower. The mean ratio of urinary lactate to creatinine was significantly higher in the infants who had adverse outcomes at one year (25.36+/-32.02) than in the infants with favorable outcomes (0.63+/-1.50) (P<0.001). Conclusions Measurement of the urinary lactate:creatinine ratio soon after birth may help identify infants at high risk for hypoxic-ischemic encephalopathy. (N Engl J Med 1999;341:328-35.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Med Ctr, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Med Ctr, Dept Publ Hlth, Tainan 704, Taiwan; Natl Cheng Kung Univ, Dept Chem, Tainan 704, Taiwan; Kaohsiung Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital	Huang, CC (corresponding author), Natl Cheng Kung Univ, Med Ctr, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Huang, Chao-Ching/0000-0003-2799-7181				AMICLTISON C, 1986, NEUROLOGICAL ASSESSM; BLENNOW M, 1995, PEDIATR RES, V37, P260, DOI 10.1203/00006450-199503000-00002; Carter BS, 1998, J PEDIATR-US, V132, P619, DOI 10.1016/S0022-3476(98)70349-X; Cheung PY, 1996, ARCH DIS CHILD-FETAL, V74, pF47, DOI 10.1136/fn.74.1.F47; DAWES GS, 1968, J PHYSIOL-LONDON, V195, P55, DOI 10.1113/jphysiol.1968.sp008446; DEPRAETER C, 1991, PEDIATRICS, V88, P1204; Ekert P, 1997, J PEDIATR-US, V131, P613, DOI 10.1016/S0022-3476(97)70072-6; FERNANDES J, 1976, CLIN CHIM ACTA, V66, P345, DOI 10.1016/0009-8981(76)90233-3; GARCIA J, 1984, J PEDIATR-US, V104, P268, DOI 10.1016/S0022-3476(84)81010-0; HAGBERG H, 1993, ACTA PAEDIATR, V82, P925, DOI 10.1111/j.1651-2227.1993.tb12601.x; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Huang CC, 1998, RADIOLOGY, V209, P49, DOI 10.1148/radiology.209.1.9769811; ILES RA, 1986, CLIN CHIM ACTA, V161, P173, DOI 10.1016/0009-8981(86)90211-1; Johnston MV, 1998, ANN NEUROL, V44, P155, DOI 10.1002/ana.410440202; Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803; MA S, 1995, APPL BIOCHEM BIOTECH, V53, P37, DOI 10.1007/BF02783480; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MCCORMICK K, 1985, AM J MED GENET, V22, P291, DOI 10.1002/ajmg.1320220211; NICHOLSON JK, 1989, PROG NUCL MAG RES SP, V21, P449, DOI 10.1016/0079-6565(89)80008-1; PERLMAN JM, 1988, J PEDIATR-US, V113, P875; Perlman JM, 1996, PEDIATRICS, V97, P456; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; RUTH V, 1988, J PEDIATR-US, V113, P880, DOI 10.1016/S0022-3476(88)80024-6; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Savman K, 1998, PEDIATR RES, V43, P746; SIEGEL MJ, 1984, RADIOLOGY, V152, P395, DOI 10.1148/radiology.152.2.6739805; THORNBERG E, 1995, ARCH DIS CHILD-FETAL, V72, pF39, DOI 10.1136/fn.72.1.F39; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; VOLPE JJ, 1995, NEUROLOGY NEWBORN, P221; Walker V, 1996, PEDIATR RES, V40, P309, DOI 10.1203/00006450-199608000-00020; WALKER V, 1992, BIOL NEONATE, V61, P162; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Zuppi C, 1997, CLIN CHIM ACTA, V265, P85, DOI 10.1016/S0009-8981(97)00110-1	33	81	82	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					328	335		10.1056/NEJM199907293410504	http://dx.doi.org/10.1056/NEJM199907293410504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423467				2022-12-28	WOS:000081666900004
J	Fisher, RS; Blum, D				Fisher, RS; Blum, D			Epilepsy surgery where there is dual pathology	LANCET			English	Editorial Material							TEMPORAL-LOBE EPILEPSY; RESECTION; LOBECTOMY; SEIZURES; EXTENT		St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Fisher, RS (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA.			Fisher, Robert/0000-0003-0287-613X				Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314; AWAD IA, 1991, NEUROSURGERY, V28, P510, DOI 10.1227/00006123-199104000-00005; CASCINO GD, 1993, EPILEPSY RES, V14, P175, DOI 10.1016/0920-1211(93)90022-Y; FRIED I, 1992, J NEUROSURG, V76, P735, DOI 10.3171/jns.1992.76.5.0735; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDENSOHN ES, 1984, EPILEPSIA, V25, pS156, DOI 10.1111/j.1528-1157.1984.tb05648.x; Li LM, 1999, BRAIN, V122, P799, DOI 10.1093/brain/122.5.799; MATHERN GW, 1995, EPILEPSY RES, V21, P133, DOI 10.1016/0920-1211(95)00014-2; NAYEL MH, 1991, NEUROSURGERY, V29, P55, DOI 10.1227/00006123-199107000-00009; O'Brien TJ, 1999, ANN NEUROL, V45, P526, DOI 10.1002/1531-8249(199904)45:4<526::AID-ANA17>3.3.CO;2-E; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					267	268		10.1016/S0140-6736(99)00180-4	http://dx.doi.org/10.1016/S0140-6736(99)00180-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440297				2022-12-28	WOS:000081646000003
J	Sigwart, U				Sigwart, U			Prevention of restenosis after stenting	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; IMPLANTATION; PLACEMENT		Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England	Royal Brompton Hospital	Sigwart, U (corresponding author), Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England.							CAMPBELL EJ, 1999, AM SOC ARTIF INT ORG, V40, pM853; Chronos NAF, 1998, CIRCULATION, V98, P189; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hanekamp CEE, 1999, CIRCULATION, V99, P1015, DOI 10.1161/01.CIR.99.8.1015; HINOHARA T, 1992, J AM COLL CARDIOL, V20, P623, DOI 10.1016/0735-1097(92)90017-H; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Prati F, 1999, CIRCULATION, V99, P1011, DOI 10.1161/01.CIR.99.8.1011; ROSENSCHEIN U, 1996, ENDOLUMINAL STENTING; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; WAKSMAN R, 1995, CIRCULATION, V91, P1553	12	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					269	270		10.1016/S0140-6736(99)00137-3	http://dx.doi.org/10.1016/S0140-6736(99)00137-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440299				2022-12-28	WOS:000081646000005
J	Wagner, D; Sablowski, RWM; Meyerowitz, EM				Wagner, D; Sablowski, RWM; Meyerowitz, EM			Transcriptional activation of APETALA1 by LEAFY	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; FLOWER DEVELOPMENT; MERISTEM IDENTITY; ARABIDOPSIS; INITIATION; EXPRESSION	Plants produce new appendages reiteratively from groups of stem cells called shoot apical meristems. LEAFY (LFY) and APETALA1 (AP1) are pivotal for the switch to the reproductive phase, where instead of leaves the shoot apical meristem produces flowers. Use of steroid-inducible activation of LFY demonstrated that early expression of AP1 is a result of transcriptional induction by LFY. This AP1 induction is independent of protein synthesis and occurs specifically in the tissues and at the developmental stage in which floral fate is assumed. Later expression of AP1 appears to be only indirectly affected by LFY.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.		Wagner, Doris/F-1811-2013; Meyerowitz, Elliot M/A-7118-2009	Sablowski, Robert/0000-0002-1732-2909; Wagner, Doris/0000-0003-4656-2490				Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Hempel FD, 1998, PLANT CELL, V10, P1663, DOI 10.1105/tpc.10.10.1663; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; Liljegren SJ, 1996, CURR OPIN CELL BIOL, V8, P865, DOI 10.1016/S0955-0674(96)80089-5; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Sablowski RWM, 1998, CELL, V92, P93, DOI 10.1016/S0092-8674(00)80902-2; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	24	336	377	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					582	584		10.1126/science.285.5427.582	http://dx.doi.org/10.1126/science.285.5427.582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417387				2022-12-28	WOS:000081609500037
J	Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O				Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O			Molecular characterization of the melanin-concentrating-hormone receptor	NATURE			English	Article							ALPHA-MSH; RAT; NEUROPEPTIDE; PROTEIN; BRAIN; GENE; HYPOTHALAMUS; PEPTIDE; ENCODES; SYSTEM	Orphan G-protein-coupled receptors (GPCRs) are cloned proteins with structural characteristics common to the GPCRs but that bind unidentified ligands. Orphan GPCRs have been used as targets to identify novel transmitter molecules(1). Here we describe the isolation from brain extracts and the characterization of the natural ligand of a particular orphan GPCR (SLC-1) that is sequentially homologous to the somatostatin receptors(2,3). We show that the natural ligand of this receptor is the neuropeptide melanin-concentrating hormone (MCH)(4), MCH is a cyclic peptide that regulates a variety of functions in the mammalian brain, in particular feeding behaviour(5,6). We demonstrate that nanomolar concentrations of MCH strongly activate SLC-1-related pathways through G alpha(i) and/or G alpha(q) proteins. We have analysed the tissue localization of the MCH receptor and find that it is expressed in several brain regions, in particular those involved in olfactory learning and reinforcement mechanisms, indicating that therapies targeting the MCH receptor should act on the neuronal regulation of food consumption.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Civelli, O (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Civelli, Olivier/A-8392-2012					BAKER BI, 1993, ANN NY ACAD SCI, V680, P279, DOI 10.1111/j.1749-6632.1993.tb19690.x; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; deLecea L, 1996, NATURE, V381, P242, DOI 10.1038/381242a0; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; JEZOVA D, 1992, ENDOCRINOLOGY, V130, P1024, DOI 10.1210/en.130.2.1024; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; KOLAKOWSKI LF, 1996, FEBS LETT, V398, P255; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; LAKAYE B, 1997, BIOCHIM BIOPHYS ACTA, V1401, P216; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MILLER CL, 1993, PEPTIDES, V14, P1; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1997, J NEUROSCI RES, V48, P397, DOI 10.1002/(SICI)1097-4547(19970601)48:5<397::AID-JNR2>3.0.CO;2-9; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sanchez M, 1997, PEPTIDES, V18, P393, DOI 10.1016/S0196-9781(96)00327-0; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SKOFITSCH G, 1985, BRAIN RES B, V15; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; Winzer-Serhan UH, 1999, BRAIN RES PROTOC, V3, P229, DOI 10.1016/S1385-299X(98)00043-9	30	431	466	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					265	269		10.1038/22321	http://dx.doi.org/10.1038/22321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421368				2022-12-28	WOS:000081503800044
J	Smith, IE				Smith, IE			Screening for lung cancer: time to think positive	LANCET			English	Editorial Material									Royal Marsden NHS Trust, London SW3 6JJ, England; Inst Canc Res, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Smith, IE (corresponding author), Royal Marsden NHS Trust, London SW3 6JJ, England.							EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; KANEKO M, 1998, INT C PREV EARL DIAG; KANEKO M, 1999, IN PRESS CANCER; KUBIK A, 1990, INT J CANCER, V45, P26, DOI 10.1002/ijc.2910450107; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; STRAUSS GM, 1998, INT C PREV EARL DIAG; Tockman MS, 1997, CLIN CANCER RES, V3, P2237; TOCKMAN MS, 1986, CHEST S, V89, P324; Zhou J, 1996, J BIOL CHEM, V271, P10760, DOI 10.1074/jbc.271.18.10760	11	31	35	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					86	87		10.1016/S0140-6736(99)00228-7	http://dx.doi.org/10.1016/S0140-6736(99)00228-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408476				2022-12-28	WOS:000081377100002
J	Wear, A				Wear, A			The early modern debate about foreign drugs: localism versus universalism in medicine	LANCET			English	Review									Wellcome Inst Hist Med Sci, London NW1 2BE, England	University of London; University College London	Wear, A (corresponding author), Wellcome Inst Hist Med Sci, 183 Euston Rd, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bright Timothy, 1580, TREATISE WHEREIN IS; BRUSH SB, 1993, AM ANTHROPOL, V95, P653, DOI 10.1525/aa.1993.95.3.02a00060; BRUSH SB, 1996, VALUING LOCAL KNOWLE; COLES W, 1656, ART SIMPLING, P95; DELAPRIMAUDAYE P, 1618, FRENCH ACAD, P787; DERENOU J, 1657, MED DISPENSATORY; dOrta Garcia, 1563, COLOQUIOS SIMPLES DR; ESTES JW, 1995, PHARM HIST, V37, P2; Frampton John, 1577, IOYFULL NEWES OUT NE; FUCHS L, 1539, MEDENDIS SINGULARUM; GOODMAN J, 1993, TOBACCO HIST CULTURE, P39; HARRISON W, DESCRIPTION ENGLAND, P265; Jutte Robert, 1994, POVERTY DEVIANCE EAR; LANNING JT, 1985, ROYAL PROTOMEDICATO, P58; MONARDES N, 1574, LIBROS UNO QUE TRATA; MORAN BT, 1993, PHARM HIST, V35, P104; MUN T, 1621, DISCOURSE TRADE ENGL, P8; PAGEL W, 1958, PARACELSUS; Primrose J., 1651, POPULAR ERROURS ERRO; QUETEL C, 1990, HIST SYPHILIS; ROBERTS RS, 1965, EVOLUTION PHARM BRIT, P168; Shiva Vandana, 1997, BIOPIRACY PLUNDER NA; Slack Paul., 1988, POVERTY POLICY TUDOR, P162; Wake ChristopherH.H., 1979, J EUR ECON HIST, V8, P361; 1585, DISCOURSE MED CALLED	25	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					149	151		10.1016/S0140-6736(98)08290-7	http://dx.doi.org/10.1016/S0140-6736(98)08290-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408503				2022-12-28	WOS:000081377100045
J	Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K				Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K			A central role for cohesions in sister chromatid cohesion, formation of axial elements, and recombination during yeast meiosis	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX PROTEINS; SINGLE-DIVISION MEIOSIS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME SEGREGATION; TOPOISOMERASE-II; DNA-REPLICATION; BUDDING YEAST	A multisubunit complex, called cohesin, containing Smc1p, Smc3p, Scc1p, and Scc3p, is required for sister chromatid cohesion in mitotic cells. We show here that Smc3p and a meiotic version of Scc1p called Rec8p are required for cohesion between sister chromatids, for formation of axial elements, for reciprocal recombination, and for preventing hyperresection of double-strand breaks during meiosis. Both Rec8p and Smc3p colocalize with chromosome cores independently of synapsis during prophase I and largely disappear from chromosome arms after pachytene but persist in the neighborhood of centromeres until the onset of anaphase II. The eukaryotic cell's cohesion apparatus is required both for the repair of recombinogenic lesions and for chromosome segregation and therefore appears to lie at the heart of the meiotic process.	Univ Vienna, Inst Bot, A-1030 Vienna, Austria; IMP Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Klein, F (corresponding author), Univ Vienna, Inst Bot, Rennweg 14, A-1030 Vienna, Austria.	fklein@s1.botanik.univvie.ac.at		Buonomo, Sara/0000-0002-0177-2884; Nasmyth, Kim/0000-0001-7030-4403; Klein, Franz/0000-0001-7204-1432				Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hayashi A, 1998, GENES CELLS, V3, P587, DOI 10.1046/j.1365-2443.1998.00215.x; Heo SJ, 1998, MOL GEN GENET, V257, P149, DOI 10.1007/s004380050634; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HUGERAT Y, 1993, GENETICS, V135, P297; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KLAPHOLZ S, 1980, GENETICS, V96, P567; KLAPHOLZ S, 1980, GENETICS, V96, P589; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LAMMERS JHM, 1995, CHROMOSOMA, V104, P154, DOI 10.1007/s004120050103; Li YF, 1997, MOL MICROBIOL, V23, P869, DOI 10.1046/j.1365-2958.1997.2691632.x; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; MOSES MJ, 1958, J BIOPHYS BIOCHEM CY, V4, P633, DOI 10.1083/jcb.4.5.633; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Prinz S, 1997, GENETICS, V146, P781; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Schalk JAC, 1998, CHROMOSOMA, V107, P540, DOI 10.1007/s004120050340; Schmekel K, 1996, EXP CELL RES, V226, P20, DOI 10.1006/excr.1996.0198; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UHLMANN F, 1999, IN PRESS NATURE; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x	58	560	579	1	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					91	103		10.1016/S0092-8674(00)80609-1	http://dx.doi.org/10.1016/S0092-8674(00)80609-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412984	Bronze			2022-12-28	WOS:000081451000011
J	Quirke, P; Mapstone, N				Quirke, P; Mapstone, N			The new biology: histopathology	LANCET			English	Article							POLYMERASE CHAIN-REACTION; COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; ULCERATIVE-COLITIS; CYSTIC-FIBROSIS; CELL CARCINOMA; TISSUE; GENE; DIAGNOSIS; MUCOSA		Univ Leeds, Leeds LS2 9JT, W Yorkshire, England; Leeds Gen Infirm, Dept Histopathol, Leeds, W Yorkshire, England	University of Leeds; Leeds General Infirmary; University of Leeds	Quirke, P (corresponding author), Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.	philq@pathology.leeds.ac.uk	Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				Ahuja N, 1997, CANCER RES, V57, P3370; BARRATT P, 1999 ANN M AM SOC CL; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Belgrader P, 1999, SCIENCE, V284, P449, DOI 10.1126/science.284.5413.449; Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y; Boland CR, 1998, CANCER RES, V58, P5248; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; Brentnall TA, 1996, CANCER RES, V56, P1237; Busam KJ, 1997, CANCER METAST REV, V16, P207, DOI 10.1023/A:1005721114555; CAWKWELL L, IN PRESS GUT; Chung GTY, 1995, ONCOGENE, V11, P2591; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Duncan JA, 1998, J CLIN PATHOL-MOL PA, V51, P237, DOI 10.1136/mp.51.5.237; Ferry DR, 1998, INT J CLIN PHARM TH, V36, P29; Findlay I, 1997, NATURE, V389, P555, DOI 10.1038/39225; FOY CA, 1994, DIABETIC MED, V11, P564, DOI 10.1111/j.1464-5491.1994.tb02036.x; FOZARD JBJ, 1986, GUT, V27, P1414, DOI 10.1136/gut.27.12.1414; FUNK D, 1998, CLIN CANCER RES, V4, P1; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hurme M, 1998, ANN MED, V30, P469, DOI 10.3109/07853899809002488; Ikeda M, 1998, AM J MED SCI, V316, P257, DOI 10.1097/00000441-199810000-00006; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JACKSON DP, 1989, NUCLEIC ACIDS RES, V17, P10134, DOI 10.1093/nar/17.23.10134; JACKSON DP, 1991, PCR PRACTICAL APPROA, P29; Jiang XX, 1996, CANCER RES, V56, P3534; Kodera Y, 1998, INT J CANCER, V79, P429, DOI 10.1002/(SICI)1097-0215(19980821)79:4<429::AID-IJC20>3.0.CO;2-Z; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Larson PS, 1998, AM J PATHOL, V152, P1591; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; Mao L, 1996, J CELL BIOCHEM, P191; Marshall E, 1999, SCIENCE, V284, P406, DOI 10.1126/science.284.5413.406; Mentzel T, 1998, AM J CLIN PATHOL, V110, P660, DOI 10.1093/ajcp/110.5.660; MINAMOTO T, 1995, CANCER, V75, P1520, DOI 10.1002/1097-0142(19950315)75:6+<1520::AID-CNCR2820751523>3.0.CO;2-L; Muller C, 1997, GUT, V40, P425, DOI 10.1136/gut.40.3.425; Negrin R S, 1998, Curr Opin Hematol, V5, P488, DOI 10.1097/00062752-199811000-00023; Nucci MR, 1997, HUM PATHOL, V28, P1396, DOI 10.1016/S0046-8177(97)90230-6; Ogden GR, 1997, J PATHOL, V181, P127; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; RODMAN DM, 1991, MED HYPOTHESES, V36, P253, DOI 10.1016/0306-9877(91)90144-N; Roger M, 1998, FASEB J, V12, P625, DOI 10.1096/fasebj.12.9.625; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Schmitt CA, 1999, J PATHOL, V187, P127; Somerhausen ND, 1999, EUR J SURG ONCOL, V25, P215, DOI 10.1053/ejso.1998.0630; Tamura M, 1998, LAB INVEST, V78, P213; Thorson AG, 1999, DIS COLON RECTUM, V42, P1, DOI 10.1007/BF02235175; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wells D, 1999, NUCLEIC ACIDS RES, V27, P1214, DOI 10.1093/nar/27.4.1214; Whitehouse A, 1998, INT J MOL MED, V1, P469; Xu XH, 1996, CLIN CANCER RES, V2, P1795; Yamamoto N, 1997, CANCER, V80, P1393, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1393::AID-CNCR5>3.0.CO;2-G	57	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL	1999	354			1			SI26	SI31						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437853				2022-12-28	WOS:000081825900008
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1965: Andre Lwoff (1902-94), Francois Jacob (b 1920), and Jacques Monod (1910-76)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	9	10	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					434	434		10.1016/S0140-6736(05)75863-3	http://dx.doi.org/10.1016/S0140-6736(05)75863-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10501404				2022-12-28	WOS:000081764900071
